Clustering O 0 4.786682893609395e-06
of O 0 2.0320615021773847e-06
missense O 0 2.958166305688792e-06
mutations O 0 3.089471434236657e-08
in O 0 1.1832152146951103e-08
the O 0 4.3280770114506595e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.6277523172902875e-05
in O 0 6.1739612533529e-08
a O 0 3.5217048832691944e-08
sporadic B-Disease 0 2.7039009182772133e-06
T I-Disease 1 0.7384592294692993
- I-Disease 0 0.24995748698711395
cell I-Disease 1 0.8257920742034912
leukaemia I-Disease 1 0.9999603033065796
. O 0 1.0323897186026443e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999568462371826
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.7241359390473008e-08
is O 0 2.798465015274587e-09
a O 0 1.3623608019486255e-08
recessive B-Disease 0 1.2367627277853899e-06
multi I-Disease 1 0.9999995231628418
- I-Disease 1 1.0
system I-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9964381456375122
caused O 0 4.029668332350411e-08
by O 0 7.070079244275718e-11
mutations O 0 7.423270331763376e-11
in O 0 2.0550013080100626e-10
the O 0 1.0156718133202958e-08
ATM O 0 8.771070270086057e-08
gene O 0 7.493352605081327e-09
at O 0 2.277837829467444e-08
11q22 O 0 1.1915930997474788e-07
- O 0 3.8253060097304115e-07
q23 O 0 1.580463390382647e-06
( O 0 1.6919704748374897e-08
ref O 0 7.51690595279797e-06
. O 0 9.324987892966874e-09
3 O 0 5.7348561455228264e-08
) O 0 1.3787242458818127e-09
. O 0 4.1836120345806194e-08

The O 0 2.0715181108243996e-06
risk O 0 5.968905156805704e-07
of O 0 6.143936275293527e-07
cancer B-Disease 0 0.01301562413573265
, O 0 2.0372104003740787e-09
especially O 0 1.1029578139698515e-08
lymphoid B-Disease 0 4.541934686130844e-05
neoplasias I-Disease 0 0.04402974620461464
, O 0 2.969505086269919e-09
is O 0 6.182074852034702e-10
substantially O 0 1.3447229996188526e-08
elevated O 0 2.5650670067989267e-05
in O 0 1.797665163394413e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.00022616358182858676
and O 0 6.861197476837333e-08
has O 0 1.3714879232296084e-09
long O 0 5.054871521359416e-10
been O 0 1.752837736068713e-10
associated O 0 1.779148384173368e-09
with O 0 6.897080240264586e-09
chromosomal O 1 1.0
instability O 1 1.0
. O 0 2.820431109284982e-05

By O 0 1.0333959465924636e-07
analysing O 0 2.506650389477727e-06
tumour B-Disease 1 0.9998025298118591
DNA O 0 2.3651620040254784e-07
from O 0 3.0785698434954156e-09
patients O 0 5.151719606466543e-10
with O 0 1.624180095971539e-10
sporadic B-Disease 0 2.509070498035726e-07
T I-Disease 0 8.85183981154114e-05
- I-Disease 0 6.123103230493143e-05
cell I-Disease 0 0.00010094369645230472
prolymphocytic I-Disease 0 2.887176196963992e-05
leukaemia I-Disease 0 0.005204647779464722
( O 0 3.6409029124939707e-09
T B-Disease 0 3.3480870342827984e-07
- I-Disease 0 3.611035310768784e-07
PLL I-Disease 0 2.0593136014213087e-06
) O 0 1.1294706281361755e-09
, O 0 1.6414709869128075e-10
a O 0 1.8485790675981661e-09
rare O 0 1.8704739090935618e-08
clonal B-Disease 0 1.8572852411580243e-07
malignancy I-Disease 0 5.242526185611496e-06
with O 0 1.4257655056582053e-09
similarities O 0 9.570698900063235e-09
to O 0 7.675721391819934e-09
a O 0 1.1471313854372056e-07
mature B-Disease 0 1.1420534207218225e-07
T I-Disease 0 1.0558582289377227e-05
- I-Disease 0 4.019814696221147e-06
cell I-Disease 0 6.189683062984841e-06
leukaemia I-Disease 0 0.00010248164471704513
seen O 0 1.895575074684075e-08
in O 0 8.368483683796057e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 1.2354096412536819e-08
we O 0 1.421399331569262e-09
demonstrate O 0 1.4237300227648575e-09
a O 0 2.5755209076550045e-09
high O 0 7.461392392826838e-09
frequency O 0 3.580001184388948e-09
of O 0 6.240543193314352e-09
ATM O 0 1.536033096272149e-07
mutations O 0 1.8368889742603756e-09
in O 0 7.70701191754597e-09
T B-Disease 0 1.3942905752628576e-05
- I-Disease 0 8.43912857817486e-06
PLL I-Disease 0 0.00010558289068285376
. O 0 9.485775080975145e-07

In O 0 4.749953177451971e-07
marked O 0 2.674391055279557e-07
contrast O 0 8.398613715598913e-08
to O 0 1.9825332486789193e-08
the O 0 8.281188712544463e-08
ATM O 0 2.4016222255340836e-07
mutation O 0 1.4624969013610212e-09
pattern O 0 5.5506448326525515e-09
in O 0 1.2024741202765199e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 2.160442313936528e-08
the O 0 1.5599297853441385e-08
most O 0 6.233747407158319e-10
frequent O 0 3.8257466639102233e-10
nucleotide O 0 1.2472233246185738e-09
changes O 0 8.217924257758469e-11
in O 0 5.977828648751071e-11
this O 0 2.9587107763795473e-10
leukaemia B-Disease 0 2.4893717636587098e-05
were O 0 3.975185336457798e-08
missense O 0 8.286346542263345e-07
mutations O 0 9.226412345242352e-08
. O 0 2.887828713937779e-07

These O 0 2.0569059699937497e-07
clustered O 0 4.367590520359954e-07
in O 0 5.519258827746398e-09
the O 0 5.595043095496521e-09
region O 0 1.8505897925180648e-09
corresponding O 0 3.518352720277562e-09
to O 0 2.1595564447807192e-08
the O 0 4.928117505187402e-07
kinase O 0 8.738455790080479e-07
domain O 0 2.046675362521455e-08
, O 0 1.5008093379176302e-10
which O 0 3.088005545714978e-11
is O 0 4.16829695759624e-11
highly O 0 4.1061493094574075e-10
conserved O 0 5.290815563441242e-10
in O 0 5.698693184008619e-10
ATM O 0 3.809280002542437e-08
- O 0 9.970400505210364e-09
related O 0 5.840135597345864e-10
proteins O 0 5.345088607833226e-11
in O 0 2.0614748796887739e-10
mouse O 0 1.7607305835554143e-08
, O 0 2.652434383243474e-10
yeast O 0 1.285326618472027e-07
and O 0 4.5738833165387405e-08
Drosophila O 0 1.2613382978088339e-06
. O 0 3.6316944829195563e-07

The O 0 2.12233771890169e-06
resulting O 0 6.908602472321945e-07
amino O 0 2.07928721351891e-07
- O 0 3.2844943120835524e-07
acid O 0 4.7747008125043067e-08
substitutions O 0 7.296842596815623e-08
are O 0 9.673745138272238e-10
predicted O 0 8.355090841405399e-08
to O 0 9.644236520500726e-09
interfere O 0 9.48923428722992e-08
with O 0 9.040794779480166e-09
ATP O 0 1.3948351806902792e-06
binding O 0 3.0804272910245345e-08
or O 0 2.1053057963626998e-08
substrate O 0 1.0328348025723244e-06
recognition O 0 1.2775177538060234e-07
. O 0 2.6725706447905395e-07

Two O 0 1.9690830868057674e-06
of O 0 2.7203536774322856e-06
seventeen O 0 6.544315738210571e-07
mutated O 0 3.68213022738928e-07
T B-Disease 0 1.3556145859183744e-06
- I-Disease 0 5.497240067597886e-07
PLL I-Disease 0 1.8634269736139686e-06
samples O 0 1.2533241111611915e-08
had O 0 1.4897935329827305e-08
a O 0 5.166462369032843e-09
previously O 0 2.847625957258515e-08
reported O 0 6.930921614412e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999929666519165
T I-Disease 1 1.0
allele O 0 2.8211848075443413e-06
. O 0 1.2781091527358512e-06

In O 0 2.3079837774275802e-07
contrast O 0 2.0002298128929397e-07
, O 0 4.081010196443913e-09
no O 0 1.7509274030658162e-09
mutations O 0 6.276722475107022e-10
were O 0 1.9096362269266365e-09
detected O 0 8.646686922020308e-09
in O 0 1.5847542167435336e-09
the O 0 1.5008854603593136e-08
p53 O 0 1.4327552477766403e-09
gene O 0 2.614642724552141e-09
, O 0 6.464929980243284e-11
suggesting O 0 1.339009181311468e-10
that O 0 8.688371549991913e-11
this O 0 7.233677212781231e-09
tumour B-Disease 1 1.0
suppressor O 0 1.5053719835123047e-05
is O 0 6.634814919692644e-10
not O 0 1.1686308865055395e-10
frequently O 0 2.4243271279367207e-10
altered O 0 2.8705333665612898e-09
in O 0 7.791597367301506e-10
this O 0 4.295239719454003e-09
leukaemia B-Disease 0 0.000512702448759228
. O 0 3.153568570724019e-07

Occasional O 0 8.962231731857173e-06
missense O 0 1.559060183353722e-05
mutations O 0 1.0436266251190318e-07
in O 0 3.47998536653904e-08
ATM O 0 5.625388894259231e-06
were O 0 8.830290454397982e-08
also O 0 3.4644465074507025e-09
found O 0 3.2028368845971045e-09
in O 0 4.140962239773671e-09
tumour B-Disease 1 0.999997615814209
DNA O 0 2.2692326240303373e-07
from O 0 5.346531661842846e-09
patients O 0 1.5388174068320382e-09
with O 0 2.3335626764264816e-09
B B-Disease 0 1.6440941180917434e-05
- I-Disease 0 4.3605559767456725e-05
cell I-Disease 1 0.9237599968910217
non I-Disease 1 0.6101816892623901
- I-Disease 1 0.9976359605789185
Hodgkins I-Disease 1 1.0
lymphomas I-Disease 0 0.0006804105942137539
( O 0 4.52902515490905e-09
B B-Disease 0 9.176552140388594e-08
- I-Disease 0 4.0115704535992336e-08
NHL I-Disease 0 6.618099064326088e-07
) O 0 3.398447356861567e-10
and O 0 4.434745071169033e-10
a O 0 6.7041092677300185e-09
B B-Disease 0 7.211610295598803e-07
- I-Disease 0 1.199238568005967e-06
NHL I-Disease 0 0.00019225022697355598
cell O 0 8.290717232739553e-05
line O 0 2.3688538931310177e-05
. O 0 1.4313513929664623e-06

The O 0 1.2823896895497455e-06
evidence O 0 6.405325052583066e-07
of O 0 3.9405549046023225e-07
a O 0 1.3861659375891122e-08
significant O 0 4.60567672888601e-09
proportion O 0 4.591589775060356e-09
of O 0 2.3562304107827003e-08
loss O 0 2.415417270640319e-07
- O 0 3.850435916774586e-07
of O 0 5.738407253375044e-06
- O 0 8.742724162402737e-07
function O 0 1.2649856717672492e-09
mutations O 0 3.7843789213454215e-10
and O 0 3.204368992371087e-10
a O 0 3.901635903247325e-09
complete O 0 5.5944592958212525e-08
absence O 0 1.555140102027508e-06
of O 0 6.685895073132997e-07
the O 0 5.628688271031024e-08
normal O 0 8.01951394180378e-09
copy O 0 2.1866595645292364e-08
of O 0 3.4928593350969095e-08
ATM O 0 1.7630502213705768e-07
in O 0 2.022791489864062e-09
the O 0 4.9775303878618615e-09
majority O 0 4.763308081301432e-10
of O 0 1.2364303358936013e-08
mutated O 0 5.028182954447402e-07
tumours B-Disease 1 0.9999998807907104
establishes O 0 1.6447107498152036e-07
somatic O 0 7.183639354479965e-07
inactivation O 0 5.382086328609148e-06
of O 0 3.5427245137498176e-08
this O 0 5.221441612413003e-10
gene O 0 4.0860551053789607e-10
in O 0 2.1776670744433346e-10
the O 0 3.6245577650362293e-09
pathogenesis O 0 1.2441074431990273e-05
of O 0 8.194877523237665e-07
sporadic B-Disease 0 5.5040170991560444e-05
T I-Disease 0 0.02763710729777813
- I-Disease 0 2.0300285541452467e-05
PLL I-Disease 0 8.15834391687531e-06
and O 0 4.242098228246505e-09
suggests O 0 7.495278286917539e-10
that O 0 4.820244203784796e-11
ATM O 0 2.188591352592084e-08
acts O 0 2.264343157420967e-09
as O 0 3.53300566580117e-09
a O 0 1.2398646731526242e-07
tumour B-Disease 1 1.0
suppressor O 0 0.00027376814978197217
. O 0 1.1992694908258272e-06

As O 0 7.954269563015259e-07
constitutional O 0 9.245082424058637e-07
DNA O 0 8.299815021928225e-07
was O 0 1.5360200222858111e-07
not O 0 2.332537774041299e-10
available O 0 1.2428728046742776e-09
, O 0 7.980858751643893e-10
a O 0 1.560155915569794e-08
putative O 0 0.00011412370076868683
hereditary O 1 1.0
predisposition O 1 1.0
to O 1 0.933571457862854
T B-Disease 1 1.0
- I-Disease 1 0.9999849796295166
PLL I-Disease 0 0.00041467073606327176
will O 0 9.332016048801961e-09
require O 0 1.757331169471854e-09
further O 0 2.2858273052150935e-09
investigation O 0 5.594552376919637e-09
. O 0 2.0372492581799406e-09
. O 0 1.4112211843553268e-08

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 0.0001903940865304321
kinase O 0 2.0827931166422786e-06
is O 0 2.2433679913724802e-10
involved O 0 7.037480320715161e-11
in O 0 2.4453446212380214e-11
the O 0 3.373454571242718e-10
modulation O 0 3.960569650018897e-09
of O 0 2.9573921089820487e-09
the O 0 5.6732103459467e-09
Ca2 O 0 1.6258918833500502e-07
+ O 0 2.5588406060705893e-07
homeostasis O 0 2.289597063054316e-07
in O 0 3.524874836458025e-09
skeletal O 0 4.577417769269232e-07
muscle O 0 6.369081262391774e-08
cells O 0 1.1506440245057092e-07
. O 0 2.3434662921317795e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0004140170640312135
DM B-Disease 1 1.0
) O 0 2.833814782832178e-08
, O 0 2.844659230394342e-10
the O 0 2.6429818333895128e-09
most O 0 4.944638920534317e-09
prevalent O 0 0.0006316882790997624
muscular B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999978542327881
in O 0 3.8987220563058145e-08
adults O 0 5.168256045351427e-09
, O 0 1.614842148889295e-10
is O 0 8.903151132999554e-11
caused O 0 4.654601148956772e-09
by O 0 1.89922944038301e-09
( O 0 1.2339442800879397e-09
CTG O 0 1.807288043664812e-07
) O 0 3.3508110175439754e-10
n O 0 3.0864719668954876e-09
- O 0 8.656686922847712e-09
repeat O 0 1.3342118521109114e-09
expansion O 0 3.868571685217148e-09
in O 0 2.025431211638562e-10
a O 0 2.528813825009024e-10
gene O 0 5.78794581707065e-11
encoding O 0 1.4021357408466883e-09
a O 0 8.018229635808893e-09
protein O 0 2.496391182660318e-08
kinase O 0 2.2263246535203507e-07
( O 0 9.082725682674209e-09
DM B-Disease 1 0.9999834299087524
protein O 0 9.022518838719407e-07
kinase O 0 3.892577637998329e-07
; O 0 1.703120755536247e-09
DMPK O 0 2.413574065940338e-06
) O 0 2.386518205277355e-10
and O 0 9.178377502472301e-11
involves O 0 3.21367238376169e-10
changes O 0 5.319532592196197e-10
in O 0 8.800622453009055e-10
cytoarchitecture O 0 1.9096850678579358e-07
and O 0 1.2414969496887807e-08
ion O 0 1.891411102405982e-06
homeostasis O 0 1.2784023965650704e-05
. O 0 7.084357207531866e-07

To O 0 1.605976791552166e-07
obtain O 0 3.5602019465841295e-07
clues O 0 1.6778565168351633e-06
to O 0 1.3130414977524651e-08
the O 0 2.282656730301369e-08
normal O 0 8.207750035182926e-09
biological O 0 8.95693297309208e-09
role O 0 8.948291885246817e-09
of O 0 7.206289609484884e-08
DMPK O 0 0.0029135493095964193
in O 0 9.807144607520968e-08
cellular O 0 5.044965405431867e-07
ion O 0 1.3770528539680527e-06
homeostasis O 0 3.4749225505947834e-06
, O 0 3.3868403637171696e-09
we O 0 1.1058683968556693e-09
have O 0 2.289168299363098e-10
compared O 0 1.1587235615451164e-09
the O 0 1.175470565328851e-08
resting O 0 2.2125708198927896e-07
[ O 0 1.2086712075642936e-08
Ca2 O 0 1.3386937780524022e-08
+ O 0 1.4267864223427296e-08
] O 0 6.906334615308651e-09
i O 0 3.6719163265530597e-09
, O 0 9.359600594560646e-11
the O 0 3.428291261986516e-10
amplitude O 0 1.1676979383423713e-09
and O 0 1.3992550174091178e-10
shape O 0 4.032850053903303e-09
of O 0 1.952690631412679e-08
depolarization O 0 1.1896288754087436e-07
- O 0 1.5347650617059116e-07
induced O 0 4.657023566778662e-07
Ca2 O 0 1.4071336806864565e-07
+ O 0 5.2604118394583566e-08
transients O 0 3.839098283719977e-08
, O 0 8.802565620857905e-11
and O 0 3.189660757740853e-10
the O 0 1.8516914668254003e-09
content O 0 1.477725497522897e-09
of O 0 1.0323021548686029e-08
ATP O 0 4.917948217553203e-07
- O 0 1.2976059338143386e-07
driven O 0 1.3119905872827076e-07
ion O 0 4.491948857321404e-07
pumps O 0 1.6707448935449065e-07
in O 0 1.87302653387178e-08
cultured O 0 2.7056654516854906e-07
skeletal O 0 5.009367782804475e-07
muscle O 0 2.2355790108008478e-08
cells O 0 1.804862392873474e-08
of O 0 1.4994039077009802e-07
wild O 0 5.4382347514092544e-08
- O 0 1.408596617125113e-08
type O 0 5.35835624759784e-08
and O 0 4.264938624487513e-08
DMPK O 0 9.966057405108586e-06
[ O 0 6.435928412429348e-08
- O 0 3.4592986253301206e-07
/ O 0 1.432701992598595e-06
- O 0 2.60137562690943e-06
] O 0 4.665429571559798e-07
knockout O 0 4.451270433492027e-05
mice O 0 9.09822745143174e-07
. O 0 1.5188328461590572e-07

In O 0 2.3928187147248536e-06
vitro O 0 3.6264866594137857e-06
- O 0 6.720698024764715e-07
differentiated O 0 4.6579654622291855e-07
DMPK O 0 3.061308234464377e-05
[ O 0 1.3103837659400597e-07
- O 0 4.5172302520768426e-07
/ O 0 9.267839686799562e-07
- O 0 1.2676936194111477e-06
] O 0 1.1828050361373244e-07
myotubes O 0 2.5398091452188964e-07
exhibit O 0 1.3832072154329467e-09
a O 0 3.1108098319521105e-09
higher O 0 2.3199614673785618e-08
resting O 0 3.2659656312716834e-07
[ O 0 2.3394864712145136e-08
Ca2 O 0 4.5949740012929396e-08
+ O 0 5.546043979620663e-08
] O 0 1.728124843225487e-08
i O 0 7.990839989702181e-09
than O 0 3.149062954843629e-10
do O 0 6.055938528426452e-10
wild O 0 1.4705479500776164e-08
- O 0 8.333728374054772e-09
type O 0 5.53534924563337e-08
myotubes O 0 1.965262072189944e-06
because O 0 5.8352056520050155e-09
of O 0 2.494720519052862e-08
an O 0 8.223854930378138e-10
altered O 0 1.5802093855654675e-08
open O 0 4.105464412873516e-08
probability O 0 5.108959921784617e-09
of O 0 2.389039188699371e-08
voltage O 0 3.232610765735444e-07
- O 0 7.010855540556804e-08
dependent O 0 3.184199570682722e-08
l O 0 7.1420838132496556e-09
- O 0 3.062172293510912e-09
type O 0 2.5723541074995637e-09
Ca2 O 0 5.749156706258418e-09
+ O 0 4.519507434963543e-09
and O 0 2.1500901059567923e-09
Na O 0 2.727703076743637e-07
+ O 0 2.7218298725983914e-08
channels O 0 3.722230701441731e-08
. O 0 2.8217922221074332e-08

The O 0 7.160313543863595e-05
mutant O 0 2.9130851544323377e-05
myotubes O 0 9.384714758198243e-06
exhibit O 0 1.4814541593466402e-08
smaller O 0 8.66474803018491e-09
and O 0 4.558604604909533e-09
slower O 0 1.9605059264904412e-07
Ca2 O 0 3.079555597196304e-07
+ O 0 4.1342797629795314e-08
responses O 0 6.443869882133413e-10
upon O 0 3.8265364210587904e-09
triggering O 0 5.336710184877802e-09
by O 0 1.0435894509663868e-10
acetylcholine O 0 1.677024208390776e-08
or O 0 4.690284605146644e-09
high O 0 1.5775622586033933e-08
external O 0 4.9745150221269796e-08
K O 0 2.2497854956782248e-07
+ O 0 1.132884932530942e-07
. O 0 4.4296601942050984e-08

In O 0 5.386606858337473e-07
addition O 0 4.1818406515403694e-08
, O 0 2.8216617931065002e-09
we O 0 3.4030267492823896e-10
observed O 0 3.271666548787522e-10
that O 0 2.7198691215923887e-11
these O 0 3.6993233476501075e-10
Ca2 O 0 2.959575624572608e-07
+ O 0 7.749636665721482e-07
transients O 0 3.418722940295993e-07
partially O 0 1.2120787040714731e-08
result O 0 1.019854756201255e-09
from O 0 5.271234004844416e-10
an O 0 5.106480863159568e-11
influx O 0 2.2833554491619168e-10
of O 0 1.1976004632430204e-09
extracellular O 0 2.781065155943452e-09
Ca2 O 0 1.086976997299871e-08
+ O 0 4.4261616594098996e-09
through O 0 6.703543276032065e-10
the O 0 8.204662504951443e-10
l O 0 4.0149955582435837e-10
- O 0 1.0168867969895246e-09
type O 0 4.338499337563917e-09
Ca2 O 0 8.052502664668282e-08
+ O 0 1.8687413216866844e-07
channel O 0 4.819690957447165e-07
. O 0 2.649807662180592e-08

Neither O 0 4.428347892826423e-05
the O 0 1.7289195284320158e-06
content O 0 7.151710690322943e-08
nor O 0 5.086910093154984e-08
the O 0 6.66850263897345e-09
activity O 0 9.985468008011367e-10
of O 0 9.202313577816312e-09
Na O 0 1.806440224072503e-07
+ O 0 1.1055905524415266e-08
/ O 0 1.399539417690221e-08
K O 0 2.1544549255736456e-08
+ O 0 5.956438009491194e-09
ATPase O 0 8.706130039115578e-09
and O 0 2.587100533801845e-09
sarcoplasmic O 0 6.43919463527709e-07
reticulum O 0 1.3151478697182029e-06
Ca2 O 0 4.532303066184795e-08
+ O 0 2.469618998190981e-08
- O 0 1.4089566846564594e-08
ATPase O 0 3.4296532280819747e-09
are O 0 7.23330770280306e-12
affected O 0 1.2539205784811713e-10
by O 0 2.0629656316550893e-10
DMPK O 0 3.713928163051605e-05
absence O 0 7.180062311817892e-06
. O 0 2.4544242478441447e-06

In O 0 5.188497311792162e-07
conclusion O 0 3.9925868122736574e-07
, O 0 2.3156907502652757e-08
our O 0 1.8869393159093306e-08
data O 0 4.8998565205238265e-09
suggest O 0 8.608537216403533e-10
that O 0 9.251268084931041e-10
DMPK O 0 4.278356209397316e-05
is O 0 1.7373711358459332e-09
involved O 0 9.37364741382396e-10
in O 0 9.698242209310592e-10
modulating O 0 1.0291570617937396e-07
the O 0 2.123745268534094e-08
initial O 0 1.2857037212654632e-08
events O 0 2.6402546815518235e-10
of O 0 1.0089001856172786e-09
excitation O 0 1.7490530979102914e-07
- O 0 2.595089370061032e-07
contraction O 0 1.1602833360768727e-08
coupling O 0 3.534018588879917e-08
in O 0 7.509478372469403e-09
skeletal O 0 1.9047319028686616e-06
muscle O 0 2.849261875326192e-07
. O 0 6.247191208785807e-08
. O 0 2.112800672193771e-07

Constitutional O 0 0.00017746891535352916
RB1 O 0 0.005936007481068373
- O 0 2.4844863219186664e-05
gene O 0 1.1781797759624624e-08
mutations O 0 1.2789111991651225e-09
in O 0 2.2983207004223516e-10
patients O 0 3.266387160749673e-09
with O 0 1.6746324327243656e-09
isolated O 0 3.1230308650265215e-06
unilateral B-Disease 0 0.0001908370031742379
retinoblastoma I-Disease 1 1.0
. O 0 0.026955660432577133

In O 0 1.5229666416871623e-07
most O 0 7.608960572724754e-09
patients O 0 3.2819806872197432e-09
with O 0 2.6215227211245917e-10
isolated O 0 1.5980322132236324e-07
unilateral B-Disease 0 5.089732894703047e-06
retinoblastoma I-Disease 1 1.0
, O 0 2.5384892410329485e-07
tumor B-Disease 0 1.3328487511898857e-05
development O 0 3.5564411859922984e-08
is O 0 1.1642369013298293e-10
initiated O 0 6.772814531430527e-10
by O 0 1.9841872936354754e-11
somatic O 0 6.599970348020179e-09
inactivation O 0 1.3053609393409715e-07
of O 0 2.980916846695436e-09
both O 0 2.732938597649337e-10
alleles O 0 1.6313426998149083e-10
of O 0 3.901747813728207e-09
the O 0 2.4915106422440658e-08
RB1 O 0 1.2713832802546676e-05
gene O 0 8.774852489068508e-08
. O 0 1.192372991454249e-07

However O 0 5.689184376933554e-07
, O 0 2.4673671994435153e-09
some O 0 6.95393881366968e-11
of O 0 1.4388703561962757e-09
these O 0 1.5692150356905188e-10
patients O 0 2.0489789864797103e-09
can O 0 1.3300271994864943e-09
transmit O 0 5.602595365417073e-07
retinoblastoma B-Disease 0 0.0008400239166803658
predisposition O 0 4.708565029432066e-05
to O 0 1.786052195029697e-07
their O 0 2.72942043011426e-06
offspring O 0 3.51316666638013e-05
. O 0 8.959376032180444e-07

To O 0 1.268986267177752e-07
determine O 0 4.7035548789153836e-08
the O 0 2.685229105736653e-08
frequency O 0 1.823812212364828e-08
and O 0 9.639541387329587e-10
nature O 0 1.056294274270897e-09
of O 0 3.916906798906439e-09
constitutional O 0 1.2292987605633243e-07
RB1 O 0 5.162365414435044e-05
- O 0 3.257834180203645e-07
gene O 0 1.0835361496930318e-09
mutations O 0 1.9993232069914768e-10
in O 0 8.343230967211568e-11
patients O 0 7.407023328021012e-10
with O 0 7.668430335172616e-10
isolated O 0 1.6346104985132115e-06
unilateral B-Disease 0 5.05317329952959e-05
retinoblastoma I-Disease 1 1.0
, O 0 6.632708249298958e-08
we O 0 7.611337116131267e-10
analyzed O 0 4.3208411848461026e-10
DNA O 0 6.217695691645986e-09
from O 0 5.795880442249768e-10
peripheral O 0 5.817183250655944e-07
blood O 0 1.4301136275207682e-07
and O 0 2.6163203159512705e-08
from O 0 6.524648199501826e-08
tumor B-Disease 0 7.950072904350236e-05
tissue O 0 3.550355904735625e-05
. O 0 6.890606414344802e-07

The O 0 7.189348139036156e-07
analysis O 0 6.079750392018468e-08
of O 0 8.563565074837243e-07
tumors B-Disease 1 1.0
from O 0 7.600237950100563e-07
54 O 0 3.4405286442051874e-07
( O 0 1.076655431475615e-09
71 O 0 2.616899053009547e-08
% O 0 3.7973502120536295e-10
) O 0 1.0784716869549626e-10
of O 0 8.571612752916735e-09
76 O 0 2.4484293703608273e-07
informative O 0 3.868483311464388e-09
patients O 0 8.076063373607667e-09
showed O 0 4.582281221132689e-09
loss O 0 3.896699851679841e-08
of O 0 1.5984728918283508e-07
constitutional O 0 1.2874143067165278e-05
heterozygosity O 1 0.9999983310699463
( O 0 1.4929323697288055e-05
LOH O 1 1.0
) O 0 2.0671782507974967e-08
at O 0 7.992931472244891e-08
intragenic O 0 2.3161076114774914e-06
loci O 0 4.3948534766968805e-07
. O 0 6.262413876356732e-07

Three O 0 1.3507932408174383e-06
of O 0 1.9753822471102467e-06
13 O 0 1.821969931370404e-06
uninformative O 0 0.0014107291353866458
patients O 0 4.633991466107545e-06
had O 0 7.499081107198435e-07
constitutional O 0 5.0118087528971955e-06
deletions O 0 2.541210960771423e-05
. O 0 2.140424157914822e-06

For O 0 1.3613109786092537e-06
39 O 0 2.928295998572139e-06
randomly O 0 4.188482094491519e-08
selected O 0 2.206254748671199e-06
tumors B-Disease 1 1.0
, O 0 3.119040741239587e-07
SSCP O 1 0.8408932685852051
, O 0 9.940250578210907e-08
hetero O 0 2.626721425258438e-06
- O 0 4.4444456648307096e-07
duplex O 0 9.867304697763757e-07
analysis O 0 1.498804858002245e-09
, O 0 5.219616752705214e-11
sequencing O 0 1.6139654057667485e-09
, O 0 7.00622060367806e-11
and O 0 4.5004086568489754e-10
Southern O 0 5.459477492308906e-08
blot O 0 1.6826380715428968e-06
analysis O 0 2.3594941556126514e-09
were O 0 3.5217750937732717e-10
used O 0 7.152918257702368e-10
to O 0 2.4571900070213815e-09
identify O 0 3.309155971464861e-08
mutations O 0 8.626378900089549e-08
. O 0 2.694045520001964e-07

Mutations O 0 4.3854080900018744e-07
were O 0 6.828896914612415e-08
detected O 0 7.476937469164113e-08
in O 0 3.86015441833365e-09
21 O 0 2.364198437021514e-08
( O 0 3.019403616022487e-10
91 O 0 2.0173096970665938e-08
% O 0 2.710812130324314e-10
) O 0 1.155372880701222e-10
of O 0 5.9291693332852446e-08
23 O 0 0.0009764652932062745
tumors B-Disease 1 1.0
with O 1 0.9575070142745972
LOH O 1 1.0
. O 0 0.0008131961221806705

In O 0 1.4767266520721023e-06
6 O 0 1.527535573586647e-06
( O 0 1.6819116099853204e-09
38 O 0 1.2796316006813413e-08
% O 0 7.726569939414674e-10
) O 0 6.123772045008025e-10
of O 0 8.086979619292833e-08
16 O 0 0.0001640402479097247
tumors B-Disease 1 1.0
without O 1 0.9990437626838684
LOH O 1 1.0
, O 0 1.7993558643070173e-08
one O 0 8.284262165147993e-10
mutation O 0 1.973476798644569e-10
was O 0 3.2995115528677843e-09
detected O 0 1.6288407289621887e-09
, O 0 5.7041930207057945e-11
and O 0 3.101571777186507e-10
in O 0 3.8666394530650905e-09
9 O 0 9.932708167070814e-08
( O 0 6.16295514621612e-10
56 O 0 8.459961620133072e-09
% O 0 5.752970877459518e-10
) O 0 2.1617427292675018e-10
of O 0 9.817905777254055e-08
the O 0 0.0031422339379787445
tumors B-Disease 1 1.0
without O 1 0.999798595905304
LOH O 1 1.0
, O 0 6.829766974192353e-09
both O 0 5.783556411564916e-10
mutations O 0 1.0333851552246642e-09
were O 0 2.464930703993673e-09
found O 0 8.13816303235626e-09
. O 0 7.963608084082807e-08

Thus O 0 4.937639346280775e-07
, O 0 4.6497743433349115e-09
a O 0 1.3562776457476389e-09
total O 0 1.2723704034822703e-10
of O 0 1.17727616544272e-09
45 O 0 1.5461844027342408e-09
mutations O 0 3.524947000954626e-10
were O 0 1.4018416427674651e-09
identified O 0 1.8507106958054464e-08
in O 0 9.152952884505794e-08
tumors B-Disease 1 1.0
of O 0 0.03382696583867073
36 O 0 3.672885213745758e-05
patients O 0 3.199457978553255e-06
. O 0 4.653335054172203e-06

Thirty O 0 3.869094143738039e-05
- O 0 3.5147777452948503e-06
nine O 0 1.8037856364117033e-07
of O 0 3.745433119206609e-08
the O 0 1.293345697206405e-08
mutations O 0 1.4913535961724733e-09
- O 0 1.7141106312124066e-08
including O 0 2.5807478376549398e-09
34 O 0 5.4606228871989515e-08
small O 0 1.691954487625935e-08
mutations O 0 1.624125900434592e-08
, O 0 4.187042268455343e-09
2 O 0 2.1819211326601362e-07
large O 0 3.4622157585317836e-08
structural O 0 0.00011442531103966758
alterations O 0 0.34501466155052185
, O 0 3.905360657086021e-08
and O 0 5.1691664282316196e-08
hypermethylation O 1 0.6842873096466064
in O 0 9.457472515350673e-06
3 O 0 0.005165216512978077
tumors O 1 1.0
- O 0 1.8510463632992469e-06
were O 0 1.0499674907293866e-08
not O 0 6.373547800642143e-10
detected O 0 1.665961413266359e-08
in O 0 3.9214048674907076e-10
the O 0 1.1528860088816373e-09
corresponding O 0 2.441283397658367e-09
peripheral O 0 1.5064887293192442e-06
blood O 0 2.7275575575913535e-07
DNA O 0 6.213149845279986e-06
. O 0 6.01410249601031e-07

In O 0 4.473891294765053e-06
6 O 0 2.7351738935976755e-06
( O 0 3.2516798142978587e-09
17 O 0 1.11413429593199e-08
% O 0 2.2807873645280807e-10
) O 0 7.453916650579373e-11
of O 0 4.276805132263917e-09
the O 0 7.89199532391649e-08
36 O 0 9.938071343640331e-08
patients O 0 1.3455927927452649e-08
, O 0 7.658023659651292e-10
a O 0 6.668731344916523e-09
mutation O 0 3.1085085616666674e-09
was O 0 4.159106481438357e-08
detected O 0 8.440427023970187e-09
in O 0 4.928216168487154e-10
constitutional O 0 7.659429535067375e-09
DNA O 0 1.0528837179890616e-07
, O 0 4.558237121088382e-10
and O 0 1.0183599519208997e-09
1 O 0 2.5386409419070333e-08
of O 0 8.172321486199507e-09
these O 0 1.5563419442088389e-09
mutations O 0 1.8719255034937987e-09
is O 0 1.6667481284038388e-10
known O 0 5.215589071738691e-10
to O 0 1.6821963266799855e-10
be O 0 4.4044992653091697e-10
associated O 0 9.339886197778924e-09
with O 0 1.970589025290792e-09
reduced O 0 7.096055014699232e-07
expressivity O 0 9.223711094819009e-05
. O 0 9.854844620349468e-07

The O 0 1.6608682926744223e-06
presence O 0 5.3558629531380575e-08
of O 0 1.3789515662665508e-07
a O 0 1.699312157654731e-08
constitutional O 0 2.1711745290531326e-08
mutation O 0 1.7399213181334972e-09
was O 0 2.6917397200065807e-09
not O 0 1.3416466722315779e-11
associated O 0 2.1076582146228873e-10
with O 0 2.5948273044140713e-11
an O 0 2.7875094593676764e-11
early O 0 3.6893705868124016e-08
age O 0 1.0029031827230028e-08
at O 0 1.9004840368097575e-08
treatment O 0 3.124965246570355e-07
. O 0 3.508584711653384e-07

In O 0 8.869830026014824e-07
1 O 0 1.8131747765437467e-06
patient O 0 6.554584501827776e-07
, O 0 1.4038171514130227e-08
somatic O 0 1.8575079593574628e-05
mosaicism O 1 0.9950939416885376
was O 0 1.811925017136673e-06
demonstrated O 0 2.7514919231919066e-09
by O 0 2.708578153431951e-11
molecular O 0 3.7043648704049303e-10
analysis O 0 4.105387904629332e-11
of O 0 1.3814346888629814e-10
DNA O 0 9.954377322429764e-10
and O 0 3.276106330662998e-10
RNA O 0 2.4387249553114998e-08
from O 0 3.3049785130856435e-09
peripheral O 0 5.74832120037172e-06
blood O 0 3.395971134523279e-06
. O 0 2.1996938812662847e-06

In O 0 1.7493980521976482e-06
2 O 0 3.584011210477911e-06
patients O 0 5.2765778413288444e-09
without O 0 2.57591881158703e-09
a O 0 2.8725872791568463e-09
detectable O 0 4.2198678329441464e-08
mutation O 0 2.153583089636868e-09
in O 0 1.1702508961874969e-09
peripheral O 0 2.357248195039574e-05
blood O 0 3.671663307613926e-06
, O 0 5.874066122402155e-09
mosaicism O 0 3.091815597144887e-05
was O 0 2.6306420863875246e-07
suggested O 0 1.4334440301411178e-09
because O 0 9.249609966843764e-10
1 O 0 1.680341377152672e-08
of O 0 4.3673753502559975e-09
the O 0 5.228263333378891e-08
patients O 0 2.640169896039879e-07
showed O 0 2.0575703274516854e-06
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 4.666062523028813e-06
the O 0 6.802850407439109e-07
other O 0 2.2756565520865024e-09
later O 0 2.8584878464243957e-08
developed O 0 7.111148647709342e-08
bilateral B-Disease 0 6.836442935309606e-06
retinoblastoma I-Disease 1 0.9999666213989258
. O 0 8.93937158252811e-06

In O 0 7.055007813505654e-07
conclusion O 0 5.257749648990284e-07
, O 0 1.2012087324819731e-08
our O 0 7.356973252825583e-09
results O 0 8.507466398022245e-10
emphasize O 0 2.8090856307727563e-09
that O 0 1.2189677045526537e-10
the O 0 3.0496056790951798e-09
manifestation O 0 3.8504137478412304e-07
and O 0 7.343164298845295e-09
transmissibility O 0 6.877259693283122e-06
of O 0 4.1158460817314335e-07
retinoblastoma B-Disease 0 1.782615618139971e-05
depend O 0 2.3331060106102086e-07
on O 0 3.5852855262419325e-07
the O 0 8.988404687215734e-09
nature O 0 2.373590879400922e-09
of O 0 6.666747154326913e-09
the O 0 6.385110218332102e-09
first O 0 2.0417811885664605e-09
mutation O 0 2.7962651638624436e-10
, O 0 6.937921764871291e-11
its O 0 3.2834132634995683e-10
time O 0 2.7416382497591485e-09
in O 0 6.442161804010027e-10
development O 0 7.368754939562905e-09
, O 0 2.3995083697769815e-10
and O 0 6.668003371679276e-10
the O 0 9.729633099198054e-09
number O 0 1.6718040840579818e-10
and O 0 3.406572524067286e-10
types O 0 1.8999830597721257e-09
of O 0 1.1145552036850859e-08
cells O 0 3.9900944770465685e-09
that O 0 2.0564482061669054e-10
are O 0 5.874317698939535e-11
affected O 0 1.1756021711661901e-09
. O 0 6.980217737151406e-09
. O 0 1.6775494771081867e-07

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999866485595703
the I-Disease 0 0.01699005626142025
fifth I-Disease 0 4.696268661064096e-05
component I-Disease 0 1.0340776270822971e-06
of I-Disease 0 2.1362505719935143e-07
complement I-Disease 0 4.181745225650957e-07
in O 0 1.5509959894188796e-06
man O 0 0.0002220696915173903
. O 0 6.613458026549779e-06

I O 0 0.03894426301121712
. O 0 2.6192437871941365e-05

Clinical O 0 3.664094037958421e-05
, O 0 1.345975704225566e-07
immunochemical O 0 7.671364437555894e-05
, O 0 1.8797189582642204e-08
and O 0 1.6478342246273314e-08
family O 0 1.5017536725281388e-07
studies O 0 8.999950118493416e-09
. O 0 1.0182073850728557e-07

The O 0 3.1635859158996027e-06
first O 0 2.6477141545910854e-07
recognized O 0 5.8786081780226596e-08
human O 0 2.773595326743816e-07
kindred O 0 0.05280756950378418
with O 0 7.256626304297242e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 0.9999991655349731
fifth I-Disease 0 0.011017732322216034
component I-Disease 0 5.997737389407121e-06
of I-Disease 0 1.0211874723609071e-05
complement I-Disease 0 3.218096935597714e-06
( O 0 1.0657394113877672e-06
C5 O 1 0.9999524354934692
) O 0 3.6574334671968245e-09
is O 0 2.90672574898565e-09
described O 0 1.1231343677309269e-07
. O 0 4.567135931665689e-07

The O 0 6.233470048755407e-05
proband O 0 0.00023207861522678286
, O 0 1.0148705342771791e-07
a O 0 6.926111240090904e-08
20 O 0 3.3128564780327e-08
- O 0 2.096582107924405e-08
year O 0 2.1569753982930706e-08
- O 0 1.1069525953644188e-06
old O 0 3.2296788958774414e-06
black O 0 2.790051034651242e-08
female O 0 4.98584173946881e-10
with O 0 1.3059773262824592e-09
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 1.0
age O 1 0.9809755086898804
11 O 0 4.984621000403422e-07
, O 0 6.717904565967103e-10
lacked O 0 1.874892774367254e-07
serum O 0 3.113809725618921e-07
hemolytic O 0 0.00016070096171461046
complement O 0 2.2811248001630702e-08
activity O 0 5.15406117784778e-09
, O 0 5.2106742531865535e-11
even O 0 2.3749027744379703e-10
during O 0 2.2144828193404464e-08
remission O 0 2.20830202124489e-07
. O 0 5.06698150104512e-08

C5 O 1 0.9998561143875122
was O 0 7.652989006601274e-05
undetectable O 0 4.9505856623e-06
in O 0 6.800208396384733e-09
her O 0 6.700245358537416e-10
serum O 0 5.965056004697544e-09
by O 0 1.5633715155782824e-10
both O 0 1.5007586284809804e-09
immunodiffusion O 0 2.5602664663892938e-06
and O 0 7.210208252672601e-08
hemolytic O 1 0.9999998807907104
assays O 0 0.0006758544477634132
. O 0 3.005530743394047e-05

Other O 0 2.8253953843204727e-08
complement O 0 2.0220902285927878e-08
components O 0 1.0378304438063424e-07
were O 0 1.865474219542307e-09
normal O 0 2.1917778703084423e-09
during O 0 1.146199224422162e-08
remission O 0 3.1295339653070187e-08
of O 0 1.047235453910389e-08
lupus O 0 1.571476605022326e-05
, O 0 3.021893846266721e-09
but O 0 5.091411292568182e-09
C1 O 0 9.740673476699158e-07
, O 0 1.1706980274084344e-08
C4 O 0 4.358101250545587e-06
, O 0 2.2949226963220326e-09
C2 O 0 1.3654440067512041e-07
, O 0 2.0333283945461744e-09
and O 0 3.665641301608957e-08
C3 O 0 0.0018368687015026808
levels O 0 8.303995855385438e-07
fell O 0 5.674360727425665e-05
during O 0 1.0986943834723206e-06
exacerbations O 0 0.003985528368502855
. O 0 1.0720800673880149e-06

A O 0 0.00010831364488694817
younger O 0 9.451458026887849e-06
half O 0 1.5354603419837076e-06
- O 0 2.518266046536155e-05
sister O 0 0.0003434040700085461
, O 0 7.373873511795637e-09
who O 0 9.453551719218467e-09
had O 0 2.505564289378981e-08
no O 0 1.4810643378382338e-08
underlying O 0 0.01196564082056284
disease O 1 0.9653970003128052
, O 0 2.2089892137699962e-09
was O 0 7.583375918329693e-07
also O 0 3.098226786235614e-09
found O 0 3.2065960997584853e-09
to O 0 9.965114955434728e-09
lack O 0 0.00010687828034861013
immunochemically O 0 0.09460665285587311
detectable O 0 0.004674657713621855
C5 O 1 0.9991752505302429
. O 0 3.9846286199463066e-06

By O 0 6.30802276191389e-07
hemolytic O 1 0.9999797344207764
assay O 0 0.0017689545638859272
, O 0 2.0072717177299637e-07
she O 0 5.430437433062707e-09
exhibited O 0 1.4478210630386457e-08
1 O 0 1.2464920473576058e-07
- O 0 6.722191159269642e-08
2 O 0 2.0660417021645117e-07
% O 0 1.422997053524e-09
of O 0 8.883703550566224e-09
the O 0 3.434761453036117e-08
normal O 0 1.6317869722115574e-07
serum O 0 1.442401526219328e-06
C5 O 0 3.427574847592041e-05
level O 0 5.153346194219921e-08
and O 0 5.649192780232681e-10
normal O 0 2.2235391305969188e-09
concentrations O 0 2.3269932647451697e-09
of O 0 1.0250930104760414e-09
other O 0 7.589067568813945e-11
complement O 0 2.2149124756509764e-09
components O 0 6.523690103676927e-07
. O 0 3.6611072573577985e-07

C5 O 1 0.9848461151123047
levels O 0 9.583669680068851e-07
of O 0 4.24385262931537e-07
other O 0 8.770765447252415e-09
family O 0 1.6005328618007297e-08
members O 0 5.8917662415503e-11
were O 0 3.805797621492246e-10
either O 0 1.2967833473709334e-09
normal O 0 2.0483625462475175e-08
or O 0 3.371783741101808e-09
approximately O 0 1.7017755260528844e-10
half O 0 4.658677887903195e-09
- O 0 1.5119329788149116e-08
normal O 0 7.674228363896418e-09
, O 0 9.63661372921365e-11
consistent O 0 2.1147141815447412e-09
with O 0 9.248427579322538e-10
autosomal O 0 1.2046852759795001e-07
codominant O 0 4.639884991775034e-07
inheritance O 0 3.5623408223273145e-08
of O 0 1.7377663752426997e-08
the O 0 2.2981126335253066e-08
gene O 0 1.378431022658333e-07
determining O 0 4.19524894823553e-06
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 8.79562139743939e-06

Normal O 0 3.9135655242716894e-05
hemolytic O 1 0.9994828701019287
titers O 0 0.0011922833509743214
were O 0 1.2235692565809586e-06
restored O 0 1.3975055480841547e-05
to O 0 1.4964603778366836e-08
both O 0 1.9936514661367255e-08
homozygous O 0 1.1311115486023482e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 4.066097972099669e-06
C5D B-Disease 1 1.0
) O 0 2.0319530946721898e-08
sera O 0 6.230816751440216e-08
by O 0 6.213918962716392e-11
addition O 0 7.618134456599535e-10
of O 0 2.5785155344237864e-08
highly O 0 1.1467518135077626e-07
purified O 0 4.6857047664161655e-07
human O 0 3.8868279261805583e-07
C5 O 0 0.0027465899474918842
. O 0 8.951775498644565e-07

In O 0 5.800071676276275e-07
specific O 0 5.015176043343672e-07
C5 O 0 0.0008172496454790235
titrations O 0 6.019788088451605e-06
, O 0 7.42969463729537e-09
however O 0 7.598735862757167e-09
, O 0 6.227793281077254e-10
it O 0 3.0897098768356557e-10
was O 0 2.1541387340562324e-08
noted O 0 5.883549203389293e-10
that O 0 1.72520088492778e-11
when O 0 3.5029501521677275e-10
limited O 0 3.898651124156771e-10
amounts O 0 9.365213049505883e-10
of O 0 3.8949313108105343e-08
C5 O 0 1.9057848476222716e-05
were O 0 2.56358312356042e-08
assayed O 0 7.565102322359962e-08
in O 0 1.188788512074268e-09
the O 0 3.4285938532718774e-09
presence O 0 9.222481112125536e-10
of O 0 1.2948019545433453e-08
low O 0 4.628072645118664e-07
dilutions O 0 1.9117611373076215e-05
of O 0 1.1332516578477225e-06
either O 0 1.8212646182291792e-06
C5D B-Disease 1 1.0
serum O 0 9.284646694140974e-06
, O 0 3.638105594561125e-09
curving O 0 2.2429082591202132e-08
rather O 0 1.5654609830662025e-09
than O 0 5.931104912759722e-11
linear O 0 1.3695143907810348e-09
dose O 0 6.87958205958239e-08
- O 0 1.4491416067130558e-08
response O 0 2.8942945817789223e-09
plots O 0 1.4579635276845693e-08
were O 0 4.934800346134693e-10
consistently O 0 1.6339521402564117e-10
obtained O 0 1.7998003087882353e-10
, O 0 3.5837825762552455e-11
suggesting O 0 1.2392789572324148e-10
some O 0 6.630990895262201e-11
inhibitory O 0 2.8932641171763862e-08
effect O 0 5.5273734034244626e-08
. O 0 1.3841638235589926e-07

Further O 0 1.3246283003809367e-07
studies O 0 8.014315433513275e-09
suggested O 0 6.9524737078552334e-09
that O 0 2.861179349000764e-10
low O 0 1.2448883524029952e-07
dilutions O 0 7.228231697808951e-05
of O 0 2.1448935513035394e-05
C5D B-Disease 1 1.0
serum O 0 4.476857611734886e-06
contain O 0 2.1008334627481418e-08
a O 0 1.2306589525223899e-08
factor O 0 2.0743933237810097e-09
( O 0 5.674903602592707e-11
or O 0 2.383911401615535e-10
factors O 0 6.202980906699906e-10
) O 0 1.484603828760811e-10
interfering O 0 3.937070225390471e-09
at O 0 2.951858091293502e-09
some O 0 1.0254874727166907e-10
step O 0 2.8953726527447543e-08
in O 0 2.294624934506828e-09
the O 0 2.253302078258912e-08
hemolytic O 0 0.006680333986878395
assay O 0 3.805169035331346e-05
of O 0 0.11804591864347458
C5 O 1 0.9999719858169556
, O 0 2.7883311215504136e-09
rather O 0 1.1693672696821977e-09
than O 0 3.791126301777581e-10
a O 0 7.522121592273834e-09
true O 0 1.6574774974742468e-07
C5 O 0 5.321800199453719e-05
inhibitor O 0 1.824014503881699e-07
or O 0 3.113257207587594e-08
inactivator O 0 2.387960876149009e-06
. O 0 2.540938055517472e-07

Of O 0 9.64172159001464e-06
clinical O 0 1.4211733287083916e-05
interest O 0 1.368644717558709e-07
are O 0 9.77281477965164e-10
( O 0 2.8118180006586613e-10
a O 0 2.073115901168876e-09
) O 0 4.828968128145483e-11
the O 0 3.2007524408683707e-10
documentation O 0 3.1271053302361906e-08
of O 0 2.589963798982353e-07
membranous O 1 1.0
glomerulonephritis B-Disease 1 1.0
, O 0 2.729217385422089e-06
vasculitis B-Disease 1 1.0
, O 0 5.266556257765842e-08
and O 0 3.8777152440161444e-06
arthritis B-Disease 1 1.0
in O 0 1.9787817109317984e-06
an O 0 8.090524694637224e-09
individual O 0 1.5735376335257456e-09
lacking O 0 6.044463953003287e-05
C5 O 0 0.401479572057724
( O 0 1.1613786599085074e-09
and O 0 1.0716767473439859e-09
its O 0 9.90114989996016e-10
biologic O 0 1.5303497491458984e-07
functions O 0 2.3136488558339607e-10
) O 0 2.070892762828791e-11
, O 0 1.467642847530204e-11
and O 0 8.665020090337094e-11
( O 0 1.206769545403219e-10
b O 0 9.527043154378134e-09
) O 0 2.655137221196924e-10
a O 0 3.024511974203392e-09
remarkable O 0 8.419653418911821e-09
propensity O 0 1.8426523240577808e-07
to O 0 9.569621539640139e-09
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 8.659956307610628e-09
the O 0 2.7609349473323164e-08
proband O 0 9.912341738527175e-07
, O 0 3.495188305446817e-10
even O 0 8.46786807340294e-10
during O 0 1.140305094793348e-08
periods O 0 6.092717086403354e-08
of O 0 2.131114129610978e-08
low O 0 7.653342493085802e-08
- O 0 2.6365973848641033e-09
dose O 0 8.595121059329358e-09
or O 0 9.416942781115267e-10
alternate O 0 1.2746888877757101e-08
- O 0 9.069987783050237e-08
day O 0 1.1691760448684363e-08
corticosteroid O 0 5.783832875749795e-06
therapy O 0 5.2032910389243625e-06
. O 0 3.1366488428830053e-07

Other O 0 1.8660877287857147e-07
observations O 0 9.889814123198448e-08
indicate O 0 9.193962036135872e-09
that O 0 1.4569674355868756e-09
the O 0 2.5464493091931217e-07
C5D B-Disease 1 1.0
state O 0 2.694463674401959e-08
is O 0 6.669376717560738e-10
compatible O 0 4.223169014494488e-08
with O 0 2.4958460298485363e-10
normal O 0 1.0371017822308204e-08
coagulation O 0 3.5394961628298915e-08
function O 0 7.572833471414242e-10
and O 0 2.2642555885798998e-10
the O 0 4.3898390478247507e-10
capacity O 0 2.4474364201942933e-10
to O 0 1.6786618761699401e-09
mount O 0 4.925927896692883e-06
a O 0 3.559034098543634e-07
neutrophilic O 0 0.00039803850813768804
leukocytosis O 0 0.00010793792171170935
during O 0 2.192432702941005e-06
pyogenic B-Disease 0 7.054960587993264e-05
infection I-Disease 0 1.1905087831109995e-06
. O 0 1.0216268719887012e-08
. O 0 3.209632382095151e-08

Susceptibility O 0 0.00016482811770401895
to O 0 1.0708440640883055e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 1 0.9933250546455383
twins O 0 0.00041302916361019015
: O 0 4.081381899112557e-10
the O 0 1.078048650349217e-09
role O 0 5.2309534481764786e-09
of O 0 1.3778416629861567e-08
genes O 0 3.5785949759059577e-09
, O 0 1.3284552347059275e-09
HLA O 0 8.54695315410936e-07
, O 0 2.8108113614422336e-09
and O 0 1.0098979430495092e-08
the O 0 3.3027092172233097e-07
environment O 0 1.0353495554227266e-06
. O 0 3.1174940318123845e-07

OBJECTIVE O 0 3.45597873092629e-05
To O 0 6.671749019915296e-08
determine O 0 2.4252265973245812e-08
the O 0 5.322336349422585e-09
relative O 0 2.6337689362776473e-08
effects O 0 5.2704347552889885e-08
of O 0 1.5285069210335678e-08
genetic O 0 2.2142384636936185e-07
and O 0 4.199533221171947e-10
environmental O 0 8.951667740397795e-10
factors O 0 8.394662048827328e-11
in O 0 7.765910831070144e-11
susceptibility O 0 4.062467269250192e-07
to O 0 2.0434883936104598e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.9973183274269104
AS B-Disease 1 1.0
) O 0 6.403221508577417e-09
. O 0 3.981764606919569e-08

METHODS O 0 2.511195998522453e-05
Twins O 0 0.0007863183855079114
with O 0 1.692428952537739e-08
AS B-Disease 1 1.0
were O 0 4.316057733433354e-09
identified O 0 5.752883169840572e-10
from O 0 3.040160900802391e-10
the O 0 4.19161283460312e-09
Royal O 0 1.1207413308511605e-06
National O 0 1.8999953965703753e-07
Hospital O 0 8.815651381155476e-05
for O 0 3.36339667228458e-08
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 4.3714437197195366e-05
. O 0 6.835869862698019e-05

Clinical O 0 2.1748901417595334e-05
and O 0 1.0383174497974323e-07
radiographic O 0 4.888457988272421e-05
examinations O 0 2.340701712455484e-06
were O 0 2.004854771087139e-08
performed O 0 1.4855959795667673e-09
to O 0 3.2096905688838717e-10
establish O 0 1.224027013080331e-08
diagnoses O 0 0.007358946371823549
, O 0 1.1488388018676687e-08
and O 0 3.4168316176419467e-08
disease O 0 0.00029631200595758855
severity O 0 0.07093571871519089
was O 0 8.905055892682867e-07
assessed O 0 1.4549021543075469e-08
using O 0 1.2308954966400165e-09
a O 0 2.8241546878859936e-09
combination O 0 9.673121859066214e-09
of O 0 8.368232329303282e-08
validated O 0 1.310170034685143e-07
scoring O 0 2.2922645825929067e-07
systems O 0 2.2321326468954794e-05
. O 0 8.090179903774697e-07

HLA O 0 7.967376586748287e-05
typing O 0 2.36444088841381e-06
for O 0 6.58121734886663e-08
HLA O 0 3.0672541129206365e-07
- O 0 2.175905393642097e-07
B27 O 0 8.266471809292852e-07
, O 0 3.3222200546134673e-09
HLA O 0 9.072461182313418e-08
- O 0 8.480257207565955e-08
B60 O 0 3.302661752968561e-07
, O 0 1.7947962005493423e-09
and O 0 6.261467788704067e-09
HLA O 0 1.4483770200968138e-06
- O 0 3.324242243252229e-06
DR1 O 0 0.00041873479494825006
was O 0 2.3353074141141406e-07
performed O 0 2.3751938194038758e-09
by O 0 2.250233194223128e-10
polymerase O 0 5.67130911122149e-08
chain O 0 1.4557321570407566e-08
reaction O 0 5.741592201680135e-10
with O 0 1.1485397355404103e-10
sequence O 0 2.0367588171588125e-10
- O 0 4.109448059619325e-10
specific O 0 4.950220094945834e-11
primers O 0 1.2304782082139809e-08
, O 0 2.34611108318461e-10
and O 0 9.637023401509737e-10
zygosity O 0 5.027118845646328e-07
was O 0 8.112130700510534e-08
assessed O 0 3.855388541751381e-08
using O 0 6.093458626565962e-09
microsatellite O 0 1.7243897900698357e-06
markers O 0 2.3487152134293865e-07
. O 0 3.255805722801597e-07

Genetic O 0 2.0480481907725334e-05
and O 0 3.9412949348616166e-08
environmental O 0 2.8969802556844115e-08
variance O 0 6.539247365822121e-09
components O 0 4.596315150706687e-08
were O 0 5.670138136792957e-09
assessed O 0 4.219320359766243e-08
with O 0 9.224855879175209e-10
the O 0 6.723948331455176e-08
program O 0 1.3746417337756611e-08
Mx O 0 1.6451875239908986e-07
, O 0 2.8239955512932013e-11
using O 0 4.5218655209122716e-11
data O 0 1.0405126760204553e-10
from O 0 6.126923274285545e-11
this O 0 5.272357550545337e-11
and O 0 9.685704321915622e-11
previous O 0 5.667799563013887e-10
studies O 0 4.1140806039674516e-11
of O 0 1.4531820191621136e-09
twins O 0 2.463069108671334e-07
with O 0 8.42080982721427e-09
AS B-Disease 1 1.0
. O 0 5.779234470537631e-06

RESULTS O 0 2.140926426363876e-06
Six O 0 9.9565102118504e-07
of O 0 8.246919946941489e-07
8 O 0 1.6041582284742617e-06
monozygotic O 0 2.265380862809252e-05
( O 0 6.791682238826979e-08
MZ O 0 0.00029347772942855954
) O 0 1.2482782807410331e-08
twin O 0 1.102913643080683e-06
pairs O 0 1.857450193654131e-09
were O 0 1.152587536523697e-08
disease O 0 6.134790737633011e-07
concordant O 0 2.262334191982518e-06
, O 0 9.92357196416549e-10
compared O 0 2.329373360865361e-09
with O 0 1.2631581336464137e-09
4 O 0 2.8862567091891833e-07
of O 0 1.2601560683833668e-07
15 O 0 5.860986007633073e-08
B27 O 0 1.8861446449136565e-07
- O 0 3.205117948823499e-08
positive O 0 6.813213881962099e-10
dizygotic O 0 1.1915266213691211e-06
( O 0 6.141484654165197e-09
DZ O 0 2.7288165256322827e-06
) O 0 1.514781189371206e-09
twin O 0 1.1603678018445862e-07
pairs O 0 4.723481605850566e-10
( O 0 3.9834316400977343e-10
27 O 0 1.3243195873258173e-08
% O 0 3.620182487118484e-10
) O 0 6.93284180064424e-11
and O 0 1.574762653611117e-09
4 O 0 8.778953741739315e-08
of O 0 2.4192488012886315e-07
32 O 0 1.1072619372498593e-06
DZ O 0 6.871594814583659e-05
twin O 0 3.4706602036749246e-06
pairs O 0 1.985158482042948e-09
overall O 0 4.339817394338752e-08
( O 0 1.0226245406030898e-09
12 O 0 1.244733383032326e-08
. O 0 1.992707554521189e-09
5 O 0 3.181910557259471e-08
% O 0 1.556077711128978e-09
) O 0 1.2507062052691253e-09
. O 0 7.265718693361123e-08

Nonsignificant O 0 0.00017923804989550263
increases O 0 1.721105888918828e-07
in O 0 4.6758681371272814e-09
similarity O 0 1.765037893619592e-08
with O 0 2.8014168762524605e-10
regard O 0 2.1040614583967e-08
to O 0 5.689920534734938e-09
age O 0 5.607417818964677e-08
at O 0 2.0114159227091477e-08
disease O 0 3.4241165280946007e-07
onset O 0 0.07565618306398392
and O 0 8.597531575560424e-09
all O 0 4.5239895163362576e-10
of O 0 1.1336886096557919e-08
the O 0 4.9896620168965455e-08
disease O 0 5.442197448246588e-07
severity O 0 2.4735913939366583e-07
scores O 0 1.4507892664994415e-09
assessed O 0 2.567007051368364e-09
were O 0 5.075758702233202e-10
noted O 0 5.547837189645577e-10
in O 0 5.653547630046774e-10
disease O 0 1.7430816967589635e-07
- O 0 2.425914544801344e-07
concordant O 0 2.4952661988209002e-05
MZ O 0 0.03694475442171097
twins O 0 4.465341135073686e-06
compared O 0 1.6852649054044377e-08
with O 0 6.443123812260865e-09
concordant O 0 0.000827595591545105
DZ O 1 0.9999954700469971
twins O 0 0.11669857800006866
. O 0 5.104461251903558e-06

HLA O 0 0.0003292374312877655
- O 0 2.2373154934030026e-05
B27 O 0 4.569267275655875e-06
and O 0 1.6251517465093457e-08
B60 O 0 2.2719351022715273e-07
were O 0 2.578588009782834e-09
associated O 0 1.1500621788229637e-08
with O 0 7.361390941262869e-10
the O 0 6.090916571110938e-08
disease O 0 5.6915355344244745e-06
in O 0 3.3659426357246502e-09
probands O 0 1.3941243196313735e-05
, O 0 1.0620782031622866e-09
and O 0 1.5792023244642905e-09
the O 0 2.2705027191705085e-08
rate O 0 1.677382499565283e-08
of O 0 1.0540004424797189e-08
disease O 0 2.4918631424952764e-07
concordance O 0 1.3527085229725344e-07
was O 0 9.128962830118326e-08
significantly O 0 7.54748707976205e-09
increased O 0 6.029271748531073e-09
among O 0 4.523768026842845e-09
DZ O 0 1.0874894542212132e-05
twin O 0 6.075740088817838e-07
pairs O 0 2.7872554264618543e-10
in O 0 4.840681744333608e-10
which O 0 4.279715748456425e-10
the O 0 1.3644307017557367e-08
co O 0 6.647753991728678e-08
- O 0 1.6138575631430285e-07
twin O 0 2.343632331758272e-06
was O 0 9.827049041177816e-08
positive O 0 1.677089717100344e-10
for O 0 5.146671422373572e-10
both O 0 2.354104244872701e-09
B27 O 0 2.005984924835502e-06
and O 0 5.432190164356143e-07
DR1 O 0 0.00528722396120429
. O 0 8.639162274448609e-07

Additive O 0 8.053091733017936e-06
genetic O 0 6.825094374107721e-07
effects O 0 9.180472915204518e-08
were O 0 3.0545888041189073e-09
estimated O 0 2.2185729642298924e-10
to O 0 5.671952352237497e-10
contribute O 0 1.2559030482250932e-09
97 O 0 1.2814297178920242e-07
% O 0 7.423882619761457e-10
of O 0 1.4582407503738182e-09
the O 0 1.4782329804674532e-09
population O 0 9.08721708992033e-12
variance O 0 6.1782121640874266e-09
. O 0 6.045844713753468e-08

CONCLUSION O 0 9.31237627810333e-06
Susceptibility O 0 0.00012240407522767782
to O 0 3.384106094017625e-06
AS B-Disease 1 1.0
is O 0 2.4912681695354877e-08
largely O 0 7.574903371221353e-09
genetically O 0 3.792719471817918e-09
determined O 0 7.060720008666976e-09
, O 0 5.057397833851951e-10
and O 0 1.2464147491897393e-09
the O 0 8.140336404949267e-09
environmental O 0 2.071496219002711e-08
trigger O 0 4.150150001436259e-09
for O 0 3.244670920832249e-10
the O 0 2.5445260121159663e-08
disease O 0 6.988005225139204e-06
is O 0 1.0232956704214757e-09
probably O 0 2.73507936299211e-08
ubiquitous O 0 3.4137903526243463e-07
. O 0 2.3690650152730086e-07

HLA O 0 0.0001152175827883184
- O 0 4.287570391170448e-06
B27 O 0 9.61272235144861e-07
accounts O 0 2.6803970154531953e-09
for O 0 9.89661796957364e-10
a O 0 4.666352637627824e-09
minority O 0 1.368921531685885e-09
of O 0 9.006132728472949e-09
the O 0 1.2902214407972679e-08
overall O 0 1.0634266800479963e-08
genetic O 0 3.1947482881378164e-08
susceptibility O 0 3.763364588849072e-07
to O 0 1.3613846761018067e-07
AS B-Disease 1 1.0
. O 0 0.00010705975000746548

Cell O 0 6.269291770877317e-05
cycle O 0 8.765147754274949e-07
- O 0 5.377865477385058e-07
dependent O 0 1.1411324152277302e-07
colocalization O 0 3.79151015295065e-06
of O 0 4.155606632139097e-07
BARD1 O 0 0.010281864553689957
and O 0 6.39808419578003e-08
BRCA1 O 0 5.81730308368833e-09
proteins O 0 2.115620872933377e-10
in O 0 3.385792479715377e-10
discrete O 0 4.73196273276244e-08
nuclear O 0 1.7293120890826685e-06
domains O 0 3.2769133895271807e-07
. O 0 5.899747748117079e-07

Germ O 0 0.005751481279730797
- O 0 0.00013167934957891703
line O 0 2.715685241128085e-06
mutations O 0 2.1913065140211074e-08
of O 0 3.428838510899368e-07
the O 0 5.974845294076658e-07
BRCA1 O 0 8.71005383373813e-08
gene O 0 7.601852480831894e-09
predispose O 0 2.941871635186999e-08
women O 0 6.504485144942507e-11
to O 0 3.3764091522670014e-10
early O 0 1.2741154932882637e-05
- O 0 0.05516498535871506
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 3.6039371487106564e-10
compromising O 0 1.9093494785238363e-08
the O 0 1.8901019416261988e-08
genes O 0 2.8173487987004364e-09
presumptive O 0 3.320927817185293e-06
function O 0 8.896383074663561e-10
as O 0 6.595360368955028e-10
a O 0 7.944973567930447e-09
tumor B-Disease 0 2.9718210043938598e-06
suppressor O 0 4.477554830373265e-05
. O 0 9.234420303982915e-07

Although O 0 1.937496563186869e-06
the O 0 4.633203900539229e-07
biochemical O 0 7.562190148746595e-06
properties O 0 1.8775494936562609e-06
of O 0 6.644216909990064e-07
BRCA1 O 0 2.4944872833998488e-08
polypeptides O 0 1.3843269641711231e-08
are O 0 9.318772836719447e-11
not O 0 2.798831721939621e-10
understood O 0 1.4360828082260468e-08
, O 0 3.9364825288323857e-10
their O 0 4.237462603029485e-10
expression O 0 5.834334682042197e-10
pattern O 0 5.747555764656909e-09
and O 0 1.8593785400256024e-09
subcellular O 0 2.586061782494653e-07
localization O 0 6.107774197516846e-07
suggest O 0 1.843649344301923e-09
a O 0 6.390995732630245e-09
role O 0 1.0881199941081832e-08
in O 0 6.031549482088394e-09
cell O 0 3.841896614176221e-06
- O 0 9.273462637793273e-07
cycle O 0 1.0148009010890746e-07
regulation O 0 3.0627700198238017e-07
. O 0 1.2340983346348366e-07

When O 0 8.654032171762083e-06
resting O 0 7.045172242214903e-05
cells O 0 1.4426929340061179e-07
are O 0 1.064079491186476e-09
induced O 0 2.8528020834528434e-07
to O 0 4.471592873755981e-09
proliferate O 0 2.7853346296069503e-08
, O 0 2.927523778950558e-09
the O 0 2.9480446528395987e-08
steady O 0 8.863177924922638e-08
- O 0 2.1737642796892942e-08
state O 0 5.620035548048463e-10
levels O 0 3.0570135312046887e-09
of O 0 3.357229161338182e-09
BRCA1 O 0 4.5946010884811983e-10
increase O 0 7.967759785287853e-11
in O 0 6.051204537449451e-10
late O 0 1.465744958295545e-06
G1 O 0 2.9758237474197813e-07
and O 0 3.9318321931602895e-09
reach O 0 1.1202926586406647e-08
a O 0 2.0432888714339015e-09
maximum O 0 7.120660505677279e-09
during O 0 6.105805283596055e-08
S O 0 2.2778956463298528e-06
phase O 0 3.3130920655821683e-06
. O 0 6.606559281863156e-07

Moreover O 0 2.605092277008225e-06
, O 0 6.942697439171752e-08
in O 0 2.5173385154175776e-08
S O 0 1.6490059806528734e-06
phase O 0 1.210067580359464e-06
cells O 0 1.1191890081363454e-07
, O 0 1.2842742425078768e-09
BRCA1 O 0 1.332314703006432e-09
polypeptides O 0 3.7128549124076926e-09
are O 0 2.5599550257382475e-10
hyperphosphorylated O 0 6.092799367252155e-07
and O 0 1.1465665750165499e-08
accumulate O 0 9.470699779967617e-08
into O 0 4.42793712807088e-08
discrete O 0 3.5900688999390695e-07
subnuclear O 0 4.213010015519103e-06
foci O 0 2.063449983324972e-06
termed O 0 1.073618818736577e-06
" O 0 3.848273593121121e-07
BRCA1 O 0 2.3980427954484185e-07
nuclear O 0 3.589224206734798e-06
dots O 0 1.4755456732018501e-06
. O 0 5.858303779859853e-07

" O 0 2.8454045605030842e-05
BRCA1 O 0 4.500800514506409e-06
associates O 0 5.289801947583328e-07
in O 0 1.048834530337217e-08
vivo O 0 5.3487578810518244e-08
with O 0 4.828215049990092e-10
a O 0 1.8178250016376296e-08
structurally O 0 7.68222605529445e-07
related O 0 1.7346938818718627e-07
protein O 0 1.530355461909494e-06
termed O 0 2.1693631424568594e-06
BARD1 O 0 0.003899665316566825
. O 0 8.483328883812646e-07

Here O 0 1.5758860172354616e-05
we O 0 1.7069355351395643e-07
show O 0 5.482034826087556e-09
that O 0 1.9973832310338224e-10
the O 0 8.573688425883574e-09
steady O 0 4.517992735486587e-08
- O 0 2.169390356243639e-08
state O 0 3.1969088487571184e-10
levels O 0 3.873910081608756e-09
of O 0 1.1254842391394959e-08
BARD1 O 0 3.9130798541009426e-05
, O 0 3.0868116396298717e-10
unlike O 0 5.504348643547985e-10
those O 0 4.998610969586537e-10
of O 0 2.212452088201644e-08
BRCA1 O 0 1.077120170833723e-08
, O 0 1.168862784339808e-10
remain O 0 6.814773190200185e-10
relatively O 0 1.1671502653243238e-09
constant O 0 9.222731911506798e-09
during O 0 5.5041439850356255e-08
cell O 0 8.110673661576584e-07
cycle O 0 3.4429671558200425e-08
progression O 0 9.259114364112975e-08
. O 0 8.261689998789734e-08

However O 0 1.7759507500159089e-06
, O 0 7.254931944089549e-08
immunostaining O 0 4.066032033733791e-06
revealed O 0 3.693183714403858e-07
that O 0 8.979340826442694e-09
BARD1 O 0 0.0017435727640986443
resides O 0 3.8881216823938303e-07
within O 0 3.804197490353545e-08
BRCA1 O 0 2.5777042722552324e-08
nuclear O 0 1.4089651756421517e-07
dots O 0 2.8371516691549914e-08
during O 0 8.249439531482494e-08
S O 0 7.498624086110794e-07
phase O 0 8.182960300473496e-07
of O 0 9.271980161429383e-08
the O 0 2.9731847206448947e-08
cell O 0 2.9581608274042992e-08
cycle O 0 1.7610152225344677e-09
, O 0 3.0345746748761115e-11
but O 0 3.79779714620998e-11
not O 0 1.990715925437314e-10
during O 0 3.280536731153916e-08
the O 0 5.613025066963928e-08
G1 O 0 4.3489987433531496e-07
phase O 0 5.029966700931254e-07
. O 0 9.989458504833237e-08

Nevertheless O 0 5.427968790172599e-05
, O 0 4.935897095492692e-07
BARD1 O 0 0.00012698066711891443
polypeptides O 0 7.601086622344155e-07
are O 0 1.2535338322905432e-09
found O 0 4.617533466699797e-09
exclusively O 0 1.616346723132267e-09
in O 0 9.563158043235376e-10
the O 0 1.0742970069088642e-08
nuclear O 0 2.3204310650726256e-07
fractions O 0 1.6296059612841418e-08
of O 0 3.0639267123433456e-08
both O 0 2.128854204030972e-09
G1 O 0 7.842297122806485e-08
- O 0 3.532286640961502e-08
and O 0 5.753566068023019e-09
S O 0 9.198164434565115e-07
- O 0 9.40578530617131e-08
phase O 0 2.5084196408897697e-07
cells O 0 1.346494400422671e-07
. O 0 8.163367226643459e-08

Therefore O 0 3.0459889899248083e-07
, O 0 6.152529152814168e-09
progression O 0 2.1194235699795172e-08
to O 0 1.821457873418808e-09
S O 0 4.0620642494104686e-07
phase O 0 3.2158652629732387e-07
is O 0 4.617742299650729e-10
accompanied O 0 3.022987693501733e-10
by O 0 2.8914391714263132e-11
the O 0 1.8947823310355716e-09
aggregation O 0 5.364458655066073e-09
of O 0 1.3845461666051051e-08
nuclear O 0 1.232596787303919e-06
BARD1 O 0 4.112700480618514e-05
polypeptides O 0 6.17926389168133e-07
into O 0 8.414718308813462e-07
BRCA1 O 0 2.297839216680586e-07
nuclear O 0 4.700094450527104e-06
dots O 0 2.785704282359802e-06
. O 0 2.948706594452233e-07

This O 0 2.7042210604122374e-07
cell O 0 7.947975859678991e-07
cycle O 0 3.1288056590028646e-08
- O 0 2.0784220566838485e-08
dependent O 0 1.4544194293364399e-08
colocalization O 0 1.213211703543493e-06
of O 0 1.2797053727808816e-07
BARD1 O 0 0.009124334901571274
and O 0 2.9804240853081865e-08
BRCA1 O 0 1.5700331035262138e-09
indicates O 0 3.160736672391806e-10
a O 0 3.818886040729552e-10
role O 0 2.040994706575816e-09
for O 0 1.5485631665868027e-09
BARD1 O 0 0.00025060068583115935
in O 0 7.240057442459147e-08
BRCA1 O 0 1.8355561337557447e-07
- O 0 9.769241842150223e-07
mediated O 0 1.8240009012515657e-05
tumor B-Disease 0 0.07426954805850983
suppression O 0 0.0008310920093208551
. O 0 5.487873977472191e-07

Ethnic O 0 7.084357207531866e-07
differences O 0 2.4674873202457093e-06
in O 0 2.0446783821626013e-07
the O 0 5.992987439640274e-07
HFE O 0 0.00031198046053759754
codon O 0 1.2683417480729986e-06
282 O 0 2.3344443889072863e-06
( O 0 7.581092376085508e-08
Cys O 0 0.0005504793953150511
/ O 0 9.72777070273878e-06
Tyr O 0 1.7863185348687693e-05
) O 0 9.849901339009648e-09
polymorphism O 0 4.1641914094725507e-07
. O 0 9.8302358253477e-08

Recent O 0 2.779052579171548e-07
studies O 0 1.745220146176507e-08
have O 0 1.6712118355854955e-09
shown O 0 1.2175097374722554e-08
that O 0 1.6847305062128726e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 7.59664544602856e-05
HH B-Disease 1 0.9999853372573853
) O 0 6.882883707426402e-10
is O 0 6.942634661610825e-11
likely O 0 1.2437740837256683e-09
to O 0 4.3419243200837343e-10
be O 0 6.880967462485899e-10
caused O 0 9.660952926537902e-09
by O 0 3.576109408598427e-10
homozygosity O 0 9.450310045622246e-08
for O 0 1.3322385417069427e-09
a O 0 1.0218685453367016e-08
Cys282Tyr O 0 1.3545829347094696e-07
mutation O 0 1.023678364298064e-09
in O 0 5.621612064743431e-10
the O 0 1.7178221511926495e-08
HFE O 0 2.880086685763672e-05
gene O 0 1.774987907765535e-07
located O 0 1.0533558025827006e-07
4 O 0 3.4879269605880836e-07
. O 0 1.0081700452246878e-07

5 O 0 2.6434365281602368e-05
Mb O 0 3.128954631392844e-05
telomeric O 0 1.64400007633958e-05
to O 0 2.3717778674381407e-07
HLA O 0 1.4668310541310348e-05
- O 0 3.660300990304677e-06
A O 0 5.9331441661925055e-06
. O 0 1.0855142136279028e-06

Population O 0 3.291986905296085e-09
studies O 0 1.153264261866127e-09
of O 0 1.9577988119579004e-09
this O 0 8.277261515088341e-11
polymorphism O 0 8.235349291396687e-09
are O 0 2.217036276785933e-11
facilitated O 0 1.4482014476513427e-09
by O 0 2.0170960735033105e-10
the O 0 1.6350378828633438e-09
fact O 0 2.629173823098796e-10
that O 0 1.544432776112714e-10
the O 0 8.359183567563377e-09
Cys282Tyr O 0 9.157203066934017e-07
mutation O 0 1.098226221074583e-08
creates O 0 1.6363147281595047e-08
a O 0 4.481277571244391e-08
Rsal O 0 4.296628503652755e-06
restriction O 0 8.739975498883723e-08
site O 0 4.163345863616996e-07
. O 0 7.310521965564476e-08

We O 0 3.953220755192888e-07
have O 0 6.375521000023809e-09
studied O 0 3.052225849842216e-08
the O 0 1.4089673427974958e-08
codon O 0 2.3248206915127412e-08
282 O 0 2.097664548728062e-07
( O 0 2.4535429687944088e-08
Cys O 0 0.0003162324137520045
/ O 0 9.157245585811324e-06
Tyr O 0 1.4534064575855155e-05
) O 0 8.782713445398826e-10
polymorphism O 0 5.304357841851015e-09
in O 0 1.9114755611671086e-10
different O 0 7.350191288946206e-11
ethnic O 0 3.9635597581799686e-10
groups O 0 1.8433811421747492e-10
. O 0 2.5332044018000488e-08

In O 0 1.187273568348246e-07
agreement O 0 1.7305266908351769e-07
with O 0 3.745274312905167e-09
previous O 0 1.612855982102701e-07
observations O 0 1.2952297367974097e-07
the O 0 6.434345323214075e-08
Tyr O 0 5.445766873890534e-06
allele O 0 5.346534237560263e-08
appeared O 0 2.9304191073720176e-08
to O 0 1.0919719573010411e-09
be O 0 2.0670984923754077e-09
rare O 0 1.9276528817613325e-08
or O 0 2.5767112887820076e-08
absent O 0 3.8437582361439127e-07
in O 0 5.429349858587784e-09
Asiatic O 0 3.3666825771661024e-08
( O 0 1.1716261294481e-10
Indian O 0 3.0088842528641635e-09
, O 0 3.0332103495567253e-10
Chinese O 0 1.8748664842860308e-09
) O 0 6.114318495953341e-10
populations O 0 5.097922084473794e-09
. O 0 1.0760322766145691e-07

The O 0 8.102278457045031e-07
highest O 0 2.4236365447904973e-07
allele O 0 2.9374127574754993e-09
frequency O 0 3.2003819594450533e-09
( O 0 1.0870878502933223e-10
7 O 0 1.2423940765060593e-09
. O 0 2.721100011982003e-10
5 O 0 2.7841753347246367e-09
% O 0 1.0965840735455146e-10
) O 0 6.197609092595258e-11
was O 0 8.620931524205844e-09
found O 0 3.0485762803067473e-09
in O 0 1.2591081066659626e-08
Swedes O 0 9.774892532732338e-06
. O 0 3.2882628602237673e-06

Saamis O 0 0.0003702955145854503
( O 0 9.657474464574989e-08
2 O 0 2.6536523023423797e-07
% O 0 1.6055158313932338e-09
) O 0 3.624147926206689e-10
and O 0 1.8415020619499956e-09
Mordvinians O 0 2.504416215742822e-06
( O 0 3.2521512149941145e-09
1 O 0 7.681686042815272e-08
. O 0 9.593119632000935e-10
8 O 0 8.260834682971563e-09
% O 0 9.82789752357327e-11
) O 0 1.0620143653383707e-11
had O 0 2.5326415964421756e-10
significantly O 0 5.887781928670677e-10
lower O 0 2.634226170528109e-08
frequencies O 0 8.29206037167296e-09
of O 0 5.686578763430816e-09
the O 0 9.708315040768412e-09
Tyr O 0 3.2079763059300603e-06
allele O 0 1.2002851690340322e-07
. O 0 9.196736527883331e-08

Comparisons O 0 6.172195980980177e-07
with O 0 7.602085183577856e-09
allele O 0 2.9003693668983033e-08
frequencies O 0 1.043853181670329e-08
based O 0 2.994416714585668e-09
on O 0 5.486113785480029e-09
prevalence O 0 6.227416804449604e-09
estimates O 0 4.442485490585568e-09
of O 0 4.883959547896666e-08
HH B-Disease 1 0.9999916553497314
showed O 0 1.7441260524719837e-07
some O 0 2.5092647959468195e-09
disagreements O 0 1.3560796219280746e-07
with O 0 1.721310982638613e-09
the O 0 2.0716898418982055e-08
RFLP O 0 1.6512390743628202e-07
data O 0 5.5868532022884665e-09
, O 0 2.5843277517978436e-10
particularly O 0 1.9261301442696777e-09
in O 0 1.0752152945769922e-08
Finns O 0 3.8050179682613816e-06
. O 0 7.542898856627289e-07

The O 0 1.948884892044589e-05
newly O 0 3.322528209537268e-05
described O 0 3.464096153038554e-06
HFE O 0 0.010004357434809208
marker O 0 7.786880814819597e-06
provides O 0 1.1127283983114467e-08
a O 0 6.884409931018354e-09
new O 0 1.115477599178405e-09
approach O 0 4.1588981147810955e-09
to O 0 7.487405695449922e-10
the O 0 2.86515655645303e-09
screening O 0 1.3491213479710495e-08
of O 0 5.322003815422249e-08
HH B-Disease 1 0.9755116701126099
as O 0 4.377301721092408e-08
well O 0 2.608371518775243e-09
as O 0 1.527971776882353e-10
studies O 0 2.8712150712539852e-11
of O 0 2.899735729311459e-10
the O 0 8.612774937688528e-10
relationship O 0 1.0582867915331917e-09
between O 0 3.6341594178423975e-09
the O 0 4.499297290294635e-08
HFE O 0 0.00011136376269860193
Tyr O 0 8.228786100517027e-06
allele O 0 1.540821159551342e-08
and O 0 1.4547127946684668e-09
different O 0 7.5917672148762e-09
disorders O 0 0.017422374337911606
including O 0 5.993444460727915e-07
cancer B-Disease 1 1.0

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999581575393677
associated O 0 3.3130845622508787e-07
with O 0 2.7998476870294553e-09
a O 0 3.229726175391079e-08
missense O 0 1.0939449879288077e-07
mutation O 0 6.23912699282414e-09
encoding O 0 1.0735804067962817e-07
Gly23 O 0 8.147341759467963e-06
- O 0 2.874452547985129e-06
- O 0 7.1218428274733014e-06
> O 0 6.664398824796081e-06
Val O 0 3.640180011643679e-06
in O 0 1.7858573286844148e-08
neurophysin O 0 1.3252211829239968e-05
II O 1 1.0
. O 0 4.893316145171411e-06

Autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 7.713413197052432e-08
ADNDI B-Disease 0 0.028796887025237083
) O 0 5.217239973376309e-10
is O 0 1.8774024002077283e-10
an O 0 5.966895866293953e-10
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.23468931019306183
by O 0 3.9673302865139703e-08
progressive O 1 0.9980162382125854
degeneration O 1 1.0
of O 0 9.207536095345858e-06
the O 0 1.0659467761797714e-06
magnocellular O 0 1.06749657788896e-05
neurons O 0 7.086371311970652e-08
of O 0 9.331609618357106e-08
the O 0 5.64073559417011e-07
hypothalamus O 0 8.751316613597737e-07
leading O 0 2.062927251245128e-07
to O 0 2.1190669219350866e-09
decreased O 0 2.7020600867899702e-08
ability O 0 1.7332446589080064e-08
to O 0 2.4391438202542304e-08
produce O 0 7.068228313755753e-08
the O 0 4.2910613728963654e-07
hormone O 0 6.217722159362893e-08
arginine O 0 2.409881574294559e-07
vasopressin O 0 4.25532618919533e-07
( O 0 9.876766071670318e-09
AVP O 0 9.392587685397302e-07
) O 0 3.0590550093023694e-09
. O 0 5.3050083437256035e-08

Affected O 0 3.798904799623415e-07
individuals O 0 2.506431728832581e-10
are O 0 3.7693209664624305e-11
not O 0 3.410232651823719e-10
symptomatic O 0 1.869575135060586e-05
at O 0 1.1340215877453375e-08
birth O 0 1.3327424497333595e-08
, O 0 5.269100433746843e-11
but O 0 1.3055782843718333e-10
usually O 0 7.469365570500486e-09
develop O 0 3.419476797716925e-06
diabetes B-Disease 1 1.0
insipidus I-Disease 1 0.9945304989814758
at O 0 1.1051667570427526e-05
1 O 0 7.046151949907653e-06
- O 0 6.997589025559137e-06
6 O 0 2.323130138393026e-05
yr O 0 2.730799860728439e-05
of O 0 6.806971697415065e-08
age O 0 1.1973389746344765e-07
. O 0 1.931904591856437e-07

The O 0 1.1977607528024237e-06
genetic O 0 9.234315143658023e-07
locus O 0 2.529330629386095e-07
of O 0 1.9651744764814794e-07
the O 0 6.004377155477414e-07
disease O 0 0.000432277302024886
is O 0 1.5949865428410703e-08
the O 0 7.602029086228868e-07
AVP O 0 0.00030669564148411155
- O 0 0.00013312442752067
neurophysin O 0 0.09685413539409637
II O 1 1.0
( O 0 1.2776273194958776e-07
NPII O 0 1.2403922482917551e-05
) O 0 1.760591256116939e-10
gene O 0 2.9739982698728795e-10
, O 0 5.6187790531403436e-11
and O 0 3.583948138263793e-10
mutations O 0 8.037243093284019e-10
that O 0 1.4003176396215622e-10
cause O 0 2.8121783657297783e-07
ADNDI B-Disease 0 0.0054330057464540005
have O 0 3.5493239458617154e-09
been O 0 8.717856991857786e-10
found O 0 2.1987271725532054e-10
in O 0 6.00237012871041e-11
both O 0 1.1338820854467357e-10
the O 0 6.007014441422598e-09
signal O 0 1.436909400354125e-07
peptide O 0 4.152670030066474e-08
of O 0 3.8139117464197625e-07
the O 0 2.6340965177951148e-06
prepro O 0 8.979058475233614e-05
- O 0 7.406670192722231e-05
AVP O 0 0.00029586005257442594
- O 0 1.8165106666856445e-05
NPII O 0 0.0001697330008028075
precursor O 0 2.0335910448920913e-06
and O 0 2.1277715589462787e-08
within O 0 2.1469849897925997e-08
NPII O 0 8.569129568058997e-05
itself O 0 1.376152027887656e-07
. O 0 1.3938523579781759e-07

An O 0 1.545210039921585e-07
affected O 0 1.2251018688402837e-07
girl O 0 1.7293587006861344e-07
who O 0 7.041273786256852e-09
presented O 0 4.6254601926420946e-08
at O 0 8.18037193539567e-08
9 O 0 1.546173322708455e-08
months O 0 3.2740090638583297e-09
of O 0 1.5161635502636273e-08
age O 0 1.3920105956799489e-08
and O 0 7.880649910418924e-09
her O 0 7.653379596739285e-10
similarly O 0 9.779285159439155e-10
affected O 0 2.1540964567634546e-09
younger O 0 5.985184969858892e-08
brother O 0 4.54192741017323e-06
and O 0 3.921872604450982e-08
father O 0 4.155775059189182e-06
were O 0 2.4759390981898832e-08
all O 0 6.247793393754364e-10
found O 0 1.1627084850474034e-09
to O 0 8.043070098828764e-10
have O 0 4.261551389550533e-10
a O 0 1.9249450033953508e-08
novel O 0 3.966203010463687e-08
missense O 0 1.0117703652667842e-07
mutation O 0 3.1383133869411495e-09
( O 0 4.428549194024356e-10
G1758 O 0 4.587548119161511e-08
- O 0 1.5187458757282002e-07
- O 0 4.0598104078526376e-07
> O 0 2.1639834812958725e-07
T O 0 5.4690346473762474e-08
) O 0 6.412368552810577e-11
encoding O 0 1.6371380917590272e-09
the O 0 1.4054988284328829e-09
amino O 0 3.2730460008956186e-10
acid O 0 8.024039210852152e-10
substitution O 0 7.278879721184239e-09
Gly23 O 0 3.6074525269214064e-06
- O 0 1.9438800791249378e-06
- O 0 7.482795808755327e-06
> O 0 1.0660988664312754e-05
Val O 0 1.4565769561158959e-05
within O 0 3.6698673966384376e-07
NPII O 0 0.00040421957965008914
. O 0 1.1337618843754171e-06

The O 0 1.461989540985087e-06
mutation O 0 1.943353993283381e-07
was O 0 1.1918613296302283e-07
confirmed O 0 6.720573431096e-09
by O 0 6.267487084876677e-10
restriction O 0 2.2178177516707365e-08
endonuclease O 0 8.615770639153197e-07
analysis O 0 2.7775888256087455e-08
. O 0 1.5854571699946973e-07

A O 0 0.00023329128453042358
T1 O 0 0.0004987083957530558
- O 0 1.7309076838500914e-06
weighted O 0 7.458492490286517e-08
magnetic O 0 7.428563719713566e-08
resonance O 0 1.3405507104380376e-07
imaging O 0 2.3203213004308054e-06
of O 0 1.7843270825323998e-06
the O 0 2.3146671082940884e-05
fathers O 0 0.0001516063930466771
pituitary O 0 0.0002346883266000077
gland O 0 4.149525466345949e-06
demonstrates O 0 5.352431742267072e-08
an O 0 1.2972929397392363e-09
attenuated O 0 1.8730015654000454e-06
posterior O 0 4.225226348353317e-06
pituitary O 0 7.921300857560709e-05
bright O 0 9.161823254544288e-05
spot O 0 0.0005161302979104221
. O 0 2.8695717446680646e-06

This O 0 9.264307720968645e-08
mutation O 0 5.445874151632779e-08
may O 0 5.906771516350773e-09
be O 0 6.426355003696926e-10
valuable O 0 2.51881786539343e-08
for O 0 2.3273473426232982e-10
developing O 0 2.7602859997699625e-09
models O 0 4.557509480918043e-09
of O 0 2.81240630783941e-07
dominantly B-Disease 1 0.9999949932098389
inherited I-Disease 1 1.0
neurodegeneration I-Disease 1 1.0
, O 0 4.210180293284793e-08
as O 0 7.700807769239759e-10
the O 0 1.6279708692223949e-09
early O 0 8.754202696081848e-09
age O 0 5.586062168383421e-10
of O 0 1.718722608679002e-09
onset O 0 0.0019885587971657515
of O 0 2.208708593798292e-07
symptoms O 0 1.761485009410535e-06
suggests O 0 3.3374754071502366e-09
that O 0 4.768887021389112e-11
this O 0 2.1888273138426229e-10
mutation O 0 8.311151766804414e-10
may O 0 3.150162075638008e-10
be O 0 3.214665478257217e-10
particularly O 0 2.154741496340762e-09
deleterious O 0 3.386066893540374e-08
to O 0 4.628414096430333e-09
the O 0 1.257126456266633e-07
magnocellular O 0 1.2523079931270331e-05
neuron O 0 4.932231831844547e-07
. O 0 4.846846479722444e-09
. O 0 2.9109271437732787e-08

Frequent O 0 1.886575887510844e-06
inactivation O 0 0.0003211639414075762
of O 0 2.0824851162615232e-05
PTEN O 1 0.9999973773956299
/ O 0 0.45614466071128845
MMAC1 O 1 0.9992052912712097
in O 0 6.349468435473682e-07
primary O 1 0.9999914169311523
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1730508958862629e-05

Sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.5116648834664375e-05
the O 0 5.022063191972848e-07
most O 0 9.27089349733734e-10
common O 0 6.73192985800597e-08
male B-Disease 0 1.2728667897476953e-08
cancer I-Disease 0 7.766588169033639e-06
in O 0 8.186643363217172e-09
the O 0 3.443766445343499e-06
Western O 0 0.017969246953725815
world O 0 2.0016764779029472e-07
, O 0 3.230190837033575e-10
yet O 0 3.907368595346128e-10
many O 0 5.897669158594354e-11
of O 0 1.8388872646823984e-09
the O 0 6.175313593814735e-09
major O 0 9.737505024531856e-09
genetic O 0 3.961884154080053e-09
events O 0 2.0065119704648637e-11
involved O 0 2.9551788099935195e-11
in O 0 1.468561938722246e-10
the O 0 3.354131417054873e-09
progression O 0 1.889085510242694e-08
of O 0 7.828186099345658e-09
this O 0 4.952754317777419e-10
often O 0 2.5407965509316455e-08
fatal O 0 0.00024068643688224256
cancer B-Disease 0 0.023313548415899277
remain O 0 5.257373345557426e-07
to O 0 4.230424721640702e-08
be O 0 3.6182120766170556e-07
elucidated O 0 0.0042452458292245865
. O 0 1.0059733540401794e-05

Numerous O 0 4.628965143638197e-06
cytogenetic O 0 0.0018017115071415901
and O 0 9.03174679933727e-07
allelotype O 0 1.552680078020785e-05
studies O 0 5.503007383111935e-09
have O 0 6.782083783463122e-10
reported O 0 1.952071393418464e-09
frequent O 0 2.9233724330168798e-09
loss O 0 6.673187158412475e-08
of O 0 8.080926363618346e-07
heterozygosity O 1 0.9994955062866211
on O 0 0.0009417268447577953
chromosomal O 0 0.0002707931853365153
arm O 0 0.00019954240997321904
10q O 0 8.717633136257064e-06
in O 0 3.020181793544907e-07
sporadic B-Disease 1 1.0
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00016449038230348378

Deletion O 0 1.1685979188769124e-05
mapping O 0 2.579072031494434e-07
studies O 0 7.515525091150721e-09
have O 0 1.6242986955461447e-09
unambiguously O 0 2.6888933746249677e-08
identified O 0 1.834347962414995e-08
a O 0 2.214854433191249e-08
region O 0 4.2350347229103136e-08
of O 0 4.1367098901901045e-07
chromosome O 0 4.2097386199202447e-07
10q23 O 0 5.406519107964414e-07
to O 0 4.418393650951202e-09
be O 0 3.32872773789461e-09
the O 0 1.401612514939643e-08
minimal O 0 1.0864939667953877e-06
area O 0 1.8226147346922517e-07
of O 0 7.155025372185264e-08
loss O 0 6.411087838387175e-07
. O 0 6.703791655127134e-07

A O 0 2.060623955912888e-05
new O 0 9.228785984305432e-07
tumor B-Disease 0 1.0473131624166854e-06
suppressor O 0 7.956386411933636e-07
gene O 0 3.199852471880149e-08
, O 0 7.384626243833736e-09
PTEN O 0 0.000511242775246501
/ O 0 5.564095044974238e-05
MMAC1 O 1 0.986361026763916
, O 0 4.6595332037213666e-08
was O 0 3.3008147966029355e-06
isolated O 0 6.579409728146857e-07
recently O 0 9.944176326825982e-08
at O 0 9.497070685426934e-09
this O 0 1.7232876237116557e-10
region O 0 3.7591871837605595e-09
of O 0 6.823399623101523e-09
chromosome O 0 8.21514234417009e-09
10q23 O 0 2.599448123419279e-08
and O 0 5.009663794908192e-10
found O 0 1.405149607780487e-10
to O 0 5.5279763405691185e-11
be O 0 1.0565959912556266e-10
inactivated O 0 5.349796161624454e-09
by O 0 5.6933013858895265e-11
mutation O 0 4.094676264720931e-10
in O 0 3.2637963442994078e-09
three O 0 1.5410702189910808e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.06339703500270844
lines O 0 1.253290292879683e-06
. O 0 4.3083412037958624e-07

We O 0 2.491124632797437e-06
screened O 0 2.7486208637128584e-05
80 O 0 1.0770876542665064e-05
prostate B-Disease 1 1.0
tumors I-Disease 1 1.0
by O 0 1.1425627555183837e-08
microsatellite O 0 6.662916689492704e-07
analysis O 0 5.388115731363996e-09
and O 0 3.536228421197052e-09
found O 0 2.2094652774029555e-09
chromosome O 0 6.5048637587494795e-09
10q23 O 0 4.8822364817624475e-08
to O 0 2.8124522710726296e-09
be O 0 4.803847986067922e-09
deleted O 0 2.9163119918962366e-08
in O 0 2.6980313538871314e-09
23 O 0 1.624324141857869e-08
cases O 0 3.5784790686221868e-09
. O 0 1.3612873317470076e-07

We O 0 2.408480099802546e-07
then O 0 4.0794326139348414e-08
proceeded O 0 2.0463787109292753e-08
with O 0 1.5209810841354532e-11
sequence O 0 5.5885528843502286e-11
analysis O 0 1.0222223068012681e-10
of O 0 1.82739789966746e-09
the O 0 2.274043708894169e-08
entire O 0 8.038221608330787e-07
PTEN O 0 0.012972315773367882
/ O 0 2.8484590075095184e-05
MMAC1 O 0 0.0001139794840128161
coding O 0 8.980942993730423e-07
region O 0 1.933338111825833e-08
and O 0 1.2523437842304475e-09
tested O 0 1.8896610942675807e-09
for O 0 6.601049151733207e-10
homozygous O 0 3.98138277901694e-09
deletion O 0 9.137268719427993e-09
with O 0 2.6729418678428374e-10
new O 0 2.0541921941230612e-08
intragenic O 0 2.8471154109865893e-06
markers O 0 4.187635482821861e-08
in O 0 7.28276383643589e-10
these O 0 1.732442939106349e-10
23 O 0 1.814000283317796e-09
cases O 0 1.5003227826770882e-10
with O 0 1.9380766436150054e-10
10q23 O 0 7.321496582335385e-07
loss O 0 1.0171296480621095e-06
of O 0 1.659378358453978e-05
heterozygosity O 1 0.9999836683273315
. O 0 8.442517719231546e-05

The O 0 3.9618487335246755e-07
identification O 0 1.5655579943540943e-07
of O 0 3.9008349972391443e-07
the O 0 3.188432913248107e-07
second O 0 1.6823155419842806e-06
mutational O 0 1.0823586308106314e-05
event O 0 4.352102322968676e-08
in O 0 9.164199177291721e-09
10 O 0 6.710774158591448e-09
( O 0 3.497335476776442e-10
43 O 0 3.4053872610684266e-08
% O 0 1.3727369463367722e-08
) O 0 8.380931149076787e-08
tumors B-Disease 1 1.0
establishes O 0 6.104470230638981e-05
PTEN O 1 0.9999969005584717
/ O 0 0.0018151841359212995
MMAC1 O 0 0.0004937052144668996
as O 0 1.2520959380424301e-08
a O 0 5.951282133764835e-09
main O 0 3.3399988552673676e-08
inactivation O 0 1.1311791325852028e-07
target O 0 5.489997345620168e-09
of O 0 7.915992306095632e-09
10q O 0 2.0468615957724978e-07
loss O 0 7.539016166902002e-08
in O 0 2.7346933606509083e-08
sporadic B-Disease 1 0.9999395608901978
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.3702313001194852e-07
. O 0 1.3507710150406638e-07

Risk O 0 2.9227826416899916e-06
reversals O 0 1.5076327599672368e-06
in O 0 3.347375931994634e-09
predictive O 0 2.2384163855804218e-08
testing O 0 3.8860715534383417e-08
for O 0 8.478445323589767e-08
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 4.151077519054525e-06

The O 0 1.0784480082293157e-06
first O 0 3.9079388614027266e-08
predictive O 0 3.2805616001496674e-08
testing O 0 3.021538219627473e-08
for O 0 1.3005521282138943e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 5.285966331314285e-09
HD B-Disease 0 3.2753684990893817e-06
) O 0 2.8822616515711275e-10
was O 0 2.602120297012789e-09
based O 0 4.756979810061068e-10
on O 0 1.7913660554924604e-09
analysis O 0 4.822435228923894e-10
of O 0 1.7989706391219329e-09
linked O 0 1.0163753394465402e-08
polymorphic O 0 3.074698540217469e-08
DNA O 0 1.3108962093610899e-07
markers O 0 5.290555549208875e-09
to O 0 1.3315341884645449e-10
estimate O 0 1.2615738453902736e-09
the O 0 3.5031724188172575e-09
likelihood O 0 3.8402259150416285e-08
of O 0 5.905873123879246e-08
inheriting O 0 1.8433132709105848e-07
the O 0 4.865178482305055e-08
mutation O 0 2.015958733281309e-09
for O 0 2.177348301657389e-09
HD B-Disease 0 3.782409112318419e-05
. O 0 7.141629225770885e-07

Limits O 0 7.813226261532691e-07
to O 0 3.1295698477151745e-08
accuracy O 0 1.1166536495466062e-07
included O 0 1.8951764602093135e-09
recombination O 0 1.7899075555050104e-09
between O 0 3.7654138140830185e-10
the O 0 2.076202321177334e-09
DNA O 0 3.035586715327554e-08
markers O 0 6.440592503764719e-09
and O 0 5.865319341324948e-10
the O 0 6.032722765780818e-09
mutation O 0 5.256738599968003e-09
, O 0 6.603038671393335e-10
pedigree O 0 1.407616245785448e-08
structure O 0 6.501765881239407e-08
, O 0 6.724416579118042e-10
and O 0 2.6090021809643815e-10
whether O 0 3.0206073753369367e-10
DNA O 0 2.8371014426653574e-09
samples O 0 3.738463705271755e-10
were O 0 4.0918421428948193e-10
available O 0 9.913961873664334e-10
from O 0 1.6165666139045243e-08
family O 0 1.7719501954616135e-07
members O 0 5.191493457346041e-09
. O 0 1.7262115648009058e-07

With O 0 1.4880413345963461e-08
direct O 0 3.7649865447519915e-08
tests O 0 5.9243387973140216e-09
for O 0 2.5098869649298194e-09
the O 0 2.31508590076146e-08
HD B-Disease 0 1.0595711501082405e-05
mutation O 0 2.335335835823571e-08
, O 0 1.0302854125399108e-09
we O 0 2.3081524191947977e-10
have O 0 1.2691175887979966e-10
assessed O 0 9.981893533961284e-09
the O 0 3.3170153290740245e-09
accuracy O 0 5.912226708204571e-09
of O 0 1.7934753682169458e-09
results O 0 1.360988127752094e-10
obtained O 0 8.009298779754204e-10
by O 0 1.6937319602394751e-10
linkage O 0 2.2264217136580555e-08
approaches O 0 2.6488475413088963e-08
when O 0 6.817142406134735e-09
requested O 0 3.6108559697822784e-08
to O 0 4.7179375961547976e-09
do O 0 3.9790118422367016e-10
so O 0 3.2970559615819184e-10
by O 0 1.188520393213821e-10
the O 0 2.7151809689485162e-09
test O 0 3.872809628546747e-09
individuals O 0 3.117544000730277e-10
. O 0 8.752436997383484e-08

For O 0 2.7635650212687324e-07
six O 0 4.526082975075951e-08
such O 0 4.5622905453512885e-10
individuals O 0 8.849094373930555e-11
, O 0 3.208956156353082e-10
there O 0 1.4096110390049432e-10
was O 0 1.0976586750643946e-08
significant O 0 1.1727668836059024e-09
disparity O 0 3.869413234269814e-09
between O 0 2.337545046415812e-09
the O 0 1.670763261074626e-08
tests O 0 3.480562682511845e-08
. O 0 1.2073374477949983e-07

Three O 0 4.610993073583813e-06
went O 0 1.2782273870470817e-06
from O 0 1.1232731189636525e-08
a O 0 1.4845713103284197e-08
decreased O 0 2.6031791833247553e-08
risk O 0 9.450361382334904e-09
to O 0 7.61855578623738e-10
an O 0 1.1448193781848914e-10
increased O 0 2.9981242488652526e-10
risk O 0 5.054757945543997e-09
, O 0 7.99250873817492e-11
while O 0 1.152586359687291e-10
in O 0 1.5212225923377787e-10
another O 0 1.326839638160493e-09
three O 0 6.513327655000012e-10
the O 0 3.738864773339401e-09
risk O 0 1.1360935303628139e-08
was O 0 1.3980165647353715e-07
decreased O 0 8.63166249587266e-08
. O 0 1.5255919549872488e-07

Knowledge O 0 3.1423238397110254e-05
of O 0 2.3413504095515236e-05
the O 0 4.690886612479517e-07
potential O 0 3.1521004473233916e-08
reasons O 0 1.049314768408749e-08
for O 0 4.339241743700484e-10
these O 0 6.112577805028607e-11
changes O 0 8.783350713414961e-10
in O 0 5.769112965126055e-10
results O 0 7.592951822843474e-10
and O 0 5.217897225406887e-10
impact O 0 1.58713273634703e-08
of O 0 5.099633160199346e-09
these O 0 4.167575451408112e-10
risk O 0 1.0127102711976477e-08
reversals O 0 6.83258463141101e-08
on O 0 3.747391019714996e-08
both O 0 4.25755403155037e-10
patients O 0 6.549607967087923e-09
and O 0 1.4459279107370548e-08
the O 0 3.546416849076195e-07
counseling O 0 5.853389595245062e-08
team O 0 2.182824587748655e-09
can O 0 1.7023793486004024e-10
assist O 0 6.9811765257554725e-09
in O 0 3.834946582514931e-09
the O 0 1.2954466832582057e-08
development O 0 9.187493432705196e-09
of O 0 3.361470879426065e-09
strategies O 0 5.240780698301251e-09
for O 0 3.7919653528284414e-10
the O 0 6.293112697619563e-09
prevention O 0 1.4798705194607464e-07
and O 0 5.085071252963758e-10
, O 0 2.7042833250501275e-11
where O 0 1.0858941523750332e-10
necessary O 0 2.4547728294521676e-09
, O 0 1.5456322333129435e-10
management O 0 1.6190496721080194e-09
of O 0 3.3744986804862265e-09
a O 0 5.003669478753636e-09
risk O 0 9.505842335499892e-09
reversal O 0 2.1097115165957803e-08
in O 0 1.3048145897087693e-09
any O 0 2.2476434047291605e-09
predictive O 0 1.491320134050511e-08
testing O 0 2.269485399608584e-08
program O 0 1.1256560128458659e-08
. O 0 2.6650426310226294e-09
. O 0 2.9708152382568187e-08

A O 0 1.8843782527255826e-05
novel O 0 1.8700173995966907e-06
common O 0 1.0734294164649327e-06
missense O 0 1.06339007288625e-06
mutation O 0 5.847330442065868e-08
G301C O 0 2.465802424467256e-07
in O 0 7.412340963242059e-09
the O 0 3.232832312960454e-08
N O 0 1.4578195361991675e-07
- O 0 7.961815384760484e-08
acetylgalactosamine O 0 1.0058696489068097e-06
- O 0 1.7432829224617308e-07
6 O 0 2.1919507275924843e-07
- O 0 5.5079038219219e-08
sulfate O 0 3.526814111864951e-07
sulfatase O 0 2.3857414817030076e-06
gene O 0 3.87750489494465e-08
in O 0 1.836770735508253e-08
mucopolysaccharidosis B-Disease 0 7.685687160119414e-05
IVA I-Disease 1 0.9999711513519287
. O 0 1.1813156561402138e-05

Mucopolysaccharidosis B-Disease 1 0.7204738259315491
IVA I-Disease 1 1.0
( O 0 3.9114689570851624e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.7992777873464547e-08
is O 0 3.5896969841076043e-09
an O 0 1.1595642668282835e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999964237213135
by O 0 1.8104586274603207e-07
a O 0 0.00021341534738894552
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.4371918243559776e-06
N O 0 2.034832732533687e-06
- O 0 8.164229257090483e-07
acetylgalactosamine O 0 1.0746190127974842e-05
- O 0 9.69498273661884e-07
6 O 0 2.11926749216218e-06
- O 0 6.520033366541611e-07
sulfate O 0 8.204455298255198e-06
sulfatase O 0 9.38486700761132e-05
( O 0 3.249226310231279e-08
GALNS O 0 7.103985990397632e-05
) O 0 1.3970644197058846e-08
. O 0 1.1979101088854804e-07

In O 0 3.0988672961029806e-07
previous O 0 6.640239291755279e-08
studies O 0 7.4965118557202e-09
, O 0 6.216305803441458e-10
we O 0 1.6953155546062249e-10
have O 0 4.121699509473942e-11
found O 0 2.483101502193108e-10
two O 0 2.1946212902523854e-10
common O 0 4.400907194224146e-09
mutations O 0 1.7879150382427156e-09
in O 0 9.099644926457984e-10
Caucasians O 0 5.0904233717119496e-08
and O 0 2.726667247543446e-08
Japanese O 0 1.9354474716237746e-05
, O 0 2.2349693651335656e-08
respectively O 0 2.1028381524956785e-07
. O 0 9.394881317348336e-07

To O 0 7.19620743439009e-07
characterize O 0 9.572595445206389e-06
the O 0 4.245875061315019e-06
mutational O 0 0.0006868927739560604
spectrum O 0 5.526757831830764e-06
in O 0 1.0200978950436479e-09
various O 0 1.5533309360993286e-10
ethnic O 0 7.36710414894759e-11
groups O 0 1.0448994967882097e-11
, O 0 2.702128104603574e-11
mutations O 0 7.742793906029277e-11
in O 0 3.4080349653464737e-10
the O 0 1.074421973612516e-08
GALNS O 0 2.0801096525246976e-06
gene O 0 3.2531253246759206e-09
in O 0 2.657144948514656e-09
Colombian O 0 4.6146004024194553e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 1 0.7285635471343994
were O 0 1.9834378406358155e-07
investigated O 0 1.8323623862670502e-07
, O 0 1.4230648881508046e-09
and O 0 1.2664583826094145e-09
genetic O 0 2.1928075355504006e-08
backgrounds O 0 7.2588037802745475e-09
were O 0 2.6215589699063457e-09
extensively O 0 1.0444800579989533e-09
analyzed O 0 2.571044488419716e-09
to O 0 5.107944067717085e-10
identify O 0 1.07529274373519e-09
racial O 0 4.256969499127905e-10
origin O 0 2.719948155593954e-10
, O 0 3.671933937465788e-11
based O 0 2.328723602840199e-10
on O 0 3.795758818370132e-09
mitochondrial O 0 1.0715582865472584e-09
DNA O 0 2.0395976019216278e-09
( O 0 3.1103085385009166e-11
mtDNA O 0 1.719780984288377e-10
) O 0 2.1446007469894113e-10
lineages O 0 1.647906522350695e-08
. O 0 9.754201357736747e-08

Three O 0 1.7985739759751596e-06
novel O 0 1.7736758763930993e-06
missense O 0 3.3862979762488976e-06
mutations O 0 6.278751385480064e-08
never O 0 6.407903185845498e-08
identified O 0 4.482627957713703e-08
previously O 0 6.245618067168834e-08
in O 0 2.205406524069531e-09
other O 0 6.640804017798985e-10
populations O 0 8.148068331159664e-10
and O 0 6.715021871883664e-10
found O 0 1.8996133555049255e-09
in O 0 5.6540896409273955e-09
16 O 0 4.415101528820742e-08
out O 0 6.369176741571891e-09
of O 0 6.644052774618103e-08
19 O 0 7.257712582031672e-07
Colombian O 0 0.00010161055251955986
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
unrelated O 0 9.183299312098825e-07
alleles O 0 8.905958748250953e-10
account O 0 1.2285986117355208e-10
for O 0 1.4991393681995646e-09
84 O 0 5.826088909088867e-07
. O 0 9.05420392882661e-07

2 O 0 4.565974450088106e-06
% O 0 3.9809422425207686e-09
of O 0 5.670548919312068e-09
the O 0 5.2198410038784004e-09
alleles O 0 2.9472208007419454e-10
in O 0 1.433508867165756e-10
this O 0 2.9057817263478114e-10
study O 0 1.4483948485022324e-09
. O 0 3.959257099950264e-08

The O 0 1.3657407180289738e-05
G301C O 0 2.2252292183111422e-05
and O 0 6.850082456821838e-08
S162F O 0 1.4551831384324032e-07
mutations O 0 1.3111738361715197e-09
account O 0 1.075394703842214e-10
for O 0 2.0177435278156963e-09
68 O 0 7.124167495931033e-07
. O 0 4.954677024215925e-07

4 O 0 1.7793172446545213e-05
% O 0 7.307455263116935e-08
and O 0 5.299041561102058e-08
10 O 0 7.745315855345325e-08
. O 0 2.088321195969911e-07

5 O 0 1.2077813380528823e-06
% O 0 7.587425798760705e-09
of O 0 7.539616042606667e-09
mutations O 0 5.900158694949198e-10
, O 0 2.0091631136587296e-10
respectively O 0 1.4096924738637995e-09
, O 0 3.2389391169118653e-10
whereas O 0 5.952315529356156e-09
the O 0 4.5855446728637617e-07
remaining O 0 7.650943189219106e-06
F69V O 0 3.884607212967239e-05
is O 0 1.0689821250409182e-09
limited O 0 5.90866133798329e-10
to O 0 5.974947758780047e-10
a O 0 8.535605111603672e-09
single O 0 3.3595497939131747e-08
allele O 0 1.0455912047291349e-07
. O 0 1.817069801290927e-07

The O 0 3.7847908060939517e-06
skewed O 0 5.766356707681553e-07
prevalence O 0 2.0939211253789836e-07
of O 0 4.706202361148826e-08
G301C O 0 1.5410952869387984e-07
in O 0 6.571101995866968e-10
only O 0 2.940011845087298e-10
Colombian O 0 2.7291282123087512e-08
patients O 0 8.442230914340598e-09
and O 0 2.3729163078911597e-09
haplotype O 0 3.200170084483034e-08
analysis O 0 1.69616293232977e-10
by O 0 4.751091881027847e-11
restriction O 0 1.883068839747537e-10
fragment O 0 2.9637221565792515e-09
length O 0 1.4132568448843585e-09
polymorphisms O 0 9.679490098335464e-09
in O 0 1.4728067654345978e-09
the O 0 3.327231468119862e-08
GALNS O 0 8.53670007927576e-06
gene O 0 7.6069293086789e-09
suggest O 0 9.015683755109194e-10
that O 0 7.125706968924561e-11
G301C O 0 4.31359907793194e-08
originated O 0 3.8761056586622544e-09
from O 0 1.3135694754140559e-09
a O 0 1.9183978849923733e-09
common O 0 1.549751793561427e-08
ancestor O 0 1.8329267277295003e-06
. O 0 3.2704349450796144e-07

Investigation O 0 1.4870623090246227e-05
of O 0 3.97265739593422e-06
the O 0 1.1336198468825387e-07
genetic O 0 2.615172789433018e-08
background O 0 1.2907475088752562e-09
by O 0 5.723155283021697e-11
means O 0 3.569160744731903e-09
of O 0 3.2695425034035e-08
mtDNA O 0 2.5771373923788587e-09
lineages O 0 3.391531777641177e-10
indicate O 0 8.436234349984417e-11
that O 0 8.247146021655993e-11
all O 0 1.1043213010708541e-09
our O 0 1.3518259400768784e-08
patients O 0 1.1689749168652952e-09
are O 0 2.2773128868780468e-11
probably O 0 7.591609119117493e-09
of O 0 3.163960826668699e-08
native O 0 1.8345055252666498e-08
American O 0 2.5967901251533476e-07
descent O 0 2.8096497771912254e-05

Low O 0 3.954313342546811e-06
frequency O 0 1.4601070574826736e-07
of O 0 6.860229717631228e-08
BRCA1 O 0 2.465359827397151e-08
germline O 0 3.0557849584056385e-08
mutations O 0 1.2622182465893417e-10
in O 0 8.529623535258324e-11
45 O 0 9.168744874443746e-09
German O 1 0.9648429751396179
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 7.949348059810291e-07
. O 0 2.1256587956486328e-07

In O 0 2.3214050770548056e-07
this O 0 2.2801578403175427e-09
study O 0 3.6470867992299816e-10
we O 0 8.798805434251378e-11
investigated O 0 1.087511525277307e-09
45 O 0 8.127180706196668e-09
German O 0 0.009484181180596352
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.797656411563821e-09
for O 0 1.617971312484201e-10
germline O 0 6.228141113950869e-09
mutations O 0 1.6266385460816934e-10
in O 0 3.9744763036253516e-10
the O 0 1.3271111320989348e-08
BRCA1 O 0 1.2800392745759837e-08
gene O 0 1.1174607017494509e-08
. O 0 4.4589050673948805e-08

We O 0 1.3605111348624632e-07
identified O 0 5.862316498905784e-08
four O 0 2.5413829263243315e-08
germline O 0 1.5834353916943655e-07
mutations O 0 5.095880162286903e-09
in O 0 7.431650850264759e-09
three O 0 1.6985872264285717e-07
breast B-Disease 1 0.9997974038124084
cancer I-Disease 1 0.9988963603973389
families O 0 4.0709757342938246e-08
and O 0 2.2602838711804907e-08
in O 0 2.8079654157409095e-07
one O 1 0.999588668346405
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.0007957321940921247
. O 0 6.501263416502923e-10
among O 0 2.2078705183559144e-11
these O 0 1.652225231629778e-11
were O 0 4.210810311544577e-10
one O 0 1.0410352579981463e-09
frameshift O 0 9.646885956726692e-09
mutation O 0 4.3905759583573456e-10
, O 0 7.363409187943759e-11
one O 0 1.5124015928513757e-10
nonsense O 0 4.3687169437589546e-09
mutation O 0 5.86193038554228e-10
, O 0 6.380696665475583e-11
one O 0 2.4850202451354164e-10
novel O 0 1.0800187411064144e-08
splice O 0 8.259293053924921e-07
site O 0 4.383083407333288e-08
mutation O 0 9.786730315042291e-10
, O 0 2.113390573654783e-10
and O 0 1.4649789159548732e-09
one O 0 6.4138676592051524e-09
missense O 0 7.925956992949068e-07
mutation O 0 2.014299838037914e-07
. O 0 3.6090901289753674e-07

The O 0 2.5868289412755985e-06
missense O 0 3.33364596372121e-06
mutation O 0 3.5332028858192643e-08
was O 0 2.917581696237903e-07
also O 0 9.275881174275469e-10
found O 0 1.2364038681766942e-09
in O 0 6.0494764753116215e-09
2 O 0 1.9050515902563347e-06
. O 0 6.383158392964106e-07

8 O 0 4.3648897189996205e-06
% O 0 1.0884894763307784e-08
of O 0 2.557283274029487e-08
the O 0 1.1537422572871492e-08
general O 0 2.2000969934765635e-08
population O 0 4.786063906303539e-11
, O 0 1.145755972736806e-11
suggesting O 0 1.0780480674821291e-10
that O 0 1.27898308263652e-11
it O 0 3.2992938242548675e-11
is O 0 3.247244834136964e-11
not O 0 1.166003682495642e-10
disease O 0 6.531321616876085e-08
associated O 0 8.33697484381446e-08
. O 0 4.0571126191935036e-07

The O 0 1.3193624681662186e-06
average O 0 3.968246176100365e-08
age O 0 6.329792689996339e-09
of O 0 1.1297211166549914e-08
disease O 0 1.5531585404460202e-06
onset O 1 0.9451766014099121
in O 0 5.943183278844799e-09
those O 0 1.1320415715943e-09
families O 0 1.8896177955696203e-09
harbouring O 0 2.1569096730900128e-08
causative O 0 1.6764806431979196e-08
mutations O 0 1.8721755257189443e-09
was O 0 1.034954237866259e-07
between O 0 1.3809172472178943e-08
32 O 0 5.548170065594604e-07
. O 0 1.0064906064144452e-06

3 O 0 3.579426265787333e-05
and O 0 7.391484473373566e-07
37 O 0 6.31236434855964e-06
. O 0 2.3628901999472873e-06

4 O 0 1.3623210179503076e-05
years O 0 1.471586728030161e-07
, O 0 2.624605865975127e-09
whereas O 0 1.4795142000423311e-08
the O 0 1.4794670732953819e-07
family O 0 3.5401720310801466e-07
harbouring O 0 7.793475447215314e-07
the O 0 8.8377717588628e-08
missense O 0 2.119282669355016e-07
mutation O 0 9.855031457561836e-09
had O 0 2.1114344050943146e-08
an O 0 1.444382807802569e-10
average O 0 2.5486035504229676e-10
age O 0 9.812487489213595e-10
of O 0 1.8511697064127475e-08
onset O 0 0.22615957260131836
of O 0 0.00019371657981537282
51 O 0 1.421904016751796e-05
. O 0 1.4471054328168975e-06

2 O 0 6.615035090362653e-05
years O 0 1.9244441773480503e-06
. O 0 9.777752438822063e-07

These O 0 1.555559947519214e-07
findings O 0 1.6845714867486095e-07
show O 0 2.3664091131081477e-08
that O 0 1.001442262449359e-09
BRCA1 O 0 1.3112195773601343e-08
is O 0 6.593348089722895e-10
implicated O 0 3.446072760482366e-09
in O 0 5.473234643282865e-10
a O 0 1.6811418923623478e-09
small O 0 1.9107318505184878e-10
fraction O 0 9.515742638299685e-10
of O 0 8.17222007754026e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.1484607688223605e-09
suggesting O 0 3.2942149008619026e-10
the O 0 4.882557691487932e-10
involvement O 0 5.714584361271591e-10
of O 0 1.2922648506830114e-09
another O 0 5.264963465201333e-10
susceptibility O 0 1.0026525387729635e-08
gene O 0 3.728296782412599e-09
( O 0 1.823352246965726e-09
s O 0 2.755364448603359e-06
) O 0 3.393943188712001e-07

Paternal O 0 0.001892036641947925
transmission O 0 0.07605821639299393
of O 0 0.0027616405859589577
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9927567839622498

We O 0 6.58896652794283e-08
report O 0 1.7849437483619113e-09
a O 0 9.343641416137416e-10
rare O 0 1.9572685694413394e-09
case O 0 3.5532798925430598e-09
of O 0 1.1589390425115198e-07
paternally O 1 0.9999876022338867
transmitted O 1 1.0
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0019495877204462886
DM B-Disease 1 1.0
) O 0 1.2830537343688775e-07
. O 0 2.733223709583399e-07

The O 0 1.2750320820487104e-05
proband O 0 3.084888157900423e-05
is O 0 1.3085762695652647e-08
a O 0 2.35992736463686e-08
23 O 0 3.607620158163627e-08
year O 0 7.379641786542379e-09
old O 0 0.0003771041810978204
, O 0 6.635911176999798e-06
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 1.766095738275908e-05
who O 0 3.7135728803150414e-07
suffers O 1 0.8768148422241211
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.9999990463256836

He O 0 2.252890141107855e-07
presented O 0 1.5346479642630584e-07
with O 0 4.00562178981545e-08
respiratory O 1 1.0
and O 0 3.292190058346023e-07
feeding O 0 8.928380452744022e-07
difficulties O 0 1.9324570530443452e-06
at O 0 1.6332081713699154e-06
birth O 0 1.019535102386726e-05
. O 0 1.9872277334798127e-06

His O 0 4.583317422657274e-05
two O 0 6.570884124812437e-06
sibs O 1 0.6253713369369507
suffer O 0 1.636227921153477e-06
from O 0 3.0980129395175027e-07
childhood O 1 0.6256104707717896
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.0009127832599915564

Their O 0 6.515750214930449e-07
late O 0 0.0003165793023072183
father O 0 1.3009856957069132e-05
had O 0 6.328576063197033e-08
the O 0 3.5857687930018756e-09
adult O 0 2.7440955063795514e-10
type O 0 1.2225027656853626e-09
of O 0 2.707007062952016e-08
DM B-Disease 1 1.0
, O 0 6.603495528167969e-09
with O 0 1.233626534258292e-09
onset O 1 0.9997653365135193
around O 0 2.4645981255844163e-08
30 O 0 2.3189350883967563e-08
years O 0 1.3710360846630465e-08
. O 0 4.4028993784195336e-08

Only O 0 7.429314763385264e-08
six O 0 2.7773014998899725e-09
other O 0 1.52478030202019e-11
cases O 0 1.6508076156052098e-11
of O 0 5.173421691040403e-10
paternal O 0 2.1899084003962344e-06
transmission O 0 0.00018658462795428932
of O 0 0.00894310511648655
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.00014441937673836946
been O 0 4.4408739086065907e-07
reported O 0 2.660945064292264e-08
recently O 0 6.865883506179671e-08
. O 0 6.166264654439146e-08

We O 0 5.941978429291339e-07
review O 0 8.602833645454666e-08
the O 0 8.217148739220193e-09
sex O 0 3.903956879991455e-10
related O 0 6.992793566418243e-10
effects O 0 8.20009837809721e-09
on O 0 1.749953248975089e-08
transmission O 0 7.847688721085433e-07
of O 0 1.9059893929807004e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9886224865913391

Decreased O 0 9.545942702970933e-07
fertility O 0 4.6881584125912923e-07
of O 0 2.0821033785978216e-09
males O 0 2.352463709942576e-11
with O 0 2.877135682477494e-11
adult O 0 4.753544224911366e-09
onset O 0 0.19364385306835175
DM B-Disease 1 1.0
and O 0 1.4761620548142673e-07
contraction O 0 1.197533094909886e-07
of O 0 5.2366466718467564e-08
the O 0 1.8856079364582e-08
repeat O 0 3.4899005907362834e-09
upon O 0 3.874065512832203e-09
male O 0 3.973702755732944e-10
transmission O 0 3.288351535513101e-10
contribute O 0 2.8765649584538977e-11
to O 0 2.9897184727900594e-10
the O 0 4.135673581373567e-09
almost O 0 6.510818550964359e-10
absent O 0 4.872438008618474e-09
occurrence O 0 1.0663468996696679e-09
of O 0 2.122545472715842e-09
paternal O 0 2.129741289991216e-07
transmission O 0 2.491592567821499e-06
of O 0 2.880011834349716e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.052132535725831985

Also O 0 5.591855369857512e-07
the O 0 1.8688589875637263e-07
fathers O 0 1.0473117129095044e-07
of O 0 2.1228057534017353e-08
the O 0 3.563897266189997e-08
reported O 0 5.228602617535216e-08
congenitally O 0 0.0001582562254043296
affected O 0 5.137820124900827e-08
children O 0 3.4689298100687438e-09
showed O 0 5.22443244221904e-09
, O 0 8.478890367591418e-10
on O 0 4.276848031281588e-08
average O 0 6.502060667656906e-09
, O 0 1.5568437650159694e-09
shorter O 0 1.2331540801824303e-06
CTG O 0 0.0001372595870634541
repeat O 0 7.284103844540368e-07
lengths O 0 2.0040802155563142e-06
and O 0 1.8015219316325215e-09
hence O 0 6.039031941185158e-09
less O 0 2.008888166926681e-09
severe O 0 2.60766228166176e-07
clinical O 0 1.4186109353886422e-07
symptoms O 0 1.8486510100501619e-07
than O 0 2.140702060060562e-10
the O 0 6.540869179616493e-09
mothers O 0 3.7302227973157187e-10
of O 0 2.2877452710012847e-10
children O 0 2.075457028460903e-10
with O 0 6.976863531349409e-09
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9999912977218628

We O 0 9.075507989564358e-08
conclude O 0 8.087643266208033e-08
that O 0 3.4886876720818805e-10
paternal O 0 6.061167709958681e-07
transmission O 0 2.7684870929078897e-06
of O 0 1.7430998013878707e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.377435177753796e-06
rare O 0 2.2384890385751532e-08
and O 0 1.2211877342682698e-10
preferentially O 0 7.102720495089088e-11
occurs O 0 1.5287261040386468e-11
with O 0 3.692080061817871e-12
onset O 0 3.821710379270371e-06
of O 0 5.5144282669061795e-06
DM B-Disease 1 1.0
past O 0 9.805411309571355e-07
30 O 0 1.2545079641768098e-08
years O 0 7.615403307958957e-10
in O 0 1.5611187342834398e-10
the O 0 1.3449891200778552e-09
father O 0 1.8450503347366976e-08
. O 0 4.129761865812043e-09
. O 0 5.456125506952958e-08

The O 0 3.8357352423190605e-06
RB1 O 0 3.513635601848364e-05
gene O 0 1.1210237182979199e-08
mutation O 0 1.521365478041048e-09
in O 0 4.172936440838271e-10
a O 0 5.6398077319386175e-09
child O 0 1.1421448675719148e-07
with O 0 1.5169047173912986e-07
ectopic B-Disease 1 0.9999328851699829
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.0004465449310373515

The O 0 8.599553439125884e-06
RB1 O 0 0.00014179279969539493
gene O 0 9.396676148298866e-08
mutation O 0 8.464787981665722e-09
was O 0 2.529747256119208e-08
investigated O 0 6.564490728777628e-09
in O 0 7.069516638757989e-10
a O 0 1.4040179685537169e-08
child O 0 4.192234825950436e-07
with O 0 8.511467086691482e-08
ectopic B-Disease 0 0.41448989510536194
intracranial I-Disease 1 0.9999712705612183
retinoblastoma I-Disease 0 3.621192809077911e-05
using O 0 8.533830531121112e-09
DNA O 0 1.5395345442925645e-08
obtained O 0 1.4058044728315622e-09
from O 0 1.772959445922595e-09
both O 0 1.545978012273963e-09
the O 0 7.799812351549917e-08
pineal B-Disease 1 0.8799741864204407
and I-Disease 0 1.172767269963515e-06
retinal I-Disease 1 0.9999969005584717
tumours I-Disease 1 1.0
of O 0 0.2774510085582733
the O 0 0.00014923838898539543
patient O 0 0.000539054861292243
. O 0 3.105641326328623e-06

A O 0 1.5257654013112187e-05
nonsense O 0 1.9263500234956155e-06
mutation O 0 2.2647071773462812e-08
in O 0 1.092151613590886e-08
exon O 0 2.7602249019764713e-07
17 O 0 5.06910815545325e-08
( O 0 4.339697212696336e-10
codon O 0 4.294977262730981e-09
556 O 0 1.4027089711987628e-08
) O 0 3.6304995121305694e-10
of O 0 2.9095227560560488e-08
the O 0 2.9730438200203935e-07
RB1 O 0 8.321131463162601e-05
gene O 0 4.5633566259084546e-08
was O 0 1.6935565838593902e-07
found O 0 1.0759738655607975e-09
to O 0 4.4520345743315204e-10
be O 0 2.9200494799930254e-10
present O 0 9.549929735896967e-09
homozygously O 0 1.3851670701114926e-05
in O 0 6.5487584244294794e-09
both O 0 4.813055731744953e-09
the O 0 7.055903239461259e-08
retinal B-Disease 0 3.0960665753809735e-05
and I-Disease 0 1.7794380937630194e-06
the I-Disease 0 0.00019923990475945175
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 6.074893462937325e-05

The O 0 7.926848866190994e-07
same O 0 2.686232924986598e-08
mutation O 0 1.4499323519601148e-08
was O 0 4.55267219479083e-08
present O 0 7.880469610199725e-09
heterozygously O 0 2.058830432360992e-06
in O 0 5.414055426200548e-09
the O 0 6.914361527776691e-09
DNA O 0 4.0938445522442635e-08
from O 0 6.134390329037842e-09
the O 0 1.8551743252714914e-08
constitutional O 0 7.208833352478905e-08
cells O 0 4.481602289274633e-08
of O 0 1.0166083086460276e-07
the O 0 9.113166754559643e-08
patient O 0 2.762479311968491e-07
, O 0 1.3220373684674769e-09
proving O 0 3.59693608231737e-08
it O 0 4.564814637397774e-10
to O 0 4.2281136924948726e-10
be O 0 1.3547600818952787e-09
of O 0 2.147165112376115e-08
germline O 0 2.5730432184900565e-07
origin O 0 2.6035666067514285e-08
. O 0 1.5225629113047034e-07

The O 0 2.5032341000041924e-07
initial O 0 1.5846680412323622e-07
mutation O 0 2.7388798784500068e-08
was O 0 6.931238516472149e-08
shown O 0 3.415989047184098e-09
to O 0 1.7080590275497798e-09
have O 0 1.0832861274678862e-09
occurred O 0 1.5020701482626464e-07
in O 0 2.343276905847347e-09
the O 0 2.2708796620918292e-08
paternally O 0 9.332336503575789e-07
derived O 0 5.316941269484232e-07
RB1 O 0 0.00020290608517825603
allele O 0 2.3229451926454203e-06
. O 0 3.8038933780626394e-07

The O 0 3.104202278336743e-06
mutation O 0 8.597207568072918e-08
is O 0 3.067298859349421e-09
in O 0 6.240932770573693e-10
an O 0 2.2032610458300184e-10
area O 0 1.0200127853465801e-08
of O 0 7.160347426093949e-09
the O 0 1.275476879669668e-08
gene O 0 1.344268474312571e-09
that O 0 6.074297176361654e-10
encodes O 0 4.448717838556604e-09
the O 0 1.5751840720668042e-08
protein O 0 1.6522687218412102e-08
- O 0 1.9650352456324072e-08
binding O 0 1.7946806707413998e-08
region O 0 3.327904494199174e-07
known O 0 7.931060395094391e-07
as O 0 1.9319408295359608e-08
the O 0 1.7874453916988386e-08
pocket O 0 2.907328962464817e-05
region O 0 2.5575741346983705e-07
and O 0 8.729929135142811e-08
has O 0 4.0514458454765645e-09
been O 0 2.874225968341193e-09
detected O 0 5.676544123645044e-09
in O 0 8.329843065313369e-11
other O 0 3.7772805716596025e-11
cases O 0 2.494941475639223e-10
of O 0 3.093923339747562e-08
retinoblastoma B-Disease 0 0.0001559228840051219
. O 0 5.091113166599825e-07
. O 0 2.2253746010392206e-06

Low O 0 8.189399522962049e-06
levels O 0 2.913032126627968e-08
of O 0 4.6190333335971445e-08
beta O 0 3.08614431787646e-07
hexosaminidase O 0 1.428020368621219e-06
A O 0 1.1333928284784633e-07
in O 0 9.010027723910241e-10
healthy O 0 5.902330846296877e-10
individuals O 0 3.1789926593916995e-12
with O 0 9.641137194149607e-11
apparent O 0 2.8989870770601556e-06
deficiency O 1 0.9983499050140381
of O 0 0.00017304642824456096
this O 0 1.0003835626548607e-07
enzyme O 0 9.742168458615197e-07
. O 0 1.7801175999920815e-07

Appreciable O 0 5.011069151805714e-05
beta O 0 2.0103352653677575e-05
hexosaminidase O 0 8.708619134267792e-05
A O 0 2.1425896193250082e-05
( O 0 5.239753875230235e-08
hex O 0 2.9846362394891912e-06
A O 0 2.7643711746350164e-06
) O 0 2.9545843549527717e-09
activity O 0 1.7946114594380447e-09
has O 0 9.170594839069679e-10
been O 0 9.85352355264979e-10
detected O 0 2.3256898629142597e-08
in O 0 3.3393539045079024e-09
cultured O 0 2.869019510853832e-07
skin O 0 4.546148375084158e-06
fibroblasts O 0 8.499784485138662e-07
and O 0 3.257796947764291e-07
melanoma B-Disease 1 0.9999953508377075
tissue O 0 8.552672625228297e-06
from O 0 1.1455789206138434e-07
healthy O 0 6.148610953715661e-09
individuals O 0 6.8376949068083e-12
previously O 0 2.375370566909396e-09
reported O 0 1.916770298038273e-09
as O 0 3.6345058074260805e-09
having O 0 1.2147383188221283e-07
deficiency B-Disease 1 0.9996849298477173
of I-Disease 0 0.13356280326843262
hex I-Disease 0 4.8165529733523726e-05
A I-Disease 0 4.821847028324555e-07
activity O 0 1.2753473832560758e-09
indistinguishable O 0 2.331514981079863e-10
from O 0 1.3071274097831154e-11
that O 0 1.5485845028181955e-12
of O 0 9.762358976761476e-11
patients O 0 8.489246527965122e-10
with O 0 3.6965062122362724e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.758928931394621e-07
TSD B-Disease 0 0.09116509556770325
) O 0 3.916564850214854e-08
. O 0 2.3562668616250448e-07

Identification O 0 4.795409950020257e-06
and O 0 7.781533213346847e-07
quantitation O 1 0.6188327074050903
of O 0 0.0038915385957807302
hex O 0 0.00015397997049149126
A O 0 5.089995283924509e-06
, O 0 2.4773361140262296e-09
amounting O 0 5.257821733550827e-09
to O 0 1.124947690556155e-08
3 O 0 1.178928073386487e-06
. O 0 2.5136066028608184e-07

5 O 0 5.795422111987136e-06
% O 0 1.5731625069292932e-07
- O 0 2.0605432382581057e-06
6 O 0 1.6536660041310824e-06
. O 0 3.891716460202588e-07

9 O 0 5.426621100923512e-06
% O 0 2.2641369668008338e-08
of O 0 1.417701422923301e-08
total O 0 2.1078039313948693e-09
beta O 0 2.1520509108086117e-07
hexosaminidase O 0 1.1547680287549156e-06
activity O 0 4.7876476116925915e-09
, O 0 2.535096577105378e-10
has O 0 2.2912725536339273e-11
been O 0 4.065987477264166e-11
obtained O 0 1.8864551587505218e-10
by O 0 4.4608913785104676e-10
cellulose O 0 2.217601377196843e-06
acetate O 0 9.314162525697611e-07
gel O 0 7.852862609070144e-07
electrophoresis O 0 5.830735858580738e-07
, O 0 3.71133452858885e-08
DEAE O 0 1.5241888831951655e-05
- O 0 6.621925194849609e-07
cellulose O 0 5.90556828683475e-06
ion O 0 3.9591481026945985e-07
- O 0 1.4098738176926418e-07
exchange O 0 4.51086314967597e-08
chromatography O 0 1.223236267833272e-07
, O 0 1.5289871591050996e-09
radial O 0 7.334740104170123e-08
immunodiffusion O 0 1.4638898164776037e-06
, O 0 1.5130804387197827e-09
and O 0 1.0204233014121655e-08
radioimmunoassay O 0 2.0617953850887716e-05
. O 0 1.2691185702351504e-06

Previous O 0 0.0010636972729116678
family O 0 1.9028600490855752e-06
studies O 0 3.6034990547051393e-09
suggested O 0 1.0676372008688872e-09
that O 0 7.983393460198052e-12
these O 0 7.222113532212582e-12
individuals O 0 1.7852542361085355e-12
may O 0 2.6232233052425613e-10
be O 0 2.181524960676029e-10
compound O 0 9.183204952023516e-08
heterozygotes O 0 2.0964781910493002e-08
for O 0 1.2167477025926132e-09
the O 0 2.2904984575689014e-08
common O 0 2.0025355240704812e-07
mutant O 0 4.63674012962656e-07
TSD B-Disease 0 2.549132204876514e-06
gene O 0 7.0038495003643675e-09
and O 0 3.3227143259040304e-09
a O 0 9.559588676211206e-09
rare O 0 1.2687848993664375e-08
( O 0 7.227936582587802e-10
allelic O 0 1.0889549884041116e-07
) O 0 2.515311958717348e-09
mutant O 0 3.052191033248164e-08
gene O 0 3.748005639181429e-08
. O 0 6.681568009980765e-08

Thus O 0 1.0285737062076805e-06
, O 0 2.1218099277575675e-08
the O 0 2.589303704780832e-08
postulated O 0 2.7130710122946766e-07
rate O 0 1.203045396636071e-08
mutant O 0 1.6305634176205785e-08
gene O 0 1.4478148679941683e-09
appears O 0 3.233860734752625e-09
to O 0 3.07470715554814e-10
code O 0 5.385133450275248e-10
for O 0 3.131250536636543e-10
the O 0 2.0955535084965504e-09
expression O 0 6.445074474115131e-10
of O 0 4.481403692579988e-09
low O 0 2.8790285711011165e-08
amounts O 0 2.193212056411653e-09
of O 0 3.8206604102697383e-08
hex O 0 1.0765070328488946e-06
A O 0 2.8225408641446847e-06
. O 0 8.642928150948137e-07

Heterozygotes O 0 3.976959487772547e-05
for O 0 6.856369623164937e-07
the O 0 2.433995632600272e-06
rare O 0 1.0682364290914848e-06
mutant O 0 4.637359154457954e-07
may O 0 1.0223129898179195e-08
be O 0 1.0395133642759902e-09
indistinguishable O 0 1.89663840188814e-08
from O 0 1.4058259001359374e-09
heterozygotes O 0 4.4051507330777895e-08
for O 0 5.180603057652888e-09
the O 0 1.3531730758131744e-07
common O 0 7.69027610658668e-06
TSD B-Disease 0 0.0025617077481001616
mutant O 0 1.3329885405255482e-05
. O 0 8.266803206424811e-07

However O 0 6.561388659065415e-07
, O 0 5.53824008875381e-09
direct O 0 8.010769825261832e-09
visualization O 0 1.3570141845775652e-06
and O 0 3.483611266119624e-08
quantitation O 1 0.9993541836738586
of O 0 0.009066862985491753
hex O 0 4.865376467932947e-05
A O 0 3.6969680650145165e-07
by O 0 8.081946223370551e-10
the O 0 3.009848592583353e-09
methods O 0 1.4725772601309473e-08
described O 0 4.206686110563851e-09
may O 0 6.543985353602011e-10
prevent O 0 2.5100352907259094e-09
false O 0 1.1880478822945406e-08
- O 0 6.441329247763861e-09
positive O 0 4.9211686808936506e-11
prenatal O 0 7.152556236178498e-08
diagnosis O 0 1.4482734513876494e-06
of O 0 1.0907011471772421e-07
TSD B-Disease 0 0.000287966598989442
in O 0 4.330374636651868e-08
fetuses O 0 2.607652049846365e-07
having O 0 1.0264277428007063e-08
the O 0 1.1592474180588397e-07
incomplete O 0 4.4060976506443694e-05
hex B-Disease 0 0.0008455861825495958
A I-Disease 0 0.0005812339950352907
deficiency I-Disease 1 0.9999202489852905
of O 0 0.2578844428062439
the O 0 6.166128059703624e-06
type O 0 4.522128165262984e-06
described O 0 2.040844435668987e-07
in O 0 5.827497595589648e-09
the O 0 3.263891983351641e-07
four O 0 1.2054231035563134e-07
healthy O 0 7.012928904259752e-08
individuals O 0 2.0503325259824123e-08

The O 0 6.6220150074514095e-06
tumor B-Disease 0 1.6992617020150647e-05
suppressor O 0 5.017930561734829e-06
gene O 0 1.8619351749293855e-07
Smad4 O 0 3.642966112238355e-05
/ O 0 3.085325261054095e-06
Dpc4 O 0 2.7878861601493554e-06
is O 0 6.764242499457396e-10
required O 0 4.5614029220431007e-10
for O 0 1.5127420149863013e-10
gastrulation O 0 9.802095490840657e-08
and O 0 1.3817674782146128e-09
later O 0 3.3559249601466945e-08
for O 0 5.3164489477453e-10
anterior O 0 1.55574326754504e-08
development O 0 3.749378763018285e-08
of O 0 6.068755453725316e-08
the O 0 1.3458782177622197e-07
mouse O 0 1.581637889103149e-06
embryo O 0 4.017252308585739e-07
. O 0 2.4673360599081207e-07

Mutations O 0 8.556984880669916e-07
in O 0 1.1168260982685752e-07
the O 0 7.029655080259545e-07
SMAD4 O 0 0.006323802284896374
/ O 0 6.127922824816778e-05
DPC4 O 0 0.00017117625975515693
tumor B-Disease 0 2.4344344637938775e-06
suppressor O 0 1.8858099792851135e-07
gene O 0 2.068628823792551e-09
, O 0 3.859078057111276e-10
a O 0 8.940069129437234e-09
key O 0 1.2128091384511208e-06
signal O 0 1.2055937986588106e-05
transducer O 0 2.545862344049965e-06
in O 0 4.001605091730198e-08
most O 0 1.901912938251371e-08
TGFbeta O 0 1.4631481462856755e-05
- O 0 7.367801799773588e-07
related O 0 1.1666838162227577e-07
pathways O 0 6.859417567284254e-08
, O 0 2.1364424118708314e-11
are O 0 5.462254997271043e-13
involved O 0 1.6069113054073547e-11
in O 0 1.0917673015642393e-10
50 O 0 4.458764468751042e-10
% O 0 8.649552740713773e-10
of O 0 1.720984187159047e-06
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.00014767009997740388

Homozygous O 0 9.554054850013927e-05
Smad4 O 0 0.0006299642263911664
mutant O 0 1.1987264770141337e-05
mice O 0 4.437897587195039e-07
die O 0 1.8186578643053508e-07
before O 0 2.22937345029095e-07
day O 0 3.201110700956633e-07
7 O 0 1.6445269466203172e-06
. O 0 2.7921598189095675e-07

5 O 0 8.326109309564345e-06
of O 0 1.3862315881851828e-06
embryogenesis O 0 7.308208296308294e-05
. O 0 3.2552827633480774e-06

Mutant O 0 3.85124767490197e-05
embryos O 0 1.0821436262631323e-06
have O 0 4.657736418778313e-09
reduced O 0 2.8118101624841074e-08
size O 0 3.724773023350281e-08
, O 0 1.4629099043261817e-09
fail O 0 3.883670629534208e-08
to O 0 1.0589616294964799e-08
gastrulate O 0 1.3260758350952528e-05
or O 0 1.095839152753797e-07
express O 0 8.225428338448637e-09
a O 0 8.825353781105605e-09
mesodermal O 0 1.5367760397566599e-06
marker O 0 2.555197625042638e-06
, O 0 1.6454535511911672e-08
and O 0 2.734161519413192e-08
show O 0 2.0993232041632837e-08
abnormal O 0 1.9639298187712484e-08
visceral O 0 4.136561983614229e-06
endoderm O 0 0.001222921651788056
development O 0 8.83360826264834e-06
. O 0 4.658512011701532e-07

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 0.0689743235707283
the O 0 5.026048529543914e-05
Smad4 O 0 0.40764912962913513
- O 0 0.00012910988880321383
deficient O 0 1.4231168279366102e-05
embryos O 0 7.301130011683199e-08
results O 0 6.968800536633069e-10
from O 0 7.186503614420303e-10
reduced O 0 2.5514564683248864e-08
cell O 0 8.887267455293113e-08
proliferation O 0 5.909318367969263e-09
rather O 0 1.3331427628493486e-10
than O 0 3.426916736493091e-11
increased O 0 1.1458948234732702e-09
apoptosis O 0 4.5293171524463105e-07
. O 0 8.309669397021935e-08

Aggregation O 0 1.348849127680296e-05
of O 0 5.951063030806836e-06
mutant O 0 4.792557319888147e-06
Smad4 O 0 3.710091550601646e-05
ES O 0 3.020374151674332e-06
cells O 0 9.05532626660488e-09
with O 0 1.0846983311552094e-09
wild O 0 4.5546784122052486e-08
- O 0 1.6690783866124548e-08
type O 0 2.1933642813110055e-07
tetraploid O 0 4.5387954742182046e-05
morulae O 0 0.0001101853558793664
rescues O 0 7.334561814786866e-06
the O 0 4.098814372355264e-07
gastrulation B-Disease 0 0.00014562811702489853
defect I-Disease 0 2.7574267733143643e-05
. O 0 7.87108206168341e-07

These O 0 7.234674370693028e-08
results O 0 2.0775422271412936e-08
indicate O 0 4.51821424718446e-09
that O 0 8.423038377891601e-10
Smad4 O 0 1.1232623364776373e-06
is O 0 6.790069617679251e-10
initially O 0 1.522837411727096e-09
required O 0 3.698222839076948e-10
for O 0 3.6010511239581433e-10
the O 0 1.4040734130915666e-09
differentiation O 0 8.016562524915116e-09
of O 0 3.0469966105783897e-08
the O 0 2.4659712494212727e-08
visceral O 0 7.900999321464042e-07
endoderm O 0 7.366871432168409e-05
and O 0 1.0501197245105232e-08
that O 0 3.010272031644945e-10
the O 0 9.101108311426742e-09
gastrulation B-Disease 0 2.7758499072660925e-06
defect I-Disease 0 4.857982958128559e-07
in O 0 5.715350859247792e-09
the O 0 1.3472252646806737e-07
epiblast O 0 6.590818520635366e-05
is O 0 8.527095474164526e-09
secondary O 0 1.0089279811609231e-07
and O 0 2.3764854528707247e-09
non O 0 8.680913765601872e-08
- O 0 3.3859428185678553e-06
cell O 0 4.0023704059422016e-05
autonomous O 0 6.313890708042891e-07
. O 0 1.12587486000848e-06

Rescued O 0 0.0008381794323213398
embryos O 0 1.0254012522636913e-05
show O 0 2.5910139811458066e-07
severe O 0 5.887685802008491e-06
anterior O 0 2.766571742540691e-05
truncations O 1 0.9960517287254333
, O 0 8.790313898998647e-08
indicating O 0 6.946989117295743e-08
a O 0 1.1905651575716547e-07
second O 0 5.170201688997622e-07
important O 0 3.852859720154811e-08
role O 0 2.1606489042369503e-07
for O 0 8.553291763746529e-08
Smad4 O 0 0.0008428616565652192
in O 0 1.2302933782848413e-07
anterior O 0 2.0034682165714912e-05
patterning O 0 0.00011120829003630206
during O 0 3.496382123557851e-05
embryogenesis O 0 3.551121335476637e-05
. O 0 9.515638907942048e-07

Prevalence O 0 6.202777512953617e-06
of O 0 6.721870704495814e-07
p16 O 0 4.148645018631214e-07
and O 0 8.039903320877784e-08
CDK4 O 0 0.0006234361790120602
germline O 0 9.26045140658971e-06
mutations O 0 3.896967726291223e-08
in O 0 1.4082420562999687e-08
48 O 0 6.401172640835284e-07
melanoma B-Disease 1 1.0
- O 1 0.6670390367507935
prone O 0 0.0006631927099078894
families O 0 5.436492145349803e-08
in O 0 1.5768915062608357e-08
France O 0 3.6569858252732956e-07
. O 0 1.9722197066585068e-06

The O 0 2.010770549532026e-05
French O 0 7.158169319154695e-05
Familial B-Disease 1 0.847460925579071
Melanoma I-Disease 1 1.0
Study O 0 2.4873043003026396e-07
Group O 0 2.1146506767877327e-08
. O 0 1.1913840580746182e-07

Germline O 0 0.00013903978106100112
mutations O 0 2.4539204446227814e-07
in O 0 4.312908075121413e-08
the O 0 1.0754618529063009e-07
p16 O 0 8.196505518753838e-08
and O 0 3.3387760112191245e-08
CDK4 O 0 0.00041824349318630993
genes O 0 1.9942978823905833e-08
have O 0 2.1486799006709134e-09
been O 0 3.747096410933182e-09
reported O 0 2.355159844924515e-09
in O 0 1.165235019584543e-09
a O 0 9.250849863917665e-09
subset O 0 2.8358531523053898e-08
of O 0 1.3154146927263355e-07
melanoma B-Disease 1 0.9913671612739563
pedigrees O 0 1.2840247336498578e-06
, O 0 1.7785343198184478e-09
but O 0 2.846428370784082e-10
their O 0 3.90392690396979e-10
prevalence O 0 4.788159202462339e-09
is O 0 3.132216708223723e-11
not O 0 2.97396864079591e-11
well O 0 4.407844089726609e-10
known O 0 7.792020539909572e-08
. O 0 2.4964728595477936e-07

We O 0 4.947141860611737e-07
searched O 0 5.54683651898813e-07
for O 0 9.830846137148797e-10
such O 0 8.049673816401537e-09
germline O 0 3.222556415494182e-06
mutations O 0 6.891283987897623e-08
in O 0 3.221580158196957e-08
48 O 0 1.0711286222431227e-06
French O 0 0.00011547781468834728
melanoma B-Disease 1 1.0
- O 1 0.9999401569366455
prone O 0 0.00024112677783705294
families O 0 5.965875349289718e-09
selected O 0 3.9914019311915183e-10
according O 0 1.3501702533780247e-10
to O 0 5.727329721594288e-10
two O 0 1.9370502979398907e-09
major O 0 2.7290084858577757e-08
criteria O 0 3.268819526169864e-08
families O 0 2.5200372899547574e-09
with O 0 1.051981501909438e-09
at O 0 8.669562134855369e-08
least O 0 1.1011914713421334e-09
three O 0 3.3567426616087914e-09
affected O 0 4.371683903769963e-09
members O 0 1.1454904802477017e-09
( O 0 8.578672772152629e-10
n O 0 1.2361993206866373e-08
= O 0 6.756818660136332e-09
20 O 0 7.471071539200125e-10
) O 0 2.95664465133072e-11
or O 0 1.9915211146859235e-10
families O 0 2.1224595692093118e-10
with O 0 1.7456509848745583e-10
two O 0 1.970799523576261e-09
affected O 0 4.631204753025031e-09
members O 0 9.137037237927359e-10
, O 0 5.16813536410865e-10
one O 0 5.158149463113659e-10
of O 0 4.840813527806631e-09
them O 0 4.6313966550748376e-10
affected O 0 2.307713353744134e-09
before O 0 9.673159162559841e-09
the O 0 8.722418343154459e-09
age O 0 3.8216496633936e-09
of O 0 6.613604774940995e-09
50 O 0 1.7853658551558738e-09
( O 0 1.240406943825434e-10
n O 0 5.029216154639471e-09
= O 0 6.754551140630838e-09
28 O 0 8.154850128505586e-09
) O 0 1.2210341071572373e-10
, O 0 6.654848894172005e-11
and O 0 1.7609033675647368e-10
one O 0 2.0744279904949536e-10
additional O 0 1.2183662967402142e-09
minor O 0 9.834921002038755e-07
criterion O 0 4.085392356500961e-05
. O 0 8.273009939330223e-07

Sixteen O 0 3.3069461551349377e-06
different O 0 2.795468212468677e-08
p16 O 0 2.3225165080020815e-07
germline O 0 3.4260372672179074e-07
mutations O 0 1.1311004355363252e-09
were O 0 6.235150729061445e-10
found O 0 4.0758041386368404e-10
in O 0 1.012130490529728e-09
21 O 0 2.064731319251223e-08
families O 0 1.2238325908242587e-09
, O 0 1.6748871733973658e-10
while O 0 4.2905046182539763e-10
one O 0 1.4520432634057556e-09
germline O 0 1.0300937702822921e-07
mutation O 0 2.889914751946776e-09
, O 0 9.582000748409314e-10
Arg24His O 0 1.914590029628016e-06
, O 0 4.2647245734883654e-09
was O 0 1.6555438264731492e-07
detected O 0 4.9157257819842926e-08
in O 0 5.616212828130074e-09
the O 0 5.5239798513184724e-08
CDK4 O 0 9.652884909883142e-05
gene O 0 5.040497512709408e-07
. O 0 3.464260771579575e-07

The O 0 3.4419301186972007e-07
frequency O 0 8.806289741869477e-08
of O 0 4.1395900041152345e-08
p16 O 0 4.597268343786709e-09
gene O 0 3.128659553652824e-10
mutation O 0 3.2727401344523344e-10
in O 0 3.0009048024304263e-10
our O 0 1.6012099424145276e-09
sample O 0 2.3350038569347475e-10
( O 0 1.7470368207650466e-10
44 O 0 2.1655981452539663e-09
% O 0 8.082131075504151e-10
) O 0 1.7475765279328925e-10
is O 0 1.0324980453946253e-10
among O 0 4.7501589467424665e-11
the O 0 1.7816274011650535e-09
highest O 0 6.022171561426148e-08
rates O 0 1.05535979955107e-09
yet O 0 3.273508131229619e-10
reported O 0 5.166381211729743e-10
and O 0 3.8189806872424015e-10
the O 0 4.939341380350015e-09
CDK4 O 0 1.1109492561445222e-06
mutation O 0 6.771419536200085e-10
is O 0 1.6274702419050158e-10
the O 0 9.063459982527888e-10
second O 0 2.964310130693093e-09
mutation O 0 1.6377306455428453e-10
detected O 0 1.1500396190911033e-09
in O 0 1.0891217788744356e-10
this O 0 4.181102686295901e-10
gene O 0 1.3602420523284309e-08
worldwide O 0 7.53303286415985e-09
. O 0 4.4417933509066643e-07

In O 0 1.3833248431183165e-06
summary O 0 5.073168722447008e-06
, O 0 3.475090082361021e-08
our O 0 3.869990550242619e-08
results O 0 9.618737806249555e-09
show O 0 4.222812766130346e-09
frequent O 0 2.0721315774352433e-09
involvement O 0 8.387820216171349e-09
of O 0 8.223953074093515e-09
the O 0 8.739438506211172e-09
p16 O 0 3.9660119632856095e-09
gene O 0 3.488969113618623e-09
in O 0 1.7617542980019607e-09
familial B-Disease 0 3.9372862374875695e-06
melanoma I-Disease 1 0.9999986886978149
and O 0 2.711952795664274e-08
confirm O 0 4.031967293371963e-08
the O 0 1.1575626501780789e-07
role O 0 1.6113953904550726e-07
of O 0 2.5397246190550504e-06
the O 0 4.654413260141155e-06
CDK4 O 0 0.0013606830034404993
gene O 0 1.1253859355520035e-07
as O 0 1.694854923073308e-08
a O 0 1.0206223066688835e-07
melanoma B-Disease 1 0.9882774949073792
- O 0 1.2386522030283231e-05
predisposing O 0 5.707210675609531e-06
gene O 0 1.0834441610541035e-07
. O 0 4.893059823984913e-08
. O 0 2.5513790546938253e-07

Progression O 0 3.711811586981639e-05
of O 0 8.412372153543402e-06
somatic O 0 0.00010084046516567469
CTG O 0 2.9145357984816656e-05
repeat O 0 1.4853253560431767e-07
length O 0 7.2408137263835215e-09
heterogeneity O 0 2.4589636993255226e-08
in O 0 8.07821587400781e-10
the O 0 2.0047083992835724e-09
blood O 0 6.484436987364006e-09
cells O 0 1.8193441420066847e-08
of O 0 1.9485391078433167e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.20161451399326324
. O 0 3.060459675907623e-06

The O 0 2.397400180598197e-07
genetic O 0 1.1382141451576899e-07
basis O 0 5.958304427622352e-08
of O 0 2.737177965173032e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.7962300262297504e-05
DM B-Disease 1 1.0
) O 0 3.342444321319249e-09
is O 0 3.58344937056998e-10
the O 0 3.0591251753975257e-09
expansion O 0 8.008115059965348e-08
of O 0 7.095527365663656e-08
an O 0 5.966307448090902e-09
unstable O 0 1.8339985672355397e-06
CTG O 0 2.316600330232177e-06
repeat O 0 2.014960109875119e-08
in O 0 6.747427061526423e-10
the O 0 4.8646193739898536e-09
34 O 0 9.68172386706101e-09
UTR O 0 3.015199581568595e-05
of O 0 9.150370061661306e-08
the O 0 3.7794634977217356e-07
DM B-Disease 1 0.999980092048645
protein O 0 1.307548842532924e-07
kinase O 0 9.484782736990383e-08
gene O 0 2.321655534487377e-09
on O 0 2.46480027499274e-08
chromosome O 0 3.195973263814267e-08
19 O 0 1.390098276488061e-07
. O 0 2.146361026689192e-07

One O 0 2.1331642585664667e-07
of O 0 1.6566967531161936e-07
the O 0 5.1617178087326465e-08
principal O 0 4.73615244800385e-08
features O 0 1.9397492501127545e-09
of O 0 6.377919703481894e-08
the O 0 2.60940123553155e-06
DM B-Disease 1 1.0
mutation O 0 1.8063678908220027e-07
is O 0 1.9550823182612476e-09
an O 0 1.3787787578323218e-10
extraordinarily O 0 2.3382373370850473e-08
high O 0 9.366382158759734e-08
level O 0 8.133231688134401e-08
of O 0 1.3369233897719823e-07
somatic O 0 9.871448128251359e-06
mosaicism O 0 0.00012792754569090903
, O 0 1.2026776241569337e-09
due O 0 5.582616680044339e-08
to O 0 3.5403586728932623e-09
an O 0 3.2221300627632843e-10
extremely O 0 3.283627592054472e-09
high O 0 7.470049467883655e-09
degree O 0 4.572173750716502e-08
of O 0 5.5859825209836345e-08
somatic O 0 1.4138392998575e-06
instability O 0 1.675726792882415e-07
both O 0 5.816168102690256e-10
within O 0 2.2984534275849455e-09
and O 0 1.155435191968479e-09
between O 0 2.717894520554154e-10
different O 0 6.522949957954438e-10
tissues O 0 5.39738493898767e-07
. O 0 2.1233124414266058e-07

This O 0 1.4020316712048952e-06
instability O 0 2.668252454895992e-05
appears O 0 2.0302800862737058e-07
to O 0 5.3673963051892315e-09
be O 0 1.4648084967205932e-09
biased O 0 2.0643652121066225e-08
towards O 0 3.3452650427534536e-08
further O 0 6.609644831456762e-09
expansion O 0 5.4313098019065364e-08
and O 0 1.6097995159114475e-09
continuous O 0 1.334171795264183e-08
throughout O 0 3.280948179806842e-09
the O 0 1.2711442565205289e-08
life O 0 5.081777221249695e-09
of O 0 2.9513063104502635e-09
an O 0 8.924914279839768e-11
individual O 0 3.0515343724113464e-11
, O 0 4.407589571098214e-11
features O 0 2.2525391274452744e-10
that O 0 2.53177548370509e-11
could O 0 3.6380826129445154e-10
be O 0 2.4186369573797606e-10
associated O 0 5.208970144110481e-09
with O 0 1.023635398667011e-09
the O 0 1.9381458571388066e-07
progressive O 0 5.498568953044014e-06
nature O 0 2.4652280217196676e-08
of O 0 1.4785317148380273e-07
the O 0 5.253083372736e-07
disease O 0 2.2518970581586473e-05
. O 0 5.349023695089272e-07

Although O 0 1.0295889296685345e-07
increasing O 0 9.51491152534345e-09
measured O 0 1.2919156411328458e-08
allele O 0 3.4567702034138392e-09
size O 0 8.645000271201297e-10
between O 0 1.3945318233510307e-09
patients O 0 4.22377910425098e-09
clearly O 0 1.0532483774028378e-09
correlates O 0 6.8293499744243036e-09
with O 0 4.0905761417020514e-11
an O 0 9.008215180739132e-12
increased O 0 1.1836565061429383e-10
severity O 0 1.4651915307695162e-06
of O 0 2.2183091630267882e-07
symptoms O 0 2.3888014766271226e-06
and O 0 3.5633449524397065e-09
an O 0 4.505370382323903e-11
earlier O 0 4.291993982441511e-10
age O 0 4.407306186671178e-10
of O 0 1.6541882308374056e-09
onset O 0 5.155689905222971e-06
, O 0 4.2269340805312083e-11
this O 0 7.868172259561934e-12
correlation O 0 4.164021558117348e-11
is O 0 8.23687645867821e-12
not O 0 3.510645116625022e-12
precise O 0 5.767014421564909e-09
and O 0 2.203392579502861e-09
measured O 0 6.4779466235620475e-09
allele O 0 1.0929179783403242e-09
length O 0 5.585263362917203e-10
cannot O 0 3.710870777329234e-10
be O 0 1.292052298484947e-10
used O 0 8.171225918118807e-10
as O 0 3.3836231039252596e-10
an O 0 3.664699099736879e-11
accurate O 0 1.1968087854086207e-08
predictor O 0 2.4303534473801847e-07
of O 0 2.6556364218777162e-08
age O 0 5.05072250689409e-08
of O 0 2.4174107693397673e-07
onset O 1 0.8847388625144958
. O 0 1.8420654441797524e-06

In O 0 4.326981581925793e-07
order O 0 1.6397648039401247e-07
to O 0 1.0636154179621826e-08
further O 0 4.869781022875941e-09
characterize O 0 7.08120992953809e-08
the O 0 8.311808841199309e-08
dynamics O 0 8.693993436281744e-07
of O 0 7.717879270785488e-06
DM B-Disease 1 1.0
CTG O 0 0.005997668020427227
repeat O 0 1.8030855244433042e-06
somatic O 0 1.4877629837428685e-05
instability O 0 2.3542593226011377e-06
, O 0 1.0311878018143261e-09
we O 0 3.2508223890559407e-10
have O 0 5.542144174142116e-11
studied O 0 1.4199008635529253e-09
repeat O 0 1.9433032960591845e-10
length O 0 6.3674447658979e-11
changes O 0 3.829869754667925e-11
over O 0 7.986687006189541e-11
time O 0 2.527270615004795e-10
in O 0 6.676822428275386e-10
111 O 0 8.193627536456916e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 1.5330769542742928e-07
with O 0 1.9542834017727273e-10
varying O 0 6.819743880726037e-09
clinical O 0 3.249292035434337e-07
severity O 0 0.0005307373940013349
and O 0 8.285943522423622e-07
CTG O 0 5.52452411284321e-06
repeat O 0 1.7950641861830263e-08
size O 0 3.841381435165658e-09
over O 0 7.330314133469074e-10
time O 0 2.438290125361675e-10
intervals O 0 5.512417744490961e-10
of O 0 2.883401295505905e-09
1 O 0 5.940409408822234e-08
- O 0 4.5964291928157763e-08
7 O 0 1.1867324900549647e-07
years O 0 3.552793614858274e-08
. O 0 1.6685984860487224e-07

We O 0 6.067083972993714e-07
have O 0 8.397312178942684e-09
found O 0 4.025195732282327e-09
a O 0 3.435454143385641e-09
direct O 0 1.1417262690827101e-08
progression O 0 6.812102526509989e-08
of O 0 7.849914851476569e-08
the O 0 7.535005153158636e-08
size O 0 4.092486349804858e-08
heterogeneity O 0 1.9534996908987523e-07
over O 0 1.239313185408264e-08
time O 0 2.849971814100627e-09
related O 0 7.3636972075519225e-09
to O 0 4.695816624433746e-09
initial O 0 1.8098441501024354e-07
CTG O 0 3.602247943490511e-06
repeat O 0 1.1201088945256288e-08
size O 0 1.6621169995900686e-09
and O 0 6.740442648478506e-10
the O 0 2.2432664614768782e-09
time O 0 7.145908864636397e-10
interval O 0 1.3532955867034957e-09
and O 0 3.258681657847262e-10
always O 0 6.742525426872703e-10
biased O 0 2.6714754852719125e-09
towards O 0 1.2452891162695323e-08
further O 0 4.7178114748192e-09
expansion O 0 3.2996206300595077e-07
. O 0 2.0877558881693403e-07

Attempts O 0 1.718375460768584e-05
to O 0 1.9590555666582077e-07
mathematically O 0 2.3657484859995748e-07
model O 0 5.6863321162836655e-08
the O 0 1.6947490166785428e-07
dynamics O 0 5.363407922232e-07
have O 0 1.0410615480793695e-08
proved O 0 1.5034231637400808e-06
only O 0 2.4299668943683628e-09
partially O 0 4.775393236400305e-08
successful O 0 7.157848536110123e-09
suggesting O 0 6.396943530440069e-10
that O 0 9.092037019098331e-12
individual O 0 2.8835729377202357e-12
specific O 0 7.869647294933557e-11
genetic O 0 8.885466584729329e-09
and O 0 1.9979289334060013e-09
/ O 0 1.9473350221232977e-06
or O 0 2.3629091572274774e-08
environmental O 0 6.548248876470097e-08
factors O 0 1.4727028485594928e-09
also O 0 5.420748294682198e-10
play O 0 3.1960569746303236e-09
a O 0 7.408270441544573e-09
role O 0 1.4213242138794158e-08
in O 0 1.1808073629993032e-08
somatic O 0 4.31383159593679e-06
mosaicism O 0 0.00026147085009142756
. O 0 5.6539416704026735e-08
. O 0 1.9181506161203288e-07

Aspartylglucosaminuria B-Disease 1 1.0
among O 0 2.4299185952258995e-06
Palestinian O 0 8.532109859515913e-06
Arabs O 0 3.858143827528693e-06
. O 0 1.0788862709887326e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.004096653778105974
AGU B-Disease 1 1.0
) O 0 6.361796778264761e-08
is O 0 3.1359557173260555e-09
a O 0 3.066077880475859e-08
rare O 0 1.13278483695467e-05
disorder B-Disease 1 1.0
of I-Disease 1 0.9999934434890747
glycoprotein I-Disease 1 0.9999605417251587
metabolism I-Disease 0 0.03559992462396622
caused O 0 1.0847323750340365e-07
by O 0 4.925509444753118e-10
the O 0 5.7449941692766515e-08
deficiency B-Disease 0 7.547644781880081e-05
of I-Disease 0 4.668920155381784e-06
the I-Disease 0 5.1307870307937264e-06
lysosomal I-Disease 0 3.3019336115103215e-05
enzyme I-Disease 0 4.230856802678318e-07
aspartylglucosaminidase I-Disease 0 9.439714290238044e-07
( O 0 1.363163248946364e-09
AGA O 0 3.431528602959588e-05
) O 0 4.874427528278602e-09
. O 0 5.985184969858892e-08

AGU B-Disease 1 1.0
is O 0 3.0324065392051125e-06
inherited O 1 0.879135012626648
as O 0 3.1647067544327e-07
an O 0 1.0718204990212143e-08
autosomal O 0 0.0009790825424715877
recessive O 0 6.196882895892486e-05
trait O 0 2.0613274500647094e-06
and O 0 4.720781987543887e-09
occurs O 0 1.3352251526654868e-09
with O 0 5.400559513479841e-11
a O 0 1.9738994883056193e-09
high O 0 5.3265232224930514e-08
frequency O 0 1.948802363926916e-08
in O 0 5.087877674725405e-09
Finland O 0 9.542227452641328e-09
because O 0 3.9905208026880246e-09
of O 0 1.2449784492218896e-07
a O 0 1.9361839065368258e-07
founder O 0 1.3799135558656417e-06
effect O 0 1.0091742552731375e-07
. O 0 2.7990864737148513e-07

While O 0 6.696271270811849e-07
very O 0 5.744862718870536e-08
few O 0 6.908642546932242e-08
patients O 0 1.0199470068528171e-07
with O 0 6.998978108185838e-08
AGU B-Disease 1 1.0
have O 0 7.068787226671702e-07
been O 0 4.5000096093872344e-08
reported O 0 3.786388091953086e-09
from O 0 1.1963515733626195e-09
non O 0 1.009874850410597e-08
- O 0 3.094690725902183e-08
Finnish O 0 5.329530949893524e-07
origin O 0 3.335886233912788e-08
, O 0 6.976091704302689e-09
we O 0 7.155582348872258e-09
diagnosed O 0 4.084823012817651e-05
the O 0 3.2937853688963514e-07
disorder O 0 6.790840870962711e-06
in O 0 2.805893961621564e-09
8 O 0 8.503333148723868e-09
patients O 0 1.6181071760268395e-10
originating O 0 7.981848515470347e-10
from O 0 9.722546323587267e-09
3 O 0 3.952293639031268e-07
unrelated O 0 8.25923223146674e-08
families O 0 3.84889853322079e-09
, O 0 2.429687562255367e-10
all O 0 2.363650386527638e-10
Palestinian O 0 3.5971005729606986e-08
Arabs O 0 5.482055254191209e-09
from O 0 6.087554349498703e-10
the O 0 2.5081210441868507e-09
region O 0 2.642578600386969e-09
of O 0 1.4119158286973743e-08
Jerusalem O 0 4.88905743623036e-06
. O 0 8.134501285894657e-07

The O 0 3.46697447639599e-07
clinical O 0 4.487064416025532e-06
diagnosis O 1 1.0
of O 1 1.0
AGU B-Disease 1 1.0
is O 0 2.8484544145612745e-06
often O 0 4.3782679703952e-09
difficult O 0 2.5144450077618785e-08
, O 0 1.6948598080546162e-10
in O 0 8.092029130102318e-11
particular O 0 5.578034145692357e-10
early O 0 4.010545922028541e-07
in O 0 3.856180708083912e-09
the O 0 1.0269565642317957e-08
course O 0 1.503022595272796e-08
of O 0 4.265635844546978e-09
the O 0 7.565171600276699e-09
disease O 0 3.188022503763932e-07
, O 0 6.557676623941688e-11
and O 0 1.3955715749691677e-10
most O 0 6.156000709189868e-10
of O 0 3.122593383864114e-08
the O 0 1.4710788320826396e-07
patients O 0 1.1244371656005114e-08
are O 0 1.7988324718665183e-10
diagnosed O 0 4.106694859729032e-07
after O 0 2.0451777515972935e-07
the O 0 5.464894670126341e-08
age O 0 1.797496729238901e-08
of O 0 7.127430023956549e-08
5 O 0 8.944149243461652e-08
years O 0 2.1769384517256185e-08
. O 0 2.0923481258705579e-07

However O 0 9.533478078083135e-07
, O 0 1.107739411310149e-08
since O 0 7.853640404675843e-09
these O 0 4.355161786762096e-10
patients O 0 4.720368096400307e-09
excrete O 0 1.1160340562810234e-07
early O 0 5.187952822893749e-08
large O 0 7.685386216316203e-10
amounts O 0 2.1286756801686124e-09
of O 0 1.009703751719826e-07
aspartylglucosamine O 0 3.3419253213651245e-06
in O 0 1.5714268997157887e-08
urine O 0 1.484200407020353e-08
, O 0 2.754310113317615e-10
biochemical O 0 8.386012773087259e-09
screening O 0 7.13978423050321e-08
is O 0 1.8607266838444048e-09
easy O 0 7.641014931891732e-09
by O 0 1.505098712328845e-09
urine O 0 2.14623163685701e-08
chromatography O 0 1.9835286479974457e-07
. O 0 7.221122189093876e-08
. O 0 3.688994638650911e-07

Detection O 0 6.11982904956676e-05
of O 0 2.209748117820709e-06
heterozygous O 0 1.6017544623991853e-08
carriers O 0 4.079967474979185e-09
of O 0 7.703606286213471e-08
the O 0 1.2542381227831356e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 5.350696596906346e-07
ATM O 0 1.5199124163700617e-06
) O 0 2.9225233344476464e-10
gene O 0 2.713419489097646e-10
by O 0 1.6613840858603623e-10
G2 O 0 3.711593592470308e-07
phase O 0 4.010438487966894e-07
chromosomal O 0 9.056483918357117e-07
radiosensitivity O 0 2.09575205190049e-06
of O 0 1.4796178504639101e-07
peripheral O 0 0.00014283960626926273
blood O 0 7.179316071415087e-06
lymphocytes O 0 3.5686496175912907e-06
. O 0 6.420443128263287e-07

In O 0 6.208755075931549e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9863280057907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.4545359583451045e-08
patients O 0 7.650917233092969e-09
, O 0 9.029480635414089e-11
mutations O 0 3.193762615483209e-11
in O 0 2.1635204738856828e-10
a O 0 1.4676722059903113e-09
single O 0 1.0785010662317518e-09
gene O 0 3.6158764871174753e-10
, O 0 4.57030073508502e-11
ATM O 0 5.54289014687015e-09
, O 0 7.80688187707046e-12
result O 0 1.2700911156127148e-10
in O 0 3.1854918702833857e-09
an O 0 6.957516802685859e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 3.0298366482384154e-08
embraces O 0 3.608425203083243e-08
a O 0 9.958573965462847e-10
variety O 0 9.56301260401915e-10
of O 0 1.9460722811004416e-08
clinical O 0 8.466420808872499e-07
features O 0 9.533714546705596e-07
and O 0 3.090756592882826e-07
manifests O 0 7.404374287034443e-07
extreme O 0 4.619632818503305e-05
radiosensitivity O 0 7.43762866477482e-05
and O 0 1.803469302785743e-07
a O 0 1.5836270961244736e-07
strong O 0 1.5346508064340014e-07
pre O 0 0.0025139828212559223
- O 0 3.163208020851016e-05
disposition O 0 0.00010057608596980572
to O 0 5.116950205774629e-07
malignancy B-Disease 1 0.899109423160553
. O 0 1.4514425856759772e-06

Heterozygotes O 0 1.8429282135912217e-05
for O 0 2.8114487804487e-07
the O 0 6.363283659993613e-07
ATM O 0 1.3327090755410609e-06
gene O 0 6.106652516990607e-09
have O 0 2.11911418968036e-10
no O 0 3.292204842075819e-10
clinical O 0 2.5417210558487113e-09
expression O 0 4.885345461502766e-09
of O 0 2.264445129185333e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 5.561021865219118e-08
may O 0 3.891203803618737e-08
be O 0 5.228021127123839e-09
cancer B-Disease 0 4.750800599140348e-06
prone O 0 2.934244491825666e-08
with O 0 2.5805399483935787e-10
a O 0 3.32001732772369e-08
moderate O 0 2.1112700210323965e-07
increase O 0 2.2239758923348063e-09
in O 0 1.8031348858471574e-08
in O 0 3.278772808812391e-08
vitro O 0 1.982361027330626e-06
radiosensitivity O 0 1.0746631232905202e-05
. O 0 4.3729380649892846e-07

We O 0 3.203118694727891e-06
performed O 0 1.0651185675669694e-06
a O 0 4.535277753348055e-07
blind O 0 4.244706985900848e-07
chromosomal O 0 2.7092187337984797e-07
analysis O 0 2.1337173805591192e-08
on O 0 1.1664190679994135e-07
G2 O 0 3.074983396800235e-07
- O 0 1.105615865526488e-08
phase O 0 2.993659009575822e-08
lymphocytes O 0 6.4403224975251305e-09
from O 0 1.3616430205587449e-09
7 O 0 9.181782445466524e-09
unrelated O 0 3.690461625183161e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 6.242129302336252e-07
, O 0 1.256866499765863e-09
13 O 0 8.166555431898814e-09
obligate O 0 7.100766907797151e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 5.629553470498649e-06
( O 0 3.8599190510524295e-09
parents O 0 6.0787130884421e-10
of O 0 5.0111381710848946e-09
the O 0 5.169656258630084e-09
patients O 0 6.771471716682242e-10
) O 0 5.241055159310726e-11
, O 0 8.08425409948299e-11
and O 0 1.8219200592639595e-09
14 O 0 1.6713178396798867e-08
normal O 0 2.587289493760636e-08
controls O 0 3.2331776367300336e-08
following O 0 8.044287014286056e-09
X O 0 9.626171504351078e-07
- O 0 4.760160976502448e-08
irradiation O 0 1.9394217076751374e-07
with O 0 3.841806428539485e-09
1 O 0 2.0937993383540743e-07
Gy O 0 9.974120075639803e-06
in O 0 7.748618413572217e-10
order O 0 2.069947102611991e-09
to O 0 1.158820706059771e-09
evaluate O 0 3.4600748932689385e-09
this O 0 8.316194399782262e-10
cytogenetic O 0 4.176806953637424e-07
method O 0 3.106115897821837e-08
as O 0 1.243038783016459e-09
a O 0 1.0356701052316453e-09
tool O 0 9.506241127610338e-09
for O 0 3.542031945524826e-10
detection O 0 1.7351153474010061e-06
of O 0 5.003219030186301e-07
ATM O 0 1.2706052075373009e-05
carriers O 0 2.8365627713355934e-07
. O 0 1.1144211384817027e-06

Both O 0 4.267280746717006e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 1 0.5166921019554138
and O 0 3.0096066439000424e-07
heterozygotes O 0 5.55330530005449e-07
showed O 0 9.694917757485655e-09
significantly O 0 2.0577597403814707e-09
increased O 0 3.4017549888076815e-10
levels O 0 1.8625376796421733e-09
of O 0 6.355342474506642e-09
radiation O 0 0.0031312049832195044
- O 0 4.788390924659325e-06
induced O 0 2.388525717833545e-05
chromatid O 0 0.00022239725512918085
damage O 0 0.0001221161219291389
relative O 0 4.603233207944868e-07
to O 0 2.0630492869599948e-09
that O 0 2.507225260739432e-10
of O 0 2.2256108067608693e-08
normal O 0 1.2416158767791785e-07
controls O 0 5.499473445524927e-07
. O 0 1.1535535549000997e-07

These O 0 3.161741233270732e-07
results O 0 1.247890821787223e-07
show O 0 1.7749700376157307e-08
that O 0 1.2967091844728884e-09
the O 0 4.351678484226795e-08
G2 O 0 7.678427209611982e-06
- O 0 1.3296279348651296e-06
phase O 0 4.089520643901778e-06
chromosomal O 0 9.834464435698465e-06
radiosensitivity O 0 3.569143245840678e-06
assay O 0 1.982427875191206e-07
can O 0 3.82999576498122e-10
be O 0 1.7567101939786056e-10
used O 0 4.4562312173646035e-10
for O 0 1.0685859835879441e-10
the O 0 8.318193356338099e-10
detection O 0 1.020769786919118e-06
of O 0 1.9574601992644602e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 7.402836490655318e-05
. O 0 2.8989484235353302e-06

In O 0 3.547604023879103e-07
combination O 0 3.908364476501447e-07
with O 0 1.2337848964705245e-08
molecular O 0 7.55822895825986e-07
genetic O 0 2.2720327308434207e-07
analyses O 0 2.8123574580263266e-08
, O 0 6.500891491789673e-10
this O 0 1.775422031613516e-10
test O 0 2.729178882887595e-09
may O 0 3.618649824232989e-10
be O 0 5.898996568998172e-11
of O 0 2.430568246669651e-10
value O 0 1.0400325045623049e-10
in O 0 1.7125786899718776e-11
studies O 0 2.2121955309262198e-11
of O 0 1.3540133458889159e-09
familial B-Disease 0 2.9009763125031895e-07
and I-Disease 0 4.815463938712128e-08
sporadic I-Disease 0 2.503303221601527e-06
cancers I-Disease 0 0.12087303400039673
aimed O 0 2.3193780407382292e-07
at O 0 5.674684899759086e-08
determination O 0 2.3874859422789996e-08
of O 0 2.5316829521671025e-08
the O 0 5.150287307742474e-09
potential O 0 2.9722759808947785e-09
involvement O 0 6.448533262926048e-09
of O 0 3.754044186621286e-08
ATM O 0 3.166108854202321e-06
mutations O 0 9.090455499460859e-09
in O 0 2.0742865203260408e-09
tumor B-Disease 0 6.546883923874702e-06
risk O 0 1.913410585530073e-08
or O 0 1.1074900996277393e-08
development O 0 5.818437998073023e-08
. O 0 2.0904327158177693e-08
. O 0 4.3400328308962344e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 1.058693470668004e-07
identification O 0 7.461466111635673e-08
and O 0 4.306165646283944e-09
detection O 0 2.9823157092323527e-05
of O 0 8.621388587926049e-06
founder O 0 0.0002226401848020032
- O 0 6.079611694076448e-07
effect O 0 4.417814025714506e-08
mutations O 0 2.047994218656868e-09
in O 0 1.1434428959233855e-09
the O 0 1.1452967463299046e-08
ATM O 0 1.5352715365679614e-07
gene O 0 1.674753780100957e-09
in O 0 5.182705375972319e-10
ethnic O 0 5.8687210646724e-10
populations O 0 1.0253633497825376e-08
. O 0 1.9533580086772417e-07

To O 0 2.111932388970672e-07
facilitate O 0 1.390893942243565e-07
the O 0 4.314454926657163e-08
evaluation O 0 1.668178413183341e-07
of O 0 3.991996777585882e-07
ATM O 0 7.695125532336533e-06
heterozygotes O 0 1.9662316219637432e-07
for O 0 1.7957139109014975e-09
susceptibility O 0 6.583313734154217e-07
to O 0 3.6177960627270522e-09
other O 0 3.642424362126917e-09
diseases O 1 0.9572255611419678
, O 0 2.8098826043709835e-10
such O 0 6.100273619580321e-09
as O 0 6.365068111335859e-05
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
, O 0 3.771640333383175e-09
we O 0 6.354999859681243e-10
have O 0 3.969793938018995e-10
attempted O 0 8.001687490377662e-08
to O 0 4.654689966798742e-09
define O 0 1.2497864076976839e-08
the O 0 1.8975937265963694e-08
most O 0 7.811432611859459e-10
common O 0 1.1862969495624043e-09
mutations O 0 1.2473559685144409e-10
and O 0 1.0359857416375462e-10
their O 0 5.580076956057667e-10
frequencies O 0 1.928498782888255e-08
in O 0 1.0361689817273145e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.12959682941436768
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.796235338247243e-08
homozygotes O 0 2.880924512282945e-07
from O 0 9.55723677975584e-09
10 O 0 3.05197400685131e-09
ethnic O 0 3.9181302646795757e-10
populations O 0 5.26347054830012e-09
. O 0 9.889531327189616e-08

Both O 0 1.4169951612075238e-07
genomic O 0 1.0681835647119442e-06
mutations O 0 4.971745326542987e-08
and O 0 3.7446028500198736e-09
their O 0 1.56252855099126e-09
effects O 0 9.6661736392889e-08
on O 0 1.321252085517699e-07
cDNA O 0 1.573581158709203e-07
were O 0 8.520006034018479e-09
characterized O 0 2.2015878187175986e-07
. O 0 3.0292710562207503e-07

Protein O 0 2.132018380507361e-06
- O 0 5.455713676383311e-07
truncation O 0 1.69996599197475e-06
testing O 0 8.517736205249093e-08
of O 0 8.510557591989709e-08
the O 0 6.230543903029684e-08
entire O 0 1.090622063770752e-07
ATM O 0 2.767779676560167e-07
cDNA O 0 6.174903433020518e-08
detected O 0 2.914877406112737e-08
92 O 0 5.414275250359424e-08
( O 0 5.512985068456544e-10
66 O 0 6.43685904577751e-09
% O 0 2.6819196863314687e-10
) O 0 8.731098483094613e-11
truncating O 0 2.0934294298058376e-08
mutations O 0 1.4727479236142926e-09
in O 0 1.7805913410384733e-09
140 O 0 7.500059240328483e-09
mutant O 0 1.5840177169934577e-08
alleles O 0 6.478659830833067e-10
screened O 0 9.172526915790513e-08
. O 0 1.0594812493991412e-07

The O 0 1.0658081009751186e-05
haplotyping O 0 0.00041115417843684554
of O 0 3.8104283248685533e-06
patients O 0 2.1851799658634263e-07
with O 0 1.8703980586565194e-09
identical O 0 8.339096666531987e-07
mutations O 0 4.639801076677941e-08
indicates O 0 1.2653821990227243e-08
that O 0 4.019830579515826e-10
almost O 0 5.245498480022093e-10
all O 0 1.4640647028052456e-10
of O 0 1.081896461307963e-09
these O 0 2.8292359774417797e-11
represent O 0 1.8576891760990755e-11
common O 0 1.324470422225943e-09
ancestry O 0 4.834610489723445e-10
and O 0 1.0233049824170948e-10
that O 0 1.6879646985712426e-11
very O 0 4.2853193216174645e-10
few O 0 1.6445866890535399e-09
spontaneously O 0 9.09020803074867e-10
recurring O 0 3.714202279070378e-08
ATM O 0 2.0642448816943215e-06
mutations O 0 1.2370460211741374e-08
exist O 0 1.2447737063325803e-08
. O 0 2.7149863512931915e-07

Assays O 0 1.2341139154159464e-05
requiring O 0 4.1592423372094345e-07
minimal O 0 1.070975372385874e-06
amounts O 0 1.6143419045988594e-08
of O 0 8.72709460253418e-09
genomic O 0 1.2014218953027012e-08
DNA O 0 1.639488722560145e-08
were O 0 9.563649872035285e-10
designed O 0 6.054879264638657e-09
to O 0 6.776885719261827e-10
allow O 0 1.3042225077697367e-09
rapid O 0 7.918347755264676e-09
screening O 0 1.3955091304751477e-08
for O 0 1.4722696672908597e-10
common O 0 1.12784326322668e-09
ethnic O 0 6.927822759905666e-10
mutations O 0 1.1273877831285972e-08
. O 0 7.409050795104122e-08

These O 0 6.928647877657568e-08
rapid O 0 2.664515932337963e-07
assays O 0 1.3827916234276927e-07
detected O 0 7.165473903114616e-08
mutations O 0 1.067339994165195e-09
in O 0 1.0214743495495782e-09
76 O 0 2.1343197431633598e-08
% O 0 4.99116081797979e-10
of O 0 4.160524813556776e-09
Costa O 0 3.2526094173590536e-07
Rican O 0 1.4531391343552968e-06
patients O 0 5.690965565463557e-08
( O 0 9.304498282958207e-10
3 O 0 2.1230121660664736e-08
) O 0 6.098382909769384e-11
, O 0 3.8638630489584713e-11
50 O 0 1.1759919427145604e-10
% O 0 1.0621809681810035e-10
of O 0 4.65872274091339e-09
Norwegian O 0 8.637572364023072e-07
patients O 0 8.20145906743619e-09
( O 0 3.860130826094377e-10
1 O 0 1.3729987813348998e-08
) O 0 3.713368501578884e-11
, O 0 3.536643200519052e-11
25 O 0 6.969784194232886e-10
% O 0 1.5871158554059406e-10
of O 0 4.998508718045969e-09
Polish O 0 4.596983126248233e-05
patients O 0 2.3437567620021582e-07
( O 0 2.014601818700612e-09
4 O 0 4.348791193820034e-08
) O 0 1.8459143935611877e-10
, O 0 1.0939726902137181e-10
and O 0 9.142162027409029e-10
14 O 0 4.631522720899284e-09
% O 0 2.0908973163979994e-10
of O 0 7.864943363244947e-09
Italian O 0 1.944686573551735e-06
patients O 0 6.777499095278472e-08
( O 0 1.1018701506770867e-09
1 O 0 9.805255274386582e-08
) O 0 1.717610775830991e-10
, O 0 1.1206035405164627e-10
as O 0 6.239980754330077e-10
well O 0 1.2298699836321703e-09
as O 0 1.4678738224915833e-09
in O 0 3.656657476813763e-10
patients O 0 2.047291225437675e-09
of O 0 5.19535987564268e-08
Amish O 0 1.4052832284505712e-06
/ O 0 1.1233759096285212e-06
Mennonite O 0 1.571270331623964e-06
and O 0 3.869356035579585e-08
Irish O 0 1.938434053272431e-07
English O 0 1.397232836097828e-07
backgrounds O 0 1.4853706886697182e-07
. O 0 2.54002202382253e-07

Additional O 0 1.587875146924489e-07
mutations O 0 2.016213329625316e-08
were O 0 2.8558813092161017e-09
observed O 0 1.9290569142071945e-09
in O 0 1.619108402906022e-09
Japanese O 0 8.335502457157418e-07
, O 0 6.184932122010878e-09
Utah O 0 5.449140871860436e-07
Mormon O 0 7.688942105232854e-08
, O 0 2.7584950990089396e-10
and O 0 2.525006037590316e-10
African O 0 2.0492680885553227e-09
American O 0 6.029087895598195e-09
patients O 0 1.5228092564711915e-08
. O 0 1.4046827345737256e-07

These O 0 4.581374568601859e-08
assays O 0 8.68702585421488e-08
should O 0 1.6816870118674387e-09
facilitate O 0 1.3886076732916308e-09
screening O 0 1.8245847499542833e-08
for O 0 9.23540621755592e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 4.097941655345494e-06
in O 0 6.727409296303222e-09
the O 0 4.84034234915498e-09
populations O 0 1.426382206792809e-10
studied O 0 1.1150607104326582e-09
. O 0 1.093585222378124e-09
. O 0 5.837869210267854e-08

The O 0 2.8192478566779755e-05
von B-Disease 1 0.9999992847442627
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999996423721313
Lindau I-Disease 1 0.9998987913131714
tumor I-Disease 0 0.0004526874690782279
suppressor O 0 2.864027010218706e-06
gene O 0 2.6282775955621673e-09
is O 0 7.32952726290037e-11
required O 0 2.3055961306805983e-10
for O 0 3.448727414756547e-10
cell O 0 3.017978400521315e-08
cycle O 0 2.4970421286241162e-09
exit O 0 2.8222646442088717e-09
upon O 0 4.231778483188009e-09
serum O 0 5.400464431204455e-08
withdrawal O 0 1.4198019471223233e-07
. O 0 3.6083088161831256e-07

The O 0 5.775334102509078e-06
inactivation O 0 6.241023220354691e-05
of O 0 1.7790122228689143e-06
the O 0 6.562239605045761e-07
von B-Disease 1 0.9999880790710449
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999997615814209
Lindau I-Disease 1 0.9999994039535522
( I-Disease 0 1.014873987514875e-06
VHL I-Disease 1 0.9999998807907104
) I-Disease 0 2.7014036163564015e-07
tumor I-Disease 0 0.042837850749492645
suppressor O 0 0.0004221982671879232
gene O 0 2.8894265824419563e-07
predisposes O 0 1.521879227084355e-07
affected O 0 7.414175384745647e-10
individuals O 0 8.472851760477074e-12
to O 0 3.801176318152244e-10
the O 0 3.421083505372735e-08
human O 0 0.00030110051739029586
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 4.4899398088382725e-10
is O 0 1.2859348134941495e-11
associated O 0 9.229127878596088e-11
with O 0 5.2532853067610574e-11
sporadic B-Disease 0 2.1444702724693343e-05
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 0 1.3978565505112783e-07
RCC B-Disease 1 0.511734664440155
) O 0 1.630715829037399e-08
and O 0 8.863260063662892e-07
brain B-Disease 1 0.9999945163726807
hemangioblastomas I-Disease 0 0.0029538003727793694
. O 0 2.211512764915824e-06

VHL O 0 0.04104406759142876
- O 0 8.002524555195123e-05
negative O 0 1.5866429521338432e-06
786 O 0 2.0703644622699358e-05
- O 0 3.783025749726221e-05
0 O 0 8.077882966972538e-07
RCC B-Disease 0 0.0003316714137326926
cells O 0 1.089486431737896e-06
are O 0 6.5537193449927145e-09
tumorigenic O 0 0.00016175063501577824
in O 0 1.3887122918276873e-07
nude O 0 5.5340823479355095e-08
mice O 0 8.738687995446526e-09
which O 0 2.8714572386512316e-10
is O 0 1.2267346860550532e-10
suppressed O 0 3.1620288609701674e-09
by O 0 3.5408836973616076e-10
the O 0 3.405315851523483e-08
reintroduction O 0 3.132173105768743e-06
of O 0 3.8647948485959205e-07
VHL B-Disease 0 0.18808458745479584
. O 0 7.0243331720121205e-06

Remarkably O 0 5.2136390877421945e-05
, O 0 9.956034219271714e-09
this O 0 3.947746018972964e-10
occurs O 0 2.1263504290658375e-09
without O 0 9.96792426377624e-10
affecting O 0 6.677307040625635e-10
the O 0 1.1203370453571893e-09
growth O 0 2.0894301566709572e-10
rate O 0 7.645704624970051e-10
and O 0 6.846380129488239e-10
cell O 0 1.8258873524246155e-07
cycle O 0 4.209896875551067e-09
profile O 0 1.061169041527421e-09
of O 0 9.530273237245979e-10
these O 0 8.495300990452037e-11
cells O 0 2.2971560209583686e-09
in O 0 1.3135819099119317e-09
culture O 0 3.5935347142412866e-08
. O 0 6.161503307566818e-08

The O 0 8.188243555196095e-06
786 O 0 1.3339423276192974e-05
- O 0 3.0503949801641284e-06
0 O 0 1.8016797298514575e-07
cell O 0 4.43683120465721e-07
line O 0 1.2072896424797364e-06
, O 0 2.3260524617541023e-09
like O 0 3.0373630277580332e-09
many O 0 2.0964532332357066e-09
cancer B-Disease 0 4.852759957429953e-06
cells O 0 7.236426569079413e-08
, O 0 2.848624003348732e-09
fails O 0 9.300496373043643e-08
to O 0 3.510826473984707e-08
exit O 0 1.5336619298977894e-06
the O 0 1.2015689776490035e-07
cell O 0 9.991059357616905e-08
cycle O 0 1.6810649539067413e-09
upon O 0 1.4250367552648413e-09
serum O 0 2.9926766842436336e-08
withdrawal O 0 6.337466373906864e-08
. O 0 1.9820348029497836e-07

Here O 0 1.8880120933317812e-06
, O 0 7.531783197123332e-09
it O 0 3.069445253522929e-10
is O 0 1.3538423160319724e-10
shown O 0 8.508176108090737e-11
that O 0 3.738404377728877e-11
reintroduction O 0 9.322839389369619e-08
of O 0 1.9043957522058008e-08
the O 0 6.671774599453784e-08
wild O 0 9.261817268679806e-08
- O 0 6.333068114372509e-08
type O 0 3.2511920267097594e-07
VHL B-Disease 1 0.786949872970581
gene O 0 1.3712318605030305e-06
restores O 0 7.618491963512497e-06
the O 0 1.2090474399428786e-07
ability O 0 3.231303580264466e-08
of O 0 1.0269956192132668e-06
VHL O 1 1.0
- O 0 0.02968190796673298
negative O 0 4.344662727362447e-07
RCC B-Disease 1 0.9995899796485901
cancer I-Disease 0 6.015854887664318e-05
cells O 0 1.2853679010049746e-08
to O 0 3.4740545995504135e-09
exit O 0 4.452038737667863e-08
the O 0 9.150854296535726e-09
cell O 0 3.2080290424119084e-08
cycle O 0 1.3668577381054092e-09
and O 0 4.3328407528520074e-10
enter O 0 3.449822827406024e-08
G0 O 0 0.00011302057828288525
/ O 0 7.282559636223596e-06
quiescence O 0 7.011998150119325e-06
in O 0 2.609169058587213e-08
low O 0 6.979807380957936e-07
serum O 0 8.572577598897624e-07
. O 0 2.5641682555033185e-07

Both O 0 6.693188879580703e-06
VHL O 1 0.9998847246170044
- O 0 0.00026140359113924205
positive O 0 7.372469923438985e-08
and O 0 2.016190876474866e-07
VHL O 1 1.0
- O 0 0.058400459587574005
negative O 0 2.876619475955522e-07
RCC B-Disease 0 0.07030039280653
cells O 0 9.170748853648547e-07
exit O 0 4.970247573510278e-07
the O 0 1.0367219971385566e-08
cell O 0 1.373978530949671e-08
cycle O 0 1.3505049856199491e-10
by O 0 6.306284487667124e-12
contact O 0 1.8860242256835136e-09
inhibition O 0 1.2087349432476913e-07
. O 0 3.24794115158511e-07

The O 0 2.0293684428907e-05
cyclin O 0 3.752065822482109e-05
- O 0 4.53302209280082e-06
dependent O 0 7.785348543620785e-07
kinase O 0 9.931436579790898e-07
inhibitor O 0 1.263612290358651e-07
, O 0 1.1459668769475684e-09
p27 O 0 2.3071187627010659e-07
, O 0 3.03376601618055e-10
accumulates O 0 5.530470748027483e-09
upon O 0 1.1744188954665447e-09
serum O 0 1.660986370666251e-08
withdrawal O 0 7.678035096603253e-09
, O 0 2.7992108631025303e-10
only O 0 4.887456064861517e-11
in O 0 1.3030407308711744e-10
the O 0 1.505414570779351e-09
presence O 0 2.900345963396944e-09
of O 0 1.3215041860803467e-07
VHL B-Disease 1 0.9998282194137573
, O 0 2.2343172645378218e-08
as O 0 4.2738941274933495e-09
a O 0 1.1190171012032124e-09
result O 0 1.1890606277376037e-09
of O 0 8.257841521697173e-09
the O 0 1.0941845651757376e-08
stabilization O 0 7.958032597343845e-07
of O 0 1.837822537709144e-06
the O 0 1.0563451269263169e-06
protein O 0 1.6581999489062582e-06
. O 0 4.284420924705046e-07

We O 0 3.51961688238589e-07
propose O 0 9.553995994338038e-08
that O 0 2.448427460777225e-09
the O 0 4.1391636784737784e-08
loss O 0 2.6241048090014374e-07
of O 0 5.251270067674341e-07
wild O 0 6.924664717189444e-07
- O 0 2.072858649171394e-07
type O 0 6.43287307866558e-07
VHL B-Disease 1 0.9993969202041626
gene O 0 1.0385235071908028e-07
results O 0 5.243170342339454e-09
in O 0 3.2678577621680915e-09
a O 0 1.807949523424668e-08
specific O 0 1.5018152055290557e-07
cellular O 0 4.731710305350134e-06
defect O 0 9.999312169384211e-07
in O 0 1.0875119471620565e-08
serum O 0 3.2279451716021867e-06
- O 0 4.011443252238678e-06
dependent O 0 1.278166052998131e-07
growth O 0 5.835561367462105e-09
control O 0 1.1130197208331083e-07
, O 0 1.9679512186510095e-10
which O 0 5.682073561663614e-11
may O 0 2.476863603106949e-09
initiate O 0 2.6432202204773603e-08
tumor B-Disease 0 1.1273167501713033e-06
formation O 0 7.253394755935005e-07
. O 0 5.299860390550748e-07

This O 0 8.979874621672934e-08
is O 0 4.589908453311864e-09
corrected O 0 2.6207652936705017e-08
by O 0 3.3874006377665467e-10
the O 0 9.444468318520194e-09
reintroduction O 0 5.335924129212799e-07
of O 0 1.1229030150161634e-07
wild O 0 2.2711228098160063e-07
- O 0 1.1367550456498066e-07
type O 0 2.4836901957314694e-06
VHL B-Disease 1 1.0
, O 0 2.64400000560272e-07
implicating O 0 4.5740645873593166e-05
VHL B-Disease 1 1.0
as O 0 7.203676432254724e-06
the O 0 1.6115826610985096e-06
first O 0 1.1018543233376477e-07
tumor B-Disease 0 6.884589538458386e-07
suppressor O 0 1.1493850848864895e-07
involved O 0 1.2703244012257642e-09
in O 0 1.9793584549177012e-09
the O 0 6.566997967638599e-08
regulation O 0 2.0062822159161442e-07
of O 0 6.124104601212821e-08
cell O 0 5.29972908225318e-07
cycle O 0 1.797037363360232e-08
exit O 0 2.313628932881784e-08
, O 0 4.263890629463418e-11
which O 0 1.039643284656e-11
is O 0 2.075828051117945e-11
consistent O 0 6.375152628024239e-10
with O 0 1.6368374711195344e-10
its O 0 6.242269368073039e-09
gatekeeper O 0 3.1257462751455023e-07
function O 0 1.01387898077121e-09
in O 0 6.74139410961061e-10
the O 0 9.84559989092304e-09
kidney O 0 1.2471650734369177e-05
. O 0 2.339669258333288e-08
. O 0 1.7449178812967148e-07

Piebaldism B-Disease 1 1.0
with O 1 0.9999736547470093
deafness B-Disease 1 1.0
: O 0 1.988168030209181e-08
molecular O 0 3.0749095714099894e-08
evidence O 0 1.5231462313636257e-08
for O 0 1.2251686332120926e-09
an O 0 1.4605511244880631e-09
expanded O 0 7.65302320360206e-06
syndrome O 1 1.0
. O 0 1.666883508733008e-05

In O 0 4.830910143027722e-07
a O 0 2.754439947239007e-07
South O 0 1.7964586618290923e-07
African O 0 1.215342759763871e-08
girl O 0 5.3848921766075364e-08
of O 0 2.955797562265161e-08
Xhosa O 0 1.4365163224283606e-05
stock O 0 1.298452190212629e-08
with O 0 1.0498642927236901e-10
severe O 0 3.3300275390502065e-05
piebaldism B-Disease 0 0.3233957588672638
and O 0 7.5235038821119815e-06
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 1.7547515653859591e-06
identified O 0 1.1586313242162305e-08
a O 0 2.787618580413209e-09
novel O 0 8.61113669259339e-09
missense O 0 5.038118899847177e-08
substitution O 0 2.0445887116693484e-07
at O 0 2.4876959514585906e-07
a O 0 2.14623163685701e-08
highly O 0 3.4998080877812754e-08
conserved O 0 3.3288689138544214e-08
residue O 0 7.18771673291485e-08
in O 0 1.7837865629033445e-09
the O 0 8.55077608719057e-09
intracellular O 0 8.055663691663995e-09
kinase O 0 2.3036950125288058e-08
domain O 0 3.2190847765178887e-09
of O 0 1.051414333375078e-08
the O 0 4.275216980431651e-08
KIT O 0 2.111346839228645e-05
proto O 0 4.381531471153721e-05
- O 0 8.163643542502541e-06
oncogene O 0 1.0715469215938356e-05
, O 0 9.571647474615474e-09
R796G O 0 1.1558356618479593e-06
. O 0 3.3990480119427957e-07

Though O 0 7.6056930993217975e-06
auditory B-Disease 0 0.007738777901977301
anomalies I-Disease 0 3.033904249605257e-05
have O 0 1.1948221967372774e-08
been O 0 8.713755050848704e-09
observed O 0 8.63669757933394e-09
in O 0 4.26026947053515e-09
mice O 0 1.9377903726081058e-08
with O 0 2.267986909387787e-09
dominant O 0 0.0001285933394683525
white O 0 5.4770112910773605e-05
spotting O 0 1.1830834409920499e-05
( O 0 2.856514491611506e-08
W O 0 1.7967447547562188e-06
) O 0 9.962349695191719e-11
due O 0 1.8359932241196475e-08
to O 0 3.139301041343856e-09
KIT O 1 0.9998482465744019
mutations O 0 1.2024042007396929e-05
, O 0 9.88222154774121e-07
deafness B-Disease 1 1.0
is O 0 3.0141114049087037e-09
not O 0 1.020410700380836e-10
typical O 0 5.757452736787627e-09
in O 0 7.45177364258609e-10
human O 0 1.1891746254377722e-08
piebaldism B-Disease 0 4.6587879296566825e-06
. O 0 5.510966616384394e-07

Thus O 0 2.2573870239739335e-07
, O 0 2.003003762851563e-09
the O 0 6.846105349289644e-10
occurrence O 0 1.4049260421700183e-08
of O 0 1.0694944876377122e-06
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 0 1.8699656720855273e-06
this O 0 2.449694669337532e-08
patient O 0 5.006951369068702e-07
extends O 0 7.739084395552709e-08
considerably O 0 1.1739473393390654e-07
the O 0 2.2868839266720897e-08
phenotypic O 0 2.7657366175048992e-08
range O 0 2.9668626666534692e-08
of O 0 3.4751831634594055e-08
piebaldism B-Disease 0 9.146467618847964e-07
due O 0 2.2546332445472217e-07
to O 0 6.838683397347722e-09
KIT O 0 4.070117483934155e-06
gene O 0 7.932194456827801e-09
mutation O 0 1.0464362709683428e-09
in O 0 7.781256194938635e-11
humans O 0 1.7093561011094494e-09
and O 0 1.6597189178568783e-09
tightens O 0 6.514103745303146e-08
the O 0 2.2890822570786895e-09
clinical O 0 8.930917339000644e-09
similarity O 0 1.583504172231187e-08
between O 0 1.649481973231559e-08
piebaldism B-Disease 0 2.587033804957173e-06
and O 0 1.0918116410962853e-09
the O 0 3.798205083782591e-10
various O 0 1.0198852873344322e-10
forms O 0 4.417382459820374e-09
of O 0 1.1979401506323484e-06
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.6892239784738194e-07
. O 0 6.002539407745644e-07

Cycloheximide O 0 0.00012162710481788963
facilitates O 0 4.556125077215256e-07
the O 0 6.823233178465671e-08
identification O 0 6.271677932545572e-08
of O 0 2.1161945085168554e-07
aberrant O 0 2.4235188789134554e-07
transcripts O 0 9.950001356173743e-08
resulting O 0 3.5381869878392536e-08
from O 0 5.5667919163227e-09
a O 0 1.209644384658759e-08
novel O 0 5.3776560093865555e-08
splice O 0 5.9244366639177315e-06
- O 0 1.8770427914205357e-06
site O 0 7.797849121971012e-08
mutation O 0 1.7082740777496497e-09
in O 0 3.467009734858806e-10
COL17A1 O 0 5.3951698646415025e-06
in O 0 3.136751525190107e-09
a O 0 8.526411576781356e-09
patient O 0 5.717818041262035e-08
with O 0 7.283240233135757e-09
generalized O 0 0.456093966960907
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
. O 0 4.405189974932e-05

Patients O 0 5.96913787376252e-06
with O 0 1.1226331508851217e-07
generalized O 1 0.9998231530189514
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
often O 0 8.499970931552525e-07
show O 0 1.1232046404074936e-08
decreased O 0 1.920649417286313e-09
expression O 0 4.0012654300980444e-10
of O 0 9.197957395734591e-10
type O 0 1.7138557240059527e-08
XVII O 0 8.160385914379731e-05
collagen O 0 2.1610230760416016e-06
, O 0 7.33020577570187e-09
a O 0 6.816336384218857e-09
transmembrane O 0 7.668608859034975e-09
hemidesmosomal O 0 2.0549759227606046e-08
protein O 0 4.455262270219862e-10
encoded O 0 1.2335529819829105e-10
by O 0 3.9455178013625414e-10
COL17A1 O 0 4.152749534114264e-05
. O 0 1.1962197277171072e-06

This O 0 7.633122578454277e-08
report O 0 8.309554822005794e-09
documents O 0 6.980193489880548e-08
a O 0 1.0063007493954501e-07
novel O 0 4.366411872069875e-07
splice O 0 3.6287641705712304e-05
- O 0 5.281633093545679e-06
site O 0 1.0367580927095332e-07
mutation O 0 2.4671977794099575e-09
in O 0 8.362544545725825e-10
COL17A1 O 0 1.8442275177221745e-05
in O 0 4.011139864701363e-09
a O 0 1.7278841468737483e-08
patient O 0 2.825447609211551e-07
with O 0 2.1973626473936747e-08
generalized O 1 0.9998212456703186
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.8332644913243712e-07
and O 0 1.2004277571975308e-08
applies O 0 9.009395895986927e-09
a O 0 3.275539617320078e-09
new O 0 1.6284119608300784e-09
methodology O 0 2.398040876983032e-09
to O 0 5.557050375415429e-10
define O 0 1.1656530185533143e-09
and O 0 1.1702218083442517e-09
characterize O 0 1.7784470784931727e-08
the O 0 8.347552871157404e-09
resulting O 0 9.279053081456823e-09
mRNA O 0 4.3678607397623637e-08
splice O 0 6.88263980919146e-07
variants O 0 8.035181053855922e-08
. O 0 1.1121962728566359e-07

Mutational O 0 0.00036503103910945356
analysis O 0 6.863585326755128e-07
of O 0 2.528961886127945e-06
COL17A1 O 0 0.003961803391575813
identified O 0 9.310752489000151e-07
a O 0 3.535344035299204e-07
maternally O 0 4.812985139324155e-07
inherited O 0 6.447363830375252e-06
G O 0 8.405057997151744e-06
- O 0 8.377841368201189e-06
to O 0 7.759065283607924e-07
- O 0 0.0001461975771235302
T O 0 4.944800821249373e-05
transversion O 0 2.694356589927338e-05
at O 0 7.752528574656026e-08
the O 0 1.2763262446924273e-08
- O 0 1.8125209777508644e-08
1 O 0 1.3903258100356197e-08
position O 0 2.1452086329531994e-08
of O 0 6.906521576865998e-08
exon O 0 1.001072291728633e-06
32 O 0 2.9257287792461284e-07
. O 0 1.2035553709210944e-07

This O 0 8.771823445385962e-08
acceptor O 0 4.9978631011526886e-08
splice O 0 1.125376729760319e-05
- O 0 1.266890990336833e-06
site O 0 1.0543246276029095e-07
mutation O 0 5.813332037973851e-09
led O 0 4.910587492190643e-09
to O 0 1.6779320155535515e-09
the O 0 2.9121487443717342e-08
formation O 0 3.645039612365508e-07
of O 0 3.6070227906748187e-06
aberrant O 0 5.983837922940438e-07
transcripts O 0 3.6307494610809954e-07
present O 0 9.451121485426484e-08
at O 0 8.995629485752943e-08
extremely O 0 3.9021365694225096e-08
low O 0 6.81239384903165e-07
levels O 0 8.26479436000227e-08
. O 0 3.1041616921356763e-07

Based O 0 1.514753648734768e-06
on O 0 2.149482043023454e-06
our O 0 2.88104988754867e-08
recent O 0 2.0001407197156595e-09
finding O 0 5.855441465030253e-09
that O 0 6.742898461808977e-10
cycloheximide O 0 1.810353182918334e-06
stabilized O 0 1.3121826668793801e-05
mutant O 0 1.6286726349790115e-06
COL17A1 O 0 1.535680166853126e-05
transcripts O 0 1.2470246701923315e-07
in O 0 2.785439434660475e-09
keratinocytes O 0 2.1519154813631758e-07
homozygous O 0 1.7809657748557584e-08
for O 0 1.0904629421659706e-09
a O 0 1.4951309523780765e-08
frameshift O 0 4.862910714109603e-07
mutation O 0 2.267590026860944e-08
, O 0 7.454986628019356e-10
the O 0 1.5630801097898939e-09
effects O 0 1.3158813771951827e-07
of O 0 5.580039896813105e-07
the O 0 9.788258239495917e-07
splice O 0 9.455361578147858e-06
- O 0 3.853951398014033e-07
site O 0 2.938086396397921e-08
mutation O 0 8.263005280007008e-10
on O 0 2.2969195434541234e-09
splicing O 0 7.269556068223437e-09
of O 0 9.521374799703608e-09
COL17A1 O 0 1.5126608559512533e-05
transcripts O 0 9.416447710464126e-08
were O 0 3.114193569686563e-09
determined O 0 5.111777223731906e-09
using O 0 1.3561076706025688e-08
reverse O 0 2.1609518796594784e-07
transcriptase O 0 2.7274248282083136e-07
polymerase O 0 7.06221726431977e-07
chain O 0 2.900778994785469e-08
reaction O 0 2.1176123077282227e-09
of O 0 4.138451359381179e-09
total O 0 1.3781371877019666e-10
RNA O 0 8.230917059037779e-10
from O 0 8.612441315669628e-11
keratinocytes O 0 1.981130814954213e-08
incubated O 0 1.496332124872879e-08
for O 0 9.68009450375007e-10
2 O 0 1.2793307746505889e-07
. O 0 7.498717735643368e-08

5 O 0 7.474750873370795e-06
h O 0 9.863334753390518e-07
in O 0 1.4972313167049833e-08
the O 0 1.3976641177748661e-08
presence O 0 3.5305807166707837e-09
or O 0 1.632439783350037e-08
absence O 0 3.81885428168971e-07
of O 0 6.853728109490476e-07
10 O 0 7.999840789807422e-08
microg O 0 1.3378588619161746e-06
cycloheximide O 0 1.1506576811370905e-06
per O 0 3.8762035359241054e-08
ml O 0 6.57968598716252e-07
. O 0 4.1656335270090494e-07

Using O 0 1.1978711711435608e-07
this O 0 1.3274553900544106e-08
approach O 0 2.213026562003506e-07
, O 0 2.2802404409105748e-09
an O 0 4.769653560998677e-10
abnormally O 0 1.5196784275417485e-08
spliced O 0 7.108124577825947e-08
transcript O 0 3.7968547417222e-07
was O 0 1.0597258182087899e-07
identified O 0 1.0798472116491098e-09
that O 0 2.8978658014877645e-11
contains O 0 1.1936591992611767e-10
an O 0 5.486903639773111e-11
extra O 0 2.374197505261577e-09
264 O 0 6.291455800777612e-09
bases O 0 2.4700948841882564e-08
upstream O 0 2.8826548259530682e-08
from O 0 1.518131398370315e-08
exon O 0 1.9720006605439266e-07
32 O 0 1.367886071079738e-08
, O 0 5.2414347168072695e-11
resulting O 0 1.3333952830762996e-09
in O 0 3.3122231624105325e-09
a O 0 2.604063098488041e-08
premature O 0 8.446002652817697e-08
termination O 0 7.66241953442659e-07
codon O 0 2.6064043368023704e-07
27 O 0 1.4318510466182488e-06
bp O 0 3.0342666832439136e-06
downstream O 0 2.769992306639324e-07
from O 0 2.956192268754876e-08
the O 0 1.5990781321306713e-07
cryptic O 0 4.528700628725346e-06
splice O 0 8.234695997089148e-05
site O 0 8.28201518743299e-06
. O 0 6.626296453760006e-07

Three O 0 1.029137933983293e-06
other O 0 3.874954401794639e-08
splice O 0 2.074261828965973e-06
variants O 0 2.1847527875706874e-07
, O 0 2.155724043717555e-09
including O 0 9.776799508864897e-11
one O 0 1.3315265556812506e-10
derived O 0 1.2196428311739282e-09
from O 0 7.960506032134163e-09
the O 0 2.6147835896495053e-08
skipping O 0 4.253645968788078e-08
of O 0 6.478913405771891e-08
exon O 0 6.745824521203758e-08
32 O 0 1.1484772244330088e-08
, O 0 1.610959837750059e-10
were O 0 5.784682177711886e-10
also O 0 3.2138334216114117e-09
identified O 0 6.870364188671374e-08
. O 0 3.849114023068978e-07

These O 0 1.0593903709832375e-07
results O 0 2.288319400634009e-08
indicate O 0 2.2754408135483573e-08
the O 0 3.427209804840459e-08
usefulness O 0 5.682211963176087e-07
of O 0 3.890053434929541e-08
cycloheximide O 0 8.017068466870114e-07
treatment O 0 6.782393029425293e-07
in O 0 3.287757399661473e-09
evaluating O 0 8.286178854177706e-09
the O 0 8.62372750987106e-09
abnormal O 0 2.1513208992018917e-09
processing O 0 4.1302364195416885e-08
of O 0 3.396118231080436e-08
mRNA O 0 5.72560985290238e-08
due O 0 4.147185848069057e-07
to O 0 4.784054041806485e-08
splice O 0 1.550765045976732e-05
- O 0 1.4910349364072317e-06
site O 0 4.549929144559428e-08
mutations O 0 4.1765357838841055e-10
, O 0 7.962411285866722e-11
because O 0 3.4690803007997317e-10
( O 0 8.013073538037929e-10
i O 0 3.4072389354378174e-08
) O 0 8.841641863099881e-10
aberrant O 0 1.2448047037594279e-08
splicing O 0 4.31058921890326e-08
often O 0 3.031128403829797e-10
generates O 0 1.040203131963402e-10
a O 0 6.085580928072432e-10
premature O 0 3.5968108491601924e-09
termination O 0 4.8502521110549424e-08
codon O 0 7.468098139895574e-09
, O 0 1.2227593382263535e-09
( O 0 1.3970363754722825e-10
ii O 0 5.15756182721816e-05
) O 0 1.8282904079569562e-09
transcripts O 0 2.067675097805477e-08
with O 0 1.0579193077120408e-09
premature O 0 1.0836074437747811e-07
termination O 0 1.942621793205035e-06
codons O 0 7.888699116165299e-08
can O 0 5.239111366961424e-09
occur O 0 1.6109275691178482e-08
at O 0 5.914688472330454e-08
low O 0 2.7968982863058045e-07
or O 0 5.168522498877337e-09
undetectable O 0 7.664167611665107e-08
levels O 0 5.184013218695327e-09
due O 0 6.060242441208175e-08
to O 0 2.8410815922086385e-09
nonsense O 0 4.025428168574763e-08
- O 0 1.4022059957596866e-08
mediated O 0 3.680437288267058e-08
mRNA O 0 9.929919997375691e-09
decay O 0 1.199676376018033e-07
, O 0 1.9228552083916384e-10
and O 0 2.2049258252554438e-10
( O 0 1.9380286264691904e-10
iii O 1 0.8294748663902283
) O 0 3.7299896504805474e-09
the O 0 1.2173703822782045e-08
levels O 0 2.6421955734434732e-09
of O 0 1.6874641683983782e-09
these O 0 1.19214832450254e-10
transcripts O 0 1.4473950926685575e-09
can O 0 1.7669147395205087e-11
be O 0 4.4287327277681143e-11
increased O 0 1.1554478207553842e-10
by O 0 6.439287436599272e-10
cycloheximide O 0 3.258090600866126e-06
. O 0 3.6278490256336227e-07

A O 0 1.2924272596137598e-05
deletion O 0 1.8535246226747404e-06
mutation O 0 2.7610509434339292e-08
in O 0 5.0785025074162604e-09
COL17A1 O 0 1.0436298907734454e-05
in O 0 4.811596454601386e-09
five O 0 4.7894928023595185e-09
Austrian O 0 3.503004677440913e-07
families O 0 4.6631676298147795e-09
with O 0 7.474468155521663e-09
generalized O 1 0.9981691837310791
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999860525131226
represents O 0 7.348575792320844e-08
propagation O 0 3.306720941509411e-07
of O 0 3.511475910045192e-08
an O 0 1.025038165458625e-09
ancestral O 0 1.3498630835329095e-07
allele O 0 5.295606442246026e-08
. O 0 6.341988267877241e-08

Patients O 0 4.395772975840373e-06
with O 0 2.948567789928802e-08
generalized O 0 0.12201640009880066
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 1.2018533368518547e-07
a O 0 1.1940908706264963e-08
usually O 0 3.273584736618318e-09
nonlethal O 0 5.150015454091772e-07
form O 0 2.0382516652261984e-07
of O 0 0.0004832422127947211
junctional B-Disease 1 1.0
epidermolysis I-Disease 1 0.9999996423721313
bullosa I-Disease 1 0.9990746974945068
, O 0 1.3419174216267038e-08
have O 0 6.717981171355802e-10
generalized O 0 1.2738605903450662e-07
blistering B-Disease 0 8.924991561798379e-06
, O 0 5.4490744361146426e-08
nail B-Disease 1 0.9999934434890747
dystrophy I-Disease 1 1.0
, O 0 6.583401841453451e-07
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 2.433415033920028e-07
and O 0 4.073728632647544e-06
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 0 0.0004120471712667495

Skin B-Disease 1 1.0
fragility I-Disease 1 0.9999998807907104
in O 0 6.163572408013351e-08
most O 0 1.0909123604463389e-09
cases O 0 1.7999375601096546e-10
is O 0 5.255690674332847e-11
due O 0 3.6932339408934922e-09
to O 0 3.3436417523624584e-10
mutations O 0 1.6828670401647372e-10
in O 0 3.9679015628735215e-10
the O 0 5.51019141425968e-09
gene O 0 1.0197379607390644e-09
encoding O 0 1.5853416357458627e-08
type O 0 1.8715500118560158e-06
XVII O 0 0.3677140474319458
collagen O 0 8.021075336728245e-05
( O 0 1.0151318718953917e-07
COL17A1 O 0 9.250947186956182e-05
) O 0 1.214925582360138e-08
. O 0 9.371242271072333e-08

Recently O 0 1.6367152056773193e-05
, O 0 3.8685882941535965e-08
we O 0 2.687646105670183e-09
reported O 0 3.6661917945934874e-09
five O 0 2.004173271785703e-09
Austrian O 0 2.2359463969223725e-07
families O 0 6.543527053537446e-09
with O 0 4.466257141899632e-09
generalized O 0 0.03492656722664833
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
who O 0 3.9988194657780696e-06
share O 0 3.781164537031145e-08
the O 0 1.0579626774642747e-07
same O 0 1.0050712262454908e-07
COL17A1 O 0 0.0011053080670535564
mutation O 0 5.932313342782436e-07
. O 0 2.763688939921849e-07

Affected O 0 4.3488330447871704e-07
individuals O 0 8.171662790878997e-10
in O 0 5.638248090633624e-09
three O 0 2.524910946988257e-09
families O 0 3.087789191003054e-10
are O 0 3.690357394670052e-11
homozygous O 0 7.794510592518122e-10
for O 0 2.485266714646883e-10
4003delTC O 0 4.5899632539203594e-08
, O 0 1.9600995826429823e-10
whereas O 0 8.077954416485511e-10
those O 0 1.75343384256621e-09
in O 0 4.016468047041144e-09
two O 0 1.494508627963853e-09
others O 0 1.291269535741435e-09
are O 0 1.9868011402746077e-10
compound O 0 5.879908826500468e-07
heterozygotes O 0 1.5992335420378367e-06
. O 0 8.593015650149027e-07

To O 0 6.498876246041618e-07
determine O 0 1.4791396552027436e-07
if O 0 8.118876237972472e-09
the O 0 5.574080308434759e-09
occurrence O 0 5.200492481094443e-09
of O 0 8.040773380457722e-09
4003delTC O 0 4.2612793293983486e-08
in O 0 2.0969319336483494e-10
these O 0 6.659318929624902e-11
unrelated O 0 3.6012868243062712e-09
families O 0 8.314382515806074e-11
signifies O 0 1.1088627932531736e-10
propagation O 0 1.1198291183234232e-08
of O 0 4.0917269572560144e-09
an O 0 5.06024444568709e-10
ancestral O 0 5.029333749462239e-08
allele O 0 3.3737908022857255e-09
or O 0 7.871665985703657e-09
a O 0 1.065648405074171e-07
mutational O 0 5.895832509850152e-05
hot O 0 0.00019417742441873997
spot O 0 5.437753770820564e-06
, O 0 1.7839874022484992e-09
haplotypes O 0 1.2749856281857319e-08
were O 0 1.755147027715509e-09
determined O 0 8.99119978470253e-09
for O 0 2.985247160580684e-09
polymorphisms O 0 9.827236624460056e-08
both O 0 5.906399813682128e-09
within O 0 1.0133618388863397e-07
and O 0 3.465731310825504e-07
flanking O 0 0.0006435899413190782
COL17A1 O 1 0.9999316930770874
. O 0 1.0332434612791985e-05

Five O 0 8.780309144640341e-06
intragenic O 0 2.440037133055739e-05
polymorphisms O 0 8.617414550826652e-07
were O 0 2.5778811973964366e-08
chosen O 0 2.4421090927262412e-08
based O 0 6.916131667367154e-08
on O 0 7.55040446165367e-07
their O 0 1.356498842142173e-07
informativeness O 0 8.068977331276983e-05
. O 0 8.068443548836512e-07

One O 0 5.558884481615678e-07
of O 0 1.3226615180883528e-07
these O 0 1.2093922530098666e-09
, O 0 3.741102982957045e-10
not O 0 8.332320944326455e-11
previously O 0 3.907758117094318e-09
reported O 0 1.082949285802215e-09
, O 0 2.552417444068311e-10
was O 0 4.642580719860234e-08
2988 O 0 3.442731326686044e-07
A O 0 1.9817815655187587e-07
or O 0 1.3334950921262134e-08
C O 0 1.0539823733779485e-06
that O 0 1.3111813856880872e-09
introduces O 0 8.23803603111628e-09
a O 0 3.988497088158738e-09
new O 0 4.626595995205207e-09
restriction O 0 2.792482467484092e-09
site O 0 1.3824325684197447e-08
for O 0 4.262624420103833e-10
Eco0109 O 0 6.210314040799858e-07
I O 0 2.7851410777657293e-06
. O 0 3.721208656770614e-07

All O 0 8.959547130871215e-07
the O 0 3.5934152720074053e-07
4003delTC O 0 6.652319939348672e-07
alleles O 0 3.984679697310867e-09
showed O 0 1.4767731482123736e-09
the O 0 1.9015855556858696e-09
same O 0 8.861394951154011e-10
haplotype O 0 1.8226305087409855e-07
for O 0 1.0625178514800382e-09
these O 0 7.508585975202209e-10
five O 0 4.814350251791666e-09
polymorphic O 0 1.682737860164707e-07
markers O 0 7.080999466779758e-07
. O 0 9.234024105353456e-07

Fourteen O 0 2.6495496058487333e-05
microsatellite O 0 2.2752361473976634e-05
polymorphisms O 0 1.2515107528088265e-06
were O 0 1.8900442100289183e-08
selected O 0 1.3231127304891288e-08
based O 0 2.621975347949501e-08
on O 0 4.6537252273992635e-07
their O 0 2.9684702695931264e-08
high O 0 1.7381894394929986e-06
heterozygosity O 0 8.48995623528026e-05
and O 0 5.0497689585427e-08
their O 0 2.079127980891826e-08
location O 0 6.908174441377923e-07
within O 0 1.0104532321975057e-07
10q23 O 0 1.33115429434838e-06
- O 0 8.206828283618961e-07
q25 O 0 3.6825342704105424e-06
near O 0 1.1497086234157905e-05
COL17A1 O 0 0.0008640152518637478
. O 0 2.0360246253403602e-06

Three O 0 1.057062604559178e-06
families O 0 5.1477762497142976e-08
shared O 0 1.617046621049667e-07
microsatellite O 0 4.9700656745699234e-06
polymorphisms O 0 9.38305277031759e-07
covering O 0 8.250066798609623e-07
at O 0 5.032184162701014e-07
most O 0 7.062902707133389e-09
19 O 0 2.299932511107272e-08
cM O 0 8.523293359985473e-08
, O 0 6.178467737427695e-10
whereas O 0 2.645863261818704e-08
the O 0 2.8474223654484376e-06
others O 0 1.4363367029091023e-07
shared O 0 5.4162995866136043e-08
smaller O 0 1.849355868444036e-08
regions O 0 2.692962075556693e-09
consistent O 0 2.3180904307196215e-08
with O 0 1.7491315063011825e-09
cross O 0 2.7169653549208306e-07
- O 0 4.5122095571059617e-07
over O 0 7.144140834469681e-09
events O 0 2.691481759686809e-10
during O 0 1.0142000572699317e-09
passage O 0 6.069259539387417e-10
of O 0 7.414822228435369e-11
this O 0 9.272493363410295e-12
mutation O 0 3.258456005017507e-11
through O 0 7.810951885289796e-11
several O 0 4.5741924137310264e-10
generations O 0 6.556572884619527e-08
. O 0 1.5851911427944287e-07

These O 0 9.219287733230885e-08
results O 0 1.3666707765480623e-08
indicate O 0 9.627474817364146e-09
that O 0 4.1139652795507686e-10
4003delTC O 0 9.175589354981639e-08
occurs O 0 1.972040308828582e-09
on O 0 2.5572528539186123e-09
a O 0 4.857663160606762e-10
single O 0 1.1311047654061213e-09
ancestral O 0 5.269268754659606e-08
allele O 0 5.10889197613551e-09
. O 0 5.7239799566843885e-09
. O 0 1.045427637791363e-07

The O 0 1.0404071872471832e-05
haptoglobin O 0 0.00017746958474162966
- O 0 4.9622512960922904e-06
gene O 0 2.7639700306281156e-08
deletion O 0 9.899704167537493e-08
responsible O 0 1.8750066388406594e-08
for O 0 1.2199785182076539e-08
anhaptoglobinemia B-Disease 0 0.00014882285904604942
. O 0 2.5798790375120007e-06

We O 0 7.403830295515945e-07
have O 0 9.12318043333471e-09
found O 0 4.238693396274584e-09
an O 0 4.935628572511064e-10
allelic O 0 1.1339539440768931e-07
deletion O 0 1.0605386790984994e-07
of O 0 2.955471813947952e-07
the O 0 3.6082434462514357e-07
haptoglobin O 0 1.5177560271695256e-05
( O 0 9.466868178265031e-09
Hp O 0 1.364129502690048e-07
) O 0 6.192578116959169e-10
gene O 0 6.250880923985846e-10
from O 0 1.6646329870084742e-09
an O 0 3.2320396359253323e-10
individual O 0 2.921208275274978e-10
with O 0 4.679043819066919e-09
anhaptoglobinemia B-Disease 0 7.313470996450633e-05
. O 0 3.261311121605104e-06

The O 0 8.550412530894391e-06
Hp O 0 1.867730702542758e-06
gene O 0 2.485364092308373e-08
cluster O 0 3.551594218720311e-08
consists O 0 3.1611724349289716e-09
of O 0 1.649947556359166e-08
coding O 0 1.3134678056303528e-07
regions O 0 1.631397239520993e-08
of O 0 2.852017814802821e-06
the O 0 2.624820808705408e-06
alpha O 0 1.892963439331652e-07
chain O 0 2.917868613394603e-09
and O 0 7.031338844498691e-10
beta O 0 1.3259042752622463e-08
chain O 0 7.2148829133311665e-09
of O 0 1.0611150180750428e-08
the O 0 2.9147273039598076e-08
haptoglobin O 0 2.8511129812613945e-07
gene O 0 1.5328123215141432e-09
( O 0 1.3993217695684734e-10
Hp O 0 4.409561604745704e-09
) O 0 5.2682563173034325e-11
and O 0 3.3928385101411607e-10
of O 0 3.259119907284003e-08
the O 0 5.236067295300018e-07
alpha O 0 1.705625578551917e-07
chain O 0 3.323932773469096e-08
and O 0 2.2138608724020514e-09
beta O 0 3.5689311062014895e-08
chain O 0 1.2635396728910564e-08
of O 0 6.415850073437923e-09
the O 0 2.260128795228411e-08
haptoglobin O 0 9.085923124985129e-07
- O 0 6.42262349970224e-08
related O 0 1.9014557040009095e-08
gene O 0 9.11180730867045e-09
( O 0 7.50566497842442e-10
Hpr O 0 2.498795197425352e-07
) O 0 7.45581096861514e-10
, O 0 2.499862261640118e-10
in O 0 1.923039505413726e-09
tandem O 0 1.5648981843696674e-07
from O 0 3.691024730301251e-08
the O 0 6.33588228993176e-07
5 O 0 4.933219770464348e-07
side O 0 1.1071838343923446e-06
. O 0 7.495049203498638e-07

Southern O 0 0.00016019960457924753
blot O 0 0.0003935527056455612
and O 0 1.7152397902009398e-07
PCR O 0 9.52931486608577e-07
analyses O 0 2.4831987133211442e-08
have O 0 6.053467171973637e-10
indicated O 0 1.2149805606043174e-09
that O 0 5.2936287298077644e-11
the O 0 9.61059121173946e-10
individual O 0 3.2749053469061096e-11
with O 0 4.147076085314616e-11
anhaptoglobinemia B-Disease 0 8.31238011755886e-08
was O 0 7.691699011047604e-08
homozygous O 0 1.0548647511043896e-09
for O 0 2.6407431796826586e-10
the O 0 4.70116656714481e-09
gene O 0 1.0855758514338731e-09
deletion O 0 3.2865850041474687e-09
and O 0 2.2782525865849834e-10
that O 0 1.749243111470733e-11
the O 0 1.4920562563247586e-09
gene O 0 1.1175369518667821e-09
deletion O 0 9.245487930797935e-09
was O 0 3.084178246126612e-08
included O 0 2.756976424933555e-09
at O 0 6.11736661326745e-09
least O 0 9.494235259088768e-11
from O 0 1.2982632746627587e-09
the O 0 3.216631228042388e-08
promoter O 0 2.9250720672280295e-06
region O 0 1.7768304871879081e-07
of O 0 4.500895101955393e-06
Hp O 0 2.374671385041438e-05
to O 0 5.673391001437267e-07
Hpr O 0 1.1081282536906656e-05
alpha O 0 2.7207093467040977e-07
but O 0 2.2411537070610166e-09
not O 0 7.024181236658933e-10
to O 0 6.146148479047042e-09
Hpr O 0 3.590309233914013e-06
beta O 0 9.879724984784843e-07
( O 0 8.66601990168192e-09
Hpdel O 0 1.681135131548217e-06
) O 0 4.350215743187391e-09
. O 0 6.928278395434972e-08

In O 0 4.0463632444698305e-07
addition O 0 6.203554647754572e-08
, O 0 6.403575447677667e-09
we O 0 9.693027491763928e-10
found O 0 1.7711544453291594e-09
seven O 0 7.690312830987978e-10
individuals O 0 5.061233550318622e-12
with O 0 1.3216081007350056e-10
hypohaptoglobinemia B-Disease 0 6.625641162827378e-06
in O 0 3.150928407080755e-08
three O 0 2.5401083902920618e-08
families O 0 2.523047992752936e-09
, O 0 2.6228680338746813e-10
and O 0 1.1853537040806827e-09
the O 0 2.094707518551786e-08
genotypes O 0 9.066096140486479e-08
of O 0 1.4950032323213236e-07
six O 0 4.102521344861998e-08
of O 0 2.9570421133939817e-07
the O 0 1.9106468585050607e-07
seven O 0 5.150287307742474e-09
individuals O 0 4.491417220781058e-12
were O 0 9.070567630331539e-10
found O 0 1.5677739106934041e-09
to O 0 1.5008730924748193e-09
be O 0 6.937997909517435e-08
Hp2 O 0 0.004125433508306742
/ O 0 0.014694641344249249
Hpdel O 0 0.003970347810536623
. O 0 6.5443678067822475e-06

The O 0 7.344858204305638e-06
phenotypes O 0 2.603202347017941e-06
and O 0 3.055744102198332e-08
genotypes O 0 7.402736059702875e-07
in O 0 6.175148836717881e-09
one O 0 1.3791371378246708e-09
of O 0 6.671632135635264e-09
these O 0 5.121328916501966e-10
three O 0 2.6918323126068344e-09
families O 0 1.2694910678234805e-09
showed O 0 1.8456126626986702e-09
the O 0 1.4414531790407636e-08
father O 0 6.164302135402977e-07
to O 0 2.0954267654360592e-08
be O 0 1.0404267669628098e-07
hypohaptoglobinemic B-Disease 0 8.286943739221897e-06
( O 0 6.584918832430731e-09
Hp2 O 0 3.5406551432970446e-06
) O 0 2.4664166264898313e-09
and O 0 1.157072127000447e-08
Hp2 O 0 0.0001028307233355008
/ O 0 1.0235919035039842e-05
Hpdel O 0 6.407398905139416e-05
, O 0 5.553217885534423e-09
the O 0 5.565924254824495e-08
mother O 0 5.8831847837836904e-08
to O 0 2.7987476780566567e-09
be O 0 4.7250701129541994e-09
Hp2 O 0 4.746828381030355e-06
- O 0 4.949600338477467e-07
1 O 0 2.110625558771062e-07
and O 0 1.0763068658548036e-08
Hp1 O 0 1.1781677130784374e-05
/ O 0 1.3742611599809607e-06
Hp2 O 0 8.915617399907205e-06
, O 0 1.33885147413082e-09
one O 0 4.389956453909605e-10
of O 0 5.4823479089805005e-09
the O 0 1.7192085977058014e-08
two O 0 1.6262919899645567e-09
children O 0 3.1466432237614583e-10
to O 0 1.6261059165856295e-09
be O 0 2.070477123083947e-08
hypohaptoglobinemic B-Disease 0 1.2247237464180216e-05
( O 0 1.458038578761034e-08
Hp2 O 0 6.549437784997281e-06
) O 0 5.7678835041485854e-09
and O 0 3.3424459644493254e-08
Hp2 O 0 0.000254439830314368
/ O 0 7.798503065714613e-05
Hpdel O 0 0.00013172595936339349
, O 0 3.0774838233327273e-09
and O 0 3.998520625714264e-09
the O 0 1.9093748804266397e-08
other O 0 1.1869238925044101e-09
child O 0 7.842293925364174e-09
to O 0 9.927699773371046e-10
be O 0 5.3236766106579125e-09
Hp1 O 0 7.158791049732827e-06
and O 0 8.04226516493145e-08
Hp1 O 0 0.00021285790717229247
/ O 0 5.2916489948984236e-05
Hpdel O 0 6.828083860455081e-05
, O 0 5.222101417956537e-09
showing O 0 7.803796719940692e-09
an O 0 7.102358701160938e-10
anomalous O 0 1.4023616756730917e-07
inheritance O 0 3.7541201436397387e-06
of O 0 2.2250022084335797e-05
Hp O 0 2.548022530390881e-05
phenotypes O 0 9.889679404295748e-07
in O 0 1.387298009802862e-08
the O 0 1.374225462313916e-07
child O 0 9.000606127074207e-08
with O 0 1.244232628039299e-08
Hp1 O 0 0.00040237835492007434
. O 0 6.335523721645586e-06

The O 0 5.7469467719784006e-05
Hp2 O 0 0.0074204555712640285
/ O 0 0.0002994361275341362
Hpdel O 0 3.514299532980658e-05
individuals O 0 5.729689500633128e-10
had O 0 3.330069375806488e-08
an O 0 5.468757668936064e-10
extremely O 0 1.2113114067346942e-08
low O 0 6.497798494820017e-07
level O 0 7.143004836507316e-07
of O 0 6.886815526740975e-07
Hp O 0 8.423381814282038e-07
( O 0 1.49215595435237e-09
mean O 0 7.491552267424595e-09
+ O 0 6.763923643404723e-09
/ O 0 7.61566898432875e-09
- O 0 1.578558617154613e-08
SD O 0 4.7378873091474816e-07
= O 0 1.2477879174355166e-08
0 O 0 4.276274889747356e-09
. O 0 5.418959725389527e-10
049 O 0 9.528881150799862e-08
+ O 0 3.882557830792166e-09
/ O 0 7.687398273503732e-09
- O 0 1.544393057884008e-08
0 O 0 8.192312606070118e-09
. O 0 7.502057863817413e-10
043 O 0 3.7748239378743165e-07
mg O 0 6.25917806473808e-08
/ O 0 9.078204854517935e-09
ml O 0 2.1638144609426035e-09
; O 0 4.8719522860452e-10
n O 0 5.153274695857135e-09
= O 0 2.801530563090182e-09
6 O 0 3.8226266596552705e-09
) O 0 1.4253833356681067e-11
, O 0 9.733572454984074e-12
compared O 0 1.7808689245502052e-10
with O 0 1.1875370131697593e-10
the O 0 1.1125246501819674e-08
level O 0 2.954225131190924e-08
( O 0 1.311701025574763e-10
1 O 0 4.353569060810969e-09
. O 0 3.0064048472944194e-10
64 O 0 5.902142774516506e-09
+ O 0 3.802686610043793e-09
/ O 0 6.807579389089824e-09
- O 0 1.2013921413256412e-08
1 O 0 2.0212883811154825e-08
. O 0 8.721948718815042e-10
07 O 0 2.2536459809430198e-08
mg O 0 1.4862769681656118e-08
/ O 0 2.3538124782618297e-09
ml O 0 4.894454841419815e-10
) O 0 4.357434118390513e-12
obtained O 0 1.4524691172024262e-10
from O 0 4.1312584464492375e-09
52 O 0 5.14889535452312e-08
healthy O 0 3.932042247356549e-09
volunteers O 0 1.730152132672913e-09
having O 0 9.208721785114449e-09
phenotype O 0 2.902107780755614e-07
Hp2 O 0 4.496278506849194e-06
, O 0 9.256527766510203e-10
whereas O 0 4.789949326067244e-09
the O 0 2.6977653888593522e-08
serum O 0 5.159764100426401e-07
Hp O 0 2.1963072072139767e-07
level O 0 3.226204370321284e-08
of O 0 8.999160527878303e-09
an O 0 6.481672837344021e-11
individual O 0 4.4244837828222305e-12
with O 0 1.6999004981421706e-10
Hp1 O 0 1.7086811112676514e-06
/ O 0 8.16604369902052e-07
Hpdel O 0 1.4637623280577827e-05
was O 0 3.931080300390022e-06
0 O 0 5.177706725589815e-07
. O 0 1.0448555798348025e-07

50 O 0 2.3743129986542044e-06
mg O 0 3.747817117982777e-06
/ O 0 6.926150035724277e-07
ml O 0 1.2876651567239605e-07
, O 0 4.3277365024962933e-10
which O 0 1.240009483982618e-10
was O 0 1.7868588386704687e-08
approximately O 0 5.668380348433644e-11
half O 0 3.743601262318208e-10
the O 0 7.529007417517164e-10
level O 0 1.027740381687181e-08
of O 0 1.2125780379790285e-08
Hp O 0 1.7484293834968412e-07
in O 0 6.8243237727472206e-09
control O 0 6.133410010988882e-07
sera O 0 4.6353872562576726e-07
from O 0 1.1125226073716021e-08
the O 0 5.98192073653081e-08
Hp1 O 0 1.1936010650970275e-06
phenotype O 0 5.1659824862326786e-08
( O 0 3.784754176727745e-10
1 O 0 1.038053643043213e-08
. O 0 7.146781499933752e-10
26 O 0 1.240486202647162e-08
+ O 0 3.0529112571286987e-09
/ O 0 4.2099452812749405e-09
- O 0 1.211981537352358e-08
0 O 0 7.479787456077247e-09
. O 0 4.860981062115854e-10
33 O 0 6.85924472776378e-09
mg O 0 1.0945957917840587e-08
/ O 0 2.006866228754234e-09
ml O 0 1.6765052679446057e-09
; O 0 2.763413664563785e-10
n O 0 3.332895293084448e-09
= O 0 1.8338364160541687e-09
9 O 0 2.2813497757567802e-09
) O 0 3.053758634852244e-11
, O 0 1.5213988055484684e-11
showing O 0 2.7091065502027334e-10
a O 0 4.468685865788302e-09
gene O 0 8.408884255572957e-09
- O 0 5.096923061387315e-08
dosage O 0 7.405546398331353e-07
effect O 0 2.3180777475317882e-07
. O 0 2.225965971547339e-07

The O 0 5.113782208354678e-06
other O 0 5.135693825764065e-08
allele O 0 2.4108143037437912e-08
( O 0 1.3985006486194607e-09
Hp2 O 0 5.432635248325823e-07
) O 0 3.153522720733548e-10
of O 0 2.9922186950415153e-09
individuals O 0 4.842314049735563e-11
with O 0 4.9819188774336e-09
Hp2 O 0 0.0017235407140105963
/ O 0 0.00011413663014536723
Hpdel O 0 7.148428267100826e-05
was O 0 6.770353593310574e-07
found O 0 9.380837218131433e-10
to O 0 1.5741462300322695e-10
have O 0 9.425131508589146e-11
, O 0 2.905769201644315e-11
in O 0 2.0167420511363332e-10
all O 0 8.208873580883846e-10
exons O 0 2.1529170624035032e-07
, O 0 4.854273094601069e-10
no O 0 5.126019608781007e-10
mutation O 0 2.381025931974534e-10
, O 0 2.6284505821871917e-11
by O 0 5.5943544935432854e-11
DNA O 0 4.328161651301343e-08
sequencing O 0 9.580809319231776e-07
. O 0 4.121525591926911e-07

On O 0 1.0400342034699861e-05
the O 0 9.095123942870487e-08
basis O 0 1.9537784723411278e-08
of O 0 2.579656843693101e-08
the O 0 3.6942344738832844e-09
present O 0 6.437579913587399e-10
study O 0 1.762829049400949e-10
, O 0 2.2544851402406252e-11
the O 0 2.2172656766183962e-10
mechanism O 0 5.608719710892274e-09
of O 0 5.824733761983225e-08
anhaptoglobinemia B-Disease 0 2.8522817956400104e-06
and O 0 9.327175476414595e-09
the O 0 2.696273604385624e-08
mechanism O 0 9.9054645374963e-08
of O 0 1.9519609040230534e-08
anomalous O 0 2.3588074782310287e-07
inheritance O 0 6.083045605009829e-07
of O 0 5.901171675759542e-07
Hp O 0 9.590783065505093e-07
phenotypes O 0 1.116151082669603e-07
were O 0 1.4447589791188875e-08
well O 0 1.4873035247831012e-08
explained O 0 8.01641348857629e-08
. O 0 2.2962950652072323e-07

However O 0 7.361312555076438e-07
, O 0 4.338152059801814e-09
the O 0 3.286234173671687e-09
mechanism O 0 2.3189041797877508e-08
of O 0 1.0401291916650734e-07
hypohaptoglobinemia B-Disease 0 8.327489922521636e-05
remains O 0 2.2988173441262916e-05
unknown O 0 3.151065538986586e-05

ATM O 0 7.441395428031683e-05
mutations O 0 4.507319886215555e-07
and O 0 5.620223575419914e-08
phenotypes O 0 7.0814649006933905e-06
in O 0 1.6429844436061103e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 1 0.9302950501441956
in O 0 1.0820667029065589e-07
the O 0 1.6148352699474344e-07
British O 0 1.2543337390980014e-07
Isles O 0 1.5936612953737495e-06
: O 0 5.09788988800608e-10
expression O 0 2.897150075398258e-09
of O 0 2.074976102051096e-08
mutant O 0 3.723842567637803e-08
ATM O 0 7.81135014449319e-08
and O 0 3.782257285145363e-10
the O 0 5.300067051905444e-10
risk O 0 4.4238637753046817e-10
of O 0 6.175620015369532e-09
leukemia B-Disease 1 1.0
, O 0 4.745461046695709e-05
lymphoma B-Disease 1 1.0
, O 0 0.00016224540013354272
and O 0 0.02076459676027298
breast B-Disease 1 1.0
cancer I-Disease 1 0.999961256980896
. O 0 3.32566628458153e-06

We O 0 2.9525642730732216e-07
report O 0 1.7819580477862473e-08
the O 0 1.9922600458244233e-08
spectrum O 0 3.4033945439659874e-07
of O 0 1.0180539078419315e-07
59 O 0 1.0517797477405111e-07
ATM O 0 2.1817795925471728e-07
mutations O 0 3.812447246787087e-09
observed O 0 5.571285210947963e-09
in O 0 5.199582631121302e-08
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999663829803467
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.0089313323978786e-08
patients O 0 1.8374084476135977e-08
in O 0 2.536142407194575e-09
the O 0 5.912410117048239e-08
British O 0 4.3021452711400343e-07
Isles O 0 1.4334728803078178e-05
. O 0 9.165852361547877e-07

Of O 0 3.7356534448917955e-05
51 O 0 6.106718046794413e-06
ATM O 0 1.0427634151710663e-05
mutations O 0 2.9146326241402676e-08
identified O 0 1.9451038113516006e-08
in O 0 7.218847297707498e-09
families O 0 1.3507587937056087e-08
native O 0 7.44382244732833e-09
to O 0 1.891629963779451e-09
the O 0 8.3700527397923e-08
British O 0 7.461166546818276e-07
Isles O 0 1.113325015467126e-05
, O 0 5.234966238276684e-09
11 O 0 1.2440545482661491e-08
were O 0 1.1016605405700375e-08
founder O 0 2.9938505008431093e-07
mutations O 0 1.373587465991477e-09
, O 0 2.5672505787888156e-10
and O 0 1.6683391335092779e-09
2 O 0 1.2062383802913246e-07
of O 0 1.1838134028607783e-08
these O 0 1.3674106291716726e-09
11 O 0 5.0909449988978395e-09
conferred O 0 1.3928020514697437e-08
a O 0 1.959764128756092e-09
milder O 0 1.5504235761909513e-07
clinical O 0 1.955747030990551e-08
phenotype O 0 1.4292131922388762e-08
with O 0 2.814241895077174e-11
respect O 0 4.26322616098318e-10
to O 0 1.7673074115265308e-09
both O 0 6.650353867598824e-08
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 0.00031038577435538173
cellular O 0 3.7190557122812606e-06
features O 0 1.1002875766052966e-07
. O 0 1.1241245090332086e-07

We O 0 1.96757852677365e-07
report O 0 6.928738027767167e-09
, O 0 6.608305569422157e-10
in O 0 6.988393752571653e-10
two O 0 1.1304238434206582e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 4.840363772018463e-07
, O 0 2.3153892136917875e-09
an O 0 1.1554748269304582e-09
ATM O 0 8.901143644379772e-08
mutation O 0 3.824303984600874e-09
( O 0 3.5652669705399376e-10
7271T O 0 9.187129279553119e-08
- O 0 2.612204639262927e-07
- O 0 2.6128252557100495e-06
> O 0 2.0762884105351986e-06
G O 0 1.0153986522709602e-06
) O 0 1.4277022619690882e-10
that O 0 7.522023802442046e-12
may O 0 1.7600002011342042e-10
be O 0 6.774025784750393e-11
associated O 0 3.398635539664241e-10
with O 0 8.822664820939963e-12
an O 0 5.7972016943852456e-12
increased O 0 6.593848383973366e-11
risk O 0 2.4272523990731543e-09
of O 0 3.740586294043169e-07
breast B-Disease 1 0.9955689311027527
cancer I-Disease 0 0.00015211495338007808
in O 0 4.2039269843030524e-09
both O 0 4.577616063983214e-09
homozygotes O 0 6.348172973957844e-07
and O 0 7.430842607902832e-09
heterozygotes O 0 1.0322434462750607e-07
( O 0 2.8159882758949095e-10
relative O 0 4.7059508290203667e-08
risk O 0 2.109904784219907e-08
12 O 0 5.981393602638718e-09
. O 0 7.029005710812442e-10
7 O 0 1.570839636144683e-08
; O 0 1.3559335876323075e-09
P O 0 6.906059866196301e-07
= O 0 1.819378958600737e-08
. O 0 9.581379023515524e-10
0025 O 0 2.9181185823290434e-07
) O 0 5.6684455740363404e-11
, O 0 1.3132874995824828e-11
although O 0 8.508240639804043e-11
there O 0 1.0619642665243845e-10
is O 0 8.826169656250826e-11
a O 0 8.211566981941587e-10
less O 0 2.3747999122747387e-09
severe O 0 0.0006636321195401251
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 2.283541391534527e-07
in O 0 1.7891080283938265e-10
terms O 0 3.1678037970550577e-10
of O 0 7.44085182358134e-10
the O 0 2.858261127780537e-10
degree O 0 8.598171064022608e-09
of O 0 4.568791212022916e-08
cerebellar B-Disease 1 0.9999998807907104
degeneration I-Disease 1 1.0
. O 0 1.8738250219030306e-05

This O 0 1.174397539216443e-07
mutation O 0 1.9254848382388445e-08
( O 0 4.744239445741982e-10
7271T O 0 4.90402882746821e-08
- O 0 4.6284519328310125e-08
- O 0 2.1913510295235028e-07
> O 0 2.4973300583042146e-07
G O 0 2.8037885613230173e-07
) O 0 2.788755337768123e-10
also O 0 1.2809416027881326e-10
allows O 0 6.941019287109995e-11
expression O 0 1.9185029953572297e-10
of O 0 2.2253676679184764e-09
full O 0 8.039500620782292e-09
- O 0 1.4203620501973546e-08
length O 0 4.0082031027566245e-09
ATM O 0 7.655751943502764e-08
protein O 0 3.57417451191111e-09
at O 0 1.9430932418629254e-09
a O 0 3.771552237186171e-10
level O 0 5.978242345605622e-10
comparable O 0 9.628888797408308e-09
with O 0 2.4939375564692057e-10
that O 0 3.469510234666018e-10
in O 0 4.72746775059818e-09
unaffected O 0 2.6209360726170416e-07
individuals O 0 3.309095775172466e-10
. O 0 6.580891209750916e-08

In O 0 2.408089585514972e-07
addition O 0 1.812506944531833e-08
, O 0 2.2993917880853587e-09
we O 0 3.322750685708087e-10
have O 0 1.1632869667543844e-10
studied O 0 1.5281132803579567e-08
18 O 0 7.094322995726543e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.78114190325141e-06
, O 0 1.1899545793170319e-09
in O 0 1.0489140667147012e-09
15 O 0 3.4990590425110213e-09
families O 0 4.4538689403239573e-10
, O 0 1.2564391194125335e-10
who O 0 6.536650665189825e-10
developed O 0 3.122456064375001e-06
leukemia B-Disease 1 1.0
, O 1 0.9984877109527588
lymphoma B-Disease 1 1.0
, O 0 0.0002831300371326506
preleukemic O 0 0.23863224685192108
T O 0 0.0023286750074476004
- O 0 6.386949280567933e-06
cell O 0 7.066394687171851e-07
proliferation O 0 2.2595087045829132e-07
, O 0 2.4362306616509954e-10
or O 0 6.925337743268756e-07
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.7046496623152052e-06
mostly O 0 4.102503670111446e-09
in O 0 6.958285059255331e-09
childhood O 0 3.92995571019128e-06
. O 0 4.378964035822719e-07

A O 0 5.8701720263343304e-05
wide O 0 1.8058424302580534e-06
variety O 0 1.034332512972469e-07
of O 0 1.1158956425560973e-07
ATM O 0 1.0238037475573947e-06
mutation O 0 2.253868203183629e-09
types O 0 3.6607068487626293e-09
, O 0 4.895538419091849e-10
including O 0 1.7568452248539757e-09
missense O 0 1.2665564099734183e-06
mutations O 0 3.0463635170008274e-08
and O 0 4.868000758051494e-08
in O 0 7.544539215587065e-08
- O 0 8.391614301217487e-07
frame O 0 2.582335355327814e-06
deletions O 0 3.75241256733716e-07
, O 0 3.329350128922215e-09
were O 0 2.8883992975181627e-09
seen O 0 6.991117018628756e-09
in O 0 6.044975076058279e-10
these O 0 1.4414828219955211e-09
patients O 0 6.353563719585509e-08
. O 0 2.8406421392901393e-07

We O 0 2.1947987534076674e-06
also O 0 3.982911067623718e-08
show O 0 2.033444745919155e-09
that O 0 5.5159692785577974e-11
25 O 0 1.2288570161445023e-09
% O 0 1.918466357997417e-10
of O 0 5.075200260051815e-09
all O 0 4.425556099363348e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 5.47261322481063e-07
carried O 0 1.0214670886909971e-08
in O 0 5.300070160529913e-09
- O 0 9.370169351541335e-08
frame O 0 2.6893147264672734e-07
deletions O 0 1.5357841220975388e-07
or O 0 1.901056911890464e-08
missense O 0 3.576304550279019e-07
mutations O 0 3.6079419452050843e-09
, O 0 1.9934211226146914e-10
many O 0 3.095146708376184e-11
of O 0 3.623817912412619e-09
which O 0 3.4362518386288343e-10
were O 0 1.205251898284132e-09
also O 0 1.2708908925240792e-10
associated O 0 2.799734333258641e-10
with O 0 1.7980229805036885e-10
expression O 0 2.996319192760666e-09
of O 0 9.533444256248913e-08
mutant O 0 1.5557172616809112e-07
ATM O 0 4.82969824133761e-07
protein O 0 7.248969779993786e-08
. O 0 3.684455052166413e-08

The O 0 2.746161953837145e-06
DMPK O 0 0.0005936509696766734
gene O 0 3.410581825846748e-07
of O 0 1.5314724066683993e-07
severely O 0 0.0024686933029443026
affected O 0 0.0003484892949927598
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.4468221962451935
is O 0 2.4829995837194474e-08
hypermethylated O 0 9.67622213465802e-07
proximal O 0 4.537458153208718e-05
to O 0 7.313492744742689e-08
the O 0 1.4447142575590988e-06
largely O 0 5.351503205019981e-07
expanded O 0 7.57398026962619e-07
CTG O 0 2.2508300389745273e-05
repeat O 0 5.526281938728062e-07
. O 0 3.3483010497548094e-07

Using O 0 2.0602446966222487e-06
methylation O 0 1.0674385521269869e-05
- O 0 6.579474757018033e-06
sensitive O 0 1.6245509186774143e-06
restriction O 0 1.495085300007304e-08
enzymes O 0 1.2185319420154883e-08
, O 0 2.348716776623405e-10
we O 0 2.1752427636911875e-10
characterized O 0 2.626709072472977e-09
the O 0 4.232310946150619e-09
methylation O 0 7.190017470293242e-09
pattern O 0 7.026637049989404e-09
on O 0 2.4200607739999214e-08
the O 0 1.6117759571443457e-08
5 O 0 8.333315371089611e-09
side O 0 2.4707970780468713e-08
of O 0 8.293028486150433e-08
the O 0 4.187647562048369e-07
CTG O 0 8.314269507536665e-06
repeat O 0 7.867587470400395e-08
in O 0 5.354165111270959e-09
the O 0 4.1152173224645594e-08
DMPK O 0 5.897885785088874e-06
gene O 0 3.765135758726501e-09
of O 0 1.884032485577336e-09
normal O 0 7.951093672353693e-10
individuals O 0 1.577736639252203e-12
and O 0 1.463735244122688e-10
of O 0 4.614451931672647e-09
patients O 0 2.1301511665683392e-08
affected O 0 1.4881207377470673e-08
with O 0 9.724423932766513e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.300048158014988e-08
showing O 0 2.012170874365893e-09
expansions O 0 2.89437878109311e-08
of O 0 1.307548842532924e-07
the O 0 1.5681521858823544e-07
repetitive O 0 6.103127248024975e-07
sequence O 0 4.293603694804915e-08
. O 0 9.864024974604035e-08

The O 0 1.39334279083414e-05
gene O 0 5.532973545996356e-07
segment O 0 2.1830012997270387e-07
analyzed O 0 1.6751892317756756e-08
corresponds O 0 8.767085724059598e-09
to O 0 6.3752776391368116e-09
the O 0 4.4888995631708895e-08
genomic O 0 4.2816310497073573e-07
SacI O 0 2.0996067178202793e-05
- O 0 1.902247106499999e-07
HindIII O 0 9.75827333604684e-07
fragment O 0 5.107326117581579e-08
carrying O 0 1.7561724519055133e-08
exons O 0 2.8645359861911857e-07
11 O 0 1.5157999655457388e-07
- O 0 2.5420189331271104e-07
15 O 0 1.2684297701071046e-07
. O 0 2.0250320176273817e-07

There O 0 3.3329132520520943e-07
is O 0 1.4417062210725362e-08
constitutive O 0 6.097129698900972e-07
methylation O 0 6.163537591419299e-07
in O 0 9.32082997451289e-08
intron O 0 2.963109000120312e-05
12 O 0 1.3594221854873467e-06
at O 0 8.864260081509201e-08
restriction O 0 7.161890636098178e-09
sites O 0 4.19161283460312e-09
of O 0 1.2066809773614295e-08
SacII O 0 1.2446572554836166e-06
and O 0 1.8213372143804918e-08
HhaI O 0 2.119408918588306e-06
, O 0 1.0712762898990036e-09
localized O 0 3.674125181873933e-08
1 O 0 8.049400435083953e-08
, O 0 3.2012900663680455e-10
159 O 0 6.039792221912421e-09
- O 0 4.236820316805279e-08
1 O 0 1.2091938117464451e-07
, O 0 1.7480975555983491e-09
232 O 0 3.245411051011615e-08
bp O 0 3.3006591593220946e-07
upstream O 0 3.7142591224892385e-08
of O 0 3.528293746057898e-08
the O 0 1.1312720005207666e-07
CTG O 0 5.733461875934154e-06
repeat O 0 7.019807668484646e-08
, O 0 4.1990205756903265e-10
whereas O 0 7.501757548489252e-10
most O 0 1.2354867129360514e-09
, O 0 8.243104115956967e-11
if O 0 6.196699403604455e-11
not O 0 1.8009128910367878e-10
all O 0 2.5619478760674497e-10
, O 0 1.2505718682831457e-10
of O 0 1.6017108750432385e-09
the O 0 4.1725165544903575e-09
other O 0 2.622853045863849e-10
sites O 0 1.7736696555914477e-09
of O 0 9.117544053083293e-09
SacII O 0 2.484915057721082e-06
, O 0 2.6820643483915774e-09
HhaI O 0 4.4612379497266375e-06
, O 0 5.742471387293335e-09
and O 0 4.668373687621852e-09
HpaII O 0 7.374673714366509e-06
in O 0 4.126738062382174e-09
this O 0 1.736804589036467e-09
region O 0 1.2460588116880444e-08
are O 0 6.616528436254043e-10
unmethylated O 0 9.871417887552525e-07
, O 0 5.380872414306737e-10
in O 0 1.962381229736465e-10
normal O 0 2.127352516367864e-09
individuals O 0 6.97951462250157e-12
and O 0 1.9636094139574567e-10
most O 0 1.0714642506570726e-09
of O 0 1.4826923688815441e-08
the O 0 2.2847591196750727e-07
patients O 0 2.181053559979773e-07
. O 0 5.787523491562752e-07

In O 0 2.431582117878861e-07
a O 0 2.5810891202127095e-08
number O 0 6.262192986383752e-10
of O 0 1.4942242998472466e-08
young O 0 9.519813382041775e-09
and O 0 1.8248979216650696e-08
severely O 0 0.0002261965855723247
affected O 0 1.5767011518619256e-07
patients O 0 1.6807507563498802e-07
, O 0 8.463815204251546e-10
however O 0 3.2224143353687396e-09
, O 0 2.2251034348386156e-10
complete O 0 5.1380526500111046e-09
methylation O 0 2.6159408861303746e-08
of O 0 5.141964187771464e-09
these O 0 3.125063263720307e-10
restriction O 0 6.607523972412821e-10
sites O 0 5.234274680354645e-10
was O 0 5.835450345159643e-09
found O 0 1.9348929403140147e-10
in O 0 2.455319558780644e-10
the O 0 4.145419119083726e-09
mutated O 0 3.0916112336853985e-08
allele O 0 1.0919395521113984e-07
. O 0 2.3483926270273514e-07

In O 0 2.0981147486054397e-07
most O 0 4.541118148182477e-09
of O 0 3.6745435583185326e-09
these O 0 1.0062341238015193e-10
patients O 0 6.133029639698862e-10
, O 0 2.115769191790573e-11
the O 0 4.420085408796126e-10
onset O 0 0.00013683356519322842
of O 0 1.6583690864990785e-07
the O 0 5.420980642156792e-07
disease O 1 0.9982774257659912
was O 0 0.07205300033092499
congenital O 1 1.0
. O 0 1.59662540681893e-05

Preliminary O 0 7.909187843324617e-06
in O 0 1.9085612166236388e-06
vivo O 0 1.330438408331247e-05
footprinting O 0 0.00035859658964909613
data O 0 2.1093256918902625e-07
gave O 0 4.788070384620369e-08
evidence O 0 3.094301348482986e-08
for O 0 4.194716130001552e-09
protein O 0 4.419210775097326e-09
- O 0 1.9889569102815585e-08
DNA O 0 2.010644806205164e-08
contact O 0 2.7930060042535843e-08
in O 0 2.532922760423162e-09
normal O 0 2.4325974123939886e-08
genes O 0 7.148775793552886e-09
at O 0 7.089842934959734e-09
an O 0 2.774324658894045e-10
Sp1 O 0 7.66200287216634e-07
consensus O 0 3.127935315205832e-07
binding O 0 4.3328080323590257e-07
site O 0 1.958573193405755e-06
upstream O 0 9.386447885617599e-08
of O 0 2.0015383128679787e-08
the O 0 3.22524478235664e-08
CTG O 0 1.620109060240793e-06
repeat O 0 1.4180800533836191e-08
and O 0 7.600312046385227e-10
for O 0 2.3043782160225845e-10
a O 0 5.608417064095761e-10
significant O 0 5.011938641885649e-10
reduction O 0 1.2064323762217555e-08
of O 0 2.9942968104990086e-09
this O 0 1.1462111815241371e-10
interaction O 0 1.8235007948064208e-10
in O 0 9.832641645335372e-11
cells O 0 3.7105452044272624e-10
with O 0 2.3683074945601845e-10
a O 0 3.706290740979057e-08
hypermethylated O 0 4.483270458877087e-06
DMPK O 0 4.260868809069507e-05
gene O 0 8.272333218428685e-08
. O 0 2.7811248415332557e-08
. O 0 1.626046923774993e-07

The O 0 0.0003291106258984655
hemochromatosis B-Disease 1 1.0
gene O 0 7.656087319674043e-08
product O 0 6.453812151363536e-09
complexes O 0 5.628116195310895e-09
with O 0 1.421642664700684e-10
the O 0 1.2856228970292705e-08
transferrin O 0 9.44549265113892e-06
receptor O 0 1.2710538044302666e-07
and O 0 1.7758700066039523e-09
lowers O 0 2.810051746848785e-08
its O 0 2.8641386484729026e-10
affinity O 0 4.99352281746468e-10
for O 0 1.3653873864871713e-10
ligand O 0 1.771074487066926e-08
binding O 0 4.002246356549222e-08
. O 0 1.8796890799421817e-07

We O 0 5.654351298289839e-07
recently O 0 2.4026485334616154e-07
reported O 0 1.4765006106642886e-08
the O 0 6.465553870071972e-09
positional O 0 4.7163700855890056e-07
cloning O 0 7.073191454765038e-08
of O 0 9.6728642873245e-09
a O 0 7.861014061916194e-09
candidate O 0 3.438117346377112e-08
gene O 0 8.16342904386147e-08
for O 0 3.833544894860097e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 0.9999991655349731
. O 0 6.638417289650533e-06

The O 0 2.5954011562134838e-06
gene O 0 4.232393990832861e-08
product O 0 3.345444099522865e-08
, O 0 2.2895536577749453e-09
a O 0 9.147400170661513e-09
member O 0 8.79592754188252e-09
of O 0 6.832244707766222e-07
the O 0 4.183084001851967e-06
major O 0 2.6536506993579678e-05
histocompatibility O 1 0.9805538654327393
complex O 0 0.0012965333880856633
class O 0 1.5117230134364945e-07
I O 0 2.5715053197927773e-06
- O 0 3.418918481656874e-07
like O 0 9.476370799177403e-09
family O 0 7.152365100182578e-08
, O 0 2.856348213509108e-10
was O 0 1.0380695414369256e-08
found O 0 1.0126904870233489e-09
to O 0 1.7102399496593534e-09
have O 0 2.0260424449247694e-09
a O 0 1.5977024148128294e-08
mutation O 0 3.937325576686135e-09
, O 0 1.7495052073712714e-09
Cys O 0 9.436383834326989e-07
- O 0 9.285763553634752e-07
282 O 0 6.623604917876946e-07
- O 0 2.463581722622621e-06
- O 0 2.9937127692392096e-06
> O 0 2.156234586436767e-06
Tyr O 0 3.4910658541775774e-06
( O 0 1.1396805721375358e-09
C282Y O 0 9.980884563276504e-09
) O 0 3.6302898187567934e-11
, O 0 1.9011337643037862e-11
in O 0 6.038357314164244e-11
85 O 0 3.0535638462225734e-09
% O 0 5.29095656176537e-10
of O 0 1.3054650693788972e-08
patient O 0 1.5051774937546725e-07
chromosomes O 0 7.670617208077601e-08
. O 0 3.580877603326371e-07

This O 0 2.507697161036049e-07
mutation O 0 3.396734484795161e-07
eliminates O 0 5.113672045808926e-07
the O 0 4.858937430185506e-08
ability O 0 2.4248105745527937e-08
of O 0 2.960964593512472e-07
HFE O 0 0.0011557566467672586
to O 0 1.2858562570272625e-07
associate O 0 3.626067552886525e-07
with O 0 7.041407901198227e-09
beta2 O 0 6.166236562421545e-05
- O 0 3.744598870980553e-05
microglobulin O 0 0.00015316317148972303
( O 0 2.3749098687630976e-08
beta2m O 0 5.912776032346301e-06
) O 0 2.49900033999495e-09
and O 0 2.1750197198855403e-09
prevents O 0 9.335201944793425e-09
cell O 0 1.2916639207105618e-06
- O 0 2.664399119112204e-07
surface O 0 1.5154602124312078e-06
expression O 0 3.092168867624423e-07
. O 0 2.580996181222872e-07

A O 0 5.693320053978823e-05
second O 0 3.270078195782844e-06
mutation O 0 1.4438884754497394e-08
that O 0 9.71942748506649e-10
has O 0 1.3450096592038108e-09
no O 0 1.6018758541846978e-09
effect O 0 2.781183283673272e-08
on O 0 1.639886733073581e-07
beta2m O 0 5.359815531846834e-06
association O 0 7.08523240078307e-09
, O 0 1.7105563632213716e-09
H63D O 0 5.248713932815008e-05
, O 0 6.225100435131026e-09
was O 0 5.535771663289779e-08
found O 0 1.0844355413652806e-09
in O 0 5.656740631465595e-10
eight O 0 2.635531570760463e-09
out O 0 1.567355245590818e-09
of O 0 2.768755713589144e-08
nine O 0 3.6098157352171256e-08
patients O 0 4.316131896331399e-09
heterozygous O 0 7.408450519719167e-10
for O 0 1.9810355578187e-09
the O 0 5.690725970453059e-07
C282Y O 0 1.5177283785305917e-05
mutant O 0 9.763526577444281e-06
. O 0 1.7416291484551039e-06

In O 0 1.772748134953872e-07
this O 0 3.798960257483941e-09
report O 0 3.6424312455096697e-09
, O 0 8.847984567239564e-10
we O 0 6.255484463757455e-10
demonstrate O 0 3.1126616839571852e-09
in O 0 8.726728673025264e-09
cultured O 0 2.061009922726953e-07
293 O 0 6.342835234818267e-08
cells O 0 5.915703482628487e-08
overexpressing O 0 6.997028322075494e-06
wild O 0 6.106288878982014e-07
- O 0 3.184175625392527e-07
type O 0 2.1548944459937047e-06
or O 0 9.982941264752299e-07
mutant O 0 4.3324985199433286e-07
HFE O 0 1.732033751977724e-06
proteins O 0 2.3169652307863942e-10
that O 0 8.181265387374737e-11
both O 0 3.097474776669884e-10
the O 0 1.1009190004074298e-08
wild O 0 4.317278268217706e-08
- O 0 4.879946047253725e-08
type O 0 8.085667104751337e-07
and O 0 7.234631311803241e-07
H63D O 0 0.00020522906561382115
HFE O 0 2.2372898456524126e-05
proteins O 0 1.6773976652117994e-09
form O 0 7.963053549886467e-10
stable O 0 2.065349669067018e-08
complexes O 0 5.110967649102349e-09
with O 0 2.8095770154834554e-10
the O 0 2.4078870453081436e-08
transferrin O 0 4.212648946122499e-06
receptor O 0 5.4727809839505426e-08
( O 0 3.9523645467554047e-10
TfR O 0 1.9684043195411505e-07
) O 0 7.702511961582559e-10
. O 0 1.104001690066525e-08

The O 0 2.0704592316178605e-05
C282Y O 0 2.497558671166189e-05
mutation O 0 1.1363475493908481e-07
nearly O 0 5.773816535992182e-09
completely O 0 1.0200302824614482e-08
prevents O 0 2.460214920674275e-09
the O 0 1.1270415711805981e-08
association O 0 1.7829531184787584e-09
of O 0 3.091151157263994e-08
the O 0 1.3607356663669634e-07
mutant O 0 3.322551549445052e-07
HFE O 0 5.692827471648343e-06
protein O 0 1.1362343066423364e-08
with O 0 1.1022421864126386e-09
the O 0 8.918579652572589e-08
TfR O 0 5.559565397561528e-05
. O 0 6.519429689433309e-07

Studies O 0 2.6558601007309335e-07
on O 0 4.991808850718371e-07
cell O 0 3.943084720958723e-07
- O 0 7.07961618218178e-08
associated O 0 7.452818095998737e-08
transferrin O 0 6.843513256171718e-05
at O 0 2.368513918327153e-07
37 O 0 1.881749334131655e-08
degrees O 0 2.648464203502954e-07
C O 0 1.331914489810515e-07
suggest O 0 1.778714175948437e-09
that O 0 4.4244460872810976e-10
the O 0 4.568259726056567e-08
overexpressed O 0 2.9412708499876317e-06
wild O 0 4.691889046171127e-07
- O 0 2.1164912311633088e-07
type O 0 5.402241072260949e-07
HFE O 0 0.000175035820575431
protein O 0 4.856778446082899e-08
decreases O 0 2.492274608911771e-09
the O 0 3.890680277951475e-10
affinity O 0 1.2332102006240575e-09
of O 0 2.399267007291428e-09
the O 0 1.1715892256347615e-08
TfR O 0 5.732055683438375e-07
for O 0 7.591999917622161e-09
transferrin O 0 9.506291462457739e-06
. O 0 4.1879792433974217e-07

The O 0 0.00029482695390470326
overexpressed O 0 0.0016459483886137605
H63D O 0 0.07555444538593292
protein O 0 3.7039453104625863e-07
does O 0 1.6199577235198603e-09
not O 0 1.2674920835120673e-10
have O 0 3.85027530691584e-11
this O 0 4.313148449508475e-11
effect O 0 7.256032441560478e-10
, O 0 3.953636376619052e-11
providing O 0 1.6084882037414872e-10
the O 0 4.762744088004922e-10
first O 0 3.0863761546484625e-10
direct O 0 2.3040794272510823e-10
evidence O 0 2.7199185126391967e-09
for O 0 7.846060467997518e-10
a O 0 4.0153498304107416e-09
functional O 0 4.612834914041741e-08
consequence O 0 2.589808332231769e-07
of O 0 2.112865189474178e-07
the O 0 3.401395645141747e-07
H63D O 0 9.150001278612763e-05
mutation O 0 4.2127709320993745e-07
. O 0 1.653830139503043e-07

Addition O 0 6.714969913446112e-07
of O 0 4.837400865653763e-06
soluble O 0 2.299747029610444e-05
wild O 0 4.769859060616e-06
- O 0 1.0641144854162121e-06
type O 0 3.988261960330419e-05
HFE O 1 1.0
/ O 1 0.9994586110115051
beta2m O 0 0.00010127952555194497
heterodimers O 0 1.1641062883427367e-05
to O 0 3.8604582641710294e-08
cultured O 0 2.3589154807268642e-07
cells O 0 1.895867995926892e-08
also O 0 3.722993857646628e-10
decreased O 0 1.4506758017063248e-09
the O 0 1.335775379196491e-09
apparent O 0 3.779578605644929e-08
affinity O 0 2.9385796906922224e-08
of O 0 6.266082408501461e-08
the O 0 2.355780814866648e-08
TfR O 0 1.22657255019476e-07
for O 0 1.703470697833609e-10
its O 0 2.92762258879975e-10
ligand O 0 1.8479383356861945e-08
under O 0 1.266749478645579e-07
steady O 0 1.88535508982568e-07
- O 0 5.633961919215835e-08
state O 0 8.253743799535584e-10
conditions O 0 6.298254362491207e-08
, O 0 2.7137919689224077e-10
both O 0 1.136718774663592e-10
in O 0 4.4449241509703086e-10
293 O 0 6.634498506130626e-10
cells O 0 5.020664439747691e-10
and O 0 2.8180475730721355e-09
in O 0 9.242137721798827e-09
HeLa O 0 1.533093018224463e-05
cells O 0 6.437838351303071e-07
. O 0 5.688913233825588e-07

Furthermore O 0 2.53990128840087e-06
, O 0 8.23233818891822e-08
at O 0 6.806024543948297e-08
4 O 0 2.929899345360809e-08
degrees O 0 3.106939630015404e-07
C O 0 8.417487720180361e-07
, O 0 2.2404955668520188e-09
the O 0 1.313281927650678e-08
added O 0 1.6619054576949566e-08
soluble O 0 3.6253138091524306e-07
complex O 0 4.5036333062853373e-07
of O 0 4.972262104274705e-07
HFE O 0 0.16442634165287018
/ O 0 1.3705277524422854e-05
beta2m O 0 7.576595635327976e-07
inhibited O 0 1.8687872582745513e-08
binding O 0 1.3597051484737221e-08
of O 0 5.440309536197674e-08
transferrin O 0 7.97974644228816e-06
to O 0 1.291042934781217e-07
HeLa O 0 1.9653911294881254e-05
cell O 0 9.022002132041962e-07
TfR O 0 9.955826953955693e-07
in O 0 3.5176885848642314e-09
a O 0 1.871726418301023e-08
concentration O 0 1.0232043905489263e-06
- O 0 2.939522119049798e-07
dependent O 0 6.988626921611285e-08
manner O 0 3.026002559636254e-07
. O 0 3.394564771497244e-07

Scatchard O 0 0.001861276221461594
plots O 0 9.093221706280019e-06
of O 0 1.1224442459933925e-06
these O 0 3.8505802990584925e-09
data O 0 9.984445270561082e-09
indicate O 0 2.841889168436751e-09
that O 0 9.331762029773927e-10
the O 0 1.5815911069694266e-07
added O 0 5.1352333940712924e-08
heterodimer O 0 7.129360142243968e-07
substantially O 0 3.665473613523318e-08
reduced O 0 5.979627815122512e-08
the O 0 9.716540461113254e-09
affinity O 0 5.924496893072728e-09
of O 0 1.7453798406563692e-08
TfR O 0 1.0104856755788205e-06
for O 0 1.209040068061995e-08
transferrin O 0 3.1309093174058944e-05
. O 0 1.1578623571040225e-06

These O 0 2.9987337057946206e-08
results O 0 1.5413826659482766e-08
establish O 0 2.5575078055339873e-08
a O 0 6.597427493204577e-09
molecular O 0 5.746726117195067e-08
link O 0 5.830079885527084e-08
between O 0 2.4016490129952217e-08
HFE O 1 0.99989914894104
and O 0 2.2137578525871504e-06
a O 0 4.476749779769307e-07
key O 0 2.500802793292678e-06
protein O 0 3.334938014631916e-08
involved O 0 2.138474952673164e-09
in O 0 3.144730698068088e-09
iron O 0 0.0022554274182766676
transport O 0 3.4270540254510706e-06
, O 0 4.6772776762793455e-09
the O 0 2.791967190773903e-08
TfR O 0 1.3973562090541236e-05
, O 0 1.282154715731565e-09
and O 0 1.2077256972276018e-09
raise O 0 1.745338984449063e-09
the O 0 5.189552787498997e-09
possibility O 0 4.151590626833013e-09
that O 0 2.2414348155308517e-10
alterations O 0 7.328126372385668e-08
in O 0 4.653729346326685e-10
this O 0 5.1524635252819806e-11
regulatory O 0 2.7775981514821524e-09
mechanism O 0 8.672750517746408e-09
may O 0 3.1887805729269303e-09
play O 0 1.0572784425733062e-08
a O 0 8.576092724865703e-09
role O 0 8.445886656716084e-09
in O 0 1.0812735151688457e-09
the O 0 2.2076044103869208e-08
pathogenesis O 1 0.9846835732460022
of O 1 0.9639493227005005
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.000383802194846794
. O 0 7.113752644727356e-07

Genomic O 0 5.381224127631867e-06
organization O 0 1.7949722064258822e-07
of O 0 1.4100340877121198e-06
the O 0 4.771451131091453e-06
UBE3A O 1 0.7595298290252686
/ O 0 0.0009334600763395429
E6 O 0 0.002645967761054635
- O 0 5.6060021051962394e-06
AP O 0 4.289308890292887e-06
gene O 0 7.362840559466122e-09
and O 0 1.1357506046749677e-09
related O 0 2.4824363009656736e-08
pseudogenes O 0 1.9638568119262345e-05
. O 0 9.535588105791248e-07

The O 0 2.1112300601089373e-05
UBE3A O 0 0.00017488001321908087
gene O 0 3.270366448759887e-07
encodes O 0 7.211033192788818e-08
the O 0 2.6613008685671957e-07
E6 O 0 2.4954899345175363e-05
- O 0 2.7147789296577685e-06
AP O 0 2.805890835588798e-05
ubiquitin O 0 3.0325336410896853e-06
- O 0 4.998406666345545e-07
protein O 0 1.9938642736860857e-08
ligase O 0 3.0563445108100495e-08
and O 0 3.6160712202359946e-09
has O 0 9.41960065503622e-10
recently O 0 2.8768036841597677e-09
been O 0 4.936880904082841e-10
shown O 0 9.143134166444966e-11
to O 0 4.7712889195139496e-11
be O 0 1.8017512481982578e-10
mutated O 0 8.497517001160304e-08
in O 0 1.394037326463149e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9115893840789795
who O 0 4.0850775206990875e-08
lack O 0 1.8980045979333227e-06
15q11 O 0 4.213910415273858e-06
- O 0 2.2440822249336634e-06
q13 O 0 1.517574673925992e-06
deletions O 0 1.7384665795816545e-07
or O 0 4.076111181916531e-08
chromosome O 0 1.7825044551500469e-07
15 O 0 1.5776066675243783e-07
paternal O 0 4.379593156045303e-05
uniparental B-Disease 1 0.9999576807022095
disomy I-Disease 0 0.23760488629341125
. O 0 4.093012466910295e-05

Previous O 0 1.6572148524574004e-05
UBE3A O 0 0.0003559959586709738
cDNA O 0 1.1637872603387223e-06
analysis O 0 2.015659639198475e-08
has O 0 7.380426825243092e-10
shown O 0 6.739323543669684e-10
a O 0 2.564442658226085e-09
coding O 0 8.409786289576004e-08
region O 0 1.2400272808577029e-08
of O 0 4.2157324742220226e-08
approximately O 0 9.608726259102696e-09
2 O 0 4.2412591483298456e-07
. O 0 1.1094525120824983e-07

6 O 0 0.00013019634934607893
kb O 0 3.5698780266102403e-05
and O 0 2.6523264295974514e-07
a O 0 9.947598300641403e-07
3 O 0 5.382148174248869e-06
- O 0 4.14779697166523e-06
untranslated O 1 0.9999786615371704
region O 0 4.293089659768157e-06
( O 0 1.76582588551355e-08
UTR O 0 0.010410284623503685
) O 0 3.4575813323556304e-09
of O 0 3.700470685430446e-08
< O 0 3.947291418171517e-07
50 O 0 1.5878441672612098e-08
bp O 0 4.7136044400986066e-08
, O 0 1.2692967510385955e-10
whereas O 0 5.788324264344169e-10
Northern O 0 5.216178156075557e-09
analysis O 0 8.336585866075552e-10
has O 0 1.30992341973446e-10
indicated O 0 9.351035917815054e-11
mRNA O 0 9.010852619617538e-10
sizes O 0 2.248827124518016e-09
of O 0 2.631685092069347e-08
5 O 0 9.195755268365247e-08
- O 0 4.5697325390392507e-07
8 O 0 9.073886531041353e-07
kb O 0 1.1841648301924579e-05
. O 0 8.938187079365889e-07

We O 0 9.660834621172398e-07
have O 0 7.074052454925095e-09
analyzed O 0 8.12373990299875e-09
additional O 0 2.722274849986661e-09
cDNA O 0 2.2259870036123175e-07
clones O 0 4.991085233996273e-07
and O 0 1.3378278485021156e-09
provide O 0 4.394748176483887e-10
evidence O 0 2.351299599467893e-09
for O 0 3.072608278920086e-10
an O 0 4.514169940628143e-11
additional O 0 1.7759445025689047e-09
0 O 0 8.711649002179911e-08
. O 0 7.026840620483199e-08

5 O 0 2.3304304704652168e-05
kb O 0 1.9090028217760846e-05
of O 0 3.728292313098791e-06
5 O 0 1.182885739581252e-06
- O 0 3.227608260658599e-07
UTR O 0 0.00557518657296896
and O 0 1.1774770314332272e-07
> O 0 3.886527508711879e-07
2 O 0 3.109515773758176e-07
kb O 0 3.9715331467959913e-07
of O 0 2.7782678557741747e-07
3 O 0 7.903352525318041e-06
- O 0 5.354583663574886e-06
UTR O 1 0.999994158744812
. O 0 3.875474703818327e-06

We O 0 5.423420930128486e-07
have O 0 1.3194181747167022e-08
established O 0 3.609822840644483e-08
the O 0 5.272121406107999e-09
genomic O 0 8.383677752021867e-09
organization O 0 8.631193537667059e-10
of O 0 1.9845534993123692e-08
UBE3A O 0 3.930673119612038e-05
and O 0 1.3953893152063301e-08
the O 0 1.3922390351694958e-08
sequence O 0 1.9654540217572958e-09
of O 0 2.874463156388174e-08
intron O 0 2.533480710553704e-06
- O 0 2.0676732219726546e-06
exon O 0 1.9513820461725118e-06
borders O 0 1.1970260516136477e-07
. O 0 2.308056394895175e-07

We O 0 1.8895397033702466e-06
have O 0 4.6842615120112896e-08
also O 0 1.5719965773541844e-08
mapped O 0 1.0832933128313016e-07
two O 0 7.909819466078716e-09
highly O 0 1.4271429371603972e-08
homologous O 0 4.438726719513397e-08
processed O 0 1.7030281185270724e-07
pseudogenes O 0 1.979013859454426e-06
, O 0 1.0216736789914194e-08
UBE3AP1 O 0 0.00013887362729292363
and O 0 1.3784099905933545e-07
UBE3AP2 O 0 0.0002945754677057266
, O 0 2.530754494856069e-09
to O 0 1.3271155285821123e-09
chromosomes O 0 2.2447472769471233e-09
2 O 0 4.509177031764011e-08
and O 0 1.3950559596409562e-09
21 O 0 7.59454810150828e-09
, O 0 1.4709336526586014e-10
respectively O 0 1.640316882323134e-09
, O 0 1.5879607351276803e-10
and O 0 5.810358305602392e-10
determined O 0 7.500230658763485e-09
their O 0 4.081633253605332e-09
genomic O 0 6.859169587869474e-08
organization O 0 1.245464886778791e-08
. O 0 8.785754346263275e-08

These O 0 1.631432269277866e-07
results O 0 2.4573413526240984e-08
will O 0 9.503589026849113e-10
form O 0 7.917890787467741e-10
the O 0 2.0761625751930524e-09
basis O 0 3.6276615045238714e-10
for O 0 1.4885868579450623e-11
studies O 0 1.1137417377238279e-11
of O 0 2.2145439648735277e-10
mutation O 0 2.0269770584224744e-10
and O 0 1.6124085400193167e-09
imprinting O 0 1.2660347010751138e-06
of O 0 5.072336534794886e-06
UBE3A O 1 0.7016603350639343
. O 0 9.03468480828451e-06

Mutation O 0 2.259268057969166e-06
spectrum O 0 2.7215628506382927e-06
and O 0 2.5608954956624075e-08
genotype O 0 1.0075257250719005e-06
- O 0 9.186305760522373e-08
phenotype O 0 1.9090288461143246e-08
analyses O 0 8.666032336179796e-10
in O 0 4.367598227528191e-10
Cowden B-Disease 0 0.00018591756816022098
disease I-Disease 0 1.4279102060754667e-06
and O 0 2.176199487280428e-08
Bannayan B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.1848728220797966e-08
two O 0 4.683591470211468e-08
hamartoma B-Disease 1 0.9999923706054688
syndromes I-Disease 1 0.999869704246521
with O 0 7.017898042249726e-06
germline O 1 0.9999858140945435
PTEN O 1 0.9999995231628418
mutation O 0 1.4168616871756967e-05
. O 0 1.7734594166540774e-06

The O 0 0.00011394415923859924
tumour B-Disease 1 1.0
suppressor O 0 0.0008090995834209025
gene O 0 1.7845007960204384e-06
PTEN O 0 0.00015826815797481686
, O 0 1.905564817050731e-09
which O 0 2.661820486249411e-10
maps O 0 1.1208099337522981e-08
to O 0 8.202210466379256e-09
10q23 O 0 1.0143649888050277e-05
. O 0 7.817422442712996e-07

3 O 0 2.901288098655641e-06
and O 0 2.5320451513266562e-08
encodes O 0 4.79102757466876e-09
a O 0 2.7880600050878e-09
403 O 0 3.1336044870045043e-10
amino O 0 3.4639230372945917e-10
acid O 0 2.121630648943551e-09
dual O 0 2.0869668659884155e-08
specificity O 0 2.639951048877265e-07
phosphatase O 0 3.866670886054635e-05
( O 0 6.6352612293485436e-09
protein O 0 2.959041189853906e-08
tyrosine O 0 5.0832827724889285e-08
phosphatase O 0 1.1179493242252647e-07
; O 0 2.4127760900327644e-10
PTPase O 0 6.286984444159316e-08
) O 0 5.627284055398363e-11
, O 0 6.001203006755773e-11
was O 0 5.5459357106713014e-09
shown O 0 7.882841046580324e-10
recently O 0 7.1334116391597036e-09
to O 0 1.3635819140489502e-09
play O 0 2.3041870633733197e-08
a O 0 1.631577539740192e-08
broad O 0 9.454132054997899e-08
role O 0 2.422425104953163e-08
in O 0 4.510998241613606e-09
human O 0 5.964762550547675e-08
malignancy B-Disease 0 0.017908545210957527
. O 0 1.195539880427532e-06

Somatic O 0 0.001953881001099944
PTEN O 0 0.0021601635962724686
deletions O 0 2.6725069801614154e-06
and O 0 2.037615587369146e-08
mutations O 0 2.8002267171700623e-09
were O 0 4.103221373785715e-10
observed O 0 6.707354671675603e-10
in O 0 5.400974667502112e-10
sporadic B-Disease 0 1.8548366824688856e-06
breast I-Disease 1 0.9995243549346924
, I-Disease 0 2.5860167340852058e-08
brain I-Disease 1 0.7604345083236694
, I-Disease 0 4.526497576762267e-08
prostate I-Disease 1 1.0
and I-Disease 1 0.9993628859519958
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 0.06722111254930496
lines O 0 5.256239887785341e-08
and O 0 4.3645438374539935e-09
in O 0 1.5138482689636135e-09
several O 0 1.0254219695582378e-08
primary O 0 8.41464425320737e-05
tumours B-Disease 1 1.0
such O 0 2.000358989562301e-08
as O 0 3.634110908024013e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 0.9049640893936157
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.01748884841799736

In O 0 1.9044507837406854e-07
addition O 0 4.536142483857475e-08
, O 0 1.870577470697299e-08
PTEN O 0 0.00012643574154935777
was O 0 4.87659690406872e-07
identified O 0 4.734090897073884e-09
as O 0 6.059404644709332e-10
the O 0 1.0939649186525457e-09
susceptibility O 0 1.8966455073154975e-08
gene O 0 1.2435629193063846e-09
for O 0 1.3424978906328988e-09
two O 0 1.1524979015575809e-07
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
( O 0 9.067009365537615e-09
CD B-Disease 0 6.508330898213899e-06
; O 0 3.6225074495632725e-07
MIM O 0 0.0006468135979957879
158350 O 0 8.235335258177656e-07
) O 0 5.449110052069273e-10
and O 0 2.7914599520784122e-09
Bannayan B-Disease 0 2.944832158391364e-05
- I-Disease 0 8.539714326616377e-05
Zonana I-Disease 1 0.6281240582466125
( I-Disease 0 4.878112846995464e-08
BZS I-Disease 0 6.176500028232113e-05
) I-Disease 0 2.022320755301621e-09
or I-Disease 0 8.720737909584386e-09
Ruvalcaba I-Disease 0 1.5854928278713487e-05
- I-Disease 0 2.4825130822137e-06
Riley I-Disease 0 2.5834098778432235e-05
- I-Disease 1 0.9307138919830322
Smith I-Disease 1 0.9981603026390076
syndrome I-Disease 1 1.0
( O 0 7.073056451645243e-08
MIM O 0 0.000661357247736305
153480 O 0 7.522521173086716e-06
) O 0 1.4616778898357552e-08
. O 0 1.7895710868742754e-07

Constitutive O 0 9.315351235272828e-06
DNA O 0 1.5637481283192756e-06
from O 0 1.3572933710293e-07
37 O 0 1.769157478292982e-07
CD B-Disease 0 1.021975663206831e-06
families O 0 1.617695488675963e-08
and O 0 1.436526630982371e-08
seven O 0 5.8926296730987815e-08
BZS B-Disease 0 0.0003142126079183072
families O 0 3.002940474061688e-08
was O 0 1.4154217353734566e-07
screened O 0 2.9479885199634737e-08
for O 0 1.257972659374218e-08
germline O 0 8.361517757293768e-06
PTEN O 0 0.0005642502219416201
mutations O 0 7.989918913153815e-07
. O 0 3.3609796901146183e-07

PTEN O 0 0.0007644835277460515
mutations O 0 1.6485172693592176e-07
were O 0 6.920404249655121e-09
identified O 0 4.071711412478862e-09
in O 0 2.0267152400776922e-09
30 O 0 1.2150877637395752e-08
of O 0 6.711647415613697e-08
37 O 0 7.973228832724999e-08
( O 0 1.2279104399937069e-09
81 O 0 7.499546939016e-08
% O 0 9.333844808168124e-10
) O 0 1.7153452269713654e-10
CD B-Disease 0 8.028591196307389e-07
families O 0 7.2510966120376e-09
, O 0 1.1979339742396178e-09
including O 0 2.48433917882096e-09
missense O 0 3.7185020573815564e-07
and O 0 9.619823515549797e-08
nonsense O 0 7.169888931457535e-07
point O 0 1.5501220218538947e-07
mutations O 0 7.26949667129162e-10
, O 0 1.2339131105765233e-10
deletions O 0 6.938246421839267e-09
, O 0 7.102765042787951e-10
insertions O 0 3.316283070375903e-08
, O 0 1.469672383791476e-09
a O 0 1.7071219104991542e-08
deletion O 0 2.592481962437887e-07
/ O 0 2.248112451752604e-07
insertion O 0 1.6811578973374708e-07
and O 0 8.584050448234848e-08
splice O 0 8.404579421039671e-05
site O 0 5.0279900278837886e-06
mutations O 0 4.058269098550227e-08
. O 0 1.4312064422483672e-07

These O 0 7.935799573033364e-08
mutations O 0 4.301965006447972e-08
were O 0 1.4313410900967938e-08
scattered O 0 3.953634930553562e-08
over O 0 9.7261816378591e-09
the O 0 1.1268825872434718e-08
entire O 0 1.321992648684045e-08
length O 0 3.4587352981674258e-09
of O 0 1.0982387443903008e-08
PTEN O 0 1.7652283759161946e-06
, O 0 2.713243518748243e-10
with O 0 8.670310303049433e-11
the O 0 6.7897625299906395e-09
exception O 0 4.237262540840447e-09
of O 0 3.203015808139753e-08
the O 0 1.2537066496065563e-08
first O 0 6.412767206143144e-09
, O 0 8.797803041638019e-10
fourth O 0 2.1214341927588976e-07
and O 0 3.137536808139885e-08
last O 0 1.4568176993634552e-06
exons O 0 0.00010017141175922006
. O 0 6.771749212930445e-06

A O 0 0.0008714590221643448
hot O 0 0.0009322402183897793
spot O 0 1.5005359273345675e-05
for O 0 8.126455242063457e-08
PTEN O 0 1.4976937563915271e-05
mutation O 0 1.4939223191845485e-08
in O 0 4.7434185468375745e-09
CD B-Disease 0 8.607541985838907e-07
was O 0 5.585715143752168e-07
identified O 0 1.3131616682926506e-08
in O 0 3.178021179550683e-09
exon O 0 6.714553535402956e-08
5 O 0 8.600369305611366e-09
that O 0 6.438129196428832e-11
contains O 0 5.15685105728636e-10
the O 0 1.4325209463095234e-08
PTPase O 0 1.077483716471761e-06
core O 0 4.744733246297983e-07
motif O 0 2.3689832318041226e-08
, O 0 1.8062519535622101e-10
with O 0 9.060327488263908e-11
13 O 0 1.279072847637508e-08
of O 0 4.966040023646201e-08
30 O 0 2.982442737220481e-08
( O 0 5.830964044939435e-10
43 O 0 4.632176420216183e-09
% O 0 1.3640338858422751e-10
) O 0 5.71036516683332e-11
CD B-Disease 0 2.5778319923119852e-08
mutations O 0 7.22340187664372e-10
identified O 0 3.734930142940129e-09
in O 0 3.2068649957750495e-09
this O 0 1.046800068849052e-08
exon O 0 1.606681507837493e-06
. O 0 2.0441616754851566e-07

Seven O 0 6.917021437402582e-06
of O 0 2.0881548152829055e-06
30 O 0 2.0981588022550568e-07
( O 0 3.2950586703606177e-09
23 O 0 3.1267237687870875e-08
% O 0 6.470534108515835e-10
) O 0 1.1105433933567e-10
were O 0 1.5952046350520277e-09
within O 0 9.483892782213843e-09
the O 0 8.090852787745462e-08
core O 0 4.0657229760654445e-07
motif O 0 1.9984256027782976e-08
, O 0 2.460964487749351e-10
the O 0 2.8924569406285627e-09
majority O 0 2.954486932882361e-10
( O 0 1.6151717463497306e-10
five O 0 2.2325610249396277e-09
of O 0 1.3386324937414429e-08
seven O 0 1.0086504964590404e-08
) O 0 1.5168620526306853e-10
of O 0 1.4548681148696119e-09
which O 0 4.4048184544287494e-10
were O 0 1.3156788547519227e-08
missense O 0 2.2297605539733922e-07
mutations O 0 8.384845706643773e-09
, O 0 4.5371420509532356e-10
possibly O 0 7.885672559382328e-09
pointing O 0 4.0069210172077874e-08
to O 0 1.0291762997383103e-08
the O 0 5.153837889793067e-08
functional O 0 3.0742651802029286e-07
significance O 0 1.0749963053058309e-07
of O 0 3.1553792467775565e-08
this O 0 2.2573960478666777e-09
region O 0 4.9260030721143266e-08
. O 0 3.331950324536592e-07

Germline O 0 0.002239543478935957
PTEN O 0 0.0003083486808463931
mutations O 0 5.222990751008183e-08
were O 0 7.541169466662723e-09
identified O 0 1.8567275494874025e-09
in O 0 1.183386166836442e-09
four O 0 2.44525866222034e-09
of O 0 3.738766807259708e-08
seven O 0 3.95691657217867e-08
( O 0 1.3975834933788178e-09
57 O 0 1.415146329009076e-07
% O 0 1.863128318291274e-08
) O 0 1.2669542748255935e-08
BZS B-Disease 0 0.08498895168304443
families O 0 4.2459134874661686e-07
studied O 0 1.9361814338481054e-06
. O 0 1.6650456018396653e-06

Interestingly O 0 2.9936470582470065e-06
, O 0 8.255290673275795e-09
none O 0 6.418885423187248e-09
of O 0 2.7421716009001784e-09
these O 0 1.3326750814002253e-10
mutations O 0 8.58145499105234e-10
was O 0 1.289773710055897e-08
observed O 0 2.5549513615885644e-09
in O 0 2.636909135489418e-09
the O 0 9.601639305856224e-08
PTPase O 0 6.880892760818824e-05
core O 0 4.723505116999149e-05
motif O 0 5.2873788263241295e-06
. O 0 4.2046588077937486e-07

It O 0 1.3422456390799198e-07
is O 0 4.656901531063795e-09
also O 0 4.895930327819542e-10
worthy O 0 2.8526708106824117e-08
of O 0 1.1152781809187218e-08
note O 0 1.7356256432066175e-09
that O 0 1.5763124139311913e-10
a O 0 4.432151534672357e-09
single O 0 1.4792010283315449e-08
nonsense O 0 6.72285835889852e-08
point O 0 4.290959054742416e-08
mutation O 0 4.363417960284721e-10
, O 0 8.859227240698431e-11
R233X O 0 1.3253378838840035e-08
, O 0 3.2566435659298065e-10
was O 0 1.58632165181416e-08
observed O 0 1.3224258355037932e-09
in O 0 2.7279598024954055e-10
the O 0 4.27549196047039e-09
germline O 0 1.7488687831246352e-08
DNA O 0 1.0482906098729927e-08
from O 0 1.8824521941240846e-09
two O 0 1.3347082328252213e-09
unrelated O 0 2.5469637066066753e-08
CD B-Disease 0 2.8552346975629916e-06
families O 0 5.877330266912395e-08
and O 0 1.4076141496843775e-07
one O 0 4.290590993605292e-07
BZS B-Disease 1 0.9997667670249939
family O 0 6.383006257237867e-05
. O 0 2.644045480337809e-06

Genotype O 0 8.000975503819063e-05
- O 0 9.081809366762172e-06
phenotype O 0 1.4769463518859993e-07
studies O 0 1.7572038268909296e-09
were O 0 1.3420319300294636e-09
not O 0 2.3892737788244744e-10
performed O 0 5.637151634374504e-09
on O 0 6.172063304887843e-09
this O 0 2.459622505668335e-10
small O 0 3.0356082092453107e-09
group O 0 4.4530024112532374e-10
of O 0 4.529347208404033e-08
BZS B-Disease 1 0.9999905824661255
families O 0 5.321950538927922e-06
. O 0 5.705110197595786e-06

However O 0 1.8823004666046472e-06
, O 0 4.5293816697267175e-08
genotype O 0 1.1716226708813338e-06
- O 0 1.9873534995440423e-07
phenotype O 0 1.1412139855337955e-07
analysis O 0 3.0122493388518023e-09
inthe O 0 3.834364008525881e-07
group O 0 8.349538838103854e-10
of O 0 2.490636319407713e-08
CD B-Disease 0 0.0002424329286441207
families O 0 2.200575366373414e-08
revealed O 0 3.8915747069268036e-08
two O 0 6.029360899439951e-10
possible O 0 2.456782333126739e-09
associations O 0 7.884430608395832e-11
worthy O 0 7.29461575588175e-08
of O 0 3.3273963140345586e-08
follow O 0 1.3875521176487382e-08
- O 0 3.74587642681945e-07
up O 0 1.2560186668508777e-08
in O 0 1.8128726297916842e-09
independent O 0 3.568425555044996e-09
analyses O 0 2.9257389400072498e-08
. O 0 1.4283116911428806e-07

The O 0 1.972398786165286e-05
first O 0 5.221484570938628e-06
was O 0 1.0344068869017065e-05
an O 0 2.8197357782033805e-09
association O 0 8.885868152397336e-10
noted O 0 8.31438640158666e-10
in O 0 4.392460561941647e-10
the O 0 4.365393380112437e-09
group O 0 5.2763814151202126e-11
of O 0 6.847676203847186e-09
CD B-Disease 0 0.040145497769117355
families O 0 2.93042859311754e-07
with O 0 4.405755760217289e-07
breast B-Disease 1 1.0
disease I-Disease 1 0.9999843835830688
. O 0 7.282878868863918e-06

A O 0 6.221682269824669e-06
correlation O 0 1.8631679665759293e-07
was O 0 1.4158199235225766e-07
observed O 0 1.7788871486956737e-09
between O 0 1.0735549116347443e-09
the O 0 2.942268650940605e-09
presence O 0 4.614751247800086e-09
/ O 0 8.495213705828064e-07
absence O 0 7.057424227241427e-07
of O 0 7.168575848481851e-07
a O 0 1.07257754677903e-07
PTEN O 0 1.96753262571292e-06
mutation O 0 1.3655652164601406e-09
and O 0 2.432154200260328e-10
the O 0 4.825729260637956e-10
type O 0 1.182303854818656e-08
of O 0 1.2941086424689274e-07
breast O 0 1.2711032468359917e-05
involvement O 0 5.91853677178733e-07
( O 0 4.042061974018907e-08
unaffected O 0 9.02754436538089e-06
versus O 0 0.00021532231767196208
benign O 1 0.9910635948181152
versus O 0 0.06975018233060837
malignant O 1 0.9990647435188293
) O 0 2.045988445331659e-08
. O 0 1.1196970461924138e-07

Specifically O 0 1.8580718119665107e-07
and O 0 1.8647138944061226e-08
more O 0 1.8338006113616245e-10
directly O 0 1.0663306904135084e-09
, O 0 1.2936107740557645e-10
an O 0 5.2928616350866875e-11
association O 0 6.145629560805332e-10
was O 0 5.281333059770077e-08
also O 0 4.224228467020197e-10
observed O 0 2.025322826115783e-10
between O 0 1.1117811532512789e-10
the O 0 2.7032637239798873e-10
presence O 0 3.5863417791048846e-10
of O 0 1.5965296640274573e-08
a O 0 1.5471209735551383e-07
PTEN O 0 0.45353206992149353
mutation O 0 3.1337744985648897e-06
and O 0 3.412850446693483e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 0.9995711445808411
. O 0 1.1195971865163301e-06

Secondly O 0 0.00010028189717559144
, O 0 8.711865007171582e-08
there O 0 4.361581762424294e-09
appeared O 0 1.8242856114625283e-08
to O 0 8.040983989765493e-10
be O 0 1.3103838014671965e-09
an O 0 8.312705523927377e-10
interdependent O 0 8.575867838089835e-08
association O 0 3.6741301112641622e-09
between O 0 1.966152396448706e-08
mutations O 0 2.7682171221954377e-08
upstream O 0 7.897867249084811e-08
and O 0 1.6638044275651964e-09
within O 0 1.0631914904024597e-08
the O 0 4.931540331654105e-08
PTPase O 0 5.494302513397997e-06
core O 0 1.7097928548537311e-06
motif O 0 7.506388044475898e-08
, O 0 5.013754966753936e-10
the O 0 6.909694150181167e-09
core O 0 1.276463024169061e-07
motif O 0 8.855621125292146e-09
containing O 0 3.1372524023076664e-10
the O 0 2.3072996846451588e-09
majority O 0 3.644597401653016e-10
of O 0 3.88798397921164e-08
missense O 0 2.2530470289439108e-07
mutations O 0 2.002912058429729e-09
, O 0 1.7526873008488764e-10
and O 0 2.6366867023064344e-10
the O 0 2.510394558896678e-09
involvement O 0 2.0595825489522213e-08
of O 0 2.6941451736206545e-08
all O 0 7.70205621503095e-10
major O 0 3.142651650023254e-08
organ O 0 1.1208642717974726e-05
systems O 1 0.9995866417884827
( O 0 2.688960876184865e-06
central O 1 0.9994532465934753
nervous O 1 0.9953643083572388
system O 1 1.0
, O 0 5.387871715356596e-05
thyroid O 1 1.0
, O 0 4.265192728780676e-06
breast O 1 1.0
, O 0 1.6544042580335372e-07
skin O 1 1.0
and O 1 0.8905739188194275
gastrointestinal O 1 1.0
tract O 1 0.9999822378158569
) O 0 5.556452009614077e-08
. O 0 6.659149676124798e-07

However O 0 3.50957589034806e-06
, O 0 2.144087751787538e-08
these O 0 8.978068843923381e-10
observations O 0 1.0846098241756863e-08
would O 0 1.25608279333278e-09
need O 0 1.0469153322034686e-09
to O 0 9.352859597910879e-10
be O 0 2.680753674599856e-10
confirmed O 0 7.05842717607652e-10
by O 0 4.6741693848773025e-11
studying O 0 2.2689118639451777e-10
a O 0 2.999239745449245e-10
larger O 0 5.538501879343016e-10
number O 0 8.043419402747887e-11
of O 0 4.864405767079916e-09
CD B-Disease 0 7.2296215876122005e-06
families O 0 1.4127623160220537e-07
. O 0 9.067364317161264e-07

Molecular O 0 0.17996373772621155
defects O 1 0.9999998807907104
leading O 0 2.7266730739938794e-06
to O 0 3.850780672109977e-08
human O 0 5.923211574554443e-07
complement B-Disease 1 0.9590352177619934
component I-Disease 1 1.0
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.5733794711536575e-08
an O 0 2.0378312926006004e-10
African O 0 6.786664008551213e-10
- O 0 9.095971087447197e-09
American O 0 7.483254904627756e-09
family O 0 7.501979126800506e-08
. O 0 4.237992357047915e-08

Complement B-Disease 0 0.0001786413777153939
component I-Disease 1 0.9999998807907104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.0791357968619195e-08
C6D B-Disease 0 2.203768781328108e-05
) O 0 1.895809065288745e-09
was O 0 2.724544287957542e-07
diagnosed O 0 1.3676065009349259e-06
in O 0 1.538422012004048e-08
a O 0 8.494097869515826e-08
16 O 0 7.658555745138074e-08
- O 0 3.426470840395268e-08
year O 0 1.6330252705643034e-08
- O 0 2.219959895910506e-07
old O 0 3.932730123779038e-06
African O 0 9.284651270036193e-08
- O 0 8.662025408057161e-08
American O 0 2.0698955882636483e-09
male O 0 7.540216784285292e-10
with O 0 7.633435550324918e-10
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.2280335795367137e-05

The O 0 1.035355467138288e-06
patients O 0 1.90405486932832e-07
father O 0 2.4704822862986475e-06
and O 0 5.13441094085465e-08
two O 0 5.23670635743656e-08
brothers O 0 1.7173286323668435e-05
also O 0 3.62214755966761e-08
had O 0 6.393363491952186e-07
C6D B-Disease 1 0.999976634979248
, O 0 4.913857765131979e-09
but O 0 1.3527072795227468e-09
gave O 0 4.849185941679934e-09
no O 0 9.428696712276974e-10
history O 0 2.8569928645083564e-09
of O 0 1.7172915534047206e-08
meningitis B-Disease 1 0.9999998807907104
or O 0 2.1103232938912697e-08
other O 0 2.839705581791918e-09
neisserial B-Disease 0 1.1380884643585887e-05
infection I-Disease 0 0.0005301974015310407
. O 0 3.916493824362988e-06

By O 0 8.382738059253825e-08
using O 0 4.201267955750154e-08
exon O 0 2.5555968363732973e-07
- O 0 3.496204925568236e-08
specific O 0 2.1549018125455177e-09
polymerase O 0 1.6617222797776776e-07
chain O 0 1.7673016827757237e-08
reaction O 0 1.9078050250698197e-09
( O 0 1.2823252182325717e-10
PCR O 0 9.122135935513143e-09
) O 0 3.402494674897838e-10
/ O 0 3.72983333107868e-09
single O 0 6.1502527515244765e-09
- O 0 1.3433950840635589e-08
strand O 0 1.1150867784692764e-08
conformation O 0 4.914126883193148e-10
polymorphism O 0 6.951621500661531e-10
as O 0 1.4245360446807354e-10
a O 0 1.8198699491822623e-10
screening O 0 1.3924348341021187e-09
step O 0 7.839124016584265e-09
and O 0 4.216146598512438e-10
nucleotide O 0 2.285600597673465e-09
sequencing O 0 4.873684122941313e-09
of O 0 1.2104614199870412e-08
target O 0 2.4400417686365472e-08
exons O 0 3.914668695870205e-07
, O 0 2.1113688575269407e-09
we O 0 2.3139754001810786e-10
determined O 0 1.4362134814760452e-09
that O 0 6.42841127551641e-11
the O 0 2.8850408728686716e-09
proband O 0 2.2017998446699494e-07
was O 0 4.252526863979256e-08
a O 0 2.3131381254870576e-09
compound O 0 4.224844829536778e-08
heterozygote O 0 1.6742858122142934e-07
for O 0 3.028425510365196e-09
two O 0 2.3106302649011923e-08
C6 O 0 6.856558320578188e-05
gene O 0 1.9587341171245498e-07
mutations O 0 8.223314296174067e-08
. O 0 1.440484993509017e-07

The O 0 3.666677002911456e-06
first O 0 4.472409784739284e-07
, O 0 6.281635656080198e-09
1195delC O 0 4.91520097511966e-07
located O 0 5.5375032559368265e-08
in O 0 4.5180765795294064e-09
exon O 0 1.0956238583048616e-07
7 O 0 9.49361478319588e-08
, O 0 3.297257467060888e-10
is O 0 5.5924879310831344e-11
a O 0 4.872417469492518e-10
novel O 0 2.3547195304729485e-09
mutation O 0 4.310502510485037e-10
, O 0 1.047789841002178e-10
while O 0 3.9821856923083487e-10
the O 0 1.490600709530554e-08
second O 0 2.3204796661957516e-07
, O 0 2.2182142789262116e-09
1936delG O 0 9.061929517883982e-08
in O 0 1.258517468016862e-08
exon O 0 2.3051943287555332e-07
12 O 0 6.389839768417005e-08
, O 0 8.958158104199754e-10
has O 0 1.4896925359941804e-10
been O 0 3.1528610278108715e-10
described O 0 2.1024637586464223e-09
before O 0 1.614834665986109e-08
to O 0 6.660265672309151e-09
cause O 0 1.7328400190308457e-06
C6D B-Disease 1 0.7977108955383301
in O 0 5.67299665021892e-08
an O 0 4.801758990424787e-09
unrelated O 0 9.031904113498967e-08
African O 0 3.8063603824411985e-08
- O 0 2.5276597170886816e-07
American O 0 4.7007297609980014e-08
individual O 0 1.0785098147891858e-08
. O 0 3.852929921777104e-07

Both O 0 2.995503933789223e-08
mutations O 0 8.454477118391424e-09
result O 0 3.309608809232145e-09
in O 0 5.1694390990064676e-09
premature O 0 2.079124641340968e-07
termination O 0 6.9040779635543e-06
codons O 0 5.684032657882199e-07
and O 0 3.3012415201483236e-07
C6 O 0 8.407793939113617e-05
null O 0 5.335676632967079e-06
alleles O 0 1.1627295748439792e-07
. O 0 2.2734761273568438e-07

Allele O 0 5.20697710726381e-07
- O 0 4.505428563561509e-08
specific O 0 1.2006973193479098e-09
PCR O 0 8.087889824537342e-08
indicated O 0 1.3266353349195015e-08
that O 0 3.418497152019029e-10
the O 0 5.853241447084656e-09
probands O 0 1.2086375136277638e-06
two O 0 2.1788242321463258e-08
brothers O 0 1.594574996488518e-06
also O 0 8.86295481450361e-09
inherited O 0 8.026057912502438e-06
the O 0 1.2631295476239757e-06
1195delC O 0 1.7680171993106342e-07
mutation O 0 1.5323621260776576e-09
from O 0 9.145598167670244e-10
their O 0 3.948900317851667e-09
heterozygous O 0 3.4202596310706213e-09
mother O 0 1.965447538054832e-08
and O 0 1.6590923079817799e-09
the O 0 2.074928673323484e-08
1936delG O 0 3.313077812094889e-08
mutation O 0 2.758568651284321e-10
from O 0 3.7291766896707657e-10
their O 0 1.1654061049526376e-09
homozygous O 0 2.1665371718881943e-08
father O 0 2.6983937573277217e-07
. O 0 2.574372892638621e-08
. O 0 2.9151675562388846e-07

PAX6 O 0 0.024779919534921646
mutations O 0 1.247267300641397e-05
reviewed O 0 1.2326355317782145e-05
. O 0 4.491080289881211e-06

Mutations O 0 3.6071878639631905e-06
in O 0 1.3653060193519195e-07
PAX6 O 0 0.0014150416245684028
are O 0 3.250997693271529e-09
responsible O 0 2.1583501208510825e-08
for O 0 9.353631647002203e-09
human O 0 4.179658390057739e-06
aniridia B-Disease 1 1.0
and O 0 4.180846644885605e-06
have O 0 3.95140942188732e-09
also O 0 3.8061387375165623e-10
been O 0 2.0789674148868897e-10
found O 0 5.5260785530864e-11
in O 0 1.2038973984385137e-11
patients O 0 2.602797838369142e-11
with O 0 2.357990191992343e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.317829814861398e-08
with O 0 2.5258374080294743e-05
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 0 0.11379113793373108
with O 0 0.0025538380723446608
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 3.193084907593402e-08
and O 0 7.627240172780603e-09
with O 0 8.053777378336235e-08
isolated B-Disease 1 0.9999980926513672
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 0.002270343480631709

No O 0 2.9713987714785617e-06
locus O 0 9.606491175873089e-07
other O 0 3.409675208843055e-09
than O 0 6.37290387128786e-10
chromosome O 0 1.6981942962956964e-08
11p13 O 0 2.915331549502298e-07
has O 0 1.7012701247764994e-09
been O 0 1.9218184821312434e-09
implicated O 0 2.5181115859140846e-08
in O 0 2.1747471379285344e-08
aniridia B-Disease 1 1.0
, O 0 3.737098452916143e-08
and O 0 6.998683943493234e-08
PAX6 O 1 0.9924117922782898
is O 0 4.022120236868432e-08
clearly O 0 3.413768157045638e-09
the O 0 2.164079759836568e-08
major O 0 9.36434503273631e-08
, O 0 2.1804101579814272e-10
if O 0 4.1252702642768924e-11
not O 0 2.8950316102727136e-11
only O 0 1.019204720620337e-10
, O 0 1.8275747581952828e-10
gene O 0 1.481210376574893e-09
responsible O 0 2.586066116805341e-08
. O 0 4.828874011764128e-07

Twenty O 0 1.3871234841644764e-05
- O 0 4.817930857825559e-06
eight O 0 1.5857415291975485e-07
percent O 0 9.865601668934687e-09
of O 0 9.230826769623945e-09
identified O 0 3.054777053534963e-08
PAX6 O 0 1.698600681265816e-05
mutations O 0 6.128893836887528e-09
are O 0 9.114722310243906e-10
C O 0 4.693966275226558e-06
- O 0 4.1158396925311536e-05
T O 0 4.936330242344411e-06
changes O 0 4.45763816969702e-08
at O 0 9.286050328682904e-08
CpG O 0 1.0970081376626695e-07
dinucleotides O 0 1.3831160572408407e-07
, O 0 2.6953916876237827e-10
20 O 0 2.784163177782517e-10
% O 0 2.4104565565785663e-11
are O 0 4.8368375277219045e-12
splicing O 0 1.2483758915493581e-08
errors O 0 1.0508373549100725e-07
, O 0 3.4211974919706734e-10
and O 0 2.385922015513131e-10
more O 0 1.6328266863596674e-11
than O 0 8.554518898806762e-11
30 O 0 3.0290843167080084e-09
% O 0 2.401051024669698e-10
are O 0 7.096762760783193e-11
deletion O 0 9.21650666896312e-09
or O 0 2.7243733935478076e-09
insertion O 0 9.302039671865714e-08
events O 0 9.15108167021117e-09
. O 0 7.775244625918276e-08

There O 0 3.658740865830623e-07
is O 0 2.1489432455723545e-08
a O 0 5.843628514412558e-08
noticeably O 0 2.1141058823559433e-06
elevated O 0 7.298437412828207e-05
level O 0 1.8813946667251003e-07
of O 0 2.884304706185503e-08
mutation O 0 4.538788900276813e-09
in O 0 3.3448679381820057e-09
the O 0 1.1331762195254669e-08
paired O 0 3.211504839839563e-09
domain O 0 1.2592396014809992e-09
compared O 0 3.2646102487987605e-10
with O 0 5.200665939564253e-11
the O 0 1.0481526757644133e-08
rest O 0 6.563642074297604e-08
of O 0 4.5192852127229344e-08
the O 0 9.746427309664796e-08
gene O 0 4.866710057171986e-08
. O 0 8.970442877398455e-08

Increased O 0 2.195578474584181e-07
mutation O 0 7.080750208388054e-08
in O 0 1.1244157605005967e-08
the O 0 3.030016060279195e-08
homeodomain O 0 2.574427753643249e-06
is O 0 1.4309635698595002e-09
accounted O 0 1.5466002922792654e-09
for O 0 3.08268133242251e-10
by O 0 9.504241837987593e-10
the O 0 1.4992637886734883e-07
hypermutable O 0 1.6450447219540365e-05
CpG O 0 7.088775873853592e-06
dinucleotide O 0 3.0917374260752695e-06
in O 0 1.6419203774376e-08
codon O 0 4.231974415347395e-08
240 O 0 7.600957019349153e-08
. O 0 1.0403076800002964e-07

Very O 0 4.135112590120116e-07
nearly O 0 1.653990189254273e-08
all O 0 2.975961699291929e-10
mutations O 0 3.013184424194293e-10
appear O 0 1.247570713402979e-09
to O 0 1.3105938556634555e-09
cause O 0 5.48370451269875e-07
loss O 0 9.862121714832028e-07
of O 0 2.8328051371317997e-07
function O 0 1.4045776985938119e-08
of O 0 1.6493191878907965e-07
the O 0 2.1639973368792198e-08
mutant O 0 4.127525432551238e-09
allele O 0 4.207631187913563e-10
, O 0 4.394075381330964e-11
and O 0 1.2241098412690832e-10
more O 0 1.0616902322568844e-11
than O 0 6.292794063611495e-11
80 O 0 8.658234129654829e-10
% O 0 3.0751293178532535e-10
of O 0 4.5737764686748505e-09
exonic O 0 2.7206391450818046e-07
substitutions O 0 1.0776996184347354e-08
result O 0 1.0927976745733758e-08
in O 0 1.4663802616610155e-08
nonsense O 0 5.139976337886765e-07
codons O 0 4.3017311668336333e-07
. O 0 3.2359915280721907e-07

In O 0 3.615928676481417e-07
a O 0 5.889943821557608e-08
gene O 0 3.4989788844086434e-09
with O 0 2.6645227690913487e-10
such O 0 6.840522814854921e-09
extraordinarily O 0 3.417233983782353e-06
high O 0 6.382859965015086e-07
sequence O 0 6.166274602037447e-09
conservation O 0 3.4886364908004452e-09
throughout O 0 1.0417577911425724e-10
evolution O 0 4.571515110907143e-10
, O 0 1.984346194305875e-11
there O 0 4.196168065795369e-11
are O 0 1.5610295001078356e-10
presumed O 0 3.266406793045462e-06
undiscovered O 0 0.00011368401465006173
missense O 0 2.495763737897505e-06
mutations O 0 5.343608222574403e-08
, O 0 1.0049361343078544e-09
these O 0 3.093837686041212e-10
are O 0 3.4356095746090887e-10
hypothesized O 0 2.273631594107428e-08
to O 0 1.9530621564456396e-09
exist O 0 2.3692257045127008e-09
in O 0 1.0940948591553479e-08
as O 0 4.409210774269923e-08
- O 0 1.2368671775675466e-07
yet O 0 6.940099606111971e-09
unidentified O 0 2.33734116505957e-08
phenotypes O 0 1.8240418953041626e-08
. O 0 5.5373314822304565e-09
. O 0 6.171642041863379e-08

Genetic O 0 2.9802872631989885e-06
heterogeneity O 0 1.7275041273023817e-06
and O 0 2.1915614212275614e-08
penetrance O 0 1.0338153515476733e-06
analysis O 0 5.985182571777159e-09
of O 0 1.0954441620469879e-07
the O 0 4.3906180735575617e-07
BRCA1 O 0 8.741509560650229e-08
and O 0 1.0924413373913922e-08
BRCA2 O 0 3.168901230310439e-08
genes O 0 4.0833771919324136e-09
in O 0 1.2541084615236286e-08
breast B-Disease 1 0.7202938199043274
cancer I-Disease 1 0.9858664870262146
families O 0 3.575230493879644e-07
. O 0 1.7340699969281559e-06

The O 0 0.010324331931769848
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 6.119788304204121e-05
Consortium O 0 2.124346565324231e-06
. O 0 3.543691775576008e-07

The O 0 3.1522995413979515e-07
contribution O 0 1.0396214378260993e-07
of O 0 3.890024515840196e-07
BRCA1 O 0 3.128311050204502e-07
and O 0 4.673293574342097e-08
BRCA2 O 0 1.0536265335758799e-06
to O 0 5.790698196506128e-07
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 0.009340278804302216
assessed O 0 7.137279567359656e-08
by O 0 8.036997733995577e-10
linkage O 0 3.220511501922374e-08
and O 0 1.1963128265790601e-09
mutation O 0 2.164705220630836e-10
analysis O 0 1.0455019489041817e-10
in O 0 1.5434196976027437e-10
237 O 0 8.59883886317192e-10
families O 0 1.0466272987175174e-10
, O 0 1.5985839388332757e-11
each O 0 6.414665239956596e-12
with O 0 7.297611126499959e-11
at O 0 7.188440953598274e-09
least O 0 5.949778170144526e-11
four O 0 1.1981894643131596e-10
cases O 0 6.972470378840967e-10
of O 0 3.999843158908334e-07
breast B-Disease 0 0.18903762102127075
cancer I-Disease 0 2.2439110125560546e-06
, O 0 5.944163217197485e-11
collected O 0 1.1573800251518662e-10
by O 0 3.5416805599375323e-10
the O 0 6.5288768382743e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 7.2344082582276314e-06
Consortium O 0 4.713847374659963e-07
. O 0 8.799523243396834e-08

Families O 0 6.283902962422871e-07
were O 0 2.0125058952658037e-08
included O 0 3.062394116071232e-09
without O 0 2.8669331353370353e-09
regard O 0 1.29968125150981e-08
to O 0 9.422332913899822e-10
the O 0 4.525674945909941e-09
occurrence O 0 1.0034965924887729e-07
of O 0 3.314173955004662e-05
ovarian B-Disease 1 1.0
or I-Disease 0 1.9633514511951944e-06
other I-Disease 0 2.5651368673607067e-07
cancers I-Disease 1 0.9999353885650635
. O 0 2.526488742660149e-06

Overall O 0 2.1231344362604432e-05
, O 0 2.616023948576185e-07
disease O 0 0.0003397452528588474
was O 0 4.157511284574866e-06
linked O 0 5.921291403865325e-07
to O 0 2.3385718250779064e-08
BRCA1 O 0 3.8560504123097417e-08
in O 0 2.147295008469996e-09
an O 0 1.801850890714718e-10
estimated O 0 8.418039876278982e-11
52 O 0 1.993247344955762e-09
% O 0 2.1123185145466294e-10
of O 0 6.152763631916969e-09
families O 0 4.986072887902537e-09
, O 0 6.120712270352158e-10
to O 0 2.3142014971000435e-09
BRCA2 O 0 1.756333389835163e-08
in O 0 3.6854794771556953e-09
32 O 0 8.71764527232699e-09
% O 0 2.1850064813033754e-10
of O 0 2.12549888800595e-09
families O 0 7.702644078122489e-10
, O 0 1.3352040306724433e-10
and O 0 1.9810873774783744e-10
to O 0 7.203108665088109e-10
neither O 0 9.425680680408277e-09
gene O 0 2.7337010433114983e-09
in O 0 2.6316737677944957e-09
16 O 0 5.8051106144318965e-09
% O 0 2.381480290747362e-10
( O 0 1.1755679762970317e-10
95 O 0 2.394732767641017e-08
% O 0 7.72356756328918e-09
confidence O 0 3.1661346611144836e-07
interval O 0 1.7808085317483346e-07
[ O 0 1.9564416220418934e-07
CI O 0 2.526662228774512e-06
] O 0 2.6799588326298363e-08
6 O 0 2.5589470098452693e-08
% O 0 4.5484060962053263e-10
- O 0 4.523258656519147e-09
28 O 0 4.374745454782669e-09
% O 0 1.8464532680617651e-10
) O 0 4.3932628368548166e-11
, O 0 4.791845392704275e-11
suggesting O 0 1.7235581850627568e-09
other O 0 4.340005688163728e-09
predisposition O 0 3.7543279631790938e-06
genes O 0 7.957737011565769e-07
. O 0 9.805888794289785e-07

The O 0 1.2997157682548277e-05
majority O 0 9.897721042761987e-08
( O 0 2.9018785152601367e-09
81 O 0 4.812718401581151e-08
% O 0 5.023059190811807e-10
) O 0 1.2127249204851864e-10
of O 0 9.345838769547754e-09
the O 0 5.8645990065997466e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.0729577226697984e-08
were O 0 5.085294407791707e-10
due O 0 1.4680369808672822e-08
to O 0 1.2157223006070694e-09
BRCA1 O 0 1.3485751404473945e-09
, O 0 4.5004319715324925e-11
with O 0 1.0779776377090045e-11
most O 0 1.135664007279047e-09
others O 0 2.6593758306603377e-09
( O 0 2.13864925768803e-10
14 O 0 3.608836784962932e-09
% O 0 3.545776727786887e-10
) O 0 1.356926376816503e-10
due O 0 1.635672646216335e-07
to O 0 3.4671791127038887e-07
BRCA2 O 0 8.072737728070933e-06
. O 0 1.4335480500449194e-06

Conversely O 0 5.02007515024161e-06
, O 0 1.7618695835608378e-08
the O 0 7.044578254067346e-09
majority O 0 2.508612484408701e-10
of O 0 6.979418820662886e-09
families O 0 5.929434165885539e-10
with O 0 1.3624010253288077e-10
male B-Disease 0 3.87665277656879e-09
and I-Disease 0 4.210926718428709e-08
female I-Disease 0 1.693624511744929e-07
breast I-Disease 1 0.7587542533874512
cancer I-Disease 1 0.9696437120437622
were O 0 1.6754199805291137e-07
due O 0 0.02177594043314457
to O 0 6.065527600185305e-07
BRCA2 O 0 2.8006562047266925e-07
( O 0 2.197998671960022e-09
76 O 0 6.828089738064591e-08
% O 0 1.7874102198334185e-09
) O 0 5.04148778279756e-10
. O 0 3.38260690568859e-08

The O 0 3.93813279515598e-05
largest O 0 1.0500305052119074e-06
proportion O 0 4.186740909517539e-08
( O 0 1.744194233488372e-09
67 O 0 2.829585810104618e-08
% O 0 5.211471809651869e-10
) O 0 2.475115112865467e-10
of O 0 1.8529465961591995e-08
families O 0 9.239246701042703e-09
due O 0 3.502881781969336e-06
to O 0 1.7640079619241078e-08
other O 0 2.6493260918414308e-09
genes O 0 1.3091846495782988e-09
was O 0 1.4288752403501803e-08
found O 0 2.3542917615415604e-10
in O 0 1.1322698334481629e-10
families O 0 1.19437890133689e-10
with O 0 3.951299357152216e-11
four O 0 1.3811218835257932e-09
or O 0 3.511789303800583e-09
five O 0 2.7653501710744877e-09
cases O 0 1.9298738163087137e-09
of O 0 5.08808261656668e-06
female O 0 1.0545883014856372e-05
breast B-Disease 1 0.9958983063697815
cancer I-Disease 0 0.02073458768427372
only O 0 2.2467794735803182e-07
. O 0 4.5682518248213455e-06

These O 0 6.797163365490633e-08
estimates O 0 7.749467556550371e-08
were O 0 9.884359997158754e-09
not O 0 3.219353394978697e-10
substantially O 0 1.0913395520617541e-08
affected O 0 1.87553506059146e-09
either O 0 3.0692229313622477e-10
by O 0 7.367399051938506e-11
changing O 0 7.863049100720332e-10
the O 0 1.6487010645604983e-09
assumed O 0 8.352936120559207e-09
penetrance O 0 6.897753479506719e-08
model O 0 1.6079184650408251e-09
for O 0 3.212121957307801e-10
BRCA1 O 0 9.133169776021077e-10
or O 0 2.0621671037446276e-10
by O 0 4.794350333403585e-11
including O 0 3.120149694169072e-10
or O 0 7.418875735965003e-09
excluding O 0 2.696797984924615e-08
BRCA1 O 0 2.8804896246015232e-08
mutation O 0 5.396384228362194e-09
data O 0 1.1009945843909463e-08
. O 0 9.09042441321617e-08

Among O 0 3.309137355245184e-07
those O 0 1.725002896080241e-08
families O 0 4.441832679447089e-09
with O 0 1.019990869544074e-09
disease O 0 1.2003933989035431e-05
due O 0 0.00019563348905649036
to O 0 3.1929513966133527e-07
BRCA1 O 0 1.04152675817204e-07
that O 0 1.1636293040240275e-09
were O 0 3.737374854040354e-09
tested O 0 1.7551939901494507e-09
by O 0 1.751310485520463e-10
one O 0 6.022258247639911e-10
of O 0 2.3011730299060673e-09
the O 0 2.0639623343754465e-09
standard O 0 1.9218149294175646e-09
screening O 0 8.153975827873694e-10
methods O 0 8.744435731067313e-10
, O 0 3.6445260004347446e-11
mutations O 0 2.839876077354031e-11
were O 0 1.4184790841920147e-10
detected O 0 3.7988372447728125e-09
in O 0 5.606941577696034e-10
the O 0 9.424745428532333e-09
coding O 0 3.2988147324886086e-08
sequence O 0 4.087632010651987e-09
or O 0 9.017682600642729e-09
splice O 0 7.071666345837002e-07
sites O 0 1.2956665962349234e-08
in O 0 1.0713518960869806e-09
an O 0 1.34544514418522e-10
estimated O 0 1.4632188516383593e-10
63 O 0 6.881679226466986e-09
% O 0 7.255145928475315e-10
( O 0 9.551364144044783e-10
95 O 0 1.3331828085938469e-07
% O 0 3.777718760034077e-08
CI O 0 7.436292889906326e-06
51 O 0 1.6179568262941757e-07
% O 0 7.068940099941301e-09
- O 0 5.7400217912118023e-08
77 O 0 4.44448780001494e-08
% O 0 2.6409661124660033e-09
) O 0 1.143798500358173e-09
. O 0 2.844835478299501e-08

The O 0 1.379842387905228e-06
estimated O 0 8.158833608717941e-09
sensitivity O 0 5.349206944060825e-08
was O 0 3.713203966526635e-08
identical O 0 1.9095378611666547e-09
for O 0 9.084136914916385e-11
direct O 0 2.73238598413883e-10
sequencing O 0 9.803400757846248e-09
and O 0 9.748278850807424e-10
other O 0 3.196494180457421e-10
techniques O 0 3.288205050466786e-07
. O 0 2.9783760169266316e-07

The O 0 7.510184786951868e-06
penetrance O 0 0.0006468083593063056
of O 0 2.117692565661855e-05
BRCA2 O 0 2.8496717732195975e-06
was O 0 3.264607926212193e-07
estimated O 0 3.232495937588453e-10
by O 0 2.05567160516118e-10
maximizing O 0 1.314373747618447e-07
the O 0 9.296505254496878e-08
LOD O 0 0.0032380169723182917
score O 0 4.3069567823295074e-07
in O 0 2.6455555968141198e-08
BRCA2 O 0 9.226042863019757e-08
- O 0 1.249429288918691e-07
mutation O 0 3.23242366206955e-09
families O 0 6.826624820988059e-10
, O 0 4.4754110140043935e-11
over O 0 1.37284031365148e-10
all O 0 1.3761172756865392e-10
possible O 0 2.9003860646525936e-08
penetrance O 0 6.276079147937708e-06
functions O 0 2.1845278297405457e-07
. O 0 1.36427260599703e-07

The O 0 3.7653461504305596e-07
estimated O 0 2.1020065688048817e-09
cumulative O 0 4.044311552320323e-09
risk O 0 1.4355953759093154e-08
of O 0 6.032506405517779e-08
breast B-Disease 0 0.00021721298980992287
cancer I-Disease 0 3.94511989725288e-05
reached O 0 5.70205827443715e-07
28 O 0 1.0251172710695755e-07
% O 0 6.044640343816354e-10
( O 0 1.5212950343901355e-10
95 O 0 1.7025953980009945e-08
% O 0 3.92407040195053e-09
CI O 0 2.2243602870730683e-06
9 O 0 5.9882907521569e-08
% O 0 9.750026341848184e-10
- O 0 4.107185702650895e-09
44 O 0 2.95026514329777e-09
% O 0 1.950741790324173e-10
) O 0 1.1689245925372571e-11
by O 0 1.3139464342948326e-11
age O 0 4.3340803168590014e-10
50 O 0 3.0839572562335604e-10
years O 0 5.089311749806313e-10
and O 0 7.659308742802295e-10
84 O 0 8.925314709529175e-09
% O 0 2.9178670590823685e-10
( O 0 6.516082812213497e-11
95 O 0 1.921031511642468e-08
% O 0 5.941732439396219e-09
CI O 0 1.8549729929873138e-06
43 O 0 3.8817155711967644e-08
% O 0 8.811186780199876e-10
- O 0 6.3087002288853e-09
95 O 0 8.896013703463268e-09
% O 0 1.860186310542744e-10
) O 0 3.814798303636291e-12
by O 0 1.2960576188658646e-11
age O 0 1.5518688556426241e-09
70 O 0 8.735187684294488e-09
years O 0 9.977020987150809e-09
. O 0 8.346171398443403e-08

The O 0 7.2923448897199705e-06
corresponding O 1 0.9986100196838379
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 1.1799269259427092e-06
were O 0 5.0289688857674264e-08
0 O 0 1.5598621416756941e-07
. O 0 1.1674840294517708e-07

4 O 0 6.168269010231597e-06
% O 0 1.7183070966098057e-08
( O 0 1.4405949766427284e-09
95 O 0 5.402957725664237e-08
% O 0 6.8396484032007265e-09
CI O 0 1.5373168480437016e-06
0 O 0 3.7649005690809645e-08
% O 0 6.770399796351967e-10
- O 0 5.257380308876236e-09
1 O 0 1.2306167640474541e-08
% O 0 1.2578010855079924e-10
) O 0 8.334700984935495e-12
by O 0 1.4689870847517383e-11
age O 0 6.451876255475497e-10
50 O 0 7.715760252935411e-10
years O 0 8.218805636062143e-10
and O 0 7.86394893648179e-10
27 O 0 6.412522512988517e-09
% O 0 1.0912697828713291e-10
( O 0 4.6353445387614656e-11
95 O 0 1.0287601881486808e-08
% O 0 1.3852110569700926e-09
CI O 0 3.7888898418714234e-07
0 O 0 1.1071901617754065e-08
% O 0 3.229901346379904e-10
- O 0 5.953393777957672e-09
47 O 0 6.67300659173975e-09
% O 0 1.2547961281139663e-10
) O 0 1.0887971947648456e-11
by O 0 2.478212426937354e-11
age O 0 2.5808610804034515e-09
70 O 0 8.841545273696738e-09
years O 0 2.741994897803579e-08
. O 0 1.9103663362329826e-07

The O 0 1.2194943792565027e-06
lifetime O 0 2.482290483385441e-06
risk O 0 1.1439079798947205e-06
of O 0 5.40073961019516e-06
breast B-Disease 1 0.9999994039535522
cancer I-Disease 0 0.004115509334951639
appears O 0 1.2883328182056175e-08
similar O 0 4.40779590604734e-09
to O 0 1.0977948328161347e-08
the O 0 6.053669494576752e-07
risk O 0 1.8943504187518556e-07
in O 0 4.115999985287999e-09
BRCA1 O 0 1.6788540557755027e-09
carriers O 0 7.341242058700459e-10
, O 0 7.566029053274193e-11
but O 0 9.721647098448472e-11
there O 0 1.8499678178240941e-10
was O 0 1.0525701199526338e-08
some O 0 4.521761784448408e-11
suggestion O 0 4.7348853726703055e-09
of O 0 5.900758104360193e-09
a O 0 1.942282601419265e-08
lower O 0 3.7865706303819024e-07
risk O 0 1.5751059123658706e-08
in O 0 2.775564666990249e-09
BRCA2 O 0 1.1541450462004832e-08
carriers O 0 5.4617452782679266e-09
< O 0 1.407246372764348e-07
50 O 0 4.133386966032049e-09
years O 0 2.2475747929462386e-09
of O 0 7.939762625142066e-09
age O 0 4.5162693140810006e-08
. O 0 1.4067150289065466e-07

Eye B-Disease 1 0.9999998807907104
movement I-Disease 0 0.00013906563981436193
abnormalities I-Disease 0 0.0003021424054168165
correlate O 0 1.7408024177711923e-07
with O 0 2.252656283729948e-09
genotype O 0 3.2533027933823178e-06
in O 0 9.46905700516254e-08
autosomal O 1 0.9419710040092468
dominant O 1 0.9999843835830688
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 1.4411267329705879e-05

We O 0 1.476091711083427e-06
compared O 0 1.1087200846304768e-06
horizontal O 0 1.632546445762273e-05
eye O 0 0.014259209856390953
movements O 0 4.5723524522145453e-07
( O 0 3.3828392531631835e-08
visually O 0 5.644459477593955e-08
guided O 0 5.772430995421018e-07
saccades O 0 4.33643399446737e-05
, O 0 1.7201532642729944e-08
antisaccades O 0 1.1123007652713568e-06
, O 0 2.0829056257554157e-09
and O 0 1.9210122381707606e-09
smooth O 0 4.564531863593402e-08
pursuit O 0 1.32713950051766e-07
) O 0 4.05418004723046e-10
in O 0 6.069375002581978e-10
control O 0 2.787577457752377e-08
subjects O 0 3.094236333822664e-08
( O 0 3.712229967867131e-10
n O 0 2.322825043421517e-09
= O 0 2.161257395272287e-09
14 O 0 3.887238864130893e-10
) O 0 1.7754008332926396e-11
and O 0 4.117841137518674e-11
patients O 0 1.0028600172518054e-10
with O 0 2.3666402171329537e-11
three O 0 6.232558358298945e-10
forms O 0 1.715942410385196e-08
of O 0 1.5198952496575657e-05
autosomal O 0 0.10489369928836823
dominant O 0 0.0013700064737349749
cerebellar B-Disease 1 0.9999984502792358
ataxias I-Disease 0 0.0003938499721698463
type I-Disease 0 9.997549204854295e-05
I I-Disease 0 0.004096115007996559
spinocerebellar B-Disease 0 0.06258070468902588
ataxias I-Disease 0 2.3751537810312584e-05
1 I-Disease 0 1.030716248351382e-06
and I-Disease 0 3.352380772980723e-08
2 I-Disease 0 3.582817953429185e-07
( O 0 2.832694745436015e-09
SCA1 B-Disease 0 1.6285797755699605e-05
, O 0 7.303146531967286e-09
n O 0 1.3560636169529516e-08
= O 0 5.891109378097781e-09
11 O 0 1.946086403137315e-09
; O 0 2.9054272876472e-10
SCA2 B-Disease 0 1.0153484026886872e-06
, O 0 7.05892622132609e-10
n O 0 1.8650332389569257e-09
= O 0 2.1264070504400934e-09
10 O 0 3.278894655789344e-10
) O 0 5.655335227894298e-11
and O 0 3.464433406819012e-09
SCA3 B-Disease 1 1.0
/ O 0 7.70414226280991e-06
Machado B-Disease 0 2.3892000626801746e-06
- I-Disease 0 9.42370320444752e-07
Joseph I-Disease 0 0.00016525317914783955
disease I-Disease 0 0.024244921281933784
( O 0 5.731463748048782e-09
MJD B-Disease 1 1.0
) O 0 2.2533825916326577e-09
( O 0 3.053387265250507e-10
n O 0 5.4177742292438325e-09
= O 0 1.1221146678508376e-08
16 O 0 1.1259801979690565e-08
) O 0 1.5714022305601816e-09
. O 0 3.911026169589604e-08

In O 0 5.140357188793132e-06
SCA1 B-Disease 0 0.00039036860107444227
, O 0 5.0044448585140344e-08
saccade O 0 1.6189629832297214e-06
amplitude O 0 1.243018488139569e-07
was O 0 2.1648064674195666e-08
significantly O 0 1.6518613144000938e-09
increased O 0 3.97374855243271e-10
, O 0 4.7233442851402074e-11
resulting O 0 3.360381084505093e-09
in O 0 1.0272836803437713e-08
hypermetria B-Disease 0 1.0332168130844366e-05
. O 0 9.89311274679494e-07

The O 0 2.9349692340474576e-05
smooth O 0 1.108244396164082e-05
pursuit O 0 1.9395210983930156e-06
gain O 0 7.748321877443232e-07
was O 0 9.656715747041744e-07
decreased O 0 2.696865522011649e-07
. O 0 1.675269771794774e-07

In O 0 5.358639555197442e-06
SCA2 B-Disease 0 0.00048744413652457297
, O 0 3.512353430323856e-08
saccade O 0 1.9167073332937434e-06
velocity O 0 2.785975539154606e-07
was O 0 3.864901714223379e-07
markedly O 0 6.161827172945777e-07
decreased O 0 3.479946144580026e-07
. O 0 1.5246422435666318e-07

The O 0 5.713920472771861e-06
percentage O 0 1.3101616787025705e-06
of O 0 2.4085031213871844e-07
errors O 0 7.846238986530807e-06
in O 0 1.9955427887907717e-07
antisaccades O 0 0.001008112565614283
was O 0 2.0603429220500402e-06
greatly O 0 1.4615607391021967e-08
increased O 0 3.408472171173571e-09
and O 0 2.220339245795344e-09
was O 0 7.239998822683447e-09
significantly O 0 5.768298616537493e-10
correlated O 0 1.069389909957863e-09
with O 0 6.52528656108764e-11
age O 0 5.401636471447091e-09
at O 0 2.7389999601723503e-08
disease O 0 2.1687662865588209e-07
onset O 0 0.00020656049309764057
. O 0 1.0255255347146885e-06

In O 0 1.9746730117731204e-07
addition O 0 1.818039940815197e-08
, O 0 8.319557820435364e-10
a O 0 7.03101687982155e-10
correlation O 0 4.693790911503015e-10
between O 0 3.242056179075803e-09
smooth O 0 1.478897075912755e-07
pursuit O 0 1.4533691228280077e-07
gain O 0 3.647174295906552e-08
and O 0 2.4047923652403824e-09
the O 0 4.831681277295274e-09
number O 0 5.530341185000509e-10
of O 0 1.5099127281814617e-08
trinucleotide O 0 1.0487791769264732e-05
repeats O 0 1.2364544943466171e-07
was O 0 1.448503894607711e-07
found O 0 1.3492395645187116e-08
. O 0 9.536045553204531e-08

In O 0 3.126959200017154e-05
SCA3 B-Disease 1 1.0
, O 0 2.600400875962805e-06
gaze B-Disease 0 0.00021304287656676024
- I-Disease 0 7.607483712490648e-05
evoked I-Disease 0 6.23130690655671e-05
nystagmus I-Disease 0 0.00048065281589515507
was O 0 1.3083387102597044e-06
often O 0 1.0092350288815055e-09
present O 0 2.7108446598589353e-09
as O 0 3.451282371003117e-09
was O 0 5.620803023020926e-08
saccade O 0 5.814050041408336e-07
hypometria O 0 1.1198332003914402e-06
and O 0 3.123737357668688e-08
smooth O 0 3.431478319271264e-07
pursuit O 0 6.830355232523289e-07
gain O 0 3.0177861276570184e-07
was O 0 6.510545063065365e-07
markedly O 0 4.126099497625546e-07
decreased O 0 1.238947362480758e-07
. O 0 8.788855154762132e-08

Three O 0 1.1481484989417368e-06
major O 0 6.737401463396964e-07
criteria O 0 2.552106934672338e-07
, O 0 2.6756366011682076e-09
saccade O 0 1.268101073037542e-06
amplitude O 0 1.1907025765367507e-07
, O 0 7.065917295712154e-10
saccade O 0 9.910075959851383e-08
velocity O 0 2.8130870077802683e-08
, O 0 5.397946534202447e-10
and O 0 4.509731754698265e-10
presence O 0 2.020123401891283e-09
of O 0 2.6461970037416904e-07
gaze B-Disease 0 3.3852022170322016e-05
- I-Disease 0 8.261125913122669e-06
evoked I-Disease 0 3.681758016682579e-06
nystagmus I-Disease 0 5.32754620508058e-06
, O 0 1.0444043407886738e-09
permitted O 0 1.074550559643228e-09
the O 0 1.2505153579311923e-09
correct O 0 1.9626293923380445e-09
assignment O 0 9.984217008707219e-09
of O 0 9.234877751396198e-09
90 O 0 2.668888221535326e-09
% O 0 4.070948300682886e-10
of O 0 6.624512494113333e-09
the O 0 3.5766994699315546e-08
SCA1 B-Disease 0 2.8060780095984228e-05
, O 0 4.0083865116002926e-09
90 O 0 6.9106169675592355e-09
% O 0 6.07783212647206e-10
of O 0 9.70914815212609e-09
the O 0 2.0616971241338433e-08
SCA2 B-Disease 0 1.937098022608552e-05
, O 0 1.4030454575930662e-09
and O 0 1.0393071958603173e-09
93 O 0 1.0779915626812908e-08
% O 0 1.639793578700477e-10
of O 0 1.726519371914037e-09
the O 0 8.593416644941954e-09
patients O 0 1.2683059047446932e-08
with O 0 9.440937809301886e-09
SCA3 B-Disease 1 1.0
to O 0 1.0101757652591914e-07
their O 0 9.450703331026489e-09
genetically O 0 5.1491806374315274e-08
confirmed O 0 5.120777402112253e-08
patient O 0 1.7197127135659684e-06
group O 0 6.147481967921919e-10
and O 0 1.274304217702138e-09
, O 0 1.6916623657436958e-10
therefore O 0 4.17707157751579e-09
, O 0 6.942426078460073e-10
may O 0 8.824208919122611e-09
help O 0 3.13887156266901e-08
orient O 0 5.32991236923408e-07
diagnoses O 0 3.0091614462435246e-06
of O 0 4.2234737520630006e-06
SCA1 B-Disease 1 0.9699087738990784
, O 0 2.6323577984044277e-08
SCA2 B-Disease 0 0.00018972538236994296
, O 0 1.2282905359484175e-08
and O 0 6.386319029161314e-08
SCA3 B-Disease 1 1.0
at O 0 8.916553611015843e-07
early O 0 1.0252483662043232e-07
clinical O 0 4.8815291364689983e-08
stages O 0 1.46842822346116e-07
of O 0 1.6367650346182927e-07
the O 0 5.07083939282893e-07
diseases O 0 0.0015640894416719675
. O 0 4.305527312453705e-08
. O 0 3.3979981139964366e-07

Genetic O 0 3.242692230287503e-07
basis O 0 1.6558999504923122e-08
and O 0 2.2860616177844406e-10
molecular O 0 5.001608460730722e-09
mechanism O 0 1.4563014794077844e-08
for O 0 7.479576424884726e-08
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999420642852783

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 1.2133009477111045e-05
more O 0 1.1212113459890816e-09
than O 0 7.865789963812375e-11
300 O 0 1.5384234164361743e-10
, O 0 2.793342640527996e-11
000 O 0 7.177435312755165e-10
sudden O 0 2.678046451265459e-09
deaths O 0 4.2457629079173387e-10
each O 0 5.0968278209051476e-11
year O 0 9.211089113669857e-10
in O 0 2.4515676155800747e-09
the O 0 7.282701375288525e-08
USA O 0 1.821626085529715e-07
alone O 0 4.709776391109699e-08
. O 0 1.2525262604867748e-07

In O 0 7.133107260415272e-07
approximately O 0 1.8179116878513923e-08
5 O 0 1.3264384790545591e-07
- O 0 8.507961268833242e-08
12 O 0 9.180329385571895e-09
% O 0 3.1382579868122207e-10
of O 0 3.1918884202397635e-10
these O 0 8.087797792599716e-12
cases O 0 1.2526799042511527e-10
, O 0 1.9853041086093093e-11
there O 0 5.9366253232773225e-12
are O 0 5.095055887610611e-12
no O 0 6.055037027330457e-10
demonstrable O 0 4.684219311457127e-05
cardiac O 1 0.9999996423721313
or O 0 5.5013726523611695e-05
non O 1 0.9999997615814209
- O 1 1.0
cardiac O 1 1.0
causes O 0 1.124960476772685e-06
to O 0 1.2274631311370854e-09
account O 0 1.8119694633611516e-10
for O 0 9.69202940126479e-10
the O 0 9.286741686764799e-08
episode O 0 6.600715352078623e-08
, O 0 1.8026165629625446e-11
which O 0 3.3398774197668235e-12
is O 0 1.3130439660904991e-12
therefore O 0 7.501706721091406e-12
classified O 0 1.7067391944181054e-10
as O 0 7.985081040828845e-09
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 0 0.007729289587587118
IVF B-Disease 1 1.0
) O 0 1.7827126441716246e-08
. O 0 6.869525748243177e-08

A O 0 4.60377350464114e-06
distinct O 0 1.0116797000137012e-07
group O 0 1.218064848984568e-08
of O 0 2.687358346520341e-06
IVF B-Disease 1 1.0
patients O 0 0.0003837994590867311
has O 0 3.1799129995846442e-09
been O 0 3.908546264419499e-10
found O 0 1.065207991257644e-10
to O 0 7.653740141666532e-11
present O 0 7.532008905464238e-10
with O 0 4.283750021372157e-10
a O 0 5.783286738392235e-08
characteristic O 0 1.255613597095362e-06
electrocardiographic O 0 7.281594207597664e-06
pattern O 0 1.0679492561394e-06
. O 0 6.959375014048419e-07

Because O 0 3.90263903682353e-06
of O 0 1.4492028640233912e-05
the O 0 6.96320512361126e-07
small O 0 1.5905994743548035e-08
size O 0 6.891609949377653e-09
of O 0 1.1434130087195626e-08
most O 0 1.762917367642558e-09
pedigrees O 0 5.124871549355703e-08
and O 0 2.863495662808191e-09
the O 0 8.896760661514236e-09
high O 0 3.3705504165482125e-08
incidence O 0 5.4140272709446435e-08
of O 0 1.2158898776704063e-08
sudden B-Disease 0 6.255525164533537e-08
death I-Disease 0 4.339776467077172e-07
, O 0 2.848551949874434e-10
however O 0 5.193431795724734e-10
, O 0 7.085212277990749e-11
molecular O 0 3.6968141881033034e-09
genetic O 0 1.762856860487716e-09
studies O 0 6.875273683704108e-10
of O 0 1.4682755988815188e-07
IVF B-Disease 1 1.0
have O 0 1.2676360405805553e-08
not O 0 5.176540862628087e-10
yet O 0 4.506767403711365e-09
been O 0 5.693611360158002e-09
done O 0 3.1569079794735444e-08
. O 0 3.9907664728389136e-08

Because O 0 3.9907921745907515e-05
IVF B-Disease 1 1.0
causes O 0 0.3048184812068939
cardiac O 1 1.0
rhythm O 1 0.9999866485595703
disturbance O 1 0.9999874830245972
, O 0 4.0706087389708046e-09
we O 0 7.840914029166868e-10
investigated O 0 8.224644076904042e-09
whether O 0 2.9070361673433354e-09
malfunction O 0 3.684128023451194e-05
of O 0 2.943538568445092e-08
ion O 0 3.102092478002305e-06
channels O 0 3.310346130547259e-07
could O 0 2.2760049844805508e-08
cause O 0 1.517431371667044e-07
the O 0 1.1687123269155109e-08
disorder O 0 1.1837524738211869e-08
by O 0 1.9969859099688847e-11
studying O 0 2.5248664270449694e-10
mutations O 0 4.47645254197937e-11
in O 0 1.2596185205993038e-10
the O 0 6.2735536765501365e-09
cardiac O 0 1.0678234502847772e-05
sodium O 0 2.248615373900975e-06
channel O 0 8.636114898763481e-07
gene O 0 5.5129699916278696e-08
SCN5A O 0 1.656102540437132e-05
. O 0 2.930928815203515e-07

We O 0 4.025589817047148e-07
have O 0 8.476857438211027e-09
now O 0 3.4131690807015502e-09
identified O 0 4.6872532522002075e-09
a O 0 2.594478187845084e-09
missense O 0 5.846784034702068e-08
mutation O 0 5.752249343515814e-09
, O 0 8.478906465825276e-10
a O 0 8.170887078051692e-09
splice O 0 1.6649788676659227e-06
- O 0 3.304942879367445e-07
donor O 0 1.4469679676665237e-08
mutation O 0 3.5671869902387243e-09
, O 0 2.6958901777618394e-10
and O 0 7.740139640333155e-10
a O 0 3.4455947428568834e-08
frameshift O 0 4.71027931325807e-07
mutation O 0 6.945370056854472e-09
in O 0 2.2867430171658043e-09
the O 0 1.0365361013953134e-08
coding O 0 1.9844368637222942e-07
region O 0 3.270696424806374e-08
of O 0 2.054796368611278e-07
SCN5A O 0 0.002174037043005228
in O 0 7.184221573197647e-08
three O 0 1.9049629429446213e-07
IVF B-Disease 1 1.0
families O 0 1.0760651036889612e-07
. O 0 1.4318823104986222e-07

We O 0 2.6065680458486895e-07
show O 0 4.077431281501731e-09
that O 0 4.995682686970149e-11
sodium O 0 4.582613399861657e-09
channels O 0 2.058262227322416e-09
with O 0 4.931090952231543e-11
the O 0 2.2458865878149936e-09
missense O 0 1.4724557217959955e-07
mutation O 0 1.3120150299528177e-08
recover O 0 3.2674483918526676e-07
from O 0 2.3874632049114553e-08
inactivation O 0 3.4104079531971365e-05
more O 0 7.653087608083808e-10
rapidly O 0 6.533213969817098e-09
than O 0 1.1805584287927218e-10
normal O 0 1.2238419166976655e-09
and O 0 1.9766636938367554e-10
that O 0 2.9495756531661144e-11
the O 0 4.91391416446163e-09
frameshift O 0 2.108480998685991e-07
mutation O 0 3.5763021433155018e-09
causes O 0 3.861075015265669e-09
the O 0 9.515837895435197e-09
sodium O 0 9.144734036681257e-08
channel O 0 1.1445088432537887e-07
to O 0 2.3214163924478726e-09
be O 0 4.315884982730722e-09
non O 0 2.06670392799424e-07
- O 0 9.201875741382537e-07
functional O 0 4.743601948575815e-06
. O 0 7.145621339077479e-07

Our O 0 1.2370349395496305e-05
results O 0 4.8497803106783977e-08
indicate O 0 5.166324701377789e-09
that O 0 3.35578093091371e-10
mutations O 0 1.877116906356946e-09
in O 0 2.192379833232394e-09
cardiac O 0 2.207420720878872e-06
ion O 0 7.685182936256751e-06
- O 0 0.00020357036555651575
channel O 0 6.236606964193925e-07
genes O 0 5.096305044638427e-10
contribute O 0 6.935117063955332e-11
to O 0 1.6721771189942558e-10
the O 0 2.328778281324162e-09
risk O 0 2.3250588121470628e-09
of O 0 6.601090341007421e-09
developing O 0 1.002818976303388e-06
IVF B-Disease 1 1.0
. O 0 5.569896188717394e-08
. O 0 1.288913438202144e-07

Molecular O 0 1.9479519323795103e-05
heterogeneity O 0 1.8547234503785148e-05
in O 0 2.1739970179623924e-07
mucopolysaccharidosis B-Disease 0 0.0002628651272971183
IVA I-Disease 1 0.9999877214431763
in O 0 6.850461176099998e-08
Australia O 0 3.542844684290003e-09
and O 0 2.8429247844741212e-09
Northern O 0 1.2805867299903184e-07
Ireland O 0 5.066043939905285e-08
: O 0 5.648481682385409e-10
nine O 0 2.3271176097239277e-09
novel O 0 2.3480997146663185e-09
mutations O 0 4.6029341449482786e-10
including O 0 2.3574955876348724e-10
T312S O 0 1.5004137310370425e-07
, O 0 8.29558421955312e-10
a O 0 1.2251358816328661e-09
common O 0 9.460261019000882e-09
allele O 0 1.9131067841016147e-09
that O 0 1.2381778935477428e-10
confers O 0 3.771541656760746e-08
a O 0 2.7966308380200644e-08
mild O 0 3.2572299915045733e-06
phenotype O 0 1.329743281530682e-05
. O 0 5.157171472092159e-07

Mucopolysaccharidosis B-Disease 1 0.6842024326324463
IVA I-Disease 1 1.0
( O 0 1.6143090761033818e-05
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 1.7893622583642355e-08
is O 0 2.5220181498752936e-09
an O 0 9.495150443683542e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 1 0.9999997615814209
by O 0 3.722710175679822e-07
a O 0 0.00022845830244477838
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 2.2315098249237053e-06
N O 0 1.6896603938221233e-06
- O 0 7.204818075479125e-07
acetylgalactosamine O 0 6.153755748528056e-06
- O 0 8.182616966223577e-07
6 O 0 1.6293001863232348e-06
- O 0 5.906137516831222e-07
sulfate O 0 6.103538908064365e-06
sulfatase O 0 5.394133404479362e-05
( O 0 1.1142661016094735e-08
GALNS O 0 2.8037427910021506e-05
) O 0 7.67721441974345e-09
. O 0 8.18152656734128e-08

Previous O 0 7.340743763961655e-07
studies O 0 1.6822589543608046e-08
of O 0 3.605398291028905e-08
patients O 0 1.0216853141287174e-08
from O 0 6.541792441083771e-09
a O 0 4.5242188662086846e-08
British O 0 1.5426936670337454e-06
- O 0 2.6343317585997283e-05
Irish O 0 1.5164490605457104e-06
population O 0 7.997921769309357e-11
showed O 0 4.658364805010251e-10
that O 0 4.228676089845784e-11
the O 0 4.871007597273547e-09
I113F O 0 3.885344668219659e-08
mutation O 0 1.111705394407636e-09
is O 0 8.663102873951445e-11
the O 0 3.273969984007863e-10
most O 0 3.234930726070395e-11
common O 0 4.21137263950655e-10
single O 0 7.290241188506741e-10
mutation O 0 4.6079762228146137e-10
among O 0 7.603792040455915e-10
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0004727314517367631
and O 0 2.6154619803264723e-08
produces O 0 1.2265620741302996e-09
a O 0 2.8929425521795338e-09
severe O 0 7.956166427902645e-07
clinical O 0 2.927262812590925e-06
phenotype O 0 1.6124995454447344e-05
. O 0 2.2003956701155403e-07

We O 0 2.0586250570886477e-07
studied O 0 6.897622029100603e-08
mutations O 0 3.948674276443853e-09
in O 0 3.1250828591566915e-09
the O 0 2.5040879592097554e-08
GALNS O 0 5.141166184330359e-06
gene O 0 1.1597545146457833e-08
from O 0 9.938124101438461e-09
23 O 0 3.682515981040524e-08
additional O 0 7.335075480341402e-08
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 5.070233328297036e-06
( O 0 1.4742880249940526e-09
15 O 0 2.470993409886546e-09
from O 0 1.3390812902969174e-09
Australia O 0 3.891852951021235e-10
, O 0 2.0543154677366005e-10
8 O 0 1.5812759990296854e-09
from O 0 9.152491542430141e-10
Northern O 0 4.290869171086342e-08
Ireland O 0 5.831277682943892e-09
) O 0 8.264262191248761e-11
, O 0 1.2939703995795693e-11
with O 0 5.716846267211917e-12
various O 0 6.624344961458917e-10
clinical O 0 7.825440775377501e-07
phenotypes O 0 2.8344034944893792e-05
( O 0 2.5301815753664414e-08
severe O 1 0.6746673583984375
, O 0 7.876171714826796e-09
16 O 0 3.557837358059146e-09
cases O 0 3.1397667799026863e-10
; O 0 3.227197953314942e-10
intermediate O 0 1.0748507150992737e-07
, O 0 1.7261826690262438e-10
4 O 0 2.6743509629056916e-09
cases O 0 2.755897177131317e-10
; O 0 1.6174878103569768e-09
mild O 0 5.375498585635796e-05
, O 0 8.05188538066659e-09
3 O 0 5.758718657489226e-08
cases O 0 2.799842357958937e-09
) O 0 3.0274671658503394e-09
. O 0 1.1558417867263415e-07

We O 0 7.258529421960702e-07
found O 0 5.5747214844359405e-08
two O 0 2.269536114596349e-09
common O 0 2.050644321016648e-09
mutations O 0 2.588353142929378e-10
that O 0 3.315146074323039e-11
together O 0 1.6120017820586696e-10
accounted O 0 1.131540638965589e-09
for O 0 7.267500490293344e-10
32 O 0 1.7533778873257688e-08
% O 0 1.1626154483579398e-09
of O 0 2.4168317125372596e-08
the O 0 3.636310452748148e-08
44 O 0 9.661247801773243e-09
unrelated O 0 2.089080686218381e-09
alleles O 0 7.275762631264726e-11
in O 0 3.331493414471254e-11
these O 0 1.0785293491633041e-10
patients O 0 8.100499826468877e-09
. O 0 7.36447347549074e-08

One O 0 4.77319872516091e-07
is O 0 7.807877011600795e-09
the O 0 1.4337072862247169e-08
T312S O 0 1.1620976181347942e-07
mutation O 0 2.52311038728692e-09
, O 0 1.1622290629897947e-10
a O 0 4.6024775657294015e-10
novel O 0 5.0958317565630296e-09
mutation O 0 4.2415540524309847e-10
found O 0 2.8278726582620095e-10
exclusively O 0 4.276060616703603e-10
in O 0 4.764307282023594e-10
milder O 0 0.07480831444263458
patients O 0 0.0011891804169863462
. O 0 1.1079739124397747e-05

The O 0 7.702717084612232e-06
other O 0 2.7212069042548137e-08
is O 0 2.578765201377564e-09
the O 0 4.759768135187414e-09
previously O 0 6.732697510614116e-09
described O 0 8.338338908231435e-09
I113F O 0 1.023376654529784e-07
that O 0 1.867595106341824e-10
produces O 0 1.4595068487111007e-09
a O 0 9.76667013929955e-09
severe O 0 1.2968954251846299e-05
phenotype O 0 5.5402793805114925e-05
. O 0 5.530441171686107e-07

The O 0 9.015035175252706e-06
I113F O 0 1.116968269343488e-05
and O 0 6.200301783110262e-08
T312S O 0 4.2152547052864975e-07
mutations O 0 1.6615370190820045e-09
accounted O 0 1.5130254826800638e-09
for O 0 2.056668835237474e-09
8 O 0 4.253629981576523e-08
( O 0 3.8543551683645205e-10
18 O 0 2.718445690774729e-09
% O 0 2.550879507623449e-10
) O 0 1.0916299114649419e-10
and O 0 3.101674028727075e-09
6 O 0 1.2659789661029208e-07
( O 0 7.727379847111138e-10
14 O 0 4.406442766224927e-09
% O 0 1.4024560679448683e-10
) O 0 3.854118066359824e-11
of O 0 2.3236490509503938e-09
44 O 0 3.25192783812156e-09
unrelated O 0 6.26175422624442e-09
alleles O 0 8.047504884700629e-10
, O 0 3.3325123216521035e-10
respectively O 0 1.1407271571783895e-08
. O 0 1.3340806503947533e-07

The O 0 1.0504188139748294e-05
relatively O 0 2.4315713744726963e-06
high O 0 2.6765062557387864e-06
residual O 0 2.8751803256454878e-05
GALNS O 0 0.00014595953689422458
activity O 0 2.454951975039421e-08
seen O 0 1.205891830835526e-08
when O 0 4.4934460596834924e-09
the O 0 1.1663296106689813e-08
T312S O 0 1.0279308781946384e-07
mutant O 0 3.859906172465344e-08
cDNA O 0 8.7989860730886e-08
is O 0 2.6030535504872887e-09
overexpressed O 0 2.3876617660789634e-07
in O 0 4.1198879863202365e-09
mutant O 0 1.8250338129632837e-08
cells O 0 2.1270440964116233e-09
provides O 0 2.2055736403903126e-10
an O 0 1.5312270548739626e-11
explanation O 0 4.3112424741309496e-10
for O 0 3.6783354140368374e-10
the O 0 4.9875472640792395e-09
mild O 0 5.219296212999325e-07
phenotype O 0 4.937398898618994e-07
in O 0 1.4269488923801532e-09
patients O 0 6.793256512871437e-10
with O 0 8.682341651189418e-11
this O 0 8.746971480455557e-10
mutation O 0 3.908699497401358e-08
. O 0 9.609334483684506e-08

The O 0 6.046734029041545e-07
distribution O 0 2.401713139477124e-08
and O 0 2.2881130323781917e-09
relative O 0 6.089732096370426e-08
frequencies O 0 2.924210207311262e-08
of O 0 2.6039986167347706e-08
the O 0 3.301558848534114e-08
I113F O 0 2.650359078870679e-07
and O 0 8.85068995870597e-09
T312S O 0 2.202868785161627e-07
mutations O 0 2.2151109835277794e-09
in O 0 3.883177668306814e-10
Australia O 0 1.4637911716075536e-10
corresponded O 0 1.0479856565881462e-10
to O 0 1.701463969716599e-10
those O 0 1.3174376867208792e-10
observed O 0 1.2889566081142334e-09
in O 0 1.3025145406686534e-09
Northern O 0 1.3351167638120387e-07
Ireland O 0 8.829415065747526e-08
and O 0 6.372457228565054e-09
are O 0 1.5784365481330553e-10
unique O 0 1.1073184591481322e-09
to O 0 4.801051778358101e-10
these O 0 2.2348264905325266e-10
two O 0 1.3135043053225104e-09
populations O 0 4.996485447605892e-10
, O 0 7.10185382724049e-11
suggesting O 0 4.382192941854157e-10
that O 0 3.713469531874125e-10
both O 0 1.8393467859922907e-09
mutations O 0 1.95870275554455e-09
were O 0 3.854025987237719e-09
probably O 0 7.244502331360536e-09
introduced O 0 5.038644612653798e-09
to O 0 1.0540883721432692e-09
Australia O 0 4.681086074320717e-10
by O 0 3.196524711590598e-10
Irish O 0 1.3006360433109876e-08
migrants O 0 5.114008105877588e-10
during O 0 3.6318310581151536e-09
the O 0 6.515343820012731e-09
19th O 0 2.3789679914898443e-07
century O 0 2.7910466542380163e-06
. O 0 2.563598684446333e-07

Haplotype O 0 1.6419586245319806e-05
analysis O 0 1.0463253374837223e-07
using O 0 1.0691196195011798e-07
6 O 0 1.186188683277578e-06
RFLPs O 0 4.53217035101261e-06
provides O 0 2.197370063683479e-09
additional O 0 4.3092282520085234e-10
data O 0 1.4217518273795804e-09
that O 0 1.0043761655698091e-10
the O 0 2.3266117921139085e-09
I113F O 0 5.8910448075266686e-08
mutation O 0 8.064484080527734e-10
originated O 0 4.323776059411699e-10
from O 0 2.0773105458005148e-10
a O 0 1.2141442295998672e-09
common O 0 7.821410186181765e-09
ancestor O 0 2.8347662919259164e-06
. O 0 3.9635528992221225e-07

The O 0 3.951870439777849e-06
other O 0 5.009191283988912e-08
9 O 0 1.3181458768940502e-07
novel O 0 8.308207455343108e-09
mutations O 0 9.581525572954774e-10
identified O 0 1.5421964816297873e-09
in O 0 3.1379826515021136e-10
these O 0 4.594793989731727e-10
23 O 0 2.071496219002711e-08
patients O 0 2.9906668252976942e-09
were O 0 2.288147893381165e-09
each O 0 4.893575128450678e-11
limited O 0 5.228776855936701e-10
to O 0 1.8113621713666817e-09
a O 0 9.572912063049444e-08
single O 0 1.1432231303842855e-06
family O 0 1.7820058246797998e-06
. O 0 4.4283808620093623e-07

These O 0 1.0131241623412279e-07
data O 0 4.9353417352904216e-08
provide O 0 2.7516231515534173e-09
further O 0 6.278758069022672e-10
evidence O 0 9.769949294025082e-09
for O 0 1.729904663960724e-09
extensive O 0 1.3118904007569654e-07
allelic O 0 1.3442469253277523e-06
heterogeneity O 0 4.147947038291022e-06
in O 0 5.908554499001184e-07
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
in O 0 5.217967213866359e-07
British O 0 6.543793915625429e-06
- O 0 0.00010033842409029603
Irish O 0 1.6635535757814068e-06
patients O 0 2.5206297493696184e-08
and O 0 1.5021159871508871e-09
provide O 0 6.273993546912493e-10
evidence O 0 2.9237527954251163e-08
for O 0 2.79881184894748e-09
their O 0 2.319395164818161e-08
transmission O 0 3.065417502057244e-07
to O 0 9.100378228765749e-09
Australia O 0 1.462059029400109e-09
by O 0 6.470015634363335e-10
British O 0 1.5625123239715322e-07
- O 0 5.440344921225915e-07
Irish O 0 1.8577989635559788e-07
migrants O 0 3.995608288676067e-09
. O 0 1.9075101498344793e-09
. O 0 3.534072590127835e-08

Identification O 0 1.336578407062916e-06
of O 0 3.072235813306179e-06
constitutional O 0 3.5293862310936674e-05
WT1 O 0 0.3182426691055298
mutations O 0 1.9251035610068357e-07
, O 0 4.872770520414349e-10
in O 0 4.0507019960500656e-10
patients O 0 1.886891309865746e-09
with O 0 1.5522420016012006e-09
isolated O 0 0.0004344668996054679
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 1.1150399714665582e-08
and O 0 5.944766900967124e-10
analysis O 0 1.169862540173483e-09
of O 0 1.5610787329478626e-08
genotype O 0 8.071598927017476e-07
/ O 0 1.640102595956705e-07
phenotype O 0 3.5949179189032066e-09
correlations O 0 2.792236164506079e-10
by O 0 1.3214411336004428e-11
use O 0 6.431505328308162e-10
of O 0 2.7875563191059882e-08
a O 0 2.7228839627468915e-08
computerized O 0 1.9581702304094506e-07
mutation O 0 1.4849988794196634e-08
database O 0 1.5455896118510282e-08
. O 0 4.680046217231393e-08

Constitutional O 0 1.5315677956095897e-05
mutations O 0 3.4383674574200995e-07
of O 0 6.17977036654338e-07
the O 0 4.8124888962775e-07
WT1 O 0 1.0115982149727643e-05
gene O 0 1.8156695702487013e-08
, O 0 5.530488844662784e-10
encoding O 0 1.8936887613563158e-08
a O 0 1.0573675268688021e-07
zinc O 0 3.618069240474142e-05
- O 0 7.681811257498339e-05
finger O 0 0.00013843005581293255
transcription O 0 1.970926496142056e-05
factor O 0 3.1223553520476344e-08
involved O 0 5.70282798761923e-09
in O 0 2.341884020040652e-08
renal O 1 1.0
and O 0 4.1268058339483105e-06
gonadal O 1 0.8367942571640015
development O 0 1.57132981257746e-05
, O 0 4.246880902503136e-10
are O 0 1.3105275545322037e-11
found O 0 3.440403240073664e-10
in O 0 1.6598256102895448e-10
most O 0 6.915158723419523e-11
patients O 0 1.2760401069122906e-10
with O 0 3.279482518880883e-10
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.5194435693265405e-06
DDS B-Disease 1 1.0
) O 0 6.1809934948087175e-09
, O 0 3.3958036382841783e-10
or O 0 7.895592801787643e-08
diffuse B-Disease 1 0.9999992847442627
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 4.065637426720059e-07
DMS B-Disease 0 3.860771903418936e-05
) O 0 1.6579208839129222e-10
associated O 0 2.8463211787510545e-09
with O 0 2.838222101786414e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 2.1313198885763995e-05
/ O 1 0.8628119230270386
or O 0 2.0088444216526113e-05
Wilms B-Disease 1 1.0
tumor I-Disease 0 0.02320353128015995
( O 0 4.234275152725786e-08
WT B-Disease 1 0.9999921321868896
) O 0 8.265752526881442e-09
. O 0 3.931084435748744e-08

Most O 0 3.208087946404703e-07
mutations O 0 2.76924254194455e-07
in O 0 1.3566980783252802e-07
DDS B-Disease 1 1.0
patients O 0 0.0245010107755661
lie O 0 4.392521077534184e-06
in O 0 4.5870756082422304e-08
exon O 0 3.6738450148732227e-07
8 O 0 5.427789062650845e-08
or O 0 4.47831904892837e-09
exon O 0 6.92892569986725e-08
9 O 0 3.7495645699436864e-08
, O 0 4.3183775999544594e-10
encoding O 0 2.3276521687876084e-07
zinc O 0 0.00013381957251112908
finger O 0 0.0007703846204094589
2 O 0 2.9138325771782547e-05
or O 0 8.235146538027038e-07
zinc O 0 0.0003425658505875617
finger O 0 4.5283457438927144e-05
3 O 0 1.3716608009417541e-06
, O 0 7.234529086908026e-10
respectively O 0 2.2431123625210603e-09
, O 0 2.764615758543698e-10
with O 0 8.9958962501413e-10
a O 0 2.601199753371475e-07
hot O 0 5.9013844293076545e-05
spot O 0 2.523119974284782e-06
( O 0 5.357778665171509e-10
R394W O 0 3.414382021560414e-08
) O 0 1.9260412709165564e-10
in O 0 3.3122358189530132e-09
exon O 0 5.424786309049523e-07
9 O 0 6.694297667309002e-07
. O 0 1.7153018916360452e-07

We O 0 2.3051526909512177e-07
analyzed O 0 6.565244348166743e-08
a O 0 1.0586567178449968e-08
series O 0 3.716908114625994e-09
of O 0 4.197213243628539e-09
24 O 0 9.944836065756135e-09
patients O 0 3.90410770378935e-09
, O 0 9.479186324767852e-10
10 O 0 1.153526696384688e-08
with O 0 1.61851634317145e-08
isolated B-Disease 0 0.09883687645196915
DMS I-Disease 1 1.0
( O 0 6.339243441289e-07
IDMS B-Disease 0 0.2723461985588074
) O 0 3.9783918381886e-09
, O 0 2.755518868635676e-10
10 O 0 6.942002528376179e-10
with O 0 2.5226436495273674e-09
DDS B-Disease 1 1.0
, O 0 4.9774001809055335e-08
and O 0 2.1597749366719654e-08
4 O 0 2.8529163387247536e-07
with O 0 7.98785304567673e-09
urogenital B-Disease 1 0.9999520778656006
abnormalities I-Disease 1 0.9999990463256836
and O 0 4.930217983201146e-05
/ O 1 0.9998725652694702
or O 0 0.2961064577102661
WT B-Disease 1 1.0
. O 0 5.661712293658638e-06

We O 0 7.169273317231273e-07
report O 0 1.1172991776220442e-07
WT1 O 0 4.8340294597437605e-05
heterozygous O 0 3.969850936869079e-08
mutations O 0 2.15371032119549e-09
in O 0 7.523394685016171e-10
16 O 0 1.153603701453676e-08
patients O 0 4.641586670572906e-09
, O 0 1.0996383803529852e-09
4 O 0 8.123076611354918e-08
of O 0 5.3373540254142426e-08
whom O 0 1.411910943716066e-07
presented O 0 7.451466785823868e-07
with O 0 5.720675062548253e-07
IDMS B-Disease 1 1.0
. O 0 0.0002386948181083426

One O 0 5.563402964980924e-07
male O 0 4.045517343342908e-08
and O 0 4.748451409852805e-09
two O 0 6.653815720625289e-09
female O 0 2.1363193880574727e-08
IDMS B-Disease 1 0.9838098287582397
patients O 0 8.825591066852212e-07
with O 0 3.6498747135738085e-07
WT1 O 1 1.0
mutations O 0 3.289381129434332e-05
underwent O 0 0.06747303158044815
normal O 0 5.287166914058616e-06
puberty O 0 9.985484211938456e-06
. O 0 8.513496396744813e-08

Two O 0 2.9442064715112792e-06
mutations O 0 4.127048214286333e-07
associated O 0 1.5218182625176269e-07
with O 0 8.995865385941215e-09
IDMS B-Disease 1 0.8204289078712463
are O 0 3.447951368862334e-10
different O 0 1.4188659969160966e-10
from O 0 5.900125388258459e-10
those O 0 4.506747752763829e-10
described O 0 3.0973716036442056e-08
in O 0 9.997808092521154e-08
DDS B-Disease 1 1.0
patients O 0 0.0818185806274414
. O 0 2.7359044452168746e-06

No O 0 2.8850787202827632e-05
WT1 O 0 0.000914031348656863
mutations O 0 1.9519501393006067e-07
were O 0 1.2866188114912802e-08
detected O 0 4.929198738068408e-08
in O 0 2.613087302094641e-09
the O 0 4.163066691376116e-08
six O 0 2.5698643213445393e-08
other O 0 3.2513341352569114e-08
IDMS B-Disease 1 1.0
patients O 0 0.00027409460744820535
, O 0 1.768238111488074e-09
suggesting O 0 5.853766360530699e-09
genetic O 0 6.102242622318954e-08
heterogeneity O 0 2.5708848738759116e-07
of O 0 1.4676624005005579e-07
this O 0 3.432194262131816e-08
disease O 0 0.3382682800292969
. O 0 4.2497293861742946e-07

We O 0 1.1913846265088068e-06
analyzed O 0 7.57294742470549e-07
genotype O 0 4.5011265683569945e-06
/ O 0 1.335206320618454e-06
phenotype O 0 1.4857701557957625e-07
correlations O 0 2.1719944953701997e-08
, O 0 1.0071908862485657e-09
on O 0 3.991617258947144e-09
the O 0 5.80210768319489e-10
basis O 0 1.0059832966646809e-09
of O 0 3.5313485469146144e-09
the O 0 1.0997731614281747e-08
constitution O 0 2.0454413718340447e-09
of O 0 2.60092605230966e-08
a O 0 1.0079066470325415e-07
WT1 O 0 1.0352082426834386e-05
mutation O 0 1.988327191781991e-08
database O 0 1.0938027372731085e-08
of O 0 6.299443811030869e-08
84 O 0 3.591637209865439e-07
germ O 1 0.725380003452301
- O 1 0.850341260433197
line O 0 4.006644303444773e-05
mutations O 0 1.311294539618757e-08
, O 0 1.359625884100879e-10
to O 0 9.286515306738963e-11
compare O 0 2.341543181572092e-09
the O 0 4.790918328723137e-09
distribution O 0 7.012200264888691e-10
and O 0 2.2870647042871894e-10
type O 0 1.2427620710298015e-08
of O 0 1.5626218541342496e-08
mutations O 0 4.388047702974518e-10
, O 0 1.5073955972333408e-11
according O 0 1.714010010311906e-11
to O 0 1.0763058500007361e-10
the O 0 2.11895345714197e-09
different O 0 2.807457377684841e-09
symptoms O 0 8.233920198108535e-06
. O 0 6.501157940874691e-07

This O 0 1.8360394449246087e-07
demonstrated O 0 1.9077009483225993e-07
( O 0 3.0927951311099378e-09
1 O 0 2.682403277276535e-08
) O 0 5.6889382094027496e-11
the O 0 7.654328837425339e-10
association O 0 1.04223671359982e-10
between O 0 6.727906010084439e-10
mutations O 0 4.038397394268145e-10
in O 0 2.5670949810319144e-09
exons O 0 1.5640551964679617e-07
8 O 0 5.7503878991838064e-08
and O 0 4.602313197210606e-09
9 O 0 9.835711978212203e-08
and O 0 1.6880637332405968e-08
DMS B-Disease 0 0.00016605207929387689
; O 0 1.9789668570524555e-08
( O 0 6.769796279115781e-09
2 O 0 2.3474187571537186e-07
) O 0 3.407800985844034e-10
among O 0 2.0986083704155334e-10
patients O 0 1.967059182206299e-09
with O 0 2.498147466667433e-09
DMS B-Disease 0 0.0007105027325451374
, O 0 9.008669921151125e-10
a O 0 6.529348173245353e-10
higher O 0 2.860515158076282e-09
frequency O 0 3.1475630990485115e-09
of O 0 8.473624468763319e-09
exon O 0 1.9205186774229333e-08
8 O 0 5.09470421405922e-09
mutations O 0 7.046559863388424e-11
among O 0 9.196127886967886e-11
46 O 0 9.301556858076765e-09
, O 0 1.7989637557391802e-09
XY O 0 0.0004324805340729654
patients O 0 5.692875859608648e-08
with O 0 1.430657925460821e-09
female O 0 3.1310010140117583e-09
phenotype O 0 1.753240930213451e-08
than O 0 2.0229176667108106e-10
among O 0 2.903493834249815e-10
46 O 0 2.0657397570289504e-08
, O 0 2.199118442902659e-09
XY O 0 0.003242392325773835
patients O 0 2.3893401035479656e-08
with O 0 1.57425739111261e-10
sexual O 0 8.474201895758426e-10
ambiguity O 0 1.967277718506466e-08
or O 0 1.4503576117874672e-09
male O 0 5.536705538489173e-10
phenotype O 0 1.3031458134804552e-09
; O 0 1.3281986621649366e-10
and O 0 9.715793725106892e-10
( O 0 5.524374291354661e-10
3 O 0 2.6459389346200624e-08
) O 0 6.853850126331551e-11
statistically O 0 2.496620792047377e-11
significant O 0 1.3935180787072454e-10
evidence O 0 1.4426985162074857e-09
that O 0 7.424530434896326e-11
mutations O 0 7.077297081714562e-11
in O 0 9.094230923878399e-10
exons O 0 1.8027142800747242e-07
8 O 0 4.02123063736326e-08
and O 0 2.4003106169345756e-09
9 O 0 1.581313036069787e-08
preferentially O 0 1.9149795082995524e-09
affect O 0 2.1750363732309097e-09
amino O 0 9.033860881579869e-10
acids O 0 1.6088318177676086e-10
with O 0 1.0142667955514995e-11
different O 0 9.594267047496885e-11
functions O 0 3.420553396082937e-09
. O 0 3.61208685184522e-09
. O 0 2.7674357028217855e-08

The O 0 1.4145745808491483e-05
185delAG O 0 9.332406989415176e-06
BRCA1 O 0 1.2244676383943442e-07
mutation O 0 2.7819668790840524e-09
originated O 0 6.570312072184947e-10
before O 0 9.001628331617439e-10
the O 0 6.439508370981173e-10
dispersion O 0 2.083375427730516e-08
of O 0 1.3676721088984323e-08
Jews O 0 2.1113539361294897e-08
in O 0 2.7119306800216236e-09
the O 0 1.1426107171530475e-08
diaspora O 0 5.587567297737905e-09
and O 0 1.4879268928069678e-09
is O 0 4.109181328537659e-10
not O 0 6.079918790646843e-10
limited O 0 6.4733027826946454e-09
to O 0 3.782823654319145e-08
Ashkenazim O 0 9.334741480415687e-05
. O 0 3.1384163321490632e-06

The O 0 4.575310867949156e-06
185delAG O 0 6.430385383282555e-06
mutation O 0 1.180285451596319e-07
in O 0 2.0068290140784484e-08
BRCA1 O 0 1.4536733594638918e-08
is O 0 2.609848170909146e-10
detected O 0 2.2538251265302733e-09
in O 0 2.2504821617364001e-10
Ashkenazi O 0 1.1855289017148607e-07
Jews O 0 7.561045123338772e-09
both O 0 5.580822470818703e-10
in O 0 6.094388993460598e-09
familial B-Disease 1 0.9999946355819702
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 8.813008776087372e-07
in O 0 6.452962608705093e-09
the O 0 6.335508828669845e-08
general O 0 6.070515468081794e-08
population O 0 4.922335317125714e-10
. O 0 3.5061020753346384e-08

All O 0 7.166524937929353e-07
tested O 0 4.7226217247953173e-07
Ashkenazi O 0 2.45495789386041e-06
mutation O 0 1.7027383947265662e-08
carriers O 0 5.012801285175783e-09
share O 0 7.26836368869499e-09
the O 0 8.518934002665901e-09
same O 0 6.306113409237923e-09
allelic O 0 3.1130554134506383e-07
pattern O 0 2.314243090495438e-07
at O 0 1.2447659969438973e-07
the O 0 6.06422005944296e-08
BRCA1 O 0 7.924122513713883e-08
locus O 0 2.582739568879333e-07
. O 0 1.323095517591355e-07

Our O 0 2.0203853637212887e-05
previous O 0 1.1960783012909815e-06
study O 0 5.876610309485386e-09
showed O 0 7.803971358022466e-10
that O 0 4.00251498611226e-11
this O 0 5.325989094195904e-10
Ashkenazi O 0 1.4136196568870218e-06
mutation O 0 1.413942474215446e-08
also O 0 2.470153803724173e-10
occurs O 0 4.716978890817458e-11
in O 0 1.8081879743503393e-11
Iraqi O 0 3.0551834395708966e-09
Jews O 0 5.231213240364241e-09
with O 0 1.7134289820308624e-10
a O 0 1.8310682969868708e-09
similar O 0 2.8443400967859134e-09
allelic O 0 7.37566210773366e-07
pattern O 0 7.378940267699363e-07
. O 0 1.0147317652808852e-06

We O 0 1.770924313859723e-06
extended O 0 1.0625021786836442e-06
our O 0 8.971263554258257e-08
analysis O 0 2.9771158871483294e-09
to O 0 2.7007498459852286e-09
other O 0 1.2977731111973867e-09
non O 0 3.3113405351059555e-08
- O 0 1.090474412990261e-07
Ashkenazi O 0 1.7453619420848554e-06
subsets O 0 9.507132858743716e-08
354 O 0 1.547571848448115e-08
of O 0 4.141119891443168e-09
Moroccan O 0 2.1125543980815564e-08
origin O 0 2.024775458409067e-09
, O 0 7.47050143967698e-10
200 O 0 3.633297829264137e-10
Yemenites O 0 2.1018156814989197e-07
and O 0 5.100722955120318e-09
150 O 0 3.747303356504972e-09
Iranian O 0 9.606566919728721e-08
Jews O 0 6.353466233122163e-07
. O 0 1.2086248943887767e-06

Heteroduplex O 0 6.601511995540932e-05
analysis O 0 1.7654259920618642e-07
complemented O 0 9.135685985484088e-08
by O 0 3.866460207557765e-10
direct O 0 1.8392309897308223e-09
DNA O 0 1.7890755543703563e-08
sequencing O 0 6.19255970946142e-08
of O 0 2.3806242310797643e-08
abnormally O 0 3.8486732023557124e-08
migrating O 0 4.1626919689008446e-09
bands O 0 1.499388879722119e-08
were O 0 4.141957443692945e-09
employed O 0 5.1573287862538564e-08
. O 0 1.0746006751105597e-07

Four O 0 9.748767979544937e-07
of O 0 3.1656486498832237e-07
Moroccan O 0 8.395937243221852e-07
origin O 0 1.631347323893806e-08
( O 0 7.363833987028556e-10
1 O 0 1.6277079240012426e-08
. O 0 4.932014796565909e-10
1 O 0 2.3065924281695516e-08
% O 0 1.6935380875438e-10
) O 0 4.544258372374266e-11
and O 0 5.60721913345219e-10
none O 0 2.5243632961746698e-08
of O 0 3.1676265166424855e-07
the O 0 3.058966626667825e-07
Yemenites O 0 5.472289217323123e-07
or O 0 9.068219952723666e-09
Iranians O 0 7.517933831024948e-09
was O 0 3.021710881512263e-08
a O 0 2.1922543780306114e-09
carrier O 0 7.738224283571071e-09
of O 0 1.406733307618424e-08
the O 0 4.564262212625181e-08
185delAG O 0 6.133644205874589e-07
mutation O 0 4.192806457581355e-08
. O 0 1.9684642893480486e-07

BRCA1 O 0 2.9529594030464068e-05
allelic O 0 7.713729246461298e-06
patterns O 0 4.2130636757065076e-08
were O 0 8.2629778574983e-09
determined O 0 9.30263954757038e-09
for O 0 2.436938428829194e-09
four O 0 3.1365841035579933e-09
of O 0 2.5924749014194504e-09
these O 0 5.972928401876132e-11
individuals O 0 4.999940999422803e-12
and O 0 8.109818372403765e-10
for O 0 1.4947481030702647e-09
12 O 0 5.540564007588955e-09
additional O 0 3.0375424397988127e-09
non O 0 7.797759593586306e-08
- O 0 3.899785951944068e-07
Ashkenazi O 0 5.179143727218616e-07
185delAG O 0 2.097110041177075e-08
mutation O 0 1.3549066035789536e-10
carriers O 0 1.071592467538629e-10
who O 0 1.5570188471869528e-09
had O 0 1.034099341268302e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.3057640646584332e-05

Six O 0 4.311124939704314e-05
non O 0 3.2004754757508636e-05
- O 0 1.5131789041333832e-05
Ashkenazi O 0 9.492023309576325e-06
individuals O 0 5.61665991494209e-10
shared O 0 1.3334187975999612e-08
the O 0 5.2360449309674095e-09
common O 0 2.008077260029495e-08
Ashkenazi O 0 1.3279056929604849e-06
haplotype O 0 1.9853957837767666e-06
, O 0 5.9069740210304644e-09
four O 0 7.3393833233126315e-09
had O 0 2.5311083007295565e-08
a O 0 1.0626360236187793e-08
closely O 0 6.522776208051084e-10
related O 0 1.1272630828784713e-08
pattern O 0 4.030314926239953e-07
, O 0 4.4162278278747635e-09
and O 0 1.0526424176759974e-08
the O 0 6.748120995325735e-07
rest O 0 1.267946231564565e-06
( O 0 4.9136703594854225e-09
n O 0 3.065949272240687e-08
= O 0 3.256870328982586e-08
6 O 0 3.2044454201241024e-08
) O 0 9.978419479583778e-11
displayed O 0 1.76833936382792e-09
a O 0 1.7661829332382695e-08
distinct O 0 1.0049350862573192e-07
BRCA1 O 0 5.486110694619128e-07
allelic O 0 1.802215706447896e-06
pattern O 0 9.156705118584796e-07
. O 0 4.975535716766899e-07

We O 0 3.5754044347413583e-07
conclude O 0 4.5173163698564167e-07
that O 0 4.799369346386584e-09
the O 0 9.832504588302982e-08
185delAG O 0 1.522101229056716e-06
BRCA1 O 0 5.46274812052161e-08
mutation O 0 9.379764742689645e-10
occurs O 0 1.9311655052867138e-10
in O 0 9.355192315263494e-11
some O 0 1.2107327640453747e-10
non O 0 4.170704670514169e-08
- O 0 1.2862184348705341e-06
Ashkenazi O 0 1.8870561689254828e-05
populations O 0 1.5242097362033746e-08
at O 0 2.1266057803615013e-09
rates O 0 8.636540788087288e-11
comparable O 0 6.652060569045659e-10
with O 0 4.2794854465677545e-11
that O 0 3.1960920021667505e-10
of O 0 1.815642463043332e-07
Ashkenazim O 0 2.650534952408634e-05
. O 0 9.668779057392385e-07

The O 0 2.8342203677311772e-06
majority O 0 3.250367086593542e-08
of O 0 9.15910050025559e-08
Jewish O 0 1.0016150042702066e-07
185delAG O 0 2.6320273605051625e-07
mutation O 0 1.7516956773988568e-09
carriers O 0 7.51599393833402e-10
have O 0 2.518575348275931e-10
a O 0 2.9671101131611977e-09
common O 0 1.8750961672253652e-08
allelic O 0 3.693778864999331e-07
pattern O 0 8.226984959947004e-08
, O 0 1.1453900050639731e-09
supporting O 0 6.857936885040772e-09
the O 0 5.166672849554743e-07
founder O 0 4.679623089032248e-06
effect O 0 2.8593110101837738e-08
notion O 0 1.494132391144376e-07
, O 0 6.042485400925557e-10
but O 0 2.349621885944231e-10
dating O 0 2.363493845081166e-09
the O 0 1.0025469343588611e-09
mutations O 0 2.505732600577293e-11
origin O 0 7.090430326206487e-11
to O 0 1.3781530083800675e-10
an O 0 6.096544796774239e-11
earlier O 0 2.871228810263915e-09
date O 0 7.746069030645231e-08
than O 0 7.448988093017306e-10
currently O 0 6.851527123430401e-10
estimated O 0 1.2959475714779956e-09
. O 0 8.702762954726495e-08

However O 0 4.466770917588292e-07
, O 0 5.568193905958196e-09
the O 0 3.923172453568213e-09
different O 0 9.599122607895083e-10
allelic O 0 2.2942001010051172e-07
pattern O 0 3.325170041534875e-07
at O 0 2.532270571009576e-07
the O 0 3.159799888408088e-08
BRCA1 O 0 4.122570729236941e-08
locus O 0 3.9413546204514205e-08
even O 0 1.0368916836256403e-09
in O 0 3.510233770320781e-10
some O 0 6.221687748331206e-11
Jewish O 0 2.937855292373115e-09
mutation O 0 1.0676046713342657e-09
carriers O 0 3.864616959781131e-10
, O 0 1.5246180706807166e-10
might O 0 7.472696350596664e-10
suggest O 0 1.3742189608478839e-09
that O 0 4.978306655800679e-10
the O 0 7.0085941494824056e-09
mutation O 0 2.349031413828584e-09
arose O 0 6.7240866208351235e-09
independently O 0 1.8513348631898907e-09
. O 0 3.1837303904325154e-09
. O 0 4.57820377164353e-08

Crystal O 0 0.00034265030990354717
structure O 0 4.92023718834389e-05
of O 0 0.0019420505268499255
the O 0 0.0036839721724390984
hemochromatosis B-Disease 1 1.0
protein O 0 8.79089111549547e-06
HFE O 0 0.0005575160030275583
and O 0 7.484568520510493e-09
characterization O 0 6.681528930130298e-08
of O 0 6.806232022427139e-08
its O 0 2.9807918355828633e-09
interaction O 0 2.930417686286546e-09
with O 0 1.1870348037845702e-09
transferrin O 0 7.5987918535247445e-06
receptor O 0 9.871286010820768e-07
. O 0 1.5320829049869644e-07

HFE O 1 0.8435781598091125
is O 0 1.2871633998656762e-06
an O 0 2.3548825112129634e-08
MHC O 0 7.5458297033037525e-06
- O 0 8.973375770437997e-06
related O 0 5.796704272142961e-07
protein O 0 5.745673803403406e-08
that O 0 1.3408286980709505e-10
is O 0 9.299703368492729e-11
mutated O 0 1.2569479901358704e-09
in O 0 8.79488426530628e-10
the O 0 7.347999826379237e-07
iron B-Disease 1 1.0
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.002849187236279249

HFE O 0 0.0016103297239169478
binds O 0 2.1190855932218255e-06
to O 0 4.6254865537775913e-07
transferrin O 0 2.8586418920895085e-05
receptor O 0 3.614104855387268e-07
( O 0 1.3754200001159234e-09
TfR O 0 9.460733707555846e-08
) O 0 1.6822347681522132e-10
and O 0 3.885311516960144e-10
reduces O 0 1.5168115652386405e-08
its O 0 3.4869600540332613e-09
affinity O 0 1.387747960990282e-08
for O 0 1.8424973546871115e-08
iron O 0 0.00011316410382278264
- O 0 9.64766741162748e-07
loaded O 0 5.970454139969661e-07
transferrin O 0 6.119550107541727e-06
, O 0 3.971454720641532e-09
implicating O 0 9.337535971098987e-07
HFE O 1 0.9824073314666748
in O 0 2.4541034235880943e-06
iron O 1 0.9999957084655762
metabolism O 0 0.0002044410357484594
. O 0 7.971325430844445e-07

The O 0 4.194900247966871e-05
2 O 0 5.06815777043812e-05
. O 0 3.0284672902780585e-06

6 O 0 0.00025431299582123756
A O 0 1.1747682037821505e-05
crystal O 0 2.184258119086735e-05
structure O 0 9.4031602202449e-06
of O 0 3.185141758876853e-05
HFE O 1 0.9999954700469971
reveals O 0 7.358034963544924e-07
the O 0 2.1140538208896942e-08
locations O 0 9.670060308053507e-09
of O 0 9.550385584589094e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 1.2390695474095992e-06
and O 0 8.825424657743497e-08
a O 0 7.40397922527336e-07
patch O 1 0.9999998807907104
of O 1 0.9999971389770508
histidines O 1 0.9997637867927551
that O 0 3.188216624039342e-08
could O 0 1.5593110802569754e-08
be O 0 1.229776058764287e-09
involved O 0 1.061027377069479e-09
in O 0 2.392051889898994e-09
pH O 0 1.7456815157856909e-06
- O 0 4.714989643161971e-07
dependent O 0 6.363398341591164e-08
interactions O 0 1.5717986912022752e-08
. O 0 1.6244767664375104e-07

We O 0 4.401150363264605e-06
also O 0 1.0407582351490419e-07
demonstrate O 0 3.8577425698349543e-08
that O 0 2.5542497006370013e-09
soluble O 0 2.6037359930342063e-06
TfR O 0 2.3690887246630155e-05
and O 0 4.789468022181609e-08
HFE O 0 6.82527752360329e-05
bind O 0 1.0903517022597953e-07
tightly O 0 2.4510507046215935e-07
at O 0 2.24566054640718e-08
the O 0 2.760180750627228e-09
basic O 0 3.50424329553789e-08
pH O 0 1.1258990895157694e-07
of O 0 8.789995575853027e-08
the O 0 3.202075049557607e-08
cell O 0 2.5739211650943616e-08
surface O 0 2.5102234957330438e-08
, O 0 1.9160821540520345e-10
but O 0 2.93253504812796e-10
not O 0 8.365320103287388e-10
at O 0 1.216977985052381e-08
the O 0 6.501465144026497e-09
acidic O 0 4.0086030139718787e-07
pH O 0 5.734713681704307e-07
of O 0 3.163870871958352e-07
intracellular O 0 3.085902733346302e-07
vesicles O 0 2.7549388050829293e-06
. O 0 4.4067897420063673e-07

TfR O 0 0.0008106908644549549
HFE O 0 0.0006778773968107998
stoichiometry O 0 1.1885522326338105e-05
( O 0 4.2864520821694896e-08
2 O 0 2.087381574256142e-07
1 O 0 2.4942066190192236e-08
) O 0 4.989987589798517e-11
differs O 0 7.366053877966294e-10
from O 0 2.724342085258513e-09
TfR O 0 2.2335572680276528e-07
transferrin O 0 3.575598839233862e-07
stoichiometry O 0 3.5826943189931626e-08
( O 0 3.8982719829938617e-10
2 O 0 9.231143849319778e-09
2 O 0 5.636904276684618e-09
) O 0 6.793252765868729e-11
, O 0 2.2624027651296785e-11
implying O 0 4.4107875685206466e-10
a O 0 8.103246407209497e-10
different O 0 1.1282126621825483e-10
mode O 0 1.2345640953981274e-08
of O 0 1.5650221119045682e-09
binding O 0 1.2313039476907761e-09
for O 0 2.876809235274891e-09
HFE O 0 5.392164166551083e-05
and O 0 5.566285210534261e-08
transferrin O 0 2.9725663353019627e-06
to O 0 2.7804937019482168e-08
TfR O 0 2.6479640382603975e-06
, O 0 1.0494484170564533e-09
consistent O 0 4.18038714755653e-09
with O 0 6.732321922164886e-10
our O 0 2.6118129881069763e-08
demonstration O 0 1.848336594889588e-08
that O 0 3.7071495873064464e-10
HFE O 0 2.9505383281502873e-05
, O 0 9.744639761777307e-09
transferrin O 0 2.1401506273832638e-06
, O 0 2.410486699133685e-09
and O 0 1.9920158855768477e-09
TfR O 0 2.2863305559894798e-07
form O 0 8.294464670655088e-09
a O 0 7.104898713805596e-08
ternary O 0 2.2841954887553584e-06
complex O 0 2.5086806999752298e-05
. O 0 1.1226562719457434e-06

Identification O 0 1.8150136611438938e-06
of O 0 1.0301945394530776e-06
three O 0 8.253905114941062e-09
novel O 0 1.636533220050751e-08
mutations O 0 2.0968449199187944e-09
and O 0 1.6053597340359715e-09
a O 0 7.739405560869272e-09
high O 0 8.923701244611948e-08
frequency O 0 3.7692188925575465e-08
of O 0 2.5248352741868985e-08
the O 0 1.5955221144281495e-08
Arg778Leu O 0 2.2990734294126014e-07
mutation O 0 7.420470904406784e-10
in O 0 2.2505293462149467e-10
Korean O 0 4.2301746105977145e-08
patients O 0 9.076036588950842e-10
with O 0 4.687062959973787e-10
Wilson B-Disease 0 5.514365057024406e-06
disease I-Disease 0 0.0005405685515142977
. O 0 4.878755248682864e-07

Four O 0 3.1217116429616e-06
mutations O 0 7.449733629982802e-08
- O 0 3.0926318572710443e-07
- O 0 4.4345003402668226e-07
R778L O 0 2.675041514521581e-06
, O 0 6.1684857222132905e-09
A874V O 0 2.0464926819840912e-07
, O 0 1.5726254742887136e-09
L1083F O 0 7.72370327695171e-08
, O 0 6.919040895780881e-10
and O 0 9.063684802690375e-10
2304delC O 0 4.757855265324906e-08
- O 0 3.179459895363834e-08
- O 0 9.090562969049643e-08
in O 0 1.2064186094562501e-08
the O 0 4.2803982580608135e-08
copper O 0 1.5145803899940802e-07
- O 0 3.726620789734625e-08
transporting O 0 1.9881641222241342e-08
enzyme O 0 2.5357858035590652e-08
, O 0 2.3066397680793216e-09
P O 0 7.512732054237858e-07
- O 0 1.7200359536673204e-07
type O 0 4.171978389422293e-07
ATPase O 0 2.758001755864825e-07
( O 0 7.946363567157277e-10
ATP7B O 0 2.3038668928165862e-07
) O 0 3.7845140216097306e-11
, O 0 7.153729431746969e-12
were O 0 3.024728037481772e-11
identified O 0 1.709505176306081e-10
in O 0 1.6319433304712305e-10
Korean O 0 6.63674484258081e-08
Patients O 0 2.994102743514304e-09
with O 0 1.6109145128950786e-09
Wilson B-Disease 0 1.8290351363248192e-05
disease I-Disease 0 0.03944609314203262
. O 0 1.8968283939102548e-06

Arg778Leu O 0 0.009707917459309101
, O 0 1.169484278307209e-07
the O 0 7.43538208780592e-08
most O 0 1.5960264221348552e-09
frequently O 0 5.219001897316389e-10
reported O 0 2.0663720734503954e-10
mutation O 0 1.7720593048498046e-10
of O 0 9.084748509025076e-10
this O 0 2.7472638053360754e-10
enzyme O 0 4.443731160819198e-09
, O 0 4.010785870089961e-10
was O 0 6.0444711458274014e-09
found O 0 3.132696324570361e-10
in O 0 1.3557752143178448e-10
six O 0 1.2804560745038884e-09
of O 0 5.460161656145601e-09
eight O 0 4.264350650373672e-09
unrelated O 0 7.576289817734505e-09
patients O 0 5.398996805183742e-10
studied O 0 3.083953092897218e-09
, O 0 4.593538396879815e-11
an O 0 1.8302005744263994e-11
allele O 0 1.4672292547590615e-10
frequency O 0 4.243595252972909e-09
of O 0 3.9684579178356216e-08
37 O 0 4.919805860481574e-07
. O 0 4.887407385467668e-07

5 O 0 3.975318122684257e-06
% O 0 3.412364080190855e-08
, O 0 8.103431814454609e-10
which O 0 1.6981634154422665e-10
is O 0 1.0520993798390776e-10
considerably O 0 8.657792704980238e-09
higher O 0 5.7340767689595395e-09
than O 0 7.293241705008668e-11
those O 0 9.315432453194106e-11
in O 0 3.336086407124128e-10
other O 0 6.417217313092749e-10
Asian O 0 1.574540386961587e-09
populations O 0 1.6656811485660228e-09
. O 0 2.5980106954648363e-08

The O 0 2.4572650545451324e-06
novel O 0 3.9853662769928633e-07
single O 0 2.5357373090173496e-08
nucleotide O 0 2.090747841521079e-08
deletion O 0 1.7506744498518856e-08
, O 0 2.8759519765664265e-10
2304delC O 0 6.055435619600757e-08
, O 0 4.797637287445866e-10
was O 0 1.8363994769288183e-08
found O 0 8.258342343303582e-10
in O 0 9.646695664500271e-10
one O 0 4.097185701823491e-09
patient O 0 1.3648113394992833e-07
. O 0 2.3610581934008223e-07

Since O 0 1.2407983831508318e-06
a O 0 1.9058897748891468e-07
mutation O 0 4.130685482550689e-08
at O 0 4.1362753222529136e-08
cDNA O 0 9.230548414507211e-08
nucleotide O 0 3.227644924663764e-07
2302 O 0 1.6767171473475173e-05
( O 0 3.373848755927611e-09
2302insC O 0 2.279796547099977e-07
) O 0 1.099701218976179e-09
had O 0 1.763981138935833e-08
been O 0 7.627733999981956e-09
previously O 0 1.2074361066538586e-08
described O 0 1.5586628876462783e-08
, O 0 9.20293563577701e-11
this O 0 4.2828986884790865e-11
region O 0 2.9137918744481794e-09
of O 0 6.176199462970544e-08
the O 0 1.7594021528566373e-07
ATP7B O 0 6.193396984599531e-05
gene O 0 8.084633407179354e-09
may O 0 1.418068551473084e-09
be O 0 2.8026245213474965e-10
susceptible O 0 1.9379868376745435e-07
to O 0 7.753604869265018e-09
gene O 0 6.236333547349204e-07
rearrangements O 0 0.0001345128403045237
causing O 0 8.268097008112818e-05
Wilson B-Disease 0 0.0005282085039652884
disease I-Disease 0 0.0978643074631691
. O 0 1.0833114174602088e-06

Disruption O 0 0.00011716487642843276
of O 0 2.0052063973707845e-06
splicing O 0 8.441234058409464e-07
regulated O 0 6.707191246846378e-09
by O 0 6.884327552469927e-10
a O 0 1.1061917604138216e-08
CUG O 0 1.3007846973778214e-05
- O 0 8.211590341034025e-08
binding O 0 1.9085847569044745e-08
protein O 0 1.8612463748013397e-07
in O 0 3.719079799680003e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.068712274194695e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00025333600933663547
DM B-Disease 1 1.0
) O 0 2.2225352225291317e-08
is O 0 6.045562939149818e-10
caused O 0 9.313913196251633e-09
by O 0 1.5050355406387439e-09
a O 0 9.795535049761384e-08
CTG O 0 2.534481154725654e-06
expansion O 0 2.0125830246797705e-07
in O 0 6.32445829040762e-09
the O 0 2.1571235464534766e-08
3 O 0 6.309099376267113e-08
untranslated O 0 3.0773193429922685e-05
region O 0 1.0568509622999045e-08
of O 0 4.619138849193405e-08
the O 0 5.414671591097431e-07
DM B-Disease 1 1.0
gene O 0 1.9800256723101484e-06
. O 0 4.7104322220548056e-07

One O 0 2.665319129846466e-07
model O 0 3.67488951269479e-07
of O 0 3.5317184483574238e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9993537068367004
suggests O 0 6.796619800297776e-08
that O 0 1.3535796927754973e-09
RNAs O 0 1.160958902346465e-07
from O 0 4.331587089012601e-09
the O 0 6.884278924701448e-09
expanded O 0 8.168082210602279e-09
allele O 0 2.5427491223695142e-09
create O 0 9.375364928843055e-10
a O 0 9.765888542290213e-09
gain O 0 5.344596942791213e-08
- O 0 7.3853477999819e-08
of O 0 1.1672869959511445e-07
- O 0 1.0550508733331299e-07
function O 0 7.545166158529071e-10
mutation O 0 1.6683956993723825e-10
by O 0 2.292505421608304e-11
the O 0 6.371894678558476e-10
inappropriate O 0 7.567794169105468e-10
binding O 0 4.014331533852555e-09
of O 0 1.5890348592506598e-08
proteins O 0 2.061459197788551e-10
to O 0 2.6023287968968134e-09
the O 0 1.4982032325860928e-07
CUG O 0 0.0006501501193270087
repeats O 0 2.1076618850202067e-06
. O 0 6.236107878976327e-07

Data O 0 7.203650511655724e-07
presented O 0 3.435528981299285e-07
here O 0 1.380577430154517e-08
indicate O 0 3.1944724643295785e-09
that O 0 8.838961229606923e-10
the O 0 2.2723744663721845e-08
conserved O 0 3.615300769865826e-08
heterogeneous O 0 7.416522862513375e-07
nuclear O 0 8.708129462320358e-05
ribonucleoprotein O 0 7.243605068651959e-05
, O 0 3.890565736242024e-08
CUG O 0 1.2992821211810224e-05
- O 0 1.8602668205858208e-07
binding O 0 3.551926397449279e-08
protein O 0 3.6336619047006025e-08
( O 0 5.736666697231385e-10
CUG O 0 6.968288289499469e-06
- O 0 6.619209784730629e-07
BP O 0 4.720429387816694e-06
) O 0 1.5961726385071984e-09
, O 0 5.526861746041334e-10
may O 0 7.099762111550945e-09
mediate O 0 1.132294642047782e-06
the O 0 1.7883237433125032e-06
trans O 0 1.0800629297591513e-06
- O 0 1.140607196248311e-06
dominant O 0 1.0061760491453242e-07
effect O 0 8.539952744968105e-09
of O 0 1.9544270202231928e-08
the O 0 1.877744537637227e-08
RNA O 0 2.70818532044359e-07
. O 0 4.3741220423498817e-08

CUG O 1 0.9998244643211365
- O 0 0.043634653091430664
BP O 0 0.000279326195595786
was O 0 1.415227416146081e-06
found O 0 4.402452180585215e-09
to O 0 3.0674787709905615e-10
bind O 0 2.0520920518407593e-09
to O 0 4.9624016007498994e-09
the O 0 1.732919798769217e-07
human O 0 2.5567333068465814e-06
cardiac O 1 0.9999635219573975
troponin O 0 0.0024087801575660706
T O 0 4.441165583557449e-05
( O 0 7.974807481048174e-09
cTNT O 0 9.111567322861447e-08
) O 0 1.6418905124382377e-10
pre O 0 2.2446164393841173e-07
- O 0 9.303689552098149e-08
messenger O 0 2.7445381078905484e-08
RNA O 0 1.1457970572337217e-08
and O 0 1.6839715732963612e-10
regulate O 0 9.147774204798509e-11
its O 0 1.5029608113614756e-10
alternative O 0 1.1916995390492957e-08
splicing O 0 3.6188438912176935e-07
. O 0 5.390091573076461e-08

Splicing O 0 1.580485150043387e-05
of O 0 4.8433694246341474e-06
cTNT O 0 4.6906112402211875e-05
was O 0 1.1347256986482535e-05
disrupted O 0 1.2190490451757796e-05
in O 0 3.327917283968418e-07
DM B-Disease 1 1.0
striated O 0 0.0007953505264595151
muscle O 0 2.8247164664207958e-05
and O 0 3.469600642347359e-07
in O 0 1.5031544009502795e-08
normal O 0 4.861635360953187e-08
cells O 0 3.803929260470795e-08
expressing O 0 5.011826509360162e-09
transcripts O 0 1.586161246791562e-08
that O 0 6.877345914979571e-10
contain O 0 1.1805056487901311e-08
CUG O 0 7.090558210620657e-05
repeats O 0 9.378713912155945e-07
. O 0 2.287589069283058e-07

Altered O 0 4.173194611212239e-05
expression O 0 4.386781711218646e-06
of O 0 2.7674891498463694e-06
genes O 0 7.099656329501158e-08
regulated O 0 3.8460900242398566e-08
posttranscriptionally O 0 1.1888898825418437e-06
by O 0 1.349641109982258e-08
CUG O 1 0.9994184970855713
- O 0 0.0003625942044891417
BP O 0 1.0093798664456699e-05
therefore O 0 4.151970767196644e-09
may O 0 6.326216772656323e-10
contribute O 0 1.1865181059889096e-10
to O 0 6.867728163939546e-09
DM B-Disease 1 1.0
pathogenesis O 1 0.9932945370674133
. O 0 8.709854171229381e-08
. O 0 1.0414155582338935e-07

Identification O 0 6.234627107915003e-07
of O 0 7.733121947239852e-07
a O 0 5.48984324666435e-08
novel O 0 5.686993986842026e-08
nonsense O 0 5.503031275111425e-08
mutation O 0 6.461891910447548e-09
and O 0 1.4986190066679228e-09
a O 0 2.129861398358912e-09
missense O 0 6.902002080977354e-09
substitution O 0 6.0338969376516616e-09
in O 0 2.709903634823263e-09
the O 0 3.819363669776976e-08
vasopressin O 0 2.959589835427323e-07
- O 0 1.8544710655987728e-07
neurophysin O 0 7.629774358974828e-07
II O 1 0.9967922568321228
gene O 0 9.925639865571156e-09
in O 0 1.1555939538610005e-09
two O 0 1.2341324628906136e-09
Spanish O 0 4.142283316355133e-08
kindreds O 0 8.621869937996962e-07
with O 0 1.2049421904691826e-08
familial B-Disease 1 0.9999315738677979
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 8.407016866840422e-05

Familial B-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 2.930894197561429e-06
FNDI B-Disease 1 1.0
) O 0 7.532199752802171e-09
is O 0 8.724511113555877e-10
an O 0 1.8061218076681484e-09
autosomal B-Disease 1 0.9999997615814209
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.0001646259770495817
by O 0 2.251128350394538e-08
deficiency O 1 0.9938521385192871
in O 0 1.0691909579918502e-07
the O 0 3.747792106878478e-06
antidiuretic O 0 9.84839971351903e-07
hormone O 0 2.6287153787052375e-08
arginine O 0 9.068430983916187e-08
vasopressin O 0 3.000856452217704e-07
( O 0 4.508443840478549e-09
AVP O 0 1.668916809194343e-07
) O 0 9.488695940085279e-11
encoded O 0 2.7929070167687087e-10
by O 0 3.1235553032971097e-10
the O 0 6.045960532219397e-08
AVP O 0 7.369119884970132e-06
- O 0 2.1351559098548023e-06
neurophysin O 0 5.324784797267057e-05
II O 1 1.0
( O 0 4.923612664242683e-07
AVP O 0 3.9955255488166586e-05
- O 0 1.3775389788861503e-06
NPII O 0 1.384415736538358e-05
) O 0 1.1920922027286451e-09
gene O 0 4.48009584985698e-09
on O 0 3.38034951141708e-08
chromosome O 0 5.570342409555451e-08
20p13 O 0 1.160604028882517e-06
. O 0 4.796132202500303e-07

In O 0 3.3424532830395037e-07
this O 0 6.929755880236144e-09
study O 0 1.1221654716564444e-09
, O 0 2.010067806645921e-10
we O 0 6.967945664904107e-11
analyzed O 0 3.199495113292983e-10
two O 0 5.656092816330727e-10
families O 0 6.408581443295702e-10
with O 0 1.1778510389248709e-09
FNDI B-Disease 1 1.0
using O 0 1.3436185497539554e-07
direct O 0 7.584635142166007e-08
automated O 0 5.344164151210862e-07
fluorescent O 0 1.8596352902022772e-07
, O 0 1.9581947174884817e-09
solid O 0 5.602104735658031e-08
phase O 0 5.443858412945701e-07
, O 0 1.3853140856667778e-09
single O 0 1.2661692139204206e-08
- O 0 1.680232308842733e-08
stranded O 0 1.5564822319902305e-08
DNA O 0 1.2433920559828948e-09
sequencing O 0 3.781177149164705e-09
of O 0 9.013246149436327e-09
PCR O 0 8.360469223589462e-07
- O 0 8.387771231355146e-06
amplified O 0 1.3532167940866202e-05
AVP O 0 0.00011792616714956239
- O 0 6.9954267019056715e-06
NPII O 0 7.166857540141791e-05
DNA O 0 4.133360107516637e-06
. O 0 3.5397468423070677e-07

In O 0 4.526592647380312e-07
one O 0 2.698367218556541e-08
of O 0 5.9571682697878714e-08
the O 0 2.6095074545651187e-08
families O 0 2.193567549824138e-09
, O 0 1.4677638271454185e-10
affected O 0 1.2494609513691302e-10
individuals O 0 6.533253538859585e-12
presented O 0 9.731341066299137e-09
a O 0 1.1264119414988727e-08
novel O 0 2.0202937989211023e-08
nonsense O 0 1.6408151282121253e-08
mutation O 0 9.214287666203802e-10
in O 0 6.892263426649947e-10
exon O 0 1.519319070553138e-08
3 O 0 5.637957656290382e-09
of O 0 2.793270947876181e-09
the O 0 5.132009039954255e-09
gene O 0 7.718247707622083e-10
, O 0 4.772927192364662e-11
consisting O 0 8.95658200383842e-11
in O 0 7.154487557947675e-10
a O 0 2.1749627876488375e-08
G O 0 4.929725037072785e-07
to O 0 3.9948336194584044e-08
T O 0 3.46066235579201e-06
transition O 0 5.98218821323826e-06
at O 0 7.675797775164028e-08
nucleotide O 0 3.4668872217480384e-08
2101 O 0 3.630728429016017e-07
, O 0 3.287860955714095e-11
which O 0 8.181854499467178e-12
produces O 0 2.6865669411346715e-11
a O 0 7.494077580716407e-10
stop O 0 6.120669304721105e-09
signal O 0 2.6089182370014896e-07
in O 0 1.4211505749983644e-08
codon O 0 6.566559562770635e-08
82 O 0 1.45130422879447e-06
( O 0 2.528551057423556e-08
Glu O 0 1.2599685760505963e-05
) O 0 8.714369670315136e-09
of O 0 3.0378808446585026e-07
NPII O 0 0.017623325809836388
. O 0 4.669623649533605e-06

The O 0 1.69515533343656e-05
premature O 0 1.0484381164133083e-05
termination O 0 9.614459486328997e-06
eliminates O 0 1.2061767620252795e-06
part O 0 2.5817193716193287e-08
of O 0 4.51657946598516e-08
the O 0 2.2023767698442498e-08
C O 0 5.332449291017838e-07
- O 0 9.511104792636615e-08
terminal O 0 2.372755147916905e-07
domain O 0 3.4512428470634404e-09
of O 0 6.0249267797019e-09
NPII O 0 5.95857045482262e-06
, O 0 6.083851200600066e-10
including O 0 2.2541939148634782e-10
a O 0 4.312314061394318e-09
cysteine O 0 4.744920900634497e-09
residue O 0 6.718602207911317e-08
in O 0 1.6350721887548048e-09
position O 0 1.1640542396662568e-07
85 O 0 7.798890067078901e-08
, O 0 4.6457296343227483e-10
which O 0 1.782333586275442e-10
could O 0 1.6587536899592692e-09
be O 0 6.120176032631264e-10
involved O 0 1.1893644957794436e-09
in O 0 1.034000329802609e-09
the O 0 9.133069411859651e-09
correct O 0 5.5861956838043625e-08
folding O 0 3.4086957612089464e-07
of O 0 1.904025879184701e-07
the O 0 1.5219241049635457e-06
prohormone O 0 0.0021114463452249765
. O 0 4.957189958076924e-06

In O 0 5.997103471599985e-07
the O 0 5.86583951189823e-07
second O 0 4.0566242205386516e-06
family O 0 1.384385655001097e-07
, O 0 6.393101048551841e-10
a O 0 1.9924490946010565e-09
G279A O 0 2.6363121463646166e-08
substitution O 0 7.261853340878588e-08
at O 0 1.0022991148161964e-07
position O 0 9.88613706454089e-08
- O 0 6.041292266445453e-08
1 O 0 8.048095878621098e-08
of O 0 1.538994354177703e-08
the O 0 1.6735093311126548e-08
signal O 0 1.2330183096764813e-07
peptide O 0 8.903584536312792e-09
was O 0 1.0607405620532973e-08
observed O 0 2.8608410085340097e-10
in O 0 8.51931580836407e-11
all O 0 1.1316135528627314e-10
affected O 0 6.680669351055712e-10
individuals O 0 1.2585402164866366e-10
. O 0 7.311275140864382e-08

This O 0 5.420427555691276e-07
missense O 0 9.744159797264729e-06
mutation O 0 1.2068562682543416e-07
, O 0 5.077659626095965e-09
which O 0 2.617242200741998e-09
replaces O 0 1.894009801617358e-05
Ala O 0 0.0004153203044552356
with O 0 2.2707062896643038e-08
Thr O 1 0.9144619107246399
, O 0 4.864387559422312e-09
is O 0 4.817011234337087e-10
frequent O 0 5.810073311351971e-09
among O 0 1.398973648036872e-08
FNDI B-Disease 1 1.0
patients O 0 0.017766073346138
and O 0 6.639960759002861e-08
is O 0 9.123244937292441e-10
thought O 0 1.6382000200820812e-09
to O 0 3.2695579577080025e-10
reduce O 0 4.323299940267589e-09
the O 0 7.496026022124624e-09
efficiency O 0 7.189841966237509e-08
of O 0 6.171192445947327e-09
cleavage O 0 2.322374292873519e-08
by O 0 1.496670898326613e-09
signal O 0 4.464466769604769e-07
peptidases O 0 8.055734497247613e-07
. O 0 1.2556162332089116e-08
. O 0 9.088066121876182e-08

Genetic O 0 2.1245745301712304e-05
heterogeneity O 0 4.564548362395726e-05
of O 0 4.6528501115972176e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 3.115108615503459e-09
due O 0 7.305266649382247e-07
to O 0 4.3908567448625035e-08
TWIST O 0 0.03782457485795021
and O 0 3.5809637211059453e-06
FGFR O 1 0.8885684013366699
mutations O 0 5.147599608790188e-07
. O 0 3.661931202714186e-07

Thirty O 0 9.961159230442718e-05
- O 0 3.140951957902871e-05
two O 0 1.8582838379188615e-08
unrelated O 0 7.653547839936437e-08
patients O 0 2.5625161992337553e-09
with O 0 1.4236398171441067e-10
features O 0 1.1781527753385035e-08
of O 0 7.223432930913987e-06
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 6.355218018505582e-10
a O 0 2.3112638469768854e-09
common O 0 2.7538565063878195e-06
autosomal B-Disease 1 0.6857423782348633
dominant I-Disease 1 0.8755471110343933
condition I-Disease 1 0.9999998807907104
of O 1 0.9086331129074097
craniosynostosis B-Disease 1 1.0
and O 0 0.004192284774035215
limb B-Disease 1 1.0
anomalies I-Disease 0 0.0006864680908620358
, O 0 6.4661085374950744e-09
were O 0 1.3466634918302134e-08
screened O 0 8.735275969229406e-08
for O 0 4.384452356731572e-09
mutations O 0 2.8564859366753126e-09
in O 0 3.21220938737099e-09
TWIST O 0 1.72351865330711e-05
, O 0 1.0052817245309598e-08
FGFR2 O 0 0.0001647072785999626
, O 0 4.428593936012248e-09
and O 0 5.151095905375769e-08
FGFR3 O 0 0.027542585507035255
. O 0 4.0644231376063544e-06

Nine O 0 5.706878710043384e-06
novel O 0 1.5811688172107097e-06
and O 0 7.856819905782686e-08
three O 0 2.6459593627237155e-08
recurrent O 0 2.1839143755642e-06
TWIST O 0 2.409380795143079e-05
mutations O 0 2.1372608571823548e-08
were O 0 2.8129243379027002e-09
found O 0 1.0009648665487703e-09
in O 0 1.108379166225859e-09
12 O 0 2.886352135078596e-08
families O 0 1.9940962658893113e-08
. O 0 4.087580123268708e-07

Seven O 0 7.562233349744929e-06
families O 0 1.0768186342602348e-07
were O 0 1.9682573793033953e-08
found O 0 6.555831877363971e-09
to O 0 3.8899403698167134e-09
have O 0 8.705664633623655e-09
the O 0 2.665067313500913e-07
FGFR3 O 0 0.00046186838881112635
P250R O 0 2.013430957958917e-06
mutation O 0 1.8851981309353505e-08
, O 0 1.6749199804877435e-09
and O 0 9.857659133416519e-10
one O 0 5.014118564794501e-10
individual O 0 6.924913420469636e-11
was O 0 2.386270381293798e-08
found O 0 1.7975027022387735e-09
to O 0 1.2647203284643638e-09
have O 0 1.7059686996390155e-09
an O 0 7.487908959546985e-09
FGFR2 O 0 6.265478441491723e-05
VV269 O 0 1.0990833288815338e-05
- O 0 3.875253241858445e-06
270 O 0 2.8253853656678984e-07
deletion O 0 3.750888595277502e-07
. O 0 2.524404862924712e-07

To O 0 6.176765623422398e-07
date O 0 5.9982749007758684e-06
, O 0 1.5505502659607373e-08
our O 0 9.881043538939593e-09
detection O 0 2.6564171662357694e-07
rate O 0 2.938634224847192e-09
for O 0 3.102494927631483e-10
TWIST O 0 5.020798994337383e-07
or O 0 6.200502156161747e-08
FGFR O 0 3.5547305742511526e-05
mutations O 0 2.601589388362413e-09
is O 0 4.1513356641154076e-10
68 O 0 3.3195091120319375e-09
% O 0 1.880896965955614e-10
in O 0 7.455527306632348e-10
our O 0 1.748956464098228e-07
Saethre B-Disease 1 0.9997289776802063
- I-Disease 1 0.999996542930603
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.226106729125604e-08
, O 0 1.570835128639203e-10
including O 0 1.1512681086234267e-10
our O 0 1.2146919914357568e-07
five O 0 9.246862830991631e-09
patients O 0 1.153264261866127e-09
elsewhere O 0 2.106907537324787e-09
reported O 0 3.1025200186718394e-09
with O 0 6.8624872451295e-10
TWIST O 0 2.4318971554748714e-05
mutations O 0 1.9063878653469146e-07
. O 0 1.2406287908106606e-07

More O 0 1.6980907346919594e-08
than O 0 1.886250933225142e-09
35 O 0 3.403638926258168e-09
different O 0 4.0769781994853815e-10
TWIST O 0 1.1905542578460881e-06
mutations O 0 3.795744607515417e-09
are O 0 6.159991267074005e-11
now O 0 3.5056971214864063e-10
known O 0 1.6839659666700868e-09
in O 0 5.572366457151645e-10
the O 0 4.498728500834659e-09
literature O 0 8.574228438362752e-09
. O 0 8.273563878447021e-08

The O 0 1.7189639038406312e-05
most O 0 5.260201163537204e-08
common O 0 5.044397610731721e-08
phenotypic O 0 6.078162329004044e-08
features O 0 1.2252719727712247e-08
, O 0 2.2434663848880376e-10
present O 0 5.662396662664548e-10
in O 0 3.5243555296382567e-10
more O 0 3.549983917938704e-11
than O 0 1.7219265943668738e-11
a O 0 8.7709450813378e-10
third O 0 2.6998860036542283e-08
of O 0 7.31593097214045e-09
our O 0 7.968131932045708e-09
patients O 0 5.176027384479198e-10
with O 0 7.915138683367573e-11
TWIST O 0 3.435522444306116e-07
mutations O 0 2.6990558676942555e-09
, O 0 1.638111729596048e-10
are O 0 1.633565782643842e-10
coronal B-Disease 0 0.00011735563020920381
synostosis I-Disease 0 0.00023414786846842617
, O 0 1.9121300098845495e-08
brachycephaly B-Disease 0 2.2813219402451068e-05
, O 0 6.286373377406562e-08
low B-Disease 0 0.2378844916820526
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 3.668432668746391e-07
facial B-Disease 0 0.003462383523583412
asymmetry I-Disease 0 0.00071241136174649
, O 0 5.693647153748316e-08
ptosis B-Disease 0 0.4501434862613678
, O 0 1.2460570530947734e-07
hypertelorism B-Disease 0 0.038240235298871994
, O 0 2.087090962277216e-07
broad B-Disease 0 0.07494647800922394
great I-Disease 1 0.9999994039535522
toes I-Disease 1 0.994243323802948
, O 0 2.768639539851847e-08
and O 0 1.0305418385314624e-07
clinodactyly B-Disease 0 0.0008210900705307722
. O 0 9.249885806639213e-06

Significant O 0 7.483708759536967e-05
intra O 1 0.8272437453269958
- O 0 0.2114408165216446
and O 0 3.8146680481077055e-07
interfamilial O 0 1.601752774149645e-05
phenotypic O 0 5.296450353853288e-07
variability O 0 5.455208906823827e-07
is O 0 1.844165514741647e-10
present O 0 4.4916359520641436e-10
for O 0 2.2726279191864762e-10
either O 0 4.042707502094345e-09
TWIST O 0 1.2943994079250842e-05
mutations O 0 3.5736789527618384e-08
or O 0 2.076773775172569e-08
FGFR O 0 2.053117350442335e-05
mutations O 0 4.868771341648426e-08
. O 0 4.6017802901587856e-08

The O 0 1.7357774595438968e-06
overlap O 0 1.8205805929483176e-07
in O 0 7.149811853679466e-09
clinical O 0 5.0244818083911014e-08
features O 0 1.722129638892511e-08
and O 0 4.828143662649609e-09
the O 0 8.343080004635794e-09
presence O 0 1.8918644428822518e-09
, O 0 2.821036182432124e-10
in O 0 1.7890534886877418e-10
the O 0 1.381056047300433e-09
same O 0 4.815063903151895e-10
genes O 0 4.3743261790574195e-10
, O 0 8.209542073922549e-11
of O 0 1.7818618802678543e-09
mutations O 0 9.266049594280901e-10
for O 0 1.5071757175633138e-09
more O 0 1.0468249184159006e-10
than O 0 5.058845564676062e-10
one O 0 3.713499729940395e-09
craniosynostotic B-Disease 0 7.838959845685167e-07
condition I-Disease 0 2.946049107777071e-06
- O 0 1.7289232800976606e-07
such O 0 1.0460815325075146e-08
as O 0 4.791688468230859e-08
Saethre B-Disease 0 2.3656753910472617e-05
- I-Disease 0 2.1757941794930957e-06
Chotzen I-Disease 0 5.934811269980855e-05
, I-Disease 0 1.6232339916655292e-08
Crouzon I-Disease 0 8.275749132735655e-05
, I-Disease 0 1.6207684083724416e-08
and I-Disease 0 7.403456692145483e-08
Pfeiffer I-Disease 0 0.05455412715673447
syndromes I-Disease 1 0.9999969005584717
- O 0 0.4345642030239105
support O 0 2.8614131224458106e-05
the O 0 7.763612302369438e-06
hypothesis O 0 2.2849879144359875e-07
that O 0 3.418888505635209e-10
TWIST O 0 4.5712758378613216e-07
and O 0 3.776909895947256e-09
FGFRs O 0 3.299982722637651e-07
are O 0 6.457511608770616e-11
components O 0 2.6285949417115262e-08
of O 0 3.5435625989066466e-08
the O 0 9.582024063092831e-09
same O 0 1.0754979129501407e-09
molecular O 0 6.434821120393508e-09
pathway O 0 1.2162280071947862e-09
involved O 0 9.9178477930284e-12
in O 0 7.991193644307781e-12
the O 0 1.3816824073753509e-10
modulation O 0 1.601381782734279e-08
of O 0 1.186713927125993e-08
craniofacial O 1 0.9999822378158569
and O 0 3.823018687398871e-06
limb O 1 1.0
development O 0 1.4564547200279776e-05
in O 0 7.303355253895916e-09
humans O 0 1.0344939127548969e-08
. O 0 3.482314214764415e-09
. O 0 3.262105252588299e-08

Mutation O 0 3.415815186258442e-08
analysis O 0 6.12536377175843e-09
of O 0 1.0149189222374844e-07
UBE3A O 1 0.9999856948852539
in O 0 0.0002880607789848
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.8759894371032715
. O 0 5.958184488008555e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00013087046681903303
AS B-Disease 1 1.0
) O 0 8.969412768067286e-09
is O 0 3.368285372840063e-10
caused O 0 1.2357159739906365e-08
by O 0 1.6624943643961387e-09
chromosome O 0 7.350131170369423e-08
15q11 O 0 6.719967018398165e-07
- O 0 3.2806906347104814e-07
q13 O 0 3.0981343002167705e-07
deletions O 0 2.4356664241054204e-08
of O 0 4.3652104153579785e-09
maternal O 0 3.2863218812906325e-09
origin O 0 3.8892780662713733e-10
, O 0 4.1443241199923264e-11
by O 0 1.577256936169391e-10
paternal O 0 6.316025974228978e-06
uniparental B-Disease 1 0.9997599720954895
disomy I-Disease 1 0.9964184761047363
( O 0 1.431933014828246e-06
UPD B-Disease 1 1.0
) O 0 1.1387641052351682e-08
15 O 0 7.420729808416127e-09
, O 0 9.774916986948767e-11
by O 0 3.088790612171266e-10
imprinting O 0 8.213717228500172e-05
defects O 1 0.9954869151115417
, O 0 6.552028364303908e-10
and O 0 5.306783901204426e-10
by O 0 1.942384308950551e-10
mutations O 0 4.27131663371938e-10
in O 0 1.1280110179257008e-09
the O 0 1.329642742575743e-07
UBE3A O 0 4.565989365801215e-05
gene O 0 2.388634356975672e-07
. O 0 1.274098764270093e-07

UBE3A O 0 0.0026263599283993244
encodes O 0 2.5340318643429782e-06
a O 0 7.754774742352311e-07
ubiquitin O 0 1.0954114486594335e-06
- O 0 4.3383448655731627e-07
protein O 0 1.0368248481995579e-08
ligase O 0 2.01099403795979e-08
and O 0 9.30592314318801e-09
shows O 0 2.131171150665523e-08
brain O 0 1.1308227385598002e-06
- O 0 3.473526533070981e-08
specific O 0 1.146927530726316e-08
imprinting O 0 1.128459825849859e-05
. O 0 4.3468801891322073e-07

Here O 0 2.4761620807112195e-06
we O 0 5.2533330574533466e-08
describe O 0 2.0473788708841312e-07
UBE3A O 0 0.0002288129908265546
coding O 0 2.758602386165876e-05
- O 0 4.398792043502908e-06
region O 0 3.380504409733476e-08
mutations O 0 3.0136284578929917e-09
detected O 0 5.119788148988391e-09
by O 0 1.1553155654375757e-10
SSCP O 0 1.1032018392143073e-06
analysis O 0 2.510969210334224e-09
in O 0 4.593026403654221e-09
13 O 0 6.84239154224997e-08
AS B-Disease 1 0.9999982118606567
individuals O 0 1.089846962676333e-10
or O 0 6.5427161466402595e-09
families O 0 1.4425011407581678e-08
. O 0 7.667588874937792e-08

Two O 0 7.399249284389953e-07
identical O 0 1.000259203465248e-06
de O 0 1.3844539353158325e-05
novo O 0 8.457544754492119e-05
5 O 0 1.9786346456385218e-05
- O 0 5.372608939069323e-06
bp O 0 2.3752734250592766e-06
duplications O 0 9.13686847070494e-07
in O 0 3.793546099473133e-08
exon O 0 4.290901927106461e-07
16 O 0 5.896475130384715e-08
were O 0 3.5799192499297305e-09
found O 0 2.9957838876271126e-08
. O 0 1.8588764305604855e-07

Among O 0 1.4885443988532643e-06
the O 0 4.337513246355229e-07
other O 0 6.670156427190932e-09
11 O 0 6.594986778907241e-09
unique O 0 1.5096528471758575e-09
mutations O 0 2.9504734211371897e-09
, O 0 1.112362868482819e-09
8 O 0 6.337805302791821e-08
were O 0 1.9083882918380368e-08
small O 0 1.890714784735792e-08
deletions O 0 2.618679957322456e-07
or O 0 8.785101357489111e-08
insertions O 0 4.153661166128586e-07
predicted O 0 3.021106351752678e-07
to O 0 1.6418544745988584e-08
cause O 0 4.664540938392747e-06
frameshifts O 0 0.00041820979095064104
, O 0 1.4227671485400606e-08
1 O 0 1.4533718228904036e-07
was O 0 8.419544172966198e-08
a O 0 2.597587922537059e-09
mutation O 0 3.1209709816515385e-10
to O 0 5.58326052058078e-10
a O 0 3.950308968825311e-09
stop O 0 5.625390375740835e-09
codon O 0 2.535078369447774e-09
, O 0 2.2070307803545575e-09
1 O 0 3.612846910527878e-08
was O 0 3.6843708528522257e-08
a O 0 6.5494956125178305e-09
missense O 0 1.9336367174105362e-08
mutation O 0 1.0757644774983532e-09
, O 0 1.7651169414989454e-10
and O 0 1.3304660706481286e-09
1 O 0 1.6682228931585996e-07
was O 0 3.789330662584689e-07
predicted O 0 1.8465678763845972e-08
to O 0 2.3267092696954705e-09
cause O 0 2.0638532660655073e-08
insertion O 0 1.3950040056442958e-07
of O 0 1.1901371976819064e-07
an O 0 1.8213710539782824e-09
isoleucine O 0 1.4612407994718524e-07
in O 0 7.304246540940085e-09
the O 0 1.3184427416490507e-07
hect O 0 1.2276450434001163e-06
domain O 0 2.263381482237037e-08
of O 0 5.5914405550083757e-08
the O 0 8.037587662101942e-08
UBE3A O 0 7.7435352068278e-06
protein O 0 2.9433589787686287e-08
, O 0 2.6118898710514316e-10
which O 0 5.134804387241232e-11
functions O 0 1.109021985357117e-09
in O 0 4.4021830625240455e-09
E2 O 0 3.724034911556373e-07
binding O 0 1.3790852015915789e-08
and O 0 9.628062791477987e-09
ubiquitin O 0 6.346005534396681e-07
transfer O 0 1.7121980135925696e-06
. O 0 7.06882076428883e-07

Eight O 0 1.434580553905107e-06
of O 0 2.0564685598856158e-07
the O 0 4.202203474079624e-09
cases O 0 3.0703234399354074e-10
were O 0 1.675814709223289e-09
familial O 0 4.090980780802056e-07
, O 0 2.3689545880500873e-09
and O 0 6.28266683122547e-09
five O 0 9.070260986732137e-09
were O 0 2.1311873155127614e-08
sporadic O 0 5.632641659758519e-06
. O 0 7.2749098762869835e-06

In O 0 3.418390406295657e-07
two O 0 3.0196829925444035e-08
familial O 0 8.496753025610815e-07
cases O 0 9.549619761628492e-09
and O 0 5.247271950281629e-09
one O 0 8.593313283178361e-10
sporadic O 0 5.7248563223311066e-08
case O 0 8.464485290460289e-08
, O 0 3.0156408481474273e-09
mosaicism O 0 3.327830563648604e-05
for O 0 7.431100357280229e-08
UBE3A O 0 0.0003028899081982672
mutations O 0 2.7057733831270525e-08
was O 0 8.634857096012638e-08
detected O 0 6.859087964272703e-09
in O 0 4.3515913095149017e-10
the O 0 2.974090529406226e-09
mother O 0 1.3417971622686764e-08
of O 0 2.379135288776979e-08
three O 0 5.095270694255305e-08
AS B-Disease 1 1.0
sons O 0 0.0009800768457353115
, O 0 4.806273712354425e-10
in O 0 4.0242570387150067e-10
the O 0 8.332298406799055e-09
maternal O 0 2.4181923663491034e-07
grandfather O 0 3.0050430268602213e-06
of O 0 1.0812574373630923e-06
two O 0 6.212115408743557e-07
AS B-Disease 1 1.0
first O 0 4.7410694605787285e-06
cousins O 0 3.033560460607987e-05
, O 0 3.793833691645432e-09
and O 0 7.716411509761656e-09
in O 0 1.4680425763913263e-08
the O 0 9.072285820366233e-07
mother O 0 1.7675586150289746e-07
of O 0 1.974484717948144e-07
an O 0 5.154260662720844e-08
AS B-Disease 1 1.0
daughter O 0 0.0023803398944437504
. O 0 2.1745705453213304e-05

The O 0 1.0590545116428984e-06
frequencies O 0 4.237159600961604e-08
with O 0 3.080729837900975e-10
which O 0 2.290242578917301e-10
we O 0 9.71951408246241e-11
detected O 0 1.5464379776730652e-09
mutations O 0 1.8951971936242984e-10
were O 0 2.152819034151321e-09
5 O 0 1.3128111930882369e-08
( O 0 2.2769450214177311e-10
14 O 0 7.514803779251622e-10
% O 0 1.8265187973209862e-10
) O 0 4.340522732904084e-11
of O 0 2.152010347700184e-09
35 O 0 7.453497374854123e-09
in O 0 7.22965964872202e-10
sporadic O 0 2.062660975354902e-08
cases O 0 7.824931813615876e-09
and O 0 1.112147085535753e-08
8 O 0 3.8987366224318976e-08
( O 0 2.766625539774026e-10
80 O 0 1.2214632638674061e-09
% O 0 8.97077204187191e-11
) O 0 4.5706143730894766e-11
of O 0 3.133916903763634e-09
10 O 0 3.672911086383124e-09
in O 0 1.146465367085625e-09
familial O 0 1.0507712744356468e-07
cases O 0 5.208314224347532e-09
. O 0 8.65011795525561e-09
. O 0 1.0351437396138863e-07

The O 0 0.0002649954694788903
hemochromatosis B-Disease 1 1.0
845 O 0 1.5598201571265236e-05
G O 0 1.4147241245154873e-06
- O 0 4.635815855635883e-07
- O 0 4.85469513478165e-07
> O 0 1.516123688816151e-07
A O 0 1.2098108470581792e-07
and O 0 1.5469689973457434e-09
187 O 0 4.4693054812583455e-10
C O 0 1.9882399726611766e-08
- O 0 5.198452512900076e-08
- O 0 2.0861557459284086e-07
> O 0 1.2997267049286165e-06
G O 0 1.6968964473562664e-06
mutations O 0 6.1335363454873004e-09
: O 0 7.028144038967454e-11
prevalence O 0 3.353773037062524e-09
in O 0 4.123683339241069e-10
non O 0 2.212928862377339e-08
- O 0 1.963810376537367e-07
Caucasian O 0 2.0975106451714964e-07
populations O 0 2.5852276763771442e-08
. O 0 9.613312812462027e-08

Hemochromatosis B-Disease 1 0.9999998807907104
, O 0 7.069272669468774e-07
the O 0 0.00021137682779226452
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 1.0
iron I-Disease 1 1.0
metabolism I-Disease 1 1.0
, O 0 3.7169954225646507e-07
leads O 0 1.9064801790591446e-06
, O 0 1.2482092692778224e-08
if O 0 1.4179388472257415e-06
untreated O 1 1.0
, O 0 6.14185040603843e-08
to O 0 6.147089379737736e-07
progressive O 1 1.0
iron B-Disease 1 1.0
overload I-Disease 1 0.9999957084655762
and O 0 2.8723209766212676e-07
premature B-Disease 0 1.1430267932155402e-06
death I-Disease 0 4.8977653932524845e-06
. O 0 5.103036642140069e-07

The O 0 0.0004076385812368244
hemochromatosis B-Disease 1 1.0
gene O 0 5.006887931813253e-06
, O 0 3.703562967416474e-08
HFE O 1 0.7861482501029968
, O 0 8.39160065879696e-08
recently O 0 8.382002647522313e-08
has O 0 6.354733406155333e-10
been O 0 3.349948651809598e-10
identified O 0 1.0100766889564738e-09
, O 0 4.000751813171277e-11
and O 0 1.6699110150231178e-10
characterization O 0 7.702328730374575e-08
of O 0 1.7697513499115303e-07
this O 0 4.81229367466085e-09
gene O 0 1.038764718686025e-08
has O 0 5.477056586045137e-10
shown O 0 1.7592047263370603e-10
that O 0 2.6985072162921675e-11
it O 0 4.3799595894622456e-11
contains O 0 4.8494770699125667e-11
two O 0 5.6623292860047414e-11
mutations O 0 2.0280199394817622e-11
that O 0 1.432447650079327e-11
result O 0 7.749269004264647e-10
in O 0 2.586686198569055e-09
amino O 0 1.5208200254690496e-09
acid O 0 3.5165215184207455e-09
substitutions O 0 6.766388338519391e-09
- O 0 4.716716262009868e-08
cDNA O 0 1.1040779668292089e-07
nucleotides O 0 9.301468928413215e-09
845 O 0 2.5724880003963335e-08
G O 0 2.1341568512411868e-08
- O 0 3.2449158027247904e-08
- O 0 1.2205724431169074e-07
> O 0 1.4981860374518874e-07
A O 0 1.847815553901455e-07
( O 0 2.1943032113558303e-10
C282Y O 0 6.520018303035613e-09
) O 0 2.88138627541068e-11
and O 0 2.6952012843750595e-10
187 O 0 7.634688437008208e-10
C O 0 1.3288613764927959e-08
- O 0 2.0323444260839096e-08
- O 0 8.081305935547789e-08
> O 0 2.3524768266725005e-07
G O 0 7.070641458994942e-07
( O 0 1.6332706298527455e-09
H63D O 0 5.758482984674629e-06
) O 0 4.377575191227834e-09
. O 0 4.556016719448053e-08

Although O 0 0.00010120711522176862
hemochromatosis B-Disease 1 1.0
is O 0 2.8998051959661097e-08
common O 0 2.4060962999783442e-08
in O 0 7.896083231706541e-10
Caucasians O 0 1.889535994337166e-08
, O 0 4.250243768044726e-10
affecting O 0 3.529705638882774e-09
> O 0 2.355938875098218e-07
= O 0 5.5812432009361146e-08
1 O 0 7.003745139400053e-08
/ O 0 1.7891848003159794e-08
300 O 0 2.145484484517013e-10
individuals O 0 5.239573531989894e-12
of O 0 2.103386353979886e-09
northern O 0 1.2112328029445507e-08
European O 0 3.652281810317959e-09
origin O 0 4.5882453392209754e-09
, O 0 3.4830030526400435e-10
it O 0 4.13854991943019e-11
has O 0 1.642735426854447e-11
not O 0 7.446197304583624e-12
been O 0 9.03933802809398e-11
recognized O 0 2.539742860463434e-10
in O 0 5.98266824969329e-10
other O 0 6.519144113426023e-10
populations O 0 3.2821372286662154e-09
. O 0 6.288267684340099e-08

The O 0 1.833884880397818e-06
present O 0 1.6662855983895497e-08
study O 0 6.986154432730984e-10
used O 0 4.15185830160425e-10
PCR O 0 4.397670494427075e-08
and O 0 2.576532986964253e-09
restriction O 0 6.6795644571016055e-09
- O 0 1.7669849583512587e-08
enzyme O 0 3.5176819235260837e-09
digestion O 0 1.8628510289886435e-08
to O 0 5.55190171613873e-10
analyze O 0 3.669291093189031e-09
the O 0 4.5870902631861554e-09
frequency O 0 8.70526672969163e-09
of O 0 8.533782569486448e-09
the O 0 1.1523765053311763e-08
845 O 0 2.1047759091175067e-08
G O 0 3.475063792279798e-08
- O 0 2.6883345327632924e-08
- O 0 5.9405227403885874e-08
> O 0 7.920737488120722e-08
A O 0 1.1580418401990755e-07
and O 0 2.4661439557149833e-09
187 O 0 1.1800120880423037e-09
C O 0 1.2014494288337119e-08
- O 0 1.9889188962451954e-08
- O 0 7.645478916629145e-08
> O 0 2.1056436594335537e-07
G O 0 3.879791563576873e-07
mutations O 0 3.0074154278025844e-09
in O 0 2.030522416873737e-09
HLA O 0 3.151757965724755e-08
- O 0 1.3395775155800038e-08
typed O 0 6.610804792472891e-09
samples O 0 1.596221266275677e-09
from O 0 3.4888492095319634e-09
non O 0 5.2338705813781417e-08
- O 0 1.5636987882317044e-07
Caucasian O 0 1.31143011117274e-07
populations O 0 6.6613581317653825e-09
, O 0 3.2956226636571273e-10
comprising O 0 1.0047362941634219e-10
Australian O 0 8.858999756000685e-09
Aboriginal O 0 1.0723235632781325e-08
, O 0 1.1272748706714353e-10
Chinese O 0 5.760195653792266e-10
, O 0 2.9371199916639057e-10
and O 0 9.732528560846276e-09
Pacific O 0 2.113745040333015e-06
Islanders O 0 3.190395000274293e-05
. O 0 1.4490926787402714e-06

Results O 0 1.1852253010147251e-06
showed O 0 1.1965923363277398e-07
that O 0 2.0007129286625513e-09
the O 0 4.7649482581846314e-08
845 O 0 1.5849673218326643e-07
G O 0 2.2210251415799576e-07
- O 0 4.6885296001164534e-07
- O 0 8.983366797110648e-07
> O 0 2.777274517029582e-07
A O 0 6.725204571012e-08
mutation O 0 6.385131867681082e-10
was O 0 2.644222174552624e-09
present O 0 1.0594252558560058e-10
in O 0 7.616678121546983e-11
these O 0 3.183447949695051e-11
populations O 0 3.538613152498371e-11
( O 0 2.0878984305361392e-12
allele O 0 3.6163298050562176e-11
frequency O 0 5.100759259413223e-10
0 O 0 1.1002510014179734e-09
. O 0 6.189540546763794e-11
32 O 0 6.022775056457874e-10
% O 0 5.606757072507129e-11
) O 0 5.769924121823422e-11
, O 0 7.017307568357722e-11
and O 0 4.664553188149512e-10
, O 0 1.491313045276499e-10
furthermore O 0 3.6233065436874767e-09
, O 0 3.2030733621013496e-10
it O 0 3.795510850057582e-10
was O 0 7.65163505889177e-08
always O 0 2.5549125037827025e-09
seen O 0 1.658712611707358e-09
in O 0 1.905033214510965e-10
conjunction O 0 8.088484326762568e-10
with O 0 1.1284048140325353e-09
HLA O 0 8.857109037307964e-07
haplotypes O 0 6.706964228442303e-08
common O 0 1.7708285326989426e-07
in O 0 1.630031754018546e-08
Caucasians O 0 9.013749036057561e-08
, O 0 1.086008616368872e-09
suggesting O 0 2.282882105575368e-09
that O 0 8.08613953573456e-10
845 O 0 8.83019026787224e-08
G O 0 4.276652134649339e-07
- O 0 1.8576354250399163e-06
- O 0 1.181952393380925e-05
> O 0 3.18375532515347e-06
A O 0 2.2902027012605686e-06
may O 0 1.4455804553392682e-08
have O 0 4.797371389031468e-10
been O 0 5.672179392846033e-10
introduced O 0 8.539362550408214e-10
into O 0 1.7468501645190315e-10
these O 0 1.6262902483021868e-11
populations O 0 3.925242075819568e-11
by O 0 8.444508980964827e-11
Caucasian O 0 6.109567607381905e-08
admixture O 0 2.3350210085482104e-06
. O 0 1.174512249235704e-06

187 O 0 5.693923412763979e-07
C O 0 4.992032245354494e-07
- O 0 2.0144649681697047e-07
- O 0 1.8933677381482994e-07
> O 0 1.870128301106888e-07
G O 0 1.2964791551439703e-07
was O 0 1.593663689902769e-08
present O 0 6.567819066383151e-10
at O 0 5.272339786976943e-10
an O 0 3.3669328176194613e-12
allele O 0 8.218829262995886e-12
frequency O 0 4.0769393416795197e-10
of O 0 6.386304374217389e-09
2 O 0 3.244278730107908e-07
. O 0 1.2907413804441603e-07

68 O 0 1.504314332123613e-05
% O 0 7.104708998895148e-08
in O 0 1.0508088621463685e-08
the O 0 4.1500094027924206e-08
two O 0 3.4243849977855234e-09
populations O 0 8.411784047090975e-10
analyzed O 0 5.316431295199209e-09
( O 0 6.378473305090893e-10
Australian O 0 6.409712227650743e-08
Aboriginal O 0 1.5083331561527302e-07
and O 0 1.1695864721161797e-08
Chinese O 0 2.4678108445641556e-08
) O 0 3.663696235278735e-09
. O 0 7.528669954126599e-08

In O 0 2.6742993668449344e-06
the O 0 1.27117289139278e-06
Australian O 0 2.0803899758448097e-07
Aboriginal O 0 1.5651513862735555e-08
samples O 0 3.124783209962345e-10
, O 0 1.7139063779314512e-10
187 O 0 1.0550137430342943e-09
C O 0 6.133175389777534e-08
- O 0 1.3301982448865601e-07
- O 0 6.48902926059236e-07
> O 0 1.203692363560549e-06
G O 0 1.1296908724034438e-06
was O 0 4.69988705731339e-08
found O 0 2.361987549992506e-10
to O 0 6.426437854090139e-11
be O 0 4.328386260521455e-11
associated O 0 1.120753712058331e-09
with O 0 5.053695795176338e-10
HLA O 0 2.097757715091575e-06
haplotypes O 0 5.3747744033216804e-08
common O 0 1.0962447305473688e-07
in O 0 7.141470526050853e-09
Caucasians O 0 1.8436824689160858e-07
, O 0 3.2787569881342904e-10
suggesting O 0 7.74883990306563e-10
that O 0 9.075270396285973e-11
it O 0 2.819906530504568e-10
was O 0 5.246181267182237e-09
introduced O 0 2.895800543800675e-10
by O 0 4.676889084342939e-11
recent O 0 2.126289588844088e-09
admixture O 0 4.2557766732898017e-07
. O 0 3.6931766089765006e-07

In O 0 2.0519737518043257e-06
the O 0 2.6335612801631214e-07
Chinese O 0 9.287410840386201e-09
samples O 0 4.496547301169329e-10
analyzed O 0 6.164518895346305e-10
, O 0 1.3089568318136457e-10
187 O 0 5.157284044265964e-10
C O 0 1.0830759400448642e-08
- O 0 1.7359509385528327e-08
- O 0 5.458936058744257e-08
> O 0 1.8622014863467484e-07
G O 0 2.726038701439393e-07
was O 0 2.806741150607195e-08
present O 0 7.514947553133311e-10
in O 0 4.001906306339009e-10
association O 0 1.3485899896803488e-10
with O 0 1.5195725233674295e-10
a O 0 8.694712505530333e-09
wide O 0 5.12092377391582e-08
variety O 0 1.703179997036841e-08
of O 0 8.180246879874176e-08
HLA O 0 3.794468966589193e-06
haplotypes O 0 1.415903625456849e-07
, O 0 3.605023501940252e-10
showing O 0 6.621780901383545e-10
this O 0 1.933767590500679e-10
mutation O 0 1.1425971280232261e-09
to O 0 6.88737455956101e-10
be O 0 2.0239336873117963e-09
widespread O 0 4.642421558287424e-08
and O 0 2.4190731195972148e-08
likely O 0 1.807442551182703e-08
to O 0 2.8486022429774494e-09
predate O 0 1.7640858231970924e-06
the O 0 1.818234665051932e-07
more O 0 4.698143540871058e-10
genetically O 0 2.018967881767253e-09
restricted O 0 1.2418301942318521e-09
845 O 0 7.695070358693101e-09
G O 0 9.029097469692715e-08
- O 0 2.332082686962167e-07
- O 0 5.300780685502104e-07
> O 0 3.445910863320023e-07
A O 0 1.9676160434300982e-07
mutation O 0 2.1998955546109755e-08
. O 0 1.996158793815539e-08

Genotype O 0 7.16576396371238e-05
- O 0 3.8576763472519815e-06
phenotype O 0 3.0955234819884936e-07
correlations O 0 2.1668311944722518e-07
in O 0 6.287967835305608e-08
attenuated B-Disease 1 0.9999959468841553
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
. O 0 0.0004693459195550531

Germ O 0 0.024551164358854294
- O 0 0.0003822811704594642
line O 0 1.821443561311753e-06
mutations O 0 1.4115657087643285e-08
of O 0 1.3678964627672485e-08
the O 0 2.1040614583967e-08
tumor B-Disease 0 1.206223942062934e-06
suppressor O 0 1.1671194215523428e-06
APC O 0 1.6036619143733333e-08
are O 0 5.3917495468347454e-11
implicated O 0 1.5873174774583276e-08
in O 0 8.266276552149066e-08
attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.633376450627111e-05
AAPC B-Disease 1 1.0
) O 0 5.134493941127971e-10
, O 0 1.7069465632624237e-11
a O 0 1.32425501120359e-10
variant O 0 1.675948738011357e-06
of O 1 0.9868156313896179
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 3.535809582899674e-06
FAP B-Disease 0 1.44433397508692e-05
) O 0 1.669657834213467e-08
. O 0 2.8217181125000934e-07

AAPC B-Disease 1 1.0
is O 0 2.6546393883108976e-07
recognized O 0 2.183500491526047e-08
by O 0 9.097840258931456e-10
the O 0 2.5292490324346772e-09
occurrence O 0 7.329129303457194e-09
of O 0 3.530730907641555e-08
< O 0 7.439984983648174e-07
100 O 0 1.814423278290178e-08
colonic B-Disease 0 9.23744937608717e-06
adenomas I-Disease 0 7.702649895691138e-07
and O 0 1.1231976460024384e-09
a O 0 1.8292739545344716e-09
later O 0 3.8298242799328364e-08
onset O 1 0.999936580657959
of O 1 0.9999983310699463
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 4.172244216782417e-10
age O 0 1.5713512713233513e-09
> O 0 1.1598696225689764e-08
40 O 0 7.776335131381984e-10
years O 0 5.468726582691374e-10
) O 0 4.420894761381078e-10
. O 0 1.920181524894815e-08

The O 0 5.80422192797414e-06
aim O 0 4.7541544745399733e-07
of O 0 1.0187532240024666e-07
this O 0 1.3170540213991444e-09
study O 0 7.547670266561113e-10
was O 0 1.237168678613898e-08
to O 0 8.664577944017537e-10
assess O 0 1.2462638210308796e-07
genotype O 0 4.417520813149167e-06
- O 0 1.276575403608149e-06
phenotype O 0 4.955853682986344e-07
correlations O 0 2.919337873663608e-07
in O 0 2.6151235488214297e-07
AAPC B-Disease 1 1.0
families O 0 1.3108691518937121e-06
. O 0 7.465707199116878e-07

By O 0 2.425777836378984e-07
protein O 0 2.7300663418827753e-07
- O 0 3.358256321916997e-07
truncation O 0 3.7209358652035007e-06
test O 0 6.822796763117367e-07
( O 0 2.2836323054775676e-08
PTT O 0 2.480283569639141e-07
) O 0 9.086112418010828e-11
assay O 0 2.9357112296679588e-08
, O 0 5.163012239961517e-10
the O 0 7.474411312102802e-09
entire O 0 1.3061256254331965e-07
coding O 0 2.814767583458888e-07
region O 0 2.947999711011562e-08
of O 0 3.4932323700331835e-08
the O 0 1.0040135833833119e-07
APC B-Disease 0 6.692064147273413e-08
gene O 0 7.041756955317169e-09
was O 0 4.259833019659709e-08
screened O 0 5.859105645100726e-09
in O 0 2.2780961839163894e-10
affected O 0 5.130401659059203e-10
individuals O 0 5.220024759666764e-11
from O 0 5.976480821345831e-08
11 O 0 2.53333000728162e-05
AAPC B-Disease 1 1.0
kindreds O 1 0.9265087842941284
, O 0 1.7683333908280474e-08
and O 0 3.0706177600592355e-09
their O 0 2.135568832883905e-09
phenotypic O 0 8.667578299537126e-08
differences O 0 2.460920001112754e-08
were O 0 3.952828109277107e-08
examined O 0 4.047609820645448e-07
. O 0 2.6819205345418595e-07

Five O 0 1.4955579672459862e-06
novel O 0 3.435194457779289e-07
germ O 0 0.00010772127279778942
- O 0 7.075484518281883e-06
line O 0 2.5134199859166984e-06
APC B-Disease 0 6.589356615904762e-08
mutations O 0 1.133346416715142e-09
were O 0 1.2088042788960252e-09
identified O 0 3.835341377822488e-09
in O 0 6.961178744546714e-09
seven O 0 9.22166165651106e-08
kindreds O 0 4.21507065766491e-05
. O 0 2.2376539163815323e-06

Mutations O 0 8.452601036879059e-07
were O 0 1.5485616700061655e-07
located O 0 2.2249231790283375e-08
in O 0 1.1386637188692816e-09
three O 0 1.5586554269475528e-10
different O 0 3.7693067417299275e-11
regions O 0 1.4644648826944717e-09
of O 0 9.7554661238064e-08
the O 0 3.255262583934382e-07
APC B-Disease 0 4.034675171737945e-08
gene O 0 2.7466522389829606e-09
( O 0 1.7621969161663031e-10
1 O 0 1.0886451740077518e-08
) O 0 1.2288986495079257e-10
at O 0 7.513517807922199e-09
the O 0 2.3050223063592057e-08
5 O 0 6.476714276004714e-08
end O 0 1.665846127707482e-07
spanning O 0 4.723450430788034e-08
exons O 0 1.0649048221011981e-07
4 O 0 3.157546402121625e-08
and O 0 1.2454666187267094e-09
5 O 0 8.32751556600897e-09
, O 0 2.7312396788659044e-10
( O 0 1.1366579899529938e-10
2 O 0 3.6186122542858357e-08
) O 0 1.608715244350023e-10
within O 0 3.419718286323814e-09
exon O 0 5.650426970760236e-08
9 O 0 1.945244676448965e-08
, O 0 8.717553068304795e-11
and O 0 3.995317132687859e-10
( O 0 3.006920823445114e-10
3 O 0 2.3134878901487355e-08
) O 0 4.387838425934376e-10
at O 0 8.489445590953437e-09
the O 0 1.0731501021155054e-08
3 O 0 1.0394647631528642e-07
distal O 0 2.009983518291847e-06
end O 0 6.360365887303487e-07
of O 0 2.75125529469733e-07
the O 0 2.1197233479597344e-07
gene O 0 1.272877057090227e-07
. O 0 2.1816028095145157e-07

Variability O 0 2.594220859464258e-05
in O 0 5.740262309927857e-08
the O 0 3.518361424426075e-08
number O 0 5.444313444513682e-09
of O 0 2.8273874704609625e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9999996423721313
most O 0 1.0295375219016023e-08
apparent O 0 1.4590769126243686e-07
in O 0 2.0390053534491415e-10
individuals O 0 4.8858972423460045e-12
with O 0 8.226581221792983e-11
mutations O 0 2.283047528806037e-09
in O 0 8.754352798234777e-09
region O 0 2.1708760868932586e-06
1 O 1 0.8249112963676453
, O 0 3.976679252559734e-08
and O 0 1.0169376309931977e-06
upper O 1 1.0
- O 1 0.9999998807907104
gastrointestinal O 1 0.99997878074646
manifestations O 0 0.0003671988670248538
were O 0 3.161005324159305e-08
more O 0 1.72960354372087e-10
severe O 0 5.006010610486555e-07
in O 0 4.842383383163451e-09
them O 0 4.372042727851522e-09
. O 0 2.2330205240450596e-07

In O 0 8.863329981068091e-08
individuals O 0 2.1403957772836435e-10
with O 0 5.328265606507898e-10
mutations O 0 9.738986284091311e-10
in O 0 8.853690558474625e-10
either O 0 7.326180551103789e-09
region O 0 4.4684495037472516e-07
2 O 0 8.816236913844477e-06
or O 0 8.582822630387454e-08
region O 0 3.9583440525348124e-07
3 O 0 2.3432432953995885e-06
, O 0 1.92052485026295e-09
the O 0 1.3370044626981326e-08
average O 0 2.959784639600116e-09
number O 0 5.455869644954703e-10
of O 0 6.019002540824658e-08
adenomas B-Disease 0 0.00011762608482968062
tended O 0 1.6513729406142375e-07
to O 0 6.684254483246832e-09
be O 0 1.2351317302261577e-08
lower O 0 7.386628908534476e-07
than O 0 1.204876615146233e-10
those O 0 7.015072550631274e-11
in O 0 4.647694729076335e-11
individuals O 0 7.983845789344413e-13
with O 0 2.259078167587969e-11
mutations O 0 1.1699914648222176e-10
in O 0 3.9433209475525643e-10
region O 0 1.4828506422759347e-08
1 O 0 2.238066940662975e-07
, O 0 1.5806478348423525e-10
although O 0 3.255898328724527e-10
age O 0 2.8470650281775534e-09
at O 0 2.470484483652058e-09
diagnosis O 0 1.2660369463901588e-07
was O 0 1.6446001893655193e-08
similar O 0 8.781110061306663e-09
. O 0 1.90139829214786e-07

In O 0 6.8315093812998384e-06
all O 0 2.2969002202444244e-06
AAPC B-Disease 1 1.0
kindreds O 0 0.0003978351305704564
, O 0 1.494874268814783e-08
a O 0 1.4776106560532298e-08
predominance O 0 3.298693854958401e-06
of O 0 0.0024570391979068518
right O 1 1.0
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999998807907104
rectal B-Disease 1 1.0
polyp I-Disease 1 0.9999656677246094
sparing O 0 6.718974873365369e-06
was O 0 1.2993028803975903e-06
observed O 0 3.5504903905803076e-08
. O 0 1.1119671938786269e-07

No O 0 0.0020493913907557726
desmoid B-Disease 1 1.0
tumors I-Disease 1 1.0
were O 0 1.1049413615182857e-06
found O 0 3.532765191494036e-08
in O 0 4.298870148744527e-09
these O 0 1.0388003346406549e-08
kindreds O 0 6.08859263593331e-05
. O 0 1.5020660839581979e-06

Our O 0 2.2142194211483002e-05
data O 0 2.4906702833504824e-07
suggest O 0 1.951082317930286e-08
that O 0 1.0264155081429749e-09
, O 0 2.0770181130558285e-09
in O 0 2.2261753329644307e-08
AAPC B-Disease 1 1.0
families O 0 8.685815799935881e-08
, O 0 4.371073503151024e-10
the O 0 1.4107817136732592e-09
location O 0 3.4198830434206684e-08
of O 0 2.1696635599255387e-08
the O 0 6.489995030278806e-08
APC B-Disease 0 2.3360179568499007e-07
mutation O 0 2.659164266560765e-08
may O 0 1.669708815654758e-08
partially O 0 3.186074195582478e-07
predict O 0 1.668518123665308e-08
specific O 0 3.1425017255060084e-08
phenotypic O 0 1.5346406598837348e-06
expression O 0 1.0436351658427157e-06
. O 0 9.275904062633344e-07

This O 0 2.9731515382991347e-07
should O 0 3.521335401046599e-08
help O 0 2.6095325011965542e-08
in O 0 3.8645158184635875e-09
the O 0 8.500755654949899e-09
design O 0 7.64934426911168e-08
of O 0 1.485690237501558e-08
tailored O 0 2.1351381107592715e-08
clinical O 0 4.4906380480824737e-07
- O 0 8.528413673047908e-07
management O 0 3.240462831399782e-08
protocols O 0 1.3659250726050232e-06
in O 0 1.2901174573087815e-09
this O 0 7.747166103078129e-11
subset O 0 5.952369153128245e-10
of O 0 9.843023063282885e-10
FAP B-Disease 0 1.2412701266839576e-07
patients O 0 1.5350806847891363e-08
. O 0 1.6830387750133013e-08
. O 0 2.449748990329681e-07

Wilms B-Disease 1 0.9999996423721313
' I-Disease 1 0.5418453812599182
tumor I-Disease 0 0.00012820791744161397
1 O 0 1.7349350400763797e-06
and O 0 5.164258354284357e-08
Dax O 0 0.00010908003605436534
- O 0 7.651707392142271e-07
1 O 0 1.0699513950385153e-06
modulate O 0 3.4008314742095536e-07
the O 0 6.759044595128216e-07
orphan O 0 2.1063838175905403e-06
nuclear O 0 2.2751514734409284e-06
receptor O 0 2.449550606797857e-07
SF O 0 5.5226766562554985e-05
- O 0 1.6585431694693398e-07
1 O 0 1.4772470358082046e-08
in O 0 3.603069578805851e-11
sex O 0 2.1093824603690692e-11
- O 0 1.060539225883339e-10
specific O 0 9.791089813915299e-12
gene O 0 5.687117998753877e-10
expression O 0 4.057632452258986e-09
. O 0 1.9558290986765314e-08

Products O 0 4.1014759517565835e-06
of O 0 1.1385486686776858e-05
steroidogenic O 0 0.021476497873663902
factor O 0 3.0055591651034774e-06
1 O 0 5.508229037332057e-07
( O 0 1.5372245698586084e-09
SF O 0 3.0349779990501702e-05
- O 0 3.0385240279429127e-07
1 O 0 1.6607098984877666e-07
) O 0 6.152572895601338e-10
and O 0 2.1733869814966056e-08
Wilms B-Disease 1 0.9741896986961365
tumor I-Disease 0 0.00010330809891456738
1 O 0 2.0251027308404446e-06
( O 0 1.680702688133806e-09
WT1 O 0 1.058170141732262e-06
) O 0 1.3736836668165608e-10
genes O 0 5.718463202963875e-11
are O 0 1.0083700367757853e-11
essential O 0 1.4044617691055805e-09
for O 0 8.280202634658451e-10
mammalian O 0 1.4340429288495216e-06
gonadogenesis O 0 6.461759198828076e-07
prior O 0 4.069011438900816e-08
to O 0 1.9356061198294583e-09
sexual O 0 1.2305457763872596e-09
differentiation O 0 2.6624832116795005e-08
. O 0 8.157499564731552e-08

In O 0 1.1394141807841152e-07
males O 0 5.143239611982153e-09
, O 0 1.3110045493647249e-08
SF O 1 0.9981260895729065
- O 0 0.00030042952857911587
1 O 0 9.429294891560858e-07
participates O 0 3.2100349045549592e-09
in O 0 1.0313642995196659e-10
sexual O 0 4.190010144400347e-11
development O 0 1.1877747396749072e-10
by O 0 7.204887728096132e-12
regulating O 0 4.741507741989892e-10
expression O 0 4.662187302884035e-10
of O 0 8.575373300345746e-09
the O 0 3.9187622036251923e-08
polypeptide O 0 5.329064265424677e-07
hormone O 0 1.0190502663931511e-08
Mullerian O 0 1.8859246893043746e-06
inhibiting O 0 2.8017669961855063e-08
substance O 0 2.7547018888185448e-08
( O 0 4.146273102634268e-09
MIS O 0 1.70336315932218e-05
) O 0 4.088965166459957e-09
. O 0 4.2119712162502765e-08

Here O 0 1.3220364962762687e-05
, O 0 1.26838259006945e-07
we O 0 2.434960322261759e-08
show O 0 2.5501474709699323e-08
that O 0 4.467466840907264e-09
WT1 O 0 0.00016117545601446182
- O 0 1.584192978043575e-05
KTS O 0 0.00034076895099133253
isoforms O 0 5.83708924750681e-07
associate O 0 4.3044150288551464e-07
and O 0 1.3928552533570837e-08
synergize O 0 8.17450541035214e-07
with O 0 2.6897501115286104e-08
SF O 1 0.9999301433563232
- O 0 7.319710130104795e-05
1 O 0 1.364904164802283e-06
to O 0 3.279948757040074e-08
promote O 0 2.220726429413844e-07
MIS O 0 0.0012632891302928329
expression O 0 1.365556130394907e-07
. O 0 2.11433658137139e-07

In O 0 3.07574907765229e-07
contrast O 0 7.0754038006271e-07
, O 0 1.0380798443065942e-07
WT1 O 0 0.0007496582111343741
missense O 0 5.155729013495147e-06
mutations O 0 2.4920858265886636e-08
, O 0 6.167141797241982e-10
associated O 0 5.5512696661708105e-09
with O 0 1.915220870785106e-09
male B-Disease 0 1.3313810143245064e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 8.78075979926507e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.0791831073220237e-07
fail O 0 5.183833309274632e-07
to O 0 8.974190279786853e-08
synergize O 0 2.777357258310076e-05
with O 0 1.5212841617540107e-06
SF O 1 1.0
- O 1 0.9999024868011475
1 O 0 0.00012572581181302667
. O 0 6.957085929570894e-07

Additionally O 0 5.5702425925119314e-06
, O 0 5.936093927516595e-08
the O 0 6.140221842088067e-08
X O 0 1.6654423234285787e-05
- O 0 2.445214249746641e-06
linked O 0 1.1103783208454843e-06
, O 0 1.9177246457502406e-09
candidate O 0 5.566855865168918e-09
dosage O 0 3.098039655924367e-07
- O 0 2.1315943854460784e-07
sensitive O 0 1.58306093567262e-07
sex O 0 1.25139576478972e-09
- O 0 4.770056349912011e-09
reversal O 0 5.4452065079146905e-09
gene O 0 2.208032867656584e-09
, O 0 1.2921466119308889e-09
Dax O 0 1.531039015389979e-05
- O 0 1.8390516061117523e-06
1 O 0 1.7534935068397317e-06
, O 0 1.0396963290304484e-08
antagonizes O 0 8.210625423998863e-07
synergy O 0 1.567193663731814e-07
between O 0 6.509296923695729e-08
SF O 0 0.003939241170883179
- O 0 3.2440980248793494e-06
1 O 0 3.3400411325601453e-07
and O 0 6.434035970670493e-09
WT1 O 0 1.4640820154454559e-05
, O 0 7.795432632740074e-10
most O 0 4.394178354516498e-10
likely O 0 2.187217296167887e-09
through O 0 8.443610810537905e-10
a O 0 8.307411980545965e-10
direct O 0 5.890882226466942e-10
interaction O 0 1.0123389904137525e-09
with O 0 6.899339433097396e-10
SF O 1 0.9854040741920471
- O 0 4.010260454379022e-05
1 O 0 4.765184712596238e-06
. O 0 2.4726267611185904e-07

We O 0 1.2330129948168178e-06
propose O 0 6.542737196468806e-07
that O 0 3.824845862254733e-08
WT1 O 0 0.00010488587577128783
and O 0 6.351939418891561e-07
Dax O 0 0.026061134412884712
- O 0 1.355739550490398e-05
1 O 0 9.53011522142333e-07
functionally O 0 9.354508279102447e-08
oppose O 0 8.991268174440847e-09
each O 0 4.192930447288745e-10
other O 0 7.901069798421645e-10
in O 0 4.6235619777235115e-09
testis O 0 2.98475356430572e-07
development O 0 4.411547127602944e-09
by O 0 4.605226200382617e-10
modulating O 0 2.0357903451895254e-07
SF O 0 0.0026877946220338345
- O 0 5.24067127116723e-06
1 O 0 7.73830095113226e-07
- O 0 1.7441809063711844e-07
mediated O 0 9.832033356360625e-07
transactivation O 0 1.2656698345381301e-05
. O 0 2.7969081273226948e-08
. O 0 5.817483739178897e-08

A O 0 1.8300852389074862e-05
mouse O 0 1.4744146028533578e-06
model O 0 4.233443817724947e-08
for O 0 1.1733876448261071e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999998807907104
centre O 0 8.22196961962618e-05
mutations O 0 8.34935605098508e-08
. O 0 5.579391526566724e-08

Imprinting O 0 6.036894774297252e-05
in O 0 4.3714948105844087e-07
the O 0 4.096313830359577e-07
15q11 O 0 2.7670353119901847e-06
- O 0 5.466577590595989e-07
q13 O 0 1.4836846276011784e-06
region O 0 2.036007273886753e-08
involves O 0 2.039544000353999e-08
an O 0 1.751689016060709e-09
imprinting O 0 3.6632795286095643e-07
centre O 0 1.0360321311964071e-06
( O 0 1.9270305351426487e-09
IC O 0 6.545464543705748e-07
) O 0 8.638077475531247e-10
, O 0 3.1023469904134515e-10
mapping O 0 3.054390740331314e-09
in O 0 1.3933434406254719e-09
part O 0 5.805022240679136e-09
to O 0 3.121091607383164e-09
the O 0 3.9602159773721723e-08
promoter O 0 7.66176185607037e-07
and O 0 1.5345507975439432e-08
first O 0 4.901036732007924e-08
exon O 0 4.459904801024095e-07
of O 0 2.2713611258495803e-07
SNRPN O 0 0.00034997283364646137
. O 0 2.174773499064031e-06

Deletion O 0 1.1754001207009424e-05
of O 0 9.041485213856504e-07
this O 0 4.683493060042565e-08
IC O 0 3.212388764950447e-05
abolishes O 0 9.286621207138523e-06
local O 0 5.949038239805304e-08
paternally O 0 4.297257660823561e-08
derived O 0 2.4654620567332586e-09
gene O 0 8.363086889673355e-10
expression O 0 1.013466741084379e-10
and O 0 2.829408755899987e-11
results O 0 5.105195086119174e-11
in O 0 1.4690257010840924e-08
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.7332572340965271
PWS B-Disease 1 1.0
) O 0 2.675403720786562e-07
. O 0 2.799345111270668e-07

We O 0 7.600448839184537e-07
have O 0 9.278061874340437e-09
created O 0 2.430988033097492e-08
two O 0 2.0519668186835816e-09
deletion O 0 3.103539825133339e-08
mutations O 0 3.6895448918272677e-09
in O 0 1.5341342640695643e-09
mice O 0 3.4595355913324966e-08
to O 0 1.6284312565062464e-08
understand O 0 9.382808457303327e-06
PWS B-Disease 1 1.0
and O 0 1.7872387616080232e-05
the O 0 1.9356669156422868e-07
mechanism O 0 8.178687238569182e-08
of O 0 1.5293963429030555e-08
this O 0 2.906980656192104e-09
IC O 0 1.1037069270969369e-05
. O 0 2.6062352276312595e-07

Mice O 0 0.00010670160554582253
harbouring O 0 9.146826778305694e-05
an O 0 1.6155685500507388e-07
intragenic O 0 3.6822348192799836e-05
deletion O 0 4.258592070982559e-06
in O 0 1.1682670475465784e-07
Snrpn O 0 0.00044785597128793597
are O 0 2.402308751925375e-08
phenotypically O 0 0.0002559185668360442
normal O 0 2.9037046260782517e-06
, O 0 1.450092046439977e-09
suggesting O 0 1.2323848608275512e-09
that O 0 9.094157371603018e-11
mutations O 0 1.5378843754021432e-09
of O 0 1.672714766698391e-08
SNRPN O 0 9.53106937231496e-05
are O 0 1.1611876737926963e-10
not O 0 1.5184338508777984e-10
sufficient O 0 1.7646877736865463e-08
to O 0 1.503739355257494e-08
induce O 0 2.8833756005042233e-06
PWS B-Disease 1 1.0
. O 0 8.263620838988572e-05

Mice O 0 7.990856829565018e-06
with O 0 1.6838447081113372e-08
a O 0 5.467397201641688e-08
larger O 0 5.362261745744945e-08
deletion O 0 1.892232432965102e-07
involving O 0 6.42365005631973e-09
both O 0 5.320925478002891e-09
Snrpn O 0 1.2161773156549316e-05
and O 0 9.344879714490162e-08
the O 0 3.2908371849771356e-07
putative O 0 0.0010769406799227
PWS O 1 1.0
- O 0 0.020002029836177826
IC O 0 7.223380816867575e-05
lack O 0 7.63785521940008e-07
expression O 0 1.1796570831279496e-08
of O 0 1.6701992677781163e-08
the O 0 1.5361496963350874e-08
imprinted O 0 1.9897536063240295e-08
genes O 0 4.380506624102054e-09
Zfp127 O 0 1.494290472692228e-06
( O 0 4.216325510952856e-09
mouse O 0 4.905053287984629e-07
homologue O 0 4.6354853111552075e-06
of O 0 1.6686524304532213e-06
ZNF127 O 0 0.013517523184418678
) O 0 3.789453018043787e-08
, O 0 1.5362493499537777e-08
Ndn O 0 1.5615392840118147e-05
and O 0 1.6721604367830878e-07
Ipw O 0 4.763721790368436e-06
, O 0 5.748575393482724e-09
and O 0 2.287659173205725e-09
manifest O 0 2.0485853013951782e-08
several O 0 2.164342927102325e-09
phenotypes O 0 5.2023306551518544e-08
common O 0 1.415240831192932e-07
to O 0 6.314890015346464e-07
PWS B-Disease 1 1.0
infants O 1 0.9999885559082031
. O 0 1.0353780453442596e-05

These O 0 1.0511621439945884e-07
data O 0 1.1716153380803007e-07
demonstrate O 0 1.5709145984033057e-08
that O 0 6.026854570961859e-10
both O 0 1.0733665067874654e-09
the O 0 9.927893174221936e-09
position O 0 1.0037053499445392e-07
of O 0 3.758715649837541e-08
the O 0 2.9462572825877942e-08
IC O 0 8.270043281299877e-07
and O 0 2.820095934552569e-09
its O 0 9.482494789381235e-10
role O 0 2.736518123214182e-09
in O 0 1.6264926905318333e-10
the O 0 1.4312255824933118e-09
coordinate O 0 7.694538339819701e-10
expression O 0 1.5036754064112756e-09
of O 0 9.549784074636136e-09
genes O 0 7.603038199022194e-10
is O 0 1.7454845901987426e-10
conserved O 0 9.404664824685938e-10
between O 0 3.7310998735051726e-09
mouse O 0 6.108729166953708e-07
and O 0 4.232230566003636e-09
human O 0 1.6735125285549657e-08
, O 0 6.682708830751949e-10
and O 0 6.253265683042741e-10
indicate O 0 6.606704627820648e-10
that O 0 7.725243222900247e-10
the O 0 7.465409623819141e-08
mouse O 0 1.5824390686702827e-07
is O 0 5.291885263325469e-10
a O 0 8.26376189699829e-10
suitable O 0 2.2724568893295327e-08
model O 0 6.14556228129004e-09
system O 0 5.603793340469565e-08
in O 0 9.416942781115267e-10
which O 0 1.2438350349697203e-10
to O 0 2.110325109105915e-10
investigate O 0 8.351577762688578e-10
the O 0 1.3020325928536636e-09
molecular O 0 8.065780043864379e-09
mechanisms O 0 2.1880781631011814e-08
of O 0 7.734742624165847e-09
imprinting O 0 1.3513931662600953e-07
in O 0 8.383625460517408e-10
this O 0 3.5255184882565516e-10
region O 0 4.6964792055348425e-09
of O 0 1.6350512055396393e-08
the O 0 1.9489624136781458e-08
genome O 0 9.089102803727656e-09
. O 0 6.194695867378641e-09
. O 0 8.577470822501709e-08

Mutations O 0 2.1075221923183562e-07
of O 0 2.590554402104317e-07
the O 0 7.224014808571155e-08
ATM O 0 3.170809179664502e-07
gene O 0 4.10172118492369e-09
detected O 0 8.971157150483577e-09
in O 0 2.36549624332838e-09
Japanese O 0 0.3205813467502594
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
: O 0 6.393226836820531e-09
possible O 0 2.1995221644033336e-08
preponderance O 0 6.262715942284558e-06
of O 0 2.2472937644124613e-07
the O 0 6.636365412759915e-08
two O 0 1.301621299631961e-08
founder O 0 4.7136046532614273e-07
mutations O 0 7.768896637116995e-09
4612del165 O 0 5.328855081643269e-07
and O 0 1.3645393437400344e-07
7883del5 O 0 1.403470196237322e-05
. O 0 2.455177991578239e-06

The O 0 1.118806358135771e-05
ATM O 0 3.465162808424793e-05
( O 0 3.3548568012520263e-07
A O 1 1.0
- O 1 0.9999998807907104
T O 1 1.0
, O 0 4.993810698294965e-09
mutated O 0 2.3721786757135988e-09
) O 0 1.1489867390857e-10
gene O 0 6.037059185892701e-10
on O 0 7.82338016591666e-09
human O 0 5.988036733128865e-09
chromosome O 0 1.3023444012105756e-07
11q22 O 0 2.8980416573176626e-06
. O 0 7.179700673987099e-07

3 O 0 6.644605309702456e-05
has O 0 2.729232484455224e-08
recently O 0 4.802024555772277e-09
been O 0 4.427687938513003e-10
identified O 0 3.372495893660954e-10
as O 0 8.941356682834467e-11
the O 0 2.736584570062206e-10
gene O 0 2.615269945049903e-10
responsible O 0 3.04845287901756e-10
for O 0 1.5044951395815076e-10
the O 0 9.015997726180558e-09
human O 0 4.2149929413426435e-07
recessive B-Disease 1 0.994449257850647
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9999998807907104
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.718397925287718e-06
. O 0 2.1140028820809675e-06

In O 0 3.3607361160647997e-07
order O 0 1.766112944778797e-07
to O 0 1.2305743979368344e-08
define O 0 6.486267523087008e-09
the O 0 2.8042781430315245e-09
types O 0 5.0634234582958015e-09
of O 0 3.1682667156474054e-08
disease O 0 2.935187512775883e-05
- O 0 1.911075315774724e-07
causing O 0 9.14841535859523e-08
ATM O 0 3.2601184329905664e-07
mutations O 0 1.588306930422334e-09
in O 0 2.2760082707407037e-09
Japanese O 0 0.00012857592082582414
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.1780451238155365
as O 0 1.337622421715423e-07
well O 0 8.339293700032613e-09
as O 0 2.244790131555874e-09
to O 0 1.3583565383612495e-09
look O 0 4.0043288684898926e-09
for O 0 2.8141318164642826e-09
possible O 0 1.3452186919948872e-07
mutational O 0 5.100147609482519e-05
hotspots O 0 1.1117928124804166e-06
, O 0 1.2353336131809556e-09
reverse O 0 1.2893408118941352e-08
- O 0 1.3651127339642244e-08
transcribed O 0 8.091323722148047e-10
RNA O 0 2.7805984181838994e-09
derived O 0 1.8082614572367817e-10
from O 0 8.274629315074833e-10
ten O 0 1.971762086938611e-09
patients O 0 6.306458688598582e-10
belonging O 0 3.4303206941643793e-09
to O 0 4.787045426724035e-09
eight O 0 1.941071481326162e-08
unrelated O 0 2.706238717564702e-07
Japanese O 0 0.006163646932691336
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 2.112929706754585e-07
was O 0 4.201756809152357e-08
analyzed O 0 2.9757687980414005e-10
for O 0 3.782183247147408e-11
mutations O 0 2.712983483699194e-11
by O 0 3.853588628754956e-11
the O 0 4.100782380334067e-09
restriction O 0 3.6387923785241583e-09
endonuclease O 0 9.662320366032873e-08
fingerprinting O 0 1.1664185173287933e-08
method O 0 2.1909595915303726e-08
. O 0 4.086316351958885e-08

As O 0 2.489091684765299e-06
has O 0 9.998966987723179e-09
been O 0 7.445934424588074e-10
reported O 0 1.510043756702828e-10
by O 0 5.107396450210189e-11
others O 0 8.440358967298778e-10
, O 0 1.480215533478102e-10
mutations O 0 1.503531327218255e-10
that O 0 1.6292095450509692e-10
lead O 0 2.7923720224976023e-08
to O 0 2.763738216060574e-08
exon O 0 1.8571485043139546e-06
skipping O 0 1.878151607570544e-07
or O 0 3.0099478465217544e-08
premature O 0 5.368688604789895e-08
protein O 0 1.931240944941237e-08
truncation O 0 5.040338919570786e-07
were O 0 3.377500945589418e-08
also O 0 5.647084133642011e-09
predominant O 0 1.0632714975145063e-06
in O 0 2.593257875105337e-08
our O 0 7.328433184738969e-07
mutants O 0 1.425455707249057e-06
. O 0 2.457909147324244e-07

Six O 0 2.726717411860591e-07
different O 0 1.8484168640142684e-09
mutations O 0 1.810626537590565e-09
were O 0 1.0362372071526238e-09
identified O 0 3.7483616210920445e-09
on O 0 1.5336757641648546e-08
12 O 0 3.872639542379375e-09
of O 0 2.1355493373675927e-08
the O 0 1.2157303785897966e-07
16 O 0 9.840572090524802e-08
alleles O 0 4.027668865091982e-09
examined O 0 7.560102517345513e-07
. O 0 1.3369888165470911e-06

Four O 0 6.661290399279096e-07
were O 0 2.7742055763724238e-08
deletions O 0 1.1146129708095032e-07
involving O 0 1.2740497545848939e-08
a O 0 2.9447571492369207e-08
loss O 0 4.170347551735176e-07
of O 0 2.8672739063040353e-06
a O 0 8.214094577851938e-07
single O 0 1.729124505800428e-07
exon O 0 5.703417400582111e-07
exon O 0 3.421143048853992e-07
7 O 0 1.3883176563922461e-07
, O 0 1.4107091050874487e-09
exon O 0 8.527765515964347e-08
16 O 0 1.284787458644132e-07
, O 0 1.159035800668562e-08
exon O 0 9.354845360576292e-07
33 O 0 4.0621688413011725e-07
or O 0 6.211511305309614e-08
exon O 0 6.058322924218373e-06
35 O 0 2.1310670490493067e-06
. O 0 5.78060621592158e-07

The O 0 7.068928880471503e-06
others O 0 3.107093959897611e-07
were O 0 5.9501957139218575e-08
minute O 0 7.811855198269768e-07
deletions O 0 3.718938330621313e-07
, O 0 6.594559120998156e-09
4649delA O 0 3.556862395726057e-07
in O 0 1.1195963267596198e-08
exon O 0 5.087939030090638e-07
33 O 0 1.6608572650511633e-07
and O 0 1.677542371680829e-08
7883del5 O 0 8.45256806769612e-07
in O 0 7.635991750021276e-08
exon O 0 3.283687419752823e-06
55 O 0 7.842235731914116e-07
. O 0 1.9136886919568497e-07

The O 0 1.1383859600755386e-05
mutations O 0 4.592350251186872e-07
4612del165 O 0 2.037679450950236e-06
and O 0 3.1397998867532806e-08
7883del5 O 0 5.152442668077128e-07
were O 0 1.1879957462213042e-08
found O 0 1.807238358964014e-09
in O 0 2.1137494532474932e-10
more O 0 1.1359336214711302e-11
than O 0 2.11867658833631e-11
two O 0 1.220838430349147e-10
unrelated O 0 2.1676231920508826e-09
families O 0 1.5010355458588975e-10
; O 0 1.8122149614274718e-10
44 O 0 3.17788173553879e-09
% O 0 6.315366563036662e-10
( O 0 3.6910632883468963e-10
7 O 0 6.904019045350651e-08
of O 0 4.366728134641562e-08
16 O 0 2.4690585576081503e-08
) O 0 5.232787536613159e-10
of O 0 1.2405028115836103e-08
the O 0 5.239833811288008e-08
mutant O 0 1.1929594201376403e-08
alleles O 0 2.9182900540547507e-10
had O 0 3.5786631435996696e-09
one O 0 4.3559261753145506e-10
of O 0 3.6458787100457357e-09
the O 0 2.6639765948743843e-08
two O 0 1.4138561432730512e-08
mutations O 0 3.5004891429935014e-08
. O 0 1.3735284198901354e-07

The O 0 6.851872967672534e-06
4612del165 O 0 5.836649961565854e-06
mutations O 0 1.1628821461329153e-08
in O 0 2.2892654438777527e-09
three O 0 1.3756265571096549e-10
different O 0 6.414423853184914e-11
families O 0 6.374860639368762e-10
were O 0 1.7274350838647479e-09
all O 0 2.494555950693922e-10
ascribed O 0 9.849356885638372e-09
to O 0 2.9862321504481315e-09
the O 0 4.2294729496461514e-08
same O 0 1.8313347283083203e-08
T O 0 1.7330701496121037e-07
- O 0 8.766688353034624e-08
- O 0 4.998444680381908e-08
> O 0 3.4692359207610934e-08
A O 0 1.4558071192993793e-08
substitution O 0 1.3266859610894244e-08
at O 0 9.788453603221114e-09
the O 0 3.92404064797347e-09
splice O 0 1.5291635691028205e-07
donor O 0 6.47545173038111e-09
site O 0 2.4024233269415163e-08
in O 0 3.5340976811681912e-09
intron O 0 1.0406732144474518e-05
33 O 0 3.595397629396757e-06
. O 0 7.52374546664214e-07

Microsatellite O 0 0.0006683343090116978
genotyping O 0 2.7717900593415834e-05
around O 0 7.073151664371835e-08
the O 0 1.5296565436528908e-07
ATM O 0 1.5904000747468672e-06
locus O 0 5.248145384939562e-08
also O 0 6.329547996841711e-10
indicated O 0 2.8457064482623196e-10
that O 0 2.097391010869032e-11
a O 0 3.9024530829046e-10
common O 0 3.1887805729269303e-09
haplotype O 0 2.5294247052443097e-07
was O 0 5.151360937816207e-08
shared O 0 1.1542942157660718e-09
by O 0 8.061773471013112e-11
the O 0 3.563773054438002e-09
mutant O 0 3.4554517025497944e-09
alleles O 0 2.19498128006812e-10
in O 0 5.437523764584284e-10
both O 0 4.2300354330393475e-09
mutations O 0 4.6602444569998625e-08
. O 0 3.363737164363556e-07

This O 0 3.799918957270165e-08
suggests O 0 5.914098988313299e-09
that O 0 6.367311539134946e-11
these O 0 9.92644369479656e-11
two O 0 1.7879218106031658e-09
founder O 0 2.768474018921552e-07
mutations O 0 1.975680952170933e-09
may O 0 2.301374868451944e-09
be O 0 1.845605668293615e-09
predominant O 0 2.9215661356829514e-07
among O 0 1.472958532922064e-09
Japanese O 0 2.7144608338858234e-07
ATM O 0 1.6072376638476271e-06
mutant O 0 2.2667084920158231e-07
alleles O 0 8.803044515559577e-09
. O 0 9.442598525311041e-08

W474C O 0 3.6269339034333825e-05
amino O 0 2.4263260911538964e-07
acid O 0 2.957799694058849e-08
substitution O 0 2.407124632952673e-08
affects O 0 1.2856957720686069e-09
early O 0 2.0342991291499857e-08
processing O 0 2.366458673463967e-08
of O 0 2.5409857329350416e-08
the O 0 2.8424707920748915e-08
alpha O 0 1.1140982358881502e-08
- O 0 1.906509838889292e-09
subunit O 0 4.200416459099188e-09
of O 0 5.372045475127152e-09
beta O 0 4.671154840707459e-08
- O 0 2.974937629574015e-08
hexosaminidase O 0 7.793418177470812e-08
A O 0 2.800666365487814e-08
and O 0 6.507813732348211e-10
is O 0 1.0881189005385039e-10
associated O 0 1.6858170415190443e-09
with O 0 1.09942444037614e-09
subacute O 0 0.03278129920363426
G B-Disease 0 0.0004243697039783001
( I-Disease 0 3.126503145267634e-08
M2 I-Disease 0 4.813976829609601e-06
) I-Disease 0 2.9027770409584264e-08
gangliosidosis I-Disease 0 1.1523363355081528e-05
. O 0 7.114580284905969e-07

Mutations O 0 1.2749645748044713e-06
in O 0 1.4818249383097282e-07
the O 0 5.934169280408241e-07
HEXA O 0 1.407509989803657e-05
gene O 0 7.018908121381173e-09
, O 0 4.3549708284018607e-10
encoding O 0 2.2591966075680148e-09
the O 0 3.4531673520632467e-08
alpha O 0 1.7816621067368033e-08
- O 0 2.8702760168641817e-09
subunit O 0 2.7151603188002582e-09
of O 0 2.2746467820411453e-08
beta O 0 1.1530431009987296e-07
- O 0 2.8466109824876185e-07
hexosaminidase O 0 1.469089625061315e-06
A O 0 6.692089300486259e-07
( O 0 4.808596187899639e-09
Hex O 0 2.782367403142416e-07
A O 0 1.2983387875920016e-07
) O 0 5.889039256246065e-10
, O 0 1.55682508551358e-10
that O 0 1.4167918227503407e-10
abolish O 0 9.833123471025829e-08
Hex O 0 9.33193575747282e-07
A O 0 6.158331444794385e-08
enzyme O 0 1.6034325867053667e-08
activity O 0 4.7412296311222235e-09
cause O 0 1.0503877092560288e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
( O 0 1.3763576056646798e-08
TSD B-Disease 0 0.0004903649678453803
) O 0 2.959666289825691e-09
, O 0 7.553301872853524e-10
the O 0 4.2943160138975145e-08
fatal O 0 2.2634023935097503e-06
infantile B-Disease 0 4.97085920869722e-07
form I-Disease 0 2.115905317623401e-08
of I-Disease 0 2.6544124921201728e-05
G I-Disease 0 1.5539126252406277e-05
( I-Disease 0 5.079567877430691e-09
M2 I-Disease 0 3.3414332278880465e-07
) I-Disease 0 1.440619623593875e-09
gangliosidosis I-Disease 0 3.608312226788257e-07
, I-Disease 0 4.5060258302420664e-10
Type I-Disease 0 2.1403903360805998e-07
1 I-Disease 0 3.072273784709978e-06
. O 0 2.4926950459303043e-07

Less O 0 1.891964870992524e-06
severe O 0 0.007614263333380222
, O 0 1.636583846220674e-07
subacute O 1 0.9999921321868896
( O 0 1.688795521204156e-07
juvenile O 0 0.34475600719451904
- O 0 1.3498515727405902e-05
onset O 1 1.0
) O 0 1.601492414238237e-07
and O 0 3.417197262933769e-07
chronic O 1 0.9999992847442627
( O 0 1.2576392371954626e-08
adult O 0 2.9333165230127634e-07
- O 0 5.056410259385302e-07
onset O 0 0.0011541645508259535
) O 0 2.351818739754208e-10
variants O 0 1.7627895809724237e-09
are O 0 9.388525547271431e-12
characterized O 0 1.2704545748754015e-10
by O 0 2.568355944587708e-11
a O 0 1.3662947440096218e-09
broad O 0 2.4933600073495654e-08
spectrum O 0 1.01286907749909e-07
of O 0 2.6609436876157133e-09
clinical O 0 2.396373233182203e-08
manifestations O 0 2.8222723358339863e-07
and O 0 7.415250635744997e-10
are O 0 3.246642538146105e-12
associated O 0 1.3327867975920782e-10
with O 0 2.1303063479916062e-11
residual O 0 1.6693529403255525e-07
levels O 0 5.1976591919355997e-08
of O 0 2.9086359631946834e-07
Hex O 0 2.091730721076601e-06
A O 0 2.4467021830787417e-07
enzyme O 0 5.139084180427744e-08
activity O 0 1.057776621848916e-08
. O 0 3.281638072394344e-08

We O 0 9.722120921651367e-07
identified O 0 3.942799082778947e-07
a O 0 1.3873250281903893e-07
1422 O 0 4.425752194947563e-06
G O 0 6.765899343008641e-07
- O 0 6.513631660709507e-07
- O 0 4.45892254674618e-07
> O 0 1.9061970135680895e-07
C O 0 2.2550526068698673e-07
( O 0 2.7123225887493163e-10
amino O 0 1.7506360250330033e-10
acid O 0 5.975380745759651e-10
W474C O 0 2.7317517137248615e-09
) O 0 4.983374823908093e-12
substitution O 0 6.436438049206572e-10
in O 0 5.271937886242029e-10
the O 0 2.5918223123255757e-09
first O 0 2.9670932377712234e-09
position O 0 3.476190713058713e-08
of O 0 3.967769046653302e-08
exon O 0 1.3577827928656916e-07
13 O 0 3.821965322003962e-08
of O 0 6.906481786472796e-08
HEXA O 0 0.00011372174049029127
of O 0 7.742257253084972e-07
a O 0 2.6860186608246295e-07
non O 0 4.590874311816151e-07
- O 0 1.4341442238219315e-06
Jewish O 0 7.100109655766573e-07
proband O 0 9.406620665686205e-05
who O 0 4.220479254968268e-08
manifested O 0 6.580113165455259e-08
a O 0 4.7902627642315565e-08
subacute O 0 3.115225990768522e-05
variant O 0 2.5607627321733162e-05
of O 0 0.21917858719825745
G B-Disease 0 0.03246106207370758
( I-Disease 0 3.2704406294215005e-08
M2 I-Disease 0 3.638146154116839e-06
) I-Disease 0 1.4706208695258738e-08
gangliosidosis I-Disease 0 5.4210404414334334e-06
. O 0 6.600658366551215e-07

On O 0 2.3987842723727226e-05
the O 0 1.0432798944748356e-06
second O 0 8.143140348693123e-07
maternally O 0 3.0269259809756477e-07
inherited O 0 1.315914346378122e-06
allele O 0 6.184710343859479e-08
, O 0 1.226038159884979e-09
we O 0 2.6495927674119457e-10
identified O 0 1.51096357647873e-09
the O 0 3.511722246329896e-09
common O 0 1.4126425185168046e-06
infantile O 0 0.011762591078877449
disease O 0 0.10258101671934128
- O 0 3.43675424119283e-07
causing O 0 6.323314778455824e-07
4 O 0 1.9581698325055186e-06
- O 0 2.317153899866753e-07
bp O 0 3.409898567952041e-07
insertion O 0 1.0818128259870718e-07
, O 0 5.732982977235679e-09
+ O 0 3.459991049226119e-08
TATC O 0 9.116371074924245e-06
1278 O 0 7.2061225182551425e-06
, O 0 2.2927786336168765e-09
in O 0 6.218467074603495e-09
exon O 0 6.665509886261134e-07
11 O 0 2.49087946713189e-07
. O 0 2.106836802795442e-07

Pulse O 0 0.0002840996894519776
- O 0 1.3043799299339298e-05
chase O 0 2.1687620233024063e-07
analysis O 0 6.504628391468259e-09
using O 0 6.511219563520854e-09
proband O 0 1.2703428637905745e-06
fibroblasts O 0 9.725629013246362e-08
revealed O 0 8.810910401280125e-08
that O 0 1.0974529063290106e-09
the O 0 2.4419179567303217e-08
W474C O 0 8.715172583606545e-08
- O 0 8.503252324487676e-09
containing O 0 1.7684607112045114e-09
alpha O 0 1.7833588827897984e-08
- O 0 1.130978066754551e-08
subunit O 0 6.597578483535926e-09
precursor O 0 5.18670582039249e-08
was O 0 2.0802030320510312e-08
normally O 0 1.4732669251227293e-10
synthesized O 0 1.6623675769267265e-09
, O 0 6.51917825278403e-11
but O 0 6.035087707356723e-11
not O 0 3.3562014278842867e-11
phosphorylated O 0 8.97088359153031e-09
or O 0 1.5234038475142597e-09
secreted O 0 4.919969986971751e-10
, O 0 1.2540114779913125e-10
and O 0 1.0569392028259017e-09
the O 0 2.6747549952688132e-08
mature O 0 2.0632077379900693e-08
lysosomal O 0 1.2380550060697715e-06
alpha O 0 8.871329981730014e-08
- O 0 2.7757725007404588e-08
subunit O 0 2.5555669580512586e-08
was O 0 3.6575610096178934e-08
not O 0 9.331405648183022e-10
detected O 0 1.5138134301651007e-07
. O 0 5.808934844253599e-08

When O 0 3.292150722700171e-06
the O 0 4.581680741466698e-07
W474C O 0 3.0574179277209623e-07
- O 0 2.6570905475864492e-08
containing O 0 3.266387160749673e-09
alpha O 0 1.1226541474229634e-08
- O 0 1.0406367323412269e-08
subunit O 0 3.088740641032928e-08
was O 0 9.854583993273991e-08
transiently O 0 5.1937846023975e-08
co O 0 8.974238241421517e-09
- O 0 4.164947053908463e-09
expressed O 0 1.6771897204392872e-09
with O 0 3.2532287974618157e-10
the O 0 9.850502635799785e-09
beta O 0 1.0501837621745835e-08
- O 0 7.493738962693897e-09
subunit O 0 2.530117448884539e-09
to O 0 1.0899328106717121e-09
produce O 0 8.511495508400913e-09
Hex O 0 1.4087115687289042e-06
A O 0 1.125799713008746e-06
( O 0 2.0628760921681533e-09
alphabeta O 0 2.6856702106670127e-07
) O 0 5.295944238703498e-10
in O 0 2.168057511298116e-09
COS O 0 3.325329771541874e-06
- O 0 6.594441970264597e-07
7 O 0 1.575618995275363e-07
cells O 0 5.7351048354803424e-09
, O 0 3.81000286875377e-10
the O 0 6.444672351335612e-09
mature O 0 3.001489945475555e-09
alpha O 0 8.28741164582425e-09
- O 0 5.274062520044254e-09
subunit O 0 4.499620676057248e-09
was O 0 1.4316577257034169e-08
present O 0 8.778560656175216e-10
, O 0 8.45350178746429e-11
but O 0 8.968205345016855e-11
its O 0 4.707866874120725e-10
level O 0 2.0667288325171285e-08
was O 0 2.7035396144015067e-08
much O 0 1.4549014215603506e-09
lower O 0 8.37487146299054e-09
than O 0 4.5798472653180156e-11
that O 0 4.0222904867937004e-11
from O 0 6.579303768461386e-10
normal O 0 1.3447538194100161e-08
alpha O 0 3.917700652777967e-08
- O 0 1.972496654900624e-08
subunit O 0 1.618152012383689e-08
transfections O 0 1.1647505715473017e-07
, O 0 1.014487868711278e-10
although O 0 1.3113432562050775e-10
higher O 0 2.1510253578327365e-09
than O 0 1.2037923435848086e-10
in O 0 2.753984540415644e-10
those O 0 1.6391712986951745e-10
cells O 0 1.3804345444512478e-09
transfected O 0 5.30231751838528e-08
with O 0 3.213390387113435e-10
an O 0 4.046925572431803e-10
alpha O 0 1.0178030862562082e-08
- O 0 1.6036315386713795e-08
subunit O 0 1.6484566600638573e-08
associated O 0 1.773802615900877e-08
with O 0 1.1229668750445398e-08
infantile O 0 8.068345778156072e-05
TSD B-Disease 0 0.000699796830303967
. O 0 1.8137939150619786e-06

Furthermore O 0 2.735951284194016e-06
, O 0 4.046998824946968e-08
the O 0 3.3124901932524153e-08
precursor O 0 3.4555199590613483e-07
level O 0 3.740935881069163e-07
of O 0 1.1730341498150665e-07
the O 0 7.291458103964032e-08
W474C O 0 1.1405926869656469e-07
alpha O 0 2.494863160507066e-08
- O 0 6.454834000635401e-09
subunit O 0 5.128799607234669e-09
was O 0 1.592384535342717e-08
found O 0 5.772470279552522e-10
to O 0 3.432557571514394e-10
accumulate O 0 4.074275139487327e-09
in O 0 6.156587462058383e-10
comparison O 0 4.283621901635115e-09
to O 0 2.6917397200065807e-09
the O 0 3.478777443888248e-08
normal O 0 6.870101998401879e-08
alpha O 0 1.1975879488090868e-07
- O 0 4.231393191389543e-08
subunit O 0 1.7226058801611543e-08
precursor O 0 6.468491875466498e-08
levels O 0 3.159817651976482e-08
. O 0 3.35862715417079e-08

We O 0 8.381649081456999e-07
conclude O 0 4.927868531012791e-07
that O 0 6.3216125667509004e-09
the O 0 7.825726555665824e-08
1422 O 0 3.41318241225963e-06
G O 0 4.1187871602232917e-07
- O 0 2.6767332883537165e-07
- O 0 1.0046399268048845e-07
> O 0 2.5858787111587844e-08
C O 0 5.713206618906952e-08
mutation O 0 1.7292077492125912e-10
is O 0 1.29240663310215e-11
the O 0 1.064728583077823e-10
cause O 0 2.348655048223236e-09
of O 0 3.853962127209343e-08
Hex B-Disease 0 2.904682514781598e-05
A I-Disease 0 0.0020314985886216164
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.850202480113694e-08
the O 0 1.4979490003952378e-07
proband O 0 1.2105292626074515e-05
. O 0 6.559668008776498e-07

The O 0 2.6436193820700282e-06
resulting O 0 8.139514875438181e-07
W474C O 0 9.390348623128375e-07
substitution O 0 1.776579807710732e-07
clearly O 0 2.407767674128536e-08
interferes O 0 3.9186495826015744e-08
with O 0 7.522548139959895e-10
alpha O 0 1.0609024769792086e-08
- O 0 3.6194178765214247e-09
subunit O 0 2.2016659606549638e-09
processing O 0 3.6391532010071614e-09
, O 0 2.494041084766252e-11
but O 0 1.3544563040590596e-11
because O 0 5.279471998465013e-11
the O 0 3.3645031205509213e-10
base O 0 1.3649826158257383e-08
substitution O 0 1.2842994223660753e-08
falls O 0 3.4343298693784163e-07
at O 0 5.123323987277217e-09
the O 0 1.615314326741668e-09
first O 0 2.579876756669819e-09
position O 0 2.2262094390157472e-08
of O 0 6.107167394020507e-08
exon O 0 3.049860879400512e-07
13 O 0 2.691987788239203e-08
, O 0 6.284557318991801e-10
aberrant O 0 1.3029029410915882e-08
splicing O 0 1.7952376651919622e-07
may O 0 1.1881589045970031e-08
also O 0 9.912468623696213e-10
contribute O 0 1.876959476732054e-09
to O 0 4.381938012443243e-08
Hex B-Disease 0 0.0021724568214267492
A I-Disease 0 0.008893570862710476
deficiency I-Disease 1 0.9524426460266113
in O 0 1.2501391921659888e-08
this O 0 5.985524964557953e-09
proband O 0 1.7525640032545198e-06
. O 0 9.567322933889955e-09
. O 0 5.743657283119319e-08

Two O 0 2.760414474778372e-07
frequent O 0 3.284055765107041e-07
missense O 0 5.220025741436984e-06
mutations O 0 2.8009449692945054e-07
in O 0 6.25970301371126e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 7.183730485849082e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.2035003389173653e-07
an O 0 1.4258308738135383e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 4.523055395111442e-06
by O 0 4.470908643305904e-10
early O 0 0.00013191098696552217
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999998807907104
goiter B-Disease 1 1.0
. O 1 0.9979727864265442

A O 0 1.2722445717372466e-05
century O 0 3.7813454127899604e-06
after O 0 7.905252630280302e-08
its O 0 4.895220895306807e-10
recognition O 0 1.1729374804758663e-08
as O 0 4.919240570444572e-09
a O 0 2.2005082200848847e-08
syndrome O 0 9.69487246038625e-07
by O 0 4.845023271471405e-10
Vaughan O 0 1.7134460676970775e-06
Pendred O 0 4.1475886973785236e-05
, O 0 2.0573005521384857e-09
the O 0 1.308676100819639e-08
disease O 0 1.6108361933220294e-07
gene O 0 4.047630230985533e-09
( O 0 1.0401797201353702e-09
PDS O 0 3.5141879379807506e-06
) O 0 1.6752521592167113e-09
was O 0 4.0424941971650696e-07
mapped O 0 1.6695948090728052e-07
to O 0 3.6175286766138015e-08
chromosome O 0 6.46486569166882e-07
7q22 O 0 1.2438488738553133e-05
- O 0 6.587473762920126e-06
q31 O 0 1.7018628568621352e-05
. O 0 1.270722009394376e-06

1 O 0 2.9143024221411906e-05
and O 0 1.2259363302291604e-07
, O 0 5.773331590575026e-09
recently O 0 2.8146002861717534e-08
, O 0 4.451423119000708e-10
found O 0 6.186722245615783e-10
to O 0 6.129147189781747e-10
encode O 0 9.248591226196368e-09
a O 0 1.1364471674824017e-07
putative O 0 6.148065949673764e-06
sulfate O 0 0.00011698313755914569
transporter O 0 0.006171742919832468
. O 0 6.652689535258105e-06

We O 0 2.907590328504739e-07
performed O 0 2.1947155204316005e-08
mutation O 0 4.369406225723793e-10
analysis O 0 1.757564926929689e-10
of O 0 2.6356219429146677e-09
the O 0 1.2943254468211762e-08
PDS B-Disease 0 3.820019628619775e-06
gene O 0 3.665905357053134e-09
in O 0 5.041910777769942e-10
patients O 0 5.6471058940132934e-09
from O 0 2.732404524863341e-08
14 O 0 1.5112100015812757e-07
Pendred B-Disease 0 1.1101697054982651e-05
families O 0 4.923952801050291e-09
originating O 0 2.575525792636313e-09
from O 0 3.2125218041301196e-09
seven O 0 7.444471705753131e-10
countries O 0 2.63678089779118e-11
and O 0 3.066614295832437e-09
identified O 0 2.6579421330552577e-08
all O 0 1.5451709245439815e-08
mutations O 0 8.392176908955662e-08
. O 0 1.384322274589067e-07

The O 0 1.8075239722747938e-06
mutations O 0 3.732105113840589e-08
include O 0 7.2627370784061895e-09
three O 0 8.54141912753903e-09
single O 0 2.2258271670239083e-08
base O 0 2.264227077830583e-06
deletions O 0 1.1267019317529048e-06
, O 0 1.1434784674690945e-08
one O 0 1.329832510776896e-08
splice O 0 6.599295375053771e-06
site O 0 1.15983894488636e-07
mutation O 0 2.428669487741786e-09
and O 0 1.858017184552807e-09
10 O 0 1.3260737397047251e-08
missense O 0 5.714415465263301e-07
mutations O 0 1.0953898765819758e-07
. O 0 6.122872946434654e-07

One O 0 1.8656105567060877e-06
missense O 0 2.7209659947402542e-06
mutation O 0 3.1740185590933834e-08
( O 0 1.702263330294329e-09
L236P O 0 1.039782020484381e-07
) O 0 7.242371702353978e-10
was O 0 6.818276432341008e-08
found O 0 3.660888259204853e-09
in O 0 1.0488361290583725e-09
a O 0 4.138545950382877e-09
homozygous O 0 9.78467751266976e-10
state O 0 2.791437359039861e-10
in O 0 5.218395160433431e-10
two O 0 1.7579412370238856e-09
consanguineous O 0 1.666443608883128e-06
families O 0 4.893972338493313e-09
and O 0 3.898600997587209e-09
in O 0 1.3750082183960899e-09
a O 0 6.25571416890125e-09
heterozygous O 0 1.3140974419734164e-10
state O 0 1.42450898299451e-10
in O 0 5.140137759873653e-10
five O 0 8.301962450829592e-10
additional O 0 3.0118585403471343e-09
non O 0 1.003106035568635e-06
- O 0 2.164680336136371e-05
consanguineous O 0 0.001495475065894425
families O 0 4.4556708189702476e-07
. O 0 2.971802075535379e-07

Another O 0 2.2331726086122217e-06
missense O 0 3.105220685029053e-06
mutation O 0 2.684378941353316e-08
( O 0 1.3139402899042807e-09
T416P O 0 7.024588910553575e-08
) O 0 3.266074077856729e-10
was O 0 1.4364116118770198e-08
found O 0 5.543458470036455e-10
in O 0 2.958157885313284e-10
a O 0 2.09128936390357e-09
homozygous O 0 1.0157643615116285e-09
state O 0 3.3321181924783616e-10
in O 0 8.1646206462338e-10
one O 0 2.953378652748029e-09
family O 0 8.51612380614597e-09
and O 0 7.920277211859172e-10
in O 0 1.0278751183534496e-09
a O 0 1.2097966184398956e-08
heterozygous O 0 5.181875484261411e-10
state O 0 7.93877408256094e-10
in O 0 2.9673647983230467e-09
four O 0 1.9817280261236192e-08
families O 0 3.949707760853016e-08
. O 0 3.518395317314571e-07

Pendred B-Disease 0 0.024341097101569176
patients O 0 1.762940337357577e-05
in O 0 1.7769457372196484e-07
three O 0 1.951905517216801e-07
non O 0 3.979004759457894e-06
- O 0 3.646400000434369e-05
consanguineous O 0 0.15935568511486053
families O 0 1.4630522571223992e-07
were O 0 8.001379114830343e-09
shown O 0 8.138034690574614e-10
to O 0 4.453614144139806e-10
be O 0 6.875325864186266e-10
compound O 0 5.829546267932528e-08
heterozygotes O 0 3.5019581900996855e-08
for O 0 5.699196226061076e-09
L236P O 0 3.6902261513205303e-07
and O 0 3.249765612167721e-08
T416P O 0 2.5520998860883992e-06
. O 0 3.013483933500538e-07

In O 0 2.500611628875049e-07
total O 0 6.95621471535901e-09
, O 0 1.1214850159646517e-09
one O 0 3.362738976164792e-10
or O 0 4.431126021664511e-10
both O 0 5.911185985141287e-10
of O 0 5.661438429171994e-09
these O 0 2.7307656136343894e-10
mutations O 0 2.457512249254279e-10
were O 0 4.772965911392646e-10
found O 0 2.4084539917978987e-10
in O 0 5.880823050752326e-10
nine O 0 4.882876769585209e-09
of O 0 1.7521577078127848e-08
the O 0 1.9686370933413855e-07
14 O 0 9.504087472578249e-08
families O 0 3.360688838327519e-09
analyzed O 0 6.704597410589486e-08
. O 0 1.9323726974107558e-07

The O 0 2.067153417328882e-07
identification O 0 1.24877416851632e-07
of O 0 2.4455869152006926e-07
two O 0 2.786567421253494e-08
frequent O 0 6.367745442048545e-08
PDS B-Disease 0 2.408223008387722e-05
mutations O 0 1.945158700777938e-09
will O 0 1.561827611684663e-10
facilitate O 0 2.8715354538633164e-09
the O 0 1.1928456444820768e-08
molecular O 0 5.213481131249864e-07
diagnosis O 1 0.9906436800956726
of O 0 0.18578851222991943
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.440953363082372e-06

Insertional O 0 5.1600418373709545e-05
mutation O 0 1.0127570249096607e-07
by O 0 2.2318629167017434e-09
transposable O 0 1.489505848439876e-06
element O 0 4.6752151661166863e-07
, O 0 1.10167102107539e-08
L1 O 0 1.8496151596991695e-06
, O 0 1.3659560149648087e-09
in O 0 2.794048770127233e-09
the O 0 1.0255338622755517e-07
DMD B-Disease 1 1.0
gene O 0 1.934843218975857e-08
results O 0 2.0078922968735924e-09
in O 0 6.537439478648821e-09
X B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999775886535645
linked I-Disease 1 0.9996316432952881
dilated I-Disease 1 0.9999992847442627
cardiomyopathy I-Disease 1 1.0
. O 0 0.00020022295939270407

X B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999986886978149
linked I-Disease 1 0.9997825026512146
dilated I-Disease 1 0.9999997615814209
cardiomyopathy I-Disease 1 1.0
( O 0 6.5741033949962e-07
XLDCM B-Disease 1 0.7194346189498901
) O 0 8.305700571753505e-10
is O 0 9.345686724504532e-11
a O 0 6.576970079663624e-10
clinical O 0 4.445479717674061e-08
phenotype O 0 2.546253199398052e-06
of O 0 1.535483875159116e-06
dystrophinopathy B-Disease 0 2.1574134734692052e-05
which O 0 1.0587308807430418e-09
is O 0 5.7434512007459304e-11
characterized O 0 1.123972859229383e-10
by O 0 1.8746535573876955e-11
preferential O 0 3.6075238796229314e-08
myocardial B-Disease 0 0.003918332047760487
involvement I-Disease 0 1.5304351563827367e-08
without O 0 1.5666230535060777e-09
any O 0 5.10917197438232e-10
overt O 0 2.421232103699822e-09
clinical O 0 8.476242818744595e-09
signs O 0 4.6207777160134356e-08
of O 0 6.164993010315811e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 1 0.9999630451202393

To O 0 8.24457870862716e-08
date O 0 8.845257752909674e-07
, O 0 2.041084190551601e-09
several O 0 4.776681827856066e-10
mutations O 0 9.699500091997493e-10
in O 0 1.0204149747394808e-09
the O 0 4.6459336999760126e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 0 0.0007836250588297844
, O 0 7.513978630413476e-07
DMD O 1 1.0
, O 0 2.296911816301872e-08
have O 0 2.650735186904285e-10
been O 0 6.633334992400819e-10
identified O 0 4.3991091325246146e-10
in O 0 1.7623785764087074e-10
patients O 0 4.929551211674266e-10
with O 0 7.617989017383309e-10
XLDCM B-Disease 1 0.9999849796295166
, O 0 1.4375872936511769e-08
but O 0 3.0135018924681845e-09
a O 0 9.385602517397729e-09
pathogenic O 0 1.6293945748202532e-08
correlation O 0 1.6521449763828855e-09
of O 0 3.41488815003288e-09
these O 0 5.022148807931615e-10
cardiospecific O 0 2.1230208346878499e-07
mutations O 0 2.191284487196299e-09
in O 0 3.2531934923696326e-09
DMD O 1 1.0
with O 0 1.1240833153181029e-08
the O 0 7.222078579616209e-07
XLDCM B-Disease 0 0.0010615936480462551
phenotype O 0 1.0941794243990444e-06
has O 0 3.243800339447489e-09
remained O 0 1.8645929245053594e-08
to O 0 4.839961764702139e-10
be O 0 3.0659592642479083e-09
elucidated O 0 1.5255310245265719e-05
. O 0 8.616863738097891e-07

We O 0 2.692707425921981e-07
report O 0 1.2192061582538827e-08
here O 0 6.111403605402188e-10
the O 0 4.3134798510813255e-10
identification O 0 3.548403570974301e-09
of O 0 1.2406471405768116e-08
a O 0 1.3259245257302155e-08
unique O 0 2.864780768163655e-08
de O 0 2.1201853996899445e-06
novo O 0 1.4319371985038742e-05
L1 O 0 7.3621376941446215e-06
insertion O 0 5.912280016673321e-07
in O 0 2.483516148288345e-08
the O 0 4.5113623059478414e-08
muscle O 0 9.798129418925328e-09
exon O 0 1.4379691037902376e-07
1 O 0 2.1360056834396346e-08
in O 0 1.7195750379173091e-09
DMD O 1 1.0
in O 0 6.139788411019254e-08
three O 0 5.694635518693758e-08
XLDCM B-Disease 0 0.0009250904549844563
patients O 0 2.8260583206929368e-08
from O 0 5.746854547794555e-09
two O 0 3.0975355613804822e-09
unrelated O 0 4.5442831719810783e-08
Japanese O 0 1.5637123169653933e-06
families O 0 5.3212126260859804e-08
. O 0 4.356080296474829e-07

The O 0 3.5338612178748008e-06
insertion O 0 2.1759290120826336e-06
was O 0 3.184854676874238e-06
a O 0 4.8502428739993775e-08
5 O 0 2.6855669688075068e-08
- O 0 7.800612600306067e-09
truncated O 0 2.4468507220376523e-08
form O 0 1.3399966469762603e-08
of O 0 1.5379151818706305e-07
human O 0 4.809727016663601e-08
L1 O 0 7.600440881105897e-07
inversely O 0 1.3266472365103255e-07
integrated O 0 2.5691591076792974e-07
in O 0 8.039485521749157e-09
the O 0 5.1898727093657726e-08
5 O 0 5.765367916410469e-08
- O 0 9.196246253395657e-08
untranslated O 0 0.12436556816101074
region O 0 1.50285686117968e-07
in O 0 1.207876021425136e-08
the O 0 3.8214036379713434e-08
muscle O 0 3.520737479334457e-08
exon O 0 2.1077894984955492e-07
1 O 0 4.642306450364231e-08
, O 0 8.199980972012355e-11
which O 0 6.218294629212195e-11
affected O 0 2.0120864974160213e-09
the O 0 3.749900656657701e-08
transcription O 0 2.931242022441438e-07
or O 0 2.443744584468277e-08
the O 0 9.10746607019064e-08
stability O 0 1.2205880466353847e-06
of O 0 5.411073402683542e-07
the O 0 2.0079819762486295e-07
muscle O 0 3.5329268399664215e-08
form O 0 4.84536073486197e-08
of O 0 1.0094647677760804e-06
dystrophin O 0 1.8261604282088229e-06
transcripts O 0 7.121858658365454e-08
but O 0 6.099176719231991e-10
not O 0 5.297658839387154e-11
that O 0 8.082928076857954e-11
of O 0 2.633683671149356e-08
the O 0 1.3656575958975736e-07
brain O 0 5.682770279236138e-06
or O 0 3.3610753291668516e-08
Purkinje O 0 0.000225053183385171
cell O 0 5.89052724535577e-05
form O 0 2.290155975970265e-07
, O 0 7.876592711397734e-09
probably O 0 9.633944131337557e-08
due O 0 2.4734272301429883e-05
to O 0 3.249213875733403e-08
its O 0 9.462463701481738e-09
unique O 0 6.5323910725112455e-09
site O 0 5.8477429121239766e-08
of O 0 8.131661566324055e-09
integration O 0 8.505981696771414e-08
. O 0 1.914922904688865e-07

We O 0 4.902803425466118e-07
speculate O 0 6.361457138837068e-08
that O 0 1.1452189890848175e-10
this O 0 4.7681775194874376e-11
insertion O 0 5.591928253778633e-09
of O 0 8.209441126894035e-09
an O 0 3.0420635455108425e-10
L1 O 0 1.2798176385331317e-07
sequence O 0 8.831331221870187e-09
in O 0 2.2031205304529067e-08
DMD O 1 1.0
is O 0 1.4201371634214865e-08
responsible O 0 2.773352436591381e-09
for O 0 1.4038262219351338e-10
some O 0 4.128300826189424e-11
of O 0 1.3439223067734929e-09
the O 0 6.532188678853856e-10
population O 0 2.5217545066014146e-12
of O 0 1.0153318463768102e-10
Japanese O 0 1.8833507198223742e-08
patients O 0 4.0534864353958255e-09
with O 0 3.4421969719033996e-09
XLDCM B-Disease 0 0.000661709695123136
. O 0 1.9581365506837756e-07
. O 0 6.89413582222187e-07

Severe O 1 0.7132400870323181
early O 1 0.9999886751174927
- O 1 0.9999980926513672
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 1.0063868103316054e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 3.029605431947857e-05
red O 0 0.3700368106365204
hair O 0 1.077303386409767e-05
pigmentation O 0 0.0027933884412050247
caused O 0 7.980331133694563e-07
by O 0 7.001726309852074e-09
POMC O 0 0.31999096274375916
mutations O 0 3.0591849053962505e-08
in O 0 3.515488566918634e-09
humans O 0 4.774027217990806e-08
. O 0 1.4177102514167927e-07

Sequential O 0 5.486259851750219e-06
cleavage O 0 1.2934196092828643e-05
of O 0 8.575590072723571e-06
the O 0 4.671574060921557e-07
precursor O 0 6.088942541282449e-07
protein O 0 5.3349317852280365e-08
pre O 0 3.0660012271255255e-06
- O 0 2.479420800227672e-06
pro O 0 1.2640992281376384e-05
- O 0 1.860818338172976e-05
opiomelanocortin O 0 6.933401164133102e-05
( O 0 1.6157988724785355e-08
POMC O 0 2.052477066172287e-05
) O 0 1.1440581815236328e-09
generates O 0 9.132472555961613e-10
the O 0 1.7191398526961166e-08
melanocortin O 0 6.274888164625736e-06
peptides O 0 5.930243318630346e-08
adrenocorticotrophin O 0 1.4497161373583367e-06
( O 0 1.5199993486092467e-09
ACTH O 0 1.6188010931728058e-07
) O 0 2.4746251714447e-09
, O 0 3.0381568372206402e-09
melanocyte O 0 8.653668373881374e-06
- O 0 5.602250439551426e-06
stimulating O 0 1.4799381631291908e-07
hormones O 0 4.7335850794638645e-09
( O 0 4.4815293143152246e-10
MSH O 0 6.055817038941314e-07
) O 0 5.055122431762982e-10
alpha O 0 4.159913746804023e-09
, O 0 7.155561559946122e-11
beta O 0 1.4511545298745432e-09
and O 0 4.4573447710583025e-10
gamma O 0 3.852740348975203e-09
as O 0 9.199746520138774e-10
well O 0 3.510052803967767e-10
as O 0 4.439941747591547e-10
the O 0 2.1074662015507784e-09
opioid O 0 2.5024789351846266e-08
- O 0 1.0461892685498242e-08
receptor O 0 1.8082382258199914e-09
ligand O 0 6.615853465063992e-08
beta O 0 3.915266120202432e-07
- O 0 4.336971244356391e-07
endorphin O 0 1.9853689082083292e-05
. O 0 1.8786980149343435e-07

While O 0 4.4445474145504704e-07
a O 0 6.115385531302309e-08
few O 0 7.910151644807684e-09
cases O 0 9.829689062712532e-09
of O 0 4.4876884430777864e-07
isolated O 0 0.0006392407231032848
ACTH B-Disease 1 0.9986116886138916
deficiency I-Disease 1 0.9999995231628418
have O 0 3.413014937336811e-08
been O 0 2.4691198419191096e-08
reported O 0 8.351104696657785e-09
( O 0 1.6647758727117434e-09
OMIM O 0 2.166588637919631e-05
201400 O 0 1.068525875780324e-06
) O 0 6.940228391982828e-10
, O 0 3.26618593282646e-10
an O 0 2.3325656961503682e-09
inherited O 1 0.9999992847442627
POMC O 1 1.0
defect O 1 1.0
has O 0 3.850795735615975e-07
not O 0 1.3468631765434225e-09
been O 0 5.635807376336288e-09
described O 0 1.1339308159108441e-08
so O 0 1.464283250207643e-09
far O 0 1.6809407199502857e-08
. O 0 6.669650076673861e-08

Recent O 0 2.7025143367609417e-07
studies O 0 1.6634212229860168e-08
in O 0 3.492777622682297e-09
animal O 0 5.469126040935635e-09
models O 0 3.754185851079228e-09
elucidated O 0 2.01573061531235e-06
a O 0 1.7421245956938947e-07
central O 0 1.858472273852385e-07
role O 0 3.046387178073928e-07
of O 0 6.591897999896901e-06
alpha O 0 1.4867729987599887e-05
- O 0 3.1643521651858464e-06
MSH O 0 5.150150536792353e-05
in O 0 8.227201142574359e-09
the O 0 2.660219244887685e-08
regulation O 0 1.6720735018793675e-08
of O 0 1.5442952472355387e-09
food O 0 4.1900521940974045e-10
intake O 0 2.9508812060541345e-11
by O 0 4.8588260151416485e-12
activation O 0 5.59312285375313e-09
of O 0 7.11611463088957e-08
the O 0 2.664884277692181e-07
brain O 0 2.2551073470822303e-06
melanocortin O 0 1.433522174920654e-05
- O 0 5.413236294771195e-07
4 O 0 2.0557449431635177e-07
- O 0 2.290594380838229e-08
receptor O 0 6.069610147818594e-09
( O 0 6.722159495708979e-10
MC4 O 0 9.97978168015834e-06
- O 0 5.567850394072593e-07
R O 0 3.051708574730583e-07
; O 0 5.019939131045703e-09
refs O 0 4.0469072359883285e-07
3 O 0 6.721614198568204e-08
- O 0 1.3006284937944201e-08
5 O 0 3.1711304693260445e-09
) O 0 1.817083809807496e-11
and O 0 3.574402579475944e-11
the O 0 1.1737000260580999e-09
linkage O 0 1.1467442107004899e-07
of O 0 1.5583120571704967e-08
human O 0 1.35747200147307e-07
obesity B-Disease 1 0.9754968881607056
to O 0 2.279857858056289e-09
chromosome O 0 1.2217482137089064e-08
2 O 0 1.4690515115489688e-07
in O 0 6.588524392725503e-09
close O 0 2.318592748906667e-07
proximity O 0 5.866925221198471e-06
to O 0 1.6653426371249225e-07
the O 0 1.9053695723414421e-06
POMC O 0 0.0007409495301544666
locus O 0 3.9431824916391633e-07
, O 0 8.60190640938896e-10
led O 0 1.6780408174099648e-09
to O 0 1.0685377027641607e-09
the O 0 7.594722184478542e-09
proposal O 0 7.727207318453111e-09
of O 0 1.6565001814683455e-08
an O 0 4.6046727542048416e-10
association O 0 7.597674156478718e-10
of O 0 2.2119287734767568e-08
POMC O 0 0.11419694125652313
with O 0 1.1226781282402953e-07
human O 0 0.0005331510910764337
obesity B-Disease 1 1.0
. O 0 3.2895989079406718e-06

The O 0 4.441802957444452e-06
dual O 0 2.352872343180934e-06
role O 0 2.1803473373438464e-06
of O 0 1.5090285160113126e-05
alpha O 0 0.00013928911357652396
- O 0 9.804104774957523e-05
MSH O 0 0.018130524083971977
in O 0 4.8650580453113434e-08
regulating O 0 4.9391182699309866e-08
food O 0 3.9745863489315525e-08
intake O 0 1.0368783165404238e-08
and O 0 1.3640761853395134e-09
influencing O 0 9.626633357129322e-08
hair O 0 8.589017852500547e-07
pigmentation O 0 2.070030677714385e-05
predicts O 0 3.431461337299879e-08
that O 0 2.5719260055012683e-10
the O 0 6.308387145992356e-09
phenotype O 0 1.8180918104349075e-08
associated O 0 9.067731010503621e-10
with O 0 1.529307236403099e-10
a O 0 9.09468678145231e-09
defect O 0 2.0483605567278573e-06
in O 0 1.1626674734088738e-07
POMC O 1 0.9920967817306519
function O 0 1.68838965919349e-07
would O 0 2.7690937542956817e-08
include O 0 5.276414754007419e-07
obesity B-Disease 1 1.0
, O 0 1.1659508913908212e-09
alteration O 0 1.4809309050178854e-06
in O 0 1.5346941495408828e-08
pigmentation O 1 0.9491438269615173
and O 0 1.4612479617426288e-06
ACTH B-Disease 0 0.014907225035130978
deficiency I-Disease 1 0.9982715845108032
. O 0 2.2382982933777384e-06

The O 0 3.1405479603563435e-06
observation O 0 3.355907028890215e-05
of O 0 4.682881069584255e-07
these O 0 3.0433300324261836e-09
symptoms O 0 3.890357675118139e-06
in O 0 1.8981944904794545e-08
two O 0 2.231523410500813e-08
probands O 0 4.8568990678177215e-06
prompted O 0 8.290798092502882e-08
us O 0 7.90344056866843e-09
to O 0 7.201464313766337e-09
search O 0 3.829575945246688e-08
for O 0 9.839588033244695e-10
mutations O 0 6.280507225397969e-10
within O 0 3.5738201287216498e-09
their O 0 7.906096755050385e-08
POMC O 0 0.0004553964245133102
genes O 0 2.1011965145589784e-07
. O 0 2.473032338912162e-07

Patient O 0 0.00017019989900290966
1 O 0 9.751317520567682e-06
was O 0 1.946923049445104e-07
found O 0 8.480653401754523e-10
to O 0 1.8377922794687862e-10
be O 0 3.365960565826498e-10
a O 0 2.465570192455857e-09
compound O 0 5.591803287074981e-08
heterozygote O 0 1.1240366148967951e-07
for O 0 1.1313119330225163e-09
two O 0 1.9902688386252976e-09
mutations O 0 1.2909345814549056e-09
in O 0 1.6155492943425998e-08
exon O 0 4.826617896469543e-07
3 O 0 4.922415541841474e-07
( O 0 1.839676411208302e-09
G7013T O 0 1.2902515322821273e-07
, O 0 4.419952848166986e-09
C7133delta O 0 1.8186472061643144e-06
) O 0 7.922044686914376e-10
which O 0 2.227583395519872e-10
interfere O 0 6.322453116602844e-10
with O 0 3.038942014699231e-11
appropriate O 0 1.8952415192785566e-09
synthesis O 0 1.9369847947814378e-08
of O 0 9.54734424851722e-09
ACTH O 0 4.090235847797885e-07
and O 0 1.1365609964286705e-07
alpha O 0 4.038080987811554e-06
- O 0 6.309271157078911e-06
MSH O 0 0.00010340163862565532
. O 0 5.907179456698941e-07

Patient O 0 0.00011653510591713712
2 O 0 5.896232323721051e-06
was O 0 3.9035293752931466e-07
homozygous O 0 3.740990628386953e-09
for O 0 1.0335329259092418e-09
a O 0 3.048547192463502e-09
mutation O 0 1.0727565502577363e-09
in O 0 4.011109222545883e-09
exon O 0 1.9675108831052057e-07
2 O 0 2.4184831204365764e-07
( O 0 3.6896624644455756e-10
C3804A O 0 3.664410996861989e-08
) O 0 2.7274393854526124e-10
which O 0 2.519662256617039e-09
abolishes O 0 7.215673576865811e-06
POMC O 0 0.00039468961767852306
translation O 0 2.2543224531546002e-06
. O 0 1.2198257763884612e-06

These O 0 4.688874000180476e-08
findings O 0 3.201964915433564e-08
represent O 0 1.3744968496709475e-09
the O 0 8.19808132490607e-09
first O 0 3.19215787136784e-09
examples O 0 4.2122021426393985e-09
of O 0 7.747192398710467e-08
a O 0 4.086987530627084e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 2.987869152093481e-07
the O 0 2.8124597406531393e-07
POMC O 0 1.646320743020624e-05
gene O 0 4.4134913501636674e-09
and O 0 4.732327862910779e-10
define O 0 5.115864176730156e-09
a O 0 5.317935247717287e-08
new O 0 8.183114914572798e-06
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 0 0.0014395150355994701
resulting O 0 1.1977877534263826e-07
in O 0 9.378498866396967e-09
early O 0 0.0005365010583773255
- O 0 0.45189014077186584
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 1.1323433000143268e-06
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 3.4384368063911097e-06
red O 0 0.00011517342500155792
hair O 0 2.7653468350763433e-06
pigmentation O 0 5.5973669077502564e-05
. O 0 8.043584642791757e-08
. O 0 1.6606369968030776e-07

A O 0 1.0415906217531301e-05
European O 0 1.1660491736620315e-06
multicenter O 0 0.00010537901835050434
study O 0 5.58962653940398e-07
of O 1 0.9865282773971558
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.8064842894082176e-08
classification O 0 2.837555825863092e-07
of O 0 3.0450439680862473e-06
105 O 0 8.690917638887186e-07
mutations O 0 3.0813074314295363e-09
and O 0 2.8226361248329113e-09
a O 0 8.851364974304943e-09
general O 0 3.76210103070207e-08
system O 0 1.207420297077988e-07
for O 0 9.908177611706037e-10
genotype O 0 1.7120880713150655e-08
- O 0 4.5563965933581585e-09
based O 0 1.0714275022749575e-09
prediction O 0 2.6383830231679894e-07
of O 0 8.918596705598247e-08
metabolic O 0 0.0006563278147950768
phenotype O 0 1.6959921822490287e-06
. O 0 7.466348961315816e-08

Phenylketonuria B-Disease 0 0.020504124462604523
( O 0 5.5473020665886e-07
PKU B-Disease 0 0.000241291883867234
) O 0 1.0769208635963423e-08
and O 0 3.09555261424066e-08
mild B-Disease 1 1.0
hyperphenylalaninemia I-Disease 1 1.0
( O 1 1.0
MHP B-Disease 1 1.0
) O 0 6.561426175721863e-07
are O 0 8.881365864965574e-09
allelic B-Disease 0 0.03952012211084366
disorders I-Disease 0 0.3938625752925873
caused O 0 1.502824709120887e-08
by O 0 1.5925286089846225e-10
mutations O 0 5.904692707003889e-11
in O 0 1.2498900525681478e-10
the O 0 2.553792066706251e-09
gene O 0 3.7383656170675295e-09
encoding O 0 2.420107421130524e-07
phenylalanine O 0 2.00815120479092e-05
hydroxylase O 0 0.0009386984747834504
( O 0 3.7850722378607315e-07
PAH O 1 1.0
) O 0 7.401691703989854e-08
. O 0 3.7069207792228553e-07

Previous O 0 2.0261111330910353e-06
studies O 0 1.4534460746062905e-08
have O 0 5.178891204771219e-10
suggested O 0 1.1141210176646155e-09
that O 0 2.2585480360937105e-11
the O 0 1.1429589497069514e-09
highly O 0 2.468262927379783e-08
variable O 0 1.243496853930992e-06
metabolic O 1 0.9999887943267822
phenotypes O 0 0.0007931836298666894
of O 1 0.9789395928382874
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 4.419302786118351e-05
with O 0 5.899123607377987e-06
PAH O 1 1.0
genotypes O 1 0.7564820051193237
. O 0 6.9280931711546145e-06

We O 0 3.357346045618215e-08
identified O 0 8.262285078330933e-09
both O 0 3.2876867894771067e-10
causative O 0 4.9584681249825735e-08
mutations O 0 4.2544554545997926e-09
in O 0 1.4255180369460163e-09
686 O 0 9.954610504792072e-07
patients O 0 2.56009002441715e-07
from O 0 5.304345336298866e-07
seven O 0 8.022323640943796e-07
European O 0 1.1780997510868474e-06
centers O 0 4.3897866817133036e-06
. O 0 1.4367644780577393e-06

On O 0 3.733202220246312e-06
the O 0 3.399254921987449e-08
basis O 0 1.9969204956282738e-08
of O 0 1.9123307382074017e-08
the O 0 9.624097074834026e-09
phenotypic O 0 5.419885340529618e-08
characteristics O 0 2.030566115251986e-08
of O 0 7.250878297782037e-08
297 O 0 2.1760417467930893e-08
functionally O 0 8.405694984503498e-07
hemizygous O 0 6.440781817218522e-06
patients O 0 5.7792508556531175e-08
, O 0 5.224231047762373e-10
105 O 0 2.9071040685835214e-08
of O 0 3.646416146807496e-08
the O 0 1.5175348977436443e-08
mutations O 0 3.771538081842607e-10
were O 0 4.241117457226551e-10
assigned O 0 4.706935730069972e-09
to O 0 8.305859333646026e-10
one O 0 2.2904533825141016e-09
of O 0 1.5809149545020773e-08
four O 0 3.2969635910262696e-09
arbitrary O 0 7.635070353728679e-09
phenotype O 0 1.4746606780136062e-07
categories O 0 4.113349660883614e-08
. O 0 1.069770334538589e-07

We O 0 3.523435623264959e-07
proposed O 0 2.269332242121891e-07
and O 0 1.0194526112172753e-08
tested O 0 5.09470421405922e-09
a O 0 6.29238938731902e-10
simple O 0 8.307728394107983e-10
model O 0 2.622622674586239e-10
for O 0 3.209432025697012e-11
correlation O 0 2.5857874175194695e-10
between O 0 9.41098088347303e-10
genotype O 0 7.707457427841291e-08
and O 0 6.161312793295792e-09
phenotypic O 0 1.8320653794035024e-07
outcome O 0 7.110273259058886e-07
. O 0 5.180161792850413e-07

The O 0 1.4188398154146853e-06
observed O 0 7.169943927465283e-08
phenotype O 0 1.888985110554131e-07
matched O 0 2.95307032160963e-08
the O 0 3.900894185449033e-08
predicted O 0 3.756393596177077e-08
phenotype O 0 9.18460685284117e-08
in O 0 4.410958265310683e-09
79 O 0 2.9387477340492296e-08
% O 0 4.070901671315852e-10
of O 0 1.873929678097852e-09
the O 0 1.1127957444401204e-09
cases O 0 3.3873165383724313e-10
, O 0 6.399918095478796e-11
and O 0 5.0659299671851343e-11
in O 0 1.494484952457853e-10
only O 0 6.516082812213497e-11
5 O 0 8.928136563390865e-10
of O 0 5.739139719018738e-10
184 O 0 2.8789939321427482e-09
patients O 0 4.744956871860495e-09
was O 0 5.259424256109924e-07
the O 0 2.3442256136263495e-08
observed O 0 4.684759691286899e-09
phenotype O 0 9.360610064845787e-09
more O 0 5.217874743390638e-11
than O 0 3.545004220728565e-11
one O 0 1.7800401430623225e-10
category O 0 2.409850929918633e-10
away O 0 2.9364939369003196e-09
from O 0 1.8891267716814042e-10
that O 0 1.201475585688172e-10
expected O 0 3.356411326649322e-08
. O 0 2.7565027949094656e-07

Among O 0 2.9178534077800578e-06
the O 0 1.9829924440273317e-06
seven O 0 1.1651272302515281e-07
contributing O 0 1.061428633875039e-08
centers O 0 1.0049692633629093e-08
, O 0 2.5610930043384883e-10
the O 0 7.944969682149861e-10
proportion O 0 4.721842361554707e-10
of O 0 5.047898099519443e-09
patients O 0 3.036557894020575e-09
for O 0 1.6404795299962416e-09
whom O 0 7.127933088213467e-08
the O 0 2.2249831488352356e-07
observed O 0 1.187193898743999e-08
phenotype O 0 2.4677731857991603e-08
did O 0 2.2009438715997476e-09
not O 0 7.381637523451445e-10
match O 0 1.8028117665380705e-08
the O 0 4.226601646450945e-08
predicted O 0 2.8251529116118945e-08
phenotype O 0 1.9726583033730094e-08
was O 0 4.432297018297504e-08
4 O 0 1.4086288580017481e-08
% O 0 8.653974759020855e-10
- O 0 1.313266917435385e-08
23 O 0 4.025558553166775e-08
% O 0 2.643052443573879e-09
( O 0 1.7460782819611609e-09
P O 0 4.661729690269567e-06
< O 0 5.813456596115429e-07
. O 0 8.027350340000794e-09
0001 O 0 4.857686803916295e-07
) O 0 1.0356379642750824e-10
, O 0 2.926437911443536e-11
suggesting O 0 2.3689536443605164e-10
that O 0 3.4244208163558554e-11
differences O 0 7.466143259193814e-10
in O 0 5.063321983911351e-11
methods O 0 9.466465389351697e-10
used O 0 6.287266263171887e-10
for O 0 2.480020355744017e-10
mutation O 0 1.9109296367503248e-09
detection O 0 1.5797927517269272e-06
or O 0 7.785154743089606e-09
phenotype O 0 3.945416438000393e-08
classification O 0 3.286409588909578e-09
may O 0 4.394329067292091e-10
account O 0 5.446177189782908e-11
for O 0 1.597420390408999e-10
a O 0 7.515721378581475e-10
considerable O 0 3.027622819118392e-09
proportion O 0 1.5431056432646528e-09
of O 0 2.110162178325936e-08
genotype O 0 7.546950087089499e-07
- O 0 1.5686651977375732e-06
phenotype O 0 6.159113468129362e-07
inconsistencies O 0 3.098964782566327e-07
. O 0 3.12967785021101e-07

Our O 0 2.440460775687825e-05
data O 0 3.079220789459214e-07
indicate O 0 2.7813742420335075e-08
that O 0 4.026793121170158e-09
the O 0 3.3284570122305013e-07
PAH O 1 1.0
- O 0 8.120828169921879e-06
mutation O 0 1.0219601165317727e-08
genotype O 0 1.2183576814095431e-08
is O 0 6.608730923618467e-11
the O 0 3.5275768417442066e-10
main O 0 9.19743570193532e-09
determinant O 0 6.191721269033224e-08
of O 0 4.3918369385664846e-08
metabolic O 0 0.23733893036842346
phenotype O 0 4.5296152961782354e-07
in O 0 3.7825889642739696e-10
most O 0 6.22579765519049e-10
patients O 0 3.701670436839777e-08
with O 0 1.2021287147945259e-06
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0063952612690627575

In O 0 3.865129940550105e-07
the O 0 2.721066572064501e-08
present O 0 2.941163090852683e-09
study O 0 2.0518875487596233e-10
, O 0 2.7905842567288452e-11
the O 0 2.447604341426768e-10
classification O 0 1.4500319167609632e-08
of O 0 7.999487934284844e-07
105 O 0 0.000586364243645221
PAH O 1 1.0
mutations O 0 5.279178481032432e-07
may O 0 9.363181341370819e-09
allow O 0 3.0976066156540583e-09
the O 0 1.830227702726006e-08
prediction O 0 2.3210020572150825e-07
of O 0 2.3490507317092124e-08
the O 0 7.496683274155203e-09
biochemical O 0 4.0490526487246825e-08
phenotype O 0 6.338989777532333e-08
in O 0 3.2790714588060155e-09
> O 0 4.310654944106318e-08
10 O 0 2.1256936211244692e-09
, O 0 1.2390188874888963e-10
000 O 0 1.2089240719603822e-09
genotypes O 0 2.302210333482435e-08
, O 0 2.8095556436902314e-10
which O 0 9.566729353149839e-11
may O 0 6.083561432390638e-10
be O 0 2.2467937232928392e-10
useful O 0 6.66824429007562e-10
for O 0 2.954853306480487e-10
the O 0 4.732898961634646e-09
management O 0 3.3035686186622115e-08
of O 0 1.1983225078893156e-07
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.4701306838560413e-07
newborns O 0 9.159481919596146e-07
. O 0 5.779790512860927e-07

Somatic O 0 0.0005762540968134999
instability O 0 0.0004130638262722641
of O 0 2.6470997909200378e-05
the O 0 8.538157999282703e-06
CTG O 0 0.0001598590170033276
repeat O 0 3.8299492644000566e-07
in O 0 1.753087097711159e-08
mice O 0 6.692140885888875e-08
transgenic O 0 4.6820638033295836e-08
for O 0 1.781613856444153e-09
the O 0 1.481866911490215e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.14173680543899536
is O 0 5.25132692885677e-09
age O 0 8.466139456153599e-10
dependent O 0 2.0980241155488244e-10
but O 0 1.6375361136522493e-11
not O 0 3.685628191529844e-12
correlated O 0 1.1320473725096036e-10
to O 0 1.0136755324019475e-10
the O 0 1.8492984921181232e-09
relative O 0 2.946910058199137e-07
intertissue O 0 4.57197847936186e-06
transcription O 0 1.6499043908879685e-07
levels O 0 1.6317207141014478e-08
and O 0 1.3800983467149308e-08
proliferative O 0 0.000124892991152592
capacities O 0 2.714693437155802e-06
. O 0 7.843402158869139e-07

A O 0 0.0003847746702376753
( O 0 3.997928672561102e-07
CTG O 0 1.6300822608172894e-05
) O 0 8.946158480682698e-09
nexpansion O 0 1.7744948763720458e-06
in O 0 1.630087709258987e-08
the O 0 1.5179178092239454e-07
3 O 0 2.0763159227499273e-06
- O 0 1.2038623253829428e-06
untranslated O 1 0.9995419979095459
region O 0 7.799200716362975e-07
( O 0 7.00926250374323e-09
UTR O 0 0.0018920628353953362
) O 0 1.1933092292082392e-09
of O 0 1.1321737325431513e-08
the O 0 2.163523191711647e-07
DM O 1 1.0
protein O 0 2.943135370969685e-07
kinase O 0 7.619609476705591e-08
gene O 0 9.279720880606135e-10
( O 0 5.4578865732457515e-11
DMPK O 0 2.08879129104389e-07
) O 0 4.8602923768958917e-11
is O 0 1.1251991526017857e-11
responsible O 0 4.0266526224463917e-10
for O 0 8.258120853810169e-10
causing O 0 2.362103714403929e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.641096898514661e-06
DM B-Disease 1 1.0
) O 0 4.416836674181468e-08
. O 0 1.518505570174966e-07

Major O 0 0.001621887320652604
instability O 1 0.9306054711341858
, O 0 2.8407905361405028e-08
with O 0 1.0816880724462408e-09
very O 0 2.2397435017751377e-09
large O 0 3.123282965589169e-09
expansions O 0 2.3422412454010555e-08
between O 0 9.991151017629818e-09
generations O 0 1.2812635930004035e-07
and O 0 2.4800497211430184e-09
high O 0 7.130010803990672e-09
levels O 0 1.7595983559104411e-09
of O 0 3.248784796738846e-09
somatic O 0 8.502915704866609e-08
mosaicism O 0 1.9636322576843668e-06
, O 0 8.43517269921712e-11
is O 0 1.467318107295501e-11
observed O 0 1.3308358581820556e-10
in O 0 2.885347238912317e-10
patients O 0 2.495324835649626e-08
. O 0 2.0567176761687733e-07

There O 0 2.697786385397194e-07
is O 0 1.1912177022566084e-08
a O 0 1.5157183952396736e-08
good O 0 1.2969869622736496e-08
correlation O 0 3.630224121309311e-09
between O 0 5.9045186517892034e-09
repeat O 0 1.525067538921121e-08
size O 0 1.877748090350906e-08
( O 0 6.086730008902919e-10
at O 0 2.5039386120084828e-09
least O 0 8.291071301735897e-11
in O 0 3.725494079898084e-10
leucocytes O 0 1.7812587316257122e-07
) O 0 1.0429645341814009e-10
, O 0 1.1696650592529778e-11
clinical O 0 2.0760280161624678e-09
severity O 0 5.615615350507142e-07
and O 0 5.037299466437162e-09
age O 0 1.3804641874060053e-08
of O 0 6.833848686937927e-08
onset O 0 0.26235440373420715
. O 0 1.3834013543601031e-06

The O 0 0.00030125014018267393
trinucleotide O 1 0.9807863831520081
repeat O 0 4.842362613999285e-06
instability O 0 2.450663259878638e-06
mechanisms O 0 2.1808163808145764e-07
involved O 0 5.1635069553412904e-09
in O 0 3.2789852610903836e-08
DM B-Disease 1 1.0
and O 0 5.785989856121887e-07
other O 0 1.4645549661906898e-08
human O 0 4.821069978788728e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 2.2810527078309661e-10
unknown O 0 1.425059821258401e-07
. O 0 9.223474251029984e-08

We O 0 6.660584972451034e-07
studied O 0 1.604114004294388e-06
somatic O 0 1.9177687136107124e-05
instability O 0 1.7883373857330298e-06
by O 0 4.1636605274675276e-09
measuring O 0 1.1761610494431807e-06
the O 0 4.105144171262509e-07
CTG O 0 5.422912181529682e-06
repeat O 0 4.0541141999028696e-08
length O 0 9.872151984779975e-09
at O 0 3.7856509038647346e-09
several O 0 7.387943035119804e-11
ages O 0 4.366706995995173e-10
in O 0 7.537941104640566e-11
various O 0 2.3960006201306783e-10
tissues O 0 3.534625392376256e-08
of O 0 8.105619286880028e-08
transgenic O 0 1.5019428190043982e-07
mice O 0 6.427534948727498e-09
carrying O 0 3.351720456734597e-09
a O 0 7.815046387804614e-08
( O 0 8.556910735535439e-09
CTG O 0 6.022945854056161e-06
) O 0 5.4812607785947876e-09
55expansion O 0 4.2721111981336435e-07
surrounded O 0 1.2169994079158641e-07
by O 0 1.145272099378758e-09
45 O 0 2.680194022275373e-08
kb O 0 4.969015208189376e-07
of O 0 7.403640722714044e-08
the O 0 3.0736902090211515e-07
human O 0 1.2528540764833451e-06
DM B-Disease 1 1.0
region O 0 4.7682485160294164e-07
, O 0 2.3849269226161596e-09
using O 0 1.1723381376782527e-08
small O 0 2.8345825242581668e-08
- O 0 2.3919693603602354e-07
pool O 0 2.4231280804087874e-07
PCR O 0 1.2912956890431815e-06
. O 0 4.975255478711915e-07

These O 0 1.3132089407008607e-06
mice O 0 1.4824556728854077e-06
have O 0 4.2587826598605716e-09
been O 0 4.57759874450403e-09
shown O 0 1.8096458775929136e-09
to O 0 6.502639537941945e-10
reproduce O 0 3.272437609780354e-08
the O 0 3.3967658907840814e-08
intergenerational O 0 1.0119422455545646e-07
and O 0 6.250478357117117e-09
somatic O 0 2.8089639272366185e-06
instability O 0 8.57696932143881e-07
of O 0 6.097716891417804e-07
the O 0 2.0236238924553618e-06
55 O 0 4.291139532597299e-07
CTG O 0 4.051860742038116e-06
repeat O 0 3.6724436824897566e-08
suggesting O 0 8.868331846656474e-09
that O 0 3.782271718044683e-10
surrounding O 0 8.626556358137805e-09
sequences O 0 7.460960738114863e-10
and O 0 6.600621160757214e-10
the O 0 1.8207422236571347e-09
chromatin O 0 3.387882330230241e-08
environment O 0 8.779552196358509e-09
are O 0 2.157173745187535e-11
involved O 0 1.7494443393939463e-10
in O 0 4.953812360319887e-10
instability O 0 2.8296781806602667e-07
mechanisms O 0 5.818897989229299e-06
. O 0 9.110122505262552e-07

As O 0 4.152072961005615e-07
observed O 0 4.4154049305689114e-08
in O 0 1.3879218885293199e-09
some O 0 7.145877639613829e-11
of O 0 1.775273927862031e-09
the O 0 1.4939470771579977e-09
tissues O 0 3.047874486128421e-08
of O 0 2.365756017752574e-06
DM B-Disease 1 1.0
patients O 0 0.032539237290620804
, O 0 3.368042733598031e-09
there O 0 4.5305179052768096e-10
is O 0 4.587175916892505e-10
a O 0 1.0925219617874404e-09
tendency O 0 4.0676884083268305e-10
for O 0 6.194622037547504e-10
repeat O 0 4.663416763861505e-09
length O 0 6.401304375458494e-09
and O 0 5.4152535788887235e-09
somatic O 0 3.050038230867358e-07
mosaicism O 0 1.1511153843457578e-06
to O 0 8.741167789594328e-10
increase O 0 1.9218283908717382e-10
with O 0 1.5535443764758128e-10
the O 0 4.045067836244698e-09
age O 0 4.429083766410713e-09
of O 0 1.0463608646205103e-08
the O 0 3.1372973552379335e-08
mouse O 0 1.9956580672442215e-06
. O 0 1.3008002497372217e-07

Furthermore O 0 1.4257220755098388e-06
, O 0 1.5738805814180523e-08
we O 0 6.249127881829963e-10
observed O 0 4.721013580066824e-10
no O 0 1.8089307829427526e-10
correlation O 0 3.113705127066879e-10
between O 0 3.350357491438416e-10
the O 0 3.8878340546943946e-09
somatic O 0 2.7927083579015743e-07
mutation O 0 1.7530034313040233e-08
rate O 0 1.032050089833092e-08
and O 0 1.161520435388752e-09
tissue O 0 9.234088338416768e-08
proliferation O 0 5.540365464185015e-07
capacity O 0 8.772208559548744e-08
. O 0 1.825173541192271e-07

The O 0 6.023106379871024e-06
somatic O 0 2.2335401808959432e-05
mutation O 0 1.2680257555075514e-07
rates O 0 4.690374311167034e-09
in O 0 8.694637371187142e-11
different O 0 1.2624108702841141e-10
tissues O 0 1.0668198058283451e-07
were O 0 1.552805350968356e-08
also O 0 7.842110294475901e-10
not O 0 8.426939007710743e-11
correlated O 0 2.506265639468097e-09
to O 0 3.3977169966448173e-09
the O 0 2.0126522315422335e-07
relative O 0 6.0660018789349124e-05
inter O 0 0.058367013931274414
- O 0 1.6836553186294623e-05
tissue O 0 6.396717822099163e-07
difference O 0 1.2833149654056797e-08
in O 0 4.3718573206064093e-10
transcriptional O 0 1.191769971597978e-08
levels O 0 1.944512995066816e-09
of O 0 4.905055472903541e-09
the O 0 8.748394009217009e-09
three O 0 2.3761363987517825e-09
genes O 0 1.1428977764182946e-09
( O 0 2.6992449941865004e-10
DMAHP O 0 3.310314059490338e-05
, O 0 9.571283321463397e-09
DMPK O 0 0.002459228038787842
and O 0 3.8063717511249706e-07
59 O 0 3.384901958725095e-07
) O 0 8.447735289074387e-10
surrounding O 0 4.2265696720278356e-08
the O 0 6.322301970840272e-08
repeat O 0 6.496137672229452e-08
. O 0 1.2873208277142112e-08
. O 0 1.2272161598048115e-07

A O 0 5.068400696472963e-06
novel O 0 4.564062123790791e-07
missense O 0 5.657554993376834e-07
mutation O 0 9.422984170726068e-09
in O 0 1.112549607995561e-09
patients O 0 6.245282513361872e-09
from O 0 2.0829066471605984e-08
a O 0 4.171310195033584e-07
retinoblastoma B-Disease 1 0.9984567165374756
pedigree O 0 3.024971556442324e-05
showing O 0 3.779088331157254e-08
only O 0 2.3030348739183637e-09
mild O 0 2.3045095076668076e-06
expression O 0 3.545577698105262e-08
of O 0 1.5704777922564972e-07
the O 0 1.2791538495093846e-07
tumor B-Disease 0 1.7204213236254873e-06
phenotype O 0 3.8149372016960115e-07
. O 0 4.799902697527614e-08

We O 0 3.8177799410732405e-07
have O 0 3.310429708136553e-09
used O 0 6.877651337333646e-09
single O 0 1.1995489046512375e-08
strand O 0 1.729463505739659e-08
conformation O 0 7.393078371720208e-10
polymorphism O 0 1.2992790177079883e-09
analysis O 0 1.0200292693829383e-10
to O 0 7.71449085168463e-11
study O 0 9.361458136458722e-11
the O 0 4.8925348217210285e-09
27 O 0 6.607945834957718e-08
exons O 0 3.8489966414090304e-07
of O 0 5.6375302648348224e-08
the O 0 9.522195654199095e-08
RB1 O 0 3.3834055557235843e-06
gene O 0 1.6002573710593992e-09
in O 0 5.3870206906392326e-11
individuals O 0 5.127853003328298e-12
from O 0 1.6225615295795137e-09
a O 0 5.80564503138703e-08
family O 0 3.751747215119394e-07
showing O 0 1.4486662536228323e-08
mild O 0 3.4721733754849993e-06
expression O 0 1.8075533603223448e-07
of O 0 1.98157840713975e-06
the O 0 1.7967619214687147e-06
retinoblastoma B-Disease 0 0.00015778552915435284
phenotype O 0 6.9323227762652095e-06
. O 0 1.8077464858379244e-07

In O 0 4.299409681607358e-07
this O 0 3.165856554687707e-08
family O 0 7.362914544728483e-08
affected O 0 5.213698917039267e-10
individuals O 0 2.1497845170692642e-11
developed O 0 2.648456813858502e-07
unilateral B-Disease 1 0.9975340366363525
tumors I-Disease 1 1.0
and O 0 0.19074204564094543
, O 0 4.967950939516186e-09
as O 0 9.842778814217468e-10
a O 0 1.355739742692208e-09
result O 0 1.5629607608147467e-09
of O 0 6.64377175496611e-09
linkage O 0 3.992959207721469e-08
analysis O 0 3.1309712600346984e-09
, O 0 2.560003875551331e-10
unaffected O 0 5.290596405416181e-09
mutation O 0 1.9927522132423547e-10
carriers O 0 1.6206430641929614e-10
were O 0 9.968799119519645e-10
also O 0 6.509999206372186e-10
identified O 0 3.5814899934649702e-09
within O 0 1.5464653557728525e-08
the O 0 2.885527123908105e-07
pedigree O 0 4.261610683897743e-06
. O 0 3.528886622916616e-07

A O 0 3.313466004328802e-05
single O 0 7.61700732709869e-07
band O 0 4.235745905134536e-07
shift O 0 1.0308485087762165e-07
using O 0 1.9402609297003437e-08
SSCP O 0 1.817677002691198e-05
was O 0 3.0896984526407323e-07
identified O 0 8.721886324281058e-09
in O 0 4.299682387909343e-09
exon O 0 9.057989558414192e-08
21 O 0 4.605325010231809e-09
which O 0 3.620290872641263e-11
resulted O 0 5.977105477228406e-09
in O 0 3.480474797257216e-09
a O 0 3.120307212611806e-08
missense O 0 3.203425364972645e-07
mutation O 0 1.4837504558329329e-08
converting O 0 1.4301026851626375e-07
a O 0 1.3659077069405612e-07
cys O 0 3.9186570575111546e-06
- O 0 2.2896697373653296e-06
- O 0 2.5552708393661305e-06
> O 0 1.0973216149068321e-06
arg O 0 4.0718498439673567e-07
at O 0 1.1006524580636778e-08
nucleotide O 0 2.413007349488794e-09
position O 0 1.5906358896700112e-08
28 O 0 2.1884622114498598e-08
in O 0 1.3189345171582545e-09
the O 0 6.064485802426134e-08
exon O 0 1.6288854567392264e-06
. O 0 2.2927412146600545e-07

The O 0 4.861009074375033e-06
mutation O 0 4.240976068103919e-07
destroyed O 0 1.218932811752893e-05
an O 0 1.1243148634321187e-08
NdeI O 0 4.422920937940944e-06
restriction O 0 1.9111681126560143e-07
enzyme O 0 3.2125242910296947e-07
site O 0 6.825692935308325e-07
. O 0 2.0720165139209712e-07

Analysis O 0 1.4963211469876114e-07
of O 0 2.7718342607840896e-06
all O 0 6.650328288060336e-08
family O 0 1.6868864349817159e-07
members O 0 7.448959782330178e-10
demonstrated O 0 6.738555935470458e-09
that O 0 7.671941415487993e-10
the O 0 4.7042455264545424e-08
missense O 0 4.915120825899066e-07
mutation O 0 8.65418101625437e-08
co O 0 1.0157511951547349e-06
- O 0 4.48916625828133e-06
segregated O 0 4.47763781608046e-08
with O 0 1.202599686500605e-09
patients O 0 1.38321638587513e-07
with O 0 4.314487966894376e-07
tumors B-Disease 1 1.0
or O 1 0.9999998807907104
who O 0 0.0026562397833913565
, O 0 1.0486425061628779e-08
as O 0 7.407394253533539e-09
a O 0 5.857675233755799e-09
result O 0 3.0883444690488204e-09
of O 0 8.891348990403003e-09
linkage O 0 5.927740964750683e-09
analysis O 0 4.771418815607831e-10
had O 0 1.4830197070381246e-09
been O 0 7.787051004015666e-10
predicted O 0 1.7816648156809833e-09
to O 0 1.8136257773360143e-10
carry O 0 1.3515313312950639e-09
the O 0 7.154316250534976e-08
predisposing O 0 4.374191121314652e-06
mutation O 0 2.9336942475310934e-07
. O 0 5.787375130239525e-07

These O 0 1.394400186427447e-07
observations O 0 3.217417372525233e-07
point O 0 7.47981871995762e-08
to O 0 5.390086710299613e-10
another O 0 5.624131715897818e-10
region O 0 5.151505888534302e-09
of O 0 1.2360806067590602e-07
the O 0 3.9063002077455167e-07
RB1 O 0 4.212246494716965e-05
gene O 0 1.8329631146229985e-08
where O 0 1.9248156402085215e-09
mutations O 0 1.2754537703774105e-10
only O 0 4.538740563941879e-11
modify O 0 1.8261610001957251e-09
the O 0 5.054179297303563e-09
function O 0 9.658516209043455e-10
of O 0 5.154070947810396e-09
the O 0 7.836043813824745e-09
gene O 0 4.822318100394796e-09
and O 0 1.1005112376949455e-09
raise O 0 4.5647799429282543e-10
important O 0 1.5702756872570944e-09
questions O 0 1.1512730768714619e-09
for O 0 1.5872188285914746e-10
genetic O 0 1.0749507950436055e-08
counseling O 0 2.1189050514180963e-09
in O 0 1.4726656005770167e-10
families O 0 7.162771070712282e-11
with O 0 1.0341412622072443e-11
these O 0 2.156932132901801e-10
distinctive O 0 2.993590442201821e-08
phenotypes O 0 3.25279870594386e-07
. O 0 2.9711779703234242e-08
. O 0 1.9259701389273687e-07

Maternal B-Disease 0 0.0006757107912562788
disomy I-Disease 0 0.0025201893877238035
and O 0 0.00013612015754915774
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.0059341201558709145
with O 0 1.5341234060883835e-08
gamete O 0 4.3742477373598376e-07
complementation O 0 1.7671789009909844e-06
in O 0 2.0890964513853305e-09
a O 0 7.154149272992072e-09
case O 0 1.8537914314720183e-08
of O 0 4.0493461028745514e-08
familial O 0 5.434956733552099e-07
translocation O 0 3.747956327515567e-07
( O 0 6.194657564684292e-10
3 O 0 1.7224843773533394e-08
; O 0 8.683521124375204e-10
15 O 0 9.566373471159295e-09
) O 0 1.8442533611384704e-10
( O 0 2.8348551284196333e-10
p25 O 0 8.430070153053748e-08
; O 0 1.0736531663724236e-09
q11 O 0 3.750151122972056e-08
. O 0 1.180615383233885e-09
2 O 0 2.860080172695234e-08
) O 0 1.3357956962778417e-09
. O 0 3.493991940217711e-08

Maternal B-Disease 1 0.6294578909873962
uniparental I-Disease 1 0.9999979734420776
disomy I-Disease 1 0.9999300241470337
( I-Disease 0 1.3929043234384153e-05
UPD I-Disease 1 1.0
) I-Disease 0 1.9624394553829916e-08
for I-Disease 0 2.835311097015847e-09
chromosome I-Disease 0 3.914518487135865e-08
15 I-Disease 0 8.836790854616083e-09
is O 0 1.487381467990545e-10
responsible O 0 8.220436553685317e-10
for O 0 3.803598824791976e-10
an O 0 1.3099334117416817e-10
estimated O 0 4.920717999734592e-11
30 O 0 4.74471906208862e-10
% O 0 3.449910149222468e-11
of O 0 1.1804797417358515e-10
cases O 0 2.8858210265880757e-10
of O 0 8.083708848971582e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.008995012380182743
PWS B-Disease 1 1.0
) O 0 3.995290853708866e-07
. O 0 4.685061298914661e-07

We O 0 4.742756232190004e-07
report O 0 3.608893450746109e-08
on O 0 3.608494125728612e-08
an O 0 8.801055023655024e-11
unusual O 0 5.353283927256314e-10
case O 0 3.6645417811342895e-09
of O 0 2.0458324812011597e-08
maternal B-Disease 0 9.096326721191872e-06
disomy I-Disease 0 0.000562116561923176
15 I-Disease 0 6.76295144330652e-07
in O 0 1.8954852976094116e-07
PWS B-Disease 1 1.0
that O 0 1.758912162586057e-07
is O 0 3.337462750607756e-09
most O 0 2.190029962934048e-10
consistent O 0 1.6493364451974912e-09
with O 0 4.434017597532147e-10
adjacent O 0 3.673361845812906e-07
- O 0 5.873110922038904e-07
1 O 0 1.6610441377906682e-07
segregation O 0 1.011880002010912e-08
of O 0 2.311898672502366e-09
a O 0 2.9133528922642427e-09
paternal O 0 2.7457318196866254e-08
t O 0 1.8647707378249834e-08
( O 0 3.4270494775334726e-10
3 O 0 7.514636024552601e-09
; O 0 4.3046854969475135e-10
15 O 0 3.1915734499676773e-09
) O 0 1.3559667277895926e-10
( O 0 1.0598011357387804e-10
p25 O 0 4.093641692293204e-08
; O 0 5.055758589556092e-10
q11 O 0 1.4244995405476857e-08
. O 0 4.1912190384962855e-10
2 O 0 1.4754977240016842e-09
) O 0 7.665819368174454e-12
with O 0 1.7046010436505554e-11
simultaneous O 0 4.238620565644169e-09
maternal O 0 2.3216661304559238e-07
meiotic O 0 1.4001961972098798e-05
nondisjunction O 0 5.995061201247154e-06
for O 0 1.334805688202323e-08
chromosome O 0 9.590712579665706e-08
15 O 0 1.6839274508129165e-07
. O 0 1.7204264679548942e-07

The O 0 6.512831987492973e-06
patient O 0 2.76154128187045e-06
( O 0 4.157755917333361e-09
J O 0 4.085389946340001e-07
. O 0 3.516413826787357e-09
B O 0 9.950267099156918e-08
. O 0 6.166647192884511e-10
) O 0 8.713497284817961e-11
, O 0 8.210998547752979e-11
a O 0 2.791002096103057e-09
17 O 0 6.844973032826829e-09
- O 0 1.041649522193211e-08
year O 0 1.8830707659844848e-08
- O 0 5.593684591076453e-07
old O 0 7.107322744559497e-06
white O 0 1.506539035744936e-07
male O 0 8.174125820659128e-10
with O 0 4.2493197849324815e-10
PWS B-Disease 1 1.0
, O 0 5.143850145827855e-08
was O 0 2.2497627014672616e-06
found O 0 9.490696228908746e-09
to O 0 4.207440618131386e-09
have O 0 4.157470812060637e-09
47 O 0 2.999866310915422e-08
chromosomes O 0 1.2782574998482232e-09
with O 0 5.781351508638011e-10
a O 0 8.475551993569752e-08
supernumerary O 0 0.00040880992310121655
, O 0 2.215467098665158e-08
paternal O 0 2.542775746405823e-06
der O 0 6.040268635842949e-05
( O 0 2.843651314421436e-09
15 O 0 4.211535120646204e-09
) O 0 6.031807692208346e-11
consisting O 0 2.466660209421434e-10
of O 0 1.77813497259649e-08
the O 0 1.1811705746822554e-07
short O 0 1.275701180247779e-07
arm O 0 1.1623852742559393e-06
and O 0 1.477041422504044e-08
the O 0 1.9198122913621773e-07
proximal O 0 0.003223924431949854
long O 0 8.83766097103944e-06
arm O 0 3.437472969380906e-06
of O 0 2.560930454365007e-07
chromosome O 0 4.4796880871444955e-08
15 O 0 2.700298118440969e-08
, O 0 9.444751647436078e-10
and O 0 1.8681706848155955e-08
distal O 0 0.004681858234107494
chromosome O 0 9.529326052870601e-05
arm O 1 0.9438701272010803
3p O 1 0.999980092048645
. O 0 0.00010397569712949917

The O 0 4.602110857376829e-05
t O 0 1.8542494899520534e-06
( O 0 7.48750927925812e-09
3 O 0 6.017796749802073e-08
; O 0 1.5851775447828231e-09
15 O 0 5.107060552234088e-09
) O 0 2.1189201782068068e-10
was O 0 1.1267171196038817e-08
present O 0 3.2084435108714615e-09
in O 0 1.1479796002689113e-09
the O 0 1.6614103426348947e-09
balanced O 0 1.0155104535058967e-09
state O 0 5.7378019002740643e-11
in O 0 5.874542519102022e-11
the O 0 9.671642375863598e-10
patients O 0 1.4833138051173478e-09
father O 0 1.662324535800508e-07
and O 0 3.020022631972097e-08
a O 0 1.1489887583593372e-06
sister O 0 8.830182196106762e-05
. O 0 5.88464308748371e-06

Fluorescent O 0 1.892975160444621e-05
in O 0 1.3461965409078402e-07
situ O 0 1.712397192932258e-06
hybridization O 0 5.3587239534635955e-08
analysis O 0 2.7270248281752174e-09
demonstrated O 0 5.049872520146437e-09
that O 0 1.8030713033745371e-10
the O 0 6.192879453692512e-08
PWS B-Disease 1 1.0
critical O 0 1.7453156033298e-05
region O 0 1.4242256440866186e-07
resided O 0 6.380444119713502e-07
on O 0 4.7658755164547983e-08
the O 0 2.9472841944766515e-09
derivative O 0 6.967474597274759e-09
chromosome O 0 9.585039428827713e-09
3 O 0 1.2423733153354988e-08
and O 0 1.7863528711803411e-10
that O 0 4.6975229262002927e-11
there O 0 2.813851374128262e-10
was O 0 4.084477822630106e-08
no O 0 1.631785373490402e-09
deletion O 0 4.786789631339161e-09
of O 0 4.522387353489421e-09
the O 0 5.6534023684662316e-08
PWS B-Disease 1 1.0
region O 0 2.9942868877697038e-06
on O 0 2.5789786377572455e-06
the O 0 5.550975501478206e-08
normal O 0 3.1617890527968484e-08
pair O 0 2.0837887859670445e-08
of O 0 1.2721144138083673e-08
15s O 0 7.481744432880078e-07
present O 0 1.8348875130413944e-07
in O 0 3.117488063253404e-07
J O 0 0.0005928412429057062
. O 0 1.948624230863061e-06

B O 0 0.00034887719084508717
. O 0 8.896286999515723e-06

Methylation O 0 1.3607231039713952e-06
analysis O 0 1.4911273638062994e-07
at O 0 3.7881525827287987e-07
exon O 0 4.7072526854208263e-07
alpha O 0 1.765173323065028e-07
of O 0 3.673991955110978e-08
the O 0 3.0397469430454294e-08
small O 0 2.186542680249204e-08
nuclear O 0 7.320888926187763e-07
ribonucleoprotein O 0 1.0649840987753123e-05
- O 0 3.706146571857971e-07
associated O 0 7.217472841603012e-08
polypeptide O 0 2.9982078331158846e-07
N O 0 8.332190049031851e-08
( O 0 2.3443216812246703e-10
SNRPN O 0 3.5713250667868124e-07
) O 0 2.3233466539540615e-10
gene O 0 5.214146892029703e-10
showed O 0 6.439090372012402e-10
a O 0 4.3832965035406346e-10
pattern O 0 1.320374143354286e-09
characteristic O 0 5.405140335312808e-09
of O 0 1.0606919786937397e-08
only O 0 6.150366882451408e-10
the O 0 6.368253036015403e-09
maternal O 0 3.798918868369583e-08
chromosome O 0 1.3575827573220067e-08
15 O 0 1.7109291761130407e-08
in O 0 1.9433274545122003e-08
J O 0 0.00012373544450383633
. O 0 2.5373253720317734e-06

B O 0 0.0005873741465620697
. O 0 1.0059483429358806e-05

Maternal B-Disease 0 0.00022518585319630802
disomy I-Disease 0 5.720733679481782e-05
was O 0 5.305079184836359e-07
confirmed O 0 7.21114012947055e-09
by O 0 2.004470339711517e-10
polymerase O 0 9.53944763182335e-08
chain O 0 1.9225417702273262e-08
reaction O 0 6.356966952836274e-09
analysis O 0 3.807353099460897e-09
of O 0 3.365976297686757e-08
microsatellite O 0 1.2296358136154595e-06
repeats O 0 6.400232166470232e-08
at O 0 9.002748768693891e-09
the O 0 2.4250035313144735e-09
gamma O 0 4.151957355702507e-08
- O 0 2.537314713890737e-08
aminobutyric O 0 2.675508312677266e-07
acid O 0 2.1813525208358442e-08
receptor O 0 1.2770859925126388e-08
beta3 O 0 1.703408258890704e-07
subunit O 0 9.327318473140167e-09
( O 0 3.8432557136758305e-10
GABRB3 O 0 9.048748665918538e-07
) O 0 2.1162391838913663e-09
locus O 0 9.889210872415788e-08
. O 0 5.0981288524099e-08

A O 0 6.740815297234803e-05
niece O 0 3.670907244668342e-05
( O 0 3.737053777541632e-09
B O 0 4.581461965358358e-08
. O 0 4.3422140882931615e-10
B O 0 1.0596648003513565e-08
. O 0 1.0199728561754995e-10
) O 0 1.213999387128517e-11
with O 0 2.11440968900245e-11
45 O 0 6.940201746630237e-10
chromosomes O 0 2.3112141367409578e-10
and O 0 6.397614660258455e-10
the O 0 3.3961813361571558e-09
derivative O 0 3.7858409740465504e-08
3 O 0 3.5497794925731796e-08
but O 0 3.3703803636875307e-10
without O 0 2.0001558187487944e-09
the O 0 2.6415518661337956e-08
der O 0 4.417464936068427e-07
( O 0 5.047164353122469e-10
15 O 0 3.1207940676125645e-09
) O 0 9.567440589774989e-11
demonstrated O 0 3.4687972494396035e-09
a O 0 7.731276063793757e-09
phenotype O 0 1.0980837572560631e-08
consistent O 0 3.268668002931463e-09
with O 0 5.6362966377454526e-11
that O 0 5.500735283936464e-11
reported O 0 5.594037455480816e-10
for O 0 1.206063693359738e-09
haploinsufficiency O 0 7.552529268650687e-07
of O 0 1.586714120094257e-07
distal O 0 0.0005646773497574031
3 O 0 0.00011604220344452187
p O 0 3.8651229260722175e-05
. O 0 1.0331648354622303e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 1.0
associated O 0 0.00010182860569329932
with O 0 2.0247615850621514e-07
unbalanced O 0 2.9463744795066305e-05
segregation O 0 9.847452020039782e-06
of O 0 8.448691914964002e-07
non O 0 2.7520031835592818e-06
- O 0 5.971694463369204e-06
Robertsonian O 0 4.312802411732264e-05
translocations O 0 4.678815457737073e-06
has O 0 9.678658763334624e-09
been O 0 1.0666642014101058e-09
reported O 0 7.190918971389237e-10
previously O 0 3.4028404538588575e-09
but O 0 4.31405577927535e-10
has O 0 1.142905978190889e-10
not O 0 6.956632492283177e-11
, O 0 6.258655399493662e-11
to O 0 1.864057658229612e-10
our O 0 6.134167840343707e-09
knowledge O 0 3.358486111437742e-08
, O 0 2.653365305249622e-10
been O 0 1.2638612378879088e-10
observed O 0 1.1782594344644792e-10
in O 0 9.127243405515628e-11
a O 0 2.019661105023829e-09
case O 0 8.698664544226631e-08
of O 0 2.543161372159375e-06
PWS B-Disease 1 1.0
. O 0 0.00030354756745509803

Furthermore O 0 9.674944521975704e-06
, O 0 1.5643074391391565e-07
our O 0 2.539512600208127e-08
findings O 0 6.529252249976025e-09
are O 0 2.1498307301026642e-10
best O 0 3.3218017225777885e-09
interpreted O 0 3.6268468228684014e-09
as O 0 5.825519622248976e-09
true O 0 4.2296825597532006e-08
gamete O 0 2.6596768520903424e-07
complementation O 0 2.184310005759471e-06
resulting O 0 1.0494572677544056e-07
in O 0 3.965968531360886e-08
maternal B-Disease 0 0.0014753007562831044
UPD I-Disease 1 1.0
15 I-Disease 0 1.7593562006368302e-05
and O 0 5.984533800074132e-06
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999998807907104
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
type I-Disease 0 8.558153785998002e-05
2 I-Disease 0 3.6171692045172676e-05
and O 0 1.255846768799529e-07
Stuve B-Disease 1 0.9999687671661377
- I-Disease 1 0.9999990463256836
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 2.6811231013113e-09
a O 0 4.77752237770801e-09
case O 0 7.613911279236163e-09
for O 0 1.326735943329993e-09
" O 0 8.194532163940949e-09
lumping O 0 4.8665242502465844e-08
" O 0 5.623033061397109e-08
. O 0 1.4370999679158558e-07

Recent O 0 3.2892870649448014e-07
studies O 0 4.628963878872128e-08
demonstrated O 0 2.914332597470093e-08
the O 0 1.5777580131270952e-08
existence O 0 5.070935671369625e-08
of O 0 7.117295552916403e-08
a O 0 2.251433350863863e-08
genetically O 0 1.80040284902816e-08
distinct O 0 1.0428244046067903e-08
, O 0 4.5793779879232943e-10
usually O 0 3.949779392442565e-10
lethal O 0 6.982801448174314e-09
form O 0 2.346443039868973e-09
of O 0 2.4453072455798974e-07
the O 0 5.065744517196435e-07
Schwartz B-Disease 0 0.48309051990509033
- I-Disease 1 0.9970912933349609
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 4.282300736235811e-08
SJS B-Disease 0 0.013405178673565388
) O 0 3.191829245352551e-09
of O 0 5.85212205805874e-07
myotonia B-Disease 1 1.0
and O 0 0.05464344844222069
skeletal B-Disease 1 1.0
dysplasia I-Disease 1 1.0
, O 0 1.4295000028141658e-07
which O 0 1.8212190866506717e-08
we O 0 3.5908215068047866e-08
called O 0 6.643425081165333e-07
SJS B-Disease 0 0.00033622985938563943
type I-Disease 0 4.6598497647210024e-06
2 I-Disease 0 5.727128609578358e-06
. O 0 2.1752910583927587e-07

This O 0 2.3741320092085516e-06
disorder O 1 0.9932204484939575
is O 0 1.1404900135403295e-08
reminiscent O 0 3.2471252779942006e-06
of O 0 2.471292361860833e-07
another O 0 8.67313154628846e-09
rare O 0 6.073734937217523e-08
condition O 0 7.333305256906897e-05
, O 0 2.4885313809619447e-09
the O 0 9.504503850621404e-08
Stuve B-Disease 1 0.9997692704200745
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.8600410385261057e-06
SWS B-Disease 0 0.06514590233564377
) O 0 6.937793117778313e-10
, O 0 6.646553446509884e-11
which O 0 1.2454159925567865e-10
comprises O 0 6.35636987489363e-10
campomelia B-Disease 0 7.326168542931555e-07
at O 0 2.052504122218579e-08
birth O 0 3.5340320891918964e-08
with O 0 7.163926785125341e-09
skeletal B-Disease 1 0.9999995231628418
dysplasia I-Disease 1 1.0
, O 0 2.75116349257587e-07
contractures B-Disease 1 0.9983900785446167
, O 0 1.0428800045758635e-08
and O 0 7.268530222148684e-09
early B-Disease 0 5.562104888667818e-06
death I-Disease 0 5.431960744317621e-05
. O 0 8.871581371749926e-07

To O 0 3.931602066131745e-07
test O 0 1.4433631179144868e-07
for O 0 5.014848092343982e-09
possible O 0 1.85396174856578e-07
nosologic O 0 0.00012446558685041964
identity O 0 1.416804593645793e-07
between O 0 2.7480894004838774e-08
these O 0 5.5080269234508705e-09
disorders O 0 9.595937444828451e-05
, O 0 4.473134918026034e-10
we O 0 2.7790275636263573e-10
reviewed O 0 2.5535240588681063e-09
the O 0 2.4898418882202122e-09
literature O 0 8.217771463314705e-10
and O 0 1.662125714840812e-10
obtained O 0 5.844202344285065e-10
a O 0 1.242716374250108e-09
follow O 0 1.0347539491917246e-09
- O 0 2.0464646866003022e-08
up O 0 4.631328653914579e-09
of O 0 9.86375781053539e-09
the O 0 1.085425260782813e-08
only O 0 3.8035549709825034e-10
two O 0 6.400079910484635e-10
surviving O 0 1.9563930209187674e-07
patients O 0 6.20154061437006e-09
, O 0 6.738925528715356e-10
one O 0 9.392905342409108e-10
with O 0 2.323728764963562e-09
SJS B-Disease 0 0.0007795265410095453
type I-Disease 0 0.01575908437371254
2 I-Disease 0 0.007658656220883131
at O 0 1.1801504484765246e-07
age O 0 6.945104935596191e-09
10 O 0 1.926946158192777e-09
years O 0 4.702375155929417e-10
and O 0 6.419445530703172e-10
another O 0 4.343765347414319e-09
with O 0 4.486089721922326e-09
SWS B-Disease 0 0.00019430817337706685
at O 0 4.4509519625535177e-08
age O 0 7.612996455463872e-09
7 O 0 4.1937262551527965e-08
years O 0 1.589544140756516e-08
. O 0 7.329859386118187e-08

Patients O 0 6.207429123605834e-06
reported O 0 7.909505228553826e-08
as O 0 6.93287560693534e-09
having O 0 1.0824708240875225e-08
either O 0 1.0138176094187656e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 0.13725529611110687
SWS B-Disease 0 0.24253179132938385
presented O 0 1.4887964638887752e-08
a O 0 1.0377068093703201e-09
combination O 0 3.954817362483709e-09
of O 0 1.4358802147285132e-08
a O 0 1.335658694756603e-08
severe O 0 4.565020844893297e-06
, O 0 6.4456062709439266e-09
prenatal O 0 0.0053999163210392
- O 0 0.07449039071798325
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 1.7003358721012773e-09
with O 0 5.771085831440814e-09
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.9999972581863403
feeding O 0 0.0422184132039547
difficulties O 0 1.2412217984092422e-05
, O 0 2.4315525148921324e-09
tendency O 0 6.123786810974252e-09
to O 0 2.3579568519949134e-08
hyperthermia B-Disease 1 0.9999949932098389
, O 0 1.8689501057878033e-09
and O 0 8.290506059438485e-10
frequent O 0 3.1326796712249916e-09
death O 0 4.097989858564688e-07
in O 0 5.9732534474221666e-09
infancy O 0 4.921363938592549e-07
) O 0 4.1752035856434944e-11
with O 0 1.96464251117634e-11
a O 0 3.3325648907123195e-09
distinct O 0 5.898645838442462e-08
campomelic B-Disease 1 0.9970725774765015
- I-Disease 1 0.9999637603759766
metaphyseal I-Disease 1 0.9999815225601196
skeletal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 0 0.005410862620919943

The O 0 6.080435355215741e-07
similarity O 0 6.713951847814315e-07
of O 0 1.1793667908932548e-06
the O 0 1.1278571321327036e-07
clinical O 0 5.309690322974348e-07
and O 0 8.337003087888206e-09
radiographic O 0 0.009166629053652287
findings O 0 3.2223103971773526e-06
is O 0 3.741021004088907e-08
so O 0 1.0104023173695964e-09
extensive O 0 2.120899544877375e-08
that O 0 5.304942041206573e-10
these O 0 3.5118561392266656e-09
disorders O 0 1.6496840089530451e-06
appear O 0 6.574063515785156e-09
to O 0 3.1570268621550213e-09
be O 0 3.5329248415649772e-09
a O 0 4.2215262396894104e-08
single O 0 4.8245929917811736e-08
entity O 0 2.0877179451872507e-07
. O 0 1.506666876593954e-06

The O 0 5.9312433222658e-06
follow O 0 6.427623588933784e-07
- O 0 1.4841375559626613e-06
up O 0 2.372148166784882e-08
observation O 0 2.1311269904344954e-07
of O 0 1.9568515696732902e-08
an O 0 1.5811907339013942e-10
identical O 0 1.8373025323370484e-09
and O 0 7.902561383055229e-10
unique O 0 1.7900031457074306e-09
pattern O 0 2.1022968610395765e-07
of O 0 0.0001822736085159704
progressive O 1 1.0
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 2.339324737477e-06
the O 0 7.44970966479741e-05
two O 0 1.6401776292696013e-07
patients O 0 4.1163396247156925e-08
( O 0 9.02113661549464e-10
one O 0 7.972023041702414e-09
with O 0 1.8329282980289463e-08
SJS B-Disease 0 0.0011120123090222478
type I-Disease 0 0.00026617723051458597
2 I-Disease 0 1.9013952623936348e-05
, O 0 1.476505584463439e-09
one O 0 2.1200450284197814e-09
with O 0 2.608461224795633e-09
SWS B-Disease 0 4.4963788241147995e-05
) O 0 2.9498317122289563e-09
surviving O 0 1.8851585537049687e-06
beyond O 0 3.2409436698799254e-06
infancy O 0 1.6356805645045824e-05
adds O 0 5.295037741603892e-09
to O 0 7.76422648396391e-10
the O 0 2.0331267780449025e-09
evidence O 0 7.437989335556949e-09
in O 0 1.46714329574138e-09
favor O 0 3.86892793358129e-08
of O 0 4.6310834278529e-08
identity O 0 1.2685943318047066e-07
. O 0 5.240763130132109e-07

The O 0 4.017714672954753e-06
hypothesis O 0 2.7173432499694172e-06
that O 0 7.183756167705724e-08
SWS B-Disease 0 0.017105627804994583
and O 0 6.833294037278392e-07
SJS B-Disease 1 0.9998503923416138
type I-Disease 0 0.0007182357949204743
2 I-Disease 0 1.1813370292657055e-05
are O 0 2.5944080217499277e-10
the O 0 7.532372059415593e-09
same O 0 3.644462154284156e-08
disorder O 0 5.876360319234664e-06
should O 0 1.1434364566298427e-09
be O 0 3.1967015146072697e-10
testable O 0 3.6369882661091424e-09
by O 0 7.255623185598026e-12
molecular O 0 3.2497374236051257e-10
methods O 0 1.7970090970820252e-09
. O 0 2.5867701314297165e-09
. O 0 6.82695713294379e-08

A O 0 7.071666004776489e-06
mouse O 0 7.468976264135563e-07
model O 0 9.855576799111532e-09
of O 0 1.5631433925022975e-08
severe O 1 0.9951434135437012
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9991050362586975
defects O 1 1.0
in O 0 4.727245084268361e-07
hemostasis O 1 0.9999748468399048
and O 0 9.758601663634181e-06
thrombosis B-Disease 1 0.9999998807907104
. O 0 0.0003329789615236223

von B-Disease 1 0.9999992847442627
Willebrand I-Disease 1 1.0
factor I-Disease 0 0.06330937147140503
( I-Disease 0 9.342381304122682e-07
vWf I-Disease 0 0.04171609878540039
) I-Disease 0 2.818294433382107e-07
deficiency I-Disease 1 0.9999439716339111
causes O 0 9.435800166102126e-05
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.9843304753303528
humans O 0 0.0004575489729177207
. O 0 1.2510739679783e-06

We O 0 4.5879329491071985e-07
generated O 0 1.3766122464176078e-08
a O 0 1.1687167678076094e-08
mouse O 0 1.6970901128843252e-08
model O 0 5.048994000667051e-10
for O 0 4.9912157740195084e-11
this O 0 8.22472923101003e-11
disease O 0 1.4712485674195364e-09
by O 0 9.99756007147301e-12
using O 0 5.472691744223823e-10
gene O 0 3.6857044083404844e-09
targeting O 0 2.0940964517990324e-08
. O 0 5.885250331516545e-08

vWf B-Disease 0 0.0809721127152443
- I-Disease 1 0.9999982118606567
deficient I-Disease 1 0.9999711513519287
mice O 0 6.339240826491732e-06
appeared O 0 1.4861429065149423e-07
normal O 0 4.900083538927902e-08
at O 0 6.720970446849606e-09
birth O 0 4.150830790194959e-09
; O 0 3.1044480874875546e-10
they O 0 5.758789556331578e-10
were O 0 5.5832103385000664e-09
viable O 0 1.6393125861213775e-06
and O 0 4.440505207981005e-08
fertile O 0 7.233497399283806e-06
. O 0 2.3338269272699108e-07

Neither O 0 9.779324318515137e-05
vWf O 0 0.0008059953106567264
nor O 0 4.5997632696526125e-05
vWf O 0 0.00026737345615401864
propolypeptide O 0 0.0002139205753337592
( O 0 8.409481466742363e-08
von B-Disease 0 0.04273846372961998
Willebrand I-Disease 1 0.9999504089355469
antigen O 0 0.0005916028749197721
II O 1 1.0
) O 0 3.642592716346371e-08
were O 0 7.887567043951549e-09
detectable O 0 3.496965561566867e-08
in O 0 6.622917214649249e-10
plasma O 0 1.2896358647651596e-08
, O 0 1.8656369504821413e-10
platelets O 0 1.059032328498688e-08
, O 0 1.3754665462162308e-10
or O 0 3.700015016594449e-10
endothelial O 0 4.621868665566353e-09
cells O 0 2.026119938491888e-09
of O 0 1.7451933231882322e-08
the O 0 2.33747101674453e-07
homozygous O 0 4.840770202463318e-07
mutant O 0 1.8060457023238996e-06
mice O 0 7.157298114179866e-07
. O 0 3.268311843385163e-07

The O 0 4.13220732298214e-05
mutant O 0 0.00013178613153286278
mice O 0 1.9275298654974904e-06
exhibited O 0 9.390602428993589e-08
defects O 0 0.0010770884109660983
in O 0 2.7840757255148674e-08
hemostasis O 0 0.00022495065059047192
with O 0 5.3878479455704564e-09
a O 0 1.0090703739251694e-07
highly O 0 5.6349840633629356e-06
prolonged O 1 0.9999998807907104
bleeding O 1 0.9999996423721313
time O 0 2.6646023343346315e-06
and O 0 1.400804592321947e-07
spontaneous O 0 6.994640955326759e-08
bleeding O 0 4.390756487282488e-07
events O 0 1.6106771472124137e-10
in O 0 6.30272847801372e-11
approximately O 0 1.3488593054999942e-11
10 O 0 8.150737029755106e-11
% O 0 7.418754499610714e-11
of O 0 3.2089086943187795e-09
neonates O 0 1.0014771305577597e-06
. O 0 6.346162990666926e-07

As O 0 6.008174864291504e-07
in O 0 3.221438760192541e-08
the O 0 2.0909871167873462e-08
human O 0 1.506725055833158e-08
disease O 0 9.144094974544714e-07
, O 0 3.938262493896616e-10
the O 0 5.904135402801103e-09
factor O 0 2.2684034206577053e-08
VIII O 1 0.9999998807907104
level O 0 0.0011534523218870163
in O 0 1.0434848540796793e-08
these O 0 5.14883136126798e-10
mice O 0 1.8583574679098547e-09
was O 0 4.582281221132689e-09
reduced O 0 3.75391362439359e-09
strongly O 0 3.4941500803853387e-09
as O 0 2.4673529885888e-09
a O 0 1.8649477517840296e-09
result O 0 2.0796979693926687e-09
of O 0 2.188787640022838e-08
the O 0 9.254238264588821e-09
lack O 0 7.87979672622896e-08
of O 0 5.383903989297778e-09
protection O 0 2.449979774610256e-08
provided O 0 2.8836872889570486e-09
by O 0 3.3770095608787187e-09
vWf O 0 7.1196359385794494e-06
. O 0 1.0350988759455504e-06

Defective O 1 0.9709792137145996
thrombosis B-Disease 1 0.9999995231628418
in O 0 4.005543814855628e-05
mutant O 0 4.9465317715657875e-05
mice O 0 7.431057724716084e-07
was O 0 4.1290951457995106e-07
also O 0 1.2454166586906013e-09
evident O 0 3.53540734465696e-08
in O 0 1.128359627955433e-09
an O 0 1.1359991419768178e-10
in O 0 1.392224391327801e-10
vivo O 0 2.253352393566388e-09
model O 0 2.014720834608852e-09
of O 0 1.9176530940967496e-07
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 0 0.0007198951789177954

In O 0 2.8292575393606967e-07
this O 0 6.91095936034003e-09
model O 0 3.0121245941927555e-08
, O 0 2.530648357534915e-09
the O 0 1.879181255048934e-08
exteriorized O 0 5.712367510568583e-06
mesentery O 0 3.784458385780454e-05
was O 0 1.0238310323984479e-06
superfused O 0 1.4002331454321393e-06
with O 0 3.6535778846769063e-09
ferric O 0 4.50229890702758e-05
chloride O 0 2.753735770966159e-06
and O 0 4.5219630351311935e-07
the O 0 3.269667843142088e-07
accumulation O 0 6.690085569971416e-07
of O 0 7.708572979936434e-07
fluorescently O 0 2.8794989702873863e-05
labeled O 0 5.090851118438877e-07
platelets O 0 4.08517593086799e-07
was O 0 1.7974629429318156e-07
observed O 0 1.6410272030142892e-09
by O 0 2.1672746930434528e-10
intravital O 0 3.7231399119264097e-07
microscopy O 0 3.680771385461412e-07
. O 0 7.667909471820167e-07

We O 0 6.070481504139025e-07
conclude O 0 2.7872380314875045e-07
that O 0 1.1110694586591308e-09
these O 0 1.0522404059187807e-09
mice O 0 3.624863609275053e-08
very O 0 1.0690636154109256e-09
closely O 0 7.500301713037061e-09
mimic O 0 1.7840633290688857e-06
severe O 1 0.7682353258132935
human O 1 0.9999904632568359
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 1 0.9999974966049194
will O 0 5.540842096252163e-08
be O 0 1.5460457358784652e-09
very O 0 1.8242696242509737e-10
useful O 0 2.2406909661043528e-10
for O 0 1.712506872419972e-11
investigating O 0 7.456305711750488e-11
the O 0 3.765988632054018e-10
role O 0 3.768792833369616e-09
of O 0 2.0272883816119247e-08
vWf O 0 4.055557383253472e-07
in O 0 6.8139578424109e-09
normal O 0 8.021781638944958e-08
physiology O 0 5.112686807251521e-08
and O 0 1.8102467302938408e-09
in O 0 5.495536248290023e-10
disease O 0 4.7273442049799996e-08
models O 0 8.465562473247701e-09
. O 0 5.0001229823237736e-08
. O 0 8.108277143037412e-07

Oral O 0 0.0004538746434263885
contraceptives O 0 0.0007674982771277428
and O 0 9.272259404724537e-09
the O 0 7.881792107866659e-09
risk O 0 7.233514764948268e-08
of O 0 4.031872595078312e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.514117608778179e-05

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999995231628418
Clinical O 0 2.5118282792391255e-05
Study O 0 9.798786493320222e-08
Group O 0 3.295613737464009e-08
. O 0 1.2913348257370671e-07

BACKGROUND O 0 5.101473107060883e-06
Women O 0 1.4417329552429692e-09
with O 0 1.511692021560762e-10
mutations O 0 6.988780110184223e-10
in O 0 1.1412597533677626e-09
either O 0 7.531999024479319e-09
the O 0 3.7896489857303095e-07
BRCA1 O 0 3.5878095161478996e-08
or O 0 1.750687772528181e-08
the O 0 4.062389180603532e-08
BRCA2 O 0 4.667919828449385e-09
gene O 0 5.123888535685239e-10
have O 0 1.2572590191162192e-10
a O 0 2.2792188136833147e-09
high O 0 4.212340698472872e-08
lifetime O 0 1.1150616785471357e-07
risk O 0 7.07858930582006e-07
of O 1 0.9689745306968689
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.8444069357647095e-06

Oral O 0 0.14406897127628326
contraceptives O 1 0.9999977350234985
protect O 1 0.9997150301933289
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.248884527489281e-07
general O 0 7.248119118230534e-07
, O 0 8.892649949743259e-10
but O 0 2.6258661911526815e-10
it O 0 1.4625520239341938e-10
is O 0 3.777691354178714e-11
not O 0 1.1273882868922946e-11
known O 0 4.993865321267776e-10
whether O 0 2.3568796914119616e-10
they O 0 7.071445096151763e-10
also O 0 1.3154122235903287e-09
protect O 0 5.106066680582444e-09
against O 0 2.5966631511664673e-08
hereditary B-Disease 1 0.9999921321868896
forms I-Disease 1 0.9335255026817322
of I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.214811029778502e-07

METHODS O 0 1.914435597427655e-05
We O 0 1.2198044885280979e-07
enrolled O 0 3.827166139558358e-08
207 O 0 1.3517743369106938e-08
women O 0 4.959898464163004e-11
with O 0 3.3435156865380122e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.237249863261241e-07
161 O 0 6.130625962441627e-08
of O 0 3.0232326935220044e-06
their O 0 8.4255552792456e-05
sisters O 0 0.4769267737865448
as O 0 6.156112135613512e-07
controls O 0 8.803256150713423e-07
in O 0 2.4666674036666336e-08
a O 0 1.2499012314037827e-07
case O 0 7.446309382430627e-07
- O 0 6.246809789445251e-07
control O 0 1.2656506953589997e-07
study O 0 8.072336576958605e-09
. O 0 5.100803335267301e-08

All O 0 1.3701975376534392e-07
the O 0 6.497896976043194e-08
patients O 0 4.923746299567711e-09
carried O 0 6.489729309500092e-10
a O 0 5.189015883644288e-10
pathogenic O 0 2.1171355779614487e-09
mutation O 0 1.6376190403732949e-09
in O 0 1.5241159445622543e-09
either O 0 1.550012029838399e-08
BRCA1 O 0 3.478604782003458e-08
( O 0 5.302817629448953e-10
179 O 0 6.297687704659438e-09
women O 0 5.212582795954823e-11
) O 0 1.7785165007389026e-10
or O 0 9.651523136255946e-09
BRCA2 O 0 1.351813523342571e-07
( O 0 4.14407530513472e-09
28 O 0 9.067652229077794e-08
women O 0 1.181626324564533e-10
) O 0 1.3439223067734929e-09
. O 0 1.1321310466883006e-07

The O 0 0.0002606937778182328
control O 0 3.380217822268605e-05
women O 0 1.0191973931483744e-09
were O 0 1.4877226117704367e-09
enrolled O 0 2.4556252586904748e-09
regardless O 0 5.434001248971754e-09
of O 0 3.298818995745023e-09
whether O 0 3.89030946346125e-10
or O 0 7.973997018240198e-10
not O 0 1.3628376205332415e-10
they O 0 4.2030109947965855e-10
had O 0 4.935790887117264e-09
either O 0 1.1388466170103584e-08
mutation O 0 7.708280236329301e-08
. O 0 1.7759090553681744e-07

Lifetime O 0 2.7099547878606245e-05
histories O 0 5.26836265635211e-06
of O 0 1.4799792324993177e-06
oral O 0 2.760757524811197e-05
- O 0 8.040368015826971e-07
contraceptive O 0 1.2516905201209738e-07
use O 0 1.4415432181280607e-09
were O 0 2.2827240098166612e-10
obtained O 0 7.165056881142107e-10
by O 0 3.6159109040312387e-10
interview O 0 7.402959578683976e-09
or O 0 2.133287851924237e-10
by O 0 4.522141341944952e-11
written O 0 1.0845818687599262e-10
questionnaire O 0 1.338023719599235e-10
and O 0 1.281054012869376e-10
were O 0 3.473429877054457e-10
compared O 0 7.335936857977288e-10
between O 0 1.6549077663796652e-09
patients O 0 6.311338296427493e-08
and O 0 3.0699457198579694e-08
control O 0 1.5331836493714945e-06
women O 0 9.64235011280401e-11
, O 0 5.905841093944986e-11
after O 0 1.7687002973332255e-09
adjustment O 0 3.5055920388771256e-09
for O 0 1.5011415721577492e-10
year O 0 2.774335206012779e-10
of O 0 3.1187827875811536e-09
birth O 0 6.681338504677115e-08
and O 0 2.9580084159874787e-08
parity O 0 9.513152008366887e-07
. O 0 2.3999209020075796e-07

RESULTS O 0 6.624769412155729e-06
The O 0 1.1457618711574469e-06
adjusted O 0 4.595727887135581e-07
odds O 0 1.4171413340591243e-06
ratio O 0 1.990600821955013e-07
for O 0 1.1819670362456236e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 3.4259718972862174e-07
with O 0 4.92614837810379e-10
any O 0 1.8985701899509877e-09
past O 0 4.240367168506509e-09
use O 0 8.997268485799736e-10
of O 0 2.36026820310542e-09
oral O 0 1.4367518019753334e-07
contraceptives O 0 6.974723305575026e-07
was O 0 1.7180408917738532e-07
0 O 0 4.4607681104480434e-08
. O 0 1.9861289501932333e-08

5 O 0 3.2867988011275884e-06
( O 0 1.0864008359590116e-08
95 O 0 4.37255408769488e-07
percent O 0 4.4995204007136635e-08
confidence O 0 6.926719464672715e-08
interval O 0 1.4989399943488024e-08
, O 0 1.0928887794747766e-09
0 O 0 2.1511976644461583e-09
. O 0 1.1342107808509638e-10
3 O 0 1.990086762049259e-09
to O 0 4.177642953795413e-10
0 O 0 4.8875916647261874e-09
. O 0 8.592887512648417e-10
8 O 0 3.2468349786540784e-08
) O 0 2.823600020462891e-09
. O 0 6.630077109548438e-08

The O 0 5.675908596458612e-06
risk O 0 2.6744802994471684e-07
decreased O 0 8.644180482519914e-09
with O 0 6.901362814559775e-11
increasing O 0 2.5508892220749146e-10
duration O 0 1.5362434879762077e-08
of O 0 3.232337508762839e-09
use O 0 2.5005597592553386e-09
( O 0 2.620057781843599e-10
P O 0 8.917559313204038e-08
for O 0 3.847076546215078e-10
trend O 0 1.1018134182805284e-09
, O 0 6.312593503476904e-11
< O 0 4.0491205943737896e-09
0 O 0 1.4397516512332231e-09
. O 0 3.828905595359977e-11
001 O 0 5.253971924190637e-09
) O 0 9.147455362623624e-12
; O 0 5.322135527424665e-12
use O 0 2.891434869312093e-10
for O 0 1.5077306070310215e-09
six O 0 2.277037447484531e-09
or O 0 6.209207592533517e-10
more O 0 1.8017400071901335e-11
years O 0 3.207983045871998e-10
was O 0 2.424513256826799e-09
associated O 0 1.865334553485809e-10
with O 0 1.9473022153104758e-11
a O 0 1.5181015333709524e-09
60 O 0 1.7357250081673214e-09
percent O 0 2.6910815242864317e-10
reduction O 0 6.927429740954949e-09
in O 0 8.5904341418086e-09
risk O 0 6.031644375070755e-07
. O 0 1.8899055476140347e-06

Oral O 0 0.0009605198865756392
- O 0 1.9512481230776757e-05
contraceptive O 0 2.2594210804527393e-06
use O 0 4.2012519685385996e-08
protected O 1 0.8859010934829712
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 2.2392820930861035e-09
for O 0 7.266138385420007e-11
carriers O 0 1.373005320548515e-10
of O 0 2.6331312241723026e-08
the O 0 1.0499477554049008e-07
BRCA1 O 0 2.9388134148433664e-09
mutation O 0 1.9526515127044064e-10
( O 0 5.497114048680363e-12
odds O 0 7.095331544526573e-10
ratio O 0 1.0712552372948991e-10
, O 0 3.647655788530102e-11
0 O 0 3.070042275954421e-10
. O 0 1.0277863282670552e-10
5 O 0 1.000724281219334e-09
; O 0 2.206331090048863e-10
95 O 0 5.435994410163403e-08
percent O 0 7.537747315211618e-09
confidence O 0 1.3704294588023913e-08
interval O 0 5.767971433812136e-09
, O 0 2.988863323505342e-10
0 O 0 9.149698221300184e-10
. O 0 1.1148325318455221e-10
3 O 0 2.8878925917297238e-09
to O 0 6.802072793909986e-10
0 O 0 3.918393609581017e-09
. O 0 1.1792981868818941e-10
9 O 0 2.3954442873730386e-09
) O 0 1.3899127508654185e-11
and O 0 3.188868613612783e-11
for O 0 2.588006198234183e-11
carriers O 0 2.103537760644869e-10
of O 0 3.259213343653755e-08
the O 0 1.8559325098976842e-07
BRCA2 O 0 2.4300794265741388e-08
mutation O 0 8.400945494813072e-10
( O 0 1.0152021584497462e-10
odds O 0 7.899687126666777e-09
ratio O 0 1.1367258245797984e-09
, O 0 1.5645319761947718e-10
0 O 0 7.791626788211659e-10
. O 0 4.48369882888322e-11
4 O 0 4.315242829733279e-09
; O 0 4.686901977635216e-10
95 O 0 7.25913977817072e-08
percent O 0 1.307488517454658e-08
confidence O 0 1.9687004026991417e-08
interval O 0 8.281817898136978e-09
, O 0 3.8653247269593294e-10
0 O 0 1.926935055962531e-09
. O 0 1.459820875293616e-10
2 O 0 4.020193067333366e-09
to O 0 4.4784020936106117e-10
1 O 0 2.0507940234892885e-08
. O 0 8.901814285700027e-10
1 O 0 2.270741106258356e-08
) O 0 1.5907141159843263e-09
. O 0 3.219086508465807e-08

CONCLUSIONS O 0 3.6795354390051216e-05
Oral O 0 0.03250451385974884
- O 0 7.979336805874482e-05
contraceptive O 0 2.8861761620646575e-06
use O 0 4.216036408877244e-09
may O 0 1.1924993215117752e-09
reduce O 0 5.909517875046788e-10
the O 0 3.1157503244116924e-09
risk O 0 1.4540150061748136e-07
of O 1 0.9999587535858154
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.6773751276843996e-09
women O 0 1.1417501059179935e-12
with O 0 1.0394999748128408e-12
pathogenic O 0 7.711022931289335e-10
mutations O 0 3.683032212542514e-10
in O 0 1.1076332073756134e-09
the O 0 1.0347726231429988e-07
BRCA1 O 0 1.0365425140435036e-07
or O 0 1.7234742699656636e-07
BRCA2 O 0 1.0875378393393476e-06
gene O 0 1.771569600350631e-06

A O 0 3.5141114494763315e-05
Japanese O 0 4.441780038177967e-05
family O 0 1.9249305296398234e-06
with O 0 3.5999558889443506e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 4.315870683058165e-08
a O 0 2.054126184702909e-07
codon O 0 2.8812094043928482e-08
291 O 0 1.4629384814668356e-08
deletion O 0 2.395902320984078e-08
: O 0 9.642000392551253e-11
a O 0 6.89902357464689e-10
clinical O 0 2.2684121248062183e-08
, O 0 3.493048905678364e-10
biochemical O 0 1.1819857945738477e-06
, O 0 6.1755258684570435e-09
pathological O 0 9.816041711019352e-05
, O 0 2.508288465818964e-09
and O 0 2.731095349872703e-09
genetic O 0 1.54145396891181e-07
report O 0 2.0570347203374695e-08
. O 0 3.395069541056728e-07

We O 0 7.51210222915688e-08
report O 0 3.9442484833784874e-09
a O 0 1.0876925138347815e-08
Japanese O 0 4.7626903665332065e-07
family O 0 2.505306895272952e-07
with O 0 1.484979748056503e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0001251954963663593
ALD B-Disease 1 1.0
) O 0 1.4268816350693214e-08
with O 0 2.2956667677931364e-09
a O 0 7.553855851938351e-08
three O 0 4.9769443677405434e-08
base O 0 3.51533412867866e-06
pair O 0 3.6496763300419843e-07
deletion O 0 9.97911797639972e-08
( O 0 1.887053402427341e-09
delGAG O 0 1.432587026783949e-07
291 O 0 3.0711098109037493e-09
) O 0 1.4143618221051923e-10
in O 0 2.3772381840814205e-09
the O 0 4.0856471628103463e-07
ALD B-Disease 1 1.0
gene O 0 1.0101743100676686e-05
. O 0 1.34678634822194e-06

A O 0 6.164217211335199e-06
variety O 0 1.243464424760532e-07
of O 0 1.3235397489097522e-07
phenotypes O 0 3.6049516438652063e-07
were O 0 1.2704219010117868e-08
observed O 0 4.91631402255166e-09
within O 0 2.4397799336384196e-09
this O 0 1.6283250303672503e-09
family O 0 1.2578868791024433e-07
. O 0 5.667264701969543e-08

While O 0 1.1524806495799567e-06
the O 0 1.2825095154767041e-06
proband O 0 1.6389456504839472e-05
( O 0 6.748781533616466e-09
patient O 0 5.220112484494166e-07
1 O 0 6.880769092276751e-07
) O 0 1.016781991936e-09
was O 0 4.58995472740753e-08
classified O 0 9.705019898831324e-09
as O 0 2.803443921450821e-09
having O 0 1.4134104997509667e-09
a O 0 7.404343360661869e-09
rare O 0 3.991373453970937e-09
intermediate O 0 5.744895759107749e-08
type O 0 1.5431703559443122e-07
of O 0 4.1710077880452445e-07
adult O 0 1.6001001768017886e-07
cerebral O 0 3.7812803839187836e-06
and O 0 1.1212722483833204e-07
cerebello O 0 0.00035653170198202133
- O 0 0.00010569128062343225
brain O 0 1.2975704066775506e-06
stem O 0 2.827156508899975e-09
forms O 0 1.0628685709335173e-09
, O 0 1.326601051232501e-10
his O 0 7.330639206770684e-09
younger O 0 1.744719924090532e-07
brother O 0 2.977321400976507e-06
( O 0 6.760579873699157e-10
patient O 0 7.31430205291872e-08
2 O 0 1.6836720817536843e-07
) O 0 2.4221546990332854e-10
and O 0 3.5764862182929846e-09
nephew O 0 0.002219691639766097
( O 0 1.9784195615102362e-08
patient O 0 7.434562576236203e-06
3 O 0 1.3908052096667234e-06
) O 0 5.997189411743875e-10
had O 0 1.8166465665103715e-08
a O 0 2.4728248604333203e-07
childhood O 0 0.002668291563168168
ALD B-Disease 1 1.0
type O 1 0.9943576455116272
. O 0 7.798846127116121e-06

Another O 0 1.0394035598437767e-05
nephew O 0 0.0014170571230351925
( O 0 2.4690633537716167e-08
patient O 0 1.1613359447437688e-06
4 O 0 5.799590780952713e-07
) O 0 6.356236093019163e-10
of O 0 4.149439547518341e-08
patient O 0 6.244763062568381e-05
1 O 0 4.25998296122998e-05
was O 0 3.29498698192765e-06
classified O 0 5.4652076642014435e-08
as O 0 6.982987521553241e-09
having O 0 4.39716529854195e-09
an O 0 4.2665940225283805e-10
adolescent O 0 3.87724430339631e-09
form O 0 3.997979280967456e-09
. O 0 3.9506730331595463e-07

The O 0 3.2814888982102275e-05
tau O 0 1.001220334728714e-05
level O 0 3.2768195978860604e-07
in O 0 9.148341639786395e-09
the O 0 2.793501430176093e-08
cerebrospinal O 0 5.4769785151620454e-08
fluid O 0 4.851565904573363e-08
( O 0 7.062202378449456e-09
CSF O 0 1.5148913007578813e-05
) O 0 4.439384859722395e-09
in O 0 2.242544461239504e-08
patient O 0 0.0002173294487874955
1 O 0 0.0002611246018204838
was O 0 1.836796036513988e-05
as O 0 2.0246915255484055e-08
high O 0 4.777051287874201e-08
as O 0 1.0607516254257376e-10
that O 0 7.788320335877508e-12
of O 0 4.162404032559408e-10
patients O 0 9.86134396363525e-10
with O 0 5.1302277981335465e-09
Alzheimers B-Disease 1 1.0
disease I-Disease 0 0.04046255350112915
( O 0 1.0170457809266509e-09
AD B-Disease 0 1.3791569131171855e-07
) O 0 7.814774605208186e-09
. O 0 4.391116092961056e-08

His O 0 6.161763303680345e-05
brain O 0 0.00013975276669953018
magnetic O 0 4.030832315038424e-06
resonance O 0 2.7315609258948825e-06
image O 0 9.774591944733402e-07
( O 0 1.958143336366902e-08
MRI O 0 3.6232726415619254e-05
) O 0 6.910221728162469e-09
showed O 0 1.4911352153035295e-08
abnormalities B-Disease 0 9.621215895094792e-07
in I-Disease 0 6.1062102041375965e-09
the I-Disease 0 1.492701073857461e-07
bilateral I-Disease 0 0.0031958608888089657
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999995231628418
and O 0 0.00020527996821328998
brain O 0 0.003775605233386159
stem O 0 2.2212094563656137e-07
, O 0 8.685542285391534e-10
but O 0 3.3878919114549433e-10
not O 0 5.664816393746719e-10
in O 0 3.796946757006481e-09
the O 0 3.349150574649684e-07
cerebral O 0 1.796764445316512e-05
white O 0 1.417626265265426e-07
matter O 0 1.1233480812222751e-08
, O 0 7.387238737388557e-11
where O 0 7.198559109911074e-11
marked O 0 8.85392703597887e-10
reductions O 0 1.9975109566416904e-08
of O 0 2.3939981019793777e-07
the O 0 2.3904505042082747e-07
cerebral O 0 2.5019310214702273e-06
blood O 0 4.621729843279354e-08
flow O 0 5.25982724042251e-09
and O 0 2.8703364129967213e-09
oxygen O 0 5.401834712870368e-08
metabolism O 0 2.3307880070433384e-08
were O 0 4.4680442679023713e-10
clearly O 0 7.360912990250768e-10
demonstrated O 0 1.6885524090071158e-09
by O 0 1.0786245230320901e-09
positron O 0 1.7727886358898104e-07
emission O 0 1.1419030698789356e-07
tomography O 0 7.586457968500326e-07
( O 0 9.192629768506322e-09
PET O 0 1.4427261021410231e-06
) O 0 3.6212339793451065e-09
. O 0 4.3441072961059035e-08

In O 0 9.103296179091558e-07
patients O 0 8.303021559186163e-07
2 O 0 1.4115113344814745e-06
and O 0 2.619506034307051e-08
3 O 0 3.411138038700301e-07
, O 0 1.6985919337741961e-09
the O 0 2.4982060864431332e-08
autopsy O 0 6.463391741817759e-07
findings O 0 2.5077540044549096e-08
showed O 0 3.602662346224861e-08
massive O 0 4.393384188006166e-06
demyelination B-Disease 1 1.0
of I-Disease 1 0.9999805688858032
the I-Disease 0 0.11025441437959671
cerebral I-Disease 1 0.8592427968978882
white I-Disease 0 1.0446398164276616e-06
matter I-Disease 0 1.2056273313021393e-08
with O 0 4.608591563926012e-10
sparing O 0 2.2191323978404398e-07
of O 0 6.667069101240486e-06
the O 0 0.00013332386151887476
U O 0 0.04260707646608353
- O 0 6.155966548249125e-05
fibers O 0 2.2616629848926095e-06
, O 0 1.582863284887992e-09
compatible O 0 2.9170865900596255e-07
with O 0 1.096145507695212e-09
the O 0 1.0722314591760096e-08
findings O 0 2.7644060374143464e-09
of O 0 8.613785240640937e-08
childhood O 0 0.01836477220058441
ALD B-Disease 1 1.0
. O 0 1.1114027984149288e-05

Oleic O 0 0.031959306448698044
and O 0 2.932565621449612e-05
erucic O 0 0.19450804591178894
acids O 0 1.996933633563458e-06
( O 0 1.944202487891289e-08
Lorenzos O 0 2.5277320219174726e-06
Oil O 0 2.297079220170417e-07
) O 0 1.2312000030600956e-10
were O 0 2.9187355310433816e-10
administered O 0 1.6159059645914908e-09
to O 0 1.6891836818189176e-09
patients O 0 7.587222405902594e-09
1 O 0 1.2860132869718655e-07
and O 0 6.0831584214326995e-09
4 O 0 4.9089045717209956e-08
, O 0 8.422038066946413e-11
but O 0 4.575935463879688e-11
sufficient O 0 3.33505090210906e-09
effectiveness O 0 1.5421560917161514e-08
was O 0 1.4743281262497021e-08
not O 0 9.160362746118977e-11
obtained O 0 1.4530525227485214e-08
. O 0 1.1040021519193033e-07

The O 0 3.5770044632954523e-06
findings O 0 1.258647586155348e-07
in O 0 7.940156976360413e-09
this O 0 3.311149354701115e-09
family O 0 1.9601088752096985e-08
suggest O 0 3.0771946102348124e-10
that O 0 1.0213842271955542e-10
delGAG291 O 0 3.7187106727287755e-08
is O 0 3.658764402558745e-10
part O 0 1.3330825332502627e-09
of O 0 1.2378107427934992e-08
the O 0 8.497805126239655e-09
cause O 0 9.199491302069873e-08
of O 0 4.266549638032302e-07
Japanese O 0 0.00029056170023977757
ALD B-Disease 1 1.0
with O 0 7.726532658125507e-08
phenotypic O 0 2.6639672796591185e-06
variations O 0 1.8806389334713458e-06
. O 0 1.394031983181776e-06

Moreover O 0 1.954004119397723e-06
, O 0 1.3783935770561584e-08
although O 0 9.026527969524523e-09
the O 0 1.8477198437949482e-08
scale O 0 1.550816932649468e-07
of O 0 1.771554103413564e-08
the O 0 4.244129936381569e-09
study O 0 1.200637228526702e-10
is O 0 4.895909372359952e-11
limited O 0 2.6168214817268165e-10
, O 0 1.3817720578845893e-10
there O 0 1.3032942780544232e-10
is O 0 1.9057819211631966e-10
a O 0 2.949871236168633e-09
possibility O 0 2.257095843560819e-08
that O 0 1.4710108686699641e-08
PET O 0 0.00010475472663529217
can O 0 2.507983687394244e-08
detect O 0 3.0687688195030205e-06
an O 0 9.55548706826903e-09
insidious B-Disease 0 1.0658803148544393e-05
lesion I-Disease 0 0.09272776544094086
which O 0 3.0730784583710147e-09
is O 0 2.837159673862999e-10
undetectable O 0 3.3723239756255907e-09
by O 0 1.9409214513377293e-10
computed O 0 3.218411492866835e-08
tomogram O 0 2.043895847236854e-06
( O 0 2.8896998127692086e-09
CT O 0 8.157962838595267e-06
) O 0 2.060166925943463e-09
or O 0 2.797413412025662e-09
MRI O 0 3.4540835258667357e-07
analysis O 0 3.3725167103426656e-09
, O 0 9.029653413872296e-11
and O 0 1.160224624707773e-10
that O 0 1.9334013556804308e-11
the O 0 1.2493590606510452e-09
higher O 0 4.1948520212997664e-09
level O 0 8.927851347095839e-09
of O 0 4.364660632916184e-09
tau O 0 3.94607679865544e-09
reflects O 0 1.5430430544416396e-10
the O 0 9.479633050757386e-11
process O 0 3.9205075297310543e-10
of O 0 2.7287783144203104e-09
neuronal B-Disease 0 6.224762273632223e-06
degeneration I-Disease 1 0.9999783039093018
in O 0 5.024147071708285e-07
ALD B-Disease 1 1.0
. O 0 4.9558708269614726e-05

Lorenzos O 0 0.0009392052888870239
Oil O 0 4.190299023321131e-06
should O 0 2.555828659822623e-09
be O 0 3.2982261366498733e-10
given O 0 3.4219807543145464e-10
in O 0 6.001468766392293e-10
the O 0 2.7764222032544694e-09
early O 0 4.4525904741021805e-08
stage O 0 2.6778025130624883e-08
. O 0 4.584623791714648e-09
. O 0 5.1305242720900424e-08

Nonsense O 0 7.72757084632758e-06
mutation O 0 7.659432554874002e-08
in O 0 1.2258798420816674e-08
exon O 0 3.500957461710641e-07
4 O 0 8.4555779267248e-08
of O 0 5.5228599471490725e-09
human O 0 7.513919264567903e-09
complement O 0 1.491657997121365e-07
C9 O 0 0.04059194028377533
gene O 0 5.7313791046453844e-08
is O 0 7.657555700646412e-10
the O 0 1.337524313527183e-09
major O 0 5.765573352078945e-09
cause O 0 2.1065188704483262e-08
of O 0 8.242267313107732e-08
Japanese O 0 5.467888968269108e-06
complement B-Disease 0 6.117366865510121e-05
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
. O 0 4.7378689487231895e-06

Deficiency B-Disease 1 0.9999561309814453
of I-Disease 0 0.012576526030898094
the I-Disease 0 0.00024801577092148364
ninth I-Disease 0 0.01363044697791338
component I-Disease 0 3.794849135374534e-06
of I-Disease 0 7.210585977190931e-07
human I-Disease 0 5.329897234673808e-08
complement I-Disease 0 5.834290277562104e-07
( O 0 9.327605710041098e-08
C9 O 1 0.999997615814209
) O 0 7.078749142408469e-09
is O 0 4.5408993232243233e-10
the O 0 1.4394989644728184e-09
most O 0 3.715240337598402e-10
common O 0 1.4943560699975933e-07
complement B-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
in O 0 1.0137422457034972e-08
Japan O 0 2.6752195125823164e-08
but O 0 4.885827298295453e-10
is O 0 2.2754471917796337e-10
rare O 0 1.3175717183955271e-09
in O 0 1.8688423031321122e-10
other O 0 2.4708182722044114e-10
countries O 0 3.5527358832609934e-10
. O 0 1.6328937135767774e-07

We O 0 3.1666419886278163e-07
studied O 0 2.1888153867166693e-07
the O 0 1.8793031131281168e-08
molecular O 0 3.8062296425778186e-08
basis O 0 6.884426539954802e-08
of O 0 1.6204720623136382e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
in O 0 1.8308531934962957e-07
four O 0 4.193630331883469e-08
Japanese O 0 7.5684956755139865e-06
C9 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 0.9999997615814209
patients O 0 0.0003694159386213869
who O 0 1.7111682382164872e-07
had O 0 3.653914575352246e-07
suffered O 0 0.00015791978512424976
from O 0 1.4040574569662567e-06
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 3.9597966861038e-06

Direct O 0 1.175044417323079e-06
sequencing O 0 1.050953187586856e-06
of O 0 1.2957218586961972e-06
amplified O 0 2.9154000458220253e-06
C9 O 0 0.00016831474204082042
cDNA O 0 1.0340816061216174e-06
and O 0 1.546810501906748e-08
DNA O 0 1.1533423105447582e-07
revealed O 0 1.0404743733261057e-07
a O 0 1.9604529555294903e-08
nonsense O 0 2.3783458757975495e-08
substitution O 0 2.6125354324335603e-08
( O 0 8.960482356101807e-10
CGA O 0 3.875620109283773e-07
- O 0 1.4412063364943606e-07
- O 0 2.5167054218400153e-07
> O 0 3.112794217940973e-07
TGA O 0 7.370711614385073e-07
) O 0 3.962864203455041e-10
at O 0 1.231700963444382e-09
codon O 0 3.5204922310683173e-10
95 O 0 1.0923037585541806e-08
in O 0 2.0080836993230378e-09
exon O 0 6.07277357289604e-08
4 O 0 4.601595904318856e-08
in O 0 2.0292758584616877e-09
the O 0 1.6109645173401077e-08
four O 0 3.43719932516251e-08
C9 B-Disease 1 0.9999889135360718
- I-Disease 0 0.25462278723716736
deficient I-Disease 0 0.00014764515799470246
individuals O 0 8.790930650093287e-09
. O 0 5.218813612373197e-07

An O 0 1.6741422825816699e-07
allele O 0 7.464284124125697e-08
- O 0 5.637702926719612e-08
specific O 0 6.950538367078707e-09
polymerase O 0 1.1230845302634407e-06
chain O 0 2.4479882654304674e-07
reaction O 0 3.5921917884707e-08
system O 0 3.209721910479857e-07
designed O 0 7.669753898653653e-08
to O 0 8.19473555679906e-09
detect O 0 3.272974424817221e-08
exclusively O 0 1.9726873468073336e-09
only O 0 1.7704644694749305e-10
one O 0 2.1490394186418627e-10
of O 0 1.9315899990601793e-09
the O 0 2.9631512798999893e-09
normal O 0 4.320810376157169e-09
and O 0 9.966935055061299e-10
mutant O 0 8.479925095450369e-10
alleles O 0 1.3178442712091787e-11
indicated O 0 1.52597393054954e-10
that O 0 2.454662688389231e-11
all O 0 1.284307798998796e-10
the O 0 2.188423220417235e-09
four O 0 5.945141601237935e-10
patients O 0 5.119297208366902e-10
were O 0 1.1620101547649142e-09
homozygous O 0 2.222623196601603e-09
for O 0 9.183301896698026e-10
the O 0 9.704353765016549e-09
mutation O 0 1.5247294538056622e-09
in O 0 1.6252283963069658e-09
exon O 0 7.056294037965927e-08
4 O 0 3.825239502930344e-08
and O 0 4.79970507782923e-10
that O 0 8.494393383129406e-11
the O 0 4.36470237730191e-09
parents O 0 9.006024814794955e-10
of O 0 9.333511741260736e-09
patient O 0 2.459733536852582e-07
2 O 0 6.21774574938172e-07
were O 0 9.424461211438029e-08
heterozygous O 0 3.604332476925265e-08
. O 0 1.1495330198840747e-07

The O 0 7.371738206529699e-07
common O 0 2.833634766830073e-07
mutation O 0 1.7270869179242254e-08
at O 0 1.1602987903813755e-08
codon O 0 2.325325043628368e-09
95 O 0 1.277001331345673e-07
in O 0 3.095836120792228e-08
exon O 0 7.578069585179037e-07
4 O 0 1.0087259028068729e-07
might O 0 1.163036777995785e-09
be O 0 1.9206961021644986e-10
responsible O 0 3.0059629785306186e-10
for O 0 3.420205785253927e-10
most O 0 4.089378613514327e-09
Japanese O 0 6.45571935820044e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9994899034500122
. O 0 1.5700705091603595e-07
. O 0 3.3092257467615127e-07

BRCA1 O 0 5.500176598616235e-07
required O 0 6.26003782144835e-08
for O 0 1.944996164127133e-08
transcription O 0 2.698187472560676e-06
- O 0 3.7061961393192178e-06
coupled O 0 2.750434077825048e-06
repair O 0 0.018842855468392372
of O 0 5.185870577406604e-07
oxidative O 0 6.757692062819842e-06
DNA O 0 2.2896174414199777e-06
damage O 0 0.00011555117816897109
. O 0 4.07859289452972e-07

The O 0 0.00015913572860881686
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 1.4319630281534046e-06
gene O 0 8.62461480011234e-09
BRCA1 O 0 5.128183655500607e-09
encodes O 0 1.6369351429901258e-09
a O 0 4.5664370063036586e-09
zinc O 0 2.750578573795792e-07
finger O 0 2.565031707035814e-07
protein O 0 1.5296354405336388e-08
of O 0 4.061614333750185e-08
unknown O 0 7.320596040472083e-08
function O 0 2.5649526946835977e-08
. O 0 6.26231866363014e-08

Association O 0 1.7258344087167643e-06
of O 0 7.702922630414832e-06
the O 0 6.192194632603787e-07
BRCA1 O 0 1.4271892112560636e-08
protein O 0 1.321971865309024e-09
with O 0 1.19656326513784e-10
the O 0 9.435069614482927e-09
DNA O 0 1.229147983394796e-06
repair O 0 0.0012936488492414355
protein O 0 1.290018076360866e-06
Rad51 O 0 1.871162794486736e-06
and O 0 2.3618715871975837e-09
changes O 0 2.7505422384166422e-09
in O 0 3.681903004704168e-09
the O 0 7.540665869498753e-09
phosphorylation O 0 5.938718405928967e-09
and O 0 3.879034427001216e-09
cellular O 0 2.968962853344692e-08
localization O 0 2.0289947144647158e-07
of O 0 5.1950326707128625e-08
the O 0 2.1130379224132412e-08
protein O 0 7.804541013456401e-09
after O 0 8.936182460672626e-09
exposure O 0 1.3659123609954804e-08
to O 0 1.96735183699559e-09
DNA O 0 6.377445060934406e-07
- O 0 8.315153081639437e-07
damaging O 0 5.103426587993454e-07
agents O 0 4.192420632875837e-09
are O 0 3.333603879052127e-11
consistent O 0 1.0410093898016726e-09
with O 0 1.6809294234310102e-10
a O 0 3.445980611971322e-09
role O 0 2.1919879245047014e-08
for O 0 4.787629404034988e-09
BRCA1 O 0 3.2326536114624105e-08
in O 0 1.0376755454899467e-08
DNA O 0 6.2577910284744576e-06
repair O 1 0.8726596236228943
. O 0 8.566810720367357e-06

Here O 0 1.6523684962521656e-06
, O 0 7.41180361529814e-09
it O 0 5.06931552290979e-10
is O 0 2.8045227251638494e-10
shown O 0 9.6112873215759e-10
that O 0 8.749274083008629e-10
mouse O 0 5.267561391519848e-07
embryonic O 0 2.4277403554151533e-07
stem O 0 1.623247101179004e-07
cells O 0 4.6235817308115656e-07
deficient B-Disease 0 0.000267170078586787
in I-Disease 0 5.5615945626641405e-08
BRCA1 I-Disease 0 2.7372816902015984e-08
are O 0 3.5266617404161593e-10
defective O 0 1.112972427108616e-06
in O 0 3.0599434097666744e-08
the O 0 5.7407440579027025e-08
ability O 0 3.2014504380839526e-09
to O 0 9.132141709500274e-10
carry O 0 1.8295321924099994e-09
out O 0 8.038135490551213e-09
transcription O 0 4.561172772810096e-07
- O 0 2.2571707631868776e-06
coupled O 0 4.735398306365823e-06
repair O 0 0.012647985480725765
of O 0 4.875025183537218e-07
oxidative O 0 3.252797114328132e-06
DNA O 0 6.243705229280749e-06
damage O 1 0.6963549852371216
, O 0 2.45255926678567e-09
and O 0 2.9216553620869945e-09
are O 0 4.839371126053038e-10
hypersensitive O 0 2.3274662908079335e-06
to O 0 2.4296250344946202e-08
ionizing O 0 0.0006173377041704953
radiation O 1 0.609304666519165
and O 0 4.0081442165273984e-08
hydrogen O 0 1.1717673942257534e-07
peroxide O 0 1.6781941667431965e-06
. O 0 4.016895900349482e-07

These O 0 1.423068880512801e-07
results O 0 8.155725339520359e-08
suggest O 0 4.067242542760141e-08
that O 0 1.2867464427301911e-08
BRCA1 O 0 1.0208208323092549e-07
participates O 0 8.592858868894382e-09
, O 0 2.3396581894097324e-10
directly O 0 3.4217981226269956e-10
or O 0 8.919932570350397e-10
indirectly O 0 1.1086900286727541e-09
, O 0 2.480162186735413e-10
in O 0 3.0502107506436005e-09
transcription O 0 1.3940911230747588e-05
- O 0 6.084361666580662e-05
coupled O 0 1.1126965546282008e-05
repair O 0 0.03795129060745239
of O 0 3.233406289382401e-07
oxidative O 0 7.383487741208228e-07
DNA O 0 6.159219196888444e-07
damage O 0 9.72214274952421e-06
. O 0 1.562940710186922e-08
. O 0 8.39326474988411e-08

Truncation O 0 0.00010199429380008951
mutations O 0 4.020356811906822e-07
in O 0 1.2842063412676907e-08
the O 0 3.168007012277485e-08
transactivation O 0 2.022145054070279e-05
region O 0 5.149112212166074e-07
of O 0 2.7832984414999373e-06
PAX6 O 1 0.992994487285614
result O 0 4.652443294617115e-06
in O 0 2.616825156565028e-07
dominant O 0 4.419875767780468e-05
- O 0 1.8213548855783301e-06
negative O 0 6.125950591240326e-08
mutants O 0 2.126860181306256e-06
. O 0 2.0413817480857688e-07

PAX6 O 0 0.014649552293121815
is O 0 5.920489911659388e-07
a O 0 1.1377766639952824e-07
transcription O 0 8.326455258611531e-08
factor O 0 4.228744909795523e-09
with O 0 3.2064598198822125e-10
two O 0 1.8118079259110687e-09
DNA O 0 4.5750173427450136e-08
- O 0 6.260754048525996e-08
binding O 0 1.8192123363292012e-08
domains O 0 2.7521180001599532e-08
( O 0 7.535659318769206e-10
paired O 0 8.781344540409464e-09
box O 0 5.569013978856674e-07
and O 0 2.1097436686545734e-08
homeobox O 0 1.5118700957827969e-06
) O 0 1.4563229511210807e-09
and O 0 6.238650929191181e-09
a O 0 7.692506187595427e-08
proline O 0 3.5140161003255344e-07
- O 0 8.577582661928318e-07
serine O 0 6.465999717875093e-07
- O 0 1.4766943650101894e-06
threonine O 0 3.80534089572393e-07
( O 0 2.964677614514244e-09
PST O 0 2.289833537361119e-05
) O 0 2.6187552126799574e-09
- O 0 5.202201691645314e-08
rich O 0 3.300520035054433e-08
transactivation O 0 7.077508598740678e-06
domain O 0 2.1121157089964981e-07
. O 0 6.303938704377288e-08

PAX6 O 1 0.9999982118606567
regulates O 0 4.898659244645387e-05
eye O 0 0.06624443084001541
development O 0 5.331992269930197e-07
in O 0 2.6587063661764887e-09
animals O 0 1.1275980149605402e-09
ranging O 0 8.516562566285302e-09
from O 0 3.327673914199636e-09
jellyfish O 0 1.6203511421508665e-08
to O 0 6.028467058882825e-09
Drosophila O 0 5.255297708117723e-08
to O 0 3.9120089390110024e-09
humans O 0 1.4163425987590017e-07
. O 0 3.0616575941166957e-07

Heterozygous O 0 5.284240387481987e-07
mutations O 0 3.077960641917343e-08
in O 0 3.0096189984618604e-09
the O 0 7.348235797621783e-09
human O 0 1.5408977205311203e-08
PAX6 O 0 5.061516640125774e-05
gene O 0 7.527933831852351e-09
result O 0 2.0958614843635814e-09
in O 0 4.232664496672811e-10
various O 0 6.767804650031906e-10
phenotypes O 0 2.9559442893400956e-08
, O 0 1.4656879876451256e-10
including O 0 1.2607103139217202e-09
aniridia B-Disease 1 1.0
, O 0 5.851418904967431e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.90885882445491e-08
autosomal B-Disease 0 1.319945204159012e-05
dominant I-Disease 0 2.7883068469236605e-05
keratitis I-Disease 1 1.0
, O 0 3.071685483746478e-08
and O 0 4.0246993648906937e-07
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9836859107017517

It O 0 5.519745727156078e-08
is O 0 2.098433427022428e-09
believed O 0 3.452322649977191e-09
that O 0 7.636344334649436e-11
the O 0 9.053421345939228e-10
mutated O 0 3.1009759204891907e-09
allele O 0 7.988371741873834e-09
of O 0 4.894366867347344e-08
PAX6 O 0 5.411006713984534e-05
produces O 0 5.539064318327291e-09
an O 0 1.6574655536949479e-10
inactive O 0 6.9030288152305275e-09
protein O 0 3.048944208217108e-08
and O 0 5.050559082064865e-08
aniridia B-Disease 1 1.0
is O 0 3.194583797494488e-08
caused O 0 1.6316002415805997e-07
due O 0 8.036320764404081e-07
to O 0 2.3598824228088233e-08
genetic O 0 1.0924140951829031e-06
haploinsufficiency O 0 1.7452341126045212e-05
. O 0 8.031072979974851e-07

However O 0 1.182010578304471e-06
, O 0 1.832138352142465e-08
several O 0 2.347526617541007e-09
truncation O 0 4.055066540331609e-07
mutations O 0 1.2737702448362143e-08
have O 0 7.766359222394215e-10
been O 0 1.1549063927418501e-09
found O 0 4.819621368667981e-10
to O 0 8.032702281113302e-11
occur O 0 1.5941180320222514e-10
in O 0 9.473853923580577e-10
the O 0 1.1630707064114176e-08
C O 0 6.485058179350744e-07
- O 0 2.9466852424775425e-07
terminal O 0 1.3087305887893308e-06
half O 0 1.8103373022881897e-08
of O 0 1.9085995006662415e-08
PAX6 O 0 0.0001984063710551709
in O 0 1.7253746875667275e-08
patients O 0 1.3410807575553463e-08
with O 0 1.4422425032023511e-08
Aniridia B-Disease 1 1.0
resulting O 0 1.3976055015518796e-05
in O 0 6.698193999454816e-08
mutant O 0 1.3783357566410359e-08
proteins O 0 9.259985139786764e-11
that O 0 9.527251210172949e-11
retain O 0 1.4747584486940468e-08
the O 0 2.187001690856505e-08
DNA O 0 7.06704241792977e-08
- O 0 2.6975182976229917e-08
binding O 0 7.377840560707227e-09
domains O 0 4.142866050216298e-09
but O 0 1.6303449701382533e-09
have O 0 8.057042810705184e-10
lost O 0 5.470547392860681e-08
most O 0 7.909377597314915e-10
of O 0 7.371679711098977e-09
the O 0 4.835980504935833e-08
transactivation O 0 4.451081167644588e-06
domain O 0 5.560056024478399e-07
. O 0 2.1419953100121347e-07

It O 0 1.8954816027871857e-07
is O 0 5.577291961600395e-09
not O 0 5.864077556871905e-10
clear O 0 7.3203834105584065e-09
whether O 0 3.2641949143652482e-09
such O 0 7.007457281105189e-09
mutants O 0 5.6535168369009625e-06
really O 0 1.5582413936954254e-07
behave O 0 4.050959123702569e-09
as O 0 4.778269779848188e-09
loss O 0 7.50653015302305e-08
- O 0 1.6200365848817455e-07
of O 0 1.8932084913103608e-06
- O 0 2.670893991307821e-06
function O 0 1.1917813402817501e-08
mutants O 0 1.9338765255838553e-08
as O 0 1.097903101765496e-09
predicted O 0 6.695572540849071e-09
by O 0 2.3045463315440884e-09
haploinsufficiency O 0 1.4830176951363683e-05
. O 0 1.1235493957428844e-06

Contrary O 0 2.7283767849439755e-06
to O 0 2.999019699245764e-08
this O 0 1.16477727463149e-09
theory O 0 5.8018816417870767e-08
, O 0 1.6023709026313782e-09
our O 0 4.011874388254455e-09
data O 0 3.6889113985694166e-09
showed O 0 2.255162501185737e-09
that O 0 1.2497373969022618e-10
these O 0 1.4169654338758164e-09
mutants O 0 1.0180811216287111e-07
are O 0 6.87926104969705e-10
dominant O 0 2.782072670015623e-07
- O 0 6.8795166896507e-08
negative O 0 3.5438447731905853e-09
in O 0 1.4956778038310858e-09
transient O 0 1.6221623866385926e-07
transfection O 0 2.389121789292403e-07
assays O 0 1.3448794966564037e-08
when O 0 9.643629006461651e-09
they O 0 6.521980178142428e-10
are O 0 1.157450593702869e-10
coexpressed O 0 2.449150997563265e-07
with O 0 3.143992843845922e-09
wild O 0 5.292658329381084e-07
- O 0 3.6914548218192067e-07
type O 0 1.016899841488339e-05
PAX6 O 1 0.9989909529685974
. O 0 4.16237116951379e-06

We O 0 4.362877916719299e-07
found O 0 2.9718695060410028e-08
that O 0 2.5032702577476584e-09
the O 0 5.395398972041221e-08
dominant O 0 3.832239599432796e-06
- O 0 3.430630783896049e-07
negative O 0 1.634966162455953e-09
effects O 0 3.4802241088982555e-08
result O 0 7.382654931831212e-09
from O 0 5.330646590806509e-09
the O 0 6.627153936733521e-09
enhanced O 0 1.452431774850993e-08
DNA O 0 1.1505404629019722e-08
binding O 0 3.013157057196736e-09
ability O 0 2.8532134432879275e-09
of O 0 1.6439415162494697e-08
these O 0 3.751522648087757e-09
mutants O 0 4.202798891128623e-07
. O 0 8.691350927847452e-08

Kinetic O 0 4.562758022075286e-06
studies O 0 3.182481123076286e-08
of O 0 2.7815493908178723e-08
binding O 0 2.2487681050620267e-08
and O 0 8.233308257388217e-09
dissociation O 0 1.3084793692996755e-07
revealed O 0 1.7220015635643904e-08
that O 0 1.451031933497049e-10
various O 0 7.857022810142666e-10
truncation O 0 3.186441688285413e-07
mutants O 0 1.2939506177644944e-07
have O 0 5.2334088174177396e-09
3 O 0 5.8706525862817216e-08
- O 0 4.7363691635382565e-08
5 O 0 9.371117215550839e-08
- O 0 9.669049916283257e-08
fold O 0 8.283242891593545e-08
higher O 0 3.094088896204994e-08
affinity O 0 6.898080329165168e-09
to O 0 1.7067433022432965e-09
various O 0 4.862799052318678e-10
DNA O 0 1.0106995240732886e-08
- O 0 3.2534788196869613e-09
binding O 0 8.851867017156678e-10
sites O 0 7.520051803489025e-10
when O 0 3.4686500893776895e-10
compared O 0 1.6397123936418012e-10
with O 0 7.780737859564013e-11
the O 0 1.3255325725936018e-08
wild O 0 1.501802415759812e-07
- O 0 1.3515067109892698e-07
type O 0 4.389681635075249e-06
PAX6 O 1 0.9988573789596558
. O 0 6.5354120124538895e-06

These O 0 6.049582168543566e-08
results O 0 1.5968067756944038e-08
provide O 0 5.990252738286017e-09
a O 0 1.3526511466466218e-08
new O 0 8.023722131156319e-09
insight O 0 5.5772391149844225e-09
into O 0 1.8841976867634003e-09
the O 0 2.0223902552629625e-09
role O 0 5.778156619840047e-09
of O 0 4.47603234476901e-08
mutant O 0 1.0266558092553169e-06
PAX6 O 0 0.0012904794421046972
in O 0 9.396120503879501e-08
causing O 0 9.729849807627033e-06
aniridia B-Disease 1 1.0
. O 0 3.1293166102841496e-07
. O 0 4.673712510339101e-07

Reversal O 0 4.776624700753018e-05
of O 0 1.0342559107812122e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 1 0.9999994039535522
excellent O 0 0.09380463510751724
neuropsychologic O 0 0.0022270171903073788
outcome O 0 2.363753992540296e-05
in O 0 2.0168525338704058e-07
very B-Disease 0 5.37354445384608e-08
- I-Disease 0 1.9943023232826818e-07
long I-Disease 0 1.2783854685949336e-07
- I-Disease 0 1.7485494652191846e-07
chain I-Disease 0 1.1355349727182329e-07
acyl I-Disease 0 7.107107791171074e-08
- I-Disease 0 1.9709872844941856e-07
coenzyme I-Disease 0 8.443441856798017e-08
A I-Disease 0 4.954174983140547e-06
dehydrogenase I-Disease 0 1.65276705956785e-05
deficiency I-Disease 0 1.9402705220272765e-05
. O 0 2.176689832822376e-07

Very B-Disease 0 3.496430053928634e-06
- I-Disease 0 2.746992322499864e-06
long I-Disease 0 2.7065252083957603e-07
- I-Disease 0 1.192782406178594e-07
chain I-Disease 0 5.7049412305332226e-08
acyl I-Disease 0 2.674515364731178e-08
- I-Disease 0 3.2965250085226216e-08
coenzyme I-Disease 0 1.2673965876786042e-08
A I-Disease 0 7.063820817165833e-07
dehydrogenase I-Disease 0 3.775486163704045e-07
( I-Disease 0 2.659730879983613e-09
VLCAD I-Disease 0 0.00044929678551852703
) I-Disease 0 1.4846533780144e-08
deficiency I-Disease 0 7.068300328683108e-05
is O 0 2.612444260918778e-09
a O 0 7.039182037260616e-08
disorder O 0 0.015667950734496117
of O 0 4.165152131463401e-05
fatty O 0 1.0422146260680165e-05
acid O 0 3.765727001336927e-07
beta O 0 3.581703467148145e-08
oxidation O 0 1.3738160831167079e-08
that O 0 1.7099748006454973e-10
reportedly O 0 1.6152043258443882e-08
has O 0 2.9891253361391534e-10
high O 0 3.5768683570580606e-09
rates O 0 2.593987524779351e-10
of O 0 7.307224825225944e-10
morbidity O 0 1.3969263079616212e-07
and O 0 4.245708673522586e-09
mortality O 0 3.0211123203116586e-07
. O 0 7.98842023641555e-08

We O 0 4.638305881599081e-07
describe O 0 1.5944031872550113e-07
the O 0 8.926407701892458e-08
outcome O 0 6.479358205524477e-08
of O 0 8.485952207593073e-08
a O 0 1.8042566551912387e-08
5 O 0 1.0995969468297062e-08
- O 0 4.502410888562736e-09
year O 0 3.891677202716437e-09
- O 0 1.4713145901623648e-07
old O 0 5.4359079513233155e-06
girl O 0 1.1493083462710274e-07
with O 0 2.633763962478497e-08
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.3763066110404907e-06
was O 0 1.3082714076517732e-06
first O 0 3.25930642475214e-08
seen O 0 3.0192566669029475e-08
at O 0 2.87416721533873e-08
5 O 0 2.2097266239029523e-09
months O 0 8.833112574713198e-10
of O 0 6.207597214036298e-10
age O 0 6.234650573588851e-10
with O 0 5.659222535037145e-10
severe O 0 0.1130436360836029
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999864101409912
hepatomegaly B-Disease 1 1.0
, O 1 0.9209214448928833
encephalopathy B-Disease 1 0.9999998807907104
, O 0 3.418702831936571e-08
and O 0 1.5471491678908933e-06
hypotonia B-Disease 1 0.9999665021896362
. O 0 0.0004665213346015662

Biochemical O 0 1.140305812441511e-05
studies O 0 4.2116499798794393e-07
indicated O 0 0.00015293319302145392
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.00011726792581612244
by O 0 2.1741612954429e-09
a O 0 1.5616862469869375e-08
stable O 0 1.429491902626978e-07
yet O 0 6.60400232277425e-08
inactive O 0 1.8033503010883578e-06
enzyme O 0 2.1245714378892444e-06
. O 0 3.7013606402069854e-07

Molecular O 0 1.3402953982222243e-06
genetic O 0 7.447091832091246e-08
analysis O 0 4.262870501037241e-09
of O 0 1.0647585924061786e-07
her O 0 4.633681527366207e-08
VLCAD O 0 8.691131370142102e-05
gene O 0 3.264040771000509e-08
revealed O 0 1.229744270858646e-07
a O 0 3.375156865104145e-08
T1372C O 0 2.393281306467543e-07
( O 0 1.896818258018129e-09
F458L O 0 1.2701825369276776e-07
) O 0 1.7573444921481496e-09
missense O 0 1.589268947554956e-07
mutation O 0 6.615623604488974e-09
and O 0 7.291830250721887e-09
a O 0 7.437864724124665e-08
1668 O 0 0.00012933721882291138
ACAG O 0 0.009392901323735714
1669 O 0 0.0002840393572114408
splice O 0 0.00020368510740809143
site O 0 2.3192308162833797e-06
mutation O 0 1.955029631517391e-07
. O 0 1.7454972578434536e-07

After O 0 8.568654266127851e-07
initial O 0 1.3440337909287337e-07
treatment O 0 8.484494173899293e-07
with O 0 3.1628730745580924e-09
intravenous O 0 2.0051709270774154e-07
glucose O 0 5.52685833099531e-06
and O 0 4.90447789047721e-08
carnitine O 0 1.6515965626240359e-06
, O 0 3.283627592054472e-09
the O 0 6.301799260199914e-08
patient O 0 1.0657394113877672e-06
has O 0 2.5361230893139464e-09
thrived O 0 1.384569969786753e-08
on O 0 4.250010565698403e-09
a O 0 4.813377252332884e-09
low O 0 6.735153306181019e-07
- O 0 6.914838195370976e-07
fat O 0 1.0401287227068678e-06
diet O 0 5.978589712185567e-08
supplemented O 0 4.3495274049121235e-09
with O 0 6.059936441538127e-10
medium O 0 3.16402315547748e-06
- O 0 4.447402261575917e-06
chain O 0 6.25861673597683e-07
triglyceride O 0 2.568963282101322e-07
oil O 0 1.0825125684732484e-07
and O 0 1.2527928694439083e-09
carnitine O 0 5.135732905614532e-08
and O 0 5.372083888843804e-10
avoidance O 0 7.919663289612799e-07
of O 0 9.550261381718883e-08
fasting O 0 2.378560338911484e-06
. O 0 2.2692110235311702e-07

Her O 0 6.04587075940799e-05
ventricular O 1 0.9999821186065674
hypertrophy O 1 0.999580442905426
resolved O 0 3.76310599676799e-05
significantly O 0 1.2111817113691359e-06
over O 0 5.6045948326755024e-08
1 O 0 4.9201062779502536e-08
year O 0 1.4050270946697196e-09
, O 0 4.2773984354482764e-10
and O 0 2.0831756319950046e-09
cognitively O 0 5.621774107567035e-06
, O 0 3.3833666979177224e-09
she O 0 1.1556181567229373e-09
is O 0 1.4024988115313164e-10
in O 0 1.2907763746738965e-10
the O 0 1.5161165656252251e-09
superior O 0 3.040883598259825e-07
range O 0 1.2807382177015825e-07
for O 0 9.948574408724653e-09
age O 0 2.1888884305099054e-07
. O 0 3.2152090057024907e-07

Clinical O 0 7.641631782462355e-06
recognition O 0 0.0005143265007063746
of O 1 1.0
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 4.299951115172007e-07
important O 0 7.101238264084486e-09
because O 0 3.723512054243372e-10
it O 0 3.358743838610678e-11
is O 0 1.625493316337323e-11
one O 0 1.3526697990873249e-11
of O 0 7.983036454106696e-10
the O 0 4.067799430629293e-09
few O 0 1.9983481536200998e-09
directly O 0 5.908889821881758e-09
treatable O 1 0.8797802329063416
causes O 0 2.1511789327632869e-07
of O 0 1.8653294318937697e-05
cardiomyopathy B-Disease 1 1.0
in O 0 6.206700618349714e-06
children O 0 1.57686734780782e-08
. O 0 6.8835697142333174e-09
. O 0 4.350782134565634e-08

Cloning O 0 6.15535827819258e-06
of O 0 3.889278730184742e-07
a O 0 4.954346266572429e-08
novel O 0 7.055096062913435e-08
member O 0 1.1735954430491802e-08
of O 0 8.333159939866164e-08
the O 0 1.0610971656888069e-07
low O 0 1.7514846604171908e-06
- O 0 8.664124351298597e-08
density O 0 1.4112911728147992e-08
lipoprotein O 0 3.262875907239504e-06
receptor O 0 2.841918558260659e-07
family O 0 2.557952427650889e-07
. O 0 5.4200814503246875e-08

A O 0 4.727452051156433e-06
gene O 0 6.059721613382862e-08
encoding O 0 2.2572039881652017e-07
a O 0 1.356542753683243e-07
novel O 0 7.576928595653953e-08
transmembrane O 0 1.2347760147690678e-08
protein O 0 2.8295843446102253e-09
was O 0 2.6866260327551572e-09
identified O 0 8.506487875203916e-11
by O 0 5.615765664990224e-12
DNA O 0 2.0219802221443928e-10
sequence O 0 4.800755626366282e-11
analysis O 0 1.7789261383405197e-11
within O 0 8.724922173630745e-11
the O 0 1.246990288805705e-09
insulin B-Disease 0 9.81657431111671e-05
- I-Disease 0 0.0021087967325001955
dependent I-Disease 1 0.9992151260375977
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 6.682893172182958e-08
IDDM B-Disease 0 5.255515588942217e-06
) O 0 7.387679357151455e-10
locus O 0 3.4114918889827095e-08
IDDM4 O 0 9.682324844106915e-07
on O 0 4.261328001575748e-08
chromosome O 0 3.3859635095723206e-08
11q13 O 0 6.316648750726017e-07
. O 0 1.372661557752508e-07

Based O 0 1.2437340046744794e-06
on O 0 7.252164095916669e-07
its O 0 7.156578885059162e-09
chromosomal O 0 1.6910291833482916e-07
position O 0 9.003834122722765e-08
, O 0 2.1657624305060352e-10
this O 0 4.1491012015004713e-11
gene O 0 3.7064143421083884e-10
is O 0 9.809487944156814e-11
a O 0 5.186542306745423e-10
candidate O 0 9.407714607334583e-10
for O 0 2.6815924480949604e-10
conferring O 0 1.427451081781328e-07
susceptibility O 0 1.21513512567617e-05
to O 0 7.313519745366648e-07
diabetes B-Disease 1 1.0
. O 0 3.166527676512487e-05

The O 0 5.525609140022425e-06
gene O 0 1.955106228024306e-07
, O 0 6.73384104032948e-09
termed O 0 2.124491373933779e-07
low O 0 2.2422252641263185e-06
- O 0 8.700805409489476e-08
density O 0 2.10070805195528e-09
lipoprotein O 0 5.965820548681222e-08
receptor O 0 2.3611823607438964e-09
related O 0 1.8481454144847476e-09
protein O 0 2.9282776203842786e-09
5 O 0 2.769208418129665e-09
( O 0 4.228804806327702e-11
LRP5 O 0 2.090154396228172e-07
) O 0 1.0003401579306015e-10
, O 0 6.440512012595434e-11
encodes O 0 1.1302005858970787e-10
a O 0 5.640826694630618e-10
protein O 0 2.209878280368116e-09
of O 0 5.752205822773249e-09
1615 O 0 1.342104809509692e-07
amino O 0 4.2952965628728634e-09
acids O 0 1.766889523580062e-09
that O 0 1.7350619552214397e-10
contains O 0 6.348941927747376e-10
conserved O 0 2.8571289778511755e-09
modules O 0 2.536538978858971e-09
which O 0 2.336593245277907e-11
are O 0 6.6735818260443835e-12
characteristic O 0 3.786523317117485e-10
of O 0 6.375435734895518e-09
the O 0 1.649022784988574e-08
low O 0 2.1701524133277417e-07
- O 0 6.147531816935725e-09
density O 0 4.498314498668776e-10
lipoprotein O 0 9.475000695147173e-08
( O 0 5.362000843334158e-10
LDL O 0 1.5526224217410345e-07
) O 0 1.405689231681606e-09
receptor O 0 5.7061821934212276e-08
family O 0 1.851950912623579e-07
. O 0 6.054604284599918e-08

These O 0 3.558042394047334e-08
modules O 0 2.644905521265173e-07
include O 0 3.869605080808469e-09
a O 0 2.3143794436464304e-08
putative O 0 4.637925599126902e-07
signal O 0 1.887019038804283e-07
peptide O 0 5.037395389706489e-09
for O 0 2.90648588530118e-10
protein O 0 1.187619003140128e-09
export O 0 7.576029581457533e-09
, O 0 6.408557573500673e-10
four O 0 2.5186532859322597e-09
epidermal O 0 3.120938174561161e-08
growth O 0 1.3695691247761488e-09
factor O 0 2.724892977923332e-09
( O 0 7.018891023946594e-10
EGF O 0 1.5389275631605415e-07
) O 0 5.411563974710987e-10
repeats O 0 7.4819990203423e-09
with O 0 5.338132713639254e-10
associated O 0 2.820119249236086e-08
spacer O 0 1.8841309668005124e-07
domains O 0 1.0863717925246874e-08
, O 0 7.667859125426446e-10
three O 0 1.844458252797665e-09
LDL O 0 2.3199952181585104e-07
- O 0 3.662105996227183e-07
receptor O 0 4.3388322268356205e-08
( O 0 8.317685984415846e-10
LDLR O 0 1.45646617966122e-06
) O 0 4.4853262770594426e-10
repeats O 0 4.107577389333983e-09
, O 0 3.008297499995649e-10
a O 0 5.167349215184913e-09
single O 0 5.3140212230573525e-08
transmembrane O 0 2.0888425211751382e-08
spanning O 0 2.1913189485189832e-08
domain O 0 9.464665495784175e-09
, O 0 5.456640139733793e-10
and O 0 1.2073478883323219e-09
a O 0 1.2269254057173384e-08
cytoplasmic O 0 5.227545329944405e-08
domain O 0 7.619885877829802e-08
. O 0 9.209129814280459e-08

The O 0 3.832883066934301e-06
encoded O 0 1.361675572297827e-07
protein O 0 8.959516151207936e-08
has O 0 1.27808197358803e-09
a O 0 2.0176280646211353e-09
unique O 0 1.7779170358167562e-09
organization O 0 2.162160228635912e-09
of O 0 5.889426901717343e-08
EGF O 0 2.9197573894634843e-05
and O 0 7.068417318123466e-08
LDLR O 0 0.0002586435875855386
repeats O 0 3.9078944524817416e-08
; O 0 6.518696693547099e-10
therefore O 0 4.017418397950223e-09
, O 0 7.413666347488856e-10
LRP5 O 0 5.214706561673665e-06
likely O 0 3.7359725979513314e-08
represents O 0 1.9043404630991745e-09
a O 0 3.462821585031861e-09
new O 0 1.940452243331947e-09
category O 0 2.5787110224939624e-09
of O 0 1.5416091514453e-08
the O 0 2.3275455873772444e-07
LDLR O 1 0.8264939188957214
family O 0 7.662006282771472e-06
. O 0 5.109752692078473e-07

Both O 0 1.6973561969280127e-06
human O 0 1.2502712252171477e-06
and O 0 7.847067990951473e-07
mouse O 0 7.340357115026563e-05
LRP5 O 0 0.14152896404266357
cDNAs O 0 3.3403575798729435e-05
have O 0 1.374775404627826e-08
been O 0 2.4102991602603652e-08
isolated O 0 7.726355732984302e-08
and O 0 3.4480318600316195e-09
the O 0 6.169239341602406e-09
encoded O 0 1.6443608696903311e-09
mature O 0 1.4565673112088007e-09
proteins O 0 5.460385615885244e-11
are O 0 1.2443042256282677e-11
95 O 0 4.501011563462498e-09
% O 0 1.68571337444412e-10
identical O 0 7.146535585533798e-10
, O 0 7.977217497678879e-11
indicating O 0 1.5359497007594314e-09
a O 0 4.69026684157825e-09
high O 0 2.7141467739966174e-08
degree O 0 4.044151680204777e-08
of O 0 4.779071804961177e-09
evolutionary O 0 1.552165684870488e-08
conservation O 0 2.1893167279074532e-09
. O 0 5.796787494460887e-10
. O 0 9.856196747648482e-09

The O 0 1.3513843441614881e-05
APC B-Disease 0 1.3623553059005644e-06
variants O 0 6.447785381169524e-07
I1307K O 0 3.1203780963551253e-06
and O 0 1.0450843745957172e-08
E1317Q O 0 7.243013300239909e-08
are O 0 8.269245010961157e-11
associated O 0 4.769567567564081e-07
with O 1 0.9971567392349243
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.706828680260514e-07
but O 0 1.4040332230180752e-09
not O 0 6.097641280788935e-10
always O 0 1.7279822017712831e-09
with O 0 1.2439013707954416e-10
a O 0 1.3299085388496223e-08
family O 0 1.2763840118168446e-07
history O 0 6.595492152428051e-08
. O 0 1.9528755501596606e-07

Classical O 0 0.34935620427131653
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 7.548067969764816e-06
FAP B-Disease 0 1.556071401864756e-05
) O 0 1.5795638130811085e-09
is O 0 8.317130872903533e-10
a O 0 2.6315946755062214e-08
high O 1 0.9821619391441345
- O 1 1.0
penetrance O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999920129776001
that O 0 3.046082941438044e-09
predisposes O 0 2.628678430482978e-07
to O 0 4.020369814838887e-09
hundreds O 0 4.406568443471315e-09
or O 0 1.5324680191497464e-08
thousands O 0 2.1416516560179844e-08
of O 0 0.4369152784347534
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
and O 0 5.001935505788424e-07
that O 0 2.250748198928676e-10
results O 0 1.2983524255716361e-09
from O 0 4.177629353563361e-09
truncating O 0 8.624602543250148e-08
mutations O 0 1.3359944261992496e-09
in O 0 1.0591307830765118e-09
the O 0 4.6678859888515944e-08
APC B-Disease 0 2.230092093213898e-07
gene O 0 1.9495168146477226e-07
. O 0 4.3724622855734196e-07

A O 0 1.693653302936582e-06
variant O 0 4.118918695894536e-06
of O 0 1.2542444665086805e-06
FAP B-Disease 0 2.613562719488982e-05
is O 0 5.134646130500187e-07
attenuated B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
, O 0 1.9749836610571947e-07
which O 0 5.981230510876401e-10
results O 0 8.079140134675811e-10
from O 0 1.2255588766052483e-09
germ O 0 0.0002688424719963223
- O 0 5.474077170219971e-06
line O 0 7.631520588802232e-07
mutations O 0 1.3070763360545357e-09
in O 0 8.525122829894372e-10
the O 0 1.4997121766668897e-08
5 O 0 5.879368103478555e-09
and O 0 8.486041869204541e-10
3 O 0 6.741975422386304e-09
regions O 0 6.330127533260566e-10
of O 0 6.135152830211155e-08
the O 0 4.5057853981234075e-07
APC B-Disease 0 3.9713773958283127e-07
gene O 0 1.451881104230779e-07
. O 0 3.5568592693380197e-07

Attenuated B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.997310996055603
have O 0 1.0182812104631012e-07
" O 0 1.4853961260996584e-07
multiple O 0 3.835403185803443e-05
" O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 7.3193642258218006e-09
typically O 0 5.642215028522912e-10
fewer O 0 2.758284711745773e-10
than O 0 8.719215627284171e-11
100 O 0 3.627612932266544e-10
) O 0 2.638612071892421e-11
without O 0 4.0164049863733453e-10
the O 0 9.03903618620916e-09
florid O 0 2.3766732226704335e-07
phenotype O 0 7.190952544533502e-08
of O 0 9.706703885115076e-09
classical O 0 7.48382902315825e-08
FAP B-Disease 0 1.421125602973916e-06
. O 0 2.5645252321737644e-07

Another O 0 7.557529215773684e-07
group O 0 5.303285810498437e-09
of O 0 3.532630188374242e-08
patients O 0 3.617576993519833e-08
with O 0 2.885244265726783e-09
multiple O 0 1.6711044736439362e-05
adenomas B-Disease 1 0.9999988079071045
has O 0 1.5059845281939488e-07
no O 0 1.5914675799422184e-08
mutations O 0 7.353756492634034e-10
in O 0 4.3590925313807816e-10
the O 0 5.972045968860584e-09
APC B-Disease 0 4.201538228443269e-09
gene O 0 6.447054001768038e-10
, O 0 7.461313511480938e-11
and O 0 2.718029412651646e-10
their O 0 1.3917870189672499e-09
phenotype O 0 2.9586010086291026e-08
probably O 0 3.0779123694202326e-09
results O 0 2.7833454985248807e-10
from O 0 1.3119143549289447e-09
variation O 0 2.5714285811773152e-08
at O 0 1.7078644276580235e-08
a O 0 4.385740215440137e-09
locus O 0 6.381360773133338e-09
, O 0 7.037641303053732e-11
or O 0 2.6429503030556134e-10
loci O 0 1.46480294560547e-09
, O 0 2.299662404947611e-10
elsewhere O 0 2.555302414108951e-09
in O 0 4.502247907822721e-09
the O 0 1.0350351686838621e-07
genome O 0 1.41164179012776e-07
. O 0 2.0869197214778978e-07

Recently O 0 3.170363243043539e-06
, O 0 3.226153566515677e-09
however O 0 3.6632630262545263e-09
, O 0 3.6216327159444006e-10
a O 0 4.460170455189427e-09
missense O 0 9.190213745569054e-08
variant O 0 1.9517656255629845e-06
of O 0 5.2743940614163876e-05
APC B-Disease 0 4.943773546983721e-06
( O 0 8.994287092889408e-09
I1307K O 0 2.669933962806681e-07
) O 0 6.396858598378685e-10
was O 0 1.4035065554196535e-08
described O 0 8.790305705552726e-10
that O 0 2.5369041936618153e-11
confers O 0 7.100056653719378e-10
an O 0 3.3320002573028473e-12
increased O 0 8.333974482743756e-11
risk O 0 7.893286912974418e-09
of O 1 0.9091711044311523
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 2.783452544008469e-07
including O 0 3.1212941120628557e-09
multiple O 0 3.3934736620722106e-07
adenomas B-Disease 1 0.7030953764915466
, O 0 2.9029154191562156e-08
in O 0 2.7810196456812264e-07
Ashkenazim O 0 0.06534300744533539
. O 0 1.1955892659898382e-05

We O 0 3.0064825295994524e-07
have O 0 2.4375148566235794e-09
studied O 0 1.7758200243633837e-08
a O 0 4.1735117584096315e-09
set O 0 2.433037105120661e-09
of O 0 2.048642810947854e-09
164 O 0 4.934068265072256e-09
patients O 0 1.1485182804804595e-09
with O 0 2.076178562404607e-09
multiple O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
/ I-Disease 1 1.0
or I-Disease 1 0.9999964237213135
carcinoma I-Disease 1 1.0
and O 0 5.168890027107409e-08
analyzed O 0 4.476662152086419e-09
codons O 0 1.2939008087187176e-08
1263 O 0 1.1044451184716308e-06
- O 0 1.4942449411137204e-07
1377 O 0 1.5840078049222939e-06
( O 0 1.922210834948146e-09
exon O 0 6.775250227519791e-08
15G O 0 7.190527639977518e-08
) O 0 8.837590381727267e-11
of O 0 3.3719960157441164e-09
the O 0 1.768367141607996e-08
APC B-Disease 0 2.2895113360732466e-08
gene O 0 2.458816927841667e-09
for O 0 2.734738879794918e-09
germ O 0 0.00011242455366300419
- O 0 8.338568477483932e-06
line O 0 1.763468503668264e-06
variants O 0 2.2816961973148864e-06
. O 0 1.1454668538135593e-06

Three O 0 1.2117617416151916e-06
patients O 0 9.435271408619883e-08
with O 0 3.747725241254329e-09
the O 0 1.039665065150075e-07
I1307K O 0 3.186150081546657e-07
allele O 0 4.901501871046321e-09
were O 0 1.9134389628305826e-09
detected O 0 7.214167041524888e-09
, O 0 5.94486612714995e-11
each O 0 4.935513109316503e-11
of O 0 1.3871551018951322e-08
Ashkenazi O 0 6.217061581992311e-06
descent O 0 6.810166723880684e-06
. O 0 9.671572342995205e-07

Four O 0 5.318053808878176e-06
patients O 0 7.265427370839461e-07
had O 0 2.0806123757211026e-07
a O 0 7.858438522134747e-08
germ O 0 0.00035434457822702825
- O 0 2.8671682230196893e-05
line O 0 1.2210096429043915e-05
E1317Q O 0 3.0890967082086718e-06
missense O 0 4.4631386231230863e-07
variant O 0 1.041042651195312e-06
of O 0 9.014090096570726e-07
APC O 0 1.008662380286296e-07
that O 0 6.28714691419674e-10
was O 0 5.881423348341741e-08
not O 0 8.734029471879623e-11
present O 0 4.987097401709661e-10
in O 0 1.0257109606115478e-09
controls O 0 7.408638147410329e-09
; O 0 7.50440487529147e-10
one O 0 1.0957922347287763e-09
of O 0 3.6988878626686983e-09
these O 0 1.4259279867978591e-10
individuals O 0 3.420308480883705e-11
had O 0 9.711018655877979e-09
an O 0 6.477424152606659e-10
unusually O 0 1.2362724177705786e-08
large O 0 2.435516455179254e-09
number O 0 6.701241783702017e-10
of O 0 1.7854867451205791e-07
metaplastic B-Disease 0 0.00013246521120890975
polyps I-Disease 0 2.6318408345105127e-05
of I-Disease 0 5.732483714382397e-06
the I-Disease 0 5.881557171960594e-06
colorectum I-Disease 0 0.00034329245681874454
. O 0 3.2076181923912372e-06

There O 0 6.185188681229192e-07
is O 0 3.3371889696098833e-09
increasing O 0 2.1214112411183095e-10
evidence O 0 1.2280860772762026e-09
that O 0 3.068752890689197e-11
there O 0 3.8978684863133495e-11
exist O 0 1.7849564881711188e-10
germ O 0 1.8688675709199742e-06
- O 0 1.0420394147558909e-07
line O 0 2.2164138968605585e-08
variants O 0 2.7193857832230606e-08
of O 0 1.1658585208351724e-07
the O 0 5.7196828606720374e-08
APC B-Disease 0 1.2475951827184417e-08
gene O 0 4.2876330264007834e-10
that O 0 4.4960132838944844e-11
predispose O 0 6.318309431208036e-09
to O 0 1.0258244254046645e-09
the O 0 7.606624663480943e-09
development O 0 2.3324199460716954e-08
of O 0 1.4711798712596647e-07
multiple O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 4.362297190141362e-09
but O 0 3.6926969815276323e-10
without O 0 4.173599243983972e-09
the O 0 1.2772468416244465e-08
florid O 0 8.661777428642381e-08
phenotype O 0 1.4499599743089675e-08
of O 0 1.8056774964136935e-09
classical O 0 9.272789647241098e-09
FAP B-Disease 0 3.555437544378037e-08
, O 0 4.314423818208013e-11
and O 0 5.344364534254353e-11
possibly O 0 2.4485663496776056e-10
with O 0 3.654940239350424e-11
importance O 0 1.2569118723604333e-07
for O 0 0.1535259336233139
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 6.274911811487982e-06
in O 0 1.0104060921278801e-09
the O 0 3.174549734197285e-09
general O 0 3.6539331560447863e-09
population O 0 2.994853670612585e-11
. O 0 1.4368383149943043e-09
. O 0 6.915524863870814e-08

Genomic O 0 6.874636824250047e-07
structure O 0 1.0883798751137874e-07
of O 0 3.363262024436153e-08
the O 0 8.295432962768245e-08
human O 0 7.575716881547123e-05
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 9.543410851620138e-05
CLD B-Disease 1 0.9999998807907104
) O 0 2.4819058808134287e-08
gene O 0 5.303166972225881e-08
. O 0 8.071093304806709e-08

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.0013856440782546997
CLD B-Disease 1 1.0
) O 0 4.478088122539248e-09
is O 0 1.2558784567850978e-10
caused O 0 7.22250648177436e-10
by O 0 5.530845226253689e-11
mutations O 0 2.0462245786667665e-10
in O 0 1.8873476392844424e-10
a O 0 2.5592630237269987e-09
gene O 0 7.493420328685829e-10
which O 0 1.9460184852437834e-10
encodes O 0 1.2524249415335476e-09
an O 0 2.4539617560215277e-10
intestinal O 0 1.730688154566451e-06
anion O 0 1.461618694520439e-06
transporter O 0 8.104881999315694e-05
. O 0 2.028972858170164e-06

We O 0 3.745751371297956e-07
report O 0 3.516616686738416e-08
here O 0 9.076526197304702e-09
the O 0 4.152350907560276e-09
complete O 0 6.685299869246819e-09
genomic O 0 2.541189125793153e-08
organization O 0 1.1997633997395951e-09
of O 0 2.632970463878337e-08
the O 0 1.3378085839121923e-07
human O 0 3.0087542768342246e-07
CLD B-Disease 1 0.8594716191291809
gene O 0 1.3762242190296092e-07
which O 0 1.82048187635786e-09
spans O 0 2.439524138253546e-09
approximately O 0 2.7380714015534657e-11
39kb O 0 2.4220000227614946e-08
, O 0 1.6107047640101513e-10
and O 0 8.390952377368421e-10
comprises O 0 2.2618180661737597e-09
21 O 0 2.0658823984831542e-07
exons O 0 6.172953362693079e-06
. O 0 6.239611707314907e-07

All O 0 4.568465556076262e-06
exon O 0 4.9190268327947706e-05
/ O 0 5.744644113292452e-06
intron O 0 2.7155299449077575e-06
boundaries O 0 6.795698936912231e-08
conform O 0 3.184290520152899e-08
to O 0 1.995062604009945e-08
the O 0 2.5999543140642345e-07
GT O 0 0.00010135817137779668
/ O 0 0.0001814848801586777
AG O 0 0.000424496567575261
rule O 0 2.5792935502977343e-06
. O 0 1.3186605656301253e-06

An O 0 1.9987076882443944e-08
analysis O 0 1.3372265073030576e-08
of O 0 9.592944394398728e-08
the O 0 1.364813897453132e-07
putative O 0 2.0533776478259824e-05
promoter O 0 8.768936822889373e-06
region O 0 1.3886911176541616e-07
sequence O 0 5.4158967088824284e-08
shows O 0 2.7809603508899272e-08
a O 0 8.953349350804274e-08
putative O 0 1.9930121197830886e-05
TATA O 0 0.0038464004173874855
box O 0 4.925251232634764e-06
and O 0 1.8911187282810715e-08
predicts O 0 9.153403368600266e-09
multiple O 0 4.3358854284747395e-09
transcription O 0 7.389336076357722e-08
factor O 0 3.167781592594565e-09
binding O 0 1.2246715641595074e-08
sites O 0 1.0728639665558148e-07
. O 0 1.0665187488712036e-07

The O 0 6.382558694895124e-06
genomic O 0 3.168827788613271e-06
structure O 0 7.417010579047201e-07
was O 0 1.5395676200569142e-07
determined O 0 1.844736252643031e-09
using O 0 2.040911745160301e-10
DNA O 0 6.355390880230516e-09
from O 0 7.010488300984719e-10
several O 0 4.812529819098188e-10
sources O 0 4.060094038749185e-09
including O 0 3.588846164692683e-10
multiple O 0 1.3457801095739796e-08
large O 0 5.671416829500231e-07
- O 0 2.733661403908627e-06
insert O 0 4.925843768432969e-07
libaries O 0 1.7763098867362714e-06
and O 0 4.230245043146397e-09
genomic O 0 7.974746196737215e-09
DNA O 0 2.9228161224637006e-08
from O 0 9.656863753093603e-09
Finnish O 0 0.0002884837449528277
CLD B-Disease 1 1.0
patients O 0 0.007979950867593288
and O 0 1.4331666307043633e-06
controls O 0 1.2471269656089135e-05
. O 0 2.359294057896477e-06

Exon O 0 3.9018344978103414e-05
- O 0 1.613742028894194e-06
specific O 0 1.4623917188316682e-08
primers O 0 3.7040510392216675e-07
developed O 0 1.1395500365551925e-07
in O 0 1.568108753957631e-09
this O 0 1.4284594340718826e-10
study O 0 7.070281859977712e-11
will O 0 1.5703461100913252e-11
facilitate O 0 2.6599425440032576e-10
mutation O 0 1.5249555784802027e-10
screening O 0 2.692760459055421e-10
studies O 0 1.5432247493785134e-11
of O 0 1.5097441352640573e-10
patients O 0 5.225187504898088e-10
with O 0 2.371227658670705e-10
the O 0 2.562635472713737e-07
disease O 0 0.0038925923872739077
. O 0 1.3512852774510975e-06

Genomic O 0 1.6541627019250882e-06
sequencing O 0 9.260189131055085e-07
of O 0 7.013557024038164e-07
a O 0 2.172700533265015e-06
BAC O 1 0.8666192889213562
clone O 1 0.9084515571594238
H O 1 1.0
_ O 0 2.3721489128547546e-07
RG364P16 O 0 3.304816686977574e-07
revealed O 0 9.0494030047239e-09
the O 0 9.60820756290559e-10
presence O 0 1.7161698451229057e-10
of O 0 2.196946624621887e-09
another O 0 2.5483617438482042e-09
, O 0 9.017588065152182e-11
highly O 0 4.560715693990858e-10
homologous O 0 2.1456165733013677e-09
gene O 0 5.293745442003228e-09
3 O 0 3.4306104623738065e-08
of O 0 2.6540515563056033e-08
the O 0 1.9227401537591504e-07
CLD B-Disease 0 0.002440317999571562
gene O 0 5.6616034527223746e-08
, O 0 4.4516693109564187e-10
with O 0 4.8994776985500366e-11
a O 0 1.8974333215737715e-09
similar O 0 3.444837304300563e-09
genomic O 0 3.0984057985961044e-08
structure O 0 5.471079589369765e-08
, O 0 3.624396893719961e-10
recently O 0 8.190761957571624e-10
identified O 0 3.5916264407021004e-10
as O 0 1.2376543123693295e-09
the O 0 2.505115617168485e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 9.495280295368502e-08
( O 0 1.169920604837671e-09
PDS B-Disease 0 1.9263793546997476e-06
) O 0 3.784638713533184e-10
. O 0 4.345240167680231e-09
. O 0 3.007176587743743e-07

The O 0 3.4120921554858796e-06
APCI1307K O 0 0.0018748902948573232
allele O 0 3.678431085063494e-06
and O 0 3.025566854830686e-07
cancer B-Disease 0 0.003748601535335183
risk O 0 1.1393924381764009e-07
in O 0 1.1405814070997167e-08
a O 0 4.8930974827499085e-08
community O 0 4.1687697738268525e-09
- O 0 6.177717004618444e-09
based O 0 2.9136737467183593e-10
study O 0 1.17486187445337e-10
of O 0 2.9048854433000315e-09
Ashkenazi O 0 1.1881519412781927e-06
Jews O 0 2.1574307140781457e-07
. O 0 5.80018820528494e-07

Mutations O 0 1.3251782320367056e-06
in O 0 4.233265826769639e-08
APC O 0 1.1349027317919536e-07
are O 0 1.9070107992735785e-10
classically O 0 2.933389282588905e-07
associated O 0 1.3065864834516105e-07
with O 0 7.36635513476358e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.1083088793384377e-06
FAP B-Disease 0 1.4079674883760163e-06
) O 0 2.3632670820283863e-10
, O 0 8.185791627868255e-11
a O 0 5.186920670752215e-09
highly O 0 0.16873608529567719
penetrant O 1 1.0
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0005666928482241929
by O 0 1.2065290988516608e-08
multiple O 0 5.251748007140122e-06
intestinal O 1 1.0
polyps B-Disease 0 1.419791533407988e-05
and O 0 7.964120918302342e-09
, O 0 1.6922981072031718e-10
without O 0 1.3428974598994614e-09
surgical O 0 0.02517314814031124
intervention O 0 2.383374157943763e-05
, O 0 1.2822231054698818e-09
the O 0 6.751331049770215e-09
development O 0 4.671346687246114e-07
of O 1 0.9538236260414124
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.2319092352063308e-07
CRC B-Disease 0 5.365727702155709e-06
) O 0 3.5005474074978338e-09
. O 0 1.3212104477133835e-07

APC B-Disease 0 1.2445430002117064e-05
is O 0 1.4642134260611783e-07
a O 0 4.0061649997369386e-07
tumour O 1 0.9999998807907104
- O 0 9.276407695324451e-07
suppressor O 0 2.2870372617944668e-07
gene O 0 2.0435695358145267e-09
, O 0 9.391914329581752e-11
and O 0 4.551234944472071e-10
somatic O 0 1.0737018101281137e-06
loss O 0 2.5037877549038967e-07
occurs O 0 8.821705677064529e-08
in O 0 6.99746962595782e-08
tumours B-Disease 1 1.0
. O 0 2.279436330354656e-06

The O 0 3.8977505028015e-05
germline O 0 1.9193237676518038e-05
T O 0 3.1815789043321274e-06
- O 0 4.65519889303323e-07
to O 0 5.6064337172756495e-08
- O 0 2.0303885150951828e-07
A O 0 4.287572323846689e-07
transversion O 0 1.9389126464375295e-06
responsible O 0 1.6392824875310907e-08
for O 0 7.768186094381235e-09
the O 0 7.325135698010854e-08
APC O 0 1.9791448835349001e-07
I1307K O 0 2.6782373652167735e-07
allele O 0 9.288013025354758e-09
converts O 0 2.3479397981418515e-08
the O 0 2.1088023771653752e-08
wild O 0 1.1451547266005946e-08
- O 0 2.035633439589901e-09
type O 0 2.5346529319847377e-09
sequence O 0 2.376458141384319e-09
to O 0 3.6509237855142374e-09
a O 0 9.855730809249508e-08
homopolymer O 0 0.0002638720616232604
tract O 0 0.0001643655850784853
( O 0 1.0723725907269e-08
A8 O 0 3.8647908695566e-07
) O 0 2.2172912117479626e-10
that O 0 1.0915382486764713e-10
is O 0 1.068875987719764e-09
genetically O 0 1.386534052016941e-07
unstable O 0 0.025467809289693832
and O 0 1.2120783594582463e-06
prone O 0 7.404420102830045e-06
to O 0 7.062286044856592e-08
somatic O 0 1.0710779861256015e-05
mutation O 0 4.187811271094688e-07
. O 0 1.7710007682580908e-07

The O 0 5.740366759710014e-06
I1307K O 0 3.321238182252273e-06
allele O 0 7.442533700441345e-08
was O 0 9.442833004413842e-08
found O 0 2.4254476205243236e-09
in O 0 5.411226577933803e-09
6 O 0 8.321539439748449e-07
. O 0 3.36450739268912e-07

1 O 0 1.1614750292210374e-05
% O 0 3.723963359902882e-08
of O 0 6.274262176475531e-08
unselected O 0 8.869711746228859e-05
Ashkenazi O 0 0.00019194545166101307
Jews O 0 5.01582633205544e-07
and O 0 1.3112245511592846e-08
higher O 0 1.8822303715637645e-08
proportions O 0 7.733225970696367e-08
of O 0 1.2755138811826328e-07
Ashkenazim O 0 9.723653420223854e-06
with O 0 7.578992544665653e-09
family O 0 2.391241764598817e-07
or O 0 2.125244513706548e-08
personal O 0 1.9793600358752883e-07
histories O 0 4.4164707446725515e-07
of O 0 0.000709765765350312
CRC B-Disease 1 0.8861107230186462
( O 0 4.1472876688430915e-08
ref O 0 0.00012814387446269393
. O 0 4.6906627915177523e-08
2 O 0 4.2658621168811806e-07
) O 0 5.109797918123604e-09
. O 0 1.3148125788120524e-07

To O 0 2.618275232180167e-07
evaluate O 0 3.197290823209187e-07
the O 0 9.569187398028589e-08
role O 0 4.621765015144774e-08
of O 0 4.344181903093158e-08
I1307K O 0 5.651558012687019e-07
in O 0 4.162175493149789e-09
cancer B-Disease 0 3.4341669561399613e-06
, O 0 1.267792426595804e-09
we O 0 1.7088541692800163e-09
genotyped O 0 1.2574517995744827e-06
5 O 0 1.2487419098761166e-07
, O 0 4.2851580062119865e-09
081 O 0 2.063441797872656e-06
Ashkenazi O 0 2.101888867400703e-06
volunteers O 0 1.7832430643238695e-08
in O 0 7.085895425973376e-09
a O 0 4.588738278243909e-08
community O 0 1.2506877311579956e-08
survey O 0 6.165028043625398e-09
. O 0 3.6688309279497844e-08

Risk O 0 1.0897506399487611e-05
of O 0 7.4028316703333985e-06
developing O 1 0.9999996423721313
colorectal B-Disease 1 1.0
, I-Disease 1 0.9990485310554504
breast I-Disease 1 1.0
and I-Disease 0 0.000388928281608969
other I-Disease 0 2.744724497460993e-06
cancers I-Disease 1 0.9999994039535522
were O 0 6.563165584339004e-07
compared O 0 3.494816098736919e-07
between O 0 7.522913278990018e-07
genotyped O 0 2.3759239411447197e-05
I1307K O 0 3.0313287879835116e-07
carriers O 0 4.5726511466170905e-09
and O 0 3.5970855183364847e-09
non O 0 1.1874067062933591e-08
- O 0 1.7590220835472792e-08
carriers O 0 1.2678020855361183e-09
and O 0 8.467221923602608e-10
their O 0 6.394247908936279e-10
first O 0 8.520786742849396e-09
- O 0 1.2739064025879543e-08
degree O 0 1.7224621728928469e-07
relatives O 0 3.8930008372517477e-07
. O 0 1.0702294872544371e-07

Sperm O 0 1.2145784467065823e-07
DNA O 0 4.185463353678642e-08
analysis O 0 4.712253698357927e-09
in O 0 4.437065381779348e-09
a O 0 2.05015325605018e-07
Friedreich B-Disease 1 0.999648928642273
ataxia I-Disease 1 1.0
premutation O 1 0.9999997615814209
carrier O 0 0.0004182061820756644
suggests O 0 6.761371196262189e-07
both O 0 3.821965322003962e-08
meiotic O 0 3.054336048080586e-05
and O 0 4.222565337386186e-07
mitotic O 0 1.8631232023835764e-06
expansion O 0 1.029344957714784e-06
in O 0 1.0792279958593554e-08
the O 0 9.01156553823057e-08
FRDA B-Disease 0 2.837630017893389e-05
gene O 0 1.3133701770584594e-07
. O 0 1.4064454489925993e-07

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 1.178237289423123e-05
usually O 0 2.803440679599589e-07
caused O 0 2.1418891549274122e-07
by O 0 4.5541528881365423e-10
an O 0 2.2096495466694677e-10
expansion O 0 6.831333365653336e-08
of O 0 4.0301762282979325e-07
a O 0 1.6521699990335037e-06
GAA O 0 6.838660192443058e-05
trinucleotide O 0 3.172409560647793e-05
repeat O 0 1.4298490214059711e-07
in O 0 1.1986842629596595e-08
intron O 0 9.871690735963057e-07
1 O 0 1.252043944077741e-07
of O 0 4.8628219673219064e-08
the O 0 1.5704088696111285e-07
FRDA B-Disease 0 0.0002232460246887058
gene O 0 6.024176286700822e-07
. O 0 6.311934157565702e-07

Occasionally O 0 2.600876996439183e-06
, O 0 6.558485665664193e-08
a O 0 5.8606509867331624e-08
fully O 0 5.9140678132507674e-08
expanded O 0 4.24620480998783e-08
allele O 0 1.3459290570949634e-08
has O 0 3.969991002605866e-10
been O 0 1.4548284799076328e-10
found O 0 1.1538841410141387e-10
to O 0 1.3603496107350566e-10
arise O 0 3.018650662767186e-09
from O 0 4.935621689128311e-09
a O 0 1.567696905624416e-08
premutation O 0 1.907633304654155e-06
of O 0 1.2557053707951127e-07
100 O 0 6.215265191400476e-09
or O 0 3.3793938758464037e-09
less O 0 3.384362301517285e-08
triplet O 0 4.004120000900002e-06
repeats O 0 8.657662533551047e-07
. O 0 3.6061379660168313e-07

We O 0 1.2453600675144116e-06
have O 0 2.2650915809663275e-08
examined O 0 8.10650035987237e-08
the O 0 8.193688394442233e-09
sperm O 0 2.018220923716285e-09
DNA O 0 8.300034437525028e-09
of O 0 2.5189285324245247e-08
a O 0 4.186972546449397e-08
premutation O 0 1.0715918506321032e-05
carrier O 0 8.736891686567105e-06
. O 0 3.975803338107653e-06

This O 0 5.545810495277692e-07
mans O 0 2.9375732992775738e-05
leucocyte O 0 3.0900364436092786e-06
DNA O 0 1.9902250869563431e-07
showed O 0 1.253257231326188e-08
one O 0 4.867624636695211e-10
normal O 0 1.14107479021186e-09
allele O 0 1.1021245027720283e-09
and O 0 3.9965364351246535e-10
one O 0 1.6041008799039247e-10
allele O 0 5.666545566107573e-10
of O 0 2.3680060134978476e-09
approximately O 0 4.601336534015843e-10
100 O 0 5.137258618503893e-09
repeats O 0 4.467452185963339e-08
. O 0 7.994456296955832e-08

His O 0 3.977532742283074e-06
sperm O 0 1.41744791903875e-07
showed O 0 8.332583512071778e-09
an O 0 1.4563249217669494e-10
expanded O 0 1.3624641415077576e-09
allele O 0 9.45896161397286e-09
in O 0 3.955677563283189e-09
a O 0 3.6956176785452044e-08
tight O 0 7.011009302004823e-07
range O 0 4.853477548749652e-07
centering O 0 9.95270397652348e-07
on O 0 2.440743003262469e-07
a O 0 9.470823236767956e-09
size O 0 7.714733740726842e-09
of O 0 7.872356988514184e-09
approximately O 0 1.6321372031669057e-09
320 O 0 1.9603406897772402e-08
trinucleotide O 0 7.0798309934616555e-06
repeats O 0 1.0575082569630467e-06
. O 0 2.760388326805696e-07

His O 0 0.00010695985110942274
affected O 0 1.653347135288641e-05
son O 1 0.9929296374320984
has O 0 6.653550599367009e-08
repeat O 0 3.289910921466799e-08
sizes O 0 8.067718937354584e-09
of O 0 1.1373839470252278e-07
1040 O 0 2.150183263438521e-06
and O 0 3.4533780279843995e-08
540 O 0 1.7975486343857483e-07
. O 0 1.7425367104806355e-07

These O 0 1.1207183803207954e-07
data O 0 4.342376058730224e-08
suggest O 0 2.4687794031308385e-09
that O 0 1.6497320176611652e-10
expansion O 0 1.3781780161536972e-08
occurs O 0 1.2263445814397755e-09
in O 0 3.1013647205924144e-10
two O 0 2.977460777930929e-10
stages O 0 5.123852009347729e-09
, O 0 1.6915557843333318e-10
the O 0 1.466636811997546e-09
first O 0 2.5137723014267976e-09
during O 0 2.935290011052416e-09
meiosis O 0 1.4151045890642422e-09
followed O 0 1.929719273263686e-09
by O 0 1.319104825370232e-10
a O 0 3.562135253432075e-09
second O 0 6.183000067494504e-08
mitotic O 0 3.0625773206338636e-07
expansion O 0 4.68233292849618e-06
. O 0 1.1915584536836832e-06

We O 0 5.666254764946643e-06
also O 0 1.0337271305616014e-07
show O 0 3.1942164469001e-09
that O 0 5.92877552607618e-11
in O 0 1.7665045815018487e-10
all O 0 1.233209506734667e-10
informative O 0 2.3037015350890755e-10
carrier O 0 4.3848533692880665e-09
father O 0 4.3459142062829414e-08
to O 0 5.226884702835832e-09
affected O 0 6.737463476014227e-09
child O 0 2.9210218244202224e-08
transmissions O 0 2.6352815041263966e-08
, O 0 1.0428292951392137e-10
with O 0 2.2511936759173068e-11
the O 0 3.2606479738461758e-09
notable O 0 1.8069695739697522e-09
exception O 0 2.4502027073936006e-09
of O 0 2.1760914847845925e-08
the O 0 3.7593466117868957e-08
premutation O 0 4.862455966758716e-07
carrier O 0 8.32836093422884e-08
, O 0 1.2424887785300598e-09
the O 0 1.0777695180763658e-08
expansion O 0 4.1724629085138076e-08
size O 0 1.3866736203738128e-08
decreases O 0 1.159577589504579e-08
. O 0 7.52361373201893e-09
. O 0 4.386261309718975e-08

The O 0 3.5400539672991727e-06
R496H O 0 3.996462965005776e-06
mutation O 0 7.249675348930396e-08
of O 0 2.0777787312908913e-07
arylsulfatase O 0 3.223872772650793e-05
A O 0 2.656609694895451e-06
does O 0 6.040691058473158e-09
not O 0 6.177151234965095e-09
cause O 0 6.867440970381722e-05
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 8.80183870322071e-06

Deficiency B-Disease 1 0.999944806098938
of I-Disease 0 0.0006296307547017932
arylsulfatase I-Disease 1 0.898617684841156
A I-Disease 0 0.017175765708088875
( O 0 4.473792216685979e-07
ARSA O 0 0.0007512884330935776
) O 0 3.4110410052079487e-09
enzyme O 0 3.853741858961257e-08
activity O 0 2.5029084582683936e-08
causes O 0 1.1151546459586825e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 2.1746026845903543e-07
MLD B-Disease 1 1.0
) O 0 2.50543035207329e-08
. O 0 8.015037877839859e-08

A O 0 4.0351360439672135e-06
number O 0 3.1591909532835416e-08
of O 0 3.04348901636331e-07
ARSA O 0 0.0002103546867147088
gene O 0 1.5076039971972932e-07
mutations O 0 1.474266220213849e-08
responsible O 0 1.9788537031217857e-08
for O 0 3.7743337344409156e-08
MLD B-Disease 1 1.0
have O 0 6.865452206739064e-08
been O 0 2.3699231022078493e-08
identified O 0 2.1485908163754175e-08
. O 0 5.5306529134213633e-08

Recently O 0 1.3027884961047675e-05
, O 0 4.636475026131848e-08
the O 0 4.8497067695052465e-08
R496H O 0 7.087181188580871e-07
mutation O 0 1.8849966920697625e-08
of O 0 1.4046452179172775e-07
ARSA O 0 0.00025633617769926786
was O 0 3.491747690986813e-07
proposed O 0 2.5662446390128935e-08
to O 0 2.635812901274903e-09
be O 0 1.6948540348948882e-09
a O 0 2.510089203155985e-08
cause O 0 2.98003271836933e-07
of O 0 3.924978045688476e-06
MLD B-Disease 1 1.0
( O 0 1.9209770130146353e-07
Draghia O 0 7.6770511441282e-06
et O 0 2.489881865130883e-07
al O 0 3.2107476499732e-07
. O 0 2.1041164366408793e-09
, O 0 3.7856928702950654e-10
1997 O 0 3.570529427676661e-09
) O 0 1.922812131738283e-09
. O 0 1.1620866047223899e-07

We O 0 1.2224146530570579e-06
have O 0 1.4342542264955682e-08
investigated O 0 1.0646021308957643e-07
the O 0 2.6322172885784312e-08
R496H O 0 6.321361212258125e-08
mutation O 0 1.3139076493473567e-09
and O 0 2.45705289447784e-10
found O 0 1.6414207493209432e-10
this O 0 6.242358019381555e-11
mutation O 0 1.1732008697862284e-09
at O 0 2.22543139472009e-09
a O 0 7.895841758198685e-10
relatively O 0 5.542826198023931e-09
high O 0 3.91010850364637e-08
frequency O 0 8.331598522204331e-09
in O 0 6.178750844298975e-10
an O 0 1.0353891355396883e-10
African O 0 4.195562230968619e-10
American O 0 4.06161049237852e-10
population O 0 1.3885922576714615e-12
( O 0 1.2017362799321418e-11
f O 0 6.040691058473158e-09
= O 0 5.614627873740119e-09
0 O 0 5.857742735315696e-09
. O 0 6.445627920292907e-10
09 O 0 1.466755161771971e-08
, O 0 4.617266846640433e-10
n O 0 1.639491920002456e-08
= O 0 2.88697989958564e-08
61 O 0 1.588628784077173e-08
subjects O 0 1.1139983158159339e-08
) O 0 1.7868854174096782e-09
. O 0 4.104274253791118e-08

The O 0 0.000470248720375821
ARSA O 0 0.008232304826378822
enzyme O 0 7.695161343690415e-07
activity O 0 1.4281667404247855e-08
in O 0 8.27357238275539e-10
subjects O 0 4.57143922716341e-09
with O 0 1.6163058391693852e-10
and O 0 1.449619202453789e-09
without O 0 7.398668344649195e-09
the O 0 3.678612969792994e-08
R496H O 0 1.229305865990682e-07
mutation O 0 3.280935523264361e-09
was O 0 9.850859683524504e-09
determined O 0 9.281101998048769e-10
and O 0 5.231559629947924e-10
found O 0 7.758675368840784e-10
to O 0 4.139538711811497e-10
be O 0 3.492484745848401e-09
normal O 0 1.8225227904622443e-07
. O 0 2.46289317828996e-07

It O 0 1.2425729778442474e-07
is O 0 2.8082711711618913e-09
therefore O 0 6.368821026114801e-10
concluded O 0 1.4221640531886237e-09
that O 0 6.29715238287254e-11
the O 0 2.982270430607059e-09
R496H O 0 7.655314249177536e-08
mutation O 0 9.130508793475656e-09
of O 0 1.215037173096789e-07
ARSA O 0 0.0005904081044718623
does O 0 1.0374618497621668e-08
not O 0 1.5146829346335267e-09
negatively O 0 5.231312716347247e-09
influence O 0 5.73437208828409e-09
the O 0 3.743959808844011e-09
activity O 0 1.743615474225635e-09
of O 0 1.7365668014690527e-08
ARSA O 0 7.752723468001932e-05
and O 0 7.632523058020979e-09
is O 0 5.406746161895626e-10
not O 0 2.750173699883618e-10
a O 0 1.6121079582376296e-08
cause O 0 1.0158636314372416e-06
of O 0 3.906599886249751e-05
MLD B-Disease 1 1.0

Down O 0 0.00028212336474098265
- O 0 3.908818143827375e-06
regulation O 0 2.33862166965082e-07
of O 0 6.902478588699523e-08
transmembrane O 0 1.8841309668005124e-07
carbonic O 0 2.200500966864638e-05
anhydrases O 0 0.00017320358892902732
in O 0 9.777481864148285e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.8914198875427246
lines O 0 8.667198159173495e-08
by O 0 2.005997368215162e-09
wild O 0 2.1888612877773994e-07
- O 0 1.3024649092585605e-07
type O 0 6.31447765044868e-05
von B-Disease 1 1.0
Hippel I-Disease 1 1.0
- I-Disease 1 0.9999781847000122
Lindau I-Disease 1 0.9839096665382385
transgenes O 0 0.0003221225051674992
. O 0 3.2376137824030593e-06

To O 0 8.88538295384933e-07
discover O 0 7.491340880960706e-08
genes O 0 6.446196465503817e-09
involved O 0 2.0244665943636164e-09
in O 0 9.42427824668357e-09
von B-Disease 1 0.999944806098938
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 0.9999998807907104
( O 0 7.466647389264836e-07
VHL B-Disease 1 0.9999887943267822
) O 0 2.405966483820521e-07
- O 0 7.3445780799374916e-06
mediated O 0 0.0020317942835390568
carcinogenesis O 1 0.999998927116394
, O 0 2.6077211501274178e-08
we O 0 2.272334320707614e-09
used O 0 3.1917460319164093e-07
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.8763851523399353
lines O 0 1.8274968169862404e-06
stably O 0 9.088445267479983e-07
transfected O 0 7.708977136644535e-07
with O 0 5.5572439983109234e-09
wild O 0 5.894663672734168e-07
- O 0 2.886507104449265e-07
type O 0 2.177010537707247e-05
VHL O 1 1.0
- O 0 0.0010377686703577638
expressing O 0 4.732360139314551e-07
transgenes O 0 0.00013415751163847744
. O 0 1.604268391020014e-06

Large O 0 1.1234669727855362e-05
- O 0 9.496921848040074e-06
scale O 0 6.194253728608601e-06
RNA O 0 1.0382357231719652e-06
differential O 0 6.015375220158603e-08
display O 0 7.480186248187692e-09
technology O 0 2.664952347686267e-08
applied O 0 3.782836266452705e-09
to O 0 5.242157818940996e-10
these O 0 1.6762358168165292e-10
cell O 0 1.2984324726517116e-08
lines O 0 1.5144431264602076e-09
identified O 0 4.702518929811106e-10
several O 0 3.0464766820337275e-10
differentially O 0 4.1443616538572314e-08
expressed O 0 2.087160888564199e-09
genes O 0 2.192087178443103e-09
, O 0 3.594319564204085e-10
including O 0 2.795486619966425e-10
an O 0 7.152590741910103e-10
alpha O 0 5.053180274217084e-08
carbonic O 0 8.27170822503831e-07
anhydrase O 0 1.4458182704402134e-05
gene O 0 7.662413281650515e-08
, O 0 3.719588637096649e-09
termed O 0 4.3441076513772714e-07
CA12 O 0 0.0004934191238135099
. O 0 8.351496489922283e-07

The O 0 2.487115125404671e-06
deduced O 0 2.0721095950193558e-07
protein O 0 1.0442833264789897e-08
sequence O 0 1.4946339721433333e-09
was O 0 1.23668275620048e-08
classified O 0 2.569510160199684e-09
as O 0 1.1124902110637436e-09
a O 0 5.7530620267698396e-09
one O 0 1.3972057288924589e-08
- O 0 2.229850679213996e-06
pass O 0 1.1498577805468813e-05
transmembrane O 0 1.5806442661414621e-06
CA O 0 1.9296228401799453e-06
possessing O 0 6.886487824431242e-08
an O 0 2.1197106292447643e-08
apparently O 0 6.326246193566476e-07
intact O 0 1.218043735207175e-06
catalytic O 0 4.151664256824006e-08
domain O 0 2.8677167307478157e-08
in O 0 4.408518883280976e-09
the O 0 3.970464490521408e-08
extracellular O 0 2.1420811435746145e-07
CA O 0 1.7160564311780035e-05
module O 0 6.498279981315136e-05
. O 0 1.1528171626196126e-06

Reintroduced O 0 5.3476429457077757e-05
wild O 0 5.266810148896184e-06
- O 0 8.745668083065539e-07
type O 0 1.0440521691634785e-06
VHL B-Disease 1 0.9997405409812927
strongly O 0 2.7041642169933766e-07
inhibited O 0 2.2154422651965433e-07
the O 0 5.2791275351182776e-08
overexpression O 0 1.1971287960932386e-07
of O 0 2.6321268720153057e-08
the O 0 4.493971061947377e-08
CA12 O 0 3.0717728805029765e-06
gene O 0 2.2689128353903243e-09
in O 0 3.0533639505669896e-10
the O 0 8.644081006536908e-09
parental O 0 1.1413731044740416e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999922513961792
lines O 0 1.8054059182759374e-05
. O 0 2.0698553271358833e-06

Similar O 0 2.1375548442392756e-07
results O 0 3.378480428750663e-08
were O 0 1.55324375583632e-08
obtained O 0 5.598907559800637e-09
with O 0 1.262440485483296e-09
CA9 O 0 2.8312209906289354e-05
, O 0 3.8501539734170365e-09
encoding O 0 1.9651969296319294e-07
another O 0 4.775238267029636e-07
transmembrane O 0 9.223878549846631e-08
CA O 0 1.4553691585206252e-07
with O 0 6.746847525107569e-10
an O 0 2.213599081812845e-09
intact O 0 6.050506726751337e-07
catalytic O 0 4.0828038549989287e-07
domain O 0 5.266104494694446e-07
. O 0 3.319308632399043e-07

Although O 0 4.83321855426766e-07
both O 0 3.574503537606688e-08
domains O 0 3.3360514350988524e-08
of O 0 1.6043067319060356e-07
the O 0 1.7278287600674958e-07
VHL B-Disease 0 0.00028700893744826317
protein O 0 7.456173989339732e-08
contribute O 0 1.6723088469561276e-09
to O 0 3.832731021446989e-09
regulation O 0 7.843402158869139e-07
of O 0 7.308249223569874e-07
CA12 O 0 0.03602178394794464
expression O 0 7.287648173814887e-08
, O 0 1.8587048566942599e-09
the O 0 4.828935917799981e-09
elongin O 0 1.4189383534812805e-07
binding O 0 1.7996717005530627e-08
domain O 0 7.855142314383556e-08
alone O 0 1.4088034738790611e-08
could O 0 1.373250224645517e-08
effectively O 0 8.922646088649344e-08
regulate O 0 9.869801687045765e-08
CA9 O 0 0.0002439044474158436
expression O 0 1.9745496047107736e-06
. O 0 9.320515914623684e-07

We O 0 4.973086106474511e-06
mapped O 0 1.919045826070942e-05
CA12 O 0 0.003451295429840684
and O 0 1.673437964200275e-06
CA9 O 0 0.0009517758153378963
loci O 0 1.0192668469244381e-06
to O 0 6.455230305846271e-08
chromosome O 0 1.9460320288544608e-07
bands O 0 7.465337148460094e-07
15q22 O 0 3.0267697184171993e-06
and O 0 1.1886580608688746e-07
17q21 O 0 9.624752237868961e-06
. O 0 7.123344971660117e-07

2 O 0 2.013800803979393e-05
respectively O 0 1.7953352937638556e-07
, O 0 1.2635396728910564e-08
regions O 0 2.05145909148996e-08
prone O 0 4.87232910018065e-06
to O 0 2.9241880028507694e-08
amplification O 0 2.9411583454930224e-05
in O 0 1.0025702934512992e-08
some O 0 4.682648713227877e-10
human O 0 1.2248939640358003e-07
cancers B-Disease 0 0.0014206342166289687
. O 0 5.833232989971293e-07

Additional O 0 3.889764741416002e-07
experiments O 0 3.9118697259254986e-07
are O 0 7.134468571479147e-10
needed O 0 2.3471070420555407e-08
to O 0 2.502811957683093e-09
define O 0 9.523408728284721e-09
the O 0 4.106427553551839e-08
role O 0 1.1651849973759454e-07
of O 0 6.652319939348672e-07
CA O 0 7.3547198553569615e-06
IX O 1 1.0
and O 0 0.00011001495295204222
CA O 0 1.6868678358150646e-05
XII O 0 0.003841589204967022
enzymes O 0 8.907122150958457e-08
in O 0 5.574516848128042e-09
the O 0 7.489594722187576e-09
regulation O 0 1.3507897023146143e-08
of O 0 4.061720737524865e-09
pH O 0 1.5168035361057264e-07
in O 0 3.353536337513674e-09
the O 0 1.3104794582829982e-08
extracellular O 0 1.3215539773625551e-08
microenvironment O 0 8.219956271204865e-07
and O 0 2.309342717055074e-09
its O 0 1.4379842872003223e-09
potential O 0 5.507900802115273e-09
impact O 0 1.3411732879831106e-07
on O 0 2.807424152706517e-06
cancer B-Disease 0 0.00024821754777804017
cell O 0 9.879095159703866e-06
growth O 0 2.3025879869464916e-08
. O 0 1.3131422349488275e-07

A O 0 1.9862404769810382e-06
gene O 0 3.053436969935319e-08
encoding O 0 6.935827912002424e-08
a O 0 4.745647075310444e-08
transmembrane O 0 7.239377541878866e-09
protein O 0 8.6179674507747e-10
is O 0 1.6261972671238745e-11
mutated O 0 4.2207970452068366e-10
in O 0 8.848013988149717e-11
patients O 0 3.762565814469099e-09
with O 0 1.3289303524288698e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 0 6.56775137031218e-06
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 2.1935342431333993e-09
. O 0 1.2970265750311682e-08

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 5.611109827441396e-06
WFS B-Disease 1 0.9457753300666809
; O 0 2.503983580481872e-07
OMIM O 0 0.0036290197167545557
222300 O 0 5.2779423640458845e-06
) O 0 8.887122704415162e-10
is O 0 6.269280650172959e-10
an O 0 9.995839711507415e-09
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 5.264728315523826e-07
by O 0 2.0341905937470983e-08
young O 0 1.1046994075059047e-07
- O 0 6.0262436818447895e-06
onset O 1 1.0
non O 1 1.0
- O 1 0.9999997615814209
immune O 1 1.0
insulin B-Disease 1 1.0
- I-Disease 1 0.8448917865753174
dependent I-Disease 0 0.4439029395580292
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.31438905000686646
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 0 0.00343394186347723
. O 0 1.7608467715035658e-06

Linkage O 0 3.5898698115488514e-05
to O 0 2.1434441066503496e-07
markers O 0 8.199927492569259e-07
on O 0 6.411619892787712e-07
chromosome O 0 5.902809903091111e-07
4p O 0 0.0009682868840172887
was O 0 6.580608555850631e-07
confirmed O 0 1.945100081002238e-08
in O 0 2.086591788241776e-09
five O 0 8.199582346435363e-09
families O 0 4.038268386352684e-09
. O 0 1.25849879850648e-07

On O 0 3.4134459383494686e-06
the O 0 4.264263253617173e-08
basis O 0 2.197065285258759e-08
of O 0 1.011807100326223e-07
meiotic O 0 0.00047845751396380365
recombinants O 1 0.8509028553962708
and O 0 1.8252431743803754e-07
disease O 0 0.00017165925237350166
- O 0 1.1203572114482085e-07
associated O 0 4.9051141814970833e-08
haplotypes O 0 4.846276056014176e-07
, O 0 3.123318714770562e-09
the O 0 9.41488522698819e-08
WFS B-Disease 0 6.431273504858837e-05
gene O 0 5.2306571518556666e-08
was O 0 2.013032229797318e-07
localized O 0 1.5199400138499186e-07
to O 0 3.2552311068911877e-08
a O 0 8.811193765723146e-07
BAC O 0 0.0007950670551508665
/ O 0 7.916666618257295e-06
P1 O 0 9.12008272280218e-06
contig O 0 1.512723997620924e-06
of O 0 8.745974611201746e-09
less O 0 2.306718815958675e-09
than O 0 4.684846399705123e-10
250 O 0 1.2225361167850224e-08
kb O 0 2.3245472675625933e-06
. O 0 3.233745644593e-07

Mutations O 0 2.0424761260073865e-07
in O 0 1.6922642842587265e-08
a O 0 8.955736596760744e-09
novel O 0 2.8310758182215068e-08
gene O 0 2.7015536474550572e-09
( O 0 5.812231806956447e-10
WFS1 O 0 2.6286309093848104e-06
) O 0 1.1109804187725558e-09
encoding O 0 1.1315243853005086e-07
a O 0 7.160410859796684e-07
putative O 0 4.417124728206545e-06
transmembrane O 0 3.8565652005218e-08
protein O 0 7.586947958770907e-09
were O 0 1.4345326038167627e-09
found O 0 5.30422372690964e-10
in O 0 6.378558237152276e-10
all O 0 3.720594388134657e-10
affected O 0 6.635359484086223e-10
individuals O 0 2.335056106805844e-11
in O 0 3.320167696330145e-09
six O 0 1.677072987149586e-07
WFS B-Disease 1 0.9961634874343872
families O 0 3.701867967720318e-08
, O 0 2.7708874084098056e-10
and O 0 9.530049666084395e-11
these O 0 3.009087770622365e-11
mutations O 0 2.2135937527423266e-10
were O 0 6.692961462828606e-11
associated O 0 5.581269890697627e-10
with O 0 3.866327258350566e-10
the O 0 1.675787615340596e-07
disease O 0 8.484581485390663e-05
phenotype O 0 7.973462743393611e-06
. O 0 5.108739173920185e-07

WFS1 O 0 0.005974403116852045
appears O 0 1.423559183422185e-06
to O 0 1.6643511457914428e-08
function O 0 3.915203716786664e-09
in O 0 2.375071694871167e-09
survival O 0 1.4570146959158592e-05
of O 0 4.43470753452857e-07
islet O 0 1.8137498045689426e-05
beta O 0 2.2287238152784994e-06
- O 0 2.1890564312343486e-06
cells O 0 3.127702186134229e-08
and O 0 7.146457647877469e-09
neurons O 0 3.2303667296673666e-08
. O 0 1.0705945463485023e-08
. O 0 1.2438628971267462e-07

Stable O 0 5.634845729218796e-05
interaction O 0 3.2808469541123486e-07
between O 0 3.2992232945616706e-08
the O 0 1.0812760464773419e-08
products O 0 5.73336578213457e-09
of O 0 3.0363047187620396e-08
the O 0 3.6582239459903576e-08
BRCA1 O 0 1.739722854665615e-08
and O 0 1.0716610709948782e-08
BRCA2 O 0 1.5246662599111005e-08
tumor B-Disease 0 5.549832238216368e-08
suppressor O 0 1.3418463140624226e-07
genes O 0 9.67798952089538e-10
in O 0 8.069223067508347e-10
mitotic O 0 1.5066081004988519e-07
and O 0 4.277680076825163e-08
meiotic O 0 1.5849802366574295e-05
cells O 0 3.33719572154223e-06
. O 0 8.090735263976967e-07

BRCA1 O 0 3.53372743120417e-05
and O 0 1.5091561067492876e-07
BRCA2 O 0 6.393960916284414e-08
account O 0 2.835558177149977e-10
for O 0 1.0836513630874123e-10
most O 0 3.8008700353753255e-11
cases O 0 9.045580950939325e-11
of O 0 3.207953902517602e-09
familial O 0 4.0071125795293483e-07
, O 0 6.570675670225512e-10
early O 0 3.21306941941657e-07
onset O 1 1.0
breast B-Disease 1 0.9999984502792358
and I-Disease 1 0.772467851638794
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.21244709009261e-08
encode O 0 3.801872427988684e-10
products O 0 2.979859692331388e-09
that O 0 7.679960140061226e-11
each O 0 5.5384669073177406e-11
interact O 0 5.8335863917236e-11
with O 0 3.061143005744782e-10
hRAD51 O 0 1.0152979257327388e-06
. O 0 1.892725265406625e-07

Results O 0 4.0262696643367235e-07
presented O 0 1.264168304260238e-06
here O 0 4.7170132688734157e-08
show O 0 5.219034537873313e-09
that O 0 3.53126583529928e-10
BRCA1 O 0 1.9420232533207127e-08
and O 0 9.867633821158961e-09
BRCA2 O 0 9.44238252031937e-08
coexist O 0 4.427928601558051e-08
in O 0 1.172104968638621e-09
a O 0 3.156135575110852e-09
biochemical O 0 1.9267932316324732e-07
complex O 0 1.2267788406461477e-05
and O 0 1.9573859333377186e-07
colocalize O 0 2.7584314011619426e-05
in O 0 9.105261256081576e-08
subnuclear O 0 2.595648584247101e-05
foci O 0 1.2507375686254818e-06
in O 0 3.0279461160631627e-09
somatic O 0 3.722429653407744e-08
cells O 0 4.781880225124269e-09
and O 0 2.271372201434474e-09
on O 0 2.650030062056885e-08
the O 0 4.201987202634427e-09
axial O 0 1.0331175914757296e-08
elements O 0 3.102995194126379e-08
of O 0 1.0947465511890186e-07
developing O 0 8.564267091060174e-07
synaptonemal O 0 3.1659117667004466e-05
complexes O 0 2.1982573343848344e-06
. O 0 7.093104272826167e-07

Like O 0 9.784191206563264e-06
BRCA1 O 0 9.69136362982681e-06
and O 0 1.1401776873753988e-06
RAD51 O 0 0.0042613293044269085
, O 0 1.6531330970792624e-07
BRCA2 O 0 6.030942358847824e-07
relocates O 0 4.7199111463669396e-07
to O 0 4.126126640358052e-08
PCNA O 0 2.5962726795114577e-05
+ O 0 1.0234313663204375e-07
replication O 0 5.039528794270609e-09
sites O 0 5.828117433104296e-10
following O 0 7.967185799984122e-10
exposure O 0 1.4760782818257212e-08
of O 0 1.4231498646211094e-08
S O 0 4.148016046201519e-07
phase O 0 1.5869790104261483e-07
cells O 0 1.7434533816640396e-08
to O 0 4.592903835032303e-09
hydroxyurea O 0 9.08062190774217e-07
or O 0 6.324750501107701e-08
UV O 0 0.003564594779163599
irradiation O 0 5.200331725063734e-05
. O 0 7.075417443047627e-07

Thus O 0 3.451697239142959e-06
, O 0 1.7374439664763486e-07
BRCA1 O 0 7.082370956368322e-08
and O 0 5.9632814242149834e-09
BRCA2 O 0 7.176727656599269e-09
participate O 0 2.5055904573356713e-10
, O 0 1.412622796514995e-10
together O 0 1.1624396584197783e-10
, O 0 1.3724239800172455e-10
in O 0 7.106504829046401e-10
a O 0 3.086273281383001e-08
pathway O 0 1.55698472781296e-07
( O 0 7.021233594528553e-10
s O 0 1.880715849722492e-08
) O 0 9.491882280165953e-11
associated O 0 1.443513308885258e-09
with O 0 4.5481632349186896e-10
the O 0 2.3561135265026678e-08
activation O 0 1.6909453393054719e-07
of O 0 2.677108739135292e-07
double O 0 6.832597421180253e-08
- O 0 9.297957035414584e-07
strand O 0 4.2457432414266805e-07
break O 0 3.19246453273081e-07
repair O 0 5.9335776313673705e-05
and O 0 2.559758343068097e-07
/ O 0 9.97879169517546e-07
or O 0 1.3441075807918423e-08
homologous O 0 1.3866392478689704e-08
recombination O 0 3.397271441940575e-08
. O 0 7.788142397657793e-08

Dysfunction O 1 0.999707043170929
of O 0 5.155702820047736e-05
this O 0 4.242675188947942e-08
pathway O 0 2.416242068647989e-07
may O 0 1.1419304390969387e-09
be O 0 2.3139136440253338e-10
a O 0 9.52656509234373e-10
general O 0 1.0223812907383945e-08
phenomenon O 0 9.751574658878326e-09
in O 0 2.994935133227017e-10
the O 0 6.366233651355913e-10
majority O 0 2.571821748620362e-11
of O 0 1.4413666094004185e-10
cases O 0 1.8557352876591438e-10
of O 0 1.4730800579343395e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 0.9999984502792358
and I-Disease 1 0.997700035572052
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.998680982585938e-07
. O 0 5.761502848145028e-07

A O 0 1.1793546946137212e-05
novel O 0 1.5314957408918417e-06
Arg362Ser O 0 4.832734248338966e-06
mutation O 0 1.3645816920870857e-08
in O 0 1.7397288054610272e-09
the O 0 1.2636360402495939e-08
sterol O 0 1.0210530945187202e-06
27 O 0 1.0651358479663031e-06
- O 0 2.163184035453014e-06
hydroxylase O 0 0.00011160784924868494
gene O 0 2.9923464239800524e-07
( O 0 1.4970884976150955e-08
CYP27 O 0 0.00014877732610329986
) O 0 5.488228094208125e-09
: O 0 4.479649429178778e-10
its O 0 2.4011486132735627e-09
effects O 0 8.271150164773644e-08
on O 0 1.384369880952363e-07
pre O 0 8.517010314790241e-07
- O 0 4.741177761502513e-08
mRNA O 0 7.100561028039465e-09
splicing O 0 1.3686219269004596e-08
and O 0 4.6029693945293104e-10
enzyme O 0 3.60826546419446e-09
activity O 0 1.477088673595972e-09
. O 0 1.8817422287042973e-08

A O 0 7.946900041133631e-06
novel O 0 5.713314976674155e-07
C O 0 1.1405866189306835e-06
to O 0 7.640183596890893e-09
A O 0 5.2900336555694594e-08
mutation O 0 5.049340390250734e-10
in O 0 3.906615864135432e-10
the O 0 5.4240500979574335e-09
sterol O 0 7.183885486483632e-07
27 O 0 9.036502888193354e-07
- O 0 1.3646490515384357e-06
hydroxylase O 0 2.5083098080358468e-05
gene O 0 1.1166280700081188e-07
( O 0 4.585690938085918e-09
CYP27 O 0 6.160274097055662e-06
) O 0 5.195215369013795e-10
was O 0 3.5670715270441633e-09
identified O 0 4.1167833031430234e-10
by O 0 5.819028245368507e-11
sequencing O 0 2.0690125168698614e-08
amplified O 0 5.366068123180412e-08
CYP27 O 0 1.074803094525123e-06
gene O 0 1.5545410514405944e-09
products O 0 2.131706589025839e-09
from O 0 1.6599215335588724e-09
a O 0 5.6309725771086505e-09
patient O 0 1.0802271788179496e-07
with O 0 3.161403228091331e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 1.8073568242016336e-07
CTX B-Disease 0 0.002284834859892726
) O 0 2.520701869457298e-08
. O 0 1.9717147381470568e-07

The O 0 2.050025614153128e-06
mutation O 0 1.6444033690277138e-07
changed O 0 6.715821854186288e-08
the O 0 6.506032690367647e-08
adrenodoxin O 0 7.383354159173905e-07
cofactor O 0 1.41861903557583e-07
binding O 0 3.634119138951064e-08
residue O 0 1.4282599636317173e-07
362Arg O 0 2.7234949584453716e-07
to O 0 1.1356883433677467e-08
362Ser O 0 1.940980837389361e-06
( O 0 3.0689740526668174e-08
CGT O 0 3.2559779356233776e-05
362Arg O 0 1.3125605619279668e-05
to O 0 2.60666780604879e-07
AGT O 0 0.0020307619124650955
362Ser O 0 2.5709584861033363e-06
) O 0 8.393641892645576e-10
, O 0 1.0461323474153517e-10
and O 0 2.9437491333439425e-10
was O 0 6.583954359484778e-08
responsible O 0 1.0010417383909953e-08
for O 0 3.117051949885763e-09
deficiency O 0 7.494737019442255e-06
in O 0 1.7777686878162058e-08
the O 0 1.6253011381195392e-07
sterol O 0 3.966577423852868e-06
27 O 0 1.1086154927397729e-06
- O 0 1.3979861250845715e-06
hydroxylase O 0 1.4731730516359676e-05
activity O 0 1.7136072116841206e-08
, O 0 3.3784836039885136e-10
as O 0 1.893477458159154e-10
confirmed O 0 9.880021245578519e-10
by O 0 2.350715733179243e-10
expression O 0 3.1990818882832173e-09
of O 0 2.37516335488408e-08
mutant O 0 6.856671319610541e-08
cDNA O 0 7.37567660280547e-08
into O 0 2.007694632766288e-07
COS O 0 1.3576311175711453e-05
- O 0 2.1908881535637192e-06
1 O 0 3.2337115385416837e-07
cells O 0 7.197854756668676e-08
. O 0 1.045555322320979e-07

Quantitative O 0 2.6364310201643093e-07
analysis O 0 3.058368136521494e-08
showed O 0 7.073877039687204e-09
that O 0 2.343955307626544e-10
the O 0 2.677045474186457e-09
expression O 0 1.4171762652281927e-09
of O 0 5.398320013227931e-09
CYP27 O 0 2.3720944852811954e-07
gene O 0 2.4986704372231827e-10
mRNA O 0 1.53137758029942e-09
in O 0 2.8813879060507475e-10
the O 0 1.5010391818393032e-09
patient O 0 1.9822307351091695e-08
represented O 0 1.493731360824313e-08
52 O 0 1.5936689123918768e-06
. O 0 1.1118479505967116e-06

5 O 0 1.9161373074894072e-06
% O 0 8.912113713677172e-09
of O 0 1.9326080291648395e-08
the O 0 3.091221856266202e-08
normal O 0 2.1463017674250295e-07
level O 0 1.2938312465848867e-06
. O 0 2.786278514577134e-07

As O 0 1.7791400352962228e-07
the O 0 7.015577807578666e-08
mutation O 0 1.1417568224203478e-08
occurred O 0 4.2122522359022696e-08
at O 0 3.421290584171288e-09
the O 0 1.51943413406741e-09
penultimate O 0 1.4775071122130612e-07
nucleotide O 0 1.6077505549105808e-08
of O 0 1.0123417837348825e-07
exon O 0 2.0195700756175938e-07
6 O 0 1.699027762924743e-07
( O 0 3.506914481032908e-10
- O 0 2.4351924921006685e-08
2 O 0 2.3864484433033795e-07
position O 0 3.844601792479807e-07
of O 0 5.667950517818099e-07
exon O 0 8.726264582037402e-07
6 O 0 1.2962334494659444e-06
- O 0 6.145647262201237e-07
intron O 0 3.7504198644455755e-06
6 O 0 1.1537904356373474e-06
splice O 0 2.258630502183223e-06
site O 0 4.6879080173312104e-08
) O 0 1.2270248705981146e-10
of O 0 1.4719979679611583e-09
the O 0 4.230164218910204e-09
gene O 0 5.7609672587943805e-09
, O 0 5.697737281984416e-10
we O 0 2.378552077519913e-10
hypothesized O 0 7.828992565350745e-09
that O 0 2.1914547954082764e-10
the O 0 2.1646163972377508e-08
mutation O 0 1.3658731923271716e-08
may O 0 1.0916227033419545e-08
partially O 0 2.9878350460421643e-07
affect O 0 1.3274022769849125e-08
the O 0 1.8255489564467098e-08
normal O 0 1.2650805736313941e-08
splicing O 0 4.973708556121892e-08
efficiency O 0 2.041252500362134e-08
in O 0 1.0677104755885125e-09
exon O 0 6.939215069223792e-08
6 O 0 2.2732370652533973e-08
and O 0 3.201937326391402e-10
cause O 0 3.292822015055208e-09
alternative O 0 7.132679513688345e-08
splicing O 0 1.0568675889999213e-07
elsewhere O 0 5.5557185518750885e-09
, O 0 3.3260335458029644e-11
which O 0 1.8410576882454954e-11
resulted O 0 1.3155275757625873e-09
in O 0 3.958188499186832e-10
decreased O 0 2.19902607234701e-09
transcript O 0 3.827064176675776e-08
in O 0 8.274550489240085e-10
the O 0 1.4029016170979958e-08
patient O 0 1.9105156923160393e-07
. O 0 1.996502163592595e-07

Transfection O 0 0.0013632843038067222
of O 0 2.4731207304284908e-05
constructed O 0 7.701395225012675e-05
minigenes O 0 4.6737379307160154e-05
, O 0 1.551821560141775e-09
with O 0 1.5549732335085054e-10
or O 0 2.9690350178412928e-09
without O 0 9.253284360966063e-09
the O 0 2.2072086380831024e-08
mutation O 0 1.816735539783565e-09
, O 0 2.76361405981973e-10
into O 0 8.406398244176216e-09
COS O 0 1.2676134247158188e-05
- O 0 1.0576978866083664e-06
1 O 0 5.1689095670326424e-08
cells O 0 5.685187876025566e-10
confirmed O 0 4.2072942352255893e-10
that O 0 1.8573420579315325e-11
the O 0 2.560727851985689e-09
mutant O 0 2.6174584277782742e-08
minigene O 0 1.6173936501218122e-07
was O 0 1.350745915118523e-08
responsible O 0 8.079603097677079e-10
for O 0 3.308597285034409e-10
a O 0 2.760391248912697e-09
mRNA O 0 1.6883687781188428e-09
species O 0 2.824288025671251e-10
alternatively O 0 3.586377861353185e-09
spliced O 0 9.003164080922943e-08
at O 0 1.2670485105559237e-08
an O 0 3.233957546200372e-10
activated O 0 5.591332978838182e-07
cryptic O 0 1.8707612525759032e-06
5 O 0 3.282277418747981e-07
splice O 0 1.2226641047163866e-05
site O 0 1.2146264225521008e-06
88 O 0 5.511402605407056e-07
bp O 0 3.310090903596574e-07
upstream O 0 3.140847937288527e-08
from O 0 2.9770532705697406e-09
the O 0 1.587701881078374e-08
3 O 0 8.149334718154932e-08
end O 0 1.1294738300193785e-07
of O 0 1.2282171724109503e-07
exon O 0 1.5666020090066013e-06
6 O 0 8.512243994118762e-07
. O 0 1.0817963413956022e-07

Our O 0 5.641010830004234e-06
data O 0 4.2284241885681695e-08
suggest O 0 3.50174289565075e-09
that O 0 1.9128833239623333e-10
the O 0 5.1674478029895e-09
C O 0 1.3097366036163294e-07
to O 0 5.219711773918334e-09
A O 0 8.336784418361276e-08
mutation O 0 7.601649976152203e-09
at O 0 1.1512824471537897e-08
the O 0 5.066321584479283e-09
penultimate O 0 1.3278307164910075e-07
nucleotide O 0 1.8271547830295276e-08
of O 0 2.5280302295982437e-08
exon O 0 9.113878718380874e-08
6 O 0 5.6470227605132095e-08
of O 0 7.023541304107539e-09
the O 0 5.124304536252566e-08
CYP27 O 0 2.257093547086697e-05
gene O 0 1.2616106381813097e-08
not O 0 8.713900712109535e-10
only O 0 4.678997189699885e-10
causes O 0 1.5048813750695444e-08
the O 0 2.5609539378024238e-08
deficiency B-Disease 0 7.428967592204572e-07
in I-Disease 0 7.246602873323127e-09
the I-Disease 0 9.412676860165448e-08
sterol I-Disease 0 2.046019517365494e-06
27 I-Disease 0 7.255837317643454e-07
- I-Disease 0 1.2565240012918366e-06
hydroxylase I-Disease 0 6.35762553429231e-05
activity I-Disease 0 4.564680011753808e-08
, O 0 7.69768027097939e-10
but O 0 1.1250265163909035e-09
also O 0 3.670585835280349e-09
partially O 0 7.875589602690525e-08
leads O 0 9.974812975599434e-09
to O 0 1.0749400258802666e-09
alternative O 0 4.7321432106173233e-08
pre O 0 1.9247286218160298e-06
- O 0 4.991023061506894e-08
mRNA O 0 1.081657607926445e-08
splicing O 0 4.498319228218861e-08
of O 0 3.521750002732915e-09
the O 0 6.798029694721208e-09
gene O 0 2.0605925854511042e-08
. O 0 9.808827883261984e-08

To O 0 1.4874972293910105e-06
our O 0 4.4425217993193655e-07
knowledge O 0 3.4448493124727975e-07
, O 0 1.1240891550912124e-09
this O 0 9.116039173528989e-11
is O 0 1.1213904110851658e-10
the O 0 5.556902160641641e-10
first O 0 7.435588256221592e-10
report O 0 1.270178406898026e-10
regarding O 0 3.1852489534855977e-09
effects O 0 3.446021779041075e-08
on O 0 9.097605158103761e-08
pre O 0 3.042966625343979e-07
- O 0 1.9043485011138728e-08
mRNA O 0 4.586828250552344e-09
splicing O 0 1.85178432587918e-08
of O 0 2.709604096651219e-09
a O 0 1.1216990669637994e-09
mutation O 0 3.1592900517907196e-10
at O 0 2.726380010642515e-09
the O 0 8.479994484389408e-09
- O 0 5.975454797635393e-08
2 O 0 1.5826638843918772e-07
position O 0 1.350894649476686e-07
of O 0 1.4001594195178768e-07
a O 0 3.439597264787153e-07
5 O 0 6.612597758248739e-07
splice O 0 1.5448002159246244e-05
site O 0 1.4954025573388208e-06
. O 0 1.7085689307805296e-07

ATM O 0 0.00011945952428504825
germline O 0 1.6758409401518293e-05
mutations O 0 5.673407699191557e-08
in O 0 1.766829882399179e-08
classical O 0 0.0014296364970505238
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 1.0
in O 0 1.080008360077045e-06
the O 0 2.0236607269907836e-06
Dutch O 0 5.589943157247035e-06
population O 0 8.487530123169051e-10
. O 0 4.785039564580984e-08

Germline O 0 5.9453810536069795e-05
mutations O 0 1.0776445691362824e-07
in O 0 6.265147511896885e-09
the O 0 1.2357301848453517e-08
ATM O 0 6.04145355964647e-08
gene O 0 1.7768991833477799e-10
are O 0 1.5708604122338654e-12
responsible O 0 9.368709280588305e-11
for O 0 4.973712552924781e-10
the O 0 0.0001965308765647933
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.026956208050251007
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.385859822126804e-06
. O 0 6.372462848958094e-06

In O 0 9.555778888170607e-07
our O 0 1.863352707687227e-07
study O 0 3.0703015685418222e-09
, O 0 5.267917213558349e-10
we O 0 6.717183059778975e-11
have O 0 3.0639626252826346e-11
determined O 0 1.5956855836662953e-09
the O 0 9.918826648913637e-09
ATM O 0 5.66428219883619e-08
mutation O 0 1.3447505331498633e-09
spectrum O 0 9.237942855122583e-09
in O 0 4.2692310797676214e-10
19 O 0 2.136330445878798e-09
classical O 0 1.752058125248368e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.7789099729270674e-05
, O 0 3.6109004675211054e-10
including O 0 3.457986674781921e-11
some O 0 6.147314601800957e-11
immigrant O 0 6.893578485822616e-10
populations O 0 1.2056353138056863e-10
, O 0 4.4460407577773253e-11
as O 0 2.2526551457513477e-10
well O 0 8.251225258604222e-10
as O 0 3.3591442960556606e-09
12 O 0 7.53493001326433e-09
of O 0 5.774190459106876e-09
Dutch O 0 3.297821251635469e-07
ethnic O 0 2.6337325653713606e-09
origin O 0 3.417835259256208e-08
. O 0 2.32027616675623e-07

Both O 0 5.197074415264069e-07
the O 0 3.040002241050388e-07
protein O 0 3.753163468900311e-08
truncation O 0 6.022378897796443e-07
test O 0 2.086768517983728e-07
( O 0 1.3520734754024488e-08
PTT O 0 5.787281338598405e-07
) O 0 3.207377419212065e-10
and O 0 9.261614253297523e-10
the O 0 1.0923808524410106e-08
restriction O 0 3.0699517594712233e-08
endonuclease O 0 5.848579576195334e-07
fingerprinting O 0 9.899779485067484e-08
( O 0 1.7201492452656453e-09
REF O 0 1.2738063333017635e-06
) O 0 6.729776458325176e-11
method O 0 4.223486838039747e-10
were O 0 1.8899126708049607e-10
used O 0 9.535363609813885e-10
and O 0 3.992399466579144e-10
compared O 0 1.1033675084703987e-09
for O 0 4.695572264346026e-10
their O 0 5.398378966070538e-10
detection O 0 2.1624794044328155e-07
efficiency O 0 3.4900754286582014e-08
, O 0 5.955602677687466e-11
identifying O 0 1.080255107588357e-09
76 O 0 1.5424854282741762e-08
% O 0 4.616712290239633e-10
and O 0 1.0903984382082399e-09
60 O 0 1.7928767359620679e-09
% O 0 2.653162967103384e-10
of O 0 2.1595225607740076e-09
the O 0 1.1440019598296658e-08
mutations O 0 2.9268649726077456e-09
, O 0 1.4211336551994691e-09
respectively O 0 3.342382370874475e-08
. O 0 3.8557638504244096e-07

Most O 0 7.387066034425516e-07
patients O 0 1.5578520162762288e-07
were O 0 1.2902485302390687e-08
found O 0 2.637462692689496e-09
to O 0 2.4207795767949847e-09
be O 0 1.391936343964062e-08
compound O 0 1.3051526366325561e-05
heterozygote O 0 0.00014843454118818045
. O 0 2.3843085728003643e-06

Seventeen O 0 6.18437297816854e-06
mutations O 0 4.6837165257329616e-08
were O 0 4.222828753341901e-09
distinct O 0 3.1482294549078915e-09
, O 0 5.513931533585037e-10
of O 0 5.457663210250985e-09
which O 0 9.407751244694396e-10
10 O 0 1.865965160163796e-09
were O 0 5.29031096707655e-10
not O 0 2.1678371597833035e-10
reported O 0 8.701515064046816e-09
previously O 0 1.1242381958709302e-07
. O 0 2.925226567640493e-07

Mutations O 0 2.637311581565882e-06
are O 0 6.298119803460622e-09
small O 0 2.7497305765677993e-08
deletions O 0 3.5332777770236135e-07
or O 0 4.414773684402462e-07
point O 0 5.227463589108083e-06
mutations O 0 4.4776975016702636e-08
frequently O 0 2.3832001261325786e-08
affecting O 0 5.460310958937953e-08
splice O 0 5.4861277021700516e-05
sites O 0 1.7110324961322476e-06
. O 0 9.0439004907239e-07

Moreover O 0 3.576260951376753e-06
, O 0 1.060225187643482e-07
a O 0 3.257858907090849e-07
16 O 0 1.4358740827447036e-06
. O 0 9.278292623093876e-07

7 O 0 0.00010414865391794592
- O 0 1.3818408660881687e-05
kb O 0 5.231523118709447e-06
genomic O 0 3.490279425477638e-07
deletion O 0 1.089046435254204e-07
of O 0 1.098488482398352e-07
the O 0 8.626592773453012e-08
3 O 0 5.355137844276214e-08
end O 0 4.8996906087950265e-08
of O 0 2.264020437792169e-08
the O 0 1.110425973394058e-08
gene O 0 2.329044734850072e-09
, O 0 1.5292897503904612e-10
most O 0 1.8930007561479556e-10
likely O 0 2.001125043449292e-09
a O 0 2.7986357675757745e-09
result O 0 2.592949854829385e-09
of O 0 1.7969481902468942e-08
recombination O 0 1.7377721484024278e-09
between O 0 7.06168679087682e-10
two O 0 6.067199520565225e-10
LINE O 0 6.906061145173226e-08
elements O 0 8.244401605850271e-09
, O 0 8.331515477522089e-10
was O 0 5.969360472590779e-08
identified O 0 2.898356399327895e-08
. O 0 1.4386769464636018e-07

The O 0 6.431820111174602e-06
most O 0 1.6490037779703925e-08
frequently O 0 1.8078657459952296e-09
found O 0 4.561229172139747e-10
mutation O 0 8.491817665712276e-11
, O 0 2.1264497107598146e-11
identified O 0 2.4817900512452695e-10
in O 0 6.384229811473574e-10
three O 0 2.9359226161318475e-09
unrelated O 0 1.266133438093675e-07
Turkish O 0 0.00010100676445290446
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.2740132504518442e-08
, O 0 8.834263098833617e-09
was O 0 4.247602305440523e-07
previously O 0 9.957666691207123e-09
described O 0 2.921449082649019e-09
to O 0 4.5864409492502034e-10
be O 0 6.699797938658492e-10
a O 0 1.9792915750826978e-08
Turkish O 0 2.461606754877721e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
founder O 0 0.0004919891362078488
mutation O 0 5.270118776934396e-07
. O 0 1.9200319911760744e-07

The O 0 9.606728781363927e-07
presence O 0 8.595420553092481e-08
of O 0 8.123013230942888e-07
a O 0 1.3434652146315784e-06
founder O 0 9.853666415438056e-05
mutation O 0 2.920487816027162e-07
among O 0 4.2837036140497275e-09
relatively O 0 1.3511092689100224e-08
small O 0 3.119103864079875e-09
ethnic O 0 1.0088264945640191e-10
population O 0 3.4135676056645803e-12
groups O 0 5.163735758428878e-12
in O 0 1.6209118769427988e-10
Western O 0 5.502632660636664e-08
Europe O 0 2.563011314293817e-08
could O 0 2.0113188892167955e-09
indicate O 0 1.4089424071883627e-09
a O 0 4.312363355296611e-09
high O 0 1.1620485018681848e-08
carrier O 0 1.5102518124976427e-09
frequency O 0 2.0047083992835724e-09
in O 0 2.6241592232523203e-10
such O 0 6.826195719789041e-10
communities O 0 1.87375555071867e-08
. O 0 1.9408999207826128e-07

In O 0 7.286716368071211e-07
patients O 0 4.312488783853041e-07
of O 0 6.041730671313417e-07
Dutch O 0 3.511601562422584e-06
ethnic O 0 1.4144596605092374e-09
origin O 0 3.8914320654726e-09
, O 0 2.064670101553645e-10
however O 0 7.216777730967294e-10
, O 0 8.560688963266117e-11
no O 0 6.585957890159477e-10
significant O 0 1.3529814602009083e-08
founder O 0 1.086157340068894e-06
effect O 0 1.509642011399137e-08
could O 0 1.019995288231712e-08
be O 0 7.3243637821462926e-09
identified O 0 9.270494416568908e-08
. O 0 1.0921708337718883e-07

The O 0 1.6814991568026016e-06
observed O 0 1.5415392340401013e-07
genetic O 0 1.0632324176640395e-07
heterogeneity O 0 2.884646903567045e-07
including O 0 3.882883348182986e-09
the O 0 5.2613952306046485e-08
relative O 0 3.115036088274792e-05
high O 0 0.00011530154733918607
percentage O 0 1.9583868038353103e-07
of O 0 2.858270420347253e-07
splice O 0 0.0001365232456009835
- O 0 2.2662756236968562e-05
site O 0 3.5316205071467266e-07
mutations O 0 2.098345275314273e-09
had O 0 3.471802401122659e-09
no O 0 1.1602184768477741e-09
reflection O 0 2.518750541469217e-08
on O 0 6.575458399993295e-08
the O 0 2.6559858312680262e-08
phenotype O 0 6.352339596560341e-07
. O 0 1.5899237837402325e-07

All O 0 2.9423159730868065e-07
patients O 0 8.928144978881392e-08
manifested O 0 8.695578657125225e-08
classical O 0 5.5105588216974866e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
and O 0 3.333914122549686e-08
increased O 0 2.3095243051329817e-08
cellular O 0 7.918668387674188e-08
radioresistant O 0 9.229703579194393e-08
DNA O 0 4.4621124573041016e-08
synthesis O 0 8.212060009782363e-08
. O 0 2.8232836513097936e-08

Determination O 0 1.6305737517541274e-05
of O 0 3.4906231576314894e-06
the O 0 1.4154082350614772e-07
genomic O 0 7.555138381576398e-08
structure O 0 2.8761855119796564e-08
of O 0 2.0461055072473755e-08
the O 0 6.349260228688536e-09
COL4A4 O 0 5.460601641971152e-07
gene O 0 4.5963013950434117e-10
and O 0 6.513895672854986e-11
of O 0 2.7444790884345593e-09
novel O 0 2.1037007513768913e-07
mutations O 0 1.6235426301136613e-06
causing O 0 6.93520587446983e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 6.268329889280722e-05

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 5.017299713472312e-07
a O 0 2.5384651962667704e-06
progressive O 1 0.999995231628418
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.17772792279720306
by O 0 1.7463364088143862e-07
glomerular B-Disease 1 1.0
basement I-Disease 1 1.0
membrane I-Disease 0 3.6488210753304884e-05
abnormalities I-Disease 0 6.683761512249475e-06
and O 0 3.267818793339927e-10
associated O 0 5.8708513606120505e-09
with O 0 6.880704894740575e-10
mutations O 0 8.440749432736538e-09
in O 0 1.8818283820110082e-08
either O 0 2.5116847268691345e-07
the O 0 1.2238341696502175e-05
COL4A3 O 0 0.01617852970957756
or O 0 7.159134440826165e-08
the O 0 9.867844852351482e-08
COL4A4 O 0 1.9019836372535792e-06
gene O 0 1.0640226477676151e-09
, O 0 9.012910556771558e-11
which O 0 7.928797896017414e-11
encode O 0 1.3926526598595501e-09
the O 0 3.0897716385425156e-08
alpha3 O 0 3.1143968044489156e-06
and O 0 2.5082133703335785e-08
alpha4 O 0 1.496792151556292e-06
type O 0 1.2935771565025789e-06
IV O 1 1.0
collagen O 0 0.05991443246603012
chains O 0 2.904776465584291e-06
, O 0 1.1161804813752951e-08
respectively O 0 3.0421013264003705e-08
. O 0 1.2461615028769302e-07

To O 0 1.5131625730191445e-07
date O 0 9.252967743123008e-07
, O 0 1.9459118760778438e-09
mutation O 0 1.291791118518404e-10
screening O 0 2.9555369263079e-09
in O 0 3.640720502851025e-10
the O 0 1.6812132130894497e-08
two O 0 6.0684293146096024e-09
genes O 0 8.064549916753094e-09
has O 0 2.4228858919173035e-09
been O 0 6.601883484336213e-09
hampered O 0 1.7826903786044568e-05
by O 0 3.795165515185772e-09
the O 0 3.895830502642639e-08
lack O 0 2.075736915685411e-07
of O 0 1.9942675066886295e-08
genomic O 0 3.540549542435656e-08
structure O 0 4.264548181254213e-08
information O 0 2.1272480665857074e-08
. O 0 1.2556526485241193e-07

We O 0 5.551917752200097e-07
report O 0 4.248942886420082e-08
here O 0 6.345083125580686e-09
the O 0 3.299033046744171e-09
complete O 0 6.17583184592263e-09
characterization O 0 6.210930081351762e-08
of O 0 2.820178401918838e-08
the O 0 7.064373619414255e-08
48 O 0 1.2011817318580142e-07
exons O 0 5.370091002987465e-07
of O 0 2.0582207582720002e-07
the O 0 3.149895633214328e-07
COL4A4 O 0 1.320861883868929e-05
gene O 0 2.611055904822024e-08
, O 0 7.01662894453392e-10
a O 0 2.920981234666442e-09
comprehensive O 0 1.065847321513047e-08
gene O 0 3.6137819403592175e-09
screen O 0 1.1072835803815906e-07
, O 0 4.552502541610437e-10
and O 0 4.261892505574849e-10
the O 0 1.8196175677331894e-09
subsequent O 0 1.1535684407704139e-08
detection O 0 3.7938903574286087e-07
of O 0 1.1024698487460682e-08
10 O 0 6.01039273906423e-10
novel O 0 6.224218918049473e-10
mutations O 0 1.9995674560568943e-10
in O 0 1.2724528375418487e-10
eight O 0 3.3170279856165052e-09
patients O 0 1.3967500933631527e-08
diagnosed O 0 7.215769983304199e-06
with O 0 6.563266197190387e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.0001284881727769971

Furthermore O 0 1.7915123180500814e-06
, O 0 3.4372646950942e-08
we O 0 1.4689325311678658e-09
identified O 0 2.354854311548138e-09
a O 0 3.2189497733980943e-09
glycine O 0 7.851244099299493e-09
to O 0 2.8633317938897562e-09
alanine O 0 2.1664090965600735e-08
substitution O 0 1.1655828302536975e-07
in O 0 3.9440319454797645e-08
the O 0 1.0822214591144075e-07
collagenous O 0 1.8539153643359896e-06
domain O 0 6.1261702377635174e-09
that O 0 4.633038050427807e-11
is O 0 5.727479601702612e-11
apparently O 0 1.8708976590176007e-09
silent O 0 2.5945540826910474e-08
in O 0 1.1378386011173802e-09
the O 0 3.2275382366719896e-09
heterozygous O 0 9.243555920690483e-11
carriers O 0 1.2239394220348032e-10
, O 0 2.3354226885707874e-10
in O 0 1.7955151809800896e-09
11 O 0 3.011521698681463e-07
. O 0 3.472132732440514e-07

5 O 0 1.915965412990772e-06
% O 0 1.2373103430718402e-08
of O 0 2.567987600343713e-08
all O 0 6.249628592414069e-10
control O 0 7.4204042910253065e-09
individuals O 0 2.3788004552272035e-11
, O 0 8.731131789785351e-11
and O 0 3.6389016799809326e-10
in O 0 7.249806865949893e-10
one O 0 7.705877047570198e-10
control O 0 2.9675288892860863e-09
individual O 0 3.1107415254805204e-11
homozygous O 0 3.07217473682897e-10
for O 0 1.8854300065651586e-10
this O 0 4.3892531276235047e-10
glycine O 0 1.6761287469080344e-08
substitution O 0 2.1559476692800672e-07
. O 0 6.683147830699454e-07

There O 0 5.13185568706831e-07
has O 0 1.1455566273355089e-08
been O 0 1.581849096154997e-09
no O 0 4.6558779054350907e-10
previous O 0 2.5739983477990336e-09
finding O 0 6.620041403948562e-09
of O 0 5.908101119445064e-09
a O 0 2.6347273252014247e-09
glycine O 0 4.530908981337234e-09
substitution O 0 8.901580805797948e-09
that O 0 2.9628954845151156e-10
is O 0 8.350809627133415e-11
not O 0 9.912798012989832e-12
associated O 0 1.248517539353955e-10
with O 0 3.1620799728626636e-11
any O 0 5.660107382787771e-10
obvious O 0 9.973101455784672e-09
phenotype O 0 2.5109704537840116e-08
in O 0 6.396296825528225e-10
homozygous O 0 3.7315621703726265e-09
individuals O 0 1.823316497784333e-10
. O 0 5.520409374071278e-08

Founder O 0 0.007104620803147554
BRCA1 O 0 4.438787527760724e-06
and O 0 1.3074190974293742e-07
BRCA2 O 0 4.31974100933985e-08
mutations O 0 9.546410328908905e-10
in O 0 7.747096297805456e-10
French O 0 1.314244713057633e-07
Canadian O 0 0.0006409620400518179
breast B-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.0277917630883167e-06
. O 0 4.4898544615534774e-07

We O 0 2.607393696507643e-07
have O 0 5.0224673309173795e-09
identified O 0 1.0375449832622508e-08
four O 0 1.45462952794162e-09
mutations O 0 6.693855192363429e-11
in O 0 1.447714587099469e-10
each O 0 8.307565746434875e-11
of O 0 1.882970508404469e-07
the O 0 0.008346554823219776
breast B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
- O 0 6.213149754330516e-05
susceptibility O 0 4.468685347092105e-06
genes O 0 1.882424349730627e-08
, O 0 1.0683257611887598e-09
BRCA1 O 0 2.1586454845845537e-09
and O 0 2.6338480285659216e-09
BRCA2 O 0 3.394471592699233e-09
, O 0 3.2008121847448834e-11
in O 0 1.0299253117018736e-10
French O 0 5.680836068222561e-08
Canadian O 0 9.305833373218775e-06
breast B-Disease 1 0.9922635555267334
cancer I-Disease 1 0.962971031665802
and O 0 0.00018099648877978325
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 5.3348607309544605e-08
from O 0 2.931883713586103e-08
Quebec O 0 1.5091259228938725e-06
. O 0 4.6837433842483733e-07

To O 0 2.0880911506537814e-06
identify O 0 6.309698164841393e-06
founder O 0 0.0005765804671682417
effects O 0 0.0010707295732572675
, O 0 2.808251409192053e-08
we O 0 2.4975661538917393e-09
examined O 0 1.3800719678158657e-08
independently O 0 1.2018750439324322e-09
ascertained O 0 4.0447996951797904e-08
French O 0 4.187611324368845e-08
Canadian O 0 4.7604652309019e-07
cancer B-Disease 0 1.8394079233985394e-05
families O 0 1.4769450107365856e-09
for O 0 2.48859655105349e-10
the O 0 9.162639535986727e-10
distribution O 0 3.3171024260703064e-10
of O 0 1.4630325839704028e-09
these O 0 6.571077015848914e-10
eight O 0 1.0278716544576127e-08
mutations O 0 1.1321112047824045e-08
. O 0 1.1134591915151759e-07

Mutations O 0 1.2199976140436775e-07
were O 0 1.5757549931549875e-08
found O 0 8.444207000302129e-10
in O 0 1.0174338038737574e-09
41 O 0 2.3827318784697127e-08
of O 0 7.009679592329121e-08
97 O 0 5.243510713626165e-06
families O 0 1.283851673861136e-07
. O 0 7.88880981872353e-07

Six O 0 2.337306796107441e-06
of O 0 3.5224107364228985e-07
eight O 0 2.0582161752713546e-08
mutations O 0 1.3635454987337425e-09
were O 0 2.5445734408435783e-09
observed O 0 1.1427808033204201e-08
at O 0 2.6264901364925208e-08
least O 0 1.0728322674680157e-09
twice O 0 3.4041402585671676e-08
. O 0 1.410836887316691e-07

The O 0 2.0974512153770775e-05
BRCA1 O 0 1.97422195924446e-06
C4446T O 0 8.640620876576577e-07
mutation O 0 1.1324696735925954e-08
was O 0 2.9779352317405028e-08
the O 0 1.5343449843996382e-09
most O 0 8.45193776077835e-11
common O 0 3.486532451635327e-10
mutation O 0 1.0746155354457443e-10
found O 0 1.4778457624320396e-10
, O 0 1.8357874248531303e-11
followed O 0 2.633510354232982e-10
by O 0 3.50576401242364e-10
the O 0 2.8436375032470096e-07
BRCA2 O 0 4.5395401571113325e-07
8765delAG O 0 7.67447886573791e-07
mutation O 0 5.422221960316165e-08
. O 0 1.0599440969372154e-07

Together O 0 7.050198860270029e-07
, O 0 3.978885221300743e-09
these O 0 2.54686383094338e-10
mutations O 0 5.710030781536091e-10
were O 0 1.1716065895228667e-09
found O 0 4.189964208922703e-10
in O 0 3.7137029562650525e-10
28 O 0 1.9012272645113626e-08
of O 0 3.775680568196549e-08
41 O 0 8.220334279940289e-08
families O 0 1.4035004269885576e-09
identified O 0 5.475367714780077e-09
to O 0 4.515319673714657e-09
have O 0 1.0060029254077563e-08
a O 0 1.9021491937110113e-07
mutation O 0 1.1879304651074563e-07
. O 0 1.9671881545946235e-07

The O 0 8.703145795152523e-06
odds O 0 6.828676305303816e-06
of O 0 1.752019755940637e-07
detection O 0 5.062951458967291e-06
of O 0 4.7844189055012976e-08
any O 0 6.613794401033601e-09
of O 0 4.817971799297993e-08
the O 0 5.078959830484564e-08
four O 0 8.036817433776378e-09
BRCA1 O 0 5.659117174872108e-09
mutations O 0 2.549256361561447e-09
was O 0 2.2801771137892501e-07
18 O 0 2.911161232077575e-07
. O 0 3.4186382436018903e-07

7x O 1 0.8218315243721008
greater O 0 7.2445573096047156e-06
if O 0 4.731267821966867e-08
one O 0 1.7703203347707586e-09
or O 0 6.165586097228726e-11
more O 0 1.1035573496687157e-12
cases O 0 8.451631061667797e-11
of O 0 1.4363110494741704e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.461865898974793e-08
also O 0 5.834167593476991e-10
present O 0 1.0808363093417483e-09
in O 0 6.845129796317906e-09
the O 0 3.28589806031232e-07
family O 0 1.0474510645508417e-06
. O 0 3.4313572427890904e-07

The O 0 5.767220955021912e-06
odds O 0 3.72440081264358e-06
of O 0 4.654168606066378e-08
detection O 0 1.38872712796001e-06
of O 0 2.4585883551253573e-08
any O 0 2.9373565801904533e-09
of O 0 5.8434839189658305e-08
the O 0 1.498641921671151e-07
four O 0 2.8723531997343343e-08
BRCA2 O 0 2.4482186944396744e-08
mutations O 0 5.86297366211852e-09
was O 0 4.1626392999205564e-07
5 O 0 2.4823873445711797e-07
. O 0 1.9345152679761668e-07

3x O 0 5.155590042704716e-05
greater O 0 2.509108867343457e-07
if O 0 3.7150793552598316e-09
there O 0 8.838573206659817e-10
were O 0 3.526448244528524e-09
at O 0 8.76433925434128e-10
least O 0 1.2715812777730484e-11
five O 0 1.517214305579717e-11
cases O 0 5.49134245020344e-11
of O 0 1.720471587418615e-08
breast B-Disease 0 0.0017084779683500528
cancer I-Disease 0 0.0001303454046137631
in O 0 2.784065245009515e-08
the O 0 3.3062776765291346e-06
family O 0 6.3863340074021835e-06
. O 0 3.903857077602879e-07

Interestingly O 0 2.6084233013534686e-06
, O 0 1.3144949129184624e-08
the O 0 9.062219419320172e-09
presence O 0 2.2018422640712743e-09
of O 0 9.518218746507046e-08
a O 0 2.3101857493657008e-07
breast B-Disease 0 2.2225274733500555e-05
cancer I-Disease 0 6.537915169246844e-07
case O 0 3.4516990154997984e-08
< O 0 1.3772982754289842e-07
36 O 0 9.984979065791322e-09
years O 0 1.3123748754395592e-09
of O 0 2.911841878727728e-09
age O 0 3.754701438651864e-09
was O 0 1.7313611877511903e-08
strongly O 0 6.011891678925352e-11
predictive O 0 9.784490995201622e-10
of O 0 2.3269666193925787e-09
the O 0 1.7725265699652937e-09
presence O 0 1.951478700856768e-10
of O 0 1.4806060821825895e-09
any O 0 3.841672535642715e-10
of O 0 5.391261215237364e-09
the O 0 1.6114624301621916e-08
eight O 0 5.819788650995861e-09
mutations O 0 3.1035203296170266e-09
screened O 0 1.2317067898948153e-07
. O 0 1.3945543742011068e-07

Carriers O 0 5.322831384546589e-07
of O 0 8.288732828987122e-07
the O 0 5.2929205907048527e-08
same O 0 4.417618271190804e-09
mutation O 0 1.412717831605903e-09
, O 0 4.893500535341211e-11
from O 0 5.542271155900558e-11
different O 0 2.0780911713647043e-10
families O 0 1.2604266519389284e-09
, O 0 9.465955796983394e-11
shared O 0 3.0381089310971277e-10
similar O 0 1.4048072705108439e-09
haplotypes O 0 2.8481908387334443e-08
, O 0 2.152115985420977e-10
indicating O 0 1.4050056673653444e-09
that O 0 4.244160023425536e-10
the O 0 2.51846259402555e-08
mutant O 0 1.881763722622054e-08
alleles O 0 3.525411074178919e-10
were O 0 3.69149988355133e-10
likely O 0 6.758465453948759e-10
to O 0 1.8972189097521408e-10
be O 0 1.424144829842433e-10
identical O 0 1.2064915733134285e-09
by O 0 2.9308297455621357e-10
descent O 0 1.854672149192993e-08
for O 0 6.4469801719369e-10
a O 0 6.251944739688042e-09
mutation O 0 1.3303798063191152e-09
in O 0 2.3072292965053975e-09
the O 0 8.20018044578319e-08
founder O 0 1.3946436183687183e-06
population O 0 4.671943387712929e-10
. O 0 5.1975202808307586e-08

The O 0 1.4970092365729215e-07
identification O 0 2.214136998190952e-07
of O 0 3.5475093795866997e-07
common O 0 7.971713785082102e-06
BRCA1 O 0 4.831670139537891e-07
and O 0 4.662182462311648e-08
BRCA2 O 0 2.27120882101417e-08
mutations O 0 5.144354942032692e-10
will O 0 1.296041052256669e-10
facilitate O 0 7.55962847875935e-10
carrier O 0 6.591692081059364e-09
detection O 0 9.040536497195717e-07
in O 0 3.4242935154082943e-09
French O 0 2.3213252120513062e-07
Canadian O 0 6.5903009272005875e-06
breast B-Disease 0 0.43175771832466125
cancer I-Disease 0 0.0008692952105775476
and O 0 1.026290647132555e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.2205867367119936e-07
. O 0 8.946589247216252e-08

Are O 0 2.1655813498000498e-07
Dp71 O 0 0.00020769090042449534
and O 0 6.771586527065665e-07
Dp140 O 0 1.6967922420008108e-05
brain O 0 9.880339348455891e-06
dystrophin O 0 1.6717502830942976e-06
isoforms O 0 2.8797535023272758e-08
related O 0 8.619911895380028e-09
to O 0 1.7394434781436985e-09
cognitive B-Disease 0 1.4031114005774725e-05
impairment I-Disease 1 0.9998775720596313
in O 0 0.00017681358440313488
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9998409748077393

Molecular O 0 4.594598067342304e-06
study O 0 3.707726037305292e-08
and O 0 2.5648827506330463e-09
neuropsychological O 0 3.50988926811624e-08
analysis O 0 2.9807918355828633e-09
were O 0 1.4333892961460037e-09
performed O 0 9.17987019732891e-10
concurrently O 0 1.4166627870793036e-09
on O 0 5.387357759900624e-08
49 O 0 3.6329691255332364e-08
patients O 0 1.4541309489857213e-08
with O 0 1.0417294049602788e-07
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0015854759840294719
DMD B-Disease 1 1.0
) O 0 8.502712978142313e-10
in O 0 2.0240099873891637e-10
order O 0 2.7338158403722446e-09
to O 0 1.1033444158314865e-09
find O 0 1.9697699027432236e-09
a O 0 4.866158032079682e-10
molecular O 0 1.370873303763176e-09
explanation O 0 9.689385960243158e-10
for O 0 1.7890362802308601e-10
the O 0 4.265342745668477e-09
cognitive B-Disease 0 4.432703235579538e-07
impairment I-Disease 0 4.5030836304249533e-07
observed O 0 1.12171667510097e-08
in O 0 2.9571325388388914e-09
most O 0 7.324213413539837e-08
DMD B-Disease 1 1.0
patients O 0 2.9941133107058704e-05
. O 0 7.344749519688776e-07

Complete O 0 4.931920898343378e-07
analysis O 0 1.786804482151183e-08
of O 0 5.010710424357967e-08
the O 0 3.05948830714442e-08
dystrophin O 0 9.247374350707105e-07
gene O 0 4.5874607224050123e-08
was O 0 5.594890239990491e-07
performed O 0 9.12875020020465e-09
to O 0 2.2403929822445434e-09
define O 0 2.236525808996248e-08
the O 0 8.606854606796333e-08
localization O 0 1.3228904208517633e-05
of O 0 1.0825642249301382e-07
deletions O 0 1.0699579888751032e-07
and O 0 6.403502617047252e-09
duplications O 0 6.474181901694465e-08
in O 0 1.1704294200498566e-09
relation O 0 5.173009576253662e-09
to O 0 1.4283348948040953e-09
the O 0 2.4472710080658544e-08
different O 0 9.631536812548802e-08
DMD B-Disease 1 1.0
promoters O 0 4.8289657570421696e-05
. O 0 9.964014680008404e-07

Qualitative O 0 1.8320005210625823e-06
analysis O 0 9.186954486040122e-08
of O 0 2.3424249206982495e-07
the O 0 2.060204167264601e-07
Dp71 O 0 1.3583589861809742e-05
transcript O 0 1.0525399147809367e-06
and O 0 2.75968581320285e-09
testing O 0 1.7319879974664332e-09
for O 0 1.7845071254019018e-10
the O 0 9.507759024529605e-10
specific O 0 7.540605362343911e-10
first O 0 1.2745965172200613e-08
exon O 0 6.47525695285367e-08
of O 0 2.294595446983294e-08
Dp140 O 0 1.2708950691830978e-07
were O 0 1.1925772369636434e-08
also O 0 2.6658508733845565e-09
carried O 0 4.333834180414442e-09
out O 0 1.932025739392884e-08
. O 0 9.341564322085105e-08

Neuropsychological O 0 2.5808440113905817e-05
analysis O 0 3.0013430318831524e-07
assessed O 0 6.928303832864913e-07
verbal O 0 7.304646487682476e-07
and O 0 1.4052722008273122e-07
visuospatial O 0 1.1752576938306447e-05
intelligence O 0 4.758118450354232e-07
, O 0 1.983265995875172e-09
verbal O 0 2.2161819401844696e-07
memory O 1 1.0
, O 0 2.006840986723546e-07
and O 0 1.6715226536234695e-07
reading O 0 1.6982709212243208e-06
skills O 0 1.0285109055985231e-05
. O 0 1.5987624237823184e-06

Comparison O 0 2.3037973733153194e-06
of O 0 1.4752979495824547e-06
molecular O 0 8.451668691122904e-06
and O 0 1.1572248581614986e-07
psychometric O 0 2.534584200475365e-05
findings O 0 1.0307796571851213e-07
demonstrated O 0 5.367378008713786e-08
that O 0 1.7678469799164986e-09
deletions O 0 1.599828607368181e-07
and O 0 8.08304445598651e-09
duplications O 0 6.742479996546535e-08
that O 0 4.248938978435035e-10
were O 0 2.509370045089554e-09
localized O 0 1.3800489284676587e-07
in O 0 6.728743784378821e-09
the O 0 3.3327186343967696e-08
distal O 0 9.832991963776294e-06
part O 0 9.725592065024102e-08
of O 0 4.856954660681367e-07
the O 0 1.4835387673883815e-07
gene O 0 5.3865947258202596e-09
seemed O 0 1.0679880979580503e-08
to O 0 1.805349481021068e-10
be O 0 1.6145557113489417e-10
preferentially O 0 2.875037541372194e-09
associated O 0 6.65970656399395e-09
with O 0 3.2239391156707597e-09
cognitive B-Disease 0 0.0002473738859407604
impairment I-Disease 1 0.7822777628898621
. O 0 1.3396869690041058e-05

Two O 0 3.7250899822538486e-06
altered O 0 9.413623047294095e-06
Dp71 O 0 0.00014527376333717257
transcripts O 0 4.405765594128752e-06
and O 0 4.372870776592208e-08
two O 0 9.805045664279533e-09
deleted O 0 1.7924843831451653e-08
Dp140 O 0 1.8696358239367328e-08
DNA O 0 1.2024253814857389e-09
sequences O 0 3.723162403379554e-11
were O 0 5.671430339249106e-11
found O 0 4.136095632656378e-11
in O 0 5.3721631310121865e-11
four O 0 3.0329849742827264e-10
patients O 0 8.233240755828319e-10
with O 0 7.661737910780175e-09
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 0 0.0007797646103426814

These O 0 9.288087454706329e-08
findings O 0 4.14643324120334e-08
suggest O 0 4.011950771598549e-09
that O 0 2.994517966925514e-10
some O 0 7.080726976971263e-11
sequences O 0 2.9994970396352016e-10
located O 0 4.862838132169145e-09
in O 0 3.9419822961406226e-10
the O 0 7.508131893985137e-09
distal O 0 1.7300774288742105e-06
part O 0 5.8624394227990706e-08
of O 0 2.134753742666362e-07
the O 0 4.073391224324041e-08
gene O 0 1.736801258367393e-09
and O 0 1.164381924212421e-09
, O 0 6.599044227728612e-11
in O 0 7.164396853553967e-11
particular O 0 3.471959664214097e-10
, O 0 1.0370868747111572e-10
some O 0 1.1932677068671182e-10
DMD B-Disease 1 0.9999992847442627
isoforms O 0 1.0512623305203306e-07
expressed O 0 9.247674626067237e-09
in O 0 3.0408815465676753e-09
the O 0 6.000501429070937e-08
brain O 0 2.180646788474405e-06
may O 0 8.919694427511615e-10
be O 0 1.0614418372023593e-10
related O 0 3.266387160749673e-09
to O 0 1.3156982170414722e-09
the O 0 4.646328122248633e-08
cognitive B-Disease 0 3.85426428692881e-05
impairment I-Disease 0 6.837015826022252e-05
associated O 0 2.716814833547687e-06
with O 0 2.0640075604205776e-07
DMD B-Disease 1 1.0
. O 0 8.930373383009282e-07
. O 0 3.5490489835865446e-07

I1307K O 0 0.00019341832376085222
APC O 0 6.44599276711233e-06
and O 0 1.5682178400311386e-07
hMLH1 O 0 1.4202354350345558e-06
mutations O 0 1.0178323073262163e-08
in O 0 2.930663489664198e-09
a O 0 1.2822630068853869e-08
non O 0 1.950145360751776e-07
- O 0 1.1514973721205024e-06
Jewish O 0 8.475129220641975e-07
family O 0 2.1727079513311764e-07
with O 0 5.551584192353687e-10
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999401569366455

We O 0 3.639166266111715e-07
describe O 0 2.717429197218735e-07
a O 0 1.4456485075697856e-07
French O 0 1.0977507827192312e-06
Canadian O 0 4.9818772822618484e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.8350775867002085e-05
HNPCC B-Disease 1 0.9999997615814209
) O 0 7.98243071642446e-09
kindred O 0 1.7202555682160892e-06
which O 0 2.887385885941285e-09
carries O 0 1.681469719017059e-08
a O 0 8.94061447098693e-09
novel O 0 2.4164261702708245e-08
truncating O 0 1.0813651130092694e-07
mutation O 0 4.6405954634565205e-09
in O 0 5.8910423206270934e-09
hMLH1 O 0 1.9423605408519506e-06
. O 0 7.245506594699691e-07

Interestingly O 0 1.1002967767126393e-05
, O 0 1.009301371368565e-07
the O 0 1.557902606919015e-07
I1307K O 0 1.1249969702475937e-06
APC O 0 5.017462711975895e-08
polymorphism O 0 2.3516058433870057e-08
, O 0 5.826136101338975e-11
associated O 0 1.1807566036026174e-10
with O 0 1.1171201984294665e-11
an O 0 1.0917625310746804e-11
increased O 0 2.576423518974025e-10
risk O 0 5.407886405350837e-08
of O 1 0.999968409538269
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.760171469162742e-08
is O 0 2.069772270241188e-10
also O 0 2.7124451990045984e-11
present O 0 1.0411519563158222e-10
in O 0 4.0213107843634077e-10
this O 0 2.0156281088645756e-09
family O 0 3.096940872637788e-07
. O 0 9.563787273236812e-08

The O 0 1.683851223788224e-05
I1307K O 0 1.6011143088690005e-05
polymorphism O 0 1.582977802172536e-06
has O 0 9.574807613432768e-09
previously O 0 2.2423423118311803e-09
only O 0 7.313551847465405e-11
been O 0 3.39592048925752e-10
identified O 0 3.7681080478080275e-10
in O 0 6.725747736524568e-11
individuals O 0 2.1194608568197992e-11
of O 0 2.6954609211315983e-08
self O 0 6.828837513239705e-07
- O 0 2.4967303033918142e-06
reported O 0 3.974404449991198e-08
Ashkenazi O 0 1.2127721902288613e-06
Jewish O 0 1.1828478108100171e-07
origins O 0 4.886950932814216e-07
. O 0 2.7359098453416664e-07

In O 0 1.921545020877602e-07
addition O 0 1.4965175765269123e-08
, O 0 9.937664025017057e-10
in O 0 6.723570034061765e-10
this O 0 1.2604386423475944e-09
family O 0 7.149991176902404e-08
, O 0 1.3025736045335634e-10
there O 0 1.0257299870586323e-10
appears O 0 2.9304791926421103e-09
to O 0 8.359928860279808e-10
be O 0 1.3486162186993056e-09
no O 0 5.532180047396196e-09
relationship O 0 4.792928720576128e-09
between O 0 1.9783779947601943e-08
the O 0 4.859020918956958e-08
I1307K O 0 2.8409694152742304e-08
polymorphism O 0 7.530418955070672e-09
and O 0 5.276867276471364e-10
the O 0 8.259948836020214e-10
presence O 0 3.372965240444614e-10
or O 0 2.0851393944809615e-09
absence O 0 2.4558752897974045e-07
of O 0 4.969020324097073e-07
cancer B-Disease 0 2.0016655980725773e-05
. O 0 2.265057119643643e-08
. O 0 1.9411386631418281e-07

Identification O 0 1.0843720019693137e-06
of O 0 7.619354391863453e-07
a O 0 5.1871218431642774e-08
novel O 0 2.4347929894474873e-08
mutation O 0 5.2442405973351924e-09
of O 0 3.603067710855612e-08
the O 0 8.396820305733854e-08
CPO O 0 6.11874611422536e-07
gene O 0 3.887922872536365e-09
in O 0 2.2924027121007384e-09
a O 0 2.969591506030156e-08
Japanese O 0 1.0706215107347816e-05
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999964237213135
family O 0 6.75366391078569e-05
. O 0 1.129325710280682e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999996423721313
( O 0 3.656337639768026e-06
HCP B-Disease 1 0.9999871253967285
) O 0 1.3648524976872523e-08
is O 0 5.039125117178855e-09
an O 0 6.3144538486881174e-09
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
characterized O 0 4.6577747525589075e-06
by O 0 3.926930780551174e-09
a O 0 2.035120587606798e-07
deficiency B-Disease 1 0.7898709774017334
of I-Disease 0 0.3169900178909302
coproporphyrinogen I-Disease 0 0.007163660135120153
oxidase I-Disease 0 1.0283323490511975e-06
( O 0 2.5523263502691407e-09
CPO O 0 1.7642140903717518e-07
) O 0 1.5943460440759338e-10
caused O 0 6.223921933390386e-10
by O 0 9.103528347820244e-11
a O 0 2.5476523113354688e-09
mutation O 0 7.120058986842537e-10
in O 0 1.1340254291170027e-09
the O 0 4.70987515654997e-08
CPO O 0 3.2766120057203807e-06
gene O 0 2.1948814321604004e-07
. O 0 4.6740245807086467e-07

Only O 0 2.1289291396442422e-07
11 O 0 8.2516272925659e-08
mutations O 0 2.1079002987534068e-09
of O 0 1.4039241769125965e-08
the O 0 2.111362107370951e-08
gene O 0 2.5525939140180753e-09
have O 0 2.1425891616466686e-10
been O 0 5.9598331825228e-10
reported O 0 1.051117082262465e-09
in O 0 3.6385425783436176e-09
HCP B-Disease 1 0.9999998807907104
patients O 0 0.00021975883282721043
. O 0 9.970714927476365e-06

We O 0 1.9340006929269293e-07
report O 0 3.6675069647884584e-09
another O 0 1.2385232839307037e-09
mutation O 0 4.830794653187809e-10
in O 0 7.272935587110396e-10
a O 0 1.519458159293663e-08
Japanese O 0 3.5511043279257137e-06
family O 0 5.147686351847369e-06
. O 0 1.1086250424341415e-06

Polymerase O 0 1.980365595954936e-05
chain O 0 8.088999265964958e-07
reaction O 0 3.524984393266095e-08
- O 0 8.695446496176373e-08
single O 0 6.528405815942051e-09
strand O 0 8.221695324550637e-09
conformational O 0 2.044278968327262e-09
polymorphism O 0 1.7301191590490816e-09
and O 0 9.949722296065389e-11
direct O 0 1.8628243392271315e-10
sequence O 0 1.0637867670082457e-10
analyses O 0 2.617175920427428e-10
demonstrated O 0 6.187430567905494e-10
a O 0 1.5863873548127572e-09
C O 0 5.440890404884158e-08
to O 0 2.303096380273928e-09
T O 0 8.15712208890318e-09
substitution O 0 4.40181402439066e-09
in O 0 2.7697790727643223e-09
exon O 0 1.7289522702412796e-08
1 O 0 6.581541089900611e-09
of O 0 1.3072682936154933e-09
the O 0 3.905313850083303e-09
CPO O 0 1.090622063770752e-07
gene O 0 1.524633419514032e-09
at O 0 2.590023528981078e-09
nucleotide O 0 7.392038536835344e-09
position O 0 2.692624612166128e-08
85 O 0 5.3610548889082565e-08
, O 0 1.0559840779578167e-09
which O 0 7.905471277602771e-10
lies O 0 7.118870115618847e-08
in O 0 2.329702208925255e-09
the O 0 1.250973991062665e-08
putative O 0 6.835086310275074e-07
presequence O 0 7.657846481379238e-07
for O 0 2.217935168857821e-09
targeting O 0 8.09373634780286e-09
to O 0 2.8277082009253718e-08
mitochondria O 0 2.6473580874153413e-06
. O 0 9.705631782708224e-07

This O 0 2.1246002290808974e-08
mutation O 0 4.960565735956379e-09
changes O 0 1.6563350691001233e-09
the O 0 2.4458228775614543e-09
codon O 0 1.036624674988218e-09
for O 0 5.050294071828887e-10
glutamine O 0 5.708095329737262e-09
to O 0 8.733001544136698e-10
a O 0 3.76386477540791e-09
termination O 0 1.0419380913617715e-07
codon O 0 6.955312326084595e-09
at O 0 7.289883363625904e-09
amino O 0 4.617522197936097e-10
acid O 0 7.637717680530898e-10
position O 0 2.969030887811641e-08
29 O 0 3.8904883581381e-07
. O 0 2.1024892760124203e-07

MaeI O 0 7.511048897868022e-05
restriction O 0 6.822062204037138e-08
analysis O 0 3.2512954550867335e-09
showed O 0 2.9665272460732695e-09
two O 0 1.4620026023148824e-10
other O 0 4.9408064445310984e-11
carriers O 0 7.394065359989099e-10
in O 0 5.145731840627832e-09
the O 0 5.086546366328548e-07
family O 0 4.8485362640349194e-06
. O 0 4.11078559636735e-07

The O 0 6.555123945872765e-06
C O 0 6.392112118192017e-05
- O 0 6.512125401059166e-05
T O 0 1.19461685699207e-06
mutation O 0 9.412278956233422e-09
is O 0 7.019507197725261e-10
located O 0 1.1125368404307778e-09
within O 0 4.722508495369482e-10
a O 0 2.399083820492365e-09
recently O 0 7.846812088985189e-09
proposed O 0 7.783388156212823e-09
putative O 0 1.8719340744155488e-07
alternative O 0 9.792844934963796e-08
translation O 0 4.6679929255333263e-08
initiation O 0 1.2528746928808232e-08
codon O 0 2.372020357910287e-09
( O 0 2.4508980955850745e-10
TIC O 0 9.676683454529211e-09
- O 0 2.7968974691816584e-08
1 O 0 2.5164553107970278e-08
) O 0 7.177417687964649e-11
, O 0 2.948861294038707e-11
supporting O 0 2.5550087046077863e-10
that O 0 7.467823581741584e-10
TIC O 0 1.16739499844698e-07
- O 0 1.4317828345156158e-06
1 O 0 2.84714332110525e-07
is O 0 2.6828728127981094e-09
the O 0 4.703330702682251e-08
real O 0 2.791917381728126e-07
TIC O 0 1.0189222621193039e-07
rather O 0 3.0844709009159033e-09
than O 0 6.634752192091753e-10
TIC O 0 4.8830653298637117e-08
- O 0 3.0398513217733125e-07
2 O 0 1.7528570595004567e-07
. O 0 1.4231470224501663e-08
. O 0 1.0711464426549355e-07

Human B-Disease 0 2.1158049889891117e-07
complement I-Disease 0 9.129082059189386e-07
factor I-Disease 0 8.732501555641647e-06
H I-Disease 1 1.0
deficiency I-Disease 1 0.9224867224693298
associated O 0 5.784803533970262e-07
with O 0 5.2636114560300484e-06
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999943971633911

This O 0 2.8295533027744568e-08
study O 0 2.8676223617907226e-09
reports O 0 2.097384932397972e-09
on O 0 6.436011723565116e-09
six O 0 4.739554859689576e-10
cases O 0 4.356067451194434e-10
of O 0 3.151222927044728e-08
deficiency B-Disease 1 0.9933207631111145
in I-Disease 0 1.0665329597259188e-07
the I-Disease 0 2.67857984681541e-07
human I-Disease 0 5.630865107519867e-09
complement I-Disease 0 1.0292193763916657e-08
regulatory I-Disease 0 3.472566447726422e-07
protein I-Disease 0 1.4515917712287774e-07
Factor I-Disease 0 8.157732622748881e-08
H I-Disease 1 0.9999810457229614
( O 0 1.3429999334846343e-09
FH O 0 3.2426143548036634e-08
) O 0 8.910231059922058e-12
in O 0 3.41223967484372e-12
the O 0 3.342001328454636e-11
context O 0 1.4343568000008133e-10
of O 0 1.907050906080343e-10
an O 0 2.558998291046777e-10
acute B-Disease 1 0.9933940768241882
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1874838492076378e-05

Five O 0 4.825329256163968e-07
of O 0 4.47279795423583e-08
the O 0 3.368466838793438e-09
cases O 0 2.890701567004328e-10
were O 0 1.1497320456799187e-10
observed O 0 1.0628092156350633e-10
in O 0 2.339844290544235e-11
children O 0 1.1173290591359741e-11
presenting O 0 3.0258834327057116e-10
with O 0 7.863652840001123e-09
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 8.571629450671026e-07
. O 0 2.0914333163091214e-06

Two O 0 3.327323838675511e-07
of O 0 4.2091886598427664e-07
the O 0 1.6954457748852292e-07
children O 0 2.330031279029754e-09
exhibited O 0 7.538120350147892e-09
a O 0 2.1989647791542666e-07
homozygous O 0 5.961366696283221e-06
deficiency O 1 0.6095510721206665
characterized O 0 4.866283234150615e-07
by O 0 1.2772176205544383e-08
the O 0 1.3468338693201076e-06
absence O 0 2.0246759504516376e-06
of O 0 8.079446729425399e-07
the O 0 1.3966320011604694e-07
150 O 0 1.9162473829936744e-09
- O 0 2.1708130848452356e-09
kD O 0 8.467968548586668e-09
form O 0 9.128153788395821e-10
of O 0 8.80701165328901e-08
Factor O 0 3.1671160627411155e-07
H O 1 1.0
and O 0 1.816594519254977e-08
the O 0 1.213758160645284e-08
presence O 0 1.0102942926693004e-09
, O 0 2.0755677732076094e-10
upon O 0 5.480790488121556e-09
immunoblotting O 0 1.2557102024857159e-07
, O 0 2.8895716375210156e-10
of O 0 4.8487973636213155e-09
the O 0 3.320055341760053e-08
42 O 0 3.724872499333287e-08
- O 0 1.948144578989286e-08
kD O 0 2.288280711582047e-07
Factor O 0 1.2546519201350748e-07
H O 0 0.08166029304265976
- O 0 6.854813250356528e-07
like O 0 1.615521583175905e-08
protein O 0 3.593246944433304e-08
1 O 0 1.2097417823042633e-07
( O 0 1.116426950886762e-09
FHL O 0 4.898372480965918e-06
- O 0 8.848438142194937e-07
1 O 0 1.1331074745157821e-07
) O 0 2.6633489857985637e-10
and O 0 6.550304743058177e-10
other O 0 2.537690724224717e-09
FH O 0 4.767293546592555e-07
- O 0 4.654195251418969e-08
related O 0 1.911601366089144e-08
protein O 0 3.730617947894643e-08
( O 0 1.1623493278989372e-09
FHR O 0 3.659721414805972e-06
) O 0 2.6162489952241685e-09
bands O 0 6.540834078805347e-07
. O 0 7.558654147032939e-07

Southern O 0 5.5333519412670285e-05
blot O 0 4.9485744966659695e-05
and O 0 1.572578334219088e-08
PCR O 0 4.52986554932977e-08
analysis O 0 5.975050454409825e-10
of O 0 1.1589754711494038e-09
DNA O 0 6.929068430139296e-09
of O 0 4.739584280599729e-09
one O 0 7.085270148365908e-10
patient O 0 9.598815964295682e-09
with O 0 1.7505066285394832e-09
homozygous O 0 5.880301614524797e-07
deficiency O 0 0.43494972586631775
ruled O 0 0.0005118102999404073
out O 0 1.282143671232916e-07
the O 0 3.873136478205197e-08
presence O 0 3.647228075109865e-09
of O 0 3.414890059616482e-08
a O 0 8.54852544307505e-09
large O 0 3.184143171353071e-09
deletion O 0 8.533081796713304e-09
of O 0 2.7520549394921545e-08
the O 0 4.550631871325095e-08
FH O 0 4.276807317182829e-07
gene O 0 5.648387535472921e-09
as O 0 2.1962134333364247e-09
the O 0 1.0329225474947634e-08
underlying O 0 7.943482160044368e-06
defect O 0 2.3575403247377835e-05
for O 0 1.317985010018674e-07
the O 0 3.2024356187321246e-05
deficiency O 1 0.9999996423721313
. O 0 1.4038663721294142e-05

The O 0 1.5915425137791317e-06
other O 0 6.554306875017346e-09
four O 0 2.6963851151862173e-09
children O 0 2.170302826343118e-10
presented O 0 5.7513500628658676e-09
with O 0 4.003481102188289e-09
heterozygous O 0 6.857625578504667e-08
deficiency O 0 0.016975024715065956
and O 0 1.4071927978420717e-07
exhibited O 0 1.2450830411125935e-07
a O 0 3.8529557855326857e-07
normal O 0 1.5605986618538736e-06
immunoblotting O 0 7.956864465086255e-07
pattern O 0 1.4062610631526695e-08
of O 0 3.1410680723098494e-09
proteins O 0 2.5526705749179257e-10
of O 0 4.9299484494724766e-09
the O 0 1.0618178691856883e-07
FH O 0 1.5308522051782347e-05
family O 0 2.6212333636976837e-07
. O 0 7.209493446680426e-08

Factor B-Disease 1 0.999683141708374
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
is O 0 5.278359971327973e-09
the O 0 4.564207678470211e-09
only O 0 1.0336216327289094e-09
complement B-Disease 1 0.9950991272926331
deficiency I-Disease 1 1.0
associated O 0 8.28833526611561e-06
with O 0 4.420899415435997e-07
HUS B-Disease 1 1.0
. O 0 0.00032960204407572746

These O 0 8.385712391145717e-08
observations O 0 5.5921869801522917e-08
suggest O 0 5.6875553156032765e-09
a O 0 1.2341379473923553e-08
role O 0 1.7876089941637474e-08
for O 0 6.4083409689885684e-09
FH O 0 2.980543058583862e-06
and O 0 7.580600680512362e-08
/ O 0 1.4619839703300386e-06
or O 0 2.8930708495522595e-08
FH O 0 3.8874284769008227e-07
receptors O 0 1.040608377245178e-09
in O 0 1.1322914827971431e-10
the O 0 8.030683895654533e-10
pathogenesis O 0 3.681410589706502e-06
of O 0 3.550111955519242e-07
idiopathic O 1 0.9999929666519165
HUS B-Disease 1 1.0
. O 0 2.2543051727552665e-06
. O 0 9.183903557641315e-07

Further O 0 5.3710749625679455e-08
evidence O 0 4.533652031568636e-08
for O 0 2.0998989214149333e-09
a O 0 4.300354738973056e-09
major O 0 1.8650126776265097e-08
ancient O 0 3.8023480897209083e-07
mutation O 0 4.470121893973555e-06
underlying O 1 0.9947968125343323
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.13201223636861e-06
linkage O 0 1.0657546454240219e-06
disequilibrium O 0 5.47426282082597e-07
studies O 0 1.4048072705108439e-09
in O 0 4.5194534226133953e-10
the O 0 5.403573588580457e-09
Japanese O 0 1.0719230658651213e-07
population O 0 4.190603419829131e-10
. O 0 3.481339660993399e-08

The O 0 0.00012696879275608808
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.653109211474657e-05
DM B-Disease 1 1.0
) O 0 9.810171341939622e-09
mutation O 0 3.872617782008092e-09
is O 0 5.498849708907017e-10
an O 0 7.244291277963555e-10
unstable O 0 1.6270921605610056e-06
( O 0 7.98014809788583e-09
CTG O 0 5.229073849477572e-06
) O 0 2.3144268723740424e-09
n O 0 5.676565439927117e-09
repeat O 0 5.231822086670945e-09
, O 0 8.4656830157126e-11
present O 0 1.519979031527896e-09
at O 0 6.4900667062772754e-09
a O 0 2.1691108631483047e-10
copy O 0 2.0100840991688074e-09
number O 0 1.1793790943848137e-10
of O 0 5.367314148685409e-09
5 O 0 4.167349132444542e-08
- O 0 9.99229854414807e-08
37 O 0 9.194720007599244e-08
repeats O 0 5.608765718534414e-08
on O 0 6.835660570914115e-08
normal O 0 4.703642364489724e-09
chromosomes O 0 9.47150469166047e-10
but O 0 6.524443207922559e-10
amplified O 0 5.448842710364943e-09
to O 0 3.1618176965508837e-09
50 O 0 7.972662530164598e-09
- O 0 1.4531550185381548e-08
3000 O 0 2.9714255500579156e-09
copies O 0 6.860841228473191e-09
on O 0 5.628065196106036e-07
DM B-Disease 1 0.9999899864196777
chromosomes O 0 6.576505029443069e-07
. O 0 3.4141092442041554e-07

Previous O 0 4.041170996060828e-06
findings O 0 8.868623524449504e-08
in O 0 7.659049394703743e-09
Caucasian O 0 1.2816961714179342e-07
populations O 0 1.0966187069527678e-08
of O 0 1.7350562586671003e-07
a O 0 1.0009348443418276e-05
DM B-Disease 1 1.0
founder O 1 0.9998049139976501
chromosome O 0 8.873205956660968e-07
raise O 0 7.792047007626479e-09
a O 0 2.692192024866813e-09
question O 0 7.978286920007349e-10
about O 0 3.2199905936058926e-11
the O 0 3.8166067528599967e-10
molecular O 0 7.964101045310201e-10
events O 0 1.7615173208973545e-11
involved O 0 6.251402173695908e-11
in O 0 3.494214917409977e-10
the O 0 1.2954269656972883e-08
expansion O 0 4.306012328925135e-07
mutation O 0 1.5499209382596746e-07
. O 0 1.5787639995323843e-07

To O 0 4.53934518418464e-07
investigate O 0 1.9398987660679268e-07
whether O 0 2.315606906222456e-08
a O 0 1.475451227861413e-07
founder O 0 7.514860840274196e-07
chromosome O 0 2.1437687180991816e-08
for O 0 5.225100352390655e-09
the O 0 8.682691259309649e-07
DM B-Disease 1 1.0
mutation O 0 6.48218829724101e-08
exists O 0 1.8989974037708635e-09
in O 0 3.381661894952259e-10
the O 0 2.0283084101180293e-09
Japanese O 0 2.7427169868587953e-08
population O 0 2.0222724536611558e-11
, O 0 4.271094589114455e-11
we O 0 1.6989604167960692e-10
genotyped O 0 7.080656416746933e-08
families O 0 3.792891278830979e-10
using O 0 9.3540553081084e-10
polymorphic O 0 4.725775326619441e-08
markers O 0 1.014715707015057e-07
near O 0 3.694945462484611e-06
the O 0 4.179428856332379e-07
( O 0 9.189649929908228e-09
CTG O 0 2.7981304810964502e-06
) O 0 3.194313924481662e-09
n O 0 2.4989017077814424e-08
repeat O 0 1.8918330013661944e-08
region O 0 1.0041127929127924e-08
and O 0 1.16028546770508e-08
constructed O 0 8.41895325720543e-06
haplotypes O 0 4.100337719137315e-06
. O 0 3.5219071037317917e-07

Six O 0 4.575663297146093e-07
different O 0 4.208596582344626e-09
haplotypes O 0 1.2937729820805544e-07
were O 0 3.6340206399643193e-09
found O 0 2.0815076329228077e-09
and O 0 1.4818271942829142e-08
DM B-Disease 1 1.0
alleles O 0 1.0818784090815825e-08
were O 0 3.0387901972517284e-08
always O 0 3.7061493429746406e-08
haplotype O 0 1.1770812307076994e-06
A O 0 2.978272959808237e-06
. O 0 3.7631781424352084e-07

To O 0 6.408160402315843e-07
find O 0 8.72435208520983e-08
an O 0 4.1982997633915886e-10
origin O 0 1.2385988901186806e-09
of O 0 3.3482653094552006e-08
the O 0 5.3652694731454176e-08
( O 0 2.1184280996067173e-09
CTG O 0 8.079739473032532e-07
) O 0 1.0361305147199573e-09
n O 0 8.607589307985108e-09
repeat O 0 4.1237795400661525e-09
mutation O 0 1.5548080600780168e-09
and O 0 5.686857651454602e-10
to O 0 9.594179894989452e-10
investigate O 0 8.603748824498325e-09
the O 0 1.2720611231031853e-08
mechanism O 0 3.9164156362403446e-08
of O 0 1.6983044304197392e-08
the O 0 4.5576138418823575e-09
expansion O 0 5.713236106430486e-09
mutation O 0 2.7862348539464676e-10
in O 0 1.3003444154779942e-10
the O 0 2.6882100989666924e-09
Japanese O 0 2.1234212610465875e-08
population O 0 1.2481239999861948e-11
we O 0 1.0643062819948312e-10
have O 0 4.0093459802159614e-11
studied O 0 5.943364467242418e-09
90 O 0 7.14512182753424e-09
Japanese O 0 6.641974437116005e-07
DM B-Disease 1 1.0
families O 0 4.8542410979734996e-08
comprising O 0 1.0594499721960915e-09
190 O 0 1.669485105715296e-09
affected O 0 1.3773705509478873e-09
and O 0 3.877229648452385e-09
130 O 0 2.22023039953001e-08
unaffected O 0 6.440116067096824e-07
members O 0 1.2506996327488196e-08
. O 0 2.367220020005334e-07

The O 0 9.049645996128675e-06
results O 0 1.0636462377533462e-07
suggest O 0 1.864013299268663e-08
that O 0 1.9142711860098416e-09
a O 0 1.5370698491778967e-08
few O 0 7.453227368614534e-09
common O 0 5.1956074997860924e-08
ancestral O 0 2.9439258923957823e-06
mutations O 0 3.6558434057809563e-09
in O 0 1.1047806003361416e-09
both O 0 1.5523662355576562e-09
Caucasian O 0 3.5138685916535906e-07
and O 0 1.8606145602007018e-07
Japanese O 0 1.086634165403666e-05
populations O 0 1.8116904643150633e-09
have O 0 1.9511622872947498e-10
originated O 0 1.4940013670639019e-09
by O 0 7.556164721700398e-11
expansion O 0 1.9190245836853137e-08
of O 0 9.895339658783087e-09
an O 0 6.396052576462807e-10
ancestral O 0 1.2358669643219855e-08
n O 0 4.617877191748221e-09
= O 0 4.2803303124117065e-09
5 O 0 2.1465171862189436e-09
repeat O 0 2.2494317519772267e-09
to O 0 3.36666849953815e-09
n O 0 2.6193761826220907e-08
= O 0 5.0768292680913873e-08
19 O 0 9.370670994712782e-08
- O 0 1.2148309735948715e-07
37 O 0 4.261604402699959e-08
copies O 0 2.1741582756362732e-08
. O 0 2.212262728562564e-07

These O 0 1.282755164311311e-07
data O 0 9.847050108646727e-08
support O 0 3.402679737973813e-08
multistep O 0 1.0626115454215324e-06
models O 0 1.0170059283609589e-07
of O 0 1.097860717891308e-06
triplet O 0 1.2414514458214398e-05
repeat O 0 1.5704507916325383e-07
expansion O 0 9.180087801041736e-08
that O 0 1.542807548382541e-10
have O 0 4.6767908989941986e-11
been O 0 7.748791885919815e-11
proposed O 0 3.735391440606861e-10
for O 0 1.3508451301991187e-10
both O 0 3.507063306429359e-09
DM B-Disease 1 1.0
and O 0 1.021948378365778e-06
Friedreichs B-Disease 0 0.0014404681278392673
ataxia I-Disease 1 0.9831966161727905
. O 0 2.9437077841976134e-07
. O 0 5.606502782029565e-07

The O 0 2.990292387039517e-07
molecular O 0 2.5055123842321336e-07
basis O 0 5.063634489488322e-07
of O 0 0.02110305055975914
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.549021106939108e-07
the O 0 4.337119818842439e-08
western O 0 2.265766170239658e-07
Cape O 0 2.251320893265074e-06
, O 0 1.0329338495651541e-09
South O 0 7.265397616862401e-09
Africa O 0 8.933983330905448e-09
. O 0 5.958168003417086e-08

Deficiency B-Disease 1 0.999975323677063
of I-Disease 0 0.01718316413462162
the I-Disease 0 0.00012348497693892568
sixth I-Disease 0 0.0002463770506437868
component I-Disease 0 2.2019585230736993e-06
of I-Disease 0 6.213436449797882e-07
human I-Disease 0 6.91535291252876e-08
complement I-Disease 0 3.47670209066564e-07
( O 0 2.1132763095010887e-07
C6 O 1 0.9284507036209106
) O 0 2.131661958060249e-09
has O 0 4.215214011171753e-10
been O 0 3.967129680315651e-10
reported O 0 4.946976162045758e-10
in O 0 1.3446678492901043e-10
a O 0 4.0153785851870794e-10
number O 0 5.647574075062778e-11
of O 0 1.0742615685899182e-09
families O 0 7.072172847344405e-10
from O 0 1.4169762030391553e-09
the O 0 1.1925749276997522e-08
western O 0 1.4837397088740545e-07
Cape O 0 3.7687732401536778e-06
, O 0 3.0494078373521916e-09
South O 0 1.1480545403230735e-08
Africa O 0 1.2756618872344916e-08
. O 0 1.5165777256243018e-07

Meningococcal B-Disease 1 0.9999988079071045
disease I-Disease 1 0.9999998807907104
is O 0 2.8989260769662906e-08
endemic O 0 2.575984048291957e-08
in O 0 1.145617267717114e-09
the O 0 2.4276518573174144e-08
Cape O 0 1.4587695886802976e-06
and O 0 1.4473510168144799e-09
almost O 0 2.365269369253298e-10
all O 0 1.4557724470343203e-10
pedigrees O 0 1.406701066741789e-08
of O 0 2.901697371271439e-08
total O 0 1.9785976235198177e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.9169394960272257e-08
C6Q0 O 0 1.3798299733025488e-05
) O 0 1.0482075624151932e-10
have O 0 5.1169520010052594e-11
been O 0 5.311006634478588e-10
ascertained O 0 2.26143530568379e-08
because O 0 9.8968822026535e-10
of O 0 1.0344978207399436e-08
recurrent O 0 1.3968113307782914e-05
disease O 0 0.005589776206761599
. O 0 1.3629477280119318e-06

We O 0 2.3647852742669784e-07
have O 0 3.760435074440238e-09
sequenced O 0 3.04589882205164e-08
the O 0 2.9472239759797958e-08
expressed O 0 2.1251027604307637e-08
exons O 0 1.3519749018087168e-06
of O 0 4.6528418806701666e-07
the O 0 3.9489933101322094e-07
C6 O 0 1.0694438060454559e-05
gene O 0 2.0202544082081886e-09
from O 0 2.66137861748561e-10
selected O 0 2.651331654224265e-10
cases O 0 2.8753815994875254e-10
and O 0 4.2555570178848257e-10
have O 0 1.6231611887906894e-10
found O 0 1.0685357043627164e-09
three O 0 2.7294029258939645e-09
molecular O 0 9.509646588412579e-06
defects O 1 0.9999090433120728
leading O 0 2.393825297986041e-06
to O 0 1.4449304330810264e-07
total O 0 2.8408348384800775e-07
deficiency O 1 1.0
879delG O 0 0.17259246110916138
, O 0 9.881194529270942e-09
which O 0 7.686720149280291e-10
is O 0 1.2862892972975715e-09
the O 0 7.556143266640447e-09
common O 0 1.4568882988896803e-07
defect O 0 1.1445997643022565e-06
in O 0 1.0208087708463154e-08
the O 0 3.904281413724675e-07
Cape O 0 5.468718427437125e-06
and O 0 9.139621504061779e-09
hitherto O 0 4.722243573951346e-08
unreported O 0 1.953286599132298e-08
, O 0 2.5370119893786125e-10
and O 0 7.664306411747646e-10
1195delC O 0 1.0833119290509785e-07
and O 0 1.8106964816411164e-08
1936delG O 0 9.358994930153131e-07
, O 0 2.499110030029783e-09
which O 0 2.8991276046497205e-10
have O 0 6.251917872290846e-10
been O 0 2.116142372443619e-09
previously O 0 3.5255605101980336e-09
reported O 0 6.566064914004244e-10
in O 0 5.953549875314934e-10
African O 0 8.024287900809668e-09
- O 0 1.889839325031062e-07
Americans O 0 1.7118694017881353e-08
. O 0 6.25685629529471e-07

We O 0 6.079680133552756e-06
also O 0 6.059895696353124e-08
show O 0 3.3941480737098573e-09
that O 0 6.897704629693635e-11
the O 0 3.157406336384838e-09
879delG O 0 2.3039109464662033e-07
and O 0 1.1008518541189005e-08
1195delC O 0 8.89208877197234e-06
defects O 0 1.3341865269467235e-05
are O 0 1.69569067121067e-10
associated O 0 5.102739919493615e-08
with O 0 3.082061184045415e-08
characteristic O 1 0.9974306225776672
C6 O 1 1.0
/ O 1 0.9995625615119934
C7 O 0 0.00010314647079212591
region O 0 3.4475075239015496e-08
DNA O 0 1.280481711773973e-07
marker O 0 1.0357776858427314e-07
haplotypes O 0 2.6495245109003918e-08
, O 0 1.3430043188655816e-10
although O 0 2.670266785465003e-10
small O 0 4.845762680005805e-10
variations O 0 4.4040313618154414e-09
were O 0 8.357765146627116e-09
observed O 0 3.898260914070306e-08
. O 0 2.627106994168571e-07

The O 0 2.7441841666586697e-05
1936delG O 0 0.00013516754552256316
defect O 0 0.00042779758223332465
was O 0 2.976378937091795e-06
observed O 0 3.183980723520108e-08
only O 0 3.857651975636145e-09
once O 0 1.973079832850999e-08
in O 0 1.805019911316208e-09
the O 0 2.2478289452010358e-08
Cape O 0 1.664277192503505e-06
, O 0 3.158049100004945e-10
but O 0 1.7465302815100614e-10
its O 0 7.719263561689615e-10
associated O 0 1.555627449079111e-08
haplotype O 0 1.2319575262154103e-06
could O 0 4.108127527047145e-08
be O 0 2.2687929757125858e-08
deduced O 0 1.2757295735355e-06
. O 0 3.9632621451346495e-07

The O 0 3.3773255836422322e-06
data O 0 1.2668147064687219e-07
from O 0 2.4717586200040387e-08
the O 0 1.5728783608892627e-08
haplotypes O 0 4.734978276133006e-08
indicate O 0 1.6031687088968738e-09
that O 0 9.663118222258404e-11
these O 0 3.818237948038927e-10
three O 0 1.560464646388482e-09
molecular O 0 2.171947528495366e-07
defects O 0 6.45303884994064e-07
account O 0 5.294368832231555e-10
for O 0 7.47572226345028e-09
the O 0 0.0002024430432356894
defects O 1 0.9999997615814209
in O 0 1.8665541290374676e-07
all O 0 3.700308326415325e-08
the O 0 4.809892288903939e-07
38 O 0 9.495914810031536e-08
unrelated O 0 7.677672186900963e-08
C6Q0 O 0 1.926438562804833e-05
individuals O 0 3.5196598413556046e-10
we O 0 9.029554326467348e-10
have O 0 1.603513571923898e-10
studied O 0 4.445782408879495e-09
from O 0 3.270788306863892e-09
the O 0 4.500481765035147e-08
Cape O 0 7.5083157753397245e-06
. O 0 1.842387149508795e-07

We O 0 1.304357169829018e-06
have O 0 3.687435778942927e-08
also O 0 3.1743137007822497e-09
observed O 0 5.24777243882113e-09
the O 0 1.5435508871064485e-08
879delG O 0 5.749158731305215e-07
defect O 0 5.144743226992432e-07
in O 0 4.955933974315485e-08
two O 0 7.372961476903583e-07
Dutch O 1 1.0
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
kindreds O 0 0.49965226650238037
, O 0 1.3946682919652176e-08
but O 0 3.1850544424116833e-09
the O 0 2.8973394350373383e-08
879delG O 0 5.096087534184335e-07
defect O 0 9.674949978943914e-07
in O 0 1.90154274548604e-08
the O 0 8.889629157238232e-07
Cape O 0 2.8316395400906913e-05
probably O 0 8.88692781586542e-08
did O 0 2.3642603430573672e-09
not O 0 1.9331516942777682e-10
come O 0 2.525526177077353e-10
from O 0 3.4256378289576617e-10
The O 0 6.7171384010578095e-09
Netherlands O 0 1.7913292182925034e-08
. O 0 1.2602637156078345e-08
. O 0 1.6609681097179418e-07

Complement B-Disease 1 1.0
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.5845337243454196e-08
seven O 0 6.299730070935539e-09
further O 0 4.575093637271266e-09
molecular O 0 3.005284042956191e-06
defects O 0 1.807578155421652e-05
and O 0 2.229165518841114e-09
their O 0 6.7823848759474e-09
associated O 0 2.241143647552235e-06
marker O 0 4.269133205525577e-05
haplotypes O 0 1.6505558960488997e-05
. O 0 3.332580945425434e-06

Seven O 0 5.278473622638558e-07
further O 0 1.2062897347675516e-08
molecular O 0 2.7178671757610573e-07
bases O 0 1.0811522770381998e-06
of O 0 0.002001615008339286
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.2286021089380483e-08
described O 0 2.1004210282171698e-07
. O 0 1.1555299295196164e-07

All O 0 1.8129070156192029e-07
these O 0 1.6090483612174467e-08
new O 0 9.308730852808367e-08
molecular O 0 1.4270946167016518e-06
defects O 0 1.1158163033542223e-06
involve O 0 1.1123591825423773e-08
single O 0 2.4444071300422365e-07
- O 0 7.028334607639408e-07
nucleotide O 0 2.8130554596828006e-07
events O 0 3.906580392509795e-09
, O 0 4.703379907766703e-10
deletions O 0 1.4609948806310058e-08
and O 0 3.2850682174512258e-09
substitutions O 0 3.5023990818672246e-08
, O 0 9.116496446637257e-10
some O 0 2.0162382874389095e-10
of O 0 1.5646678619418708e-08
which O 0 4.35238201035304e-09
alter O 0 1.673452629802341e-07
splice O 0 2.6680759219743777e-06
sites O 0 1.7977434652038937e-08
, O 0 4.6005382836611375e-10
and O 0 1.969499452414425e-09
others O 0 1.0672814632073369e-08
codons O 0 5.760695671597205e-07
. O 0 1.195427103084512e-06

They O 0 9.74752438764881e-08
are O 0 1.2363000623238918e-09
distributed O 0 3.879182308708096e-09
along O 0 1.14328440048439e-08
the O 0 7.596754159067132e-08
C7 O 0 4.740671556646703e-06
gene O 0 3.7209229031276436e-09
, O 0 8.970258563723021e-11
but O 0 1.0059366534198588e-10
predominantly O 0 1.3469858561876435e-10
towards O 0 6.934105734046625e-09
the O 0 2.7551115167057105e-08
3 O 0 1.4145756210837135e-07
end O 0 2.7167371285941044e-07
. O 0 3.181929457696242e-07

All O 0 6.831606924606604e-08
were O 0 1.4740300535720507e-08
found O 0 1.5768667482873866e-09
in O 0 1.5608219161578063e-09
compound O 0 1.4397775771612942e-07
heterozygous O 0 8.20139689494681e-09
individuals O 0 5.276102332807397e-10
. O 0 1.3554978295360343e-07

The O 0 0.00030902493745088577
C6 O 1 0.9999935626983643
/ O 0 0.005916100926697254
C7 O 0 0.00017818955529946834
marker O 0 4.935939728056837e-07
haplotypes O 0 1.2597139686931769e-07
associated O 0 1.8952569291741383e-08
with O 0 6.9442576133837974e-09
most O 0 1.0093443052028306e-05
C7 B-Disease 1 1.0
defects I-Disease 1 1.0
are O 0 1.3313323776742436e-08
tabulated O 0 1.9254412109148689e-07
. O 0 7.306981331112183e-08
. O 0 3.8191748785720847e-07

A O 0 5.3166008001426235e-05
genome O 0 3.731233846338e-06
- O 0 1.6784582612672239e-06
wide O 0 1.069019717192532e-07
search O 0 3.440531415321857e-08
for O 0 2.1438983921484578e-09
chromosomal O 0 3.460701691437862e-06
loci O 0 5.560469844567706e-07
linked O 0 1.048761168931378e-05
to O 0 2.2703692081904592e-07
mental O 1 1.0
health O 0 0.3384521007537842
wellness O 0 2.455546382407192e-05
in O 0 1.8724113370893747e-09
relatives O 0 1.3421887601339222e-08
at O 0 3.80310533065753e-10
high O 0 2.2841799562911547e-09
risk O 0 6.931764939821505e-09
for O 0 1.6880902364846406e-07
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 0.4955494999885559
the O 1 0.972043514251709
Old O 1 0.9914870262145996
Order O 0 7.65995355322957e-05
Amish O 0 6.194182788021863e-05
. O 0 1.2316802440182073e-06

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 1 0.9811692833900452
BPAD B-Disease 1 1.0
; O 1 1.0
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 2.871000504001131e-08
is O 0 3.883488530753709e-10
characterized O 0 6.485533776690033e-10
by O 0 2.344652805241765e-10
episodes O 0 1.0258390403805606e-07
of O 0 4.4874360582980444e-07
mania B-Disease 0 0.0003737460938282311
and O 0 1.1076173223045771e-07
/ O 0 0.0001934334432007745
or O 0 1.871969885769431e-07
hypomania B-Disease 0 0.00021849462063983083
interspersed O 0 1.0276187900615241e-08
with O 0 2.68048621493433e-11
periods O 0 1.0259662985845353e-07
of O 0 2.9495754461095203e-07
depression B-Disease 0 0.005640105344355106
. O 0 6.573720838787267e-07

Compelling O 0 2.6993534447683487e-06
evidence O 0 1.1733591236406937e-06
supports O 0 9.796973898801298e-08
a O 0 1.3261445275247752e-08
significant O 0 2.031235402100151e-09
genetic O 0 2.0629638441960196e-08
component O 0 1.1275538014388076e-07
in O 0 2.6120459128975426e-09
the O 0 4.882711479581303e-08
susceptibility O 0 2.525267291275668e-06
to O 0 6.43944062517221e-08
develop O 0 0.007449120283126831
BPAD B-Disease 1 1.0
. O 0 0.0004057170881424099

To O 0 2.572994048932742e-07
date O 0 2.584291451057652e-06
, O 0 4.825584376533243e-09
however O 0 3.5105034434934623e-09
, O 0 2.466876702911236e-10
linkage O 0 7.800046830652718e-09
studies O 0 5.330196839459234e-10
have O 0 2.3381593883264884e-10
attempted O 0 7.060157258820254e-08
only O 0 8.566475306892585e-10
to O 0 5.362586819046555e-09
identify O 0 7.143884772631282e-08
chromosomal O 0 3.457818093011156e-05
loci O 0 6.480717615886533e-07
that O 0 4.717577883894819e-09
cause O 0 4.865545406573801e-07
or O 0 3.2707510033702647e-09
increase O 0 4.007535969741127e-10
the O 0 8.204963819480326e-09
risk O 0 1.1905953556379245e-08
of O 0 1.0940494377109644e-07
developing O 0 5.6800774473231286e-05
BPAD B-Disease 1 1.0
. O 0 2.5537150577292778e-05

To O 0 9.04966270809382e-07
determine O 0 8.484793170282501e-07
whether O 0 5.361873434139852e-08
there O 0 5.469887209841318e-09
could O 0 6.191565926627618e-09
be O 0 1.3288328215566025e-09
protective O 0 3.0409242413043103e-07
alleles O 0 1.2639967961192156e-09
that O 0 3.0105820614245715e-10
prevent O 0 7.139455249216553e-09
or O 0 6.778103855964446e-09
reduce O 0 2.048870406667902e-08
the O 0 2.802226539699859e-08
risk O 0 2.4893019201499555e-08
of O 0 4.855000312886659e-08
developing O 0 1.3959789612272289e-05
BPAD B-Disease 1 1.0
, O 0 4.284632648676734e-10
similar O 0 2.465912196658593e-10
to O 0 2.1513196779565646e-10
what O 0 1.1751981332519534e-10
is O 0 3.2711722219858075e-11
observed O 0 6.219966902643037e-11
in O 0 6.80792297536037e-11
other O 0 5.124438651193941e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 2.369180851502506e-09
we O 0 4.5781031743352685e-10
used O 0 1.28939814203477e-06
mental O 1 1.0
health O 0 0.16019892692565918
wellness O 0 8.886010618880391e-06
( O 0 1.2988075892561568e-10
absence O 0 6.675399788491632e-09
of O 0 2.5535888070749024e-08
any O 0 3.978891527367523e-07
psychiatric B-Disease 1 1.0
disorder I-Disease 0 6.875809049233794e-05
) O 0 3.5258951314176556e-10
as O 0 1.78330350486533e-09
the O 0 2.738044280192753e-08
phenotype O 0 2.442384641199169e-07
in O 0 1.4171283702069104e-08
our O 0 4.204025572107639e-07
genome O 0 1.292724647328214e-07
- O 0 2.1551748830006545e-07
wide O 0 2.452788123719074e-07
linkage O 0 7.833012318769761e-07
scan O 0 9.808338745642686e-07
of O 0 1.8309091842638736e-07
several O 0 1.5036304645832388e-08
large O 0 2.906305951455579e-08
multigeneration O 0 5.954349489911692e-06
Old O 0 9.02060855878517e-06
Order O 0 2.0155614492978202e-06
Amish O 0 5.486950158228865e-06
pedigrees O 0 4.353638587417663e-07
exhibiting O 0 1.306762964503605e-08
an O 0 1.043958142155077e-09
extremely O 0 2.5205576292819387e-08
high O 0 1.9328317080180568e-07
incidence O 0 5.130068075231975e-06
of O 0 1.1737334716599435e-05
BPAD B-Disease 1 1.0
. O 0 0.00011527428432600573

We O 0 1.0816472695296397e-06
have O 0 7.929864764832928e-09
found O 0 1.5223640126293958e-09
strong O 0 5.018711002335863e-10
evidence O 0 5.518047796471137e-09
for O 0 8.239618987104791e-10
a O 0 8.951228203102346e-09
locus O 0 1.395469695353313e-07
on O 0 2.2624367090884334e-07
chromosome O 0 1.1702228874810316e-07
4p O 0 0.0006396761746145785
at O 0 5.423229367806925e-07
D4S2949 O 0 1.2884562750059558e-07
( O 0 7.934565782186098e-10
maximum O 0 3.1001260225593796e-08
GENEHUNTER O 0 6.006214789522346e-06
- O 0 2.3825644746011676e-07
PLUS O 0 1.1704460689543339e-07
nonparametric O 0 1.6951450731994555e-07
linkage O 0 4.6582183443888425e-08
score O 0 4.3991978060375914e-08
= O 0 1.0246594683849253e-08
4 O 0 1.0320580834388693e-08
. O 0 7.43377304157633e-10
05 O 0 1.876946669199242e-07
, O 0 1.423368867214947e-09
P O 0 1.8378787558503973e-07
= O 0 1.7983746047889326e-08
5 O 0 7.508704769065844e-09
. O 0 5.681870529627986e-10
22 O 0 7.299511661784663e-09
x O 0 4.755323956828761e-08
10 O 0 9.108279463987401e-09
( O 0 6.149874498539987e-10
- O 0 2.6169489686367342e-08
4 O 0 5.558476701139625e-08
) O 0 3.1481320328374807e-10
; O 0 2.4451138891379287e-09
SIBPAL O 0 3.9099777495721355e-06
Pempirical O 0 1.3885986618333845e-06
value O 0 2.0310888970698215e-08
< O 0 3.203987120059537e-08
3 O 0 1.915842950950264e-08
x O 0 3.480263899291458e-08
10 O 0 7.512027444533942e-09
( O 0 2.65760996542852e-10
- O 0 1.711242525459511e-08
5 O 0 1.0181992138313944e-08
) O 0 6.949762293428918e-11
) O 0 4.2090098767433304e-11
and O 0 6.124668827656166e-11
suggestive O 0 5.844570383217729e-10
evidence O 0 6.009661657202514e-09
for O 0 1.3570254919770264e-09
a O 0 1.6647669909275464e-08
locus O 0 1.0612469480975051e-07
on O 0 1.5606298120474094e-07
chromosome O 0 5.0245493099509986e-08
4q O 0 5.060730927652912e-06
at O 0 1.6456175444545806e-07
D4S397 O 0 2.3727281472929462e-07
( O 0 1.6586998441425749e-09
maximum O 0 1.4633968703492428e-07
GENEHUNTER O 0 2.253731872770004e-05
- O 0 6.306236173259094e-07
PLUS O 0 3.842951912247372e-07
nonparametric O 0 3.883093313561403e-07
linkage O 0 7.508822363888612e-08
score O 0 3.5048046242991404e-08
= O 0 7.0527521600638465e-09
3 O 0 6.5251937186872055e-09
. O 0 2.148113215083569e-10
29 O 0 1.1666188015624357e-08
, O 0 5.335201169742732e-10
P O 0 1.0631412550310415e-07
= O 0 8.343938873167644e-09
2 O 0 1.0904531499988934e-08
. O 0 2.9131125289794113e-10
57 O 0 1.153141671039748e-08
x O 0 7.311763283723849e-08
10 O 0 8.353175040554106e-09
( O 0 3.07900871465705e-10
- O 0 1.6415288683901963e-08
3 O 0 3.840724005499396e-08
) O 0 2.34331581916436e-10
; O 0 7.271382385098946e-10
SIBPAL O 0 6.841243703092914e-06
Pempirical O 0 6.278523869696073e-07
value O 0 1.6413597592190854e-08
< O 0 3.011010107911716e-08
1 O 0 1.9514097004957875e-08
x O 0 3.180236163302652e-08
10 O 0 7.997991602337606e-09
( O 0 5.321034168837002e-10
- O 0 1.8679461533110953e-08
3 O 0 3.470096388014099e-08
) O 0 1.3387740915860036e-10
) O 0 2.2974693328348117e-11
that O 0 8.66131385363067e-12
are O 0 3.53256417173764e-11
linked O 0 9.468136141776995e-08
to O 0 9.093389508052496e-08
mental O 1 0.9999933242797852
health O 0 0.00048626906936988235
wellness O 0 7.379577436950058e-05
. O 0 3.922273492662498e-07

These O 0 8.772024528980182e-08
findings O 0 4.894927130294491e-08
are O 0 2.2966642476696109e-10
consistent O 0 7.749687114255721e-09
with O 0 1.8826305792085662e-10
the O 0 5.88089354991439e-09
hypothesis O 0 1.0129690863891483e-08
that O 0 4.437958334158054e-11
certain O 0 3.899580935939895e-10
alleles O 0 1.5286897303568026e-09
could O 0 1.5782567475142173e-09
prevent O 0 9.776362830393737e-09
or O 0 4.701014244545831e-09
modify O 0 2.9735931050822728e-08
the O 0 1.0457743115921403e-08
clinical O 0 3.6111313050923854e-08
manifestations O 0 2.6803891159943305e-06
of O 0 1.0927122275461443e-05
BPAD B-Disease 1 1.0
and O 0 1.8190423389796706e-08
perhaps O 0 9.674999690290065e-10
other O 0 4.225025884707634e-10
related O 0 9.89802174444776e-06
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.00011244975030422211

Segregation O 0 0.00017090453184209764
distortion O 0 0.000225516312639229
in O 0 2.1428545551316347e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0002860134991351515

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0006388658657670021
DM B-Disease 1 1.0
) O 0 3.045236240950544e-08
is O 0 1.9837200770922436e-09
an O 0 1.535574667421713e-09
autosomal B-Disease 1 0.7442943453788757
dominant I-Disease 1 0.9999996423721313
disease I-Disease 1 1.0
which O 0 1.4056068309287184e-08
, O 0 3.3851463299150453e-10
in O 0 4.731182112749366e-10
the O 0 2.0458090332908796e-08
typical O 0 1.843327339656753e-07
pedigree O 0 1.1738466554334082e-07
, O 0 2.901279216871444e-10
shows O 0 2.988110869850402e-10
a O 0 3.780210811044071e-09
three O 0 1.3108195417999013e-08
generation O 0 1.8722997765507898e-06
anticipation O 0 1.0860694601433352e-05
cascade O 0 0.00020586368918884546
. O 0 2.3751465505483793e-06

This O 0 4.66201122151233e-09
results O 0 6.391154272478161e-09
in O 0 1.992533782413375e-08
infertility B-Disease 1 0.5347753167152405
and O 0 0.00023050980234984308
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.2736638761198265e-07
CDM B-Disease 0 1.3964963727630675e-06
) O 0 3.679379023679985e-11
with O 0 5.0546566932041515e-11
the O 0 2.0660115396253786e-08
disappearance O 0 3.069683032208559e-07
of O 0 4.820251888304483e-06
DM B-Disease 1 1.0
in O 0 2.184642227121003e-07
that O 0 1.1654400999816517e-08
pedigree O 0 1.3823239441990154e-06
. O 0 1.580556698854707e-07

The O 0 1.1724966952897375e-06
concept O 0 1.0941845403067418e-06
of O 0 5.819525199513009e-07
segregation O 0 3.408871123156132e-07
distortion O 0 4.834384981222684e-07
, O 0 1.243076058754511e-10
where O 0 6.378883532498492e-11
there O 0 9.71937981486537e-12
is O 0 4.416676226137728e-12
preferential O 0 7.094357323822464e-10
transmission O 0 6.321696499611562e-09
of O 0 2.8304640853349383e-09
the O 0 4.435102507471811e-09
larger O 0 2.619034988882163e-09
allele O 0 4.434138389797226e-09
at O 0 6.523227735755199e-09
the O 0 1.5163255540073806e-08
DM B-Disease 1 0.9999995231628418
locus O 0 5.138711571817112e-07
, O 0 1.8732506656959913e-09
has O 0 3.282085714317873e-10
been O 0 1.3000944765195754e-09
put O 0 1.274307237508765e-08
forward O 0 4.356678218186971e-08
to O 0 1.3269339405042047e-08
explain O 0 7.475497909581463e-08
partially O 0 3.7600213431687735e-07
the O 0 8.512603955068698e-08
maintenance O 0 9.779378160601482e-06
of O 0 2.372791868765489e-06
DM B-Disease 1 1.0
in O 0 5.956156812203517e-08
the O 0 5.7725419111420706e-08
population O 0 1.613373601383472e-10
. O 0 1.1185184334294718e-08

In O 0 1.332162582912133e-06
a O 0 2.015748776784676e-07
survey O 0 9.596308636616868e-09
of O 0 8.0332810625805e-08
DM B-Disease 1 1.0
in O 0 1.395035837958858e-07
Northern O 0 1.6550086456845747e-06
Ireland O 0 3.720946324392571e-07
, O 0 1.0207815925866726e-08
59 O 0 8.863634803901732e-08
pedigrees O 0 7.171612281808848e-08
were O 0 1.4529443426170019e-08
ascertained O 0 1.6025633158278652e-06
. O 0 4.262710433522443e-07

Sibships O 0 0.0015421214047819376
where O 0 6.857827656858717e-07
the O 0 1.1333030869309368e-07
status O 0 1.6308379713336763e-07
of O 0 1.2426843909452145e-07
all O 0 1.9835004749779728e-09
the O 0 5.060806440582155e-09
members O 0 1.1674146371820626e-10
had O 0 1.7789550943447807e-09
been O 0 5.178851791853845e-10
identified O 0 1.3130909692904424e-09
were O 0 1.0543075301683302e-09
examined O 0 8.057876144107468e-09
to O 0 1.2527306969545293e-09
determine O 0 1.9902396175552894e-08
the O 0 6.291026721783055e-08
transmission O 0 1.8904341914094402e-07
of O 0 9.115304777651545e-08
the O 0 9.533896445645951e-07
DM B-Disease 1 1.0
expansion O 0 2.743519507930614e-05
from O 0 7.510239896646453e-08
affected O 0 2.8228690496234776e-08
parents O 0 4.322689761693255e-09
to O 0 2.3967055007290128e-09
their O 0 2.1063341293370286e-08
offspring O 0 3.908155861154228e-07
. O 0 2.3031267915030185e-07

Where O 0 1.2302210734560504e-06
the O 0 6.210397600625583e-07
transmitting O 0 6.465139449574053e-06
parent O 0 2.191620467328903e-07
was O 0 2.3047635977491154e-07
male O 0 1.4581998719620515e-08
, O 0 3.5462517367079727e-09
58 O 0 3.4018174233096943e-07
. O 0 5.003328169550514e-07

3 O 0 4.7389266910613514e-06
% O 0 1.9479886148587866e-08
of O 0 5.589905072156398e-08
the O 0 1.9367703885109222e-08
offspring O 0 2.998173087576106e-08
were O 0 3.573724871586137e-09
affected O 0 1.2165295437682744e-09
, O 0 1.7567033938625798e-10
and O 0 1.8464003936902174e-10
in O 0 5.221700849489253e-10
the O 0 2.0864125982456017e-09
case O 0 2.4949475818658584e-09
of O 0 3.4592038122838176e-09
a O 0 2.6101980576953565e-09
female O 0 8.51993753325786e-10
transmitting O 0 3.7890483639557715e-08
parent O 0 2.087679540352383e-08
, O 0 9.33776700406952e-09
68 O 0 2.98690565614379e-06
. O 0 3.429810476518469e-06

7 O 0 2.0963934730389155e-05
% O 0 5.181465567716259e-08
were O 0 2.00423535545724e-08
affected O 0 8.293645237245073e-08
. O 0 4.4032358914591896e-07

Studies O 0 3.177611347382481e-07
on O 0 6.411546564777382e-07
meiotic O 0 7.4761769610631745e-06
drive O 0 3.8733769542886876e-06
in O 0 1.483063414298158e-07
DM B-Disease 1 1.0
have O 0 4.736312675390764e-09
shown O 0 7.747583685713266e-10
increased O 0 2.621947658987267e-10
transmission O 0 2.1554529272549416e-09
of O 0 5.282335124867643e-10
the O 0 9.608648321446367e-10
larger O 0 1.3932742737310377e-09
allele O 0 9.931070410473808e-10
at O 0 4.164740552425883e-09
the O 0 1.5440720702031285e-08
DM B-Disease 1 0.998337984085083
locus O 0 2.9817149993505154e-07
in O 0 3.796468472927472e-09
non O 0 1.8479143193417258e-07
- O 0 1.0039251719717868e-05
DM O 1 1.0
heterozygotes O 0 6.368872618622845e-06
for O 0 1.7312001432401303e-07
CTGn O 0 0.00020771507115568966
. O 0 1.691479042165156e-06

This O 0 1.3917457408751943e-07
study O 0 9.163919401089515e-09
provides O 0 1.1576631875342969e-09
further O 0 3.717912921974431e-10
evidence O 0 1.68051350613041e-09
that O 0 2.9866520367960447e-10
the O 0 1.377537302005294e-07
DM B-Disease 1 1.0
expansion O 0 3.100404137512669e-05
tends O 0 2.1934940264145553e-07
to O 0 4.502788808480318e-09
be O 0 1.899359780566101e-09
transmitted O 0 8.394366091124539e-09
preferentially O 0 2.5070223230727606e-08
. O 0 5.97943383695565e-08

Diagnosis O 1 0.9999998807907104
of O 1 0.9998921155929565
hemochromatosis B-Disease 1 1.0
. O 0 0.0018672709120437503

If O 0 0.00010226434824289754
untreated O 1 1.0
, O 0 5.110344773129327e-06
hemochromatosis B-Disease 1 1.0
can O 0 1.3659928299603052e-06
cause O 0 0.4535446763038635
serious O 0 0.007262117229402065
illness O 1 0.9909680485725403
and O 0 1.3526350040038437e-09
early B-Disease 0 1.6972883543076023e-07
death I-Disease 0 1.3764870345767122e-06
, O 0 2.3095704515530002e-10
but O 0 3.4116057201494243e-10
the O 0 2.132553689193628e-08
disease O 0 7.4041095103893895e-06
is O 0 6.546544972785284e-10
still O 0 6.786302075845185e-10
substantially O 0 1.1671040134331179e-08
under O 0 2.21988793782657e-05
- O 1 0.8891989588737488
diagnosed O 0 0.476511150598526
. O 0 1.0888132919717464e-06

The O 0 1.605098441359587e-05
cornerstone O 0 0.005153072532266378
of O 0 8.672024591760419e-07
screening O 0 3.154546277528425e-07
and O 0 2.70089417497843e-09
case O 0 4.904699757446451e-09
detection O 0 1.0037213087343844e-06
is O 0 4.429909494785278e-10
the O 0 1.1462030213849062e-09
measurement O 0 9.529335898150748e-08
of O 0 9.74495861782998e-08
serum O 0 1.8268327721671085e-06
transferrin O 0 1.4123344953986816e-05
saturation O 0 4.6382970708691573e-07
and O 0 7.374941990434536e-09
the O 0 2.194355630535938e-08
serum O 0 4.2267311073374003e-07
ferritin O 0 1.1323052603984252e-05
level O 0 7.20903869932954e-07
. O 0 1.9849743182476232e-07

Once O 0 1.09894290289958e-05
the O 0 1.7131897322997247e-07
diagnosis O 0 0.00023676319688092917
is O 0 4.511523599148859e-09
suspected O 0 4.3977252062177286e-07
, O 0 2.632978945982245e-09
physicians O 0 1.189278986402087e-08
must O 0 1.3977521362562584e-08
use O 0 4.08858596756545e-07
serum O 0 0.001176726771518588
ferritin O 1 0.958180844783783
levels O 0 2.017007545873639e-06
and O 0 4.47325874119997e-07
hepatic O 1 0.9999995231628418
iron O 1 0.9999997615814209
stores O 0 5.736720822824282e-07
on O 0 4.867328016189276e-07
liver O 0 4.363033440313302e-06
biopsy O 0 4.429694300256415e-08
specimens O 0 1.027773199879789e-09
to O 0 3.3140035160528214e-10
assess O 0 6.53915037673869e-08
patients O 0 6.239522321038748e-08
for O 0 6.129162066770277e-09
the O 0 1.2050277575781365e-07
presence O 0 4.3421024997769564e-08
of O 0 5.0590033424668945e-06
iron B-Disease 1 1.0
overload I-Disease 0 0.0021452908404171467
. O 0 1.3876864386475063e-06

Liver O 1 1.0
biopsy O 1 0.9520885944366455
is O 0 1.5093230842921912e-07
also O 0 2.7092008636486753e-09
used O 0 4.810761122797658e-09
to O 0 6.598761981280177e-09
establish O 0 1.0634920499796863e-07
the O 0 1.1999520665995078e-07
presence O 0 1.0783123727264865e-08
or O 0 5.265370717211226e-08
absence O 0 5.82503889745567e-06
of O 0 4.580272070597857e-05
cirrhosis B-Disease 1 1.0
, O 0 1.649773762046891e-09
which O 0 1.242744240848026e-10
can O 0 2.1038507047599353e-10
affect O 0 7.154667969189177e-09
prognosis O 1 0.9998008608818054
and O 0 1.198201431407142e-07
management O 0 3.1239512736647157e-06
. O 0 3.244130368784681e-07

A O 0 8.328547664859798e-06
DNA O 0 8.435616791757639e-07
- O 0 4.3157965023965517e-07
based O 0 1.587008569003956e-08
test O 0 2.2884895756192236e-08
for O 0 6.609821578962283e-09
the O 0 4.05423818961026e-08
HFE O 0 1.6704003428458236e-05
gene O 0 1.650898262539613e-08
is O 0 2.692246980906532e-10
commercially O 0 1.1622917073239591e-09
available O 0 1.5236588379874405e-10
, O 0 7.13756900805329e-11
but O 0 7.695092479886867e-11
its O 0 6.018032738808188e-10
place O 0 6.70040201100619e-09
in O 0 1.838500601758497e-10
the O 0 1.923347481280757e-09
diagnosis O 0 1.6380517990910448e-05
of O 0 1.8388902844890254e-06
hemochromatosis B-Disease 1 1.0
is O 0 3.150002925167428e-08
still O 0 7.827484438394094e-09
being O 0 1.593557286128089e-08
evaluated O 0 1.3794897313346155e-07
. O 0 3.26511553794262e-07

Currently O 0 1.0174517228733748e-06
, O 0 3.2199707789004606e-08
the O 0 3.0881281531947025e-08
most O 0 1.4853750451848668e-09
useful O 0 2.0790000831993893e-09
role O 0 6.084469816869387e-09
for O 0 2.7332200391860795e-10
this O 0 2.2950615019556864e-10
test O 0 5.905059108357591e-09
is O 0 1.4187739871829308e-10
in O 0 1.1195269017383325e-10
the O 0 7.514545652398397e-10
detection O 0 5.313795099937124e-06
of O 0 2.1721020857512485e-06
hemochromatosis B-Disease 1 1.0
in O 0 2.6027652211269015e-07
the O 0 2.0467190608997043e-07
family O 0 1.3661442643808641e-08
members O 0 3.617254065724218e-11
of O 0 1.5736276726130427e-09
patients O 0 5.985977824529698e-10
with O 0 2.235406304507137e-10
a O 0 2.7973884542120686e-08
proven O 0 1.4205593288352247e-06
case O 0 8.20318177829904e-07
of O 0 2.2347960566548863e-06
the O 0 5.269377652439289e-06
disease O 0 0.0005513610085472465
. O 0 5.397209861257579e-07

It O 0 3.715081220434513e-08
is O 0 4.009900855805881e-09
crucial O 0 2.528498441733973e-07
to O 0 2.274919985723045e-08
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 1 1.0
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.9862804412841797
because O 0 1.5428231563419104e-06
phlebotomy O 1 0.9999485015869141
therapy O 0 0.0006527900113724172
can O 0 2.1818850726162964e-08
avert O 0 0.0009823691798374057
serious O 1 0.9841989278793335
chronic O 1 1.0
disease O 1 1.0
and O 0 5.6584617880162114e-08
can O 0 3.661355885142825e-09
even O 0 8.165936549175967e-08
lead O 0 1.1642851660553788e-07
to O 0 1.7280942232744678e-09
normal O 0 4.289952570957212e-08
life O 0 2.5173770623609926e-08
expectancy O 0 3.9448879718406715e-09
. O 0 1.1994979454144072e-09
. O 0 1.9474313717182667e-08

Prevalence O 0 1.8536540665081702e-05
of O 0 1.4187153283273801e-06
the O 0 5.009664505450928e-07
I1307K O 0 8.553134307476284e-07
APC B-Disease 0 2.801489173975824e-08
gene O 0 5.56826529329868e-10
variant O 0 1.1056727977631908e-08
in O 0 6.165589150342043e-10
Israeli O 0 7.081614938897474e-08
Jews O 0 1.0689948481967804e-08
of O 0 8.637879855832864e-10
differing O 0 1.867007520806041e-10
ethnic O 0 1.2451684648639993e-11
origin O 0 7.205908786334092e-11
and O 0 1.609313654560296e-10
risk O 0 5.233697919493352e-09
for O 0 8.978724963526474e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.000562498637009412

BACKGROUND O 0 0.000169368417118676
& O 0 4.826824806514196e-05
AIMS O 0 3.395225007807312e-07
Israeli O 0 4.0659398337083985e-07
Jews O 0 1.4418057503462478e-07
of O 0 6.680637198996919e-08
European O 0 1.6353412846115134e-08
birth O 0 4.861830120717059e-07
, O 0 1.481956446447441e-09
i O 0 4.047197688095139e-09
. O 0 4.95158303248644e-10
e O 0 8.205116586168515e-10
. O 0 5.844458805803754e-10
, O 0 3.3238281571534856e-10
Ashkenazim O 0 2.270628982614653e-07
, O 0 1.826539614002698e-10
have O 0 9.214388280165409e-11
the O 0 1.7139962338319492e-08
highest O 1 0.9999076128005981
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 2.280095031892415e-06
of O 0 3.226019629209986e-08
any O 0 8.200552237269676e-09
Israeli O 0 9.67521714301256e-07
ethnic O 0 1.693639894995158e-08
group O 0 1.693462259311218e-08
. O 0 1.7678503638762777e-07

The O 0 7.759148502373137e-06
I1307K O 0 9.143152055912651e-06
APC B-Disease 0 2.767426110494853e-07
gene O 0 2.9747260210655213e-09
variant O 0 2.1099837965721235e-07
was O 0 3.8839525018374843e-07
found O 0 8.669111650760897e-09
in O 0 1.5488948790221002e-08
6 O 0 1.4359467286340077e-06
. O 0 4.873862735621515e-07

1 O 0 6.385079359461088e-06
% O 0 6.46008047056057e-09
of O 0 8.232317938450251e-09
American O 0 1.8953283387190822e-09
Jews O 0 5.9296407783904215e-09
, O 0 2.801945619967938e-10
28 O 0 2.8974487253918824e-09
% O 0 2.774864504839769e-10
of O 0 4.349850701856894e-09
their O 0 9.470408599554503e-07
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.10044322052272e-06
, O 0 3.7889433257554117e-10
but O 0 1.5009926634945714e-10
not O 0 9.826379293587095e-11
in O 0 9.753207130813735e-10
non O 0 3.2607616162749764e-08
- O 0 1.797870936570689e-07
Jews O 0 1.1946129063744593e-07
. O 0 3.878456311667833e-07

We O 0 1.5515907989538391e-06
assessed O 0 2.7910093649552437e-06
the O 0 1.7481659142504213e-07
I1307K O 0 8.01567750841059e-07
prevalence O 0 2.6570550204496612e-08
in O 0 2.3358279199747756e-10
Israeli O 0 2.280820154965113e-08
Jews O 0 3.7076606229646814e-09
of O 0 4.860564173370108e-10
differing O 0 5.845771783308251e-11
ethnic O 0 1.2324140839792275e-11
origin O 0 1.0461762012248244e-10
and O 0 2.1740481637166909e-10
risk O 0 6.284631925979056e-09
for O 0 1.0727284234235412e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0011647457722574472

METHODS O 0 5.073415650258539e-06
DNA O 0 5.962806426396128e-07
samples O 0 2.211945826502415e-08
from O 0 5.626742183295619e-09
500 O 0 1.8514018096382756e-09
unrelated O 0 9.11260666924818e-09
Jews O 0 1.8478466756732814e-08
of O 0 2.5775426593099837e-07
European O 0 2.0414712764704745e-07
or O 0 1.3827626332840737e-07
non O 0 1.665698334818444e-07
- O 0 5.225910371109421e-08
European O 0 6.826276877092141e-09
origin O 0 2.5801623060317525e-09
, O 0 2.0369839148770552e-10
with O 0 3.237455442617332e-11
or O 0 2.7851951855950574e-09
without O 0 1.9847844257014913e-08
a O 0 7.128055301564018e-08
personal O 0 1.0209946594841313e-06
and O 0 1.8184858845415874e-06
/ O 1 0.6967077255249023
or O 0 1.178884667751845e-05
family O 0 3.3681651530059753e-06
history O 0 3.789727642811158e-08
of O 0 1.212119542515211e-07
neoplasia B-Disease 0 1.0045122508017812e-05
, O 0 4.480830817499282e-09
were O 0 5.332863484142081e-09
examined O 0 9.036919124127962e-08
for O 0 3.798953152056583e-09
the O 0 5.145420090002517e-08
I1307K O 0 6.118838768998103e-08
variant O 0 3.991481989373824e-08
by O 0 2.235782670112485e-09
the O 0 2.3400176019094943e-08
allele O 0 2.6503421679535677e-09
- O 0 3.5271479070786427e-09
specific O 0 7.267264567900611e-10
oligonucleotide O 0 6.236595027075964e-07
( O 0 1.2404530735921071e-08
ASO O 0 5.769740255345823e-06
) O 0 7.422480963192868e-10
method O 0 3.6873654352120866e-08
. O 0 1.072870148277616e-07

RESULTS O 0 9.203245099342894e-07
In O 0 4.7726068430620217e-08
persons O 0 3.2734845945014968e-09
at O 0 5.458725027551736e-09
average O 0 8.571803267187761e-10
risk O 0 7.629830101052448e-09
for O 0 4.445034846867202e-07
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.215066245980779e-07
I1307K O 0 5.496731318999082e-07
was O 0 2.2023395729320328e-07
found O 0 2.0609569606477862e-09
in O 0 1.2522840542317226e-09
5 O 0 3.833756423432533e-08
. O 0 5.884699660896331e-08

0 O 0 2.126592335116584e-06
% O 0 1.6286518800257e-08
of O 0 2.1756349610768666e-08
120 O 0 1.3984426949775752e-08
European O 0 1.9546506635492733e-08
and O 0 5.8139338676710395e-08
1 O 0 3.878654752043076e-06
. O 0 6.007246611261507e-07

6 O 0 2.03873569262214e-05
% O 0 4.810855358527988e-08
of O 0 4.871279202234291e-08
188 O 0 3.824188965495523e-08
non O 0 4.375198514594558e-08
- O 0 9.090615549212089e-08
European O 0 5.326137042516166e-08
Jews O 0 9.365703590447083e-08
( O 0 2.7969173643782597e-09
P O 0 5.470635642268462e-07
= O 0 2.4478030269392548e-08
0 O 0 5.520932599978323e-09
. O 0 3.513938306998199e-10
08 O 0 8.156188613384074e-09
) O 0 9.386637023212074e-10
. O 0 1.8933201673121403e-08

It O 0 7.575354032951509e-08
occurred O 0 2.7658956014420255e-07
in O 0 1.1644712749614428e-08
15 O 0 3.929449832185128e-08
. O 0 1.1142750366843757e-07

4 O 0 1.856300173130876e-06
% O 0 4.779955986577988e-09
of O 0 6.549120801224717e-09
52 O 0 1.5111400131218033e-08
Ashkenazi O 0 1.4590629859867477e-07
Israelis O 0 2.651061414837841e-08
with O 0 2.0344068651922953e-09
familial O 0 4.682238795794547e-06
cancer B-Disease 0 8.612522651674226e-05
( O 0 1.6882045761335007e-09
P O 0 9.871851034404244e-07
= O 0 2.3418659012008902e-08
0 O 0 7.850196048764246e-09
. O 0 4.012040699663544e-10
02 O 0 8.77836381363295e-09
) O 0 4.4982264441051356e-11
and O 0 3.174172868991576e-10
was O 0 2.5152941063311118e-08
not O 0 9.245693655124398e-10
detected O 0 3.0184274635303154e-08
in O 0 4.780585260988346e-09
51 O 0 2.9899496212237864e-08
non O 0 8.341731216887638e-08
- O 0 1.9511460891408205e-07
European O 0 5.3933415955498276e-08
Jews O 0 1.967039935379944e-07
at O 0 5.673191338928518e-08
increased O 0 5.937336844397123e-09
cancer B-Disease 0 2.134195028702379e-06
risk O 0 5.421012261308533e-08
. O 0 1.0662339633427109e-07

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999986886978149
occurred O 0 0.0027671707794070244
personally O 0 5.517876502381114e-07
or O 0 1.588071540936653e-08
in O 0 2.325298398275777e-09
the O 0 9.248503296532817e-09
families O 0 9.269690570690159e-10
of O 0 1.5413974097100436e-08
13 O 0 1.6613602937809446e-08
of O 0 4.5753495214739814e-08
20 O 0 2.7754389009260194e-08
Ashkenazi O 0 4.307264873659733e-07
I1307K O 0 1.3107799645695195e-07
carriers O 0 3.975751727836041e-09
, O 0 1.6286823001365747e-09
8 O 0 3.886671606778691e-08
of O 0 7.86967291332985e-08
whom O 0 4.2086065832336317e-07
also O 0 5.690921867085308e-08
had O 0 2.668029992491938e-07
a O 0 4.9687304937151566e-08
personal O 0 5.637003255287709e-07
or O 0 2.1027980778853816e-07
family O 0 8.427401354538233e-08
history O 0 2.3587348962905708e-08
of O 0 2.605675888389669e-07
noncolonic O 0 4.017418177681975e-05
neoplasia B-Disease 0 0.0027557085268199444
. O 0 3.451429802225903e-05

CONCLUSIONS O 0 3.1755276722833514e-05
The O 0 7.476219707314158e-06
I1307K O 0 1.2230781067046337e-05
APC O 0 5.573838279815391e-07
variant O 0 9.041933708431316e-07
may O 0 1.6727051743714583e-08
represent O 0 1.6273873360006519e-09
a O 0 9.597882488776577e-09
susceptibility O 0 1.9216733448956802e-07
gene O 0 1.4546247761870745e-08
for O 0 4.371494810584409e-08
colorectal B-Disease 1 1.0
, I-Disease 0 2.368753939663293e-06
or I-Disease 0 1.9568313291529194e-05
other I-Disease 0 4.557776662750257e-07
, I-Disease 0 3.7023888399545513e-09
cancers I-Disease 0 5.5579170293640345e-05
in O 0 3.653884306231703e-09
Ashkenazi O 0 0.0001579758245497942
Jews O 0 6.234573106667085e-07
, O 0 4.904531447635918e-09
and O 0 5.21631760008745e-09
partially O 0 1.4073336274122994e-07
explains O 0 1.736244814587451e-09
the O 0 2.1878587830315155e-10
higher O 0 1.0273086825662858e-09
incidence O 0 7.96236250266702e-08
of O 0 3.0511917429976165e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.7863761076218907e-08
European O 0 2.3639190160906765e-08
Israelis O 0 1.4447100227243936e-07
. O 0 2.803272423079761e-07

Systematic O 0 8.050091793165848e-08
analysis O 0 2.5043698670401682e-08
of O 0 5.0906077575518793e-08
coproporphyrinogen O 0 5.213334588916041e-06
oxidase O 0 5.05791331306682e-06
gene O 0 3.095106421824312e-06
defects O 0 0.00024328968720510602
in O 0 2.6211601777959004e-08
hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.9999970197677612
and O 0 1.1004656244040234e-06
mutation O 0 1.5074603254561225e-07
update O 0 2.0750612748088315e-06
. O 0 1.585446511853661e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 0.999895453453064
( O 0 7.049721943985787e-07
HC B-Disease 1 0.9999144077301025
) O 0 1.8213441421721654e-08
is O 0 3.3472993266059348e-09
an O 0 1.1635055585657028e-08
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 1 0.9999874830245972
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 1 0.9663226008415222
caused O 0 3.0689325285493396e-06
by O 0 7.109257071924446e-10
deficient B-Disease 0 2.30857807537177e-07
activity I-Disease 0 1.5287364707461393e-09
of I-Disease 0 1.928664161710003e-08
coproporphyrinogen I-Disease 0 2.396740228505223e-06
III I-Disease 1 1.0
oxidase I-Disease 0 1.1682842568916385e-06
( O 0 4.839243672449811e-09
CPO O 0 4.6869871539456653e-07
) O 0 1.2303345009456734e-09
. O 0 1.9626266833938644e-08

Clinical O 0 5.138984852237627e-05
manifestations O 1 0.9977812170982361
of O 0 0.00431099021807313
the O 0 3.196753823431209e-05
disease O 0 0.041023798286914825
are O 0 1.0192819678567222e-11
characterized O 0 6.564574994705197e-10
by O 0 1.4821563421030248e-10
acute O 1 0.9975952506065369
attacks O 0 2.5804580218391493e-05
of O 1 1.0
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 2.3202755272677678e-08
precipitated O 0 9.093476194266259e-08
by O 0 7.929402273676445e-11
drugs O 0 5.972774719253948e-09
, O 0 1.4923893232321461e-09
fasting O 0 8.318203981616534e-06
, O 0 1.5039516298998024e-08
cyclical O 0 5.26241183251841e-06
hormonal O 0 3.1532065349892946e-06
changes O 0 3.535603099180662e-08
, O 0 4.0509124943355346e-09
or O 0 4.8634344551601316e-08
infectious B-Disease 0 0.0003169260162394494
diseases I-Disease 0 0.0017134593799710274
. O 0 4.2094015384464e-07

Skin O 1 1.0
photosensitivity O 1 1.0
may O 0 1.9772725863731466e-05
also O 0 2.726303272027053e-08
be O 0 2.8269624419152706e-09
present O 0 4.054122371144331e-08
. O 0 2.803579945975798e-07

The O 0 1.1775296115956735e-05
seven O 0 1.3164967640477698e-06
exons O 0 2.980398221552605e-06
, O 0 1.06316715431376e-08
the O 0 6.703766075588646e-08
exon O 0 1.1116243285869132e-06
/ O 0 3.0702801723236917e-07
intron O 0 4.205428751902218e-07
boundaries O 0 3.83644831458696e-08
and O 0 8.196611389621467e-09
part O 0 1.2444699493130429e-08
of O 0 1.2302065499625314e-07
3 O 0 1.7434740584576502e-07
noncoding O 0 3.0505387371704273e-07
sequence O 0 7.92671972504877e-09
of O 0 5.298232963468763e-08
the O 0 1.0987357512703966e-07
CPO O 0 1.0814264896907844e-06
gene O 0 9.725625638168367e-09
were O 0 3.0791453831113813e-09
systematically O 0 1.2517490377561558e-09
analyzed O 0 3.351471322687871e-09
by O 0 4.2610961981104367e-10
an O 0 5.009128667410323e-10
exon O 0 1.2911767655054973e-08
- O 0 2.715617419823957e-08
by O 0 9.15839848403266e-09
- O 0 1.1362883469701046e-06
exon O 0 2.471575726303854e-06
denaturing O 0 2.5759090931387618e-05
gradient O 0 1.987547875614837e-06
gel O 0 1.0735497113500969e-07
electrophoresis O 0 5.097486877048141e-08
( O 0 1.9480841384478254e-09
DGGE O 0 1.1937136150663719e-06
) O 0 8.670690554435367e-11
strategy O 0 2.226772988223047e-09
followed O 0 2.7024077420279013e-10
by O 0 1.338089361535566e-11
direct O 0 2.5876717435480145e-10
sequencing O 0 6.500647131701953e-09
in O 0 6.716879275003862e-10
seven O 0 4.416640830839924e-09
unrelated O 0 5.354208099106472e-08
heterozygous O 0 7.179712380178671e-09
HC B-Disease 0 3.980469045927748e-05
patients O 0 1.1253516163378663e-07
from O 0 1.1415394141067736e-07
France O 0 9.046093651932097e-08
, O 0 2.6666391317320404e-09
Holland O 0 4.816612317881663e-07
, O 0 1.890537282278615e-09
and O 0 7.17965731311665e-09
Czech O 0 5.134609637025278e-06
Republic O 0 4.191125844954513e-05
. O 0 0.00027582375332713127

Seven O 0 4.6664181354572065e-06
novel O 0 4.540834481758793e-07
mutations O 0 2.842676849468262e-08
and O 0 8.645399951490162e-09
two O 0 2.984939406758258e-09
new O 0 2.0251393451076183e-08
polymorphisms O 0 3.567784858660161e-07
were O 0 1.452019660064252e-07
detected O 0 2.74413037004706e-06
. O 0 6.540584536196548e-07

Among O 0 2.484374306277459e-07
these O 0 5.845687933714316e-09
mutations O 0 4.8933372909232276e-09
two O 0 1.7799868246015649e-09
are O 0 1.9663753958454322e-10
missense O 0 2.061831594346586e-07
( O 0 1.9435786313692915e-09
G197W O 0 2.6728790203378594e-07
, O 0 2.857526881783201e-09
W427R O 0 7.980212046732049e-08
) O 0 4.144927179261515e-10
, O 0 2.175915003732598e-10
two O 0 6.314378464544745e-10
are O 0 3.4449668118163856e-10
nonsense O 0 1.3461605874454108e-07
( O 0 2.3658028869277814e-09
Q306X O 0 1.4860508201763878e-07
, O 0 9.370769715744132e-10
Q385X O 0 5.951784487479017e-08
) O 0 6.524543127994775e-10
, O 0 6.979575251087056e-10
two O 0 9.009976653651108e-10
are O 0 2.2389991249927021e-10
small O 0 4.745300596908919e-09
deletions O 0 3.171779638933003e-08
( O 0 2.631382667317439e-09
662de14bp O 0 1.7438865995700326e-07
; O 0 1.0369850755864718e-08
1168del3bp O 0 3.5678770018421346e-06
removing O 0 7.89968112258066e-07
a O 0 1.1913613207070739e-07
glycine O 0 1.0347351064865506e-07
at O 0 8.86617073092566e-08
position O 0 4.569924527686453e-08
390 O 0 9.107012033382489e-09
) O 0 4.526507987878681e-11
, O 0 4.981305645745948e-11
and O 0 2.349693495329319e-10
one O 0 1.629605117514643e-09
is O 0 6.107522820819611e-10
a O 0 2.7386173329091434e-09
splicing O 0 3.260798919768604e-08
mutation O 0 1.3910146368090182e-09
( O 0 1.686304984538367e-10
IVS1 O 0 4.496934025155497e-07
- O 0 6.291542575809217e-08
15c O 0 7.195054649855592e-07
- O 0 1.9323763922329817e-07
- O 0 1.5923002649742557e-07
> O 0 1.1703411928465357e-07
g O 0 1.584425568523784e-08
) O 0 5.133051622641105e-11
which O 0 1.635569631119882e-11
creates O 0 5.782508916141182e-10
a O 0 7.172331062399451e-10
new O 0 3.824858207934767e-09
acceptor O 0 5.707594397108551e-09
splice O 0 7.148421445890563e-06
site O 0 1.1330895404171315e-06
. O 0 1.571319785398373e-07

The O 0 2.67469977188739e-06
pathological O 0 6.091072009439813e-06
significance O 0 2.6998714020010084e-07
of O 0 1.066246682057681e-06
the O 0 3.8299930338325794e-07
point O 0 2.1191007704146614e-07
mutations O 0 4.075440873663183e-09
G197W O 0 1.0931566407634818e-07
, O 0 1.876823363389235e-09
W427R O 0 3.525142915350443e-07
, O 0 3.6360034982863e-09
and O 0 6.526848839172317e-09
the O 0 9.09996487052922e-08
in O 0 1.9318672883628096e-08
- O 0 1.990904507920277e-07
frame O 0 5.788285193375486e-07
deletion O 0 1.8724804817793483e-07
390delGly O 0 6.187117662648234e-08
were O 0 7.613239483283962e-10
assessed O 0 2.46088149857826e-09
by O 0 2.2667964727496326e-10
their O 0 3.212215604619928e-09
respective O 0 2.4756747762921805e-08
expression O 0 7.54799067692602e-09
in O 0 3.0969034003902607e-09
a O 0 4.8965866916717005e-09
prokaryotic O 0 3.322437081010321e-08
system O 0 1.757872496455093e-07
using O 0 1.8960379932764226e-08
site O 0 2.956743401227868e-07
- O 0 8.471107548757573e-08
directed O 0 1.6847506500994314e-08
mutagenesis O 0 4.773431101057213e-06
. O 0 3.218056008336134e-07

These O 0 5.969815930484401e-08
mutations O 0 2.3518840208680558e-08
resulted O 0 3.8743849017919274e-08
in O 0 3.4180294150587542e-09
the O 0 1.2352165512652391e-08
absence O 0 7.531197354637698e-08
or O 0 8.444807519936148e-09
a O 0 7.336150353864923e-09
dramatic O 0 2.824032385717601e-08
decrease O 0 4.8643620687016664e-08
of O 0 2.0008224055345636e-06
CPO O 0 6.87405772623606e-05
activity O 0 1.1152886827403563e-06
. O 0 9.62945023275097e-07

The O 0 1.7688651041680714e-06
two O 0 3.7874730907105914e-08
polymorphisms O 0 6.607832148119996e-08
were O 0 7.33778771078164e-09
localized O 0 2.0129785127664945e-07
in O 0 1.6347986075970766e-08
noncoding O 0 8.972869522949622e-07
part O 0 2.1776942915607833e-08
of O 0 1.7041556077401765e-07
the O 0 2.1246123083074053e-08
gene O 0 5.626675236847234e-10
1 O 0 1.941459437659887e-09
) O 0 1.3115727254264797e-11
a O 0 1.1902814289754815e-09
C O 0 1.9468637901809416e-07
/ O 0 1.219648453343325e-07
G O 0 1.608837294497789e-07
polymorphism O 0 5.698536398313081e-08
in O 0 2.6546018716544495e-09
the O 0 2.135850785123239e-08
promotor O 0 1.0446697160659824e-06
region O 0 2.3216303546291783e-08
, O 0 4.6626875693789316e-09
142 O 0 5.581967243983854e-08
bp O 0 3.040173339741159e-07
upstream O 0 1.922978221102767e-08
from O 0 3.670621140372532e-09
the O 0 1.1643469299826847e-08
transcriptional O 0 2.1017976337134314e-07
initiation O 0 8.671463547216263e-08
site O 0 2.502373952495418e-08
( O 0 1.6764213628395197e-10
- O 0 3.3659235398886267e-09
142C O 0 1.0630296998215272e-07
/ O 0 3.381187951845277e-08
G O 0 7.029427706584102e-08
) O 0 5.393963609101604e-10
, O 0 3.566096862250845e-10
and O 0 2.8674087548807847e-09
2 O 0 7.281521163804427e-08
) O 0 5.809482894747475e-10
a O 0 1.2457737064153207e-08
6 O 0 1.273323846362473e-07
bp O 0 1.0930668992159553e-07
deletion O 0 3.1372120457007213e-09
polymorphism O 0 3.267172088428083e-09
in O 0 8.029397702280505e-10
the O 0 5.314505280296089e-09
3 O 0 2.4234049433857763e-08
noncoding O 0 2.3577278795983148e-07
part O 0 2.2618623418679817e-08
of O 0 1.325093279547218e-07
the O 0 1.4365188860665512e-07
CPO O 0 9.69115603766113e-07
gene O 0 7.843370397608851e-09
, O 0 1.557289186493449e-09
574 O 0 1.5090122928995697e-07
bp O 0 5.717729436582886e-07
downstream O 0 9.887607888003913e-08
of O 0 1.4736646569701861e-08
the O 0 2.023996437117148e-08
last O 0 9.682277202216483e-09
base O 0 7.965066117776587e-08
of O 0 1.1025496959859993e-08
the O 0 4.841967715663031e-09
normal O 0 2.1108133019254183e-09
termination O 0 3.156763739298185e-08
codon O 0 4.058800850970101e-09
( O 0 1.6083847587111677e-09
+ O 0 2.6338845771078923e-08
574 O 0 7.664547041486003e-08
delATTCTT O 0 5.020894491281069e-07
) O 0 4.714447499054586e-09
. O 0 1.154671807057639e-07

Five O 0 3.961999755119905e-05
intragenic O 0 0.0009566337103024125
dimorphisms O 0 0.00034085995866917074
are O 0 1.1445476566507296e-08
now O 0 5.533931535239844e-09
well O 0 2.604628068780812e-09
characterized O 0 1.2554247419416242e-08
and O 0 2.449866309817139e-09
the O 0 8.714104104967646e-09
high O 0 1.465603016725936e-08
degree O 0 6.004061958719831e-08
of O 0 2.2028514123917375e-08
allelic O 0 1.9729655775790889e-07
heterogeneity O 0 2.0411403056641575e-07
in O 0 1.1672509181437363e-08
HC B-Disease 0 0.01499885506927967
is O 0 1.5508460293744974e-08
demonstrated O 0 1.0140284167903246e-08
with O 0 7.691383641095229e-10
seven O 0 3.525251424107978e-09
new O 0 5.215439191630367e-10
different O 0 9.386596361293797e-11
mutations O 0 3.101779111336356e-10
making O 0 7.508614285889337e-10
a O 0 2.0527732846886693e-09
total O 0 3.8058192708412264e-10
of O 0 1.3276529209349519e-08
nineteen O 0 4.3238134139755857e-07
CPO O 0 2.739527371886652e-05
gene B-Disease 0 1.9813933249679394e-06
defects I-Disease 0 2.0301002223277465e-05
reported O 0 1.470421828742019e-08
so O 0 2.7891393639123407e-09
far O 0 9.072372186835764e-09
. O 0 9.55430223825715e-09
. O 0 7.410761071469096e-08

Coincidence O 0 1.7456184650654905e-05
of O 0 3.113013008260168e-06
two O 0 1.511586162905587e-07
novel O 0 2.46139023829528e-07
arylsulfatase O 0 3.59230580215808e-06
A O 0 2.6841004796551715e-07
alleles O 0 1.5477068515679093e-09
and O 0 2.0435459990864047e-09
mutation O 0 1.8089418851729988e-09
459 O 0 1.2970562401903862e-08
+ O 0 2.2398515042709732e-08
1G O 0 9.206931963490206e-07
> O 0 4.233896078176258e-08
A O 0 1.620181144801336e-08
within O 0 1.809155825149844e-09
a O 0 5.643724598769495e-09
family O 0 8.096530557111237e-09
with O 0 6.838510313578183e-10
metachromatic B-Disease 1 0.9999990463256836
leukodystrophy I-Disease 1 1.0
: O 0 4.759838634349478e-10
molecular O 0 3.21266879765858e-09
basis O 0 2.676989296901411e-09
of O 0 2.3639099566707955e-08
phenotypic O 0 1.360093847324606e-06
heterogeneity O 0 2.6804815206560306e-05
. O 0 4.035567144455854e-06

In O 0 6.663558451691642e-07
a O 0 1.8272112356498837e-07
family O 0 4.358988903163663e-08
with O 0 5.436310290818369e-10
three O 0 7.594953999046083e-09
siblings O 0 9.815266110990706e-08
, O 0 2.0117170429490017e-10
one O 0 3.2057259624629353e-10
developed O 0 3.3445250124941595e-08
classical O 0 1.1107627869932912e-05
late O 1 0.9999995231628418
infantile O 1 1.0
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 3.031368578376714e-08
MLD B-Disease 1 1.0
) O 0 3.4042881846829687e-09
, O 0 2.7479085673576265e-10
fatal O 0 2.0042513426687947e-07
at O 0 1.27131878358e-08
age O 0 3.860927577647999e-09
5 O 0 1.4751889487740755e-08
years O 0 1.956499851019089e-09
, O 0 1.194387921898965e-10
with O 0 2.8086127867865684e-10
deficient O 0 3.60991143679712e-05
arylsulfatase O 0 0.00017804927483666688
A O 0 0.0002636449644342065
( O 0 4.1734580236152397e-08
ARSA O 0 5.146964031155221e-05
) O 0 4.5558815053858837e-10
activity O 0 4.375110551624317e-10
and O 0 1.713049979645831e-10
increased O 0 2.0854775684142624e-09
galactosylsulfatide O 0 7.792464771227969e-07
( O 0 8.193625333774435e-09
GS O 0 0.3123073875904083
) O 0 2.2942485689014802e-09
excretion O 0 2.1647155179493893e-08
. O 0 3.073320442581462e-08

The O 0 2.3924333163449774e-06
two O 0 2.8713399657931404e-08
other O 0 3.276501958637823e-09
siblings O 0 6.832830763414677e-07
, O 0 5.057265273222811e-09
apparently O 0 4.3810649685838143e-07
healthy O 0 2.0414363177678752e-07
at O 0 3.0858677746437024e-07
12 O 0 1.4241028800654476e-08
( O 0 6.195212676196604e-10
1 O 0 1.0674442592062405e-06
/ O 0 3.4794882708411023e-07
2 O 0 2.9776862220387557e-07
) O 0 2.6695587407310484e-10
and O 0 1.0071504741304693e-09
15 O 0 4.831626210233253e-09
years O 0 2.280775346363839e-09
, O 0 9.073539142256948e-11
respectively O 0 3.806356341229389e-10
, O 0 5.6709109630403987e-11
and O 0 1.688364725804803e-10
their O 0 2.406526755649452e-09
father O 0 1.0213715313511784e-06
, O 0 2.3145989569428593e-09
apparently O 0 4.336979131380758e-08
healthy O 0 3.393500813686501e-09
as O 0 1.3902162754320102e-09
well O 0 1.534825044835486e-09
, O 0 7.693833903310576e-10
presented O 0 2.419392046704161e-07
ARSA O 1 0.8973851203918457
and O 0 7.390015070996014e-06
GS O 1 1.0
values O 0 2.361494466640579e-08
within O 0 4.6814006005035935e-09
the O 0 2.508958596436628e-09
range O 0 1.4145898674655655e-08
of O 0 4.8415731868090006e-08
MLD B-Disease 1 1.0
patients O 0 5.268875156616559e-06
. O 0 3.8408637692555203e-07

Mutation O 0 3.0452281407633564e-07
screening O 0 9.808772460928594e-08
and O 0 8.841574139495378e-10
sequence O 0 2.6961421983884293e-10
analysis O 0 1.2800964455106367e-10
disclosed O 0 6.5494334400284515e-09
the O 0 1.8537128498863353e-09
involvement O 0 8.4756930363028e-09
of O 0 1.8894279918413304e-08
three O 0 2.5136239756307077e-09
different O 0 5.72936498244303e-09
ARSA O 0 8.230724779423326e-05
mutations O 0 5.189414675754733e-09
being O 0 3.7054126433844203e-09
the O 0 2.3264696835667564e-09
molecular O 0 1.1186741311064452e-08
basis O 0 7.615741814959165e-09
of O 0 8.574689758233944e-08
intrafamilial O 0 1.1818250641226768e-05
phenotypic O 0 6.784548531868495e-06
heterogeneity O 0 0.00010532024316489697
. O 0 6.923469300090801e-06

The O 0 1.100176086765714e-05
late O 0 0.002354850759729743
infantile O 0 0.0033247496467083693
patient O 0 1.8641842416400323e-06
inherited O 0 4.155791975790635e-05
from O 0 2.536966974275856e-07
his O 0 1.0846080840565264e-05
mother O 0 4.360828825156204e-06
the O 0 4.646438753752591e-07
frequent O 0 3.6899688637959116e-08
0 O 0 3.9545550833963716e-08
- O 0 8.237956983236927e-09
type O 0 2.4802069731322263e-08
mutation O 0 1.9786762450735296e-08
459 O 0 1.3390717867878266e-08
+ O 0 9.907198617042923e-09
1G O 0 1.2949482197655016e-07
> O 0 5.6606501708245105e-09
A O 0 6.547534514567133e-09
, O 0 3.0518951948943496e-11
and O 0 7.171219867929679e-11
from O 0 7.563868420490394e-10
his O 0 2.7125528490046236e-08
father O 0 7.669929402709386e-08
a O 0 4.198734249172276e-09
novel O 0 6.68340049969629e-09
, O 0 2.221312578321033e-10
single O 0 4.108156925752837e-09
basepair O 0 8.180620056918997e-07
microdeletion O 0 1.0070262987937895e-06
of O 0 2.949406905372598e-07
guanine O 0 4.381311384804576e-07
at O 0 2.0849027748681692e-07
nucleotide O 0 3.146172034007577e-08
7 O 0 5.568897876173651e-08
in O 0 4.061968539303962e-09
exon O 0 1.435897161172761e-07
1 O 0 1.3987767033540877e-07
( O 0 8.41120673111817e-10
7delG O 0 2.121033588764476e-07
) O 0 4.099429240511654e-09
. O 0 1.124491291193408e-07

The O 0 2.1098639990668744e-06
two O 0 2.185567637980057e-07
clinically O 0 0.00011203082976862788
unaffected O 0 5.9498957853065804e-05
siblings O 0 2.6827185592992464e-06
carried O 0 1.5375331230416123e-08
the O 0 1.990771103521638e-08
maternal O 0 6.523354301180007e-08
mutation O 0 5.770524502679564e-09
459 O 0 1.7248778405587473e-08
+ O 0 1.816369277207741e-08
1G O 0 9.453813731852279e-07
> O 0 2.5838374995146296e-08
A O 0 1.966249740803505e-08
and O 0 7.582964811625459e-10
, O 0 3.939454665258246e-11
on O 0 8.336618062543266e-10
their O 0 1.94051053004074e-10
paternal O 0 9.669470557582827e-09
allele O 0 1.439389163415683e-09
, O 0 2.884102331957017e-11
a O 0 2.715252189755546e-10
novel O 0 1.5152377130789318e-09
cytosine O 0 8.479153379425952e-09
to O 0 2.7994151441390613e-09
thymidine O 0 1.3478424989443738e-06
transition O 0 3.015837819475564e-06
at O 0 2.2862478488150373e-07
nucleotide O 0 1.9297520736927254e-07
2435 O 0 4.658690158976242e-06
in O 0 1.04266524303398e-08
exon O 0 2.0709241255190136e-07
8 O 0 3.3433131818583206e-08
, O 0 4.953620499903444e-11
resulting O 0 4.82181017336103e-10
in O 0 2.3150259487181302e-10
substitution O 0 1.0399323180365627e-08
of O 0 4.378095042056884e-08
alanine O 0 1.0606843403593302e-07
464 O 0 5.9123085094370254e-08
by O 0 4.941829168103595e-09
valine O 0 1.443648329768621e-06
( O 0 4.434950628962042e-09
A464V O 0 6.403492989193182e-07
) O 0 7.751785879861472e-09
. O 0 1.071608224378906e-07

The O 0 1.1423858268244658e-05
fathers O 0 1.2471714398998301e-06
genotype O 0 4.63674012962656e-07
thus O 0 3.27534763755466e-08
was O 0 2.8294303433540335e-07
7delG O 0 2.2815438569523394e-06
/ O 0 1.3931680769019295e-06
A464V O 0 3.040523324671085e-06
. O 0 3.508885697556252e-07

Mutation O 0 1.6478127236041473e-06
A464V O 0 4.143669229961233e-06
was O 0 2.6298445732209075e-07
not O 0 3.4238151203069833e-10
found O 0 9.878023954357218e-10
in O 0 7.541770541408255e-10
18 O 0 2.3481817379433778e-08
unrelated O 0 3.5908194604417076e-06
MLD B-Disease 1 1.0
patients O 0 0.00028167181881144643
and O 0 3.496329554764088e-07
50 O 0 1.3592595848876954e-07
controls O 0 3.9227262504937244e-07
. O 0 6.095228854974266e-07

A464V O 0 4.867613097303547e-05
, O 0 2.356796713343101e-08
although O 0 1.02811092972388e-08
clearly O 0 4.590663849057819e-08
modifying O 0 1.679148340372194e-06
ARSA O 1 0.9981006979942322
and O 0 3.9485289562435355e-06
GS O 1 1.0
levels O 0 4.23587891873467e-07
, O 0 1.986256714658907e-09
apparently O 0 1.8912992061359546e-08
bears O 0 2.415237432273898e-08
little O 0 1.9633521475270754e-09
significance O 0 3.659757163987365e-09
for O 0 1.2781033176256784e-10
clinical O 0 1.940271943112748e-08
manifestation O 0 2.963747647299897e-05
of O 0 0.0008990860660560429
MLD B-Disease 1 1.0
, O 0 8.510752991242043e-08
mimicking O 0 1.313199788910424e-07
the O 0 2.1081693546420865e-07
frequent O 0 6.936654131095565e-07
ARSA O 0 0.0012062841560691595
pseudodeficiency O 0 5.519207479665056e-05
allele O 0 1.2811332226192462e-06
. O 0 4.818730303668417e-07

Our O 0 1.3613223018182907e-05
results O 0 6.319312007008193e-08
demonstrate O 0 2.380106600696763e-08
that O 0 7.342796370934934e-10
in O 0 7.781230659809069e-10
certain O 0 1.5018754018214509e-09
genetic O 0 7.925996925450818e-08
conditions O 0 5.804620286653517e-06
MLD B-Disease 1 1.0
- O 1 0.9999998807907104
like O 0 6.599019252462313e-05
ARSA O 1 1.0
and O 0 4.3711599573725834e-05
GS O 1 1.0
values O 0 3.538022985694056e-09
need O 0 2.268150250950285e-10
not O 0 8.011246180328335e-12
be O 0 1.254757235613635e-11
paralleled O 0 2.0593526883772029e-10
by O 0 2.9268829113832107e-12
clinical O 0 3.075171894906248e-09
disease O 0 5.418820592240081e-08
, O 0 3.339675411218046e-11
a O 0 2.387656738989108e-10
finding O 0 1.8500392329201532e-09
with O 0 1.2465282972495828e-10
serious O 0 5.014525328306263e-08
diagnostic O 0 0.0003841232683043927
and O 0 3.7508780224015936e-06
prognostic O 1 1.0
implications O 0 0.0009097811998799443
. O 0 6.0186037444509566e-05

Moreover O 0 6.2591452660853975e-06
, O 0 1.2950432903835463e-07
further O 0 1.6186682216812187e-07
ARSA O 0 0.0003966931835748255
alleles O 0 6.028940191526999e-08
functionally O 0 1.0793210947213083e-07
similar O 0 1.2942192206821801e-08
to O 0 1.3360001993589776e-08
A464V O 0 2.934833389645064e-07
might O 0 2.500354590040388e-09
exist O 0 7.709846094883233e-10
which O 0 1.5257992092010397e-10
, O 0 3.155133446175462e-11
together O 0 1.8275703866921233e-11
with O 0 9.372463222190319e-11
0 O 0 4.189904245777143e-08
- O 0 9.250923227455132e-08
type O 0 1.8887307078330196e-06
mutations O 0 2.903921370034368e-07
, O 0 1.745392275154245e-09
may O 0 1.227910360057649e-07
cause O 0 0.0001562734105391428
pathological O 1 0.9988068342208862
ARSA O 1 0.9995415210723877
and O 0 1.1201697134310962e-06
GS O 1 1.0
levels O 0 2.802991083683537e-08
, O 0 3.999249195696386e-11
but O 0 4.335299480517918e-12
not O 0 1.7205731197428298e-12
clinical O 0 6.554103371136932e-10
outbreak O 0 2.5396083014328497e-09
of O 0 2.5964932426347787e-09
the O 0 2.4209009907849577e-08
disease O 0 1.2114543324059923e-06
. O 0 9.5930143828582e-09
. O 0 1.1538175925807082e-07

Human O 1 0.9912372827529907
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.014399398118257523
to O 0 2.425019829388475e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 4.812783299712464e-05
neurofibromatosis B-Disease 1 0.9999994039535522
type I-Disease 1 0.6145382523536682
1 I-Disease 0 0.0017153770895674825
. O 0 8.956394594861194e-07

Heterozygous O 0 4.245761374477297e-06
germ O 0 0.0003245812258683145
- O 0 1.7726188161759637e-05
line O 0 6.765079660908668e-07
mutations O 0 2.757544415032953e-09
in O 0 5.363177124628749e-10
the O 0 6.6038987611705124e-09
DNA O 0 3.419296774609393e-07
mismatch O 0 0.00024522541207261384
repair O 0 0.39719849824905396
genes O 0 9.989096838580735e-08
lead O 0 2.2215652961676824e-07
to O 0 1.2041063257584028e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.40169966220855713

The O 0 6.0981515161984134e-06
disease O 0 4.241174246999435e-05
susceptibility O 0 4.275357696315041e-06
of O 0 1.2367675026325742e-06
individuals O 0 7.857686057377578e-09
who O 0 6.714439223287627e-06
constitutionally O 0 0.0004996262723580003
lack O 1 0.9500284790992737
both O 0 1.5358426708189654e-07
wild O 0 1.4668005121620808e-07
- O 0 6.475068481393009e-09
type O 0 3.6289227178798455e-09
alleles O 0 4.758894389667034e-10
is O 0 2.1927215598793737e-10
unknown O 0 9.874260520348344e-09
. O 0 4.057433145021605e-08

We O 0 6.152343701160135e-08
have O 0 1.3258505404678544e-09
identified O 0 3.075553145492904e-09
three O 0 2.6392527052720993e-10
offspring O 0 1.856483300421985e-09
in O 0 2.3134943960556598e-10
a O 0 2.7945246117155875e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 1.0
who O 0 1.5841044387343572e-07
developed O 0 1.7305615983786993e-05
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
at O 0 0.38779905438423157
a O 0 1.6879486963716772e-07
very O 0 7.389585388040132e-09
early O 0 4.0528703948439215e-07
age O 0 1.3751530580918825e-08
, O 0 3.0187816135729406e-10
and O 0 2.952746380735505e-10
at O 0 1.7698577048363973e-09
least O 0 1.7734851781581185e-11
two O 0 4.254726779229223e-11
of O 0 2.728422765496674e-10
them O 0 7.543521363118089e-11
displayed O 0 6.396739582470445e-09
signs O 0 4.010514587093894e-08
of O 0 1.2447735571186058e-06
neurofibromatosis B-Disease 1 0.9996381998062134
type I-Disease 0 0.1166883036494255
1 I-Disease 0 0.0002928243193309754
( O 0 8.284724906104657e-09
NF1 B-Disease 0 5.2879262511851266e-05
) O 0 2.1331272748170704e-08
. O 0 1.3459322190101375e-07

DNA O 0 6.251434570003767e-07
sequence O 0 1.1059237969845981e-08
analysis O 0 2.6723825374830312e-09
and O 0 3.50748985411542e-10
allele O 0 2.585949787636821e-10
- O 0 2.343472360610832e-10
specific O 0 6.055311807529051e-11
amplification O 0 2.8692376474737102e-08
in O 0 1.692615381188034e-09
two O 0 9.23706178213024e-09
siblings O 0 2.066556277213749e-07
revealed O 0 1.7533720608753356e-07
a O 0 2.218541794718476e-07
homozygous O 0 2.708229089876113e-07
MLH1 O 0 4.614574208972044e-05
mutation O 0 5.6526474168094865e-08
( O 0 1.8288693892642982e-09
C676T O 0 1.5600436142904073e-07
- O 0 5.47686852314655e-07
- O 0 1.9926894765376346e-06
> O 0 2.266022192998207e-06
Arg226Stop O 0 6.140436653367942e-06
) O 0 5.349591880587923e-09
. O 0 4.737688286127195e-08

Thus O 0 1.1025098274330958e-06
, O 0 2.7104116284704105e-08
a O 0 4.421978516688796e-08
homozygous O 0 2.1817213280428405e-07
germ O 0 0.010227781720459461
- O 0 0.0015797046944499016
line O 0 0.00019920041086152196
MLH1 O 1 0.994629442691803
mutation O 0 4.393210701891803e-07
and O 0 1.5436450340189367e-08
consequent O 0 0.00046395423123613
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 0.9999998807907104
results O 0 5.2500276126465906e-08
in O 0 1.2698453843995594e-08
a O 0 5.3990437010043024e-08
mutator O 0 8.372790034627542e-05
phenotype O 0 2.1638285829794768e-07
characterized O 0 7.065782403614662e-10
by O 0 8.860612937811041e-11
leukemia B-Disease 1 0.9999727010726929
and O 0 1.7558466424816288e-05
/ O 1 1.0
or O 1 0.9999983310699463
lymphoma B-Disease 1 1.0
associated O 0 0.000237349042436108
with O 0 4.27026165539246e-08
neurofibromatosis B-Disease 0 0.3835127353668213
type I-Disease 0 8.057677405304275e-06
1 I-Disease 0 4.375367097964045e-06
. O 0 2.263796083923353e-08
. O 0 1.8226825204692432e-07

Missense O 0 0.00023662715102545917
mutations O 0 1.3286074818097404e-06
in O 0 8.320930078298261e-08
the O 0 6.305057098643374e-08
most O 0 2.0687391799611987e-09
ancient O 0 3.618529120785752e-08
residues O 0 3.637142853563091e-08
of O 0 8.462612299808825e-08
the O 0 1.9776392434778245e-07
PAX6 O 0 0.0005786935216747224
paired O 0 1.5080109960763366e-07
domain O 0 5.2145598061770215e-08
underlie O 0 1.4845208795577491e-07
a O 0 2.0591663485447498e-08
spectrum O 0 1.4059119166631717e-06
of O 0 3.507022654503089e-07
human O 1 0.9662174582481384
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9863467812538147

Mutations O 0 1.820941690766631e-07
of O 0 1.1954152512316796e-07
the O 0 3.623128463914327e-08
human O 0 7.951298641728499e-08
PAX6 O 0 0.004690877161920071
gene O 0 7.263180123118218e-06
underlie O 1 0.9870234727859497
aniridia B-Disease 1 1.0
( O 0 0.02117859199643135
congenital B-Disease 1 1.0
absence I-Disease 1 0.6582114100456238
of I-Disease 1 0.9999890327453613
the I-Disease 0 0.030110981315374374
iris I-Disease 0 0.031995564699172974
) O 0 1.0003234907074443e-09
, O 0 1.8328773221387706e-10
a O 0 3.772160539483593e-08
rare O 0 0.007832871749997139
dominant O 1 1.0
malformation B-Disease 1 1.0
of I-Disease 1 1.0
the I-Disease 1 1.0
eye I-Disease 1 1.0
. O 0 0.0001360835594823584

The O 0 2.8922213459736668e-06
spectrum O 0 1.0718290468503255e-05
of O 0 1.0539894219618873e-06
PAX6 O 0 0.182809978723526
mutations O 0 5.790250838799693e-07
in O 0 8.34854319009537e-08
aniridia B-Disease 1 1.0
patients O 0 7.404815733025316e-06
is O 0 1.5371922623685919e-09
highly O 0 1.3663156162024848e-09
biased O 0 3.837778095316935e-09
, O 0 7.643746746666125e-11
with O 0 2.29734668788506e-11
92 O 0 1.0555456064764712e-08
% O 0 1.7088794268538265e-10
of O 0 7.191852113841435e-10
all O 0 2.0457524563255447e-10
reported O 0 1.8553080183281168e-09
mutations O 0 1.0580586407016312e-09
leading O 0 5.2569792963197415e-09
to O 0 2.599010118231604e-09
premature O 0 2.717680729347194e-07
truncation O 0 1.020406671159435e-05
of O 0 1.8429775082040578e-05
the O 0 7.194272484412068e-07
protein O 0 3.4560731165811376e-08
( O 0 2.375904195606182e-10
nonsense O 0 1.4000895554033832e-08
, O 0 2.418563127548623e-10
splicing O 0 5.080568143966957e-08
, O 0 2.681909416768491e-10
insertions O 0 9.130491918085681e-09
and O 0 1.2824139528078149e-09
deletions O 0 8.46790459974045e-09
) O 0 5.411389114584608e-10
and O 0 4.095841887874485e-09
just O 0 2.5725467978077177e-08
2 O 0 1.611665823020303e-07
% O 0 7.622203979096298e-10
leading O 0 9.424705460503446e-10
to O 0 1.5686883736432122e-10
substitution O 0 1.6253656198728095e-08
of O 0 2.6467063207746833e-08
one O 0 9.580063409231343e-10
amino O 0 3.3718719483211146e-10
acid O 0 1.447057612624647e-10
by O 0 8.790686234494416e-11
another O 0 7.713085281579879e-09
( O 0 2.867780679594034e-09
missense O 0 4.859591058448132e-07
) O 0 1.5800889485717562e-08
. O 0 1.7370248883707973e-07

The O 0 2.436517888781964e-06
extraordinary O 0 3.599881210902822e-07
conservation O 0 1.2808432359179278e-07
of O 0 2.515447405926352e-08
the O 0 4.735221992291372e-08
PAX6 O 0 2.4316559574799612e-05
protein O 0 1.3663532172358828e-07
at O 0 1.0917226234141708e-08
the O 0 2.851298530615054e-09
amino O 0 1.8744202634479734e-08
acid O 0 9.55375938360703e-08
level O 0 1.8848571414764592e-07
amongst O 0 6.552984643803939e-08
vertebrates O 0 6.414488211703429e-07
predicts O 0 5.531314961615408e-09
that O 0 7.260157475208473e-10
pathological O 0 1.8196274140791502e-06
missense O 0 6.657365361206757e-07
mutations O 0 2.49857157186284e-09
should O 0 5.801720770470808e-10
in O 0 4.762572003436105e-10
fact O 0 3.646460910999849e-10
be O 0 3.479377896908886e-10
common O 0 4.299944400543154e-09
even O 0 8.429772435647465e-10
though O 0 2.1253397652909456e-10
they O 0 1.0823458795883312e-10
are O 0 1.7891412310011567e-11
hardly O 0 7.938006696406319e-09
ever O 0 8.893435321510879e-09
seen O 0 1.9809004214721426e-08
in O 0 3.636574064103115e-08
aniridia B-Disease 1 1.0
patients O 0 2.0679672161350027e-05
. O 0 9.490896104580315e-07

This O 0 3.864149178411935e-08
indicates O 0 1.4414174742682917e-08
that O 0 3.3202038340895967e-10
there O 0 4.097449879392201e-10
is O 0 2.923660757936375e-10
a O 0 2.0792458865770413e-09
heavy O 0 9.115649390878389e-07
ascertainment O 0 7.96892709331587e-05
bias O 0 3.2669686333974823e-07
in O 0 3.900073597407072e-09
the O 0 3.855246788475597e-09
selection O 0 3.3591125436771563e-09
of O 0 4.51957626879107e-09
patients O 0 1.941755645162857e-09
for O 0 6.503148575198736e-10
PAX6 O 0 2.1685957563022384e-06
mutation O 0 8.908405124685714e-10
analysis O 0 2.8644173144520835e-10
and O 0 1.4624934596696448e-10
that O 0 7.293547710229831e-11
the O 0 4.964609701119116e-08
missing O 0 8.607373274571728e-06
PAX6 O 1 0.9989320635795593
missense O 0 0.00021607338567264378
mutations O 0 3.9725858869132935e-07
frequently O 0 1.896164469883388e-08
may O 0 2.522837405649625e-08
underlie O 0 1.7832418279795093e-06
phenotypes O 0 9.52311950186413e-07
distinct O 0 1.2755967304656224e-07
from O 0 1.9400135897740256e-07
textbook O 0 2.347162808291614e-05
aniridia B-Disease 1 1.0
. O 0 1.822260492190253e-05

Here O 0 4.755415261570306e-07
we O 0 6.537726360278384e-09
present O 0 4.214500304300373e-09
four O 0 2.9173785609515335e-09
novel O 0 4.0798763478733235e-08
PAX6 O 0 3.452032615314238e-05
missense O 0 1.0417369367132778e-06
mutations O 0 8.631165115957629e-09
, O 0 3.7401182151342027e-10
two O 0 3.1711833159420166e-10
in O 0 6.858273393639536e-10
association O 0 2.25199903169937e-09
with O 0 6.562609344840098e-10
atypical O 0 1.631908344279509e-05
phenotypes O 0 0.0005358920898288488
ectopia B-Disease 0 0.005330256186425686
pupillae I-Disease 0 0.00011813777382485569
( O 0 1.2688133876892493e-09
displaced B-Disease 0 3.1773241815358233e-09
pupils I-Disease 0 4.245975571137706e-09
) O 0 2.596062476101224e-09
and O 0 3.0359925062839466e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 0 0.04264716058969498
( O 0 5.745498299347673e-08
searching B-Disease 0 4.6833949340907566e-07
gaze I-Disease 0 1.982402636713232e-06
) O 0 1.024279883132806e-09
, O 0 2.183544040024188e-10
and O 0 1.6193925089780237e-09
two O 0 2.556969747047333e-09
in O 0 3.294995831737424e-09
association O 0 5.528991708914077e-10
with O 0 3.3334340843182986e-10
more O 0 1.0631706626185178e-09
recognizable O 0 2.2420657842303626e-05
aniridia B-Disease 1 1.0
phenotypes O 0 9.767078881850466e-05
. O 0 1.9390013221709523e-06

Strikingly O 0 3.847389598377049e-05
, O 0 1.1748556261181875e-07
all O 0 6.325858059597067e-09
four O 0 3.095244061057656e-09
mutations O 0 4.42229475261513e-10
are O 0 1.3797916975644142e-10
located O 0 1.0841796793670255e-08
within O 0 7.37069560940995e-09
the O 0 2.6293128030374646e-07
PAX6 O 0 0.00013315312389750034
paired O 0 8.141473273326483e-08
domain O 0 2.411881361297219e-08
and O 0 1.4093080036303718e-09
affect O 0 1.704576590988438e-09
amino O 0 8.239603443982446e-10
acids O 0 2.3545207450403893e-10
which O 0 4.1656421367886054e-11
are O 0 9.663924174785343e-12
highly O 0 7.426715353808788e-10
conserved O 0 3.073160614874837e-09
in O 0 9.994309824179481e-10
all O 0 7.888330544325584e-10
known O 0 4.841699929869492e-09
paired O 0 6.560760379414887e-09
domain O 0 1.0653065984911336e-08
proteins O 0 1.3645029550701793e-09
. O 0 1.0870143896113404e-08

Our O 0 1.932783743541222e-05
results O 0 2.554792786213511e-07
support O 0 2.1349940482195962e-07
the O 0 3.68678172435466e-08
hypothesis O 0 1.1429769131154899e-08
that O 0 1.8957386008211508e-11
the O 0 2.0468765571379777e-10
under O 0 1.3914578378404485e-09
- O 0 3.213177501848463e-09
representation O 0 2.1539281469529215e-09
of O 0 3.9167591836530846e-08
missense O 0 2.028419430644135e-06
mutations O 0 4.078981419297634e-08
is O 0 1.320797360371273e-09
caused O 0 9.082448571007262e-09
by O 0 9.128745537267946e-10
ascertainment O 0 3.9102003938751295e-05
bias O 0 4.840160272578942e-07
and O 0 8.55237480834603e-09
suggest O 0 6.755088710619361e-10
that O 0 6.778821254327383e-11
a O 0 7.216998665349195e-10
substantial O 0 5.722091245274896e-09
burden O 0 2.4591096803305845e-07
of O 0 1.1337057230775827e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.8813325762748718
related I-Disease 0 9.393282380187884e-05
disease I-Disease 1 0.9999973773956299
remains O 0 7.49319838178053e-07
to O 0 6.179787792603975e-10
be O 0 1.1071178418475824e-09
uncovered O 0 1.0375156733744006e-07
. O 0 6.59504939548583e-09
. O 0 7.023463410860131e-08

The O 0 1.5858532833590289e-06
chromosomal O 0 5.517184490599902e-06
order O 0 3.916670152648294e-07
of O 0 1.1832150903501315e-06
genes O 0 2.43761434148837e-07
controlling O 0 3.986141905443219e-07
the O 0 1.9367225831956603e-06
major O 0 0.00011979763075942174
histocompatibility O 1 1.0
complex O 1 0.998384952545166
, O 0 8.057999600907806e-09
properdin O 0 3.079035764130822e-07
factor O 0 6.348436443204264e-09
B O 0 3.7853106960028526e-07
, O 0 3.9192366019236147e-10
and O 0 1.5538118569580206e-09
deficiency B-Disease 0 1.428388168278616e-05
of I-Disease 0 3.342039781273343e-05
the I-Disease 0 3.5850025597028434e-06
second I-Disease 0 6.095688149798661e-07
component I-Disease 0 1.1324150506197839e-07
of I-Disease 0 4.814701526356657e-08
complement I-Disease 0 2.312994240583066e-07
. O 0 1.0110950370290084e-06

The O 0 2.0143720576015767e-06
relationship O 0 1.8284104896792996e-07
of O 0 4.2805001498891215e-07
the O 0 3.250019631195755e-08
genes O 0 1.3779959395776586e-09
coding O 0 3.087992439532172e-08
for O 0 3.2211731060272086e-09
HLA O 0 1.1713125758205933e-07
to O 0 3.160919082034752e-09
those O 0 6.617377312778672e-09
coding O 0 2.690551070827496e-07
for O 0 9.467987283073853e-09
properdin O 0 5.010356858292653e-07
Factor O 0 9.994963079407171e-09
B O 0 1.0949699458251416e-07
allotypes O 0 1.7502178195627494e-07
and O 0 9.079049734239675e-10
for O 0 6.39987229877903e-10
deficiency B-Disease 0 2.6424397674418287e-06
of I-Disease 0 6.004868737363722e-06
the I-Disease 0 4.130385150347138e-06
second I-Disease 0 1.0312688800695469e-06
component I-Disease 0 5.200456030252099e-07
of I-Disease 0 1.3819980893003958e-07
complement I-Disease 0 4.5499550793692833e-08
( O 0 5.539634528872739e-09
C2 O 0 5.5270358956249765e-08
) O 0 1.5455703383793207e-10
was O 0 2.397812171039959e-09
studied O 0 5.839645433880492e-10
in O 0 5.476113659752535e-11
families O 0 4.32710707543027e-11
of O 0 2.55391735537458e-10
patients O 0 7.723740536036416e-10
with O 0 4.790945418164938e-09
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 8.269319368992001e-05

Patients O 0 7.563019607914612e-06
were O 0 9.471368400681968e-08
selected O 0 7.13579240141371e-09
because O 0 1.4757172150936526e-09
they O 0 5.940868352816153e-10
were O 0 2.1355319734794875e-09
heterozygous O 0 8.116580740846757e-10
or O 0 2.9005784440983007e-09
homozygous O 0 7.134639190553571e-08
for O 0 1.7181868372517783e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.6748299458413385e-05

12 O 0 9.641325959819369e-06
families O 0 8.830021158701129e-08
with O 0 6.254449402831597e-09
15 O 0 5.5536126808419795e-08
matings O 0 2.4836167540343013e-06
informative O 0 1.7601773549813515e-07
for O 0 3.862779180963116e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.027213514248615e-07
found O 0 1.62612217025071e-08
. O 0 5.845635087098344e-08

Of O 0 6.440240395022556e-05
57 O 0 9.557917110214476e-06
informative O 0 3.356780098329182e-07
meioses O 0 9.019403478305321e-06
, O 0 8.647544014195319e-09
two O 0 1.467887922323996e-09
crossovers O 0 5.386368684412446e-09
were O 0 4.582945134501415e-09
noted O 0 6.898869475691072e-09
between O 0 6.65225670104519e-08
the O 0 5.95485107623972e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999998927116394
gene O 0 2.2878599015285772e-09
and O 0 3.117121838425163e-10
the O 0 1.152397954840012e-09
HLA O 0 4.833690780969846e-09
- O 0 8.552570207598365e-09
B O 0 1.5999743752104223e-08
gene O 0 2.1804974492667384e-10
, O 0 1.5394588381845153e-11
with O 0 2.540098556838566e-12
a O 0 1.9098793380134538e-10
recombinant O 0 1.5748078396882192e-09
fraction O 0 3.8467922180984715e-09
of O 0 1.5640925710158626e-07
0 O 0 3.391008931430406e-07
. O 0 1.7457568901591003e-07

035 O 0 0.021034669131040573
. O 0 6.673987809335813e-05

A O 0 2.481006049492862e-05
lod O 0 0.0003681505040731281
score O 0 1.8776908063955489e-06
of O 0 1.1261745385127142e-06
13 O 0 3.436760778185999e-07
was O 0 1.231737343232453e-07
calculated O 0 7.829560111360934e-09
for O 0 1.7507870708755036e-09
linkage O 0 1.0107189609698253e-06
between O 0 9.095694508687302e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 2.1299641161931504e-08
HLA O 0 2.9504972687277586e-08
- O 0 1.645459946075789e-08
B O 0 6.385064210689961e-08
at O 0 1.3578566049332608e-09
a O 0 5.71774363966604e-11
maximum O 0 1.0347179363323633e-10
likelihood O 0 1.7411919128740294e-10
value O 0 1.1153706430677701e-10
of O 0 4.957772525848725e-10
the O 0 4.295155064948375e-10
recombinant O 0 1.0943822514875023e-09
fraction O 0 2.071969484873648e-09
of O 0 1.6923708656690906e-08
0 O 0 1.4217368971003452e-07
. O 0 8.57694786304819e-08

04 O 0 0.007716050837188959
. O 0 7.291737711057067e-05

18 O 0 4.089228241355158e-06
families O 0 3.1442404235804133e-08
with O 0 4.779108220276385e-09
21 O 0 1.0134139927231445e-07
informative O 0 7.952978720027204e-09
matings O 0 1.09506608225729e-07
for O 0 9.183517057920199e-09
both O 0 1.1791779108705214e-08
properdin O 0 6.448710792028578e-06
Factor O 0 1.9410906304528908e-07
B O 0 4.0942671830634936e-07
allotype O 0 3.4732289577732445e-07
and O 0 6.025179466462305e-09
HLA O 0 6.761062820714869e-08
- O 0 7.15637682446868e-08
B O 0 2.569605328517355e-07
were O 0 5.648850720518794e-09
found O 0 8.993240818711001e-09
. O 0 5.0861821421221975e-08

Of O 0 0.00010390571696916595
72 O 0 1.6479321857332252e-05
informative O 0 3.710029545800353e-07
meioses O 0 1.567649087519385e-05
, O 0 9.5487635576319e-09
three O 0 6.277994568648637e-09
recombinants O 0 1.8389779370409087e-06
were O 0 1.926377457550643e-08
found O 0 3.206229060026544e-09
, O 0 1.7325356427289051e-10
giving O 0 1.0599385952270168e-10
a O 0 7.576835270306503e-10
recombinant O 0 1.8626370446028773e-09
fraction O 0 1.2317838304909401e-08
of O 0 5.333548074304417e-07
0 O 0 1.245716475750669e-06
. O 0 5.163411742614699e-07

042 O 0 0.007443523500114679
. O 0 4.818740126211196e-05

A O 0 2.5338518753414974e-05
lod O 0 0.00029736675787717104
score O 0 1.0159061503145494e-06
of O 0 1.2949891470270813e-06
16 O 0 2.010089446002894e-07
between O 0 3.246166357939728e-08
HLA O 0 1.9248061278176465e-07
- O 0 9.444994475416024e-08
B O 0 2.548417228354083e-07
and O 0 1.8004501223245484e-09
Factor O 0 7.664778145510809e-09
B O 0 5.7201084757707577e-08
allotypes O 0 2.205732130278193e-07
was O 0 1.8502660736885446e-08
calculated O 0 9.705422021610843e-10
at O 0 7.927032363852504e-10
a O 0 2.4946511523182835e-10
maximum O 0 1.1936962529546236e-09
likelihood O 0 1.9246944038542324e-09
value O 0 4.237818429508877e-10
of O 0 1.0008999185018297e-09
the O 0 7.222396569694922e-10
recombinant O 0 2.009539867842136e-09
fraction O 0 4.4343750893460765e-09
of O 0 5.737854280596366e-08
0 O 0 2.837466297478386e-07
. O 0 1.0896780366920211e-07

04 O 0 0.005594209767878056
. O 0 5.031433829572052e-05

A O 0 1.4378911146195605e-05
crossover O 0 2.1550465589825762e-06
was O 0 6.915418566677545e-07
shown O 0 4.704494571683426e-09
to O 0 1.7480442648931671e-09
have O 0 8.224420033897673e-10
occurred O 0 2.1783048254064852e-08
between O 0 3.133090453744103e-10
genes O 0 1.3216761018952639e-10
for O 0 7.663952111824912e-11
Factor O 0 1.1030119040356112e-09
B O 0 3.3101468233098785e-08
and O 0 5.738420405521083e-09
HLA O 0 8.15001897080947e-08
- O 0 3.2636307878419757e-07
D O 0 7.227811238408322e-07
, O 0 1.132603011377853e-09
in O 0 9.457369332110943e-10
which O 0 7.525274292596862e-10
HLA O 0 2.9577657656432166e-08
- O 0 4.170195921915365e-08
D O 0 1.8983942595696135e-07
segregared O 0 6.457631229750405e-07
with O 0 2.31390151483879e-09
HLA O 0 2.6107130679520196e-07
- O 0 1.6497942567639257e-07
A O 0 8.079962867668655e-07
and O 0 6.956721421147449e-08
B O 0 4.545645424514078e-06
. O 0 3.23759678622082e-07

These O 0 1.3240114782320234e-08
studies O 0 2.549567446052947e-09
suggest O 0 2.8602242796438304e-10
that O 0 2.307623016284399e-11
the O 0 4.0479830598627586e-10
genes O 0 8.155402742016093e-11
for O 0 6.420470405332779e-11
Factor O 0 1.0168716535474687e-08
B O 0 0.07853958755731583
and O 0 0.00010472167195985094
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.7297430154883386e-09
located O 0 5.93308024932071e-09
outside O 0 2.0898138775038433e-09
those O 0 1.2176339103664446e-10
for O 0 5.776280564973035e-10
HLA O 0 8.951572993964874e-08
, O 0 2.023863299172035e-10
that O 0 9.492026609159154e-11
the O 0 6.119665219017634e-09
order O 0 1.689822681782971e-08
of O 0 1.0310353104614478e-07
genese O 0 7.50068409161031e-07
is O 0 2.102896967670631e-09
HLA O 0 6.674738095568955e-09
- O 0 5.718251205877323e-09
A O 0 5.411807535438129e-08
, O 0 1.9588175526052964e-10
- O 0 1.7389789608301953e-09
B O 0 2.493982975693143e-08
, O 0 8.169387388790028e-10
- O 0 2.5004940340522808e-08
D O 0 9.147281332388957e-08
, O 0 7.230197551777451e-10
Factor O 0 2.2675727961996017e-08
B O 0 6.0285547078819945e-06
allotype O 0 0.00015753837942611426
, O 0 3.5539974874154723e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 3.065419862391394e-10
that O 0 2.6141713793670363e-11
the O 0 2.6079585158100826e-09
genes O 0 2.5558775096357067e-09
coding O 0 7.382685112133913e-07
for O 0 1.1626385543195283e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.925234702885973e-08
Factor O 0 2.6801735941717197e-08
B O 0 4.939212061572107e-08
allotypes O 0 5.5944379795391797e-08
are O 0 6.872543506508677e-11
approximately O 0 1.0459567240106438e-10
3 O 0 2.0920871701690658e-09
- O 0 2.9974451809522407e-09
- O 0 2.391930031819811e-08
5 O 0 2.3988564024080006e-08
centimorgans O 0 1.3550247501825652e-07
from O 0 4.009778287183963e-09
the O 0 2.0453562399325165e-08
HLA O 0 1.9548519247791774e-08
- O 0 1.9381968030529606e-08
A O 0 9.111914778259234e-08
and O 0 4.945525322597177e-09
HLA O 0 4.159074862286616e-08
- O 0 6.386245132716795e-08
B O 0 7.475411933910436e-08
loci O 0 8.251918037771588e-10
, O 0 5.255329851849844e-11
and O 0 3.334189174752922e-11
that O 0 1.785169928547603e-11
the O 0 4.320727775564137e-09
apparent O 0 1.5476463488539594e-07
lack O 0 3.245912978400156e-07
of O 0 2.6257687579800404e-08
recombinants O 0 5.296333682736076e-08
between O 0 4.208963455543113e-10
the O 0 1.6528036717033956e-09
Factor O 0 1.037070163079079e-08
B O 0 1.1108379567303928e-06
gene O 0 2.9837659099030134e-07
and O 0 2.5662404823378893e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 3.2368678404282036e-08
suggests O 0 5.236321931612054e-10
that O 0 6.59779479314504e-12
these O 0 1.1414153476552169e-11
two O 0 1.3393106068626537e-10
genes O 0 4.88240836649112e-10
lie O 0 1.3588522307372841e-08
in O 0 2.3958097727927452e-09
close O 0 1.943895284739483e-07
proximity O 0 3.6171193187328754e-06
to O 0 7.276772606701343e-08
one O 0 4.722171098592298e-08
another O 0 1.630926647067099e-07
. O 0 8.166019824784598e-07

Distribution O 0 7.045333063615544e-07
of O 0 1.8910105836766888e-06
emerin O 0 0.00014765755622647703
and O 0 2.331884587647437e-07
lamins O 0 0.0009067056817002594
in O 0 1.6186650952931814e-07
the O 0 1.475767930969596e-06
heart O 0 0.0001483117521274835
and O 0 1.01645287742258e-08
implications O 0 4.904206818423518e-08
for O 0 1.5409622022843905e-08
Emery B-Disease 1 0.999983549118042
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0002431190077913925

Emerin O 0 0.0017734557623043656
is O 0 5.277164518702193e-07
a O 0 1.7368243732107658e-07
nuclear O 0 5.368380584513943e-07
membrane O 0 2.0774708175963497e-08
protein O 0 2.689810152389782e-09
which O 0 1.264145732537969e-10
is O 0 2.437429980073347e-10
missing O 0 1.9337067058700086e-08
or O 0 4.467671566033005e-09
defective O 0 1.9393360162212048e-06
in O 0 2.660321456460224e-07
Emery B-Disease 1 0.9999992847442627
- I-Disease 1 1.0
Dreifuss I-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 2.719943950069137e-06
EDMD B-Disease 1 1.0
) O 0 6.142728636859829e-08
. O 0 2.3632860290945246e-07

It O 0 2.0436569059256726e-07
is O 0 1.2383774894431099e-08
one O 0 3.792184344320049e-09
member O 0 2.304449520096341e-09
of O 0 1.1932916876844502e-08
a O 0 3.7907689431904146e-08
family O 0 5.9374301031311916e-08
of O 0 1.1278732614528053e-07
lamina O 1 0.9995905756950378
- O 0 0.00034269047318957746
associated O 0 5.25786958860408e-07
proteins O 0 1.1361558360789559e-09
which O 0 2.7068958186049485e-10
includes O 0 8.88541074051119e-10
LAP1 O 0 2.020333158725407e-05
, O 0 8.719042376981179e-09
LAP2 O 0 4.0436476410832256e-05
and O 0 3.2336561162082944e-07
lamin O 0 2.7513167879078537e-05
B O 0 7.917549737612717e-06
receptor O 0 1.0859950805297558e-07
( O 0 1.837463736720224e-09
LBR O 0 1.598399535396311e-06
) O 0 5.3827533541550565e-09
. O 0 6.576787825451902e-08

A O 0 7.387166988337412e-05
panel O 0 2.523194780224003e-06
of O 0 5.36160257524898e-07
16 O 0 5.1420748548025585e-08
monoclonal O 0 4.593589508772311e-08
antibodies O 0 9.092453012726764e-08
( O 0 1.186645981476886e-08
mAbs O 0 8.355104910151567e-07
) O 0 3.283871619075285e-09
has O 0 5.16001963379864e-10
been O 0 1.0856110455037538e-09
mapped O 0 5.831299887404384e-09
to O 0 1.0279476159169576e-09
six O 0 1.1716132508610144e-09
specific O 0 1.0128411442877905e-09
sites O 0 8.614290614161746e-09
throughout O 0 3.596865916222214e-09
the O 0 2.954337929850226e-08
emerin O 0 1.9500708958730684e-07
molecule O 0 1.5376878659267845e-09
using O 0 1.8775825338934737e-09
phage O 0 6.0976210747298865e-09
- O 0 2.0693439850560935e-08
displayed O 0 2.67825073230199e-09
peptide O 0 7.46740003165769e-09
libraries O 0 3.3943161614757855e-09
and O 0 1.2464671517165016e-09
has O 0 2.7002233782269514e-10
been O 0 1.572103003333325e-10
used O 0 6.841589517136981e-10
to O 0 1.3643676188834775e-09
localize O 0 5.995170795358717e-07
emerin O 0 2.5614826881792396e-06
in O 0 2.466826076741313e-09
human O 0 1.2438458263375196e-08
and O 0 4.131544528718223e-08
rabbit O 0 8.523101132595912e-05
heart O 0 0.00027541929739527404
. O 0 3.8546245377801824e-06

Several O 0 1.9264255115558626e-06
mAbs O 0 1.052766583597986e-05
against O 0 3.0092937208792137e-07
different O 0 3.465769893296056e-08
emerin O 0 1.685832285147626e-05
epitopes O 0 2.21363961827592e-06
did O 0 3.0092188296748645e-08
not O 0 1.5025802824197854e-09
recognize O 0 6.275731934124451e-09
intercalated O 0 3.228404011679231e-06
discs O 0 1.989009888347937e-06
in O 0 2.402015297775506e-08
the O 0 3.219167012957769e-07
heart O 0 2.8702543204417452e-05
, O 0 7.196379603335856e-10
though O 0 5.068870878588427e-10
they O 0 3.1585670190459325e-10
recognized O 0 2.40528774675397e-09
cardiomyocyte O 0 3.171640798882436e-07
nuclei O 0 1.522548416232894e-07
strongly O 0 3.02511331540245e-08
, O 0 2.6502713357245966e-09
both O 0 6.629189197582264e-09
at O 0 3.879702603626356e-07
the O 0 1.1813011724370881e-07
rim O 0 1.115760937864252e-06
and O 0 1.2989477049529796e-08
in O 0 1.3595521153320078e-08
intranuclear O 0 4.117551725357771e-06
spots O 0 3.7625679283337377e-07
or O 0 1.0194044364197907e-07
channels O 0 4.634759704913449e-07
. O 0 1.8871774898343574e-07

A O 0 4.521010851021856e-05
polyclonal O 0 0.0003022291057277471
rabbit O 0 7.885457307565957e-05
antiserum O 0 2.4196157028200105e-05
against O 0 3.1614051749784267e-06
emerin O 0 0.0014387790579348803
did O 0 4.1003275441653386e-07
recognize O 0 8.5458559340168e-08
both O 0 4.392925490037669e-08
nuclear O 0 1.2826710644731065e-06
membrane O 0 4.152733268369957e-08
and O 0 6.478684255739608e-10
intercalated O 0 1.8087289888057967e-08
discs O 0 3.032473117059453e-08
but O 0 1.2698979645620057e-09
, O 0 3.5132077802479955e-10
after O 0 7.480514874202981e-09
affinity O 0 1.019083217812522e-08
purification O 0 3.689575294174574e-07
against O 0 5.945623726688609e-08
a O 0 5.694689519941676e-08
pure O 0 9.336947641713778e-07
- O 0 4.915210070066678e-07
emerin O 0 3.2147659112524707e-06
band O 0 3.514894331146934e-07
on O 0 1.0690155960446646e-07
a O 0 9.886774066103499e-09
western O 0 1.5365898775598907e-07
blot O 0 1.1710680155374575e-05
, O 0 3.928758651738917e-09
it O 0 6.412714248504869e-10
stained O 0 4.545905539998785e-06
only O 0 1.158635765108329e-08
the O 0 4.271190690019466e-08
nuclear O 0 5.958212909717986e-07
membrane O 0 7.014894549683959e-07
. O 0 2.0955653212695324e-07

These O 0 2.0416153745372867e-07
results O 0 3.996555619778519e-08
would O 0 5.340070163839528e-09
not O 0 6.750993097881519e-10
be O 0 6.847294398149018e-10
expected O 0 1.9737873557801322e-08
if O 0 7.795376788521935e-09
immunostaining O 0 3.685049705381971e-06
at O 0 6.664613749762793e-08
intercalated O 0 1.229596620078155e-07
discs O 0 2.425056209176546e-07
were O 0 7.8619430965432e-09
due O 0 3.621053110691719e-07
to O 0 4.58935733860244e-09
a O 0 5.570934824561391e-09
product O 0 2.1049393339467315e-09
of O 0 7.266855561738339e-08
the O 0 6.80464822266913e-08
emerin O 0 2.5128923653028323e-07
gene O 0 2.028250456476144e-09
and O 0 7.920866185173736e-10
, O 0 7.416010167071718e-11
therefore O 0 1.953002426446915e-09
, O 0 5.802262559306826e-10
cast O 0 4.0994687644513306e-09
some O 0 1.974764657353134e-10
doubt O 0 1.0808903994075081e-08
upon O 0 9.78236780468933e-09
the O 0 3.918819935222473e-09
hypothesis O 0 1.26332748706659e-08
that O 0 1.217007605802678e-09
cardiac B-Disease 0 0.20802874863147736
defects I-Disease 0 0.34627243876457214
in O 0 8.33807860090019e-07
EDMD B-Disease 1 1.0
are O 0 2.5176076334787467e-08
caused O 0 2.405367638402822e-07
by O 0 2.6885536019705114e-09
absence O 0 6.697669618915825e-07
of O 0 4.529141733655706e-06
emerin O 0 4.2473595385672525e-05
from O 0 3.6104978562434553e-07
intercalated O 0 1.2416918252711184e-05
discs O 0 3.105988071183674e-05
. O 0 3.451743395999074e-06

Although O 0 4.05182163376594e-06
emerin O 0 0.0003278673975728452
was O 0 3.2092157198349014e-06
abundant O 0 2.1593181998014188e-07
in O 0 2.2940997990161804e-09
the O 0 6.1842722054450405e-09
membranes O 0 3.0540313389337825e-08
of O 0 4.912913809107522e-08
cardiomyocyte O 0 7.66676862440363e-07
nuclei O 0 7.074756354086276e-07
, O 0 3.981245555451096e-09
it O 0 2.297563472808406e-09
was O 0 1.4283594964581425e-06
absent O 0 2.0237153819380183e-07
from O 0 5.2363646751985016e-09
many O 0 1.0162120034351574e-09
non O 0 4.44787140452263e-08
- O 0 5.398291023084312e-07
myocyte O 0 3.1025626867631217e-06
cells O 0 9.355897390150858e-09
in O 0 3.369347023607361e-09
the O 0 1.2943949911914387e-07
heart O 0 1.9861075998051092e-05
. O 0 9.583221753928228e-07

This O 0 4.789751173461809e-08
distribution O 0 4.538842901524731e-08
of O 0 8.944199691995891e-08
emerin O 0 1.7219364281118033e-06
was O 0 5.896530907989472e-08
similar O 0 5.081261522654756e-10
to O 0 3.827578531900855e-10
that O 0 1.3749155980402605e-10
of O 0 2.059920589658759e-08
lamin O 0 1.8299365365237463e-06
A O 0 2.427395315862668e-07
, O 0 5.324669039019625e-10
a O 0 1.2928343950946442e-09
candidate O 0 1.0955748530605547e-09
gene O 0 3.3127270371302586e-10
for O 0 2.8563265641601276e-10
an O 0 2.2047660919177758e-10
autosomal O 0 1.121263171199871e-08
form O 0 3.144313041048008e-07
of O 1 1.0
EDMD B-Disease 1 1.0
. O 0 0.01862293854355812

In O 0 5.958855240351113e-07
contrast O 0 8.695651558809914e-07
, O 0 1.6717426376544609e-07
lamin O 0 0.00018248523701913655
B1 O 0 9.040720760822296e-05
was O 0 6.237895831873175e-06
absent O 0 8.996003657557594e-07
from O 0 3.3504694130215285e-08
cardiomyocyte O 0 9.82786218628462e-07
nuclei O 0 7.169102218540502e-07
, O 0 3.0810369811007376e-09
showing O 0 1.3952322852617272e-08
that O 0 2.947178856516075e-08
lamin O 0 0.0006939694285392761
B1 O 0 2.653013143572025e-05
is O 0 2.8488740255738776e-09
not O 0 4.930613695108832e-10
essential O 0 1.6024207738496443e-08
for O 0 1.9838184428522254e-09
localization O 0 1.4196843949321192e-06
of O 0 1.4799128678077977e-07
emerin O 0 2.139921889465768e-06
to O 0 1.488779322045275e-08
the O 0 2.402219934083405e-07
nuclear O 0 1.674627128522843e-05
lamina O 1 0.9982594847679138
. O 0 6.2359335970541e-06

Lamin O 1 0.9994437098503113
B1 O 0 0.01898104138672352
is O 0 1.0162729324747488e-07
also O 0 9.895339658783087e-09
almost O 0 2.3872614995923414e-09
completely O 0 4.827492361414443e-08
absent O 0 8.8981283852263e-07
from O 0 3.631223322031474e-08
skeletal O 0 1.618810711079277e-05
muscle O 0 2.663779241629527e-06
nuclei O 0 0.0005778366466984153
. O 0 1.6530288121430203e-05

In O 0 2.0936920918757096e-05
EDMD B-Disease 1 1.0
, O 0 3.211629007182637e-08
the O 0 5.435639049977681e-09
additional O 0 1.1358806117911513e-09
absence O 0 1.313022011117937e-07
of O 0 2.4576002033427358e-06
lamin O 0 0.03353044018149376
B1 O 0 0.07312186062335968
from O 0 4.207493475405499e-06
heart O 1 1.0
and O 0 0.00019751959189306945
skeletal O 1 0.9999996423721313
muscle O 0 0.0782679095864296
nuclei O 1 0.9997668862342834
which O 0 2.716711151151685e-06
already O 0 5.428673262031225e-07
lack O 0 0.00018790630565490574
emerin O 0 1.9681634512380697e-05
may O 0 6.97925939263655e-09
offer O 0 1.3352913219577545e-09
an O 0 3.418632391061216e-11
alternative O 0 1.0959739782379074e-09
explanation O 0 1.1085589113335459e-09
of O 0 1.8046307781460769e-09
why O 0 1.9209196733260825e-10
these O 0 1.1605499200539882e-10
tissues O 0 9.720507065935635e-09
are O 0 4.315748799998964e-11
particularly O 0 8.207682866689936e-10
affected O 0 1.4597825170881151e-09
. O 0 4.796751884583728e-09
. O 0 8.035610932211057e-08

Genetic O 0 7.898341209511273e-06
mapping O 0 1.1273124300714699e-06
of O 0 1.3343113778319093e-06
the O 0 1.3372311968851136e-06
copper B-Disease 0 9.476233390159905e-05
toxicosis I-Disease 1 0.6805139780044556
locus O 0 6.374067197612021e-06
in O 0 1.473513577820995e-07
Bedlington O 0 5.2593008149415255e-05
terriers O 0 9.549425158184022e-06
to O 0 4.4912802366070537e-08
dog O 0 7.760937705825199e-07
chromosome O 0 2.6434067379454973e-08
10 O 0 8.711112720050096e-09
, O 0 1.9641262227754197e-10
in O 0 1.7360428650192716e-09
a O 0 7.735143725540183e-08
region O 0 3.4406502891215496e-07
syntenic O 0 2.3737791707389988e-05
to O 0 2.0854628246524953e-08
human O 0 1.9171807252860162e-08
chromosome O 0 4.0206550977472943e-08
region O 0 5.5977999124934286e-08
2p13 O 0 3.008134171977872e-06
- O 0 3.377537950655096e-06
p16 O 0 7.320177246583626e-07
. O 0 3.9122352291087736e-07

Abnormal O 1 0.94614577293396
hepatic B-Disease 1 1.0
copper I-Disease 0 0.02782588265836239
accumulation I-Disease 0 6.087199290050194e-05
is O 0 7.845495808567193e-09
recognized O 0 3.591066555230782e-09
as O 0 5.383657075697101e-09
an O 0 4.063883007887625e-09
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 3.5433001812634757e-06
man O 0 9.533891898172442e-06
, O 0 8.502635928664404e-09
mouse O 0 2.7088462957181036e-06
, O 0 2.495372442012922e-08
rat O 0 0.22298674285411835
and O 0 2.020426563831279e-06
dog O 0 0.26551949977874756
. O 0 7.065490990498802e-06

The O 0 3.993891368736513e-06
major O 0 4.265676579962019e-06
cause O 0 2.1116025891387835e-05
of O 0 8.524189615854993e-05
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9945977926254272
accumulation I-Disease 0 0.028942395001649857
in O 0 2.3595414404553594e-06
man O 0 4.282638110453263e-05
is O 0 1.494563584003572e-08
a O 0 1.0836942010428174e-07
dysfunctional O 0 2.1757837203040253e-06
ATP7B O 0 0.000673870905302465
gene O 0 1.305835297671365e-07
, O 0 1.6904729838174148e-09
causing O 0 1.2384701619794214e-07
Wilson B-Disease 0 6.034818397893105e-06
disease I-Disease 0 3.635903340182267e-05
( O 0 1.3021328015838662e-08
WD B-Disease 0 0.004068027716130018
) O 0 3.984879271001773e-08
. O 0 2.5506153633614304e-07

Mutations O 0 1.0794791478474508e-06
in O 0 8.675004181668555e-08
the O 0 2.517392090339854e-07
ATP7B O 0 0.0008042022818699479
genes O 0 4.1715480847415165e-08
have O 0 3.2640081748525063e-09
also O 0 2.375696750434031e-09
been O 0 1.9673442874790226e-09
demonstrated O 0 1.2679502781054452e-08
in O 0 1.0296592023451012e-08
mouse O 0 1.3403133607425843e-06
and O 0 1.590412210816794e-07
rat O 0 0.0002487660385668278
. O 0 2.411274522273743e-07

The O 0 7.59488539188169e-05
ATP7B O 0 0.0528281070291996
gene O 0 1.0941010941678542e-06
has O 0 8.422222919080014e-09
been O 0 1.809135175001586e-09
excluded O 0 7.344242547446811e-09
in O 0 6.072594094241879e-10
the O 0 2.7460447249438857e-09
much O 0 3.666275727454149e-09
rarer O 0 6.902895256644115e-05
human O 0 3.596920123527525e-06
copper B-Disease 1 0.9170040488243103
overload I-Disease 1 0.9960297346115112
disease O 1 0.9920382499694824
non B-Disease 0 7.866236046538688e-06
- I-Disease 0 8.606018127466086e-06
Indian I-Disease 0 9.949789046004298e-07
childhood I-Disease 1 0.9992376565933228
cirrhosis I-Disease 1 1.0
, O 0 2.3657398262599827e-09
indicating O 0 2.2852137959716856e-08
genetic O 0 2.1938413397037948e-07
heterogeneity O 0 1.472148369430215e-06
. O 0 5.397590712163947e-07

By O 0 1.5124664187737835e-08
investigating O 0 1.3567188261731644e-07
the O 0 1.2151369332968898e-07
common O 0 1.2893580787931569e-05
autosomal O 1 0.9996953010559082
recessive O 1 0.9969237446784973
copper B-Disease 1 0.9999873638153076
toxicosis I-Disease 1 1.0
( O 0 1.840867867031193e-07
CT B-Disease 0 0.00028060557087883353
) O 0 6.558933840494774e-09
in O 0 2.044131797163118e-08
Bedlington O 0 0.00033176346914842725
terriers O 0 2.0997287720092572e-05
, O 0 1.207076216758196e-09
we O 0 2.790010722453218e-10
have O 0 8.34366117863361e-11
identified O 0 1.2877787725074086e-10
a O 0 3.7797043273002373e-10
new O 0 4.2194772675863135e-10
locus O 0 2.2638466656843548e-09
involved O 0 2.0923414389972805e-10
in O 0 7.824573877712737e-09
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.3592388313554693e-05

We O 0 3.555506111752038e-07
examined O 0 5.908283924327407e-07
whether O 0 4.6942254527948535e-08
the O 0 3.1031316893859184e-07
WD B-Disease 0 0.00025296694366261363
gene O 0 5.466552011057502e-07
ATP7B O 0 0.00020540624973364174
was O 0 6.104454541855375e-07
also O 0 1.6019736648331673e-09
causative O 0 2.7148301384727347e-08
for O 0 1.996359744182996e-09
CT B-Disease 0 2.382583261351101e-06
by O 0 3.115096625094793e-09
investigating O 0 4.072816395250811e-08
the O 0 1.694891267334242e-07
chromosomal O 0 8.184823855117429e-06
co O 0 7.629913852724712e-06
- O 0 6.4866312641242985e-06
localization O 0 0.029461849480867386
of O 0 3.441127046244219e-05
ATP7B O 1 0.5969988703727722
and O 0 1.1560115353859146e-07
C04107 O 0 1.363515451657804e-07
, O 0 7.903220439198222e-11
using O 0 9.437076120555332e-11
fluorescence O 0 2.863027503963167e-08
in O 0 2.2609123462302705e-09
situ O 0 9.798318956200092e-08
hybridization O 0 1.4302466766480393e-08
( O 0 5.014634818500951e-10
FISH O 0 9.490555186175698e-08
) O 0 1.1412119027554013e-09
. O 0 2.732837067753735e-08

C04107 O 0 7.394426211249083e-05
is O 0 5.7425950217293575e-08
an O 0 1.4957406424542796e-09
anonymous O 0 1.4839994122439748e-08
microsatellite O 0 1.5364960290753515e-06
marker O 0 1.1518247902131407e-06
closely O 0 5.9006147523632535e-08
linked O 0 1.899819267237035e-06
to O 0 1.127374844145379e-06
CT B-Disease 1 1.0
. O 0 0.00014477911463472992

However O 0 9.294426490669139e-06
, O 0 8.194065230782144e-07
BAC O 0 0.0003295040223747492
clones O 0 5.759152827522485e-06
containing O 0 1.6862769314229809e-07
ATP7B O 0 0.0003834030940197408
and O 0 8.115674887676505e-08
C04107 O 0 9.295545737586508e-07
mapped O 0 1.5826111621208838e-07
to O 0 2.273575283595619e-08
the O 0 3.6906308764628193e-07
canine O 0 6.632848908338929e-06
chromosome O 0 4.05096187705567e-07
regions O 0 2.8583786004787726e-08
CFA22q11 O 0 1.2823828001273796e-05
and O 0 7.411765068354725e-08
CFA10q26 O 0 5.563829836319201e-05
, O 0 5.642163625196872e-09
respectively O 0 1.75712404626438e-08
, O 0 8.132030049345929e-10
demonstrating O 0 5.073264475186079e-09
that O 0 1.0496665758807922e-09
WD B-Disease 0 1.555535891384352e-05
cannot O 0 9.538897671745872e-09
be O 0 8.465509959698636e-10
homologous O 0 7.870014862021435e-09
to O 0 8.401237927557759e-09
CT B-Disease 0 0.00013892713468521833
. O 0 1.0493647550902097e-06

The O 0 8.622596396890003e-06
copper O 0 1.3288128684507683e-05
transport O 0 1.7045894082912127e-06
genes O 0 1.6615003062270262e-07
CTR1 O 0 0.00033941681613214314
and O 0 7.973958560114625e-08
CTR2 O 1 0.6632279753684998
were O 0 1.1784342035525697e-07
also O 0 3.5596154912553857e-09
excluded O 0 3.2492433188480163e-09
as O 0 3.6409029124939707e-09
candidate O 0 6.544837560795713e-09
genes O 0 4.730568159416748e-10
for O 0 6.336227098557856e-10
CT B-Disease 0 1.6495518138981424e-05
since O 0 6.61418795289137e-08
they O 0 3.6862879415622274e-09
both O 0 4.372426420928832e-09
mapped O 0 9.678994672412955e-08
to O 0 2.7133705060577995e-08
canine O 0 6.726886567776091e-06
chromosome O 0 8.315581681017647e-07
region O 0 5.008741936762817e-07
CFA11q22 O 0 0.00023313875135499984
. O 0 2.8218760235176887e-06

2 O 0 0.00022428501688409597
- O 0 3.152649514959194e-05
22 O 0 3.887817001668736e-06
. O 0 1.3438278756439104e-06

5 O 0 9.103542834054679e-05
. O 0 7.661202289455105e-06

A O 0 6.967517037992366e-06
transcribed O 0 8.307482346481265e-08
sequence O 0 7.3562009816896534e-09
identified O 0 2.5990696261857238e-09
from O 0 7.697742887557979e-09
the O 0 7.235639998270926e-08
C04107 O 0 1.3032306469540345e-06
- O 0 6.821189799666172e-07
containing O 0 4.17310772604651e-08
BAC O 0 0.0003980779438279569
was O 0 3.1524470500698953e-07
found O 0 9.511677001583507e-10
to O 0 2.1814085260363214e-10
be O 0 1.7022040721403897e-10
homologous O 0 1.7808221564052928e-09
to O 0 1.1426798396385607e-09
a O 0 1.0684607865130147e-08
gene O 0 1.5016384580235353e-08
expressed O 0 7.24466797663581e-09
from O 0 2.6075470671571566e-08
human O 0 1.877798361249461e-08
chromosome O 0 4.5932740277976336e-08
2p13 O 0 3.964365760111832e-07
- O 0 1.3143650789970707e-07
p16 O 0 1.981225317138069e-08
, O 0 8.754415525835668e-10
a O 0 3.1089708585341214e-09
region O 0 1.1656535292559056e-08
devoid O 0 1.343931330666237e-07
of O 0 5.430747851420392e-09
any O 0 2.080467575993339e-09
positional O 0 4.093853362974187e-07
candidate O 0 2.8587828637682833e-07
genes O 0 8.711233334679491e-08
. O 0 2.4058056169451447e-07

Molecular O 0 8.968455631475081e-07
analysis O 0 2.61723371863809e-08
of O 0 2.091458384256839e-07
the O 0 8.877745472091192e-08
APC B-Disease 0 7.377041555400865e-08
gene O 0 3.8506899890933255e-09
in O 0 1.213648737063977e-09
205 O 0 3.42116668328174e-09
families O 0 1.5677319442630733e-09
: O 0 6.241766548065186e-10
extended O 0 1.0151299534300051e-07
genotype O 0 1.8427894019623636e-06
- O 0 3.9522220163235033e-07
phenotype O 0 3.741648768595951e-08
correlations O 0 1.5939525255248554e-08
in O 0 1.180376796305893e-09
FAP B-Disease 0 3.1942061440304315e-08
and O 0 1.464958709895825e-10
evidence O 0 1.585709674678526e-09
for O 0 1.9186932598280748e-10
the O 0 4.755137950063215e-10
role O 0 7.897137943579935e-10
of O 0 4.550785970280913e-09
APC B-Disease 0 6.1351741464932275e-09
amino O 0 2.0416681678625537e-09
acid O 0 3.395520753457504e-09
changes O 0 1.5200843250795515e-08
in O 0 0.03531710058450699
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 0.9999996423721313
. O 0 1.110560515371617e-05

BACKGROUND O 0 6.530196696985513e-05
/ O 0 5.844247425557114e-06
AIMS O 0 7.432702631149368e-08
The O 0 6.664382823373671e-09
development O 0 1.9740321377526016e-08
of O 0 9.712682185636368e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.2337048715949095e-08
a O 0 1.1494167839742886e-09
variable O 0 2.904086415789209e-10
range O 0 2.9227478215432257e-09
of O 0 1.1015239387290876e-08
extracolonic O 0 1.5623199942638166e-06
manifestations O 0 6.85950908518862e-06
in O 0 2.730190999500337e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.2197975252092874e-07
FAP B-Disease 0 3.858982893234497e-07
) O 0 8.973099346887281e-11
is O 0 2.8065015589273656e-11
the O 0 1.9011311969130418e-10
result O 0 9.623136731917725e-10
of O 0 3.772196421891749e-08
the O 0 4.320004975966185e-08
dominant O 0 4.58758307786411e-07
inheritance O 0 1.253622713193181e-06
of O 0 1.4073274542170111e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 1.6995262086538787e-08
APC B-Disease 0 7.281604297304511e-08
) O 0 1.6279120274020897e-09
gene O 0 1.893999268531843e-08
mutations O 0 3.417457605792151e-08
. O 0 1.7840315535977425e-07

In O 0 9.824218238918547e-08
this O 0 1.4501860823301627e-09
study O 0 4.280997500938355e-10
, O 0 1.8391519210347873e-11
direct O 0 8.347178503953501e-11
mutation O 0 1.3072677662595567e-10
analysis O 0 1.464310478427322e-10
of O 0 8.992332212187648e-09
the O 0 3.125012781879377e-08
APC B-Disease 0 7.468827334378147e-08
gene O 0 1.5431682598432417e-08
was O 0 1.4217829402696225e-07
performed O 0 1.6454088092032748e-09
to O 0 3.2964525553680346e-10
determine O 0 8.754436287006229e-09
genotype O 0 3.153388092869136e-07
- O 0 1.333599897179738e-07
phenotype O 0 1.855999087752025e-08
correlations O 0 1.0270015060598325e-08
for O 0 1.919506775749369e-09
nine O 0 2.2688968925876907e-08
extracolonic O 0 3.2839307095855474e-07
manifestations O 0 1.212982624565484e-06
and O 0 1.2742611410487825e-08
to O 0 1.364164670114576e-09
investigate O 0 2.047220837297914e-09
the O 0 1.4672999482101545e-09
incidence O 0 3.070830345563991e-08
of O 0 1.1345408168494941e-08
APC B-Disease 0 1.754461820269171e-08
mutations O 0 1.1703156221898325e-09
in O 0 2.5221431609878664e-09
non O 0 0.00019226015137974173
- O 1 0.9999997615814209
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.0001340629969490692

METHODS O 0 1.0137587196368258e-05
The O 0 2.149455440303427e-06
APC B-Disease 0 3.8987525385891786e-07
gene O 0 1.6264324997905533e-08
was O 0 7.147851022182294e-08
analysed O 0 8.807276685729448e-09
in O 0 7.209706720523457e-10
190 O 0 2.8380433558794493e-09
unrelated O 0 1.7410508590387508e-08
FAP B-Disease 0 3.6075451248507306e-07
and O 0 2.6070051006854555e-08
15 O 0 2.900138156292087e-07
non O 0 0.0031520037446171045
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 1.6002273696358316e-05
using O 0 1.054897502683616e-08
denaturing O 0 3.4706370115600294e-06
gradient O 0 1.56959146124791e-07
gel O 0 7.100966925577268e-09
electrophoresis O 0 8.874220469579086e-09
, O 0 5.669010816333753e-10
the O 0 2.473653060164338e-09
protein O 0 2.9608351326260163e-09
truncation O 0 7.257007439420704e-08
test O 0 8.003805618272963e-09
, O 0 1.7368102789294682e-10
and O 0 1.9391120653633465e-10
direct O 0 6.269738062059105e-09
sequencing O 0 2.1675504058293882e-07
. O 0 1.4475303089511726e-07

RESULTS O 0 1.5533154510194436e-05
Chain O 0 2.862366955014295e-06
terminating O 0 5.31801617853489e-07
signals O 0 9.856370297711692e-08
were O 0 2.2458608306408223e-09
only O 0 8.409838103684564e-11
identified O 0 8.999637146622774e-10
in O 0 3.1250693699469423e-10
patients O 0 1.1364938989899542e-09
belonging O 0 8.707640830607488e-09
to O 0 5.36135935647053e-09
the O 0 1.417474919662709e-07
FAP B-Disease 0 1.8477043113307445e-06
group O 0 4.547176857272461e-09
( O 0 9.382877808050694e-10
105 O 0 1.7326206602774619e-07
patients O 0 2.6543553133251407e-08
) O 0 7.520744027544879e-09
. O 0 2.763757436241576e-07

Amino O 0 2.19781995269841e-07
acid O 0 1.3120001085553668e-08
changes O 0 3.6400679692683013e-10
were O 0 2.721510239389602e-10
identified O 0 4.997981473131574e-10
in O 0 1.9732811218364787e-10
four O 0 6.565664678603866e-10
patients O 0 1.193996901349692e-09
, O 0 2.6644517148177727e-10
three O 0 1.5801061570286379e-09
of O 0 6.407402679542429e-07
whom O 0 1.8275820821145317e-06
belonged O 0 0.00019280644482932985
to O 0 1.5227226413117023e-07
the O 0 2.6537079520494444e-06
non O 0 1.562674697197508e-06
- O 0 8.094470445030311e-07
FAP O 0 6.241146479624149e-07
group O 0 7.178808214547416e-09
of O 0 0.44287341833114624
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.8971098065376282
. O 0 1.7343677427561488e-06

Genotype O 0 0.000983010628260672
- O 0 5.9244972362648696e-05
phenotype O 0 1.6824118347358308e-06
correlations O 0 1.2099782509267243e-07
identified O 0 1.0706313169350778e-08
significant O 0 7.513087929567064e-09
differences O 0 1.0034239039669046e-07
in O 0 1.6368078448181222e-08
the O 0 3.551770788590147e-08
nature O 0 4.8123491858120815e-09
of O 0 6.232704574671288e-09
certain O 0 2.8661184536815654e-09
extracolonic O 0 4.7488254040217726e-07
manifestations O 0 1.8038889493254828e-07
in O 0 1.733931553893342e-09
FAP B-Disease 0 2.660762845607678e-07
patients O 0 1.7757751935576493e-09
belonging O 0 1.6025543114750462e-09
to O 0 1.9910206816575737e-09
three O 0 1.1937742350198732e-08
mutation O 0 4.7026130545191336e-08
subgroups O 0 4.73472084649984e-07
. O 0 3.1899691066428204e-07

CONCLUSIONS O 0 2.851136014214717e-05
Extended O 0 2.1936748453299515e-05
genotype O 0 8.527954923920333e-05
- O 0 8.726166925043799e-06
phenotype O 0 3.3814464472925465e-07
correlations O 0 1.0014068152486288e-07
made O 0 2.2054496895407283e-08
in O 0 2.372545049311725e-09
this O 0 4.6557713240247267e-10
study O 0 7.787526179470206e-10
may O 0 1.328893661778352e-09
have O 0 5.41451716795649e-10
the O 0 1.3385559327616647e-08
potential O 0 8.816150476320672e-09
to O 0 1.7329131463128533e-09
determine O 0 6.3756182555607666e-09
the O 0 2.394504505787154e-08
most O 0 7.909890520352292e-10
appropriate O 0 4.3704586616399865e-09
surveillance O 0 2.5902226141738538e-08
and O 0 2.3427482176430203e-10
prophylactic O 0 1.4672481540856097e-07
treatment O 0 6.860071835035342e-07
regimens O 0 3.2579058029114094e-07
for O 0 4.929005537057662e-10
those O 0 1.1179883407930191e-10
patients O 0 2.14820342070432e-10
with O 0 1.4091721713127559e-11
mutations O 0 5.7023000904488086e-11
associated O 0 3.156591654729368e-10
with O 0 1.330198867721677e-10
life O 0 2.96641005093079e-08
threatening O 0 1.348692109104377e-07
conditions O 0 4.545444608083926e-05
. O 0 1.5911145965219475e-06

This O 0 5.898724353414764e-08
study O 0 5.2909188141825325e-09
also O 0 2.9753374763963336e-10
provided O 0 1.447435643564532e-10
evidence O 0 2.46280662530296e-09
for O 0 9.516432086797977e-10
the O 0 1.0272700023961079e-08
pathological O 0 1.0757609061329276e-06
nature O 0 1.3065262649547549e-08
of O 0 1.664040105708864e-08
amino O 0 4.092460592630687e-09
acid O 0 5.8356617316235315e-09
changes O 0 2.136958165976921e-09
in O 0 5.4612034894319095e-09
APC O 0 4.855722934848927e-08
associated O 0 1.4188971775297432e-08
with O 0 2.835417733937362e-10
both O 0 1.423358098051608e-09
FAP B-Disease 0 4.1550993046257645e-07
and O 0 1.4739457654400212e-08
non O 0 0.00011677003931254148
- O 1 0.9999996423721313
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.650402843253687e-06
. O 0 9.53398693326335e-09
. O 0 3.387307145885643e-08

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.9999933242797852
cancer B-Disease 1 1.0
risk O 0 2.4857256448740372e-06
of O 0 2.484803735569585e-05
the O 0 6.612317520193756e-05
APC O 0 1.684206108620856e-05
I1307K O 0 4.500663180806441e-06
polymorphism O 0 4.541615453490522e-06
. O 0 1.1073337873312994e-06

Germ O 0 0.07489616423845291
- O 0 0.0001721147127682343
line O 0 2.763425072771497e-06
and O 0 1.2109648395153272e-08
somatic O 0 2.583394689281704e-07
truncating O 0 2.9743142704319325e-07
mutations O 0 2.9584414917849244e-09
of O 0 1.5135110942310348e-08
the O 0 2.8935122742268504e-08
APC B-Disease 0 1.2872349408610262e-08
gene O 0 3.1328037386479934e-10
are O 0 9.002821058090582e-12
thought O 0 6.981132893990605e-10
to O 0 5.96255045337557e-10
initiate O 0 2.5673858772279345e-07
colorectal B-Disease 1 1.0
tumor I-Disease 0 1.738244463922456e-05
formation O 0 6.336801448014739e-07
in O 0 3.32442482431361e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.080880949506536e-05
sporadic O 1 0.9926787614822388
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 2.5908607881319767e-07
respectively O 0 1.803285272217181e-07
. O 0 3.240987098251935e-06

Recently O 0 1.823042839532718e-05
, O 0 6.189053181060444e-08
an O 0 5.443150374873085e-09
isoleucine O 0 1.0500795042389655e-06
- O 0 2.40657277572609e-06
- O 0 6.42448821963626e-06
> O 0 2.805499889291241e-06
lysine O 0 4.5956227268106886e-07
polymorphism O 0 3.545996918319361e-08
at O 0 7.229980614198439e-09
codon O 0 1.8359853637406331e-09
1307 O 0 3.855252828088851e-07
( O 0 9.987048965598433e-10
I1307K O 0 6.38097361616019e-08
) O 0 3.3427360879301204e-10
of O 0 1.17483391903761e-08
the O 0 8.187927136305007e-08
APC B-Disease 0 1.4808473736138694e-07
gene O 0 4.14908152279736e-09
has O 0 9.356000418847543e-10
been O 0 1.155770257277311e-09
identified O 0 2.009930666346804e-09
in O 0 1.3378661511964651e-09
6 O 0 1.9844550891434665e-08
% O 0 7.891852171759695e-10
- O 0 1.3203269588757394e-08
7 O 0 6.063363855446369e-08
% O 0 8.69026517413829e-10
of O 0 8.961341002589052e-09
the O 0 6.46971329842927e-08
Ashkenazi O 0 1.2774399920090218e-06
Jewish O 0 3.147732741126674e-08
population O 0 3.331768749781361e-10
. O 0 1.5868300451415962e-08

To O 0 4.308460290758376e-07
assess O 0 1.0233322882413631e-06
the O 0 1.8288254466369835e-07
risk O 0 3.355374644797848e-08
of O 0 5.493003385481643e-09
this O 0 3.9563241571727303e-10
common O 0 1.2004482741190259e-08
APC B-Disease 0 4.1158450869716035e-08
allelic O 0 1.29618626942829e-07
variant O 0 1.4097036910243332e-05
in O 0 5.630305167869665e-06
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 4.325038389652036e-07
we O 0 6.565266996716446e-09
have O 0 5.769332789284931e-10
analyzed O 0 2.6763409266550298e-09
a O 0 2.4005715193453625e-09
large O 0 1.7570696009272524e-09
cohort O 0 3.09554089028552e-08
of O 0 6.205578273466017e-08
unselected O 0 4.489711136557162e-05
Ashkenazi O 0 2.6977686502505094e-05
Jewish O 0 2.5411560500288033e-07
subjects O 0 1.4515406121518026e-07
with O 0 5.8538889291526175e-09
adenomatous B-Disease 0 0.00024515806580893695
polyps I-Disease 0 1.7060765458154492e-05
and O 0 3.417783389636497e-08
. O 0 2.655009154750587e-07
or O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.3631684225856588e-07
for O 0 1.7545454866763066e-08
the O 0 3.0068949854467064e-06
APC O 0 1.7674149148660945e-06
I1307K O 0 1.3264325389172882e-06
polymorphism O 0 5.14335965817736e-07
. O 0 3.626240356879862e-07

The O 0 1.072840404958697e-05
APC O 0 2.9557018024206627e-06
I1307K O 0 9.681937171990285e-07
allele O 0 1.5433741396009282e-08
was O 0 4.652588714293415e-08
identified O 0 3.5428850964080993e-09
in O 0 3.5232212702851484e-09
48 O 0 1.578721153805418e-08
( O 0 2.6177701673013587e-10
10 O 0 9.148825586002829e-10
. O 0 1.8572225701785072e-10
1 O 0 8.423957531533688e-09
% O 0 1.5497383931695197e-10
) O 0 5.489269455649648e-11
of O 0 2.8917619410151474e-09
476 O 0 1.4610597531827807e-07
patients O 0 2.6761134108710394e-07
. O 0 8.86761426954763e-07

Compared O 0 2.919838948400866e-07
with O 0 2.610466731667316e-09
the O 0 1.0997941224388796e-08
frequency O 0 8.434311915550552e-09
in O 0 6.53024523344925e-10
two O 0 1.256429543738946e-10
separate O 0 2.866281101354673e-10
population O 0 1.1151191081637535e-11
control O 0 5.788798884687196e-10
groups O 0 9.231060360548327e-12
, O 0 1.9454914068628426e-10
the O 0 1.2107523872373349e-08
APC O 0 1.3493469452896534e-07
I1307K O 0 1.664418505242793e-07
allele O 0 4.8676640496125856e-09
is O 0 1.1475805722360732e-10
associated O 0 2.341417060236495e-10
with O 0 1.803658611354564e-11
an O 0 2.174378732622273e-11
estimated O 0 2.5584406121437198e-11
relative O 0 1.5212329174119077e-08
risk O 0 2.4737582648981515e-08
of O 0 6.598348250008712e-07
1 O 0 1.761550629453268e-05
. O 0 8.491933272125607e-07

5 O 0 3.571890192688443e-05
- O 0 1.3666919585375581e-05
1 O 0 3.385032186997705e-06
. O 0 3.937714723178942e-07

7 O 0 4.041195279569365e-05
for O 0 1.2080382703061332e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9995531439781189
( O 0 1.3041514534961607e-07
both O 0 8.090713521369253e-08
P O 0 3.449245559750125e-05
= O 0 1.0471200084793963e-07
. O 0 6.441968736226045e-09
01 O 0 9.714690918372071e-08
) O 0 1.3508869578515714e-09
. O 0 3.838029272174026e-08

Furthermore O 0 2.8501128213065385e-07
, O 0 5.34800026485982e-09
compared O 0 4.672952691464616e-09
with O 0 2.0969570524442815e-09
noncarriers O 0 1.059034821082605e-05
, O 0 1.9179999810603476e-08
APC O 0 2.7244249167779344e-07
I1307K O 0 2.214259495758597e-07
carriers O 0 5.703980843208001e-09
had O 0 3.814556670533875e-09
increased O 0 2.924921416180837e-10
numbers O 0 1.2960632567171615e-10
of O 0 9.905384956709895e-09
adenomas B-Disease 1 0.9983160495758057
and O 0 0.008155457675457
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999984502792358
per O 0 8.371377191451757e-08
patient O 0 1.7739787381287897e-06
( O 0 2.487772210457706e-09
P O 0 8.386862191400724e-07
= O 0 4.887740434611487e-09
. O 0 1.9205752266326925e-10
03 O 0 4.772513051420901e-09
) O 0 2.912050114933784e-11
, O 0 2.2913251157552494e-11
as O 0 2.161553019908169e-10
well O 0 5.167425376484402e-10
as O 0 1.1291648727151937e-09
a O 0 6.188802803563931e-09
younger O 0 2.3028249529488676e-08
age O 0 1.2420060535589528e-08
at O 0 2.496634010640264e-08
diagnosis O 0 1.162928583653411e-06
. O 0 1.435127643389933e-07

We O 0 3.6245151591174363e-07
conclude O 0 1.790339183571632e-07
that O 0 1.495849000221483e-09
the O 0 2.5359309319128442e-08
APC O 0 1.2647963387735217e-07
I1307K O 0 5.056270424574905e-07
variant O 0 6.457289600803051e-06
leads O 0 4.89212688137286e-08
to O 0 2.6049857826393463e-09
increased O 0 1.1955702916566224e-07
adenoma B-Disease 1 1.0
formation O 0 4.1353137930855155e-05
and O 0 1.0684285456363796e-07
directly O 0 4.706343315064032e-09
contributes O 0 2.2037233149418967e-10
to O 0 3.500144896140256e-10
3 O 0 3.7231662197712012e-09
% O 0 1.045653563735982e-10
- O 0 8.693862296738075e-10
4 O 0 1.2337371124715446e-09
% O 0 3.354083330520119e-11
of O 0 1.8664628176345843e-10
all O 0 3.0156394048574953e-10
Ashkenazi O 0 9.931049135047942e-06
Jewish O 0 0.0013592763571068645
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.16248952508613e-06

The O 0 2.800253014356713e-06
estimated O 0 1.4713166684998669e-08
relative O 0 3.1333331662608543e-07
risk O 0 4.176309076342477e-08
for O 0 9.88808923629847e-10
carriers O 0 2.8397435514193603e-09
may O 0 3.3629716789107533e-09
justify O 0 8.855587374512197e-09
specific O 0 1.060319276824373e-09
clinical O 0 5.828075355651663e-09
screening O 0 4.6469725845099674e-09
for O 0 5.147613446609967e-10
the O 0 7.801267187801386e-09
360 O 0 1.3604497084429568e-08
, O 0 1.8869085460782031e-10
000 O 0 8.400656281715158e-10
Americans O 0 1.822329093181807e-10
expected O 0 3.846887697278589e-09
to O 0 8.228095538242997e-09
harbor O 0 4.0584427551948465e-06
this O 0 6.438783395346093e-10
allele O 0 1.8028728510088854e-09
, O 0 9.031340952869726e-11
and O 0 2.345533767211805e-10
genetic O 0 1.0046601328639326e-09
testing O 0 1.7683865483064665e-09
in O 0 1.1744054617679467e-09
the O 0 2.0522811894352344e-08
setting O 0 1.4544194293364399e-08
of O 0 2.710034330277722e-08
long O 0 1.557061324319875e-08
- O 0 3.6061134522924476e-08
term O 0 3.34673671886776e-07
- O 0 2.536642682571255e-07
outcome O 0 2.1734118504923572e-08
studies O 0 4.033155198701621e-10
may O 0 2.021039585686779e-10
impact O 0 2.2452268932937613e-09
significantly O 0 1.418437705069664e-07
on O 1 0.999605119228363
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.0001035577297443524
in O 0 1.6276595349307144e-10
this O 0 7.193932949345339e-11
population O 0 2.3123286271853338e-11
. O 0 3.6428757788087296e-09

Localization O 0 0.00032898859353736043
of O 0 6.143880909803556e-06
human O 0 4.3126780724378477e-07
BRCA1 O 0 2.3098202461824258e-07
and O 0 1.5741028036586613e-08
its O 0 6.23483220607568e-09
loss O 0 3.636345695667842e-07
in O 0 4.9877780128326776e-08
high O 0 3.1453731935471296e-05
- O 0 1.7526876945339609e-06
grade O 0 9.63954153121449e-06
, O 0 2.0852956694739078e-08
non B-Disease 0 5.676146975019947e-05
- I-Disease 1 0.9999974966049194
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.1404895303712692e-05

Although O 0 1.754489460381592e-07
the O 0 1.217031950773162e-07
link O 0 8.583657518101973e-08
between O 0 2.043476854396431e-08
the O 0 1.949818084767685e-07
BRCA1 O 0 5.284200028654595e-07
tumour B-Disease 1 1.0
- O 0 1.5028813322714996e-06
suppressor O 0 5.231649993220344e-07
gene O 0 2.4182382318826967e-08
and O 0 2.9284299429832572e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 3.724842656538385e-09
established O 0 4.778616169431871e-09
, O 0 6.806962632444069e-11
the O 0 7.081216724103001e-10
role O 0 3.3103537688816687e-09
, O 0 5.937715596981974e-11
if O 0 4.626538388508017e-11
any O 0 6.666642238251086e-10
, O 0 1.7046797307074257e-10
of O 0 2.516425290366442e-09
BRCA1 O 0 8.2102555865049e-09
in O 0 3.5767797612606955e-09
non B-Disease 0 2.445371683279518e-05
- I-Disease 1 0.8023191690444946
familial I-Disease 1 0.9973564147949219
cancers I-Disease 1 0.999998927116394
is O 0 1.1713233938337453e-08
unclear O 0 3.8317756434480543e-07
. O 0 3.1161386004896485e-07

BRCA1 O 0 4.648722097044811e-06
mutations O 0 2.666640597226433e-08
are O 0 1.5335367697932867e-10
rare O 0 7.892412945409433e-09
in O 0 1.3970476997471337e-09
sporadic B-Disease 0 6.513751941383816e-06
cancers I-Disease 1 1.0
, O 0 2.2424622159178398e-09
but O 0 2.523240283380801e-09
loss O 0 4.142760644754162e-06
of O 0 5.421491732704453e-05
BRCA1 O 0 6.113123163231649e-08
resulting O 0 4.6801535091844926e-08
from O 0 4.530692709892037e-09
reduced O 0 3.2067138278080165e-08
expression O 0 6.449825118437502e-09
or O 0 4.975821976671568e-09
incorrect O 0 4.241024598172771e-08
subcellular O 0 7.348195936174307e-07
localization O 0 9.45367844451539e-07
is O 0 4.1598402500397924e-10
postulated O 0 9.212850926587635e-09
to O 0 3.2936622873513954e-10
be O 0 1.8310743199467794e-10
important O 0 9.639081754997392e-10
in O 0 2.172557023172317e-09
non B-Disease 0 1.3346078731046873e-06
- I-Disease 0 0.0026806031819432974
familial I-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 6.366154411807656e-05

Epigenetic O 0 0.22782789170742035
loss O 0 0.07784902304410934
, O 0 2.9783382871073627e-08
however O 0 1.7301399424241026e-08
, O 0 6.325046597588369e-10
has O 0 2.8631976997650632e-11
not O 0 4.6821617763481704e-12
received O 0 1.1545379929867039e-10
general O 0 1.9022057262674252e-09
acceptance O 0 3.993439179339475e-08
due O 0 6.543829158545122e-07
to O 0 1.5434743261266703e-08
controversy O 0 3.9707444443592976e-08
regarding O 0 1.9096990655498303e-08
the O 0 1.1824481838118572e-08
subcellular O 0 5.505335138877854e-07
localization O 0 5.52258507013903e-06
of O 0 1.8788986722029222e-07
BRCA1 O 0 4.894093574847602e-09
proteins O 0 1.556192813501056e-10
, O 0 4.825110450079606e-11
reports O 0 1.5125803387583403e-10
of O 0 9.383293253506508e-09
which O 0 1.4415761917518921e-09
have O 0 7.062911921984494e-10
ranged O 0 8.40446290339969e-08
from O 0 1.070165822625313e-08
exclusively O 0 5.728610918964705e-09
nuclear O 0 3.813333364632854e-07
, O 0 1.1725790338701358e-09
to O 0 3.1084315121887585e-09
conditionally O 0 6.01969702529459e-07
nuclear O 0 4.0575059756520204e-06
, O 0 4.265408026782325e-09
to O 0 5.857094365069315e-09
the O 0 2.1388946436218248e-07
ER O 0 0.0001257589174201712
/ O 0 4.4596453108169953e-07
golgi O 0 6.317532097455114e-06
, O 0 1.6159553695160866e-09
to O 0 2.2498993779151988e-09
cytoplasmic O 0 7.199420792858291e-08
invaginations O 0 1.0405453849671176e-06
into O 0 7.755753017590905e-08
the O 0 2.4489331451604812e-08
nucleus O 0 4.2184274207102135e-07
. O 0 2.3744462396280142e-07

In O 0 1.3871890587324742e-06
an O 0 4.692165944675253e-08
attempt O 0 8.02083945927734e-07
to O 0 4.297913491768668e-08
resolve O 0 9.60373427005834e-07
this O 0 1.7526890161434494e-08
issue O 0 7.826069747807196e-08
, O 0 3.952931759698686e-09
we O 0 9.729925753987345e-10
have O 0 1.7669636864781069e-09
comprehensively O 0 8.022333020107908e-08
characterized O 0 4.489481852942845e-08
19 O 0 1.0741907630062997e-07
anti O 0 9.50936112076306e-07
- O 0 3.0678295388497645e-06
BRCA1 O 0 3.980230545153063e-08
antibodies O 0 1.3975467894056237e-08
. O 0 2.1654699366990826e-07

These O 0 4.0632420450492646e-07
reagents O 0 3.943561296182452e-06
detect O 0 2.1263083453959553e-06
a O 0 2.500103732927528e-07
220 O 0 1.0153468110729591e-07
- O 0 1.1075517392100664e-07
kD O 0 3.1347587992058834e-07
protein O 0 8.150823127550666e-09
localized O 0 2.336324911311749e-08
in O 0 1.3120444730674308e-09
discrete O 0 3.817062221855849e-08
nuclear O 0 9.65524350249325e-07
foci O 0 3.600252114210889e-07
in O 0 1.5395102970217067e-09
all O 0 4.397397723732155e-10
epithelial O 0 5.465833652351648e-08
cell O 0 1.8573418003597908e-07
lines O 0 3.107263557566853e-09
, O 0 3.0936239681089717e-11
including O 0 1.621483329550255e-11
those O 0 9.045511562000286e-11
derived O 0 2.4718245228427804e-08
from O 0 1.074132910616754e-06
breast B-Disease 0 0.26274096965789795
malignancies I-Disease 0 0.0002775809552986175
. O 0 1.3065108532828162e-06

Immunohistochemical O 0 0.00031208276050165296
staining O 0 6.39852078165859e-05
of O 0 1.1424871445342433e-05
human O 0 6.862433679089008e-07
breast O 0 2.402016889391234e-06
specimens O 0 4.5308510721042694e-08
also O 0 1.6797324420281257e-08
revealed O 0 3.644897219601262e-07
BRCA1 O 0 1.3284159194881795e-07
nuclear O 0 1.7405551261617802e-05
foci O 0 3.5616554669104517e-05
in O 0 2.8897184733978065e-07
benign O 1 1.0
breast O 1 1.0
, O 0 1.032119780575158e-05
invasive B-Disease 1 1.0
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 0.0024478957056999207
low B-Disease 1 1.0
- I-Disease 1 1.0
grade I-Disease 1 1.0
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 1.3398760529526044e-05

Conversely O 0 2.0613217202480882e-05
, O 0 2.649338455285033e-07
BRCA1 O 0 8.751167968057416e-08
expression O 0 1.1979437886111555e-08
was O 0 9.786123200683505e-08
reduced O 0 9.060855177267513e-09
or O 0 2.8646101046803096e-09
undetectable O 0 2.5936833125683734e-08
in O 0 1.504679603137049e-09
the O 0 5.360295762812939e-09
majority O 0 5.332983499251043e-10
of O 0 4.726839009094874e-08
high O 0 1.2249878636794165e-05
- O 0 4.999254088033922e-06
grade O 0 1.701105065876618e-05
, O 0 1.2865899634562084e-07
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 3.1501636854613935e-09
suggesting O 0 1.0505478709177396e-09
that O 0 2.420861289209597e-10
absence O 0 3.659085905383108e-07
of O 0 2.1407854546851013e-06
BRCA1 O 0 3.0723182220526724e-08
may O 0 1.2996557163802436e-09
contribute O 0 2.2227535090291184e-10
to O 0 6.870253255186753e-10
the O 0 1.2085559220054165e-08
pathogenesis O 0 0.00022062970674596727
of O 0 9.011358770294464e-08
a O 0 8.04086575101337e-09
significant O 0 4.96450303089091e-09
percentage O 0 1.598668752933463e-08
of O 0 3.916841251339065e-08
sporadic B-Disease 0 0.004714174196124077
breast I-Disease 1 1.0
cancers I-Disease 1 0.9995173215866089
. O 0 1.195987806568155e-07
. O 0 5.385019790082879e-07

